FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Zabetian, CP Yamamoto, M Lopez, AN Ujike, H Mata, IF Izumi, Y Kaji, R Maruyama, H Morino, H Oda, M Hutter, CM Edwards, KL Schellenberg, GD Tsuang, DW Yearout, D Larson, EB Kawakami, H AF Zabetian, Cyrus P. Yamamoto, Mitsutoshi Lopez, Alexis N. Ujike, Hiroshi Mata, Ignacio F. Izumi, Yuishin Kaji, Ryuji Maruyama, Hirofumi Morino, Hiroyuki Oda, Masaya Hutter, Carolyn M. Edwards, Karen L. Schellenberg, Gerard D. Tsuang, Debby W. Yearout, Dora Larson, Eric B. Kawakami, Hideshi TI LRRK2 Mutations and Risk Variants in Japanese Patients with Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE mutation; polymorphism; Parkinson ID GLY2385ARG VARIANT; ALPHA-SYNUCLEIN; LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; ASHKENAZI JEWS; POPULATION; HAPLOTYPE; CHINESE; G2019S; PREVALENCE AB Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic determinant of Parkinson's disease (PD) in European-derived populations, but far less is known about LRRK2 mutations and susceptibility alleles in Asians. To address this issue, we sequenced the LRRK2 coding region in 36 patients with familial PD, then genotyped variants of interest in an additional 595 PD cases and 1,641 controls who were all of Japanese ancestry. We also performed a meta-analysis of studies on G2385R, a polymorphism previously reported to associate with PD. One pathogenic (G20195) and one putative pathogenic (R1067Q) mutation were each observed in two patients with sporadic PD. The overall mutation frequence among patients was 0.6% G2385R was highly associated with PD under a dominant model in our dataset (adjusted OR, 1.83; 95% CI, 1.31-2.54; P = 3.3 x 10(-4)) and similar results were seen in the meta-analysis (summary OR assuming fixed effects, 2.55; 95% CI, 2.10-3.10).G2385R represents the first consistently replicated common PD susceptibility variant in a non-European population and its effect size is substantially greater than that reported for other well-validated genetic risk factors for the disease. However, LRRK2 mutations appear to be rare among Japanese patients with PD. (C) 2009 Movement Disorder Society C1 [Zabetian, Cyrus P.; Lopez, Alexis N.; Mata, Ignacio F.; Schellenberg, Gerard D.; Yearout, Dora] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Lopez, Alexis N.; Mata, Ignacio F.; Schellenberg, Gerard D.; Yearout, Dora] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, NW Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Yamamoto, Mitsutoshi] Kagawa Prefectural Cent Hosp, Dept Neurol, Takamatsu, Kagawa, Japan. [Ujike, Hiroshi] Okayama Univ, Dept Neuropsychiat, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan. [Izumi, Yuishin; Kaji, Ryuji] Univ Tokushima, Dept Clin Neurosci, Inst Hlth Biosci, Grad Sch, Tokushima 770, Japan. [Maruyama, Hirofumi; Morino, Hiroyuki; Kawakami, Hideshi] Hiroshima Univ, Dept Epidemiol, Res Inst Radiat Biol & Med, Hiroshima, Japan. [Oda, Masaya] Sumitomo Hosp, Dept Neurol, Osaka, Japan. [Hutter, Carolyn M.; Edwards, Karen L.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. [Schellenberg, Gerard D.; Larson, Eric B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. [Tsuang, Debby W.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetien@u.washington.edu RI ; Maruyama, Hirofumi/B-9333-2011; Kawakami, Hideshi/A-2086-2009; Morino, Hiroyuki/H-9583-2013; Tsuang, Debby/L-7234-2016 OI Zabetian, Cyrus/0000-0002-7739-4306; Kawakami, Hideshi/0000-0002-1405-0901; Morino, Hiroyuki/0000-0002-5190-3547; Tsuang, Debby/0000-0002-4716-1894; Fernandez Mata, Ignacio/0000-0003-1198-0633 FU American Parkinson Disease Association; National Institutes of Health; Institute Of Neurological Disorders and Stroke. [K08 NS044138]; Department of Veterans Affairs; Smoking Research Foundation FX This work was Supported by the American Parkinson Disease Association (Research Grant to Dr Zabetian), National Institutes of Health (Nationat Institute Of Neurological Disorders and Stroke. grant K08 NS044138, to Dr Zabetian), Department of Veterans Affairs (Merit Review Award to Dr Zabetian), Smoking Research Foundation (Grant for Biomedical Research to Dr. Kawakami), and the Veterans Integrated Service Network 20 Geriatric. Mental Illness, and Parkinson's Disease Research Education and Clinical Centers. We thank the individuals who participated in the study. Positive controls for TaqMan assays were provided by Eng-King Tan, MD (R1067Q and IVS33+6T -> A) and Owen Ross, PhD (R1628P). NR 37 TC 33 Z9 34 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY 15 PY 2009 VL 24 IS 7 BP 1034 EP 1041 DI 10.1002/mds.22514 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 453NQ UT WOS:000266617900012 PM 19343804 ER PT J AU Schilero, GJ Spungen, AM Bauman, WA Radulovic, M Lesser, M AF Schilero, Gregory J. Spungen, Ann M. Bauman, William A. Radulovic, Miroslav Lesser, Marvin TI Pulmonary function and spinal cord injury SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Review DE Spinal cord injury; Respiratory Function Tests; Obstructive sleep apnea; Tetraplegia ID OBSTRUCTIVE SLEEP-APNEA; INSPIRATORY MUSCLE STRENGTH; POSITIVE AIRWAY PRESSURE; RIB CAGE MOTION; MAXIMAL EXPIRATORY PRESSURE; LOWER RESPIRATORY-TRACT; FORCED VITAL CAPACITY; TETRAPLEGIC PATIENTS; CERVICAL CORD; ELECTRICAL-STIMULATION AB Injury to the cervical and upper thoracic spinal cord disrupts function of inspiratory and expiratory muscles, as reflected by reduction in spirometric and lung volume parameters and static mouth pressures. In association, subjects with tetraplegia have decreased chest wall and lung compliance, increased abdominal wall compliance, and rib cage stiffness with paradoxical chest wall movements, all of which contribute to an increase in the work of breathing. Expiratory muscle function is more compromised than inspiratory muscle function among subjects with tetraplegia and high paraplegia, which can result in ineffective cough and propensity to mucus retention and atelectasis. Subjects with tetraplegia also demonstrate heightened vagal activity with reduction in baseline airway caliber, findings attributed to loss of sympathetic innervation to the lungs. Significant increase in airway caliber following inhalation of ipratropium bromide, an anticholinergic agent, suggests that reduction in airway caliber is not due to acquired airway fibrosis stemming from repeated infections or to abnormal hysteresis secondary to chronic inability of subjects to inhale to predicted total lung capacity. Reduced baseline airway caliber possibly explains why subjects with tetraplegia exhibit airway hyperresponsiveness to methacholine and ultrasonically nebulized distilled water. While it has been well demonstrated that bilateral phrenic nerve pacing or stimulation through intramuscular diaphragmatic electrodes improves inspiratory muscle function, it remains unclear if inspiratory muscle training improves pulmonary function. Recent findings suggest that expiratory muscle training, electrical stimulation of expiratory muscles and administration of a long-acting beta(2)-agonist (salmeterol) improve physiological parameters and cough. It is unknown if baseline bronchoconstriction in tetraplegia contributes to respiratory symptoms, of if the chronic administration of a bronchodilator reduces the work of breathing and/or improves respiratory symptoms. Less is known regarding the benefits of treatment of obstructive sleep apnea, despite evidence indicating that the prevalence of this condition in persons with tetraplegia is far greater than that encountered in able-bodied individuals. Published by Elsevier B.V. C1 [Schilero, Gregory J.; Spungen, Ann M.; Bauman, William A.; Radulovic, Miroslav; Lesser, Marvin] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rehabil Res & Dev Ctr, Bronx, NY 10468 USA. [Schilero, Gregory J.; Spungen, Ann M.; Bauman, William A.; Radulovic, Miroslav] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. [Schilero, Gregory J.; Spungen, Ann M.; Bauman, William A.; Radulovic, Miroslav] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Schilero, GJ (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rehabil Res & Dev Ctr, Rm 1 E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM greg.schilero@va.gov NR 206 TC 59 Z9 65 U1 2 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD MAY 15 PY 2009 VL 166 IS 3 BP 129 EP 141 DI 10.1016/j.resp.2009.04.002 PG 13 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 455HP UT WOS:000266749600001 PM 19442929 ER PT J AU Zhou, XH Hu, N Hu, GZ Root, M AF Zhou, Xiao-Hua Hu, Nan Hu, Guizhou Root, Martin TI Synthesis analysis of regression models with a continuous outcome SO STATISTICS IN MEDICINE LA English DT Article DE synthesis analysis; meta-analysis; linear models ID DISEASE AB To estimate the multivariate regression model from multiple individual studies, it would be challenging to obtain results if the input from individual studies only provide univariate or incomplete multivariate regression information. Samsa et al. (J. Biomed. Biotechnol. 2005; 2:113-123) proposed a simple method to combine coefficients from univariate linear regression models into a multivariate linear regression model, a method known as synthesis analysis. However, the validity of this method relies on the normality assumption of the data, and it does not provide variance estimates. In this paper we propose a new synthesis method that improves on the existing synthesis method by eliminating the normality assumption, reducing bias, and allowing for the variance estimation of the estimated parameters. Copyright (c) 2009 John Wiley & Sons, Ltd. C1 [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Zhou, Xiao-Hua; Hu, Nan] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Hu, Guizhou; Root, Martin] BioSignia Inc, Durham, NC 27713 USA. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. EM azhou@u.washington.edu FU NSFC [30728019] FX We would like to thank Vicki Ding and Hua Chen for their help in preparing this manuscript. Xiao-Hua Zhou, PhD, is presently a Core Investigator and Biostatistics Unit Director at the Northwest HSR&D Center of Excellence, Department of Veterans Affairs Medical Center, Seattle, WA. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. This study has been partially supported by NSFC 30728019. NR 6 TC 6 Z9 7 U1 0 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD MAY 15 PY 2009 VL 28 IS 11 BP 1620 EP 1635 DI 10.1002/sim.3563 PG 16 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 446TC UT WOS:000266143100006 PM 19326397 ER PT J AU Hiruma, Y Honjo, T Jelinek, DF Windle, JJ Shin, J Roodman, GD Kurihara, N AF Hiruma, Yuko Honjo, Tadashi Jelinek, Diane F. Windle, Jolene J. Shin, Jaekyoon Roodman, G. David Kurihara, Noriyoshi TI Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation SO BLOOD LA English DT Article ID HUMAN MULTIPLE-MYELOMA; KAPPA-B LIGAND; STROMAL CELLS; BONE MICROENVIRONMENT; RECEPTOR ACTIVATOR; PROGENITOR CELLS; DRUG-RESISTANCE; PAGETS-DISEASE; IN-VITRO; ADHESION AB Adhesive interactions between multiple myeloma ( MM) cells and marrow stromal cells activate multiple signaling pathways including nuclear factor kappa B (NF-kappa B), p38 mitogen-activated protein kinase (MAPK), and Jun N-terminal kinase (JNK) in stromal cells, which promote tumor growth and bone destruction. Sequesto-some-1 (p62), an adapter protein that has no intrinsic enzymatic activity, serves as a platform to facilitate formation of signaling complexes for these pathways. Therefore, we determined if targeting only p62 would inhibit multiple signaling pathways activated in the MM microenvironment and thereby decrease MM cell growth and osteoclast formation. Signaling through NF-kappa B and p38 MAPK was increased in primary stromal cells from MM patients. Increased interleukin-6 (IL-6) production by MM stromal cells was p38 MAPK-dependent while increased vascular cell adhesion molecule-1 (VCAM-1) expression was NF-kappa B-dependent. Knocking-down p62 in patient-derived stromal cells significantly decreased protein kinase C zeta(PKC zeta), VCAM-1, and IL-6 levels as well as decreased stromal cell support of MM cell growth. Similarly, marrow stromal cells from p62(-/-) mice produced much lower levels of IL-6, tumor necrosis factor-alpha (TNF-alpha), and receptor activator of NF-kappa B ligand (RANKL) and supported MM cell growth and osteoclast formation to a much lower extent than normal cells. Thus, p62 is an attractive therapeutic target for MM. (Blood. 2009;113:4894-4902) C1 [Hiruma, Yuko; Honjo, Tadashi; Roodman, G. David; Kurihara, Noriyoshi] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Jelinek, Diane F.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Windle, Jolene J.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Shin, Jaekyoon] Sungkyunkwan Univ, Sch Med, Suwon, South Korea. RP Kurihara, N (reprint author), VA Pittsburgh Healthcare Syst, Res & Dev 151U, Univ Dr C,Rm 2E-115, Pittsburgh, PA 15240 USA. EM Kuriharan@upmc.edu OI Windle, Jolene/0000-0001-6690-385X FU Multiple Myeloma Research Foundation grant; VA Merit Review grant; National Institutes of Health [R01 AR053537-02] FX We thank Dr Deborah Galson for reading the manuscript and her constructive suggestions.; This work was supported by a Multiple Myeloma Research Foundation grant, a VA Merit Review grant, and by research funds from the National Institutes of Health (NIH; grant no. R01 AR053537-02). The materials are the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Research and Development. NR 37 TC 26 Z9 26 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAY 14 PY 2009 VL 113 IS 20 BP 4894 EP 4902 DI 10.1182/blood-2008-08-173948 PG 9 WC Hematology SC Hematology GA 445ZT UT WOS:000266090700014 PM 19282458 ER PT J AU Kelly, JX Smilkstein, MJ Brun, R Wittlin, S Cooper, RA Lane, KD Janowsky, A Johnson, RA Dodean, RA Winter, R Hinrichs, DJ Riscoe, MK AF Kelly, Jane X. Smilkstein, Martin J. Brun, Reto Wittlin, Sergio Cooper, Roland A. Lane, Kristin D. Janowsky, Aaron Johnson, Robert A. Dodean, Rozalia A. Winter, Rolf Hinrichs, David J. Riscoe, Michael K. TI Discovery of dual function acridones as a new antimalarial chemotype SO NATURE LA English DT Article ID CHLOROQUINE RESISTANCE TRANSPORTER; TRANSMEMBRANE PROTEIN PFCRT; PLASMODIUM-FALCIPARUM; DIGESTIVE VACUOLE; BETA-HEMATIN; IN-VITRO; DRUG; MALARIA; MUTATIONS; MECHANISM AB Preventing and delaying the emergence of drug resistance is an essential goal of antimalarial drug development. Monotherapy and highly mutable drug targets have each facilitated resistance, and both are undesirable in effective long-term strategies against multi-drug-resistant malaria. Haem remains an immutable and vulnerable target, because it is not parasite-encoded and its detoxification during haemoglobin degradation, critical to parasite survival, can be subverted by drug-haem interaction as in the case of quinolines and many other drugs(1-5). Here we describe a new antimalarial chemotype that combines the haem-targeting character of acridones, together with a chemosensitizing component that counteracts resistance to quinoline antimalarial drugs. Beyond the essential intrinsic characteristics common to deserving candidate antimalarials ( high potency in vitro against pan-sensitive and multi-drug-resistant Plasmodium falciparum, efficacy and safety in vivo after oral administration, inexpensive synthesis and favourable physicochemical properties), our initial lead, T3.5 (3-chloro-6-(2-diethylamino-ethoxy)-10-(2-diethylamino-ethyl)acridone), demonstrates unique synergistic properties. In addition to 'verapamil-like' chemosensitization to chloroquine and amodiaquine against quinoline-resistant parasites, T3.5 also results in an apparently mechanistically distinct synergism with quinine and with piperaquine. This synergy, evident in both quinoline-sensitive and quinoline-resistant parasites, has been demonstrated both in vitro and in vivo. In summary, this innovative acridone design merges intrinsic potency and resistance-counteracting functions in one molecule, and represents a new strategy to expand, enhance and sustain effective antimalarial drug combinations. C1 [Kelly, Jane X.; Smilkstein, Martin J.; Janowsky, Aaron; Johnson, Robert A.; Dodean, Rozalia A.; Winter, Rolf; Hinrichs, David J.; Riscoe, Michael K.] Portland VA Med Ctr, Portland, OR 97239 USA. [Kelly, Jane X.; Smilkstein, Martin J.; Dodean, Rozalia A.; Winter, Rolf; Riscoe, Michael K.] Portland State Univ, Dept Chem, Portland, OR 97201 USA. [Smilkstein, Martin J.; Janowsky, Aaron; Johnson, Robert A.; Hinrichs, David J.; Riscoe, Michael K.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Brun, Reto; Wittlin, Sergio] Swiss Trop Inst, CH-4002 Basel, Switzerland. [Cooper, Roland A.; Lane, Kristin D.] Old Dominion Univ, Dept Biol Sci, Norfolk, VA 23529 USA. RP Kelly, JX (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. EM kellyja@ohsu.edu; riscoem@ohsu.edu FU Merit Review Program of the Department of Veterans Affairs FX We thank D. Kyle for the gift of P. falciparum parasite Tm90-C2B, and the Malaria Research and Reference Resource Center for supplying P. falciparum parasites D6, Dd2 and 7G8. We thank A. P. Waters and C. J. Janse for the donation of GFP- labelled P. berghei strain ANKA. We thank L. Jones- Brando and R. Yolken for the cytotoxicity (HFF) data. We are grateful to A. Cornea for the confocal imaging. We thank K. Liebman, C. Hudson, S. Burgess and D. Peyton for compound characterization. We acknowledge financial support from the Merit Review Program of the Department of Veterans Affairs. United States patent applications have been filed by the US Department of Veterans Affairs to protect the intellectual property described in this report. NR 28 TC 104 Z9 106 U1 2 U2 27 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD MAY 14 PY 2009 VL 459 IS 7244 BP 270 EP 273 DI 10.1038/nature07937 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 445FR UT WOS:000266036100045 PM 19357645 ER PT J AU Karch, CM Prudencio, M Winkler, DD Hart, PJ Borchelt, DR AF Karch, Celeste M. Prudencio, Mercedes Winkler, Duane D. Hart, P. John Borchelt, David R. TI Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE neurodegenerative disease; protein misfolding ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOLECULAR-WEIGHT COMPLEXES; SUPEROXIDE-DISMUTASE 1; MOUSE MODEL; TRANSGENIC MICE; SPINAL-CORDS; DISEASE; COPPER; SUPEROXIDE-DISMUTASE-1; MUTATIONS AB Transgenic mice that model familial (f) ALS, caused by mutations in superoxide dismutase (SOD) 1, develop paralysis with pathology that includes the accumulation of aggregated forms of the mutant protein. Using a highly sensitive detergent extraction assay, we traced the appearance and abundance of detergent-insoluble and disulfide cross-linked aggregates of SOD1 throughout the disease course of SOD1-fALS mice (G93A, G37R, and H46R/H48Q). We demonstrate that the accumulation of disulfide cross-linked, detergent-insoluble, aggregates of mutant SOD1 occurs primarily in the later stages of the disease, concurrent with the appearance of rapidly progressing symptoms. We find no evidence for a model in which aberrant intermolecular disulfide bonding has an important role in promoting the aggregation of mutant SOD1, instead, such cross-linking appears to be a secondary event. Also, using both cell culture and mouse models, we find that mutant protein lacking the normal intramolecular disulfide bond is a major component of the insoluble SOD1 aggregates. Overall, our findings suggest a model in which soluble forms of mutant SOD1 initiate disease with larger aggregates implicated only in rapidly progressing events in the final stages of disease. Within the final stages of disease, abnormalities in the oxidation of a normal intramolecular disulfide bond in mutant SOD1 facilitate the aggregation of mutant protein. C1 [Karch, Celeste M.; Prudencio, Mercedes; Borchelt, David R.] Univ Florida, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA. [Winkler, Duane D.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Winkler, Duane D.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Borchelt, DR (reprint author), Univ Florida, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA. EM borchelt@mbi.ufl.edu OI Karch, Celeste/0000-0002-6854-5547; Prudencio, Mercedes/0000-0002-4894-4858 FU National Institutes of Health [P01 NS049134] FX We thank Hilda Brown (University of Florida) for advice and assistance in generating the SOD1 expression constructs, Susan Fromholt (University of Florida) for assistance in genotyping the mice, and our colleagues for thoughtful discussions. This work was supported by National Institutes of Health Grant P01 NS049134 (to P. J. H. and D. R. B.). NR 33 TC 93 Z9 94 U1 0 U2 6 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 12 PY 2009 VL 106 IS 19 BP 7774 EP 7779 DI 10.1073/pnas.0902505106 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 447RG UT WOS:000266208900020 PM 19416874 ER PT J AU Naik, AD Petersen, LA AF Naik, Aanand D. Petersen, Laura A. TI The Neglected Purpose of Comparative-Effectiveness Research. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Naik, Aanand D.; Petersen, Laura A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Petersen, Laura A.] Baylor Coll Med, John M Eisenberg Ctr Clin Decis & Commun Sci, Houston, TX 77030 USA. [Naik, Aanand D.; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Naik, AD (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. FU NIA NIH HHS [K23 AG027144-04, K23 AG027144] NR 5 TC 53 Z9 54 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 7 PY 2009 VL 360 IS 19 BP 1929 EP 1931 DI 10.1056/NEJMp0902195 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 441QN UT WOS:000265784400003 PM 19420362 ER PT J AU Fazel, R Dhaliwal, G Saint, S Nallamothu, BK AF Fazel, Reza Dhaliwal, Gurpreet Saint, Sanjay Nallamothu, Brahmajee K. TI A Red Flag. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; EOSINOPHILIA C1 [Fazel, Reza] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30306 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. [Saint, Sanjay; Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA. [Saint, Sanjay; Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. RP Fazel, R (reprint author), Emory Univ, Sch Med, Div Cardiol, Bldg A,Suite 1-N,1256 Briarcliff Rd NE, Atlanta, GA 30306 USA. EM rfazel@emory.edu NR 11 TC 6 Z9 6 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 7 PY 2009 VL 360 IS 19 BP 2005 EP 2010 DI 10.1056/NEJMcps0802754 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 441QN UT WOS:000265784400012 PM 19420370 ER PT J AU Roodman, GD AF Roodman, G. David TI Osteoclasts Pump Iron SO CELL METABOLISM LA English DT Editorial Material ID DEFICIENCY AB Osteoclasts are the primary cells that resorb bone; they require high energy levels to degrade bone matrix, releasing minerals to maintain calcium homeostasis. Recent work on osteoclast differentiation and activity highlights an important role for mitochondrial biogenesis and explores the role of iron transferrin in generating a positive osteoclastogenic feedback loop. C1 [Roodman, G. David] Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. [Roodman, G. David] Univ Pittsburgh, Dept Med Hematol Oncol, Pittsburgh, PA 15260 USA. RP Roodman, GD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 6 TC 6 Z9 6 U1 1 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 J9 CELL METAB JI Cell Metab. PD MAY 6 PY 2009 VL 9 IS 5 BP 405 EP 406 DI 10.1016/j.cmet.2009.04.005 PG 2 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 442LC UT WOS:000265841700004 PM 19416710 ER PT J AU Kertesz, SG Weiner, SJ AF Kertesz, Stefan G. Weiner, Saul J. TI Housing the Chronically Homeless High Hopes, Complex Realities SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID HEALTH-CARE; ALCOHOL; COHORT C1 [Kertesz, Stefan G.] Univ Alabama, Div Prevent Med, Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35294 USA. [Weiner, Saul J.] Univ Illinois, Vet Affairs Ctr Management Complex Chron Care, Jesse Brown Vet Affairs Med Ctr Med & Pediat, Chicago, IL USA. RP Kertesz, SG (reprint author), Univ Alabama, Div Prevent Med, Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, 1530 3rd Ave S,MT608, Birmingham, AL 35294 USA. EM skertesz@uab.edu OI Kertesz, Stefan/0000-0001-6101-8421 NR 15 TC 34 Z9 34 U1 3 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 6 PY 2009 VL 301 IS 17 BP 1822 EP 1824 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 441AU UT WOS:000265742500036 PM 19417203 ER PT J AU Athappilly, G Pelak, VS AF Athappilly, Geetha Pelak, Victoria S. TI Teaching NeuroImages: Superior segmental optic nerve hypoplasia confirmed by optical coherence tomography SO NEUROLOGY LA English DT Editorial Material C1 [Athappilly, Geetha; Pelak, Victoria S.] Univ Colorado, Sch Med, Dept Ophthalmol, Denver, CO USA. [Pelak, Victoria S.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. [Pelak, Victoria S.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Pelak, VS (reprint author), 12631 E 17th Ave,POB 6511,Mail Stop B185, Aurora, CO 80045 USA. EM Victoria.Pelak@UCHSC.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 5 PY 2009 VL 72 IS 18 BP E91 EP E92 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 441PZ UT WOS:000265782600024 PM 19414718 ER PT J AU Terrell, KM Hustey, FM Hwang, U Gerson, LW Wenger, NS Miller, DK AF Terrell, Kevin M. Hustey, Fredric M. Hwang, Ula Gerson, Lowell W. Wenger, Neil S. Miller, Douglas K. CA SAEM Geriatric Task Force TI Quality Indicators for Geriatric Emergency Care SO ACADEMIC EMERGENCY MEDICINE LA English DT Article DE emergency medical services; emergency service; hospital; geriatrics; health services for the aged; quality indicators; health care; quality of health care ID HIP FRACTURE PATIENTS; DEPARTMENT PATIENTS; ELDERLY EMERGENCY; COGNITIVE IMPAIRMENT; OLDER EMERGENCY; NURSING-HOMES; HEALTH-CARE; ACUTE PAIN; OF-CARE; TRANSITIONAL CARE AB Emergency departments (EDs), similar to other health care environments, are concerned with improving the quality of patient care. Older patients comprise a large, growing, and particularly vulnerable subset of ED users. The project objective was to develop ED-specific quality indicators for older patients to help practitioners identify quality gaps and focus quality improvement efforts. The Society for Academic Emergency Medicine (SAEM) Geriatric Task Force, including members representing the American College of Emergency Physicians (ACEP), selected three conditions where there are quality gaps in the care of older patients: cognitive assessment, pain management, and transitional care in both directions between nursing homes and EDs. For each condition, a content expert created potential quality indicators based on a systematic review of the literature, supplemented with expert opinion when necessary. The original candidate quality indicators were modified in response to evaluation by four groups: the Task Force, the SAEM Geriatric Interest Group, and audiences at the 2007 SAEM Annual Meeting and the 2008 American Geriatrics Society Annual Meeting. The authors offer 6 quality indicators for cognitive assessment, 6 for pain management, and 11 for transitions between nursing homes and EDs. These quality indicators will help researchers and clinicians target quality improvement efforts. The next steps will be to test the feasibility of capturing the quality indicators in existing medical records and to measure the extent to which each quality indicator is successfully met in current emergency practice. C1 [Terrell, Kevin M.] Indiana Univ, Sch Med, Dept Emergency Med, Indianapolis, IN USA. [Terrell, Kevin M.; Miller, Douglas K.] Indiana Univ, Sch Med, Ctr Aging Res, Indianapolis, IN USA. [Terrell, Kevin M.; Miller, Douglas K.] Indiana Univ, Sch Med, Regenstrief Inst, Indianapolis, IN USA. [Hustey, Fredric M.] Case Western Reserve Univ, Dept Emergency Med, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA. [Hwang, Ula] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, Dept Emergency Med, New York, NY USA. [Hwang, Ula] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Gerson, Lowell W.] Northeastern Ohio Univ Coll Med & Pharm, Dept Community Hlth Sci, Akron, OH USA. [Gerson, Lowell W.] Summa Hlth Syst, Dept Emergency Med, Akron, OH USA. [Wenger, Neil S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Terrell, KM (reprint author), Indiana Univ, Sch Med, Dept Emergency Med, Indianapolis, IN USA. EM kterrel@iupui.edu RI Carpenter, Christopher/E-3720-2013 OI Carpenter, Christopher/0000-0002-2603-7157 FU AGS; John A. Hartford Foundation; Atlantic Philanthropies FX This project was funded by an award from the American Geriatrics Society (AGS) as part of the Geriatrics for Specialists Initiative, which is supported by the John A. Hartford Foundation. Drs. Terrell, Hustey, and Hwang are supported by Dennis W. Jahnigen Career Development Awards, which are funded by the AGS, the John A. Hartford Foundation, and Atlantic Philanthropies. This SAEM Geriatric Task Force Report was approved by the SAEM Board of Directors in September 2008. A related commentary appears on page 436. NR 82 TC 63 Z9 64 U1 1 U2 10 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAY PY 2009 VL 16 IS 5 BP 441 EP 449 DI 10.1111/j.1553-2712.2009.00382.x PG 9 WC Emergency Medicine SC Emergency Medicine GA 438IE UT WOS:000265548300012 PM 19344452 ER PT J AU Simon, JA Chen, YH Bent, S AF Simon, Joel A. Chen, Yea-Hung Bent, Stephen TI The relation of alpha-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article; Proceedings Paper CT 5th International Congress on Vegetarian Nutrition CY MAR, 2008 CL Loma Linda Univ, Loma Linda, CA HO Loma Linda Univ ID POLYUNSATURATED FATTY-ACIDS; DIETARY-FAT; UNITED-STATES; FISH CONSUMPTION; PUBLICATION BIAS; ASSOCIATION; SERUM; CARCINOMA; ENERGY; COHORT AB Background: alpha-Linolenic acid (ALA; 18: 3n-3) has been associated inconsistently with an increased risk of prostate cancer. Additional studies have become available since the publication of 2 previous meta-analyses. Objective: The objective was to review the published data on the relation between ALA and prostate cancer. Design: We conducted a systematic review to identify studies that included data on ALA and risk of prostate cancer. Data were pooled from studies that compared the highest ALA quantile with the lowest ALA quantile, and risk estimates were combined by using a random-effects model. Results: The relation between ALA and prostate cancer is inconsistent across studies. We pooled data from 8 case-control and 8 prospective studies. The summary estimate revealed that high ALA dietary intakes or tissue concentrations are weakly associated with prostate cancer risk (relative risk [RR]: 1.20; 95% CI: 1.01, 1.43). When examined by study type (ie, retrospective compared with prospective or dietary ALA compared with tissue concentration) or by decade of publication, only the 6 studies examining blood or tissue ALA concentrations revealed a statistically significant association. With the exception of these studies, there was significant heterogeneity and evidence of publication bias. After adjustment for publication bias, there was no association between ALA and prostate cancer (RR: 0.96; 95% CI: 0.79, 1.17). Conclusions: Studies examining the relation between ALA and prostate cancer have produced inconsistent findings. High ALA intakes or high blood and adipose tissue concentrations of ALA may be associated with a small increased risk of prostate cancer. However, these conclusions are qualified because of the heterogeneity across studies and the likelihood of publication bias. Am J Clin Nutr 2009; 89(suppl): 1558S-64S. C1 [Simon, Joel A.; Bent, Stephen] Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Simon, Joel A.; Bent, Stephen] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Chen, Yea-Hung] Univ Calif San Francisco, Sch Med, Osher Ctr Integrat Med, San Francisco, CA USA. RP Simon, JA (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA. EM joel.simon@ucsf.edu NR 77 TC 60 Z9 62 U1 1 U2 7 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAY 1 PY 2009 VL 89 IS 5 BP S1558 EP S1564 DI 10.3945/ajcn.2009.26736E PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 436EB UT WOS:000265394300044 PM 19321563 ER PT J AU Hachem, C Morgan, R Johnson, M Kuebeler, M El-Serag, H AF Hachem, Christine Morgan, Robert Johnson, Michael Kuebeler, Mark El-Serag, Hashem TI Statins and the Risk of Colorectal Carcinoma: A Nested Case-Control Study in Veterans With Diabetes SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID COENZYME-A REDUCTASE; CANCER-MORTALITY; UNITED-STATES; IN-VITRO; CHOLESTEROL; INHIBITORS; COLON; COHORT; DRUGS; APOPTOSIS AB OBJECTIVES: Experimental data indicate a possible preventive effect for statins in colorectal cancer (CRC). However, the available epidemiological data are conflicting. METHODS: We conducted a nested case-control study of veterans with diabetes in national databases of the Department of Veterans Affairs (VA) and Medicare-linked files. Cases were defined as incident CRC during January 2001-December 2002, sampled on incidence density. VA pharmacy benefits management (PBM) files were used to identify filled prescriptions for statins. Multivariable conditional logistic regression models were used to estimate odds ratios (ORs) after adjusting for potential confounding variables. Stratified analyses were conducted for potential effect modifiers. RESULTS: A total of 6,080 cases and 24,320 controls were examined. The mean age was 74 years, and the majority of patients were Caucasian (88%) and male (99%). Filled prescriptions of statins were recorded less frequently in cases (49%) than in controls (52%; OR: 0.88; 95% confidence interval (95% CI): 0.83-0.93). This inverse association remained significant after adjusting for inflammatory bowel disease, diabetes severity, cholecystectomy, liver disease, filled prescriptions for sulfonylurea, aspirin or NSAID use, or colorectal evaluation. Simvastatin comprised the majority (87%) of statin-filled prescriptions, and the association with risk of CRC with simvastatin was very similar to that of any statin. No significant associations were observed between the risk of CRC and nonstatin cholesterol (OR: 1.02; 95% CI 0.88-1.18) or triglyceride-lowering medications (OR: 0.96; 95% CI: 0.87-1.05). The significant inverse association was limited to Caucasians, patients without history of polyps, patients aged 65 years and older, and patients with colon cancer (excluding rectum). CONCLUSIONS: The use of statins was associated with a small reduction in the risk of colon cancer in patients with diabetes. However, the causal link is not clear. C1 [Hachem, Christine; Johnson, Michael; Kuebeler, Mark; El-Serag, Hashem] Dept Vet Affairs Med Ctr, Hlth Serv Res, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Hachem, Christine; El-Serag, Hashem] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Hachem, Christine] St Louis Univ, Dept Med, St Louis, MO 63103 USA. [Morgan, Robert] Univ Texas Houston, Sch Publ Hlth, Div Mangement Policy & Community Hlth, Houston, TX USA. [Johnson, Michael] Univ Houston, Dept Clin Sci & Adm, Coll Pharm, Houston, TX USA. RP El-Serag, H (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,Room 3A-320, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU Department of Veterans Affairs, Health Services Research and Development Service [HFP 90-020, IIR 02-081]; NIH [K24DK078154-03] FX This research was supported in part by the Department of Veterans Affairs, Health Services Research and Development Service, HFP 90-020 and IIR 02-081 (R. Morgan PI, M. Johnson Co-PI). EI-Serag is supported by NIH grant K24DK078154-03. NR 32 TC 39 Z9 39 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2009 VL 104 IS 5 BP 1241 EP 1248 DI 10.1038/ajg.2009.64 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 447VB UT WOS:000266219000022 PM 19352344 ER PT J AU Gellad, WF Detsky, AS Choudhry, NK AF Gellad, Walid F. Detsky, Allan S. Choudhry, Niteesh K. TI Implications of recent clinical trials on pay-for-performance SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Editorial Material ID HEALTH-CARE; VASCULAR EVENTS; GLUCOSE CONTROL; QUALITY; RISK; OUTCOMES; TELMISARTAN; MANAGEMENT; RAMIPRIL; POINT C1 [Gellad, Walid F.] RAND Hlth, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON, Canada. [Detsky, Allan S.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Choudhry, Niteesh K.] Harvard Univ, Sch Med, Boston, MA USA. [Choudhry, Niteesh K.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. RP Gellad, WF (reprint author), RAND Hlth, 4570 5 Ave,Suite 600, Pittsburgh, PA 15213 USA. EM wgellad@rand.org NR 32 TC 5 Z9 6 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD MAY 1 PY 2009 VL 66 IS 9 BP 864 EP 867 DI 10.2146/ajhp080577 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 437RD UT WOS:000265503700019 PM 19386951 ER PT J AU Heckbert, SR Wiggins, KL Glazer, NL Dublin, S Psaty, BM Smith, NL Longstreth, WT Lumley, T AF Heckbert, Susan R. Wiggins, Kerri L. Glazer, Nicole L. Dublin, Sascha Psaty, Bruce M. Smith, Nicholas L. Longstreth, W. T., Jr. Lumley, Thomas TI Antihypertensive Treatment With ACE Inhibitors or beta-Blockers and Risk of Incident Atrial Fibrillation in a General Hypertensive Population SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article ID CONVERTING ENZYME-INHIBITORS; II RECEPTOR BLOCKADE; RANDOMIZED-TRIAL; PREVENTION; ONSET; METAANALYSIS; PREVALENCE; STROKE; MORBIDITY; MORTALITY AB BACKGROUND Secondary analyses of clinical trial data suggest that, compared with other agents, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with lower risk of incident atrial fibrillation (AF) in patients with heart failure, but data from the hypertension trials have been inconsistent. Information is scant about the association of beta-blocker use with AF risk in hypertensive patients without heart failure. METHODS We conducted a population-based case-control study to determine whether anti hypertensive treatment with ACE inhibitors/ARBs or beta-blockers, compared with diuretics, was associated with the risk of incident AF in a community practice setting. All patients (810 AF cases, 1,512 control subjects) were members of Group Health (GH), an integrated health-care delivery system, were pharmacologically treated for hypertension, and did not have heart failure. Medical records were reviewed to confirm the diagnosis of incident AF and to collect information on medical conditions and health behaviors. Information on anti hypertensive medications was obtained from a pharmacy database. RESULTS Single-drug users of an ACE inhibitor/ARB had a lower risk of incident AF compared with single-drug users of a diuretic (adjusted odds ratio 0.63, 95% confidence interval 0.44-0.91). Single-drug use of beta-blockers was not significantly associated with lower AF risk (odds ratio 1.05, 95% confidence interval 0.73-1.52), and also none of the most commonly used two-drug regimens was significantly associated with AF risk, in comparison with single-drug use of diuretic. CONCLUSIONS In a general hypertensive population without heart failure, single-drug use of ACE inhibitors/ARBs was associated with lower AF risk. C1 [Heckbert, Susan R.; Wiggins, Kerri L.; Glazer, Nicole L.; Psaty, Bruce M.; Smith, Nicholas L.; Longstreth, W. T., Jr.; Lumley, Thomas] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Heckbert, Susan R.; Dublin, Sascha; Psaty, Bruce M.; Smith, Nicholas L.; Longstreth, W. T., Jr.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Heckbert, Susan R.; Dublin, Sascha; Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. [Wiggins, Kerri L.; Glazer, Nicole L.; Psaty, Bruce M.; Longstreth, W. T., Jr.] Univ Washington, Dept Med, Seattle, WA USA. [Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Lumley, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Heckbert, SR (reprint author), Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. EM heckbert@u.washington.edu RI CPRD, CPRD/B-9594-2017 FU National Heart, Lung and Blood Institute, Bethesda, MD [HL068986, HL043201, HL073410, HL068639]; National Institute on Aging [AG028954] FX This study was supported by grants HL068986, HL043201, HL073410, and HL068639 from the National Heart, Lung and Blood Institute, Bethesda, MD. S.D. was supported by grant AG028954 from the National Institute on Aging. NR 25 TC 32 Z9 34 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAY PY 2009 VL 22 IS 5 BP 538 EP 544 DI 10.1038/ajh.2009.33 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 435HP UT WOS:000265335100017 PM 19265792 ER PT J AU Rogers, AM Shlipak, MG AF Rogers, Adam M. Shlipak, Michael G. TI C-Reactive Protein, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us? SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID CORONARY-HEART-DISEASE; CHOLESTEROL LEVELS; RANDOMIZED-TRIAL; MEN; PRAVASTATIN; PREVENTION; EVENTS; WOMEN; INFLAMMATION; THERAPY C1 [Rogers, Adam M.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Shlipak, MG (reprint author), VA Med Ctr 111A1, Gen Internal Med Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsj.edu NR 11 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2009 VL 53 IS 5 BP 737 EP 740 DI 10.1053/j.ajkd.2009.03.003 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 443PY UT WOS:000265923500005 PM 19393472 ER PT J AU Slatore, CG Bryson, CL Au, DH AF Slatore, Christopher G. Bryson, Chris L. Au, David H. TI The Association of Inhaled Corticosteroid Use with Serum Glucose Concentration in a Large Cohort SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; DIABETES-MELLITUS; LUNG HEALTH; VENTILATORY CAPACITY; RISK; FRACTURE; COPD; TRIAMCINOLONE; ASTHMA; ADULTS AB BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in the treatment of obstructive lung disease. ICSs have been shown to be systemically absorbed. The association between ICS and serum glucose concentration is unknown. METHODS: To explore the association of ICS dosing with serum glucose concentration, we used a prospective cohort study of US veterans enrolled in 7 primary care clinics between December 1996 and May 2001 with 1 or more glucose measurements while at least 80% adherent to ICS dosing. The association between ICS dose from pharmacy records standardized to daily triamcinolone equivalents and serum glucose concentration was examined with generalized estimating equations controlling for confounders, including systemic corticosteroid use. RESULTS: Of the 1698 subjects who met inclusion criteria, 19% had self-reported diabetes. The mean daily dose of ICS in triamcinolone equivalents was 621 mu g (standard deviation 555) and 610 mu g (standard deviation 553) for subjects with and without diabetes, respectively. After controlling for systemic corticosteroid use and other potential confounders, no association between ICS and serum glucose was found for subjects without diabetes. However, among subjects with self-reported diabetes, every additional 100 mu g of ICS dose was associated with an increased glucose concentration of 1.82 mg/dL (P value .007; 95% confidence interval [CI], 0.49-3.15). Subjects prescribed antiglycemic medications had an increase in serum glucose of 2.65 mg/dL (P value .003; 95% CI, 0.88-4.43) for every additional 100 mu g ICS dose. CONCLUSION: Among diabetic patients, ICS use is associated with an increased serum glucose concentration in a dose-response manner. (C) 2009 Elsevier Inc. All rights reserved. The American Journal of Medicine (2009) 122, 472-478 C1 [Slatore, Christopher G.; Bryson, Chris L.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Slatore, Christopher G.; Bryson, Chris L.; Au, David H.] Univ Washington, Dept Med, Seattle, WA USA. RP Slatore, CG (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM cslatore@u.washington.edu OI Slatore, Christopher/0000-0003-0958-8122 NR 43 TC 30 Z9 32 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAY PY 2009 VL 122 IS 5 BP 472 EP 478 DI 10.1016/j.amjmed.2008.09.048 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 433XB UT WOS:000265238000015 PM 19375557 ER PT J AU Markland, AD Richter, HE Burgio, KL Bragg, C Hernandez, AL Subak, LL AF Markland, Alayne D. Richter, Holly E. Burgio, Kathryn L. Bragg, Charlotte Hernandez, Alexandra L. Subak, Leslee L. TI Fecal incontinence in obese women with urinary incontinence: prevalence and role of dietary fiber intake SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the American-Urogynecologic-Society CY SEP 04-06, 2008 CL Chicago, IL SP Amer Urogynecol Soc DE diet; fecal incontinence; female; food frequency questionnaire; obesity; stress incontinence; urge incontinence; urinary incontinence; weight loss ID FOOD-FREQUENCY QUESTIONNAIRE; PELVIC FLOOR DISORDERS; WEIGHT-LOSS SURGERY; QUALITY-OF-LIFE; ANAL INCONTINENCE; SEVERITY INDEX; UNITED-STATES; US WOMEN; COMMUNITY; HEALTH AB OBJECTIVE: This study estimates the prevalence of fecal incontinence (FI) in overweight and obese women with urinary incontinence and compares dietary intake in women with and without FI. STUDY DESIGN: A total of 36 incontinent and overweight women in the Program to Reduce Incontinence by Diet and Exercise clinical trial were included. FI was defined as monthly or greater loss of mucus, liquid, or solid stool. Dietary intake was quantified using the Block Food Frequency Questionnaire. RESULTS: Women had a mean (+/- SD) age of 53 +/- 10 years, body mass index of 36 +/- 6 kg/m(2), and 19% were African American. Prevalence of FI was 16% (n = 55). In multivariable analyses, FI was independently associated with low fiber intake, higher depressive symptoms, and increased urinary tract symptoms (all P < .05). CONCLUSION: Overweight and obese women report a high prevalence of monthly FI associated with low dietary fiber intake. Increasing dietary fiber may be a treatment for FI. C1 [Markland, Alayne D.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham Vet Affairs Med Ctr,Sch Med, Birmingham, AL 35233 USA. [Markland, Alayne D.; Burgio, Kathryn L.] Birmingham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA. [Richter, Holly E.] Univ Alabama, Sch Med, Div Womens Pelv Med & Reconstruct Surg, Dept Obstet & Gynecol, Birmingham, AL 35233 USA. [Bragg, Charlotte] Univ Alabama, Sch Med, Dept Prevent Med, Birmingham, AL 35233 USA. [Subak, Leslee L.] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Hernandez, Alexandra L.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. [Subak, Leslee L.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Subak, Leslee L.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. RP Markland, AD (reprint author), Univ Alabama, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham Vet Affairs Med Ctr,Sch Med, GRECC 11-G,Room 8220,700 S 19 St, Birmingham, AL 35233 USA. EM amarkland@aging.uab.edu FU NIDDK NIH HHS [K24 DK080775, U01 DK067860, U01 DK067860-05S1, U01 DK067861, U01 DK067862] NR 37 TC 1 Z9 1 U1 1 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAY PY 2009 VL 200 IS 5 AR 566.e1 DI 10.1016/j.ajog.2008.11.019 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 434CW UT WOS:000265253800038 PM 19136088 ER PT J AU Gourcerol, G Wang, L Adelson, DW Larauche, M Tache, Y Million, M AF Gourcerol, G. Wang, L. Adelson, D. W. Larauche, M. Tache, Y. Million, M. TI Cholinergic giant migrating contractions in conscious mouse colon assessed by using a novel noninvasive solid-state manometry method: modulation by stressors SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE colon; mice; giant migrating contractions; manometry; stress; corticotropin releasing factor-overexpressing ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; WATER-AVOIDANCE STRESS; MOTOR-ACTIVITY; MYENTERIC NEURONS; NITRIC-OXIDE; MYOELECTRICAL ACTIVITY; NITRERGIC REGULATION; POSTOPERATIVE ILEUS; RECEPTOR SUBTYPE-1 AB Gourcerol G, Wang L, Adelson DW, Larauche M, Tache Y, Million M. Cholinergic giant migrating contractions in conscious mouse colon assessed by using a novel noninvasive solid-state manometry method: modulation by stressors. Am J Physiol Gastrointest Liver Physiol 296: G992-G1002, 2009. First published March 19, 2009; doi:10.1152/ajpgi.90436.2008.-There is a glaring lack of knowledge on mouse colonic motility in vivo, primarily due to unavailability of adequate recording methods. Using a noninvasive miniature catheter pressure transducer inserted into the distal colon, we assessed changes in colonic motility in conscious mice induced by various acute or chronic stressors and determined the neurotransmitters mediating these changes. Mice exposed to restraint stress (RS) for 60 min displayed distal colonic phasic contractions including high-amplitude giant migrating contractions (GMCs), which had peak amplitudes >25 mmHg and occurred at a rate of 15-25 h (1) of which over 50% were aborally propagative. Responses during the first 20-min of RS were characterized by high-frequency and high-amplitude contractions that were correlated with defecation. RS-induced GMCs and fecal pellet output were blocked by atropine (0.5 mg/kg ip) or the corticotrophin releasing factor (CRF) receptor antagonist astressin-B (100 mu g/kg ip). RS activated colonic myenteric neurons as shown by Fos immunoreactivity. In mice previously exposed to repeated RS (60 min/day, 14 days), or in transgenic mice that overexpress CRF, the duration of stimulation of phasic colonic contractions was significantly shorter (10 vs. 20 min). In contrast to RS, abdominal surgery abolished colonic contractions including GMCs. These findings provide the first evidence for the presence of frequent cholinergic-dependent GMCs in the distal colon of conscious mice and their modulation by acute and chronic stressors. Noninvasive colonic manometry opens new venues to investigate colonic motor function in genetically modified mice relevant to diseases that involve colonic motility alterations. C1 [Million, M.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. RP Million, M (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, CURE Bldg 115,Rm 118B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmulaget@ucla.edu OI Larauche, Muriel/0000-0003-3320-3675; Adelson, David/0000-0002-4623-6030 FU National Institute of Diabetes and Digestive and Kidney Diseases [R21 DK-068155, RO1 DK078676, DK-57238]; Veterans Affairs Career Scientist Award; Veterans Affairs Merit Award; French Foreign Office; French Society of Gastroenterology FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants R21 DK-068155 and RO1 DK078676 (M. Million), DK-57238; Veterans Affairs Career Scientist Award and Veterans Affairs Merit Award (Y. Tache), the French Foreign Office (Egide program) and the French Society of Gastroenterology (S.N.F.G.E.) (G. Gourcerol). NR 63 TC 16 Z9 16 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD MAY PY 2009 VL 296 IS 5 BP G992 EP G1002 DI 10.1152/ajpgi.90436.2008 PG 11 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 451EG UT WOS:000266452900003 PM 19299579 ER PT J AU Goldman, RK Azar, AS Mulvaney, JM Hinojosa-Laborde, C Haywood, JR Brooks, VL AF Goldman, Robert K. Azar, Afaf S. Mulvaney, Julia M. Hinojosa-Laborde, Carmen Haywood, Joseph R. Brooks, Virginia L. TI Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE renal sympathetic nerve activity; ovariectomy; diurnal; telemetry ID HORMONE REPLACEMENT THERAPY; AMBULATORY BLOOD-PRESSURE; NITRIC-OXIDE SYNTHASE; POSTMENOPAUSAL WOMEN; HEART-RATE; OVARIECTOMIZED RATS; MENSTRUAL-CYCLE; FEMALE RATS; AUTONOMIC FUNCTION; GENDER-DIFFERENCES AB Goldman RK, Azar AS, Mulvaney JM, Hinojosa-Laborde C, Haywood JR, Brooks VL. Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids. Am J Physiol Regul Integr Comp Physiol 296: R1419-R1426, 2009. First published March 4, 2009; doi:10.1152/ajpregu.91030.2008.- Baroreflex sensitivity (BRS) increases in women during the luteal phase of the menstrual cycle, when gonadal hormones are elevated, but whether a similar cycle-dependent variation in BRS occurs in rats is unknown. In addition, whether cyclic BRS changes depend on gonadal steroids has not been previously investigated. To test these hypotheses, BRS was determined in cycling female rats using two approaches: 1) baroreflex control of renal sympathetic nerve activity (RSNA) in anesthetized rats; 2) cardiovagal spontaneous BRS (sBRS) in conscious rats instrumented for continuous telemetric measurements of mean arterial pressure ( MAP) and heart rate (HR). MAP, HR, and sBRS were also measured in rats 2-3 and 5-6 wk following ovariectomy (OVX), to eliminate gonadal steroids. In anesthetized rats, RSNA BRS gain was increased ( P < 0.01) during proestrus (-4.8 +/- 0.5% control/mmHg) compared with diestrus/estrus (-2.8 +/- 0.3% control/mmHg). Similarly, a proestrous peak in sBRS was observed in conscious rats (1.66 +/- 0.07 ms/mmHg, proestrus; 1.48 +/- 0.06 ms/mmHg, diestrus/estrus; P < 0.001). OVX eliminated estrous cycle-induced variation in sBRS. In addition, OVX reduced (P < 0.05) diurnal variations in MAP (5.9 +/- 0.3 vs. 3.9 +/- 0.5 mmHg) and HR [54 +/- 4 vs. 39 +/- 3 beats per minute (bpm)], and abolished diurnal variations in sBRS. Finally, while MAP, HR, and sBRS were decreased 2 - 3 wk following OVX, similar to 3 wk later, MAP and sBRS increased, and HR decreased further. No changes in MAP, HR, or sBRS were seen with time in sham OVX controls. In summary, RSNA and cardiovagal sBRS vary during the rat estrous cycle, and this variation is abolished by OVX. We conclude that sex steroid hormones are required for both cyclic and diurnal changes in BRS in rats. C1 [Azar, Afaf S.; Mulvaney, Julia M.; Brooks, Virginia L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Goldman, Robert K.] Portland VA Med Ctr, Dept Surg, Portland, OR USA. [Hinojosa-Laborde, Carmen] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesiol, San Antonio, TX 78229 USA. [Haywood, Joseph R.] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA. RP Brooks, VL (reprint author), Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. EM brooksv@ohsu.edu FU National Institutes of Health [HL-088552, HL-03153]; Medical Research Foundation; Collins Foundation; American Heart Association FX This work was supported, in part, by funding from the Medical Research Foundation ( to R. K. Goldman and V. L. Brooks), the Collins Foundation ( to R. K. Goldman), the American Heart Association ( to V. L. Brooks), and National Institutes of Health Grants HL-088552 ( to V. L. Brooks) and HL-03153 ( to C. Hinajosa-Laborde). NR 58 TC 27 Z9 27 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD MAY PY 2009 VL 296 IS 5 BP R1419 EP R1426 DI 10.1152/ajpregu.91030.2008 PG 8 WC Physiology SC Physiology GA 448EW UT WOS:000266246900016 PM 19261912 ER PT J AU Goodman, M Hazlett, EA New, AS Koenigsberg, HW Siever, L AF Goodman, Marianne Hazlett, Erin A. New, Antonia S. Koenigsberg, Harold W. Siever, Larry TI Quieting the Affective Storm of Borderline Personality Disorder SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID AFFECTIVE INSTABILITY; IMPULSIVITY; STARTLE C1 [Goodman, Marianne] James J Peters VA Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, New York, NY USA. RP Goodman, M (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Marianne.goodman@va.gov FU NIMH NIH HHS [MH-073911, MH-067918] NR 14 TC 6 Z9 6 U1 1 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAY PY 2009 VL 166 IS 5 BP 522 EP 528 DI 10.1176/appi.ajp.2009.08121836 PG 7 WC Psychiatry SC Psychiatry GA 439YA UT WOS:000265662500006 PM 19411378 ER PT J AU Zheng, L Mack, WJ Dagerman, KS Hsiao, JK Lebowitz, BD Lyketsos, CG Stroup, TS Sultzer, DL Tariot, PN Vigen, C Schneider, LS AF Zheng, Ling Mack, Wendy J. Dagerman, Karen S. Hsiao, John K. Lebowitz, Barry D. Lyketsos, Constantine G. Stroup, T. Scott Sultzer, David L. Tariot, Pierre N. Vigen, Cheryl Schneider, Lon S. TI Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT International Conference on Alzheimers Disease CY JUL 26-31, 2008 CL Chicago, IL ID PLACEBO-CONTROLLED TRIALS; DOUBLE-BLIND; BEHAVIORAL DISTURBANCES; CARDIOVASCULAR-DISEASE; CLINICAL-TRIAL; DEMENTIA; PSYCHOSIS; RISPERIDONE; OLANZAPINE; SCHIZOPHRENIA AB Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects. Method: The authors assessed 186 male and 235 female Alzheimer's disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) for changes in weight, waist circumference, blood pressure, fasting glucose, and lipids in relation to duration of second-generation antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week trial, using logistic regression and mixed-effects models. Results: Women showed significant weight gain (0.14 lb/week of use) while change was nonsignificant in men. Clinically significant weight gain (i.e., >= 7% of body weight) was seen among patients with antipsychotic use <= 12 weeks (odds ratio [OR]=1.56, 95% CI=0.53 to 4.58), between 12 and 24 weeks (OR=2.89, 95% CI=0.97 to 8.64), and >24 weeks (OR= 3.38, 95% CI=1.24 to 9.23) relative to patients who did not use antipsychotics during the trial. Olanzapine and quetiapine treatments were significantly associated with weight gain (0.12 and 0.14 lb/week, respectively). In addition, olanzapine was significantly associated with decreases in HDL cholesterol (-0.19 mg/dl/week) and increased girth (0.07 inches/week) relative to the placebo group. No treatment effects were noted for changes in blood pressure, glucose, and triglycerides. Conclusion: Second-generation antipsychotic use was associated with weight gain in women, with olanzapine and quetiapine in particular, and with unfavorable change in HDL cholesterol and girth with olanzapine. The potential consequences of these effects suggest that patients with Alzheimer's disease treated with second-generation antipsychotics should be monitored closely. C1 Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. Univ Calif San Diego, Sch Med, Div Geriatr Psychiat, La Jolla, CA 92093 USA. NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA. Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD USA. Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. VA Greater Angeles Healthcare Syst, Gero Neuropsychiat Div, Los Angeles, CA USA. Banner Alzheimers Inst, Phoenix, AZ USA. RP Schneider, LS (reprint author), 1510 San Pablo St, Los Angeles, CA 90033 USA. EM lschneid@usc.edu RI Stroup, Thomas/F-9188-2014 OI Stroup, Thomas/0000-0002-3123-0672 FU NIMH NIH HHS [N01 MH-9001, N01 MH90001] NR 29 TC 37 Z9 39 U1 1 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAY PY 2009 VL 166 IS 5 BP 583 EP 590 DI 10.1176/appi.ajp.2008.08081218 PG 8 WC Psychiatry SC Psychiatry GA 439YA UT WOS:000265662500013 PM 19369318 ER PT J AU Copeland, LA Miller, AL Welsh, DE McCarthy, JF Zeber, JE Kilbourne, AM AF Copeland, Laurel A. Miller, Alexander L. Welsh, Deborah E. McCarthy, John F. Zeber, John E. Kilbourne, Amy M. TI Clinical and Demographic Factors Associated With Homelessness and Incarceration Among VA Patients With Bipolar Disorder SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SERIOUS MENTAL-ILLNESS; JAIL DIVERSION; THERAPEUTIC ALLIANCE; MEDICATION ADHERENCE; TREATMENT RETENTION; HEALTH-SERVICES; SUBSTANCE-ABUSE; VETERANS; POPULATION; CLIENTS AB Objectives. We assessed the association between homelessness and incarceration in Veterans Affairs patients with bipolar disorder. Methods. We used logistic regression to model each participant's risk of incarceration or homelessness after we controlled for known risk factors. Results. Of 435 participants, 12% reported recent homelessness (within the past month), and 55% reported lifetime homelessness. Recent and lifetime incarceration rates were 2% and 55%, respectively. In multivariate models, current medication adherence (based on a 5-point scale) was independently associated with a lower risk of lifetime homelessness (odds ratio [OR]=0.80 per point, range 0-4; 95% confidence interval [CI]=0.66, 0.96), and lifetime incarceration increased the risk of lifetime homelessness (OR=4.4; 95% CI=2.8, 6.9). Recent homelessness was associated with recent incarceration (OR=26.4; 95% CI=5.2, 133.4). Lifetime incarceration was associated with current substance use (OR=2.6; 95% CI=2.7, 6.7) after control for lifetime homelessness (OR=4.2; 95% CI=2.7, 6.7). Conclusions. Recent and lifetime incarceration and homelessness were strongly associated with each other. Potentially avoidable or treatable correlates included current medication nonadherence and substance use. Programs that better coordinate psychiatric and drug treatment with housing programs may reduce the cycle of incarceration, homelessness, and treatment disruption within this vulnerable patient population. (Am J Public Health. 2009;99:871-877. doi:10. 2105/AJ PH.2008.149989) C1 [Copeland, Laurel A.; Miller, Alexander L.; Zeber, John E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Welsh, Deborah E.; McCarthy, John F.; Kilbourne, Amy M.] Dept Vet Affairs, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Copeland, LA (reprint author), S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd Verdict 11C6, San Antonio, TX 78229 USA. EM copelandl@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development (VA HSRD) [VA HSRD IIR 02-283, VA HSRD IIR-05-326]; Merit Review Entry Program [MRP-05-145] FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development (VA HSRD) Service (grant VA HSRD IIR 02-283; principal investigator: A.M. Mlbourne) and the VERDICT Research Program at the South Texas Veterans Health Care System, San Antonio; the University of Texas Health Science Center at San Antonio; and the Serious Mental Illness Treatment Research & Evaluation Center, VA Ann Arbor Healthcare System, Ann Arbor, MI. L.A. Copeland is funded by the Merit Review Entry Program (grant MRP-05-145; from the VA HSRD Service). A. L. Miller and J. E. Zeber are partially supported by the VA HSRD Service (grant VA HSRD IIR-05-326; principal investigator: L.A. Copeland). NR 46 TC 17 Z9 17 U1 2 U2 10 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2009 VL 99 IS 5 BP 871 EP 877 DI 10.2105/AJPH.2008.149989 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 441ZI UT WOS:000265808800021 PM 19299667 ER PT J AU Choi, E Patel, M Batra, P Verma, R Jude, C AF Choi, E. Patel, M. Batra, P. Verma, R. Jude, C. TI Back to Basics: The Language of Signs in Thoracic Radiology SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract CT 109th Annual Meeting of the American-Roentgen-Ray-Society CY APR 27-MAY 01, 2009 CL Boston, MA SP Amer Roentgen Ray Soc C1 [Choi, E.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Batra, P.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Patel, M.; Verma, R.; Jude, C.] Olive View UCLA Med Ctr, Los Angeles, CA USA. EM matilda@pol.net NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2009 VL 192 IS 5 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 436BI UT WOS:000265387200322 ER PT J AU Motamedi, D Modarresi, S Masih, S AF Motamedi, D. Modarresi, S. Masih, S. TI Illustrative Review of Superior Labral Anterior-Posterior Lesions of the Shoulder: Patterns and Pitfalls (CME Credit Available) SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract CT 109th Annual Meeting of the American-Roentgen-Ray-Society CY APR 27-MAY 01, 2009 CL Boston, MA SP Amer Roentgen Ray Soc C1 [Motamedi, D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Modarresi, S.; Masih, S.] Univ Calif Los Angeles, Vet Adm Greater Los Angeles, Los Angeles, CA USA. EM dariamot@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2009 VL 192 IS 5 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 436BI UT WOS:000265387200592 ER PT J AU Rosenthal, P AF Rosenthal, P. TI Paranasal Sinus Disease in Multiple Sclerosis-Possible Links to Periodontal Disease and Parallels to this in Other Autoimmune Diseases (CME Credit Available) SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract CT 109th Annual Meeting of the American-Roentgen-Ray-Society CY APR 27-MAY 01, 2009 CL Boston, MA SP Amer Roentgen Ray Soc C1 [Rosenthal, P.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM peter.rosenthal@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2009 VL 192 IS 5 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 436BI UT WOS:000265387200679 ER PT J AU Narayana, S Jacks, A Robin, DA Poizner, H Zhang, W Franklin, C Liotti, M Vogel, D Fox, PT AF Narayana, Shalini Jacks, Adam Robin, Donald A. Poizner, Howard Zhang, Wei Franklin, Crystal Liotti, Mario Vogel, Deanie Fox, Peter T. TI A Noninvasive Imaging Approach to Understanding Speech Changes Following Deep Brain Stimulation in Parkinson's Disease SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY LA English DT Article DE Parkinson's disease; neuroimaging; deep brain stimulation; transcranial magnetic stimulation ID SUBTHALAMIC NUCLEUS STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; BILATERAL STIMULATION; PALLIDOTOMY SURGERY; NETWORK MODULATION; MOTOR CONTROL; ORAL CONTROL; DYSARTHRIA; DISORDER; LANGUAGE AB Purpose: To explore the use of noninvasive functional imaging and "virtual" lesion techniques to study the neural mechanisms underlying motor speech disorders in Parkinson's disease. Here, we report the use of positron emission tomography (PET) and transcranial magnetic stimulation (TMS) to explain exacerbated speech impairment following subthalamic nucleus deep brain stimulation (STN-DBS) in a patient with Parkinson's disease. Method: Perceptual and acoustic speech measures, as well as cerebral blood flow during speech as measured by PET, were obtained with STN-DBS on and off. TMS was applied to a region in the speech motor network found to be abnormally active during DBS. Speech disruption by TMS was compared both perceptually and acoustically with speech produced with DBS on. Results: Speech production was perceptually inferior and acoustically less contrastive during left STN stimulation compared to no stimulation. Increased neural activity in left dorsal premotor cortex (PMd) was observed during IDBS on. "Virtual" lesioning of this region resulted in speech characterized by decreased speech segment duration, increased pause duration, and decreased intelligibility. Conclusions: This case report provides evidence that impaired speech production accompanying STN-DBS may result from unintended activation of PMd. Clinical application of functional imaging and TMS may lead to optimizing the delivery of STN-DBS to improve outcomes for speech production as well as general motor abilities. C1 [Narayana, Shalini; Jacks, Adam; Robin, Donald A.; Zhang, Wei; Franklin, Crystal; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Robin, Donald A.] Univ Texas San Antonio, Honors Coll, San Antonio, TX USA. [Poizner, Howard] Univ Calif San Diego, Inst Neural Computat, San Diego, CA 92103 USA. [Liotti, Mario] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada. [Fox, Peter T.] S Texas Vet Hlth Care Ctr, San Antonio, TX USA. [Vogel, Deanie] Our Lady Lake Univ, San Antonio, TX USA. RP Narayana, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, 7703 Floyd Curl Dr MSC 6240, San Antonio, TX 78229 USA. EM narayana@uthscsa.edu RI Fox, Peter/B-4725-2010; Robin, Donald/F-2109-2010; Narayana, Shalini/F-3031-2010; Jacks, Adam/I-3644-2013 OI Fox, Peter/0000-0002-0465-2028; Jacks, Adam/0000-0001-6358-2878 FU NIDCD NIH HHS [R01 DC001150, R01 DC001150-17]; NIMH NIH HHS [R01 MH074457, MH60246, R01 MH060246, R01 MH060246-01, R01 MH060246-02, R01 MH060246-03]; NINDS NIH HHS [NS36449, NS43738, R01 NS036449, R01 NS036449-08, R21 NS043738, R21 NS043738-01, R21 NS043738-02, R56 NS036449, R56 NS036449-09A1] NR 84 TC 32 Z9 32 U1 1 U2 5 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1058-0360 J9 AM J SPEECH-LANG PAT JI Am. J. Speech-Lang. Pathol. PD MAY PY 2009 VL 18 IS 2 BP 146 EP 161 DI 10.1044/1058-0360(2008/08-0004) PG 16 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 442UB UT WOS:000265865000005 PM 19029533 ER PT J AU Gore, JL Danovitch, GM Litwin, MS Pham, PTT Singer, JS AF Gore, J. L. Danovitch, G. M. Litwin, M. S. Pham, P-T. T. Singer, J. S. TI Disparities in the Utilization of Live Donor Renal Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Access to transplantation; kidney transplantation; live donor transplantation; racial and ethnic disparities ID LIVING KIDNEY DONATION; AFRICAN-AMERICANS; ORGAN DONATION; UNITED-STATES; RACIAL DISPARITIES; HEALTH RESEARCH; ACCESS; WILLINGNESS; NEPHRECTOMY; EXPERIENCE AB Despite universal payer coverage with Medicare, sociodemographic disparities confound the care of patients with renal failure. We sought to determine whether adults who realize access to kidney transplantation suffer inequities in the utilization of live donor renal transplantation (LDRT). We identified adults undergoing primary renal transplantation in 2004-2006 from the United Network for Organ Sharing (UNOS). We modeled receipt of live versus deceased donor renal transplant on multilevel multivariate models that examined recipient, center and UNOS region-specific covariates. Among 41 090 adult recipients identified, 39% underwent LDRT. On multivariate analysis, older recipients (OR 0.62, 95% CI 0.56-0.68 for 50-59 year-olds vs. 18-39 year-old recipients), those of African American ethnicity (OR 0.54, 95% CI 0.50-0.59 vs. whites) and of lower socioeconomic status (OR 0.72, 95% CI 0.67-0.79 for high school-educated vs. college-educated recipients; OR 0.78, 95% CI 0.71-0.87 for lowest vs. highest income quartile) had lower odds of LDRT. These characteristics accounted for 14.2% of the variation in LDRT, more than recipient clinical variables, transplant center characteristics and UNOS region level variation. We identified significant racial and socioeconomic disparities in the utilization of LDRT. Educational initiatives and dissemination of processes that enable increased utilization of LDRT may address these disparities. C1 [Gore, J. L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Gore, J. L.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Gore, J. L.; Litwin, M. S.; Singer, J. S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Danovitch, G. M.; Pham, P-T. T.] Univ Calif Los Angeles, David Geffen Sch Med, Div Kidney & Pancreas Transplantat, Dept Med, Los Angeles, CA 90095 USA. [Litwin, M. S.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA. RP Gore, JL (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. EM jgore@mednet.ucla.edu OI Gore, John/0000-0002-2847-5062 FU Health Resources and Services Administration [231-00-0115] FX This work was supported in part by Health Resources and Services Administration contract 231-00-0115. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US government. The authors have no disclosures to report. NR 36 TC 65 Z9 65 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2009 VL 9 IS 5 BP 1124 EP 1133 DI 10.1111/j.1600-6143.2009.02620.x PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA 433QZ UT WOS:000265222200019 PM 19422338 ER PT J AU Hamner, MB Faldowski, RA Robert, S Ulmer, HG Horner, MD Lorberbaum, JP AF Hamner, Mark B. Faldowski, Richard A. Robert, Sophie Ulmer, Helen G. Horner, Michael David Lorberbaum, Jeffrey P. TI A preliminary controlled trial of divalproex in posttraumatic stress disorder SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Article DE posttraumatic stress disorder; divalproex; anticonvulsant; mood stabilizer; psychopharmacology ID PLACEBO-CONTROLLED TRIAL; SLEEP QUALITY INDEX; OPEN-LABEL; DOUBLE-BLIND; VALPROATE; TOPIRAMATE; TIAGABINE; EFFICACY; SCALE; CARBAMAZEPINE AB BACKGROUND: Case reports and open trials have r ported beneficial effects of divalproex in tire treatment of posttraumatic stress disorder (PTSD). The objective of this study was to conduct a placebo-controlled study of the efficacy and tolerability of divalproex in chronic PTSD patients. METHODS: Patients were randomized to receive placebo or divalproex. T e primary outcome measure was the Clinician Administered PTSD Scale (CAPS). RESULTS: Of 29 patients randomized, 16 received divalproex and 13 placebo. There were no significant differences between groups in mean change from baseline to end point (last observation carried forward) on the CAPS total score or subscales except for a significant decrease in avoidance/numbing scores with placebo. The only significant difference in secondary outcomes was a greater improvement in Clinical Global Impression Scale-Severity favoring placebo. CONCLUSIONS: Divalproex was not superior to placebo in this study. This could be due to lack of efficacy of divalproex in this population, inadequate sample size to detect differences, or other factors. Further study of divalproex is needed to better clarify the role of this agent in PTSD. C1 [Hamner, Mark B.; Robert, Sophie; Ulmer, Helen G.; Horner, Michael David] Med Univ S Carolina, Dept Psychiat, Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC 29425 USA. [Lorberbaum, Jeffrey P.] Penn State Univ, Milton S Hershey Med Ctr, Dept Psychiat, Hershey, PA 17033 USA. RP Hamner, MB (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM hamnermb@musc.edu FU Abbott Laboratories (investigator-initiated protocol) FX This study was funded by Abbott Laboratories (investigator-initiated protocol) and was conducted at the Ralph H. Johnson VA Medical Center, Charleston, SC. The results were presented in part at the 44th Annual New Clinical Drug Evaluation Unit, June 1-4, 2004; Phoenix, AZ. We are grateful to Charlotte Teneback, MD, Jennifer Mixson, RPh, and Deborah Agbor-Tabi, MPH, for their technical support, and to the veterans who participated in this study. NR 45 TC 20 Z9 20 U1 3 U2 6 PU DOWDEN HEALTH MEDIA PI MONTVALE PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA SN 1040-1237 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD MAY PY 2009 VL 21 IS 2 BP 89 EP 94 PG 6 WC Psychiatry SC Psychiatry GA 496NH UT WOS:000269980700005 PM 19439158 ER PT J AU Hughes, DW Frei, CR Maxwell, PR Green, K Patterson, JE Crawford, GE Lewis, JS AF Hughes, Darrel W. Frei, Christopher R. Maxwell, Pamela R. Green, Kay Patterson, Jan E. Crawford, George E. Lewis, James S., II TI Continuous versus Intermittent Infusion of Oxacillin for Treatment of Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ANTIMICROBIAL THERAPY; MEDICAL PROGRESS; DIAGNOSIS; COMPLICATIONS; MANAGEMENT; CRITERIA; SURGERY AB Infective endocarditis (IE) is the fourth leading cause of life-threatening infection in the United States and imposes significant morbidity and mortality. The American Heart Association guidelines for the diagnosis and treatment of IE do not address continuous-infusion (CI) oxacillin. This retrospective study compares outcomes between CI oxacillin and intermittent-infusion (II) oxacillin in the treatment of IE caused by methicillin-susceptible Staphylococcus aureus (MSSA). A total of 709 medical records were reviewed for inpatients with definitive IE treated between 1 January 2000 and 31 December 2007. Continuous data were analyzed by Student's t test or the Wilcoxon rank sum test. The chi-square test or Fisher's exact test was used to compare nominal data. A multivariate logistic model was constructed. One hundred seven patients met eligibility criteria for inclusion into the study. Seventy-eight patients received CI oxacillin, whereas 28 received II oxacillin. CI and II groups were similar with respect to 30-day mortality (8% versus 10%, P = 0.7) and length of stay (20 versus 25 days, P = 0.4) but differed in 30-day microbiological cure (94% versus 79%, P = 0.03). Sixty-three patients received synergistic gentamicin, whereas 44 did not. The gentamicin and no-gentamicin groups were similar with respect to 30-day mortality (11% versus 4%, P = 0.2) and 30-day microbiological cure (90% versus 89%, P = 0.8); however, times to defervescence (4 versus 2 days, P = 0.02) were significantly different. CI oxacillin is an effective alternative to II oxacillin for the treatment of IE caused by MSSA and may improve microbiological cure. This convenient and pharmacodynamically optimized dosing regimen for oxacillin deserves consideration for patients with IE caused by MSSA. C1 [Hughes, Darrel W.; Maxwell, Pamela R.; Green, Kay; Lewis, James S., II] Univ Hlth Syst, Dept Pharm Serv, San Antonio, TX 78229 USA. [Hughes, Darrel W.; Frei, Christopher R.; Maxwell, Pamela R.; Lewis, James S., II] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Hughes, Darrel W.; Frei, Christopher R.; Maxwell, Pamela R.; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Patterson, Jan E.; Crawford, George E.; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. [Patterson, Jan E.; Crawford, George E.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Lewis, JS (reprint author), Univ Hlth Syst, Dept Pharm Serv, 4502 Med Dr, San Antonio, TX 78229 USA. EM james.lewis@uhs-sa.com NR 25 TC 27 Z9 27 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY 1 PY 2009 VL 53 IS 5 BP 2014 EP 2019 DI 10.1128/AAC.01232-08 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 438AQ UT WOS:000265528700040 PM 19258261 ER PT J AU Thompson, GR Rinaldi, MG Pennick, G Dorsey, SA Patterson, TF Lewis, JS AF Thompson, George R., III Rinaldi, Michael G. Pennick, Gennethel Dorsey, Sheryl A. Patterson, Thomas F. Lewis, James S., II TI Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Letter ID CELL TRANSPLANT RECIPIENTS; VERSUS-HOST-DISEASE; ORAL POSACONAZOLE; PHARMACOKINETICS; PROPHYLAXIS; FLUCONAZOLE; NEUTROPENIA; SAFETY C1 [Thompson, George R., III] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Rinaldi, Michael G.; Pennick, Gennethel; Dorsey, Sheryl A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX 78245 USA. [Lewis, James S., II] Univ Hlth Syst, Dept Pharm, San Antonio, TX 78229 USA. RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. EM james.lewis@uhs-sa.com NR 9 TC 50 Z9 51 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY 1 PY 2009 VL 53 IS 5 BP 2223 EP 2224 DI 10.1128/AAC.00240-09 PG 2 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 438AQ UT WOS:000265528700081 PM 19258264 ER PT J AU Chen, D Chai, JJ Hart, PJ Zhong, GM AF Chen, Ding Chai, Jijie Hart, P. John Zhong, Guangming TI Identifying catalytic residues in CPAF, a Chlamydia-secreted protease SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE Chlamydia; CPAF; Hidden Markov Models; HHPRED; MODELLER; Molecular modeling; Tricorn protease; Catalytic triad; Site-directed mutagenesis; Protein structure prediction ID TRACHOMATIS-INFECTED CELLS; HUMAN-ANTIBODY RESPONSES; CD4(+) T-CELLS; P55 PDZ DOMAIN; MURIDARUM INFECTION; PROTECTIVE IMMUNITY; HOMOLOGY DETECTION; BH3-ONLY PROTEINS; CRYSTAL-STRUCTURE; TRICORN PROTEASE AB A secreted chlamydial protease designated CPAF (Chlamydial Protease/proteasome-like Activity Factor) degrades host proteins, enabling Chlamydia to evade host defenses and replicate. The mechanistic details of CPAF action, however, remain obscure. We used a computational approach to search the protein data bank for structures that are compatible with the CPAF amino acid sequence. The results reveal that CPAF possesses a fold similar to that of the catalytic domains of the tricorn protease from Thermoplasma acidophilum. and that CPAF residues H105, S499, and E558 are structurally analogous to the tricorn protease catalytic triad residues H746. S965, and D1023. Substitution of these putative CPAF catalytic residues blocked CPAF from degrading substrates in vitro, while the wild type and a noncatalytic control mutant of CPAF remained cleavage-competent. Substrate cleavage is also correlated with processing of CPAF into N-terminal (CPAFn) and C-terminal (CPAFc) fragments, suggesting that these putative catalytic residues may also be required for CPAF maturation. (C) 2009 Elsevier Inc. All rights reserved. C1 [Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Chen, Ding; Zhong, Guangming] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Chai, Jijie] Natl Inst Biol Sci, Beijing, Peoples R China. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu; zhongg@uthscsa.edu FU NIAID NIH HHS [R01 AI047997, R01 AI064537-05, R01 AI064537, R01 AI047997-09] NR 49 TC 18 Z9 20 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD MAY 1 PY 2009 VL 485 IS 1 BP 16 EP 23 DI 10.1016/j.abb.2009.01.014 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 441FG UT WOS:000265754100003 PM 19388144 ER PT J AU Boster, A Hreha, S Berger, JR Bao, F Penmesta, R Tselis, A Endress, C Zak, I Perumal, J Caon, C Vazquez, J Tyler, KL Racke, MK Millis, S Khan, O AF Boster, Aaron Hreha, Stephanie Berger, Joseph R. Bao, Fen Penmesta, Ramya Tselis, Alexandros Endress, Christina Zak, Imad Perumal, Jai Caon, Christina Vazquez, Jose Tyler, Kenneth L. Racke, Michael K. Millis, Scott Khan, Omar TI Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis SO ARCHIVES OF NEUROLOGY LA English DT Article ID MAGNETIZATION-TRANSFER RATIO; RHEUMATIC-DISEASES; NATALIZUMAB; PML; PATIENT; LESIONS; VIRUS; AIDS; DEMYELINATION; DIAGNOSIS AB Objective: To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS). Design: Retrospective medical record review. Setting: Two urban teaching hospitals in Detroit, Michigan. Patients: Forty-five confirmed PML cases and 100 patients with RRMS. Main Outcome Measures: Clinical and MRI features distinguishing PML from RRMS. Results: Overall, monosymptomatic presentations were more common in multiple sclerosis (MS) than PML (85% vs 47%; P<.01). However, patients with PML presented more often with hemiparesis (24% vs 5%; P=.001) and altered mentation (19% vs 0%; P<.0001), whereas brainstem (2% vs 18%; P=.007) presentations were more common in patients with RRMS. Spinal cord and optic neuritis presentations were seen in 18% and 33% of patients with RRMS, respectively, but not in patients with PML (P<.0001). Brain MRI scans, available in 35 (78%) PML cases, revealed 7 lesion types. Large, confluent T2-weighted lesions (74% vs 2%; P<.0001) and deep gray matter lesions (31% vs 7%; P<.001) were more frequent in patients with PML than patients with RRMS. Crescentic cerebellar lesions (23% vs 0%; P<.001) were seen only in patients with PML. Gadolinium-enhancing (23%), transcallosal (9%), and periventricular (9%) lesions were noted in patients with PML. Brain magnetization transfer ratio (MTR) was low in both PML and MS lesions. However, normal-appearing brain tissue MTR in PML was higher than normal-appearing brain tissue MTR in RRMS (44.15% vs 41.04%; P=.002), suggesting that PML may be relatively more focal than MS. Conclusions: There appear to be differences between the clinical and MRI characteristics of PML and RRMS, which may help distinguish new MS activity from PML. Magnetization transfer ratio studies may provide additional clues in improving early detection of PML in patients with preexisting MS and warrant further investigation. C1 [Boster, Aaron; Hreha, Stephanie; Bao, Fen; Penmesta, Ramya; Tselis, Alexandros; Endress, Christina; Zak, Imad; Perumal, Jai; Caon, Christina; Khan, Omar] Wayne State Univ, Sch Med, Dept Neurol, Image Anal Lab,Multiple Sclerosis Ctr, Detroit, MI 48201 USA. [Zak, Imad] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI 48201 USA. [Millis, Scott] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48201 USA. [Millis, Scott] Wayne State Univ, Sch Med, Div Biostat & Clin Translat Sci, Detroit, MI 48201 USA. [Boster, Aaron; Hreha, Stephanie; Bao, Fen; Penmesta, Ramya; Tselis, Alexandros; Perumal, Jai; Caon, Christina; Khan, Omar] Detroit Med Ctr, Detroit, MI USA. [Vazquez, Jose] Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA. [Boster, Aaron; Racke, Michael K.] Ohio State Univ, Multiple Sclerosis Ctr, Div Neuroimmunol, Dept Neurol, Columbus, OH 43210 USA. [Berger, Joseph R.] Univ Kentucky, Coll Med, Dept Neurol, Lexington, KY 40506 USA. [Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. [Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Khan, O (reprint author), Wayne State Univ, Sch Med, Dept Neurol, Image Anal Lab,Multiple Sclerosis Ctr, 4201 St Antoine,8D UHC, Detroit, MI 48201 USA. EM okhan@med.wayne.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU Partners Multiple Sclerosis Fellowship Award; National Multiple Sclerosis Society Sylvia Lawry Fellowship Award; Wayne State University Neuroscience Program FX Dr Boster is a recipient of the Partners Multiple Sclerosis Fellowship Award. Dr Perumal is a recipient of the National Multiple Sclerosis Society Sylvia Lawry Fellowship Award. This study was supported in part by the Wayne State University Neuroscience Program. NR 44 TC 28 Z9 29 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAY PY 2009 VL 66 IS 5 BP 593 EP 599 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 444PU UT WOS:000265993700007 PM 19433659 ER PT J AU Petrie, EC Cross, DJ Galasko, D Schellenberg, GD Raskind, MA Peskind, ER Minoshima, S AF Petrie, Eric C. Cross, Donna J. Galasko, Douglas Schellenberg, Gerard D. Raskind, Murray A. Peskind, Elaine R. Minoshima, Satoshi TI Preclinical Evidence of Alzheimer Changes Convergent Cerebrospinal Fluid Biomarker and Fluorodeoxyglucose Positron Emission Tomography Findings SO ARCHIVES OF NEUROLOGY LA English DT Article ID CEREBRAL GLUCOSE-METABOLISM; POSTERIOR CINGULATE CORTEX; MILD COGNITIVE IMPAIRMENT; CSF PHOSPHORYLATED-TAU; APOLIPOPROTEIN-E; EPSILON-4 ALLELE; DISEASE; PULVINAR; APOE-EPSILON-4; ASSOCIATION AB Background: Alterations in cerebrospinal fluid (CSF) tau and beta-amyloid peptide 1-42 (A beta(42)) levels and rates of cerebral glucose metabolism (CMRglu) on fluorodeoxyglucose positron emission tomography (FDG-PET) occur years before clinical symptoms of Alzheimer disease (AD) become manifest, but their relationship remains unclear. Objective: To determine whether CSF AD biomarker levels and CMRglu in healthy individuals correlate in brain structures affected early in AD. Design: Cohort study. Setting: Alzheimer disease research center. Participants: Twenty individuals without dementia aged 46 to 83 years. Interventions: Lumbar CSF sampling and FDG-PET imaging of CMRglu. The CSF A beta(42), tau, and tau phosphorylated at threonine 181 (ptau(181)) levels were measured using immunobead-based multiplex assays. Main Outcome Measures: Correlations between CMRglu and CSF biomarker levels were analyzed via voxel-based and volume-of-interest approaches. Results: Voxel-based analyses demonstrated significant negative correlations between CSF tau and ptau181 levels and CMRglu in the posterior cingulate, precuneus, and parahippocampal regions. In contrast, a limited positive correlation was found between CSF A beta(42) levels and CMRglu in the inferior temporal cortex. Volume- of-interest analyses confirmed negative associations between CSF tau and ptau181 levels and CMRglu in the parietal and medial parietal lobes and a positive association between CSF A beta(42) levels and CMRglu in the parahippocampal gyrus. Conclusions: In healthy individuals, higher CSF tau and ptau181 concentrations were associated with more severe hypometabolism in several brain regions affected very early in AD, whereas lower CSF A beta(42) concentrations were associated with hypometabolism only in the medial temporal lobe. This suggests that early tau and A beta abnormalities may be associated with subtle synaptic changes in brain regions vulnerable to AD. A longitudinal assessment of CSF and FDG-PET biomarkers is needed to determine whether these changes predict cognitive impairment and incipient AD. C1 [Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Behav Sci, Seattle, WA 98195 USA. [Cross, Donna J.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Galasko, Douglas] Univ Calif San Diego, Vet Affairs Med Ctr, San Diego, CA 92161 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. RP Petrie, EC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Illness Res Educ & Clin Ctr, Mail Code S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM eric.petrie@med.va.gov FU Office of Research and Development; Medical Research Service; Department of Veterans Affairs [R01 NS045254, P50 AG05136, R01 AG023185, R01 AG05131]; National Institutes of Health [K08 AG023670] FX This material is based on work supported in part by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs; by grants R01 NS045254, P50 AG05136, R01 AG023185, R01 AG05131, and K08 AG023670 from the National Institutes of Health; NR 37 TC 54 Z9 55 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAY PY 2009 VL 66 IS 5 BP 632 EP 637 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 444PU UT WOS:000265993700011 PM 19433663 ER PT J AU Turner, AP Hawkins, EJ Haselkorn, JK Kivlahan, DR AF Turner, Aaron P. Hawkins, Eric J. Haselkorn, Jodie K. Kivlahan, Daniel R. TI Alcohol Misuse and Multiple Sclerosis SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Alcohol; Multiple sclerosis; Rehabilitation; Screening ID AT-RISK DRINKING; IDENTIFICATION TEST AUDIT; PRIMARY-CARE PATIENTS; FORM HEALTH SURVEY; VETERANS-HEALTH; COGNITIVE IMPAIRMENT; SCREENING SCORES; UNITED-STATES; USE DISORDERS; VA PATIENTS AB Objective: To describe the prevalence of alcohol misuse and medical advice to reduce drinking in a national sample of veterans with multiple Sclerosis (MS). Design: Cross-sectional cohort study linking computerized medical record information to mailed survey data from 2004 through 2006. Setting: Veterans Health Administration (VHA). Participants: Two thousand six hundred fifty-five of 4929 veterans with MS who received services in VHA between 2004 and 2006 and also a survey questionnaire (53.9% response rate). Interventions: Not applicable. Main Outcome Measures: Demographic information, Short-Form 12-Item Health Survey Mental Component Summary and Physical Component Summary, Alcohol Use Disorders Identification Test Consumption questions, and questions assessing depressive symptoms and the receipt of alcohol-related advice from a medical professional. Results: Among all survey respondents with MS, the prevalence of alcohol misuse for the sample was 13.9% (confidence interval [CI], 12.5-15.2), with 11.9% (CI, 10.6-13.2) and 2.0% (CI, 1.4-2.5) of participants scoring in the mild/moderate and severe range of alcohol misuse, respectively. In contrast to community samples there was no difference in prevalence by sex. In multivariate logistic regression, age younger than 60 years (<50y; adjusted odds ratio [AOR]=1.66; CI, 1.17-2.37, and 50-59; AOR=1.64; CI, 1.19-2.27), employment (AOR=1.54; Cl, 1.06-2.24) and better physical health (AOR= 1.02; CI, 1.01-1.04) were associated with a higher likelihood of alcohol misuse. Among persons who screened positive for alcohol misuse, only 26.2% (CI, 21.5-30.9) reported they had received advice from a medical provider in the past year to decrease or abstain from drinking. Self-report of advice was more likely among those endorsing severe misuse (AOR=3.65; Cl, 1.85-7.17) and less likely among those with better mental health (AOR=0.97; Cl, 0.94-1.00). Conclusions: Despite the numerous health and social consequences of alcohol misuse, routine screening and intervention for people with MS remain uncommon. Brief screening and advice to reduce or refrain from alcohol use can be accomplished in as little as 5 minutes and can be incorporated into the regular course of medical care. C1 [Turner, Aaron P.; Hawkins, Eric J.; Haselkorn, Jodie K.; Kivlahan, Daniel R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Vet Affairs MS Ctr Excellence W, Seattle, WA 98195 USA. [Turner, Aaron P.; Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Vet Affairs Ctr Excellence Subst Abuse Treatment, Seattle, WA 98195 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov OI Turner, Aaron/0000-0001-6897-8003 FU Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award [B4927W] FX Supported by the Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award (grant no. B4927W). and the Veterans Affairs Center of Excellence in Substance Abuse Treatment and Education, the Veterans Affairs Multiple Sclerosis Center of Excellence West, and the Veterans Affairs Office of Quality and Performance. NR 53 TC 10 Z9 10 U1 3 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAY PY 2009 VL 90 IS 5 BP 842 EP 848 DI 10.1016/j.apmr.2008.11.017 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 443ZS UT WOS:000265949900019 PM 19406306 ER PT J AU Kuy, S Roman, SA Desai, R Sosa, JA AF Kuy, SreyRam Roman, Sanziana A. Desai, Rani Sosa, Julie Ann TI Outcomes Following Thyroid and Parathyroid Surgery in Pregnant Women SO ARCHIVES OF SURGERY LA English DT Article ID VITAMIN-D DEFICIENCY; PRIMARY HYPERPARATHYROIDISM; ECONOMIC OUTCOMES; UNITED-STATES; CANCER; MANAGEMENT; DISEASE; VALIDATION; RISK AB Objectives: To perform the first population-based measurement of clinical and economic outcomes after thyroid and parathyroid surgery in pregnant women and identify the characteristics of this population and the predictors of outcome. Design: Retrospective cross-sectional study. Setting: Health Care Utilization Project Nationwide Inpatient Sample (HCUP-NIS), a 20% sample of nonfederal US hospitals. Patients: All pregnant women, compared with age-matched nonpregnant women, who underwent thyroid and parathyroid procedures from 1999 to 2005. Main Outcome Measures: Fetal, maternal, and surgical complications, in-hospital mortality, median length of stay, and hospital costs. Results: A total of 201 pregnant women underwent thyroid (n = 165) and parathyroid (n = 36) procedures and were examined together. The mean age was 29 years, 60% were white, 25% were emergent or urgent admissions, and 46% had thyroid cancer. Compared with nonpregnant women (n = 31 155), pregnant patients had a higher rate of endocrine (15.9 vs 8.1%; P < .001) and general complications (11.4 vs 3.6%; P < .001), longer unadjusted lengths of stay (2 days vs 1 day; P < .001), and higher unadjusted hospital costs ($6873 vs $5963; P = .007). The fetal and maternal complication rates were 5.5% and 4.5%, respectively. On multivariate regression analysis, pregnancy was an independent predictor of higher combined surgical complications (odds ratio, 2; P < .001), longer adjusted length of stay (0.3 days longer; P < .001), and higher adjusted hospital costs ($300; P < .001). Other independent predictors of outcome were surgeon volume, patient race or ethnicity, and insurance status. Conclusions: Pregnant women have worse clinical and economic outcomes following thyroid and parathyroid surgery than nonpregnant women, with disparities in outcomes based on race, insurance, and access to high-volume surgeons. C1 [Roman, Sanziana A.; Sosa, Julie Ann] Yale Univ, Sch Med, Dept Surg, Div Endocrine Surg, New Haven, CT 06520 USA. [Kuy, SreyRam; Desai, Rani] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA. [Desai, Rani] Yale Univ, Sch Med, Sch Epidemiol, New Haven, CT 06520 USA. [Kuy, SreyRam] US Dept Vet Affairs, Washington, DC USA. [Kuy, SreyRam] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Desai, Rani] Vet Affairs Connecticut Syst, Newington, CT USA. RP Roman, SA (reprint author), Yale Univ, Sch Med, Dept Surg, Div Endocrine Surg, 333 Cedar St,POB 208062, New Haven, CT 06520 USA. EM sanziana.roman@yale.edu FU Robert Wood Johnson Foundation; United States Department of Veterans Affairs FX This study was supported by the Robert Wood Johnson Foundation and the United States Department of Veterans Affairs. NR 38 TC 46 Z9 52 U1 2 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD MAY PY 2009 VL 144 IS 5 BP 399 EP 406 PG 8 WC Surgery SC Surgery GA 447QS UT WOS:000266207500002 PM 19451480 ER PT J AU Shlipak, MG Katz, R Kestenbaum, B Fried, LF Siscovick, D Sarnak, MJ AF Shlipak, Michael G. Katz, Ronit Kestenbaum, Bryan Fried, Linda F. Siscovick, David Sarnak, Mark J. TI Clinical and subclinical cardiovascular disease and kidney function decline in the elderly SO ATHEROSCLEROSIS LA English DT Article DE Cystatin C; Kidney disease; Atherosclerosis ID STAGE RENAL-DISEASE; VASCULAR-DISEASE; RISK-FACTORS; RENOVASCULAR DISEASE; CYSTATIN-C; MEASUREMENT ERROR; UNITED-STATES; PROGRESSION; POPULATION; MORTALITY AB Objective: Kidney function decline in elderly persons maybe the result of microvascular atherosclerosis. As a proxy for the renovascular system, we evaluated the association of clinical and subclinical cardiovascular disease (CVD) with kidney function decline. Methods: This study included 4380 subjects from the Cardiovascular Health Study, a longitudinal, community-based cohort of persons aged >= 65 from 4 U.S. communities. Creatinine and cystatin C were measured at baseline, year 3, and year 7; eligible subjects had at least two measures. Creatinine-based estimated glomerular filtration Fate (eGFR(creat)) was calculated using the MDRD equation. Rapid kidney function decline was defined as an annual eGFR loss >3 mL/min/1.73 m(2). Predictors of rapid kidney decline included prevalent and subclinical measures of CVD. Results: Mean decline in eGFR(creat) was 0.4 +/- 2.6/year; 714 (16%) had rapid progression. In multivariate models adjusted for demographics, cardiovascular risk factors, and inflammation, prevalent stroke (OR, 95% Cl: 1.55, 1.16-2.08) and heart failure (OR, 95% Cl: 1.80, 1.40-2.31) were independent predictors of rapid kidney decline. Among persons without clinical CV, the subclinical disease measures ankle-arm index <0.9 (OR, 95% Cl: 1.67, 1.25-2.24), common carotid intima-media thickness (>= 1.14 mm) (OR, 95% Cl: 1.52, 1.12-2.06) and internal carotid intima-media thickness (>1.82 mm) (OR, 95% Cl: 1.50, 1.12-2.02) had independent associations with rapid kidney function decline. Results were similar using cystatin C. Conclusion: Clinical atherosclerosis and heart failure and subclinical measures of CVD have independent associations with kidney function decline progression in the elderly, suggesting an underlying role of renal atherosclerosis. Published by Elsevier Ireland Ltd. C1 [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Kestenbaum, Bryan] Vet Affairs Puget Sound Healthcare Syst, Div Nephrol, Seattle, WA USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Sarnak, Mark J.] Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA USA. RP Shlipak, MG (reprint author), VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU American Heart Association [R01 DK066488, R01AG027002, K24DK078204-01]; National Heart, Lung, and Blood Institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295] FX Dr. Shlipak is supported by the American Heart Association Established Investigator Award and by R01 DK066488. Drs. Sarnak, Fried, Shlipak, Siscovick and Newman are also Supported by R01AG027002. Dr. Sarnak is supported by K24DK078204-01. Dr. Fried is supported by an Advanced Research Career Development award from the Office of Research and Development, Clinical Science Research and Development, of the Department of Veterans Affairs. The Cardiovascular Health Study was supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at http://www.chsnhlbi.org/pi.htm. NR 30 TC 51 Z9 55 U1 1 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAY PY 2009 VL 204 IS 1 BP 298 EP 303 DI 10.1016/j.atherosclerosis.2008.08.016 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 454GJ UT WOS:000266670100051 PM 18848325 ER PT J AU Clegg, LX Reichman, ME Miller, BA Hankey, BF Singh, GK Lin, YD Goodman, MT Lynch, CF Schwartz, SM Chen, VW Bernstein, L Gomez, SL Graff, JJ Lin, CC Johnson, NJ Edwards, BK AF Clegg, Limin X. Reichman, Marsha E. Miller, Barry A. Hankey, Benjamin F. Singh, Gopal K. Lin, Yi Dan Goodman, Marc T. Lynch, Charles F. Schwartz, Stephen M. Chen, Vivien W. Bernstein, Leslie Gomez, Scarlett L. Graff, John J. Lin, Charles C. Johnson, Norman J. Edwards, Brenda K. TI Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study SO CANCER CAUSES & CONTROL LA English DT Article DE SEER; NLMS; Cancer incidence; Stage; Education; Income; Poverty; Unemployment; SES; Race/ethnicity; Rural/urban; Health disparities; Record linkage ID BREAST-CANCER; UNITED-STATES; CERVICAL-CANCER; SOCIAL-CLASS; RACIAL-DIFFERENCES; COLORECTAL-CANCER; PROSTATE-CANCER; RESULTS PROGRAM; DEATH INDEX; US WOMEN AB Population-based cancer registry data from the Surveillance, Epidemiology, and End Results (SEER) Program at the National Cancer Institute (NCI) are mainly based on medical records and administrative information. Individual-level socioeconomic data are not routinely reported by cancer registries in the United States because they are not available in patient hospital records. The U.S. representative National Longitudinal Mortality Study (NLMS) data provide self-reported, detailed demographic and socioeconomic data from the Social and Economic Supplement to the Census Bureau's Current Population Survey (CPS). In 1999, the NCI initiated the SEER-NLMS study, linking the population-based SEER cancer registry data to NLMS data. The SEER-NLMS data provide a new unique research resource that is valuable for health disparity research on cancer burden. We describe the design, methods, and limitations of this data set. We also present findings on cancer-related health disparities according to individual-level socioeconomic status (SES) and demographic characteristics for all cancers combined and for cancers of the lung, breast, prostate, cervix, and melanoma. Records of cancer patients diagnosed in 1973-2001 when residing 1 of 11 SEER registries were linked with 26 NLMS cohorts. The total number of SEER matched cancer patients that were also members of an NLMS cohort was 26,844. Of these 26,844 matched patients, 11,464 were included in the incidence analyses and 15,357 in the late-stage diagnosis analyses. Matched patients (used in the incidence analyses) and unmatched patients were compared by age group, sex, race, ethnicity, residence area, year of diagnosis, and cancer anatomic site. Cohort-based age-adjusted cancer incidence rates were computed. The impact of socioeconomic status on cancer incidence and stage of diagnosis was evaluated. Men and women with less than a high school education had elevated lung cancer rate ratios of 3.01 and 2.02, respectively, relative to their college educated counterparts. Those with family annual incomes less than $12,500 had incidence rates that were more than 1.7 times the lung cancer incidence rate of those with incomes $50,000 or higher. Lower income was also associated with a statistically significantly increased risk of distant-stage breast cancer among women and distant-stage prostate cancer among men. Socioeconomic patterns in incidence varied for specific cancers, while such patterns for stage were generally consistent across cancers, with late-stage diagnoses being associated with lower SES. These findings illustrate the potential for analyzing disparities in cancer outcomes according to a variety of individual-level socioeconomic, demographic, and health care characteristics, as well as by area measures available in the linked database. C1 [Clegg, Limin X.] US Dept Vet Affairs, Off Healthcare Inspect, Off Inspector Gen, Washington, DC 20420 USA. [Reichman, Marsha E.; Miller, Barry A.; Edwards, Brenda K.] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Hankey, Benjamin F.] Informat Management Serv Inc, Silver Spring, MD USA. [Singh, Gopal K.] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA. [Lin, Yi Dan] Monash Univ, Sch Med, Melbourne, Vic 3004, Australia. [Goodman, Marc T.] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA. [Lynch, Charles F.] Univ Iowa, State Hlth Registry Iowa, Iowa City, IA USA. [Schwartz, Stephen M.] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Chen, Vivien W.] LSU Sch Publ Hlth, Louisiana Tumor Registry, New Orleans, LA USA. [Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA. [Gomez, Scarlett L.] No Calif Canc Ctr, Fremont, CA USA. [Graff, John J.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. [Lin, Charles C.; Johnson, Norman J.] US Bur Census, Suitland, MD USA. RP Clegg, LX (reprint author), US Dept Vet Affairs, Off Healthcare Inspect, Off Inspector Gen, 54AA,810 Vermont Ave NW, Washington, DC 20420 USA. EM Lin.Clegg@va.gov FU National Cancer Institute FX We thank Marie-Josephe Horner, epidemiologist from the National Cancer Institute, for technical and editorial assistance in the preparation of this manuscript. NR 52 TC 246 Z9 247 U1 9 U2 56 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2009 VL 20 IS 4 BP 417 EP 435 DI 10.1007/s10552-008-9256-0 PG 19 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 430VV UT WOS:000265018900002 PM 19002764 ER PT J AU Satia, JA Littman, A Slatore, CG Galanko, JA White, E AF Satia, Jessie A. Littman, Alyson Slatore, Christopher G. Galanko, Joseph A. White, Emily TI Associations of Herbal and Specialty Supplements with Lung and Colorectal Cancer Risk in the VITamins And Lifestyle Study SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID ALTERNATIVE MEDICINE USE; DIETARY-SUPPLEMENTS; UNITED-STATES; NATIONAL-SURVEY; GLUCOSAMINE; OSTEOARTHRITIS; COMPLEMENTARY; CHONDROITIN; PREVENTION; TRENDS AB Millions of Americans use dietary supplements with little knowledge about their benefits or risks. We examined associations of various herbal/specialty supplements with lung and colorectal cancer risk. Men and women, 50 to 76 years, in the VITamins And Lifestyle cohort completed a 24-page baseline questionnaire that captured duration (years) and frequency (days per week) of use of commonly used herbal/specialty supplements. Dose was not assessed due to the lack of accurate potency information. Supplement exposure was categorized as "no use" or "any use" over the previous 10 years. Hazard ratios (HR) were estimated by multivariate Cox regression models. Incident lung (n = 665) and colorectal cancers (n = 428) were obtained from the Surveillance, Epidemiology, and End Results cancer registry. Any use of glucosamine and chondroitin, which have anti-inflammatory properties, over the previous 10 years, was associated with significantly lower lung cancer risk: HR 0.74 [95% confidence interval (95% CI), 0.58-0.94] and HR 0.72 (95% CI, 0.54-0.96) and colorectal cancer risk: HR 0.73 (95% CI, 0.54-0.98) and HR 0.65 (95% CI, 0.45-0.93), respectively. There were also statistically significantly inverse associations of fish oil: HR 0.65 (95% CI, 0.42-0.99), methylsulfonylmethane: HR 0.46 (95% CI, 0.23-0.93), and St. John's wort: HR 0.35 (95% CI, 0.140.85) with colorectal cancer risk. In contrast, garlic pills were associated with a statistically significant 35% elevated colorectal cancer risk. These results suggest that some herbal/specialty supplements may be associated with lung and colorectal cancer risk; however, these products should be used with caution. Additional studies examining the effects of herbal/specialty supplements on risk for cancer and other diseases are needed. (Cancer Epidemiol Biomarkers Prev 2009;18(5):1419-28) C1 [Satia, Jessie A.] Univ N Carolina, Dept Nutr, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Satia, Jessie A.] Univ N Carolina, Dept Epidemiol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Satia, Jessie A.] Univ N Carolina, Dept Epidemiol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Satia, Jessie A.; Galanko, Joseph A.] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA. [Littman, Alyson; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Littman, Alyson] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Slatore, Christopher G.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. RP Satia, JA (reprint author), Univ N Carolina, Dept Nutr, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. EM jsatia@unc.edu OI Slatore, Christopher/0000-0003-0958-8122 FU National Cancer Institute [R01 CA74846, K22CA096556, R03 CA 119683-01] FX Grant support: National Cancer Institute grants R01 CA74846, K22CA096556, and R03 CA 119683-01. NR 49 TC 33 Z9 34 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2009 VL 18 IS 5 BP 1419 EP 1428 DI 10.1158/1055-9965.EPI-09-0038 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 445WF UT WOS:000266081500013 PM 19423520 ER PT J AU Kelly, K Kittelson, J Franklin, WA Kennedy, TC Klein, CE Keith, RL Dempsey, EC Lewis, M Jackson, MK Hirsch, FR Bunn, PA Miller, YE AF Kelly, Karen Kittelson, John Franklin, Wilbur A. Kennedy, Timothy C. Klein, Catherine E. Keith, Robert L. Dempsey, Edward C. Lewis, Marina Jackson, Mary K. Hirsch, Fred R. Bunn, Paul A. Miller, York E. TI A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without alpha Tocopherol or Observation in Subjects at High Risk for Lung Cancer SO CANCER PREVENTION RESEARCH LA English DT Article ID FAMILIAL ADENOMATOUS POLYPOSIS; BRONCHIAL EPITHELIUM; FORMER SMOKERS; BETA-CAROTENE; VITAMIN-A; INTRAEPITHELIAL NEOPLASIA; 13-CIS-RETINOIC ACID; BREAST-CANCER; RECEPTOR-BETA; END-POINT AB No chemoprevention strategies have been proven effective for lung cancer. We evaluated the effect of 13-cis retinoic acid (13-cis RA), with or without a tocopherol, as a lung cancer chemoprevention agent in a phase II randomized controlled clinical trial of adult subjects at high risk for lung cancer as defined by the presence of sputum atypia, history of smoking, and airflow obstruction, or a prior surgically cured nonsmall cell lung cancer (disease free, >3 years). Subjects were randomly assigned to receive either 13-cis RA, 13-cis RA plus a tocopherol (13-cis RA/alpha toco) or observation for 12 months. Outcome measures are derived from histologic evaluation of bronchial biopsy specimens obtained by bronchoscopy at baseline and follow-up. The primary outcome measure is treatment "failure" defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy. Seventy-five subjects were randomized (27/22/26 to obervations/13-cis RA/13-cis RA/alpha toco); 59 completed the trial; 55 had both baseline and follow-up bronchoscopy. The risk of treatment failure was 55.6% (15 of 27) and 50% (24 of 48) in the observation and combined (13 cis RA plus 13 cis RA/alpha toco) treatment arms, respectively (odds ratio adjusted for baseline histology, 0.97; 95% confidence interval, 0.36-2.66; P = 0.95). Among subjects with complete histology data, maximum histology score in the observation arm increased by 0.37 units and by 0.03 units in the treated arms (difference adjusted for baseline, -0.18; 95% confidence interval, -1.16 to 0.81; P = 0.72). Similar (nonsignificant) results were observed for treatment effects on endobronchial proliferation as assessed by Ki-67 immunolabeling. Twelve-month treatment with 13-cis RA produced nonsignificant changes in bronchial histology, consistent with results in other trials. Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of a tocopherol did not affect toxicity. C1 [Kelly, Karen; Klein, Catherine E.; Lewis, Marina; Jackson, Mary K.; Hirsch, Fred R.; Bunn, Paul A.] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA. [Kittelson, John] Univ Colorado, Dept Biostat, Denver, CO 80202 USA. [Franklin, Wilbur A.; Lewis, Marina; Hirsch, Fred R.] Univ Colorado, Dept Pathol, Denver, CO 80202 USA. [Keith, Robert L.; Dempsey, Edward C.; Miller, York E.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Klein, Catherine E.; Keith, Robert L.; Dempsey, Edward C.; Miller, York E.] Denver VAMC, Denver, CO 80220 USA. [Kennedy, Timothy C.] Univ Colorado, Ctr Canc, HealthOne, Denver, CO 80262 USA. RP Miller, YE (reprint author), Denver VAMC, Pulm 111A,1055 Clermont St, Denver, CO 80220 USA. EM york.miller@uchsc.edu FU NIH/National Cancer Institute [P50 CA058187]; Lung Cancer NIH/National Cancer Institute [P30 CA46934] FX NIH/National Cancer Institute P50 CA058187 Specialized Programs of Research Excellence in Lung Cancer NIH/National Cancer Institute P30 CA46934 Cancer Center Core Grant. NR 40 TC 12 Z9 12 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD MAY PY 2009 VL 2 IS 5 BP 440 EP 449 DI 10.1158/1940-6207.CAPR-08-0136 PG 10 WC Oncology SC Oncology GA 441IU UT WOS:000265763300007 PM 19401528 ER PT J AU Abangan, R Williams, C LaRue, A AF Abangan, Romeo Williams, Christopher LaRue, Amanda TI Regulation of hematopoietic stem cell-derived circulating fibroblast precursors in solid tumor formation SO CANCER RESEARCH LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2009 VL 69 SU 9 MA 3172 PG 1 WC Oncology SC Oncology GA V43TD UT WOS:000209702803464 ER PT J AU Gokhale, A Epperly, M Glowacki, J Wang, H Smith, T Patrene, K Roodman, G Greenberger, J AF Gokhale, Abhay Epperly, Michael Glowacki, Julie Wang, Hong Smith, Tracy Patrene, Kenneth Roodman, G. Greenberger, Joel TI Antioxidant therapy ameliorates ionizing irradiation-induced delay in bone wound healing SO CANCER RESEARCH LA English DT Meeting Abstract C1 Univ Pittsburgh, Dept Radiat Oncol, Inst Canc, Pittsburgh, PA USA. Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2009 VL 69 SU 9 MA 3966 PG 1 WC Oncology SC Oncology GA V43TD UT WOS:000209702804028 ER PT J AU Hirata, H Hinoda, Y Kikuno, N Kawakami, K Suehiro, Y Yamamura, S Dahiya, R AF Hirata, Hiroshi Hinoda, Yuji Kikuno, Nobuyuki Kawakami, Kazumori Suehiro, Yutaka Yamamura, Soichiro Dahiya, Rajvir TI BCL2-938C/A polymorphism has increased risk of biochemical recurrence after radical prostatectomy in sporadic prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi 755, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2009 VL 69 SU 9 MA 1665 PG 2 WC Oncology SC Oncology GA V43TC UT WOS:000209702702025 ER PT J AU Tobi, M Gupta, R Irwin, B Hatfield, J Jung, HS Edgar, BJ Kim, M Rodriguez, R Kim, J AF Tobi, Martin Gupta, Rasna Irwin, Bradley Hatfield, James Jung, Han Sue Edgar, Ben Josef Kim, Mijin Rodriguez, Rebecca Kim, Jyung TI Vascular mimicry may explain high baseline rectal VEGF: A potential mechanism of chronic radiation proctitis in prostate cancer patients. SO CANCER RESEARCH LA English DT Meeting Abstract C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. VAMC, Detroit, MI USA. Univ Michigan, Sch Med, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2009 VL 69 SU 9 MA 3625 PG 2 WC Oncology SC Oncology GA V43TC UT WOS:000209702702231 ER PT J AU Wu, P Wang, Q Chu, E Wu, D AF Wu, Peter Wang, Qin Chu, Elizabeth Wu, Daniel TI Telomere dysfunction reinforces therapy-induced cellular senescence SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wu, Peter; Wang, Qin; Chu, Elizabeth; Wu, Daniel] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2009 VL 69 SU 9 MA 3471 PG 1 WC Oncology SC Oncology GA V43ST UT WOS:000209701804088 ER PT J AU Yanagawa, J Walser, T Zhu, L Luo, J Hong, LS Fishbein, M Goodglick, L Strieter, R Sharma, S Dubinett, S AF Yanagawa, Jane Walser, Tonya Zhu, Li Luo, Jie Hong, Longsheng Fishbein, Michael Goodglick, Lee Strieter, Robert Sharma, Sherven Dubinett, Steven TI The zinc-finger E-box-binding transcriptional repressor Snail promotes CXCR2 ligand dependent tumor progression in non-small cell lung cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Hlth Care Ctr, Los Angeles, CA USA. Univ Virginia, Charlottesville, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2009 VL 69 SU 9 MA 1527 PG 1 WC Oncology SC Oncology GA V43ST UT WOS:000209701804327 ER PT J AU Garcia, JA Agostoni, P Green, NE Maddux, JT Chen, SYJ Messenger, JC Casserly, IP Hansgen, A Wink, O Movassaghi, B Groves, BM Van Den Heuvel, P Verheye, S Van Langenhove, G Vermeersch, P Van den Branden, F Yeghiazarians, Y Michaels, AD Carroll, JD AF Garcia, Joel A. Agostoni, Pierfrancesco Green, Nathan E. Maddux, James T. Chen, S. -Y. James Messenger, John C. Casserly, Ivan P. Hansgen, Adam Wink, Onno Movassaghi, Babak Groves, Bertron M. Van Den Heuvel, Paul Verheye, Stefan Van Langenhove, Glenn Vermeersch, Paul Van den Branden, Frank Yeghiazarians, Yerem Michaels, Andrew D. Carroll, John D. TI Rotational vs. Standard Coronary Angiography: An Image Content Analysis SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE angiography coronary; diagnostic cardiac catheterization; contrast media; percutaneous coronary intervention; quantitative coronary angiography ID INTRAVASCULAR ULTRASOUND; ARTERY-DISEASE; CLINICAL UTILITY; ANGIOPLASTY; SAFETY AB Objective: To evaluate the clinical utility of images acquired from rotational coronary angiographic (RA) acquisitions compared to standard 'fixed' coronary angiography (SA). Background: RA is a novel angiographic modality that has been enabled by new gantry systems that allow calibrated automatic angiographic rotations and has been shown to reduce radiation and contrast exposure compared to SA. RA provides a dynamic multiple-angle perspective of the coronaries during a single contrast injection. Methods: The screening adequacy, lesion assessment, and a quantitative coronary analysis (QCA) of both SA and RA were compared by independent blinded review in 100 patients with coronary artery disease (CAD). Results: SA and RA recognize a similar total number of lesions (P = 0.61). The qualitative assessment of lesion characteristics and severity between modalities was comparable and lead to similar clinical decisions. Visualization of several vessel segments (diagonal, distal RCA, postero-lateral branches and posterior-descending) was superior with RA when compared to SA (P < 0.05). A QCA comparison (MLD, MLA, LL, % DS) revealed no difference between SA and RA. The volume of contrast (23.5 +/- 3.1 mL vs. 39.4 +/- 4.1; P = 0.0001), total radiation exposure (27.1 +/- 4 vs. 32.1 +/- 3.8 Gycm(2); p = 0.002) and image acquisition time (54.3 +/- 36.8 vs. 77.67 +/- 49.64 sec; P = 0.003) all favored RA. Conclusion: Coronary lesion assessment, coronary screening adequacy, and QCA evaluations are comparable in SA and RA acquisition modalities in the diagnosis of CAD however RA decreases contrast volume, image acquisition time, and radiation exposure. (C) 2009 Wiley-Liss, Inc. C1 [Garcia, Joel A.; Green, Nathan E.; Maddux, James T.; Chen, S. -Y. James; Messenger, John C.; Casserly, Ivan P.; Hansgen, Adam; Groves, Bertron M.; Carroll, John D.] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA. [Garcia, Joel A.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO USA. [Agostoni, Pierfrancesco; Van Den Heuvel, Paul; Verheye, Stefan; Van Langenhove, Glenn; Vermeersch, Paul; Van den Branden, Frank] Antwerp Cardiovasc Inst Middelheim, Antwerp, Belgium. [Casserly, Ivan P.] Denver VA Med Ctr, Div Cardiol, Denver, CO USA. [Wink, Onno; Movassaghi, Babak] Philips Med Syst, Clin Res, Best, Netherlands. [Yeghiazarians, Yerem] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA. [Michaels, Andrew D.] Univ Utah, Div Cardiol, Salt Lake City, UT 84112 USA. RP Carroll, JD (reprint author), Univ Colorado, Hlth Sci Ctr, Div Cardiol, 4200 E 9th Ave,Box B-132, Denver, CO 80262 USA. EM john.carroll@uchsc.edu NR 20 TC 19 Z9 23 U1 1 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY 1 PY 2009 VL 73 IS 6 BP 753 EP 761 DI 10.1002/ccd.21918 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 439YJ UT WOS:000265663500008 PM 19180661 ER PT J AU Sullivan, MD Ciechanowski, PS Russo, JE Soine, LA Jordan-Keith, K Ting, HH Caldwell, JH AF Sullivan, Mark D. Ciechanowski, Paul S. Russo, Joan E. Soine, Laurie A. Jordan-Keith, Kier Ting, Henry H. Caldwell, James H. TI Understanding Why Patients Delay Seeking Care for Acute Coronary Syndromes SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE prehospital delay; attachment theory; depression; anxiety; trust ID ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; HEART-ATTACK SYMPTOMS; RAPID EARLY ACTION; HOSPITAL PRESENTATION; PREHOSPITAL DELAY; ARTERY-DISEASE; HEALTH-CARE; TIME; MORTALITY AB Background-Better insight into the psychosocial factors associated with prehospital delays in seeking care for acute coronary syndromes is needed to inform the design of future interventions. Delay in presenting for care after the onset of symptoms is common, limits the potential benefit of acute reperfusion, and has not been reduced by interventions tested thus far. Methods and Results-Seven hundred ninety-six patients with suspected ischemic heart disease scheduled for clinically indicated imaging stress tests completed questionnaires concerning psychological distress and attachment styles (worthiness to receive care, trustworthiness of others to provide care). The primary dependent variable for this study was response to a question from the rapid early action for coronary treatment trial concerning intention to "wait until very sure" before seeking care for a possible "heart attack." Responses to this question were strongly associated with actual emergency department-reported and self-reported care delay in the rapid early action for coronary treatment trial. In multivariable ordinal regression models, a more negative view of the trustworthiness of others, greater physical limitations from angina, and no previous revascularization were independently associated with increased intention to wait to seek care for a myocardial infarction. Intention to wait was not associated with inducible ischemia or self-perceived risk of myocardial infarction. Conclusions-Intention to delay seeking care for acute coronary syndromes is associated with a patient's view of the trustworthiness of others, previous experience with revascularization, and functional limitations, even after adjustment for objective and perceived acute coronary syndromes risk. These findings provide insight into novel factors contributing to longer delay times and may inform future interventions to reduce delay time. (Circ Cardiovasc Qual Outcomes. 2009; 2: 148-154.) C1 [Sullivan, Mark D.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Soine, Laurie A.; Caldwell, James H.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Soine, Laurie A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Soine, Laurie A.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Jordan-Keith, Kier] VA Puget Sound Hlth Care Syst, Dept Cardiol, Seattle, WA USA. [Ting, Henry H.] Mayo Clin, Knowledge & Encounter Res Unit, Div Cardiovasc Dis, Rochester, MN USA. RP Sullivan, MD (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560,1959 NE Pacific St, Seattle, WA 98195 USA. EM sullimar@u.washington.edu FU American Heart Association [0450094Z] FX This work was supported by a grant from the American Heart Association (0450094Z to M. S.). NR 33 TC 26 Z9 27 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAY PY 2009 VL 2 IS 3 BP 148 EP 154 DI 10.1161/CIRCOUTCOMES.108.825471 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575NN UT WOS:000276074000004 PM 20031831 ER PT J AU Popescu, I Werner, RM Vaughan-Sarrazin, MS Cram, P AF Popescu, Ioana Werner, Rachel M. Vaughan-Sarrazin, Mary S. Cram, Peter TI Characteristics and Outcomes of America's Lowest-Performing Hospitals An Analysis of Acute Myocardial Infarction Hospital Care in the United States SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE myocadial infarction; hospitals; quality of health care ID QUALITY-OF-CARE; SAFETY-NET HOSPITALS; MORTALITY-RATES; US HOSPITALS; FOR-PROFIT; MEDICARE; IMPROVEMENT; DIFFERENCE; OWNERSHIP; SURGERY AB Background-Studies suggest that most hospitals now have relatively high adherence with recommended acute myocardial infarction (AMI) process measures. Little is known about hospitals with consistently poor adherence with AMI process measures and whether these hospitals also have increased patient mortality. Methods and Results-We conducted a retrospective study of 2761 US hospitals reporting AMI process measures to the Center for Medicare and Medicaid Services Hospital Compare database during 2004 to 2006 that could be linked to 2005 Medicare Part A data. The main outcome measures were hospitals' combined compliance with 5 AMI measures (aspirin and beta-blocker on admission and discharge and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use at discharge for patients with left ventricular dysfunction) and risk-adjusted 30-day mortality for 2005. We stratified hospitals into those with low AMI adherence (ranked in the lowest decile for AMI adherence for 3 consecutive years [2004-2006, n=105]), high adherence (ranked in the top decile for 3 consecutive years [n=63]), and intermediate adherence (all others [n=2593]). Mean AMI performance varied significantly across low-, intermediate-, and high-performing hospitals (mean score, 68% versus 92% versus 99%, P<0.001). Low-performing hospitals were more likely than intermediate-and high-performing hospitals to be safety-net providers (19.2% versus 11.0% versus 6.4%; P=0.005). Low-performing hospitals had higher unadjusted 30-day mortality rates (23.6% versus 17.8% versus 14.9%; P<0.001). These differences persisted after adjustment for patient characteristics (16.3% versus 16.0% versus 15.7%; P=0.02). Conclusion-Consistently low-performing hospitals differ substantially from other US hospitals. Targeting quality improvement efforts toward these hospitals may offer an attractive opportunity for improving AMI outcomes. (Circ Cardiovasc Qual Outcomes. 2009; 2: 221-227.) C1 [Popescu, Ioana; Vaughan-Sarrazin, Mary S.; Cram, Peter] Iowa City VA Med Ctr, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA. [Popescu, Ioana; Vaughan-Sarrazin, Mary S.; Cram, Peter] Univ Iowa, Carver Coll Med, Dept Internal Med, Div Gen Internal Med, Iowa City, IA 52240 USA. [Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Popescu, I (reprint author), Univ Iowa, Hosp & Clin, Dept Internal Med, 200 Hawkins Dr,SE615 GH, Iowa City, IA 52240 USA. EM Ioana-popescu@uiowa.edu RI Cram, Peter/K-4472-2014 OI Cram, Peter/0000-0002-1910-346X; Vaughan Sarrazin, Mary/0000-0001-8717-1061 FU Health Services Research and Development Service, Veterans Health Administration, Department of Veterans Affairs [HFP 04-149]; Ruth L. Kirschstein National Research Service Award; American Heart Association; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; Agency for Healthcare Research and Quality [HS016478-01]; Department of Veterans Affairs, Health Services Research and Development Service; Williams Award; Department of Veterans Affairs, Health Services Research and Development [IIR 06-196-2]; National Center for Research Resources at the NIH [RR01997201]; Robert Wood Johnson Physician Faculty Scholars Program; National Heart Lung and Blood Institute at the NIH [R01 HL085347-01A1] FX For data acquisition, management, and analysis, this research was supported, in part, by an award (HFP 04-149) from the Health Services Research and Development Service, Veterans Health Administration, Department of Veterans Affairs. Dr Popescu is supported by a Ruth L. Kirschstein National Research Service Award, and by a National Scientist Development award from the American Heart Association. Dr Vaughan-Sarrazin is a Research Scientist in the Center for Research in the Implementation of Innovative Strategies in Practice (CRIISP) at the Iowa City VA Medical Center, which is funded through the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. Dr Werner is supported by R01 HS016478-01 from the Agency for Healthcare Research and Quality, by a Career Development Award from the Department of Veterans Affairs, Health Services Research and Development Service, by a T. Franklin Williams Award in Geriatrics, and by a Merit Award (IIR 06-196-2) from the Department of Veterans Affairs, Health Services Research and Development. Dr Cram is supported by a K23 career development award (RR01997201) from the National Center for Research Resources at the NIH, by the Robert Wood Johnson Physician Faculty Scholars Program, and by R01 HL085347-01A1 from National Heart Lung and Blood Institute at the NIH. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 32 TC 18 Z9 18 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAY PY 2009 VL 2 IS 3 BP 221 EP 227 DI 10.1161/CIRCOUTCOMES.108.813790 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575NN UT WOS:000276074000014 PM 20031841 ER PT J AU Pavlik, VN Greisinger, AJ Pool, J Haidet, P Hyman, DJ AF Pavlik, Valory N. Greisinger, Anthony J. Pool, James Haidet, Paul Hyman, David J. TI Does Reducing Physician Uncertainty Improve Hypertension Control? Rationale and Methods SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE hypertension; blacks; randomized controlled trial; blood pressure monitoring, ambulatory ID AMBULATORY BLOOD-PRESSURE; UNITED-STATES; UNCONTROLLED HYPERTENSION; ANTIHYPERTENSIVE THERAPY; PRIMARY-CARE; PREVALENCE; ADHERENCE; AWARENESS; TRENDS; POPULATION AB Hypertension affects nearly one third of the US population overall, and the prevalence rises sharply with age. In spite of public educational campaigns and professional education programs to encourage blood pressure measurement and control of both systolic and diastolic control to <140/90 mm Hg (or 130/80 mm Hg if diabetic), 43% of treated hypertensives do not achieve the recommended Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure target. Among blacks, 48% are uncontrolled on treatment. The majority of persons classified as poorly controlled hypertensives have mild systolic blood pressure elevation (in the range of 140 to 160 mm Hg). We hypothesized that physician uncertainty regarding the patient's usual blood pressure, as well as uncertainty regarding the extent of medication nonadherence, represent an important barrier to further reductions in the proportion of uncontrolled hypertensives in the United States. Using cluster randomization, 10 primary care clinics (6 from a public health care system and 4 from a private clinic system) were randomized to either the uncertainty reduction intervention condition or to usual care. An average of 68 patients per clinic were recruited to serve as units of observation. Physicians in the 5 intervention clinics were provided with a specially designed study form that included a graph of recent blood pressure measurements in their study patients, a check box to indicate their assessment of the adequacy of the patient's blood pressure control, and a menu of services they could order to aid in patient management. These menu options included 24-hour ambulatory blood pressure monitoring; electronic bottle cap assessment of medication adherence, followed by medication adherence counseling in patients found to be nonadherent; and lifestyle assessment and counseling followed by 24-hour ambulatory blood pressure monitoring. Physicians in the 5 usual practice clinics did not have access to these services but were informed of which patients had been enrolled in the study. Substudies carried out to further characterize the study population and interpret intervention results included ambulatory blood pressure monitoring and electronic bottle cap monitoring in a random subsample of patients at baseline, and audio recording of patient-physician encounters after intervention implementation. The primary study end point was defined as the proportion of patients with controlled blood pressure (<140/90 mm Hg or <130/80 mm Hg if diabetic). Secondary end points include actual measured clinic systolic and diastolic blood pressure, patient physician communication patterns, physician prescribing patient self-reported lifestyle and medication adherence, physician knowledge, attitude and beliefs regarding the utility of intervention tools to achieve blood pressure control, and the cost-effectiveness of the intervention. Six-hundred eighty patients have been randomized, and 675 remain in active follow-up after 1.5 years. Patient closeout will be complete in March 2009. Analyses of the baseline data are in progress. Office-based blood pressure measurement error and bias, as well as physician and patient beliefs about the need for treatment intensification, may be important factors that limit further progress in blood pressure control. This trial will provide data on the extent to which available technologies not widely used in primary care will change physician prescribing behavior and patient adherence to prescribed treatment. (Circ Cardiovasc Qual Oucomes. 2009; 2: 257-263.) C1 [Pavlik, Valory N.] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77098 USA. [Greisinger, Anthony J.] Kelsey Res Fdn, Houston, TX USA. [Haidet, Paul] DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Pavlik, VN (reprint author), Baylor Coll Med, Dept Family & Community Med, 3701 Kirby Dr,Suite 600, Houston, TX 77098 USA. EM vpavlik@bcm.tmc.edu FU National Heart, Lung, and Blood Institute of the National Institutes of Health [R01 HL078589] FX This study was supported by grant R01 HL078589 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. NR 31 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAY PY 2009 VL 2 IS 3 BP 257 EP 263 DI 10.1161/CIRCOUTCOMES.109.849984 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575NN UT WOS:000276074000019 PM 20031846 ER PT J AU Dixon, JA Spinale, FG AF Dixon, Jennifer A. Spinale, Francis G. TI Large Animal Models of Heart Failure A Critical Link in the Translation of Basic Science to Clinical Practice SO CIRCULATION-HEART FAILURE LA English DT Article DE myocardial infarction; myocardial remodeling; overload states; rapid pacing ID MESENCHYMAL STEM-CELLS; LEFT-VENTRICULAR FUNCTION; ACUTE MYOCARDIAL-INFARCTION; MATRIX-METALLOPROTEINASE INHIBITION; CHRONIC MITRAL REGURGITATION; VOLUME OVERLOAD HYPERTROPHY; CARDIAC SUPPORT DEVICE; BONE-MARROW-CELLS; DILATED CARDIOMYOPATHY; RECEPTOR BLOCKADE AB Congestive heart failure (HF) is a clinical syndrome, with hallmarks of fatigue and dyspnea, that continues to be highly prevalent and morbid. Because of the growing burden of HF as the population ages, the need to develop new pharmacological treatments and therapeutic interventions is of paramount importance. Common pathophysiologic features of HF include changes in left ventricle structure, function, and neurohormonal activation. The recapitulation of the HF phenotype in large animal models can allow for the translation of basic science discoveries into clinical therapies. Models of myocardial infarction/ischemia, ischemic cardiomyopathy, ventricular pressure and volume overload, and pacing-induced dilated cardiomyopathy have been created in dogs, pigs, and sheep for the investigation of HF and potential therapies. Large animal models recapitulating the clinical HF phenotype and translating basic science to clinical applications have successfully traveled the journey from bench to bedside. Undoubtedly, large animal models of HF will continue to play a crucial role in the elucidation of biological pathways involved in HF and the development and refinement of HF therapies. (Circ Heart Fail. 2009;2:262-271.) C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Strom Thurmond Res Ctr, 114 Doughty St,Suite 625, Charleston, SC 29425 USA. EM wilburnm@musc.edu FU NHLBI NIH HHS [P01 HL048788, P01 HL048788-150006] NR 79 TC 117 Z9 117 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAY PY 2009 VL 2 IS 3 BP 262 EP 271 DI 10.1161/CIRCHEARTFAILURE.108.814459 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 485YF UT WOS:000269161600015 PM 19808348 ER PT J AU Qian, DZ Huang, CY O'Brien, CA Coleman, IM Garzotto, M True, LD Higano, CS Vessella, R Lange, PH Nelson, PS Beer, TM AF Qian, David Z. Huang, Chung-Ying O'Brien, Catherine A. Coleman, Ilsa M. Garzotto, Mark True, Lawrence D. Higano, Celestia S. Vessella, Robert Lange, Paul H. Nelson, Peter S. Beer, Tomasz M. TI Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies SO CLINICAL CANCER RESEARCH LA English DT Article ID CDNA MICROARRAY ANALYSIS; COENZYME-A RACEMASE; ANDROGEN-RECEPTOR; MESSENGER-RNA; RADICAL PROSTATECTOMY; DISEASE RECURRENCE; AMPLIFIED RNA; PROTEIN; TISSUE; ID-1 AB Purpose: To accurately identify gene expression alterations that differentiate neoplastic from normal prostate epithelium using an approach that avoids contamination by unwanted cellular components and is not compromised by acute gene expression changes associated with tumor devascularization and resulting ischemia. Experimental Design: Approximately 3,000 neoplastic and benign prostate epithelial cells were isolated using laser capture microdissection from snap-frozen prostate biopsy specimens provided by 31 patients who subsequently participated in a clinical trial of preoperative chemotherapy. cDNA synthesized from amplified total RNA was hybridized to custom-made microarrays composed of 6,200 clones derived from the Prostate Expression Database. Expression differences for selected genes were verified using quantitative reverse transcription-PCR. Results: Comparative analyses identified 954 transcript alterations associated with cancer (q < 0.01%), including 149 differentially expressed genes with no known functional roles. Gene expression changes associated with ischemia and surgical removal of the prostate gland were absent. Genes up-regulated in prostate cancer were statistically enriched in categories related to cellular metabolism, energy use, signal transduction, and molecular transport. Genes down-regulated in prostate cancers were enriched in categories related to immune response, cellular responses to pathogens, and apoptosis. A heterogeneous pattern of androgen receptor expression changes was noted. In exploratory analyses, androgen receptor down-regulation was associated with a lower probability of cancer relapse after neoadjuvant chemotherapy followed by radical prostatectomy. Conclusions: Assessments of tumor phenotypes based on gene expression for treatment stratification and drug targeting of oncogenic alterations may best be ascertained using biopsy-based analyses where the effects of ischemia do not complicate interpretation. C1 [Beer, Tomasz M.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. [Qian, David Z.; O'Brien, Catherine A.; Beer, Tomasz M.] Oregon Hlth & Sci Univ, OHSU Canc Inst, Portland, OR 97239 USA. [Garzotto, Mark] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97239 USA. [Garzotto, Mark] Portland VA Med Ctr, Portland, OR USA. [Huang, Chung-Ying; Coleman, Ilsa M.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA USA. [Huang, Chung-Ying; Coleman, Ilsa M.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA USA. [True, Lawrence D.; Nelson, Peter S.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Higano, Celestia S.; Nelson, Peter S.] Univ Washington, Div Oncol, Seattle, WA 98195 USA. [Vessella, Robert; Lange, Paul H.; Nelson, Peter S.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Mail Code CR-145,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM beert@ohsu.edu FU NIH-National Cancer Institute [5R01CA119125]; Pacific Northwest Prostate Cancer Specialized Program of Research Excellence Career Development Award and Research Support [CA97186]; Department of Defense Fellowship [PC050489]; sanofi-aventis [16080]; OSI Pharmaceuticals [031.G0008]; Thomas and Gun Denhart FX NIH-National Cancer Institute grant 5R01CA119125, Pacific Northwest Prostate Cancer Specialized Program of Research Excellence Career Development Award and Research Support grant CA97186, Department of Defense Fellowship Award PC050489, sanofi-aventis 16080, OSI Pharmaceuticals 031.G0008, and Thomas and Gun Denhart. NR 53 TC 10 Z9 10 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 1 PY 2009 VL 15 IS 9 BP 3135 EP 3142 DI 10.1158/1078-0432.CCR-08-1982 PG 8 WC Oncology SC Oncology GA 440PL UT WOS:000265712100023 PM 19366833 ER PT J AU Shirley, RM Baddley, JW AF Shirley, Rhett M. Baddley, John W. TI Cryptococcal lung disease SO CURRENT OPINION IN PULMONARY MEDICINE LA English DT Article DE amphotericin B; cryptococcosis; Cryptococcus neoformans; fluconazole; pneumonia ID ORGAN TRANSPLANT RECIPIENTS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RECONSTITUTION INFLAMMATORY SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; VIRUS-NEGATIVE PATIENTS; PULMONARY CRYPTOCOCCOSIS; NEOFORMANS INFECTION; FUNGAL-INFECTIONS; HIV-INFECTION; CLINICAL MANIFESTATIONS AB Purpose of review Cryptococcosis is an important opportunistic fungal infection, especially in the immunocompromised patient. Meningitis is the most common manifestation of cryptococcosis; however, cryptococcal lung disease is probably underdiagnosed, and knowledge of epidemiology, diagnosis, and treatment is necessary. Recent findings Cryptococcal lung disease ranges from asymptomatic colonization or infection to severe pneumonia with respiratory failure. Clinical presentation of pulmonary cryptococcosis is highly variable and often is related to the immune status of the patient. There have been many important clinical trials outlining treatment of cryptococcal meningitis in patients with AIDS, but there is a lack of treatment data available for patients with cryptococcal lung disease. Treatment recommendations for cryptococcal lung disease are made on the basis of host immune status and severity of clinical illness. For less severe disease, fluconazole therapy is recommended. In immunocompromised patients, or those with severe disease, induction therapy with an amphotericin B preparation and flucytosine, followed by fluconazole as consolidation and maintenance therapy, is recommended. Summary Cryptococcal lung disease is an important and probably underdiagnosed infection. Knowledge of the epidemiology, diagnostic methodologies, and treatment is needed to ensure good patient outcomes. C1 [Shirley, Rhett M.; Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM jbaddley@uab.edu FU Pfizer; Astellas Pharma; Merck and Co FX Dr Baddley has received research support from Pfizer, Astellas Pharma, and Merck and Co. NR 67 TC 18 Z9 24 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5287 J9 CURR OPIN PULM MED JI Curr. Opin. Pulm. Med. PD MAY PY 2009 VL 15 IS 3 BP 254 EP 260 DI 10.1097/MCP.0b013e328329268d PG 7 WC Respiratory System SC Respiratory System GA 442XF UT WOS:000265873300011 PM 19352182 ER PT J AU Freedland, SJ Aronson, WJ AF Freedland, Stephen J. Aronson, William J. TI Dietary intervention strategies to modulate prostate cancer risk and prognosis SO CURRENT OPINION IN UROLOGY LA English DT Review DE carbohydrates; diet; fat; nutrition; prostate cancer ID GROWTH-FACTOR AXIS; LIFE-STYLE CHANGES; LOW-FAT DIET; BREAST-CANCER; MODIFICATION TRIAL; GENE-EXPRESSION; XENOGRAFTS; NUTRITION; ACIDS; RESTRICTION AB Purpose of review There is increasing interest in complementary and holistic approaches for cancer prevention and management. We sought to review the latest literature regarding dietary interventions for prostate cancer with a special emphasis on dietary fat and carbohydrate intake for modulating prognosis among men with prostate cancer. Recent findings Several recent prospective trials have investigated various dietary and lifestyle investigations on malignant prostate tissue biology. These interventions included a very low-fat (12% fat kcals) vegan diet with various supplements and lifestyle changes, a more traditional low-fat diet (25% fat kcals) with flaxseed supplementation, and a low-glycemic index diet. Low-glycemic index and very low-fat vegan diets (with supplements and lifestyle changes) alter tumor biology as assessed by tumor gene expression changes, with a common mechanism perhaps being weight loss whereas no effects were seen with a traditional low-fat diet. In mice, either very low-fat or low-carbohydrate diets significantly slow tumor growth independent of weight loss. Epidemiologic and preclinical data also suggest cholesterol intake and serum cholesterol levels may be linked with the development and progression of prostate cancer. Summary Small clinical trials suggest that tumor biology can be altered by either a vegan low-fat diet or eliminating simple carbohydrates accompanied by weight loss. Larger and longer term studies are needed to determine the clinical relevance of these findings. C1 [Freedland, Stephen J.] Duke Univ, Med Ctr, Dept Surg, Div Urol Surg,DPC,Sch Med, Durham, NC 27710 USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Div Urol Surg, Durham, NC 27710 USA. [Freedland, Stephen J.] Durham VA Med Ctr, Urol Sect, Dept Surg, Durham, NC USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Surg, Urol Sect,Greater Los Angeles VA Med Ctr, Los Angeles, CA 90024 USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90024 USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Dept Surg, Div Urol Surg,DPC,Sch Med, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu FU Department of Veterans Affairs; Department of Defense; AUA Foundation/Astellas Rising Star in Urology Award FX Supported by the Department of Veterans Affairs, Department of Defense, and the AUA Foundation/Astellas Rising Star in Urology Award. NR 32 TC 16 Z9 17 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0963-0643 J9 CURR OPIN UROL JI Curr. Opin. Urol. PD MAY PY 2009 VL 19 IS 3 BP 263 EP 267 DI 10.1097/MOU.0b013e328329ea6c PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 438XW UT WOS:000265590900008 PM 19300265 ER PT J AU Tierney, E Barker, A Ahdout, J Hanke, CW Moy, RL Kouba, DJ AF Tierney, Emily Barker, Allison Ahdout, Jennifer Hanke, C. William Moy, Ronald L. Kouba, David J. TI Photodynamic Therapy for the Treatment of Cutaneous Neoplasia, Inflammatory Disorders, and Photoaging SO DERMATOLOGIC SURGERY LA English DT Review ID BASAL-CELL CARCINOMA; DELTA-AMINOLEVULINIC-ACID; TOPICAL METHYL AMINOLEVULINATE; NONMELANOMA SKIN-CANCER; INTENSE PULSED-LIGHT; RENAL-TRANSPLANT RECIPIENTS; MULTIPLE ACTINIC KERATOSES; TERM-FOLLOW-UP; 5-AMINOLEVULINIC ACID; BOWENS-DISEASE AB Photodynamic therapy (PDT) has demonstrated high efficacy, minimal side effects, and improved cosmetic outcome when used for the treatment of actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma, and photoaging. To review the literature on the use of PDT in dermatologic surgery using MEDLINE. Published clinical studies using PDT in the treatment of AKs yield overall efficacy rates ranging from 50% to 71% with one treatment to as high as 88% to 90% with two or more treatments. For superficial BCC, initial clearance rates were 76% to 97%, and for Bowen's disease, initial clearance rates ranged from 72% to 94% overall. The use of PDT for photorejuvenation is a relatively new application of this technology, which has shown promise in improving the appearance of fine lines, pigmentary variation, and telangiectasias. The advantages of photodynamic therapy include the capacity for noninvasive targeted therapy through topical application of aminolevulinic acid and methyl aminolevulinic acid, with outstanding cosmetic results. Although the theory behind the use of chemical photosensitizers and ultraviolet light to treat a wide variety of skin disorders is straightforward, the practical application of this technology is evolving. Additional research into the precise mechanisms of action for specific photosensitizers and optimal light sources will be highly beneficial to the advancement of this technology. The authors have indicated no significant interest with commercial supporters. C1 [Kouba, David J.] Henry Ford Hlth Syst, Detroit, MI USA. [Tierney, Emily; Hanke, C. William] Laser & Skin Surg Ctr Indiana, Dept Dermatol, Indiana, PA USA. [Barker, Allison] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Ahdout, Jennifer; Moy, Ronald L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moy, Ronald L.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Kouba, DJ (reprint author), Henry Ford Hlth Syst Dermatol, 3031 W Grand Blvd,Suite 800, Detroit, MI 48202 USA. EM dkouba1@hfhs.org NR 93 TC 36 Z9 40 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1076-0512 J9 DERMATOL SURG JI Dermatol. Surg. PD MAY PY 2009 VL 35 IS 5 BP 725 EP 746 DI 10.1111/j.1524-4725.2009.01117.x PG 22 WC Dermatology; Surgery SC Dermatology; Surgery GA 437IV UT WOS:000265481500001 PM 19309338 ER PT J AU Eid, AA Gorin, Y Fagg, BM Maalouf, R Barnes, JL Block, K Abboud, HE AF Eid, Assaad A. Gorin, Yves Fagg, Bridget M. Maalouf, Rita Barnes, Jeffrey L. Block, Karen Abboud, Hanna E. TI Mechanisms of Podocyte Injury in Diabetes Role of Cytochrome P450 and NADPH Oxidases SO DIABETES LA English DT Article ID 20-HYDROXYEICOSATETRAENOIC ACID; ARACHIDONIC-ACID; EPITHELIAL-CELLS; RAT-KIDNEY; NEPHROPATHY; APOPTOSIS; GLUCOSE; MICE; NUMBER; CYTOTOXICITY AB OBJECTIVE-We investigated the role of cytochrome P450 of the 4A family (CYP4A), its metabolites, and NADPH oxidases both in reactive oxygen species (ROS) production and apoptosis of podocytes exposed to high glucose and in OVE26 mice, a model of type 1 diabetes. RESEARCH DESIGN AND METHODS-Apoptosis, albuminuria, ROS generation, NADPH superoxide generation, CYP4A and Nox protein expression, and mRNA levels were measured in vitro and in vivo. RESULTS-Exposure of mouse podocytes to high glucose resulted in apoptosis, with approximately one-third of the cells being apoptotic by 72 h. High-glucose treatment increased ROS generation and was associated with sequential upregulation of CYP4A and an increase in 20-hydroxyeicosatetraenoic acid (20-HETE) and Nox oxidases. This is consistent with the observation of delayed induction of NADPH oxidase activity by high glucose. The effects of high glucose on NADPH oxidase activity, Nox proteins and mRNA expression, and apoptosis were blocked by N-hydroxy-N'-(4-butyl-2-methylphenol) formamidine (HET0016), an inhibitor of CYP4A, and were mimicked by 20-HETE. CYP4A and Nox oxidase expression was upregulated in glomeruli of type I diabetic OVE26 mice. Treatment of OVE26 mice with HET0016 decreased NADPH oxidase activity and Nox1 and Nox4 protein expression and ameliorated apoptosis and albuminuria. CONCLUSIONS-Generation of ROS by CYP4A monooxygenases, 20-HETE, and Nox oxidases is involved in podocyte apoptosis in vitro and in vivo. Inhibition of selected cytochrome P450 isoforms prevented podocyte apoptosis and reduced proteinuria in diabetes. Diabetes 58:1201-1211, 2009 C1 [Eid, Assaad A.; Gorin, Yves; Fagg, Bridget M.; Maalouf, Rita; Barnes, Jeffrey L.; Block, Karen; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Barnes, Jeffrey L.; Block, Karen; Abboud, Hanna E.] S Texas Vet Healthcare Syst, San Antonio, TX USA. RP Abboud, HE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM abboud@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU National Kidney Foundation Postdoctoral Fellowship; American Heart Association South Central Affiliate; Juvenile Diabetes Research Foundation; National Institutes of Health [K01DK-076923, DK061597, DK-R01-078971]; American Diabetes Association FX Support for these studies was provided by the following sources: a National Kidney Foundation Postdoctoral Fellowship (to A.A.E.), an American Heart Association South Central Affiliate and Juvenile Diabetes Research Foundation regular research grant (to Y.G.), National Institutes of Health Grant K01DK-076923 (to K.B.), National Institutes of Health, George O'Brien Kidney Center-morphology core grant no. DK061597 (to J.L.B.), and National Institutes of Health Grant DK-R01-078971 and grants from the American Diabetes Association and the Juvenile Diabetes Research Foundation (to H.E.A.). NR 42 TC 124 Z9 132 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD MAY PY 2009 VL 58 IS 5 BP 1201 EP 1211 DI 10.2337/db08-1536 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 440YX UT WOS:000265736700020 PM 19208908 ER PT J AU Palmer, JP AF Palmer, Jerry P. TI C-peptide in the natural history of type 1 diabetes SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Review ID BETA-CELL FUNCTION; ANTI-CD3 MONOCLONAL-ANTIBODY; INSULIN-SECRETION; BLOOD-FLOW; ONSET; TRIAL; DYSFUNCTION; MELLITUS; GLUCOSE; ASSOCIATION AB Type 1 diabetes is diagnosed when the patient's endogenous insulin secretion decreases to a level which results in hyperglycemia. After diagnosis, insulin secretion continues to decline. As a reference for clinical trials trying to preserve endogenous beta-cell function in patients with recently diagnosed type 1 diabetes, in this short review I attempt to Summarize the natural history of endogenous beta-cell function after the diagnosis of type 1 diabetes. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Palmer, Jerry P.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Palmer, Jerry P.] Univ Washington, Seattle, WA 98195 USA. RP Palmer, JP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. EM jpp@u.washington.edu FU NIH [DK62203, DK17047, DK60155]; Medical Research Service of the Department of Veteran Affairs FX The author receives support from the following NIH grants: DK62203, DK17047, DK60155 and thanks Meron Rezene for helping in preparing this manuscript. Supported (in part) by the Medical Research Service of the Department of Veteran Affairs. NR 29 TC 22 Z9 23 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1520-7560 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD MAY PY 2009 VL 25 IS 4 BP 325 EP 328 DI 10.1002/dmrr.943 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 449RH UT WOS:000266347200006 PM 19267337 ER PT J AU Abudayyeh, S Hoffman, J El-Zimaity, HT Graham, DY AF Abudayyeh, S. Hoffman, J. El-Zimaity, H. T. Graham, D. Y. TI Prospective, randomized, pathologist-blinded study of disposable alligator-jaw biopsy forceps for gastric mucosal biopsy SO DIGESTIVE AND LIVER DISEASE LA English DT Article DE Adequacy; Depth; Endoscopy; Forceps; Gastric biopsy ID ENDOSCOPIC BIOPSY; GASTROINTESTINAL ENDOSCOPY; SPECIMENS; ADEQUACY; PERFORMANCE; SYSTEM; NEEDLE AB Background. Endoscopic biopsy forceps differ in the size and shape of the biopsy cup and the presence or absence of a needle. Methods. We compared four different "large cup" forceps (three with needles) designed for 2.8 min biopsy channels. A gastric antral and corpus biopsy were obtained with each. Parameters examined included: weight (mg), length (mm), orientation (poor, good), intactness (1, 2, or 3 pieces), depth (superficial, above muscularis mucosae, included muscularis mucosae), crush artefact (yes, no), and overall adequacy (inadequate, suboptimal, adequate). Results. Twenty-four patients were enrolled (191 biopsies). The median length was approximately 5 mm (range 1.1-8.2 mm). Histologically inadequate specimens were present in 4% with the forceps without needle compared to 16% of those with needles (P = 0.061) and there were significantly fewer specimens in three or more pieces than did the forceps with needles 2.1% vs. 12.6% (P<0.05). Conclusions. Current alligator style forceps provide a high proportion of acceptable specimens with only minor differences between brands. Forceps from one source were least preferred by endoscopy assistants and had the highest rates of inadequate biopsies and biopsies with crush artefact. Forceps without needles provide histologically acceptable samples slightly more frequently than those with needles. (C) 2008 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. C1 [Graham, D. Y.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU Office of Research and Development Medical Research Service Department of Veterans Affairs; Public Health Service [DK56338]; Texas Gulf Coast Digestive Diseases Center FX This was an investigator imitated project and was supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs and by Public Health Service grant DK56338 which funds the Texas Gulf Coast Digestive Diseases Center. NR 15 TC 5 Z9 5 U1 0 U2 0 PU PACINI EDITORE PI PISA PA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY SN 1590-8658 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD MAY PY 2009 VL 41 IS 5 BP 340 EP 344 DI 10.1016/j.dld.2008.07.317 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 449SI UT WOS:000266349900004 PM 18799373 ER PT J AU Peura, DA Freston, JW Haber, MM Kovacs, TO Hunt, B Atkinson, S AF Peura, David A. Freston, James W. Haber, Marian M. Kovacs, Thomas O. Hunt, Barbara Atkinson, Stuart TI Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Erosive esophagitis; Gastroesophageal reflux disease; Maintenance therapy; Lansoprazole; Heartburn; Ranitidine ID GASTROESOPHAGEAL-REFLUX DISEASE; QUALITY-OF-LIFE; NATURAL-HISTORY; DOSE LANSOPRAZOLE; OMEPRAZOLE; ESOMEPRAZOLE; PANTOPRAZOLE; RELAPSE; TRIAL; MULTICENTER AB In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after open-label treatment with lansoprazole 30 mg once daily for 8 weeks and received double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily for up to 1 year. At 1 year, 67% of lansoprazole-treated and 13% of ranitidine-treated patients remained healed (P < 0.001). Lansoprazole-treated patients experienced significantly greater symptom relief (P < 0.001), and, if asymptomatic at entry into the maintenance phase, remained asymptomatic for significantly longer than ranitidine-treated patients (P < 0.001). Symptom status correlated with healing (P = 0.001), supporting the symptom-directed management of EE. Both treatments were well tolerated and no unexpected events occurred. Daily therapy with lansoprazole to prevent the relapse of EE is effective, well tolerated, and superior to ranitidine in the maintenance of healing and symptom relief. C1 [Peura, David A.] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA. [Freston, James W.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Haber, Marian M.] Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19104 USA. [Kovacs, Thomas O.] CURE Clin, VA Greater Healthcare Syst, Los Angeles, CA USA. [Hunt, Barbara; Atkinson, Stuart] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA. RP Peura, DA (reprint author), Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA. EM dap8v@virginia.edu FU Takeda Global Research & Development Center, Inc., Deerfield, IL, USA [M94-140] FX This study (M94-140) was funded by Takeda Global Research & Development Center, Inc., Deerfield, IL, USA (TAP Pharmaceutical Products Inc. is now part of Takeda Global Research & Development Center, Inc.). Editorial support for the preparation of this article was provided by Rx Communications (UK). Dr. Peura is a consultant for Takeda Global Research & Development Center, Inc., and is a member of the speaker's bureau for Takeda Pharmaceuticals North America, Inc., Astra Zeneca, and Santarus. Dr. Freston serves as a consultant for Takeda Global Research & Development Center, Inc., Takeda Pharmaceuticals North America, Inc., GlaxoSmithKline, and EnteroMedics Inc. Dr. Haber is a consultant for Takeda Global Research & Development Center, Inc. Dr. Kovacs confirms that he has no conflicts of interest or disclosures. NR 36 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAY PY 2009 VL 54 IS 5 BP 955 EP 963 DI 10.1007/s10620-008-0466-9 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 427WP UT WOS:000264810100006 PM 18726153 ER PT J AU Pisegna, JR Karlstadt, RG Norton, JA Fogel, R Oh, DS Graepel, GJ Dorr, MB AF Pisegna, Joseph R. Karlstadt, Robyn G. Norton, Jeffrey A. Fogel, Ronald Oh, David S. Graepel, G. Jay Dorr, Mary Beth TI Effect of Preoperative Intravenous Pantoprazole in Elective-Surgery Patients: A Pilot Study SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Intravenous; Pantoprazole; Aspiration pneumonia; Gastric volume; Gastric acid output ID EMERGENCY CESAREAN-SECTION; GASTRIC-ACID HYPERSECRETION; ZOLLINGER-ELLISON-SYNDROME; PULMONARY ASPIRATION; GENERAL-ANESTHESIA; ORAL RANITIDINE; FLUID PROPERTY; OMEPRAZOLE; PH; VOLUME AB Background This study evaluated the effects of intravenous pantoprazole on gastric volume and acid output in elective-surgical patients. Methods This is a multicenter, randomized, pilot study of adult patients receiving intravenous pantoprazole: 40 mg every 24 h, 40 mg every 12 h (q12h) or 80 mg q12h. The first dose was administered 1 h before general anesthesia for surgery. All gastric fluid was aspirated through a nasogastric tube 1 h before dosing and through the postoperative period. Aspirate volume was recorded; pH and H(+) concentrations were measured. Result Twenty-six patients were enrolled and 21 were evaluable. Pantoprazole was well tolerated. All regimens decreased gastric acid output and volume, and increased pH within 1 h of dosing. Effects were sustained for up to 12 h following single-dose administration. Conclusions Intravenous pantoprazole administered prior to anesthesia induction may be efficacious for the reduction of gastric volume and acid output, and for pulmonary aspiration prophylaxis in surgical patients. C1 [Pisegna, Joseph R.; Oh, David S.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. [Pisegna, Joseph R.; Oh, David S.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol 691 111C, Los Angeles, CA 90073 USA. [Pisegna, Joseph R.; Oh, David S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Karlstadt, Robyn G.; Graepel, G. Jay; Dorr, Mary Beth] Wyeth Pharmaceut, Global Med Affairs, Collegeville, PA USA. [Norton, Jeffrey A.] Stanford Univ, Dept Surg, Sch Med, San Francisco, CA USA. [Fogel, Ronald] Henry Ford Hlth Syst, Div Gastroenterol, Detroit, MI USA. RP Pisegna, JR (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol 691 111C, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu FU Wyeth Pharmaceuticals, Collegeville, PA; Wyeth; Novartis FX This study was funded by Wyeth Pharmaceuticals, Collegeville, PA. Conflicts-of-interest: Dr. David Oh-grant support from Wyeth; Dr. Joseph Pisegna-consultant, Grant Support from and Speaker for: Wyeth, Astra Zeneca, Takeda (TAP) and Novartis; Dr. Jeffrey Norton-none to disclose; Dr. Ronald Fogel-none to disclose; Jay Graepel and Mary Beth Dorr are currently and Robyn Karlstadt was formerly employed by Wyeth Pharmaceuticals. NR 27 TC 3 Z9 4 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAY PY 2009 VL 54 IS 5 BP 1041 EP 1049 DI 10.1007/s10620-008-0445-1 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 427WP UT WOS:000264810100018 PM 18754096 ER PT J AU Batki, SL Canfield, KM Smyth, E Ploutz-Snyder, R AF Batki, Steven L. Canfield, Kelly M. Smyth, Emily Ploutz-Snyder, Robert TI Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Hepatitis C; Methadone; Opioid; Substance abuse; Quality of life; Health; Psychiatry ID INJECTION-DRUG USERS; RISK-FACTORS; SURVEY QUESTIONNAIRE; HCV-INFECTION; PREVALENCE; DEPRESSION; INTERFERON-ALPHA-2B; MANAGEMENT; REDUCTION; EQUIPMENT AB Objective: To assess health-related quality of life (HRQOL) in methadone maintenance treatment (MMT) patients with untreated chronic HCV infection and to determine the clinical factors that predict HRQOL. Method: HRQOL was measured in 100 MMT patients entering an HCV treatment trial. Subjects were mostly male (61%) and white (81%) with a mean age of 43 (+/- 10). 57% had a current non-substance use psychiatric disorder. 55% had a current (past 12 months) substance use disorder, including 44% with current opioid or cocaine abuse/dependence. HRQOL in our sample was compared to published reports for the general population as well as for non-MMT HCV patients. To assess predictors of SF-36 HRQOL, hierarchical multiple regression techniques were used to assess model improvement with four blocks of baseline predictors: Demographics, Medical Severity, Addiction Severity, and Depression Severity. Results: HRQOL scores were significantly lower than scores for the general population and were also lower than scores reported for untreated HCV patients not in MMT. Regression analysis demonstrated a consistent pattern whereby Depression Severity increased predictive accuracy for HRQOL measures over simpler models. Beck Depression Inventory scores significantly predicted quality of life across both the mental and physical composite scores and all eight sub-scales of the SF-36. Conclusions: Untreated HCV patients in MMT had lower HRQOL than HCV patients not in MMT. Depression Severity was associated with significantly lower quality of life measures, suggesting that psychiatric evaluation and intervention prior to the start of HCV treatment may improve overall quality of life and could influence HCV treatment outcomes in MMT patients. (C) Published by Elsevier Ireland Ltd. C1 [Batki, Steven L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, Addict Psychiat Res Program, San Francisco, CA 94121 USA. [Canfield, Kelly M.; Smyth, Emily] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Ploutz-Snyder, Robert] Univ Space Res Assoc, NASA JSC, Lyndon B Johnson Space Ctr, SK, Houston, TX 77058 USA. RP Batki, SL (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, Addict Psychiat Res Program, 4150 Clement St,116P, San Francisco, CA 94121 USA. EM steven.batki@ucsf.edu FU National Institute on Drug Abuse (NIDA) [R01 DA 016764] FX This work was supported by National Institute on Drug Abuse (NIDA) grant R01 DA 016764. NIDA had no further role in study design; in the collection, analysis, and interpretation of the data; in the writing of this report; and in the decision to Submit the paper for publication. NR 48 TC 11 Z9 11 U1 2 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2009 VL 101 IS 3 BP 176 EP 182 DI 10.1016/j.drugalcdep.2008.12.012 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 430PY UT WOS:000265002200006 PM 19233573 ER PT J AU Moghissi, ES Korytkowski, MT DiNardo, M Einhorn, D Hellman, R Hirsch, IB Inzucchi, SE Ismail-Beigi, F Kirkman, MS Umpierrez, GE AF Moghissi, Etie S. Korytkowski, Mary T. DiNardo, Monica Einhorn, Daniel Hellman, Richard Hirsch, Irl B. Inzucchi, Silvio E. Ismail-Beigi, Faramarz Kirkman, M. Sue Umpierrez, Guillermo E. TI AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN DIABETES ASSOCIATION CONSENSUS STATEMENT ON INPATIENT GLYCEMIC CONTROL SO ENDOCRINE PRACTICE LA English DT Review ID ACUTE MYOCARDIAL-INFARCTION; INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; INSULIN INFUSION PROTOCOL; SLIDING-SCALE INSULIN; RANDOMIZED CONTROLLED-TRIAL; ENTERAL NUTRITION THERAPY; TRAUMATIC BRAIN-INJURY; TIGHT GLUCOSE CONTROL; SHORT-TERM MORTALITY C1 [Moghissi, Etie S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Korytkowski, Mary T.] Univ Pittsburgh, Dept Med, Div Endocrinol & Metab, Pittsburgh, PA USA. [DiNardo, Monica] Univ Pittsburgh, Sch Nursing, PhD Program, Pittsburgh, PA 15261 USA. [DiNardo, Monica] Vet Affairs Pittsburgh Hlth Ctr, Div Endocrinol & Metab, Pittsburgh, PA USA. [Einhorn, Daniel] Scripps Whittier Diabet Inst, La Jolla, CA USA. [Einhorn, Daniel] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Einhorn, Daniel] Diabet & Endocrine Associates, La Jolla, CA USA. [Hellman, Richard] Univ Missouri Kansas City, Dept Med, Sch Med, Kansas City, MO USA. [Hellman, Richard] Hellman & Rosen Endocrine Associates, Kansas City, MO USA. [Hirsch, Irl B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Inzucchi, Silvio E.] Yale Univ, Sch Med, Dept Med, Endocrinol Sect, New Haven, CT 06510 USA. [Inzucchi, Silvio E.] Yale New Haven Med Ctr, Yale Diabet Ctr, New Haven, CT 06504 USA. [Ismail-Beigi, Faramarz] Case Western Reserve Univ, Dept Physiol & Med Biophys, Div Clin & Mol Endocrinol, Cleveland, OH 44106 USA. [Kirkman, M. Sue] Amer Diabet Assoc, Clin Affairs, Alexandria, VA USA. [Umpierrez, Guillermo E.] Emory Univ, Dept Med Endocrinol, Atlanta, GA 30322 USA. RP Moghissi, ES (reprint author), 4644 Lincoln Blvd,Suite 409, Marina Del Rey, CA 90292 USA. NR 167 TC 189 Z9 212 U1 2 U2 6 PU AMER ASSOC CLIN ENDOCRINOL PI JACKSONVILLE PA 1000 RIVERSIDE AVE, STE 205, JACKSONVILLE, FL 32204 USA SN 1530-891X J9 ENDOCR PRACT JI Endocr. Pract. PD MAY-JUN PY 2009 VL 15 IS 4 BP 353 EP 369 DI 10.4158/EP09102.RA PG 17 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 459ZB UT WOS:000267151600013 PM 19454396 ER PT J AU Hope, OA Zeber, JE Kressin, NR Bokhour, BG VanCott, AC Cramer, JA Amuan, ME Knoefel, JE Pugh, MJ AF Hope, Omotola A. Zeber, John E. Kressin, Nancy R. Bokhour, Barbara G. VanCott, Anne C. Cramer, Joyce A. Amuan, Megan E. Knoefel, Janice E. Pugh, Mary Jo TI New-onset geriatric epilepsy care: Race, setting of diagnosis, and choice of antiepileptic drug SO EPILEPSIA LA English DT Article DE Race; Ethnicity; Geriatric epilepsy treatment; Healthcare quality; Medical specialties ID QUALITY-OF-LIFE; HEALTH-CARE; MYOCARDIAL-INFARCTION; EMERGENCY-DEPARTMENT; SERUM CONCENTRATIONS; ADMINISTRATIVE DATA; RACIAL DISPARITIES; ELDERLY-PATIENTS; DOUBLE-BLIND; RISK-FACTORS AB There is a growing movement to assess the quality of care provided to patients in the US, but few studies have examined initial care for epilepsy patients. We examined the relationships among patient race, setting of initial diagnosis, and initial treatment for older veterans newly diagnosed with epilepsy. We used Department of Veterans Affairs (VA) inpatient, outpatient, pharmacy and Medicare data (1999-2004) to identify patients 66 years and older with new-onset epilepsy. High quality care was defined as avoiding a suboptimal agent (phenytoin, phenobarbital, primidone) as defined by experts. Predictors included demographic and clinical characteristics, and the context of the initial seizure diagnosis including the setting (e.g. emergency, neurology, hospital, primary care). We used mixed-effects multivariable logistic regression modeling to identify predictors of initial seizure diagnosis in a neurology setting, and receipt of a suboptimal AED. Of 9,682 patients, 27% were initially diagnosed in neurology and 70% received a suboptimal AED. Blacks and Hispanics were less likely to be diagnosed in neurology clinics (black OR = 0.7 95% CI 0.6-0.8; Hispanic OR = 0.6 95% CI 0.5-0.9). Diagnosis in a non-neurology setting increased the likelihood of receiving a suboptimal agent (e.g. Emergency Department OR = 2.3 95% CI 2.0-2.7). After controlling for neurology diagnosis, black race was independently associated with an increased risk of receiving a suboptimal agent. We demonstrated that differences in quality of care exist for both clinical setting of initial diagnosis and race. We discussed possible causes and implications of these findings. C1 [Pugh, Mary Jo] S Texas Vet Hlth Care Syst VERDICT, Audie L Murphy Div 11C6, Vet Affairs HSR&D, San Antonio, TX 78229 USA. [Hope, Omotola A.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX USA. [Zeber, John E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Kressin, Nancy R.; Bokhour, Barbara G.; Amuan, Megan E.] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Kressin, Nancy R.] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA. [Bokhour, Barbara G.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [VanCott, Anne C.] VA Pittsburgh Healthcare Syst, Div Neurol, Pittsburgh, PA USA. [VanCott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Cramer, Joyce A.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Cramer, Joyce A.] Epilepsy Therapy Project, Orange, CT USA. [Knoefel, Janice E.] New Mexico Vet Healthcare Syst, Med Serv, Albuquerque, NM USA. [Knoefel, Janice E.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA. [Knoefel, Janice E.] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Gen Med, San Antonio, TX 78229 USA. RP Pugh, MJ (reprint author), S Texas Vet Hlth Care Syst VERDICT, Audie L Murphy Div 11C6, Vet Affairs HSR&D, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu OI Bokhour, Barbara/0000-0001-8238-0745; Kressin, Nancy/0000-0003-2767-4286; Pugh, Mary Jo/0000-0003-4196-7763 FU VA Health Services Research and Development Service [IIR 02-274]; Robert Wood Johnson Clinical Scholars Fellowship; Department of Veterans Affairs, Health Services Research and Development Service [RCS 02-066-1] FX Disclosure of conflicts of interest: Anne C. VanCott has research funding from GlaxoSmithKline. Joyce Cramer has been a consultant to Johnson and Johnson, Pfizer, Sepracor and UCB Pharma. The other authors report no conflicts of interest. NR 62 TC 15 Z9 15 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD MAY PY 2009 VL 50 IS 5 BP 1085 EP 1093 DI 10.1111/j.1528-1167.2008.01892.x PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 441LG UT WOS:000265770000016 PM 19054416 ER PT J AU Burneo, JG Del Brutto, O Delgado-Escueta, AV Gonzalez, AE Medina, MT Montano, SM Moyano, LM Nash, T Roman, G Singh, G White, AC Wiebe, S Garcia, HH AF Burneo, Jorge G. Del Brutto, Oscar Delgado-Escueta, Antonio V. Gonzalez, Armando E. Medina, Marco T. Montano, Silvia M. Moyano, Luz M. Nash, Theodore Roman, Gustavo Singh, Gagandeep White, A. Clinton, Jr. Wiebe, Samuel Garcia, Hector H. TI Workshop Report: Developing an international collaborative research network in neurocysticercosis and epilepsy SO EPILEPSIA LA English DT Editorial Material C1 [Burneo, Jorge G.] Univ Western Ontario, Epilepsy Programme, London, ON, Canada. [Del Brutto, Oscar] Hosp Clin Kennedy, Guayaquil, Ecuador. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, Epilepsy Ctr Excellence, VA Greater Healthcare Syst, Los Angeles, CA USA. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gonzalez, Armando E.] Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru. [Gonzalez, Armando E.; Moyano, Luz M.; Garcia, Hector H.] Cysticercosis Eliminat Project, Tumbes, Peru. [Gonzalez, Armando E.; Garcia, Hector H.] Inst Peruano Parasitol Clin & Expt, Lima, Peru. [Medina, Marco T.] Univ Autonoma Honduras, Tegucigalpa, Honduras. [Montano, Silvia M.] US Naval Res Detachment, Lima, Peru. [Moyano, Luz M.; Garcia, Hector H.] Univ Peruana Cayetano Heredia, Lima, Peru. [Nash, Theodore] Natl Inst Hlth, Bethesda, MD USA. [Roman, Gustavo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Singh, Gagandeep] Dayanand Med Coll, Ludhiana, Punjab, India. [White, A. Clinton, Jr.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA. [Wiebe, Samuel] Univ Calgary, Dept Neurosci, Calgary, AB, Canada. [Garcia, Hector H.] Inst Ciencias Neurol, Dept Transmissible Dis, Lima, Peru. RP Burneo, JG (reprint author), Univ Western Ontario, Epilepsy Programme, London, ON, Canada. EM jburneo2@uwo.ca OI White, A Clinton/0000-0002-9668-4632; Delgado-Escueta, Antonio V./0000-0002-1581-6999 FU Intramural NIH HHS [ZIA AI000846-15] NR 7 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD MAY PY 2009 VL 50 IS 5 BP 1289 EP 1290 DI 10.1111/j.1528-1167.2008.01912.x PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 441LG UT WOS:000265770000043 PM 19496808 ER PT J AU Burneo, JG Del Brutto, O Delgado-Escueta, AV Gonzalez, AE Medina, MT Montano, SM Moyano, LM Nash, T Roman, G Singh, G White, AC Wiebe, S Garcia, HH AF Burneo, Jorge G. Del Brutto, Oscar Delgado-Escueta, Antonio V. Gonzalez, Armando E. Medina, Marco T. Montano, Silvia M. Moyano, Luz M. Nash, Theodore Roman, Gustavo Singh, Gagandeep White, A. Clinton, Jr. Wiebe, Samuel Garcia, Hector H. TI Benign myoclonus of early infancy or Fejerman syndrome SO EPILEPSIA LA English DT Editorial Material ID SPASMS C1 [Burneo, Jorge G.] Univ Western Ontario, Epilepsy Programme, London, ON, Canada. [Del Brutto, Oscar] Hosp Clin Kennedy, Guayaquil, Ecuador. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, Epilepsy Ctr Excellence, VA Greater Healthcare Syst, Los Angeles, CA USA. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gonzalez, Armando E.] Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru. [Gonzalez, Armando E.; Moyano, Luz M.; Garcia, Hector H.] Cysticercosis Eliminat Project, Tumbes, Peru. [Gonzalez, Armando E.; Garcia, Hector H.] Inst Peruano Parasitol Clin & Expt, Lima, Peru. [Medina, Marco T.] Univ Autonoma Honduras, Tegucigalpa, Honduras. [Montano, Silvia M.] US Naval Res Detachment, Lima, Peru. [Moyano, Luz M.; Garcia, Hector H.] Univ Peruana Cayetano Heredia, Lima, Peru. [Nash, Theodore] Natl Inst Hlth, Bethesda, MD USA. [Roman, Gustavo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Singh, Gagandeep] Dayanand Med Coll, Ludhiana, Punjab, India. [White, A. Clinton, Jr.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA. [Wiebe, Samuel] Univ Calgary, Dept Neurosci, Calgary, AB, Canada. [Garcia, Hector H.] Inst Ciencias Neurol, Dept Transmissible Dis, Lima, Peru. RP Burneo, JG (reprint author), Univ Western Ontario, Epilepsy Programme, London, ON, Canada. EM jburneo2@uwo.ca NR 16 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD MAY PY 2009 VL 50 IS 5 BP 1290 EP 1292 DI 10.1111/j.1528-1167.2009.02154.x PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 441LG UT WOS:000265770000044 ER PT J AU Balajee, SA Baddley, JW Peterson, SW Nickle, D Varga, J Boey, A Lass-Florl, C Frisvad, JC Samson, RA AF Balajee, S. Arunmozhi Baddley, John W. Peterson, Stephen W. Nickle, David Varga, Janos Boey, Angeline Lass-Floerl, Cornelia Frisvad, Jens C. Samson, Robert A. CA ISHAM Working Grp A Terreus TI Aspergillus alabamensis, a New Clinically Relevant Species in the Section Terrei SO EUKARYOTIC CELL LA English DT Article ID PULMONARY ASPERGILLOSIS; POLYPHASIC TAXONOMY; FUMIGATUS; NEOSARTORYA; EPIDEMIOLOGY; INFECTIONS; EXPERIENCE AB Phylogenetic analyses of sequences generated from portions of three genes coding for the proteins enolase (enoA), beta-tubulin (benA), and calmodulin (calM) of a large number of isolates within the section Terrei, genus Aspergillus, revealed the presence of a new cryptic species within this section, Aspergillus alabamensis. Most members of this new cryptic species were recovered as colonizing isolates from immunocompetent patient populations, had decreased in vitro susceptibilities to the antifungal drug amphotericin B, and were morphologically similar to but genetically distinct from Aspergillus terreus isolates. C1 [Balajee, S. Arunmozhi; Boey, Angeline] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Baddley, John W.] Univ Alabama, Div Infect Dis, Birmingham, W Midlands, England. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Peterson, Stephen W.] USDA, Natl Ctr Agr Utilizat Res, Peoria, IL USA. [Nickle, David] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. [Varga, Janos; Samson, Robert A.] CBS Fungal Biodivers Ctr, Utrecht, Netherlands. [Varga, Janos] Univ Szeged, Dept Microbiol, Fac Sci & Informat, Szeged, Hungary. [Lass-Floerl, Cornelia] Med Univ Innsbruck, Dept Hyg Microbiol & Social Med, Innsbruck, Austria. [Frisvad, Jens C.] Tech Univ Denmark, Ctr Microbial Biotechnol, Biocentrum DTU, DK-2800 Lyngby, Denmark. RP Balajee, SA (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Mail Stop G11,1600 Clifton Rd, Atlanta, GA 30333 USA. EM fir3@cdc.gov RI Dijksterhuis, Jan/K-5945-2014 OI Dijksterhuis, Jan/0000-0002-2649-1704 NR 18 TC 29 Z9 30 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1535-9778 J9 EUKARYOT CELL JI Eukaryot. Cell PD MAY PY 2009 VL 8 IS 5 BP 713 EP 722 DI 10.1128/EC.00272-08 PG 10 WC Microbiology; Mycology SC Microbiology; Mycology GA 443JM UT WOS:000265906000004 PM 19304950 ER PT J AU Lu, JM Wang, XW Marin-Muller, C Wang, H Lin, PH Yao, QZ Chen, CY AF Lue, Jian-Ming Wang, Xinwen Marin-Muller, Christian Wang, Hao Lin, Peter H. Yao, Qizhi Chen, Changyi TI Current advances in research and clinical applications of PLGA-based nanotechnology SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review DE cancer; cardiovascular disease; diagnosis; drug delivery; imaging; nanoparticle; nanotechnology; polylactic-co-glycolic acid; vaccine ID POLY(LACTIC-CO-GLYCOLIC ACID) NANOPARTICLES; REPEAT PERCUTANEOUS INTERVENTION; PORCINE CORONARY-ARTERIES; MUSCLE-CELL PROLIFERATION; TARGETED DRUG-DELIVERY; IN-STENT RESTENOSIS; CONTRAST AGENT; BIODEGRADABLE NANOPARTICLES; CONTROLLED-RELEASE; DENDRITIC CELLS AB Co-polymer poly(lactic-co-glycolic acid) (PLGA) nanotechnology has been developed for many years and has been approved by the US FDA for the use of drug delivery, diagnostics and other applications of clinical and basic science research, including cardiovascular disease, cancer, vaccine and tissue engineering. This article presents the more recent successes of applying PLGA-based nanotechnologies and tools in these medicine-related applications. It focuses on the possible mechanisms, diagnosis and treatment effects of PLGA preparations and devices. This updated information will benefit to both new and established research scientists and clinical physicians who are interested in the development and application of PLGA nanotechnology as new therapeutic and diagnostic strategies for many diseases. C1 [Chen, Changyi] Baylor Coll Med, Michael E DeBakey Dept Surg R413, Houston, TX 77030 USA. [Lue, Jian-Ming; Wang, Xinwen; Marin-Muller, Christian; Wang, Hao; Lin, Peter H.; Yao, Qizhi] Baylor Coll Med, Michael E DeBakey Dept Surg, Mol Surgeon Res Ctr, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. [Lue, Jian-Ming; Wang, Xinwen; Marin-Muller, Christian; Wang, Hao; Lin, Peter H.; Yao, Qizhi] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Chen, CY (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg R413, 1 Baylor Plaza,Mail Stop BCM390, Houston, TX 77030 USA. EM jchen@bcm.tmc.edu FU NIBIB NIH HHS [R01 EB002436-04, EB002436, R01 EB002436] NR 141 TC 280 Z9 294 U1 12 U2 99 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD MAY PY 2009 VL 9 IS 4 BP 325 EP 341 DI 10.1586/ERM.09.15 PG 17 WC Pathology SC Pathology GA 446SC UT WOS:000266140400005 PM 19435455 ER PT J AU Quinn, JF Crane, S Harris, C Wadsworth, TL AF Quinn, Joseph F. Crane, Susanne Harris, Christopher Wadsworth, Teri L. TI Copper in Alzheimer's disease: too much or too little? SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Review DE Alzheimer's disease; animal model; chelation; clinical trial; copper; oxidative damage AB A considerable amount of literature has accrued examining the role of copper in the pathogenesis of Alzheimer's disease. Remarkably, there is in vitro and animal data to support both copper toxicity and copper deficiency as relevant mechanisms in Alzheimer's disease. These data have prompted preliminary clinical trials of both copper complexing therapy and copper supplementation therapy, which have yielded mixed results. The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation. C1 [Quinn, Joseph F.; Crane, Susanne; Harris, Christopher; Wadsworth, Teri L.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol CR 131, Portland, OR 97239 USA. RP Quinn, JF (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol CR 131, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM quinnj@ohsu.edu FU NIA [R21AG027445A]; Department of Veteran's Affairs FX This work was supported by NIA (R21AG027445A) and the Department of Veteran's Affairs. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 54 TC 26 Z9 27 U1 1 U2 1 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 EI 1744-8360 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD MAY PY 2009 VL 9 IS 5 BP 631 EP 637 DI 10.1586/ERN.09.27 PG 7 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA V39ZQ UT WOS:000209449300011 PM 19402774 ER PT J AU Borrero, S Schwarz, EB Reeves, MF Bost, JE Creinin, MD Ibrahim, SA AF Borrero, Sonya Schwarz, Eleanor B. Reeves, Matthew F. Bost, James E. Creinin, Mitchell D. Ibrahim, Said A. TI Does vasectomy explain the difference in tubal sterilization rates between black and white women? SO FERTILITY AND STERILITY LA English DT Article DE National Survey of Family Growth (NSFG); race/ethnicity; tubal sterilization; vasectomy ID UNITED-STATES; CONTRACEPTIVE STERILIZATION AB Objective: To examine whether the observed difference in tubal sterilization rates between black and white women is dependent on racial/ethnic differences in vasectomy rates. Design: Secondary analysis of national, cross-sectional survey. Setting: 2002 National Survey of Family Growth. Patient(s): Women 15 to 44 years old with a current partner who were able to provide information about their partner's vasectomy status. Intervention(s): None. Main Outcome Measure(s): The primary outcome was tubal sterilization. Among women with a current partner who had not undergone vasectomy, a multivariable logistic regession model was used to estimate the effects of race/ethnicity on tubal sterilization after adjusting for potential confounders. Result(s): Of the 3,391 women in the sample, 14% of white women had a current partner who had undergone vasectomy compared with 5% of Hispanic women and 4% of black women. Among the 3.064 women whose partners had not undergone vasectomy, black women were more likely to undergo tubal sterilization (odds ratio: 1.6; 95% confidence interval: 1.1, 2.2) on the basis of adjusted multivariable analysis. Conclusion(s): After controlling for partner vasectomy status, black women were still more likely to undergo tubal sterilization than white women. (Fertil Steril (R) 2009;91:1642-5. (C)2009 by American Society for Reproductive Medicine.) C1 [Borrero, Sonya] Univ Pittsburgh, Ctr Res Hlth Care, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Borrero, Sonya; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA. [Schwarz, Eleanor B.; Reeves, Matthew F.; Creinin, Mitchell D.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Bost, James E.] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA USA. [Creinin, Mitchell D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, Sch Med, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15260 USA. EM borrerosp@upmc.edu RI Potter, Joseph/A-3122-2008 OI Reeves, Matthew/0000-0001-7749-7447; Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU Organon; Bayer FX M.D.C. has received research funding from, and served as a consultant for, Organon, and has received research funding and honoraria from Bayer. S.A.I. has nothing to disclose. NR 12 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD MAY PY 2009 VL 91 IS 5 BP 1642 EP 1645 DI 10.1016/j.fertnstert.2008.01.103 PG 4 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 444GR UT WOS:000265969200004 PM 18394618 ER PT J AU El-Serag, HB Johnson, ML Hachem, C Morgana, RO AF El-Serag, Hashem B. Johnson, Michael L. Hachem, Christine Morgana, Robert O. TI Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes SO GASTROENTEROLOGY LA English DT Article ID COA REDUCTASE INHIBITORS; COENZYME-A REDUCTASE; SCANDINAVIAN SIMVASTATIN SURVIVAL; COMBINATION THERAPY; PHARMACY RECORDS; FOLLOW-UP; CELLS; CANCER; APOPTOSIS; PROLIFERATION AB Background & Aims: Experimental studies indicate a potential cancer prevention effect for statins. Given the increasing prevalence of statin use, and the increasing incidence of hepatocellular carcinoma (HCC), the potential association between statins and HCC is an important issue to examine. Methods: We conducted a matched case-control study nested within a cohort of patients with diabetes. Cases comprised incident HCC at least 6 months after entry in the cohort. Controls were identified by incidence density sampling from patients who remained at risk at the date of the HCC diagnosis matched by age and sex. We identified fined statin prescriptions as well as several potential confounding conditions, medications, as well as propensity score to use statins. Odds ratios (ORs) as estimates of the relative risk for HCC associated with statin use and 95% confidence intervals were obtained using conditional logistic regression. Results: We examined 1303 cases and 5212 controls. The mean age was 72 years and 99% were men. A significantly smaller proportion of cases (34.3%) had at least one filled prescription for statins than controls (53.1%). There were no significant associations between HCC and nonstatin cholesterol- or triglyceride-lowering medications. The unadjusted OR for any statin prescription was 0.46 (9S% confidence interval, 0.40-0.517) and the adjusted OR was 0.74 (95% confidence interval, 0.64-0.87). To reduce the potential confounding effect of existing liver disease, we ran the analyses in a subgroup of patients without recorded liver disease; the ORs were slightly attenuated but remained highly significant for any statin prescription (0.63; 95% confidence interval, 0.50-0.78). Conclusions: Statin use is associated with a significant reduction in the risk of HCC among patients with diabetes. C1 [El-Serag, Hashem B.; Hachem, Christine; Morgana, Robert O.] Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. [El-Serag, Hashem B.; Hachem, Christine; Morgana, Robert O.] Michael E DeBakey Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. [El-Serag, Hashem B.; Hachem, Christine; Morgana, Robert O.] Baylor Coll Med, Houston, TX 77030 USA. [Johnson, Michael L.] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU Department of Veterans Affairs; Health Services Research and Development Service [IIR 02-081]; American College of Gastroenterology; National Institutes of Health [K24DK078154-03] FX This research was supported in part by the Department of Veterans Affairs, Health Services Research and Development Service (IIR 02-081), and by a grant from the American College of Gastroenterology. Dr EI-Serag is supported by a National Institutes of Health grant (K24DK078154-03). NR 28 TC 129 Z9 134 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2009 VL 136 IS 5 BP 1601 EP 1608 DI 10.1053/j.gastro.2009.01.053 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 440WQ UT WOS:000265730800023 PM 19208359 ER PT J AU Taylor-Young, P Hildebrandt, E AF Taylor-Young, Patricia Hildebrandt, Eugenie TI The Multidimensional Burden of Hepatitis C and Its Treatment A Case Study SO GASTROENTEROLOGY NURSING LA English DT Article ID ANTIVIRAL TREATMENT; UNITED-STATES; DEPRESSION; PREVALENCE; MANAGEMENT; INFECTION; VETERANS AB The purpose of this case study was to gain an in-depth understanding of the mental, physical, and emotional burden of being infected with the hepatitis C virus (HCV) from the perspective of an individual living with the disease and undergoing antiviral treatment. Interviews were conducted during and after antiviral therapy with 1 participant chosen from a Midwest HCV clinic population. Interviews were audio recorded, transcribed verbatim, and coded. Content analysis and thematic analysis were performed. The participant reviewed and validated the themes and the interpretation of the themes. Ten categories were identified, which were subsequently integrated in 4 themes: (1) transition or process of change, (2) maintaining control over one's life, (3) social support and communication, and (4) side effects. The results of this study can assist healthcare providers to understand what individuals experience in the course of HCV infection and its treatment. This knowledge will assist them to provide effective patient-centered care. To provide such care, it is imperative that healthcare providers understand the physical, psychological, social, and professional impact that the diagnosis of HCV infection and antiviral therapy has on individuals. C1 [Taylor-Young, Patricia] Portland VA Med Ctr, Portland, OR 97239 USA. [Hildebrandt, Eugenie] Univ Wisconsin, Coll Nursing, Milwaukee, WI 53201 USA. RP Taylor-Young, P (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd P2NR, Portland, OR 97239 USA. EM patricia.tayloryoung@va.gov NR 28 TC 7 Z9 7 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1042-895X J9 GASTROENTEROL NURS JI Gastroenterol. Nurs. PD MAY-JUN PY 2009 VL 32 IS 3 BP 180 EP 187 PG 8 WC Gastroenterology & Hepatology; Nursing SC Gastroenterology & Hepatology; Nursing GA 458JV UT WOS:000267015300003 PM 19506434 ER PT J AU Fasanella, KE McGrath, KM Sanders, M Brody, D Domsic, R Khalid, A AF Fasanella, Kenneth E. McGrath, Kevin M. Sanders, Michael Brody, Debra Domsic, Robyn Khalid, Asif TI Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/109th Annual Meeting of the American-Gastroenterological-Association CY MAY 17-22, 2008 CL San Diego, CA SP Amer Gastroenterol Assoc ID CHROMOSOME 1Q; HETEROZYGOSITY; DIAGNOSIS; INSULINOMAS; PROGRESSION; MALIGNANCY; DELETION; CRITERIA; SYSTEM AB Background: The clinical course of pancreatic endocrine tumors (PET) depends on tumor size, the presence Of invasion or metastasis, the Ki-67 index, mitose's per high power field, and mutational damage. Most of this information is not available before surgery for clinical decision making or prognostication. Objective: To evaluate PET FUS-guided FNA (EUS-FNA) microsatellite loss analysis in the context of PET-related mortality. Design: A single institution retrospective cohort. Patients: Patients with PET diagnosed by EUS-FNA who underwent DNA microsatellite loss analysis and at least 1 year of follow-up or subsequent death. Intervention: PET microsatellite loss analysis and current clinical status were compared Results: Twenty-nine patients were included in the final analysis; the mean age of the patients was 57 years, and 10 were women (35%). The mean follow-up was 33.7 months (median 30 months, range 2-66 months). Twelve patients had disease progression, and 8 died, all from disease-specific causes. Malignant PET contained multiple microsatellite losses, with a median fractional allelic loss (FAL) of 0.37 (range 0.12-0.69, interquartile range [IQR] 0.23-0.42), significantly different from benign PET, median FAL 0 (range 0-0.18, IQR 0-0.08, P < .0001). Survival analysis revealed a significant difference in disease recurrence progression at 2 years (P < .0001) and in the 5-year survival between patients with FAL <= 0.2 compared with 0.2 (P <.0001). Logistic regression could not he performed because of the perfect association between an FAL > 0.2 of the perfect association between an FAL > 0.2 and disease status or mortality. Limitations: Retrospective design, referral bias, and DNA analysis availability. Conclusions: PET EUS-FNA microsatellite loss analysis provides preoperative prognostic information. An FAL > 0.2 is not only associated with disease progression but also with mortality (Gastrointest Endosc 2009:69:1074-80.) C1 [Khalid, Asif] Univ Pittsburgh, C Wing PUH, Dept Med, Med Ctr, Pittsburgh, PA 15213 USA. [Khalid, Asif] VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA. RP Khalid, A (reprint author), Univ Pittsburgh, C Wing PUH, Dept Med, Med Ctr, M2,200 Lothrop St, Pittsburgh, PA 15213 USA. EM khalida@upmc.edu RI Fasanella, Kenneth/I-2781-2012 NR 23 TC 10 Z9 10 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2009 VL 69 IS 6 BP 1074 EP 1080 DI 10.1016/j.gie.2008.06.023 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 441KC UT WOS:000265766700014 PM 19152901 ER PT J AU Burke, GV Wong, DA Saunders, CS Pierre, JM AF Burke, Guenevere V. Wong, Donovan A. Saunders, C. Scott Pierre, Joseph M. TI Self-limited erythema multiforme with risperidone SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article C1 [Wong, Donovan A.; Saunders, C. Scott; Pierre, Joseph M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Burke, Guenevere V.; Wong, Donovan A.; Saunders, C. Scott; Pierre, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Pierre, JM (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210, Los Angeles, CA 90073 USA. EM joseph.pierre2@va.gov NR 6 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAY-JUN PY 2009 VL 31 IS 3 BP 295 EP 296 DI 10.1016/j.genhosppsych.2008.08.008 PG 2 WC Psychiatry SC Psychiatry GA 445DF UT WOS:000266029200014 PM 19410111 ER PT J AU Egede, LE Echols, CL Richardson, LK Mueller, M Gebregziabher, M AF Egede, Leonard E. Echols, Carrae L. Richardson, Lisa K. Mueller, Martina Gebregziabher, Mulugeta TI Depression, physical activity and glycemic control in adults with type 2 diabetes SO GENERAL HOSPITAL PSYCHIATRY LA English DT Letter ID MANAGEMENT; CARE C1 [Egede, Leonard E.; Echols, Carrae L.; Richardson, Lisa K.; Mueller, Martina; Gebregziabher, Mulugeta] Ralph H Johnson VAMC, Charleston VA REAP, Charleston, SC USA. [Egede, Leonard E.; Echols, Carrae L.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Richardson, Lisa K.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Richardson, Lisa K.] Murdoch Univ, Sch Psychol, Perth, WA, Australia. [Mueller, Martina; Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Ralph H Johnson VAMC, Charleston VA REAP, Charleston, SC USA. OI Gebregziabher, Mulugeta/0000-0002-4826-481X NR 5 TC 1 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAY-JUN PY 2009 VL 31 IS 3 BP 299 EP 300 DI 10.1016/j.genhosppsych.2009.01.005 PG 2 WC Psychiatry SC Psychiatry GA 445DF UT WOS:000266029200017 PM 19410114 ER PT J AU Bennetto-Hood, C Johnson, VA King, JR Hoesley, CJ Acosta, EP AF Bennetto-Hood, Chantelle Johnson, Victoria A. King, Jennifer R. Hoesley, Craig J. Acosta, Edward P. TI Novel Methodology for Antiretroviral Quantitation in the Female Genital Tract SO HIV CLINICAL TRIALS LA English DT Article DE antiretroviral; drug monitoring; women ID IMMUNODEFICIENCY-VIRUS TYPE-1; CERVICOVAGINAL SECRETIONS; HIV-1 RNA; HIV-1-INFECTED WOMEN; BLOOD; THERAPY; SEMEN; PLASMA; MEN AB Purpose: Challenges exist regarding antiretroviral quantitation in the female genital tract. Endocervical wicking using sterile tear flow test strips is an alternative to conventional methods due to the consistent sample volume obtained. Methods: A novel method for measuring antiretrovirals in cervicovaginal secretions using Sno-strip (R) wicking was developed and tested by spiking Sno-strips (R) with known concentrations of tenofovir, nevirapine, atazanavir, lopinavir, and ritonavir in blank cervicovaginal lavage fluid. Drug concentrations were determined by high-performance liquid chromatography with ultraviolet or mass spectrometry detection. Results: Mean extraction recoveries were 91% for tenofovir, 89% for nevirapine, 63% for atazanavir, 60% for lopinavir, and 61% for ritonavir relative to controls. Freezing spiked samples for 24 hours at -80 degrees C had no effect on recovery. Conclusions: Results suggest that the antiretrovirals tested can be efficiently extracted from Sno-strips (R), although a greater percentage of tenofovir and nevirapine was recovered. Storage of Sno-strip (R) samples up to 24 hours before analysis showed no difference in the percentage of drug recovered compared with immediate analysis. Quantitating antiretroviral penetration into the female genital tract may assist in determining optimal therapeutic antiretroviral regimens to both decrease the risk of HIV transmission and prevent development of HIV drug resistance. C1 [Bennetto-Hood, Chantelle; King, Jennifer R.; Acosta, Edward P.] Univ Alabama, Div Clin Pharmacol, Sch Med, Birmingham, AL 35294 USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.; Hoesley, Craig J.] Univ Alabama, Div Infect Dis, Sch Med, Birmingham, AL 35294 USA. RP Acosta, EP (reprint author), Univ Alabama, Div Clin Pharmacol, Sch Med, 1530 3rd Ave S,VH 116, Birmingham, AL 35294 USA. EM eacosta@uab.edu FU National Institute of Allergy and Infectious Diseases [U01AI38858]; Birmingham VA Medical Center; UAB CFAR core clinic and laboratory facilities; [P30 AI27767] FX This work was supported by Dr. Victoria A. Johnson's VA Merit Review entitled "Drug Resistance in Genital Tract Viruses Derived from HIV-Infected Women." The pharmacology laboratory was supported, in part, by the Adult: AIDS Clinical Trials Group Central Grant U01AI38858 of the National Institute of Allergy and Infectious Diseases. Dr. Johnson also acknowledges P30 AI27767 and the Birmingham VA Medical Center and UAB CFAR core clinic and laboratory facilities. NR 17 TC 3 Z9 3 U1 0 U2 0 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119 USA SN 1528-4336 J9 HIV CLIN TRIALS JI HIV Clin. Trials PD MAY-JUN PY 2009 VL 10 IS 3 BP 193 EP 199 DI 10.1310/hct1003-193 PG 7 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA 471SP UT WOS:000268078900008 PM 19632958 ER PT J AU Velez, JCQ Ryan, KJ Harbeson, CE Bland, AM Budisavljevic, MN Arthur, JM Fitzgibbon, WR Raymond, JR Janech, MG AF Velez, Juan Carlos Q. Ryan, Kevin J. Harbeson, Caroline E. Bland, Alison M. Budisavljevic, Milos N. Arthur, John M. Fitzgibbon, Wayne R. Raymond, John R. Janech, Michael G. TI Angiotensin I Is Largely Converted to Angiotensin (1-7) and Angiotensin (2-10) by Isolated Rat Glomeruli SO HYPERTENSION LA English DT Article; Proceedings Paper CT 62nd Annual Fall Conference and Scientific Sessions of the American-Heart-Association-Council-for-High-Blood-Pressure-Research CY SEP 17-20, 2008 CL Atlanta, GA SP Amer Heart Assoc Council High Blood Presure Res DE renin-angiotensin system; neprilysin; aminopeptidase A; angiotensin-converting enzyme; angiotensin II; podocytes; des-Asp (1)-angiotensin I ID RENOVASCULAR HYPERTENSION; FLUID CONCENTRATIONS; ANESTHETIZED RATS; PROXIMAL TUBULES; AMINOPEPTIDASE-A; MESANGIAL CELLS; KIDNEY; CONVERSION; ENZYME; CHYMASE AB Intraglomerular renin-angiotensin system enzyme activities have been examined previously using glomerular lysates and immune-based assays. However, preparation of glomerular extracts compromises the integrity of their anatomic architecture. In addition, antibody-based assays focus on angiotensin (Ang) II detection, ignoring the generation of other Ang I-derived metabolites, some of which may cross-react with Ang II. Therefore, our aim was to examine the metabolism of Ang I in freshly isolated intact glomeruli using matrix-assisted laser desorption ionization time of flight mass spectrometry as an analytic method. Glomeruli from male Sprague-Dawley rats were isolated by sieving and incubated in Krebs buffer in the presence of 1 mu mol/L of Ang I for 15 to 90 minutes, with or without various peptidase inhibitors. Peptide sequences were confirmed by matrix-assisted laser desorption ionization time of flight tandem mass spectrometry or linear-trap-quadrupole mass spectrometry. Peaks were quantified using customized valine-(13)C(center dot 15)N-labeled peptides as standards. The most prominent peaks resulting from Ang I cleavage were 899 and 1181 m/z, corresponding with Ang (1-7) and Ang (2-10), respectively. Smaller peaks for Ang II, Ang (1-9), and Ang (3-10) also were detected. The disappearance of Ang I was significantly reduced during inhibition of aminopeptidase A or neprilysin. In contrast, captopril did not alter Ang I degradation. Furthermore, during simultaneous inhibition of aminopeptidase A and neprilysin, the disappearance of Ang I was markedly attenuated compared with all of the other conditions. These results suggest that there is prominent intraglomerular conversion of Ang I to Ang (2-10) and Ang (1-7), mediated by aminopeptidase A and neprilysin, respectively. Formation of these alternative Ang peptides may be critical to counterbalance the local actions of Ang II. Enhancement of these enzymatic activities may constitute potential therapeutic targets for Ang II-mediated glomerular diseases. (Hypertension. 2009; 53: 790-797.) C1 [Velez, Juan Carlos Q.; Ryan, Kevin J.; Harbeson, Caroline E.; Bland, Alison M.; Budisavljevic, Milos N.; Arthur, John M.; Fitzgibbon, Wayne R.; Raymond, John R.; Janech, Michael G.] Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA. [Velez, Juan Carlos Q.; Budisavljevic, Milos N.; Arthur, John M.; Raymond, John R.; Janech, Michael G.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA. RP Velez, JCQ (reprint author), Med Univ S Carolina, Div Nephrol, Dept Med, 96 Jonathan Lucas St,CSB,Room 829, Charleston, SC 29425 USA. EM velezj@musc.edu RI Velez, Juan Carlos/N-3782-2016 OI Janech, Michael/0000-0002-3202-4811 FU NIDDK NIH HHS [K08 DK080944, K08 DK080944-01] NR 35 TC 25 Z9 26 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD MAY PY 2009 VL 53 IS 5 BP 790 EP 797 DI 10.1161/HYPERTENSIONAHA.109.128819 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 436XW UT WOS:000265450400010 PM 19289651 ER PT J AU Kinsey, BM Jackson, DC Orson, FM AF Kinsey, Berma M. Jackson, David C. Orson, Frank M. TI Anti-drug vaccines to treat substance abuse SO IMMUNOLOGY AND CELL BIOLOGY LA English DT Review DE anti drug; drugs; vaccine; substance abuse ID NICOTINE CONJUGATE VACCINE; MONOCLONAL-ANTIBODIES; ACTIVE IMMUNIZATION; TOBACCO DEPENDENCE; COCAINE ADDICTION; METHAMPHETAMINE; RATS; IMMUNOGENICITY; PROTECTS; EFFICACY AB Substance abuse is a growing world-wide problem. The big four drugs of abuse that might lend themselves to immunotherapy are nicotine, cocaine, morphine/heroin and methamphetamine. Tobacco abuse has a well-known enormous impact on major chronic cardiovascular and pulmonary diseases, while the last three, aside from their neuropsychological effects, are illegal, leading to crime and incarceration as well as the transmission of viral diseases. Having an efficient vaccine that would generate antibodies to sequester the drug and prevent its access to the brain could go a long way toward helping a motivated addict quit the addiction. This review will discuss what has been done to bring such vaccines to human use, and what the challenges are for the future of this promising intervention. Immunology and Cell Biology ( 2009) 87, 309-314; doi:10.1038/icb.2009.17; published online 31 March 2009 C1 [Kinsey, Berma M.] Baylor Coll Med, MEDVAMC, Dept Internal Med, Houston, TX 77030 USA. [Kinsey, Berma M.; Orson, Frank M.] Michael E DeBakey Vet Affairs Med Ctr, Res Serv, Houston, TX USA. [Jackson, David C.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia. [Orson, Frank M.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. [Orson, Frank M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Kinsey, BM (reprint author), Baylor Coll Med, MEDVAMC, Dept Internal Med, Room 221,Bldg 109,2002 Holcombe Blvd, Houston, TX 77030 USA. EM bkinsey@bcm.tmc.edu OI Jackson, David/0000-0001-7255-270X FU Department of Veterans Affairs (VA) Merit Review Program FX This study was supported by the Department of Veterans Affairs (VA) Merit Review Program. NR 53 TC 33 Z9 35 U1 2 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0818-9641 J9 IMMUNOL CELL BIOL JI Immunol. Cell Biol. PD MAY-JUN PY 2009 VL 87 IS 4 BP 309 EP 314 DI 10.1038/icb.2009.17 PG 6 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 447RF UT WOS:000266208800008 PM 19333250 ER PT J AU Stein, DJ Lydiard, RB Herman, BK Mandel, FS AF Stein, Dan J. Lydiard, R. Bruce Herman, Barry K. Mandel, Francine S. TI Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE gastrointestinal symptoms; generalized anxiety disorder; pregabalin ID IRRITABLE-BOWEL-SYNDROME; DOUBLE-BLIND; PRIMARY-CARE; DEPRESSION; MULTICENTER; VENLAFAXINE; PREVALENCE; MANAGEMENT; EFFICACY AB The objective of the study was to evaluate the response of generalized anxiety disorder (GAD) patients with prominent gastrointestinal (GO symptoms to pregabalin (PGB) treatment. Data were pooled from six double-blind, placebo (PBO)-controlled, 4-6 week trials in outpatients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria for GAD with a minimum Hamilton Anxiety Rating Scale (HAM-A) total score of 20. Treatment response was evaluated for three PGB fixed-dosage groups: 150, 300-450, and 600 mg/day, and for fixed doses of a benzodiazepine (alprazolam, 1.5 mg/day; lorazepam, 6 mg/day). A GI-high subgroup (high GI symptomatology) was defined by a baseline HAM-A item-11 (G 1) score of 3 or greater (severe/very severe). At baseline, 301 patients (16.2%) met criteria for the GI-high subgroup. Baseline characteristics were approximately similar for the four study treatments in the GI-high subgroup. For the GI-high subgroup, last observation carried forward (LOCF) endpoint reduction in HAM-A was significantly higher on PGB-300/450-13.8 +/- 1.2 and PGB-600 - 14.7 +/- 1.0 compared with PBO - 10.1 +/- 0.9 (P< 0.01 for both comparisons); but the difference on PGB-150 did not achieve significance (- 13.5 +/- 11.6; P=0.083). Also in the GI-high subgroup, endpoint reduction in HAM-A item-11 was significantly higher on PGB-300/450 compared with PBO (- 1.93 +/- 0.16 vs. - 1.52 +/- 0.13; P= 0.04), but did not achieve significance on PG B-600 mg (- 1.89 +/- 0.14; P= 0.06), or PG B-150 mg (- 1.90 +/- 0.23; P= 0.16). In the GI-high subgroup, treatment with a benzodiazepine was not associated with significant endpoint reduction in either the HAM-A total score or the HAM-A item-11 score. Patients in the GI-high subgroup had higher discontinuation rates when treated with benzodiazepines, whereas treatment with PGB 300-600 mg/day was not associated with treatment-emergent worsening in GI symptoms compared with placebo. Treatment with PGB improved overall levels of anxiety, as well as specifically improving GI symptoms. Int Clin Psychopharmacol 24:126-132 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Herman, Barry K.; Mandel, Francine S.] Pfizer Inc, Pfizer Global Pharmaceut, New York, NY 10017 USA. [Stein, Dan J.] Univ Cape Town, ZA-7925 Cape Town, South Africa. [Lydiard, R. Bruce] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Herman, BK (reprint author), Pfizer Inc, Pfizer Global Pharmaceut, 235 E 42nd St,9th Floor,Off 101,Mailstop 235-9-39, New York, NY 10017 USA. EM barry.herman@pfizer.com RI Stein, Dan/A-1752-2008 OI Stein, Dan/0000-0001-7218-7810 FU Pfizer Inc. FX The study was funded by Pfizer Inc., and editorial support was provided by Edward Schweizer, MD and funded by Pfizer Inc. NR 23 TC 9 Z9 9 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD MAY PY 2009 VL 24 IS 3 BP 126 EP 132 DI 10.1097/YIC.0b013e3283249c7b PG 7 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 438FH UT WOS:000265540800003 PM 19352198 ER PT J AU Herrera, VM Casas, JP Miranda, JJ Perel, P Pichardo, R Gonzalez, A Sanchez, JR Ferreccio, C Aguilera, X Silva, E Orostegui, M Gomez, LF Chirinos, JA Medina-Lezama, J Perez, CM Suarez, E Ortiz, AP Rosero, L Schapochnik, N Ortiz, Z Ferrante, D Diaz, M Bautista, LE AF Herrera, V. M. Casas, J. P. Miranda, J. J. Perel, P. Pichardo, R. Gonzalez, A. Sanchez, J. R. Ferreccio, C. Aguilera, X. Silva, E. Orostegui, M. Gomez, L. F. Chirinos, J. A. Medina-Lezama, J. Perez, C. M. Suarez, E. Ortiz, A. P. Rosero, L. Schapochnik, N. Ortiz, Z. Ferrante, D. Diaz, M. Bautista, L. E. CA Latin Amer Consortium Studies TI Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE coronary heart disease; screening; ethnic group; Latin America; NHANES ID BODY-MASS INDEX; NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; METABOLIC SYNDROME; MYOCARDIAL-INFARCTION; MULTIPLE IMPUTATION; CARDIOVASCULAR RISK; AFRICAN-AMERICANS; FAT DISTRIBUTION; PREVALENCE AB Background: Cut points for defining obesity have been derived from mortality data among Whites from Europe and the United States and their accuracy to screen for high risk of coronary heart disease (CHD) in other ethnic groups has been questioned. Objective: To compare the accuracy and to define ethnic and gender-specific optimal cut points for body mass index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) when they are used in screening for high risk of CHD in the Latin-American and the US populations. Methods: We estimated the accuracy and optimal cut points for BMI, WC and WHR to screen for CHD risk in Latin Americans (n = 18 976), non-Hispanic Whites (Whites; n = 8956), non-Hispanic Blacks (Blacks; n 5205) and Hispanics (n = 5803). High risk of CHD was defined as a 10-year risk >= 20% (Framingham equation). The area under the receiver operator characteristic curve (AUC) and the misclassification-cost term were used to assess accuracy and to identify optimal cut points. Results: WHR had the highest AUC in all ethnic groups (from 0.75 to 0.82) and BMI had the lowest (from 0.50 to 0.59). Optimal cut point for BMI was similar across ethnic/gender groups (27 kg/m(2)). In women, cut points for WC (94 cm) and WHR (0.91) were consistent by ethnicity. In men, cut points for WC and WHR varied significantly with ethnicity: from 91cm in Latin Americans to 102cm in Whites, and from 0.94 in Latin Americans to 0.99 in Hispanics, respectively. Conclusion: WHR is the most accurate anthropometric indicator to screen for high risk of CHD, whereas BMI is almost uninformative. The same BMI cut point should be used in all men and women. Unique cut points for WC and WHR should be used in all women, but ethnic-specific cut points seem warranted among men. International Journal of Obesity (2009) 33, 568-576; doi:10.1038/ijo.2009.35; published online 24 February 2009 C1 [Herrera, V. M.; Bautista, L. E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53726 USA. [Casas, J. P.; Miranda, J. J.; Perel, P.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England. [Pichardo, R.] Inst Dominicano Cardiol, Santo Domingo, Dominican Rep. [Sanchez, J. R.] Inst Nacl Salud, Ctr Nacl Alimentac & Nutr, Lima, Peru. [Ferreccio, C.] Pontificia Univ Catolica Chile, Dept Salud Publ, Santiago, Chile. [Aguilera, X.] Minist Salud Chile, Santiago, Chile. [Silva, E.] Univ Zulia, Fac Med, Inst Invest & Estudios Enfermedades Cardiovasc, Maracaibo 4011, Venezuela. [Orostegui, M.] Univ Ind Santander, Epidemiol Res Ctr, Cardiovasc Dis Epidemiol Observ, Bucaramanga, Colombia. [Gomez, L. F.] Fdn FES Social, Hlth Div, Bogota, Colombia. [Chirinos, J. A.] Univ Penn, Sch Med, Div Cardiol, Philadelphia, PA 19104 USA. [Chirinos, J. A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Medina-Lezama, J.] Santa Maria Catholic Univ, Arequipa, Peru. [Medina-Lezama, J.] Santa Maria Res Inst, Arequipa, Peru. [Perez, C. M.; Suarez, E.; Ortiz, A. P.] Univ Puerto Rico, Grad Sch Publ Hlth, Dept Biostat & Epidemiol, San Juan, PR 00936 USA. [Rosero, L.] Univ Costa Rica, Ctr Ctr Amer Poblac, San Jose, Costa Rica. [Schapochnik, N.] Minist Salud Prov Tierra Fuego, Ushuaia, Argentina. [Ortiz, Z.] Acad Nacl Med Buenos Aires, Inst Invest Epidemiol, Buenos Aires, DF, Argentina. [Ferrante, D.] Minist Salud & Ambiente, Buenos Aires, DF, Argentina. [Diaz, M.] Ctr Invest Med Acad, Montevideo, Uruguay. RP Bautista, LE (reprint author), Univ Wisconsin, Dept Populat Hlth Sci, 610 Walnut St,703 WARF, Madison, WI 53726 USA. EM lebautista@wisc.edu RI Herrera, Victor/C-5602-2008; Miranda, J. Jaime/A-8482-2008; Aguilera, Ximena/D-9861-2014 OI Miranda, J. Jaime/0000-0002-4738-5468; Aguilera, Ximena/0000-0002-8153-6733 FU NCRR NIH HHS [G12 RR 03051, G12 RR003051, P20 RR 011126, P20 RR011126]; NIMHD NIH HHS [G12 MD007600]; Wellcome Trust [074833] NR 49 TC 36 Z9 37 U1 2 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD MAY PY 2009 VL 33 IS 5 BP 568 EP 576 DI 10.1038/ijo.2009.35 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 443DF UT WOS:000265889700008 PM 19238159 ER PT J AU Mavandadi, S Zanjani, F Ten Have, TR Oslin, DW AF Mavandadi, Shahrzad Zanjani, Faika Ten Have, Thomas R. Oslin, David W. TI Psychological Well-Being Among Individuals Aging With HIV: The Value of Social Relationships SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 20th Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 01-04, 2007 CL New Orleans, LA SP Amer Assoc Geriat Psychiat DE aging; depressive symptoms; HIV positive; positive affect; social support ID HUMAN-IMMUNODEFICIENCY-VIRUS; QUALITY-OF-LIFE; DEPRESSIVE SYMPTOMS; SOCIOEMOTIONAL SELECTIVITY; ECONOMIC CIRCUMSTANCES; OLDER-ADULTS; HEALTH-CARE; SHORT-FORM; SUPPORT; AGE AB Objective: Utilizing a heterogenous sample of adults diagnosed with HIV infection, the current study sought to explore associations among age, various dimensions of social support, and psychological and functional well-being. Methods: Cross-sectional data capturing subjective and instrumental support, social interaction, behavioral health service utilization, and psychological well-being (ie, positive affect and depressive symptomatology), and physical functioning, wet e collected from 109 men and women living with HIV To explore a;e group differences, participants were stratified by age (<54 vs. 55- years). Results: Despite endorsing greater medical comorbidity, older adults reported significantly lower depressive symptomatology and greater positive affect and were less likely to report seeing a behavioral health specialist than their younger counterparts. No age group differences emerged for instrumental support or amount of social interaction. However, older adults reported higher subjective Support, which in turn was associated with lower depressive symptomatology, greater positive affect, and nonutilization of behavioral health services. Conclusions: More attention should be paid to the social environment of individuals diagnosed with HIV as tic quality of social relationships may be particularly important for successful psychological adaptation to HIV C1 [Mavandadi, Shahrzad; Oslin, David W.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Zanjani, Faika] Univ Kentucky, Dept Gerontol, Lexington, KY USA. [Ten Have, Thomas R.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Mavandadi, S (reprint author), Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, 3900 Woodland Ave,116A, Philadelphia, PA 19104 USA. EM shahrzad.mavandadi@va.gov FU NIAID NIH HHS [P30 AI045008, 5P30AI045008, P30 AI045008-10]; NIMH NIH HHS [P30 MH066270-05] NR 54 TC 22 Z9 22 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2009 VL 51 IS 1 BP 91 EP 98 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 438WD UT WOS:000265585800014 PM 19282781 ER PT J AU Hayashi, A Naseri, A Pennesi, ME de Juan, E AF Hayashi, Atsushi Naseri, Ayman Pennesi, Mark E. de Juan, Eugene, Jr. TI Subretinal delivery of immunoglobulin G with gold nanoparticles in the rabbit eye SO JAPANESE JOURNAL OF OPHTHALMOLOGY LA English DT Article DE IgG; gold nanoparticle; rabbit; retina; subretinal delivery ID NANOGOLD; CANCER; CELLS; TIME AB To examine the feasibility of subretinal delivery of immunoglobulin G (IgG) adsorbed onto gold nanoparticles (GNPs) and its histologic distribution in the rabbit retina after the injection. Goat IgG was adsorbed onto GNPs electrostatically. Goat IgG-adsorbed GNPs or buffer with goat IgG was injected into the subretinal space of rabbit eyes and followed up for 3 months by examination of fundus photographs, immunohistochemistry against goat IgG, and transmission electron microscopy (TEM). Human retinal pigment epithelial cells (ARPE-19 cells) were cultured, and cell proliferation with or without GNPs was assayed. At 1 week after the subretinal injection of goat IgG-adsorbed GNPs, retinal degeneration was observed in the outer retina, and goat IgG was immunolabeled in the retinal pigment epithelium (RPE) and the photoreceptor cells. TEM showed GNPs located in the outer segments and in the lysosomes in the RPE at 1 month and no apparent cytotoxicity of the RPE. There were no inhibitory effects of GNPs on proliferation of ARPE-19 cells. Goat IgG was successfully delivered into photoreceptor cells and RPE using GNPs, though retinal degeneration in the outer retina occurred in this model. This might be an alternative drug delivery method to photoreceptors and RPE. C1 [Hayashi, Atsushi; Naseri, Ayman; Pennesi, Mark E.; de Juan, Eugene, Jr.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Naseri, Ayman] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP Hayashi, A (reprint author), Toyama Univ, Dept Ophthalmol, 2630 Sugitani, Toyama 9300194, Japan. EM ganka@med.u-toyama.ac.jp NR 18 TC 14 Z9 14 U1 0 U2 7 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0021-5155 J9 JPN J OPHTHALMOL JI Jpn. J. Ophthalmol. PD MAY PY 2009 VL 53 IS 3 BP 249 EP 256 DI 10.1007/s10384-009-0655-x PG 8 WC Ophthalmology SC Ophthalmology GA 451ZS UT WOS:000266510000011 PM 19484444 ER PT J AU Wojnar, M Ilgen, MA Czyz, E Strobbe, S Klimkiewicz, A Jakubczyk, A Glass, J Brower, KJ AF Wojnar, Marcin Ilgen, Mark A. Czyz, Ewa Strobbe, Stephen Klimkiewicz, Anna Jakubczyk, Andrzej Glass, Jennifer Brower, Kirk J. TI Impulsive and non-impulsive suicide attempts in patients treated for alcohol dependence SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicide; Attempt; Alcohol dependence; Impulsive behavior; Poland ID USE-DISORDER TREATMENT; ILLICIT DRUG-USE; RISK-FACTORS; PERSONALITY-DISORDER; INHIBITORY CONTROL; HISTORY; AGGRESSION; BEHAVIOR; INDIVIDUALS; ADOLESCENCE AB Background: Suicidal behavior has been recognized as an increasing problem among alcohol-dependent subjects. The aim of the study was to identify correlates of impulsive and non-impulsive suicide attempts among a treated population of alcohol-dependent patients. Methods: A total of 154 patients with alcohol dependence consecutively admitted for addiction treatment participated in the study. Suicidal behavior was assessed together with severity of alcohol dependence, childhood abuse, impulsivity, and family history. A stop-signal procedure was used as a behavioral measure of impulsivity. Results and conclusions: Lifetime suicide attempts were reported by 43% of patients in alcohol treatment; of which 62% were impulsive. Compared to patients without a suicide attempt, those with a non-impulsive attempt were more likely to have a history of sexual abuse (OR=7.17), a family history of suicide (OR=4.09), and higher scores on a personality measure of impulsiveness (OR=2.27). The only significant factor that distinguished patients with impulsive suicide attempts from patients without a suicide attempt and from patients with a non-impulsive suicide attempt was a higher level of behavioral impulsivity (OR=1.84-2.42). Limitations: Retrospective self-report of suicide attempts and family history. Lack of diagnostic measure. (C) 2008 Elsevier B.V. All rights reserved. C1 [Wojnar, Marcin] Univ Michigan, Addict Res Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. [Wojnar, Marcin; Klimkiewicz, Anna; Jakubczyk, Andrzej] Med Univ Warsaw, Dept Psychiat, Warsaw, Poland. [Ilgen, Mark A.] US Dept Vet Affairs, Hlth Serv Res & Dev, Ann Arbor, MI USA. [Glass, Jennifer] Univ Michigan, Inst Social Res, Ann Arbor, MI 48109 USA. RP Wojnar, M (reprint author), Univ Michigan, Addict Res Ctr, Dept Psychiat, Rachel Upjohn Bldg,4250 Plymouth Rd, Ann Arbor, MI 48109 USA. EM mwojnar@umich.edu FU Fogarty International Center/NIDA International Substance Abuse Research Program [D43 TW05818]; Fogarty International Center/NLAAA International Collaborative Alcohol & Injury Research Training Program [D43 TW007569]; NIAAA [R21 AA016104]; Polish Ministry of Science and Higher Education [2P05D 004 29] FX Authors have not signed an agreement with any sponsor of the study reported in this paper that has a clause which prevents them from publishing both positive and negative results, from collaborating with other investigators to pool data across sites, or that forbids them from publishing without the approval of the sponsor. The views expressed in this report are those of the authors and do not necessarily represent those of the Supporting agencies. The supporting agencies had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 58 TC 39 Z9 41 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAY PY 2009 VL 115 IS 1-2 BP 131 EP 139 DI 10.1016/j.jad.2008.09.001 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 435CC UT WOS:000265319900015 PM 18835498 ER PT J AU Parta, M Goebel, M Matloobi, M Stager, C Musher, DM AF Parta, M. Goebel, M. Matloobi, M. Stager, C. Musher, D. M. TI Identification of Methicillin-Resistant or Methicillin-Susceptible Staphylococcus aureus in Blood Cultures and Wound Swabs by GeneXpert SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Letter ID BACTEREMIA; COMMUNITY; DISEASE C1 [Parta, M.; Goebel, M.; Matloobi, M.; Musher, D. M.] Michael E DeBakey Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Houston, TX 77030 USA. [Stager, C.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. RP Parta, M (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, 2002 Holcombe Blvd,Rm 4B370, Houston, TX 77030 USA. EM parta@bcm.edu NR 10 TC 28 Z9 28 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2009 VL 47 IS 5 BP 1609 EP 1610 DI 10.1128/JCM.00351-09 PG 2 WC Microbiology SC Microbiology GA 439QB UT WOS:000265641000060 PM 19261790 ER PT J AU Ford, JD Elhai, JD Ruggiero, KJ Frueh, BC AF Ford, Julian D. Elhai, Jon D. Ruggiero, Kenneth J. Frueh, B. Christopher TI Refining Posttraumatic Stress Disorder Diagnosis: Evaluation of Symptom Criteria With the National Survey of Adolescents SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID COMORBIDITY SURVEY REPLICATION; SCREENING INSTRUMENT; PRIMARY-CARE; PTSD; VALIDATION; CHILDHOOD; CHILDREN; MODEL; ABUSE; RISK AB Objective: To compare the prevalence estimates, comorbidity rates, and structural validity of a revised symptom criteria set for the diagnosis of posttraumatic stress disorder (PTSD) with those of the DSM-IV criteria in a representative community sample of adolescents. Method: Cross-sectional data from the National Survey of Adolescents, a 1995 household probability sample of 4,023 adolescents aged 12-17 year:, were examined. DSM-IV PTSD symptoms were assessed with a modification of the National Women's Study PTSD module. Three- and 4-factor DSM-IV models were compared to a 2-factor PTSD model that deleted symptoms potentially overlapping with depression or other anxiety disorders. Comorbidity was assessed using DSM-IV criteria for major depressive episodes and substance use disorders. Results: PTSD prevalence varied across models (ie, 5.2%-8.8%, lifetime; 3.2%-5.7%, past 6 months). When the 2-factor model was used with a proportionate symptom threshold, lifetime PTSD prevalence wits comparable to that with the 3-factor DSM-IV model, and major depressive episode comorbidity was reduced by 9%-14%. Comorbidity with substance use disorders was comparable across models. Structural validity, tested with confirmatory factor analyses, showed that the 2-factor model and a 4-factor DSM-IV model were superior to the DSM-IV 3-factor model. Conclusions: Compared to the DSM-IV 3-factor PTSD model, a 2-factor model that removed depression and anxiety symptoms and used a proportionate symptom threshold may produce comparable lifetime PTSD prevalence estimates, reduced PTSD-depression comorbidity, and Superior structural validity (comparable to a 4-factor PTSD model) when applied to community samples of adolescents. Further research on PTSD structure and diagnosis with adolescents is warranted. J Clin Psychiatry 2009:70(5):748-755 (C) Copyright 2009 Physicians Postgraduate Press, Inc. C1 [Ford, Julian D.] Univ Connecticut, Ctr Hlth, Dept Psychiat, Sch Med, Farmington, CT 06032 USA. [Elhai, Jon D.] Univ S Dakota, Dept Psychol, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA. [Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Frueh, B. Christopher] Baylor Coll Med, Menninger Clin, Houston, TX 77030 USA. [Frueh, B. Christopher] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. RP Ford, JD (reprint author), Univ Connecticut, Ctr Hlth, Dept Psychiat, Sch Med, 263 Farmington Ave, Farmington, CT 06032 USA. EM ford@psychiatry.uchc.edu FU Department of Justice Office of Juvenile Justice and Delinquency Programs [CT-52525-JS2] FX Work on this article was partially supported by a grant from the Department of Justice Office of Juvenile Justice and Delinquency Programs CT-52525-JS2 (Dr Ford, principal investigator). NR 38 TC 38 Z9 38 U1 1 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2009 VL 70 IS 5 BP 748 EP 755 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 450TO UT WOS:000266424000016 PM 19389336 ER PT J AU Graham, DY Lu, H Yamaoka, Y AF Graham, David Y. Lu, Hong Yamaoka, Yoshio TI African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths SO JOURNAL OF DIGESTIVE DISEASES LA English DT Article DE African enigma; Asian enigma; gastric cancer; gastritis; Helicobacter pylori; Indian enigma; peptic ulcer ID GASTRIC-CANCER; PEPTIC-ULCER; BIOLOGICAL-ACTIVITY; IRON-DEFICIENCY; UNITED-STATES; CAGA; INFECTION; POLYMORPHISMS; GENES; RISK AB Helicobacter pylori is etiologically related to peptic ulcer disease and gastric adenocarcinomas. Reports of geographical enigmas (African, Asian, Indian and Costa Rican enigmas) are based on perceptions that clinical presentations in a population or region are not as the authors expected. We discuss the background for these enigmas and examine the evidence whether they are real or are medical myths. The African enigma was challenged almost as soon as it was proposed and recent analyses of endoscopic data have confirmed it is a myth, as H. pylori-related diseases occur in Africa at the expected frequencies. The Asian and Indian enigmas relate to gastric cancer and peptic ulcers, respectively, and when one takes the patterns of gastritis in the different regions, these enigmas disappear. The pattern of gastritis underlies and predicts the clinical outcome and the predominant pattern of gastritis has been observed to change much more rapidly than can be accounted for by changes in host genetics. There is also no evidence that these changes relate to changes in the predominant H. pylori strain. The factors that link most closely to preventing an atrophic corpus are environmental, with food preservation and diet currently assuming the most prominent roles. This focus on diseases (cancer vs duodenal ulcers) instead of the underlying patterns of gastritis has fostered, and possibly helped to perpetuate, these mythical enigmas. We suggest that a better strategy would be to focus on the pathogenesis of underlying histopathologic differences which could also lead to the identification of specific chemoprevention strategies. C1 [Graham, David Y.; Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Graham, David Y.; Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Lu, Hong] Shanghai Jiao Tong Univ, Dept Gastroenterol, Renji Hosp, Sch Med,Shanghai Inst Digest Dis, Shanghai 200030, Peoples R China. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320 3D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU Meretek; NIH [DK62813]; National Natural Science Foundation of China [30670940] FX In the last 2 years Dr Graham has received small amounts of grant support and/or free drugs or urea breath tests from Meretek, BioHit for completely investigator-controlled research. Dr Yamaoka is supported in part by a grant from the NIH DK62813. Dr Lu is supported in part by a grant from the National Natural Science Foundation of China (30670940). NR 58 TC 35 Z9 38 U1 0 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1751-2972 J9 J DIG DIS JI J. Dig. Dis. PD MAY PY 2009 VL 10 IS 2 BP 77 EP 84 DI 10.1111/j.1751-2980.2009.00368.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 436IN UT WOS:000265407100001 PM 19426388 ER PT J AU Schuberth, JM Cobb, MD Talarico, RH AF Schuberth, John M. Cobb, Matthew D. Talarico, Ross H. TI Minimally Invasive Arthroscopic-Assisted Reduction with Percutaneous Fixation in the Management of Intra-Articular Calcaneal Fractures: A Review of 24 Cases SO JOURNAL OF FOOT & ANKLE SURGERY LA English DT Article DE arthroscopy; Boehler's angle; comminution; complication; critical angle; joint depression; Sanders classification ID INTERNAL-FIXATION; SUBTALAR JOINT; CONTACT CHARACTERISTICS; COMPUTED-TOMOGRAPHY; OPERATIVE TREATMENT; COMPLICATIONS; CLASSIFICATION; OSTEOSYNTHESIS; VIABILITY AB A retrospective analysis of 24 cases of minimally invasive, open reduction, and internal fixation of intra-articular calcaneal fractures is presented. Collected data included articular step-off, medial wall displacement, and Boehler's angle, in addition to other descriptive characteristics of the fracture and case series. The operative technique is described in detail including the optimal screw constructs. Arthroscopic assistance was used in 10 of the cases. The articular step-off of the posterior facet, medial wall displacement, and Boehler's angle all displayed statistically significant change between the preoperative and postoperative periods (P < .0001). These results were consistent with the goal of restoration of articular congruity, calcaneal morphology, and calcaneal height. There were no soft tissue complications. The mean overall follow-up duration was 2.8 years (range 1 to 10 years). Of the 18 patients who were followed for more than I year (range 1.0 to 10 years), none went on to subtalar fusion. The results of this study suggest that a minimally invasive approach can improve radiographic parameters consistent with the ultimate goals of operative reduction of calcaneal fractures, and can be used to achieve satisfactory results with minimal risk of wound complication. Level of Clinical Evidence: 4 (The Journal of Foot & Ankle Surgery 48(3):315-322, 2009) C1 [Schuberth, John M.] Kaiser Fdn Hosp, Dept Orthopaed Surg, San Francisco, CA 94118 USA. [Cobb, Matthew D.] Kaiser Fdn Hosp, Dept Podiatr Surg, Walnut Creek, CA USA. [Talarico, Ross H.] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA. [Talarico, Ross H.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Talarico, Ross H.] Univ Calif San Francisco, Podiatr Surg Sect, San Francisco, CA 94143 USA. RP Schuberth, JM (reprint author), Kaiser Fdn Hosp, Dept Orthopaed Surg, 450 6th Ave, San Francisco, CA 94118 USA. EM Jmfoot@aol.com NR 38 TC 38 Z9 44 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-2516 J9 J FOOT ANKLE SURG JI J. Foot Ankle Surg. PD MAY-JUN PY 2009 VL 48 IS 3 BP 315 EP 322 DI 10.1053/j.jfas.2009.01.002 PG 8 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 441TG UT WOS:000265792800005 PM 19423031 ER PT J AU Agopian, VG Chen, DC Avansino, JR Stelzner, M AF Agopian, Vatche G. Chen, David C. Avansino, Jeffrey R. Stelzner, Matthias TI Intestinal Stem Cell Organoid Transplantation Generates Neomucosa in Dogs SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE Intestinal stem cell transplantation; Tissue-engineered intestine; Bioscaffolds; Polyglycolic acid ID ENGINEERED SMALL-INTESTINE; BILE-ACID MALABSORPTION; SMALL-BOWEL RESECTION; MANAGEMENT; SCAFFOLDS; MODEL; REGENERATION; ENGRAFTMENT; EPITHELIUM; REPAIR AB Intestinal stem cell organoid transplantation generates functional intestinal neomucosa and has been used therapeutically to improve nutrient absorption and cure bile acid malabsorption in rats. We hypothesized that intestinal organoids can be harvested and transplanted to generate intestinal neomucosa in a large animal model. In group 1, 2-month old beagles (n = 6) underwent autotransplantation of intestinal organoids prepared from a segment of their own ileum. In group 2, intestinal organoids were harvested from fetuses and allotransplanted into 10-month old mother animals (n = 4). Tissues were harvested after 4 weeks and analyzed by hematoxylin and eosin histology and fluorescent microscopy. Large numbers of viable organoids were harvested in both groups. In group 1, no neomucosal growth was identified in any of the engraftment sites after autotransplantation of juvenile organoids. In group 2, neomucosal growth with large areas of crypts and villi was identified in 11 of 12 polyglycolic acid scaffolds after allotransplantation of fetal organoids. The neomucosa resembled normal canine mucosa in structure and composition. Intestinal stem cell organoid transplantation can be used to generate neomucosa in dogs. This is the first report of successful generation of intestinal neomucosa using intestinal stem cell organoid transplantation in a large animal model. C1 [Agopian, Vatche G.; Chen, David C.; Stelzner, Matthias] Univ Calif Los Angeles, Dept Surg, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA. [Avansino, Jeffrey R.] Univ Washington, Dept Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Agopian, VG (reprint author), Univ Calif Los Angeles, Dept Surg, VA Greater Los Angeles Hlth Care Syst, 10833 Conte Ave, Los Angeles, CA 90095 USA. EM vagopian@mednet.ucla.edu FU Clowes Career Development Award, American College of Surgeons FX Grant support from the Clowes Career Development Award, American College of Surgeons is acknowledged. NR 31 TC 17 Z9 17 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD MAY PY 2009 VL 13 IS 5 BP 971 EP 982 DI 10.1007/s11605-009-0806-x PG 12 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 431VO UT WOS:000265092500023 PM 19165549 ER PT J AU Sherbourne, CD Asch, SM Shugarman, LR Goebel, JR Lanto, AB Rubenstein, LV Wen, L Zubkoff, L Lorenz, KA AF Sherbourne, Cathy D. Asch, Steven M. Shugarman, Lisa R. Goebel, Joy R. Lanto, Andy B. Rubenstein, Lisa V. Wen, Li Zubkoff, Lisa Lorenz, Karl A. TI Early Identification of Co-Occurring Pain, Depression and Anxiety SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE targeted screening for pain and distress; depression; anxiety ID PRIMARY-CARE; SYMPTOMS; ILLNESS; HEALTH; COMORBIDITY; IMPAIRMENT; PREVALENCE; DISORDERS; SEVERITY; SCREENER AB Depression and anxiety frequently co-occur with pain and may affect treatment outcomes. Early identification of these co-occurring psychiatric conditions during routine pain screening may be critical for optimal treatment. To determine aspects of pain related to psychological distress, and, among distressed patients, to determine whether pain factors are related to provider identification of distress. Cross-sectional interview of primary care patients and their providers participating in a Veteran's Administration HELP-Vets study. A total of 528 predominately male Veterans We measured self-reported pain, including a 0-10 numeric rating scale and interference items from the Brief Pain Inventory. To evaluate distress, brief indicators of depression, anxiety and PTSD were combined. A substantial number of patients had psychological distress (41%), which was even higher (62%) among patients with moderate-severe current pain. Only 29% of those with distress reported talking to their provider about emotional problems during their visit. In multivariate analyses, other pain factors related to distress included interference with enjoyment of life and relationships with others, pain in multiple locations and joint pains. Prior diagnoses of depression and anxiety were also related to current distress. Only prior diagnosis and patient reported headaches and sleep interference because of pain were related to provider identification of distress. VA patients with moderate-severe pain are at high risk for psychological distress, which often goes unrecognized. Providers need to be more vigilant to mental health problems in patients experiencing high pain levels. Targeted screening for co-occurring conditions is warranted. C1 [Sherbourne, Cathy D.; Asch, Steven M.; Shugarman, Lisa R.; Rubenstein, Lisa V.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA 90407 USA. [Asch, Steven M.; Lanto, Andy B.; Rubenstein, Lisa V.; Zubkoff, Lisa; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven M.; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Goebel, Joy R.] Calif State Univ Long Beach, Dept Nursing, Sch Nursing, Long Beach, CA 90840 USA. [Wen, Li] Vet Adm Long Beach Healthcare Syst, Long Beach, CA USA. RP Sherbourne, CD (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM Cathy_Sherbourne@rand.org FU VA HSR D [03-150] FX Funded by the VA HSR& D 11R # 03-150. NR 24 TC 19 Z9 26 U1 4 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2009 VL 24 IS 5 BP 620 EP 625 DI 10.1007/s11606-009-0956-2 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 434XE UT WOS:000265306700012 PM 19308333 ER PT J AU Keyhani, S Federman, A AF Keyhani, Salomeh Federman, Alex TI Fact or Fiction: The Need for Independent Pharmaceutical Policy Research SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID PRIVATE-SECTOR; ROFECOXIB; INNOVATION; EZETIMIBE; DOCUMENTS; NAPROXEN; TRIAL; COSTS; PRICE; VA C1 [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA. [Keyhani, Salomeh] James J Peters Vet Adm Med Ctr, Bronx, NY USA. [Keyhani, Salomeh; Federman, Alex] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. RP Keyhani, S (reprint author), Mt Sinai Sch Med, Dept Hlth Policy, Box 1077,1 Gustave L Levy Pl, New York, NY 10029 USA. EM salomeh.keyhani@mountsinai.org NR 27 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2009 VL 24 IS 5 BP 692 EP 694 DI 10.1007/s11606-009-0964-2 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 434XE UT WOS:000265306700023 PM 19343457 ER PT J AU Eisenman, DP Glik, D Maranon, R Gonzales, L Asch, S AF Eisenman, David P. Glik, Deborah Maranon, Richard Gonzales, Lupe Asch, Steven TI Developing a Disaster Preparedness Campaign Targeting Low-Income Latino Immigrants: Focus Group Results for Project PREP SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Latino health; immigrant health; disaster preparedness; formative research ID ETHNICITY; DISSEMINATION; PERCEPTIONS; INFORMATION AB Low-income immigrant Latinos are particularly vulnerable to disasters because they are both ill-prepared and disproportionately affected. Disaster preparedness programs that are culturally appropriate must be developed and tested. To develop such a program, we conducted 12 focus groups with low-income immigrant Latinos to understand their perceptions and understanding of disaster preparedness, and facilitators and obstacles to it. Participants were concerned about remaining calm during an earthquake. Obstacles to storage of disaster supplies in a kit and developing a family communication plan were mentioned frequently. Misunderstandings were voiced about the proper quantity of water to store and about communication plans. Several focus groups spontaneously suggested small group discussions (platicas) as a way to learn about disaster preparedness. They wanted specific help with building their family communication plans. They rated promotoras de salud highly as potential teachers. Results Will guide the development of a disaster preparedness program tailored to the needs of low-income Latino immigrants. C1 [Eisenman, David P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Glik, Deborah; Maranon, Richard] Univ Calif Los Angeles, Sch Publ Hlth Community Hlth Sci, Los Angeles, CA 90095 USA. [Asch, Steven] W Los Angeles Vet Adm, Dept Med, Los Angeles, CA USA. RP Eisenman, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza, Los Angeles, CA 90095 USA. EM deisenman@mednet.ucla.edu NR 37 TC 20 Z9 20 U1 1 U2 7 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD MAY PY 2009 VL 20 IS 2 BP 330 EP 345 PG 16 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 443CF UT WOS:000265887100004 PM 19395833 ER PT J AU Tallaj, JA Franco, V Rayburn, BK Pamboukian, SV Benza, RL Kirklin, JK McGiffin, DC Smallfield, M Bourge, RC AF Tallaj, Jose A. Franco, Veronica Rayburn, Barry K. Pamboukian, Salpy V. Benza, Raymond L. Kirklin, James K. McGiffin, David C. Smallfield, Melissa Bourge, Robert C. TI Safety and Efficacy of Ibutilide in Heart Transplant Recipients SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article ID ORTHOTOPIC CARDIAC TRANSPLANTATION; ATRIAL-FLUTTER; ARRHYTHMIAS; PREVALENCE AB In this report we describe our experience with ibutilide, a relatively new Class III anti-arrhythmic agent, in 8 heart transplant patients with supraventricular tachycardia in various settings (3 patients with rejection, 2 after endomyocardial biopsy). Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in I patient. There were no complications. J Heart Lung Transplant 2009;28:505-7. Copyright (C) 2009 by the International Society for Heart and Lung Transplantation. C1 [Tallaj, Jose A.; Franco, Veronica; Rayburn, Barry K.; Pamboukian, Salpy V.; Benza, Raymond L.; Kirklin, James K.; McGiffin, David C.; Smallfield, Melissa; Bourge, Robert C.] Univ Alabama, Div Cardiovasc Dis, Sect Heart Failure Transplantat & Pulm Vasc Dis, Birmingham, AL 35294 USA. [Tallaj, Jose A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Tallaj, JA (reprint author), Univ Alabama, Div Cardiovasc Dis, Sect Heart Failure Transplantat & Pulm Vasc Dis, THT 338,703 19th St S, Birmingham, AL 35294 USA. EM jtallaj@uab.edu RI Franco, Veronica/E-3080-2011 NR 13 TC 0 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD MAY PY 2009 VL 28 IS 5 BP 505 EP 507 DI 10.1016/j.healun.2009.02.013 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 447DI UT WOS:000266171400015 PM 19416781 ER PT J AU Lieu, C Janssen, WJ Saint, S Dhaliwal, G AF Lieu, Christopher Janssen, William J. Saint, Sanjay Dhaliwal, Gurpreet TI The Tip of the Iceberg SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID A STREPTOCOCCAL INFECTIONS; TOXIC-SHOCK-SYNDROME; SPECTRUM C1 [Lieu, Christopher; Janssen, William J.; Dhaliwal, Gurpreet] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Janssen, William J.] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA. [Saint, Sanjay] Ann Arbor Vet Affairs Hlth Serv, Res & Dev Ctr Excellence, Ann Arbor, MI USA. [Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA. [Saint, Sanjay] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. RP Lieu, C (reprint author), Univ Texas MD Anderson Canc Ctr, Div Canc Med, 1515 Holcombe Blvd,Unit 10, Houston, TX 77098 USA. EM chlieu@mdanderson.org NR 13 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAY-JUN PY 2009 VL 4 IS 5 BP 317 EP 320 DI 10.1002/jhm.471 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 459NI UT WOS:000267109200009 PM 19504498 ER PT J AU Meeran, SM Akhtar, S Katiyar, SK AF Meeran, Syed M. Akhtar, Suhail Katiyar, Santosh K. TI Inhibition of UVB-Induced Skin Tumor Development by Drinking Green Tea Polyphenols Is Mediated Through DNA Repair and Subsequent Inhibition of Inflammation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; IFN-GAMMA PRODUCTION; ULTRAVIOLET-RADIATION; INTERLEUKIN-12-DEFICIENT MICE; PYRIMIDINE DIMERS; COX-2 EXPRESSION; T-CELLS; CANCER; PHOTOCARCINOGENESIS; REGRESSION AB Consumption of green tea polyphenols (GTPs) in drinking water prevents photocarcinogenesis in mice; however, the molecular mechanisms underlying this effect have not been fully elucidated. Using IL-12p40 knockout (KO) mice and their wild-type counterparts and an established photocarcinogenesis protocol, we found that although administration of GTPs (0.2%, w/v) in drinking water significantly reduced UVB-induced tumor development in wild-type mice, this treatment had a nonsignificant effect in IL-12-KO mice. GTPs resulted in reduction in the levels of markers of inflammation (cyclooxygenase-2, prostaglandin E(2), proliferating cell nuclear antigen, and cyclin D1) and proinflammatory cytokines (tumor necrosis factor-alpha, IL-6, and IL-1 beta) in chronically UVB-exposed skin and skin tumors of wild-type mice but less effective in IL-12p40-KO mice. UVB-induced DNA damage (cyclobutane pyrimidine dimers) was resolved rapidly in GTPs-treated wild-type mice than untreated wild-type mice and this resolution followed the same time course as the GTPs-induced reduction in the levels of inflammatory responses. This effect of GTPs was less pronounced in IL-12-KO mice. The above results were confirmed by treatment of IL-12-KO mice with murine recombinant IL-12 and treatment of wild-type mice with neutralizing anti-IL-12 antibody. To our knowledge, it is previously unreported that prevention of photocarcinogenesis by GTPs is mediated through IL-12-dependent DNA repair and a subsequent reduction in skin inflammation. C1 [Meeran, Syed M.; Akhtar, Suhail; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Center for Complementary and Alternative Medicine/NIH [1 RO1 AT002536]; Veterans Administration Merit Review Award FX This work was supported by grants from the National Center for Complementary and Alternative Medicine/NIH (1 RO1 AT002536, SKK) and the Veterans Administration Merit Review Award (SKK). NR 45 TC 61 Z9 62 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2009 VL 129 IS 5 BP 1258 EP 1270 DI 10.1038/jid.2008.354 PG 13 WC Dermatology SC Dermatology GA 447US UT WOS:000266218000026 PM 19020550 ER PT J AU Pott, GB Chan, ED Dinarello, CA Shapiro, L AF Pott, Gregory B. Chan, Edward D. Dinarello, Charles A. Shapiro, Leland TI alpha-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE inflammation; dilution; serine protease inhibitor; interleukin ID MONONUCLEAR-CELLS; GENE-EXPRESSION; HUMAN MONOCYTES; IN-VITRO; RHEUMATOID-ARTHRITIS; FLOW-CYTOMETRY; TNF-ALPHA; DEFICIENCY; ALPHA(1)-ANTITRYPSIN; INTERLEUKIN-18 AB Several observations suggest endogenous suppressors of inflammatory mediators are present in human blood. alpha-1-Antitrypsin (AAT) is the most abundant serine protease inhibitor in blood, and AAT possesses anti-inflammatory activity in vitro and in vivo. Here, we show that in vitro stimulation of whole blood from persons with a genetic AAT deficiency resulted in enhanced cytokine production compared with blood from healthy subjects. Using whole blood from healthy subjects, dilution of blood with RPMI tissue-culture medium, followed by incubation for 18 h, increased spontaneous production of IL-8, TNF-alpha, IL-1 beta, and IL-1R antagonist (IL-1Ra) significantly, compared with undiluted blood. Dilution-induced cytokine production suggested the presence of one or more circulating inhibitors of cytokine synthesis present in blood. Serially diluting blood with tissue-culture medium in the presence of cytokine stimulation with heat-killed Staphylococcus epidermidis (S. epi) resulted in 1.2- to 55-fold increases in cytokine production compared with S. epi stimulation alone. Diluting blood with autologous plasma did not increase the production of IL-8, TNF-alpha, IL-1 beta, or IL-1Ra, suggesting that the endogenous, inhibitory activity of blood resided in plasma. In whole blood, diluted and stimulated with S. epi, exogenous AAT inhibited IL-8, IL-6, TNF-alpha, and IL-1 beta significantly but did not suppress induction of the anti-inflammatory cytokines IL-1Ra and IL-10. These ex vivo and in vitro observations suggest that endogenous AAT in blood contributes to the suppression of proinflammatory cytokine synthesis. J. Leukoc. Biol. 85: 886-895; 2009. C1 [Pott, Gregory B.; Chan, Edward D.; Dinarello, Charles A.; Shapiro, Leland] Univ Colorado, Denver, CO 80202 USA. [Pott, Gregory B.; Chan, Edward D.; Shapiro, Leland] Denver Vet Affairs Med Ctr, Denver, CO USA. [Chan, Edward D.] Natl Jewish Med & Res Ctr, Denver, CO USA. RP Shapiro, L (reprint author), Denver Vet Affairs Med Ctr, 12700 E 19th Ave,Box B168, Aurora, CO 80045 USA. EM leland.shapiro@uchsc.edu FU National Institutes of Health [A115614]; Campbell Foundation FX This work is supported by National Institutes of Health grant A115614 ( to C. A. D.) and the Campbell Foundation ( to L. S.). The authors thank Dr. Kristin Morris and Scott Beard for reviewing the manuscript and the AAT-deficient patients for participating in these investigations. NR 53 TC 76 Z9 81 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD MAY 1 PY 2009 VL 85 IS 5 BP 886 EP 895 DI 10.1189/jlb.0208145 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 453TM UT WOS:000266635800017 PM 19197072 ER PT J AU Wang, Q Tang, XN Swanson, RA Yenari, MA AF Wang, Q. Tang, X. N. Swanson, R. A. Yenari, M. A. TI Pyruvate protects experimental stroke: the involvement of anti-inflammatory mechanisms via inhibition of NF-kappa B and MMP9 SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 3rd International-Society-of-Neurochemistry-Special-Neurochemistry Conference/8th International Meeting on Brain Energy Metabolism CY JUN 27-JUL 01, 2008 CL Beijing, PEOPLES R CHINA SP Int Soc Neurochem C1 [Wang, Q.; Tang, X. N.; Swanson, R. A.; Yenari, M. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Wang, Q.; Tang, X. N.; Swanson, R. A.; Yenari, M. A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Wang, Q.; Tang, X. N.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA. [Wang, Q.] Univ Wollongong, Fac Hlth & Behav Sci, Neurobiol Res Ctr, Wollongong, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2009 VL 109 BP 278 EP 279 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 430UF UT WOS:000265013900079 ER PT J AU Tang, KS Suh, SW Alano, CC Swanson, RA Anderson, CM AF Tang, K. S. Suh, S. W. Alano, C. C. Swanson, R. A. Anderson, C. M. TI Astrocyte poly (ADP-ribose) polymerase-1 activation causes glutamate excitotoxicity in neurons SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 3rd International-Society-of-Neurochemistry-Special-Neurochemistry Conference/8th International Meeting on Brain Energy Metabolism CY JUN 27-JUL 01, 2008 CL Beijing, PEOPLES R CHINA SP Int Soc Neurochem C1 [Tang, K. S.; Anderson, C. M.] Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB, Canada. [Tang, K. S.; Anderson, C. M.] St Boniface Gen Hosp, Res Ctr, Div Neurodegenerat Disorders, Winnipeg, MB R2H 2A6, Canada. [Suh, S. W.; Alano, C. C.; Swanson, R. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Suh, S. W.; Alano, C. C.; Swanson, R. A.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RI Anderson, Chris/J-7081-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2009 VL 109 BP 286 EP 286 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 430UF UT WOS:000265013900104 ER PT J AU Hsieh, CL Koike, M Spusta, SC Niemi, EC Yenari, M Nakamura, MC Seaman, WE AF Hsieh, Christine L. Koike, Maya Spusta, Steve C. Niemi, Erene C. Yenari, Midori Nakamura, Mary C. Seaman, William E. TI A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE apoptotic neurons; microglia; phagocytosis ID CENTRAL-NERVOUS-SYSTEM; MYELOID CELLS; IN-VIVO; FRACTALKINE RECEPTOR; PATTERN-RECOGNITION; DENDRITIC CELLS; IMMUNE-SYSTEM; CUTTING EDGE; DAP12; MACROPHAGES AB Following neuronal injury, microglia initiate repair by phagocytosing dead neurons without eliciting inflammation. Prior evidence indicates triggering receptor expressed by myeloid cells-2 (TREM2) promotes phagocytosis and retards inflammation. However, evidence that microglia and neurons directly interact through TREM2 to orchestrate microglial function is lacking. We here demonstrate that TREM2 interacts with endogenous ligands on neurons. Staining with TREM2-Fc identified TREM2 ligands (TREM2-L) on Neuro2A cells and on cultured cortical and dopamine neurons. Apoptosis greatly increased the expression of TREM2-L. Furthermore, apoptotic neurons stimulated TREM2 signaling, and an anti-TREM2 mAb blocked stimulation. To examine the interaction between TREM2 and TREM2-L in phagocytosis, we studied BV2 microglial cells and their engulfment of apoptotic Neuro2A. One of our anti-TREM2 mAb, but not others, reduced engulfment, suggesting the presence of a functional site on TREM2 interacting with neurons. Further, Chinese hamster ovary cells transfected with TREM2 conferred phagocytic activity of neuronal cells demonstrating that TREM2 is both required and sufficient for competent uptake of apoptotic neuronal cells. Finally, while TREM2-L are expressed on neurons, TREM2 is not; in the brain, it is found on microglia. TREM2 and TREM2-L form a receptor-ligand pair connecting microglia with apoptotic neurons, directing removal of damaged cells to allow repair. C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Seaman, WE (reprint author), Vet Affairs Med Ctr, 111R,4150 Clement St, San Francisco, CA 94121 USA. EM bseaman@medicine.ucsf.edu FU Department of Defense [W81XWH-05-2-0094, PT075679]; NIH NINDS [R01 NS40516]; Veterans Administration; NIH NINDS NRSA [5F32NS060338] FX The authors acknowledge and thank Dr Damiana Alvarez for her contributions during the initial phases of this project. The authors also thank Dr Eric Huang and Dr Jiasheng Zhang (UC San Francisco) for their guidance in isolating ventral midbrain neurons, and we thank Dr Daniel Cua and Dr Barbara Shaikh (Schering-Plough, Palo Alto, CA, USA) and Dr Monica Carson (UC Riverside) for their guidance regarding microglial isolation. We also appreciate the help of Ben Harmeling and Dr Ken Scalapino, who operate the flow cytometry core facility at the San Francisco VA Medical Center. This work was funded by the Department of Defense (W81XWH-05-2-0094 and PT075679 to WES), by the NIH NINDS (R01 NS40516 to MY), and by the Veterans Administration. CLH is supported by an NIH NINDS NRSA (5F32NS060338). NR 42 TC 113 Z9 114 U1 2 U2 23 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2009 VL 109 IS 4 BP 1144 EP 1156 DI 10.1111/j.1471-4159.2009.06042.x PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 433EK UT WOS:000265186900018 PM 19302484 ER PT J AU Wang, CSM Burke, JR Steffens, DC Hulette, CM Breitner, JCS Plassman, BL AF Wang, C. Sheei-Meei Burke, J. R. Steffens, D. C. Hulette, C. M. Breitner, J. C. S. Plassman, B. L. TI Twin pairs discordant for neuropathologically confirmed Lewy body dementia SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; PATHOLOGICAL DIAGNOSIS; PARKINSONS-DISEASE; RISK-FACTOR; BODIES DLB; WORK GROUP; REGISTRY; CONCORDANCE; CONSORTIUM AB Aim: Little is known about the concordance rate in twins for dementia with Lewy bodies (DLB). The rate of agreement between clinical and pathological diagnoses for DLB is typically low, necessitating confirmation of the diagnosis neuropathologically. Methods: Participants were 17 twin pairs enrolled in the Duke Twins Study of Memory in Aging in which at least one member of the pair had an autopsy confirmed diagnosis of DLB, Alzheimer's disease (AD) with Lewy bodies or frontotemporal dementia with Lewy bodies. The characteristics of those with dementia were assessed and rates of concordance for pathological confirmed dementia were examined. Results: Four monozygotic twin pairs had a proband with neuropathologically confirmed pure DLB; all remained discordant for dementia for periods up to 16 years or more. Five of 13 pairs in which the proband had AD plus DLB were concordant for dementia but only one pair was concordant for AD plus DLB, while the co-twins in the other four pairs had other types of dementia. Conclusions: The present study indicates that even among twins, a diagnosis of DLB in one twin does not predict the same diagnosis in the other twin. Neuropathological discordance in type of dementia among monozygotic pairs hints at environmental or epigenetic factors playing a role in Lewy body pathology. C1 [Steffens, D. C.; Plassman, B. L.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27701 USA. [Wang, C. Sheei-Meei] Tainan Hosp, Dept Hlth, Dept Psychiat, Tainan, Taiwan. [Burke, J. R.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA. [Hulette, C. M.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Burke, J. R.; Hulette, C. M.] Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA. [Breitner, J. C. S.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Breitner, J. C. S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Plassman, BL (reprint author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 905 Main St,Box 41,Ste 25-D, Durham, NC 27701 USA. EM brenda.plassman@duke.edu RI Burke, James/E-4245-2016 OI Burke, James/0000-0002-3408-7787 FU NIH [AG-08549, AG-05128, AG-02837]; American Health Assistance Foundation [95112] FX NIH AG-08549 (JCSB, BLP), American Health Assistance Foundation # 95112 (JCSB) and NIH AG-05128 and AG-02837 (CMH). NR 25 TC 11 Z9 11 U1 1 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD MAY PY 2009 VL 80 IS 5 BP 562 EP 565 DI 10.1136/jnnp.2008.151654 PG 4 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 433ZN UT WOS:000265244900022 PM 19372291 ER PT J AU Yehuda, R Harvey, PD Golier, JA Newmark, RE Bowie, CR Wohltmann, JJ Grossman, RA Schmeidler, J Hazlett, EA Buchsbaum, MS AF Yehuda, Rachel Harvey, Philip D. Golier, Julia A. Newmark, Randall E. Bowie, Christopher R. Wohltmann, Janelle J. Grossman, Robert A. Schmeidler, James Hazlett, Erin A. Buchsbaum, Monte S. TI Changes in Relative Glucose Metabolic Rate Following Cortisol Administration in Aging Veterans with Posttraumatic Stress Disorder: An FDG-PET Neuroimaging Study SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID MEDIAL PREFRONTAL CORTEX; CORTICOLIMBIC BLOOD-FLOW; MIXED LATERAL PREFERENCE; CHILDHOOD SEXUAL-ABUSE; SCRIPT-DRIVEN IMAGERY; HIPPOCAMPAL-FORMATION; MEMORY PERFORMANCE; ALZHEIMERS-DISEASE; PERSONALITY-DISORDER; BASOLATERAL AMYGDALA AB The authors aimed to examine central glucocorticoids effects by measuring relative glucose metabolic rate (rGMR) in the hippocampus, amygdala, and anterior cingulate cortex (ACC) and the relationship between amygdala and ACC activity. The participants were male combat veterans with and without PTSD, 52 to 81 years old. The authors utilized randomized, double-blind, placebo-controlled examinations of the rGMR response to 17.5 mg hydrocortisone (HCORT) using 2-Deoxy-2-[(18)F] fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) neuroimaging. Group differences in hemispheric laterality of rGMR were observed following placebo administration, reflecting lower rGMR in the right hippocampus and ventral amygdala, and higher rGMR in the left ventral amygdala in the PTSD+ group compared to the PTSD+ group. HCORT reduced these group differences in laterality. The net effect of HCORT was to restore a normal inverse association between the ACC and amygdala in the PTSD+ group, but disrupt this neural network in the PTSD- group. The magnitude of improvement in working memory correlated with greater hemispheric laterality in the dorsal amygdala following HCORT in both groups. The restorative effects of HCORT on metabolism and working memory provide a rationale for examining the therapeutic benefits of glucocorticoid manipulation in aging PTSD patients. C1 [Yehuda, Rachel; Golier, Julia A.; Bowie, Christopher R.; Wohltmann, Janelle J.; Grossman, Robert A.; Schmeidler, James] Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Program, New York, NY USA. [Yehuda, Rachel; Golier, Julia A.; Bowie, Christopher R.; Wohltmann, Janelle J.] James J Peters Bronx Vet Affairs Med Ctr, PTSD Program, Bronx, NY USA. [Harvey, Philip D.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. [Newmark, Randall E.; Hazlett, Erin A.; Buchsbaum, Monte S.] Mt Sinai Sch Med, Dept Psychiat, PET Lab, New York, NY USA. RP Yehuda, R (reprint author), Bronx VA OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@va.gov FU National Institute of Health [5 M01 RR00071] FX This work was supported by a VA Merit Review Grant (RY) and, in part by a grant (5 M01 RR00071) for the Mount Sinai General Clinical Research Center from the National Institute of Health. The authors wish to thank Karina Stavitsky for expert and professional coordination of this research project, Dr. Linda Bierer for database construction, Yuliya Torosjan for scanner operation, Dr. King-Wai Chu for program development and support, and Drs. Lisa Tischler and Alicia Hirsch for conducting diagnostic evaluations. Dr. Yehuda had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 69 TC 18 Z9 21 U1 2 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD MAY PY 2009 VL 21 IS 2 BP 132 EP 143 PG 12 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 472SL UT WOS:000268152300004 PM 19622684 ER PT J AU Sloan, PA Berman, ME Zeigler-Hill, V Bullock, JS AF Sloan, Paul A. Berman, Mitchell E. Zeigler-Hill, Virgil Bullock, Joshua S. TI GROUP INFLUENCES ON SELF-AGGRESSION: CONFORMITY AND DISSENTER EFFECTS SO JOURNAL OF SOCIAL AND CLINICAL PSYCHOLOGY LA English DT Article ID IDENTITY MISCLASSIFICATION; SOCIAL-INFLUENCE; DRINKING NORMS; GROUP PRESSURE; ALCOHOL-USE; BEHAVIOR; MUTILATION; CONTAGION; SUICIDE; DETERMINANTS AB Evidence that intentional self-aggressive behaviors are influenced by social groups comes almost exclusively from nonexperimental retrospective studies which fail to address underlying causal processes. Recently, we conducted a study in which experimentally manipulated group norms were found to directly influence self-aggressive behavior (Sloan, Berman, Zeigler-Hill, Greer, & Mae, 2006). The present study was designed to gain a better understanding of the process by which social groups influence self-aggression. More specifically, we examined the effects of dissenters on the adoption of a self-aggressive group norm. Participants (N = 164) were assigned to one of the following conditions: a unanimous self-aggressive group, a nonunanimous group with a single dissenter in either the first or last position who did not engage in self-aggressive behavior, and a group with no systematic agreement concerning self-aggression. Self-aggression was operationally defined as the use of an extreme shock that was self-administered by the participant within the context of an attention task. Results demonstrated that the adoption of a self-aggressive group norm was significantly weakened by the presence of a dissenter. This effect was moderated by gender such that the presence of a dissenter had a greater impact on the self-aggressive behavior of women than it did for men. Clinical and theoretical implications of these findings are discussed. C1 [Sloan, Paul A.] Michael E DeBakey Vet Affairs Med Ctr, Mental Hlth Care Line 116 CMHP, Houston, TX 77030 USA. [Sloan, Paul A.] Baylor Coll Med, Houston, TX 77030 USA. [Berman, Mitchell E.; Zeigler-Hill, Virgil; Bullock, Joshua S.] Univ So Mississippi, Hattiesburg, MS 39406 USA. RP Sloan, PA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Mental Hlth Care Line 116 CMHP, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM paul.sloan@va.gov NR 64 TC 4 Z9 4 U1 1 U2 5 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0736-7236 J9 J SOC CLIN PSYCHOL JI J. Soc. Clin. Psychol. PD MAY PY 2009 VL 28 IS 5 BP 535 EP 553 PG 19 WC Psychology, Clinical; Psychology, Social SC Psychology GA 453KX UT WOS:000266610400001 ER PT J AU Saunders, GH Lewis, MS Forsline, A AF Saunders, Gabrielle H. Lewis, M. Samantha Forsline, Anna TI Expectations, Prefitting Counseling, and Hearing Aid Outcome SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article; Proceedings Paper CT International Hearing Aid Research Conference CY 2008 CL Lake Tahoe, CA DE Counseling; expectations; hearing aids; outcome ID AUDIOLOGICAL REHABILITATION; AMPLIFICATION; BENEFIT; ADULTS; ATTITUDES; HANDICAP; SCALE; USERS AB Background: Data suggest that having high expectations about hearing aids results in better overall outcome. However, some have postulated that excessively high expectations will result in disappointment and thus poor outcome. It has been suggested that counseling patients with unrealistic expectations about hearing aids prior to fitting may be beneficial. Data, however, are mixed as to the effectiveness of such counseling, in terms of both changes in expectations and final outcome. Purpose: The primary purpose of this study was to determine whether supplementing prefitting counseling with demonstration of real-world listening can (1) alter expectations of new hearing aid users and (2) increase satisfaction over verbal-only counseling. Secondary goals of the study were to examine (1) the relationship between prefitting expectations and postfitting outcome, and (2) the effect of hearing aid fine-tuning on hearing aid outcome. Research Design: Sixty new hearing aid users were fitted binaurally with Beltone Oria behind-the-ear digital hearing aids. Forty participants received prefitting counseling and demonstration of listening situations with the Beltone AVE (TM) (Audio Verification Environment) system; 20 received prefitting counseling without a demonstration of listening situations. Hearing aid expectations were measured at initial contact and following prefitting counseling. Reported hearing aid outcome was measured after eight to ten weeks of hearing aid use. Study Sample: Sixty new hearing aid users aged between 55 and 81 years with symmetrical sensorineural hearing loss. Intervention: Participants were randomly assigned to one of three experimental groups, between which the prefitting counseling and follow-up differed: Group 1 received prefitting counseling in combination with demonstration of listening situations. Additionally, if the participant had complaints about sound quality at the follow-up visit, the hearing aids were fine-tuned using the Beltone AVE system. Group 2 received prefitting counseling in combination with demonstration of listening situations with the Beltone AVE system, but no fine-tuning was provided at follow-up. Group 3 received prefitting hearing aid counseling that did not include demonstration of listening, and the hearing aids were not fine-tuned at the follow-up appointment. Results: The results showed that prefitting hearing aid counseling had small but significant effects on expectations. The two forms of counseling did not differ in their effectiveness at changing expectations; however, anecdotally, we learned from many participants that that they enjoyed listening to the auditory demonstrations and that they found them to be an interesting listening exercise. The data also show that positive expectations result in more positive outcome and that hearing aid fine-tuning is beneficial to the user. Conclusions: We conclude that prefitting counseling can be advantageous to hearing aid outcome and recommend the addition of prefitting counseling to address expectations associated with quality of life and self-image. The data emphasize the need to address unrealistic expectations prior to fitting hearing aids cautiously, so as not to decrease expectations to the extent of discouraging and demotivating the patient. Data also show that positive expectations regarding the impact hearing aids will have on psychosocial well-being are important for successful hearing aid outcome. C1 [Saunders, Gabrielle H.] Portland VA Med Ctr, NCRAR, Portland, OR 97207 USA. [Saunders, Gabrielle H.; Lewis, M. Samantha] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Forsline, Anna] Portland VA Med Ctr, Audiol & Speech Pathol Serv, Portland, OR 97207 USA. RP Saunders, GH (reprint author), Portland VA Med Ctr, NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM Gabrielle.Saunders@va.gov NR 46 TC 20 Z9 22 U1 8 U2 26 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD MAY PY 2009 VL 20 IS 5 BP 320 EP 334 DI 10.3766/jaaa.20.5.6 PG 15 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 462DE UT WOS:000267325400006 PM 19585963 ER PT J AU Sivamani, RK Howe, WR Dellavalle, RP AF Sivamani, Raja K. Howe, William R. Dellavalle, Robert P. TI Acute onset of neurofibromas in association with esophageal adenocarcinoma SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter ID TYPE-1 NF1 GENE; SEGMENTAL NEUROFIBROMATOSIS; CARCINOMA C1 [Sivamani, Raja K.] Univ Calif Davis, Sch Med, Davis, CA 95616 USA. [Howe, William R.; Dellavalle, Robert P.] Univ Colorado, Sch Med, Dept Dermatol, Denver, CO USA. [Dellavalle, Robert P.] Dept Vet Affairs, Med Ctr, Denver, CO USA. RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,165, Denver, CO 80220 USA. EM Robert.Dellavalle@UCHSC.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X NR 10 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2009 VL 60 IS 5 BP 880 EP 881 DI 10.1016/j.jaad.2008.09.027 PG 2 WC Dermatology SC Dermatology GA 438AW UT WOS:000265529300030 PM 19389537 ER PT J AU Lin, J Lott, JP Amorosa, VK Kovarik, CL AF Lin, Jennifer Lott, Jason P. Amorosa, Valerianna K. Kovarik, Carrie L. TI Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter ID THERAPY; TONGUE C1 [Lott, Jason P.; Kovarik, Carrie L.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Lin, Jennifer] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Amorosa, Valerianna K.; Kovarik, Carrie L.] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA. [Amorosa, Valerianna K.; Kovarik, Carrie L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kovarik, CL (reprint author), Univ Penn, Sch Med, Dept Dermatol, 3600 Spruce St,2 Maloney Bldg, Philadelphia, PA 19104 USA. EM carrie.kovarik@uphs.upenn.edu OI Lott, Jason/0000-0002-4097-7225 NR 5 TC 7 Z9 7 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2009 VL 60 IS 5 BP 882 EP 883 DI 10.1016/j.jaad.2008.10.006 PG 2 WC Dermatology SC Dermatology GA 438AW UT WOS:000265529300031 PM 19389538 ER PT J AU Lorenz, KA Sherbourne, CD Shugarman, LR Rubenstein, LV Wen, L Cohen, A Goebel, JR Hagenmeier, E Simon, B Lanto, A Asch, SM AF Lorenz, Karl A. Sherbourne, Cathy D. Shugarman, Lisa R. Rubenstein, Lisa V. Wen, Li Cohen, Angela Goebel, Joy R. Hagenmeier, Emily Simon, Barbara Lanto, Andy Asch, Steven M. TI How Reliable is Pain as the Fifth Vital Sign? SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article ID CANCER PAIN; ACCURACY; MODERATE; QUALITY; MILD; CARE; CUTPOINTS; COMMUNITY; SEVERITY; VALIDITY AB Background: Although many health care organizations require routine pain screening (eg, "5th vital sign") with the 0 to 10 numeric rating scale (NRS), its accuracy has been questioned; here we evaluated its accuracy and potential causes for error. Methods: We randomly surveyed veterans and reviewed their charts after outpatient encounters at 2 hospitals and 6 affiliated community sites. Using correlation and receiver operating characteristic analysis, we compared the routinely measured "5th vital sign" (nurse-recorded NRS) with a research-administered NRS (research-recorded NRS) and the Brief Pain Inventory (BPI). Results: During 528 encounters, nurse-recorded NRS and research-recorded NRS correlated moderately (r = 0.627), as did nurse-recorded NRS and BPI severity scales (r = 0.613 for pain during the last 24 hours and r = 0.588 for pain during the past week). Correlation with BPI interference was lower (r = 0.409). However, the research-recorded NRS correlated substantially with the BPI severity during the past 24 hours (r = 0.870) and BPI severity during the last week (r = 0.840). Receiver operating characteristic analysis showed similar results. Of the 98% of cases where a numeric score was recorded, 51% of patients reported their pain was rated qualitatively, rather than with a 0 to 10 scale, a practice associated with pain underestimation (chi(2) = 64.04, P < .001). Conclusion: Though moderately accurate, the outpatient "5th vital sign" is less accurate than under ideal circumstances. Personalizing assessment is a common clinical practice but may affect the performance of research tools such as the NRS adopted for routine use. (J Am Board Fam Med 2009;22:291-8.) C1 [Lorenz, Karl A.; Rubenstein, Lisa V.; Cohen, Angela; Hagenmeier, Emily; Simon, Barbara; Lanto, Andy; Asch, Steven M.] Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA 90064 USA. [Lorenz, Karl A.; Sherbourne, Cathy D.; Shugarman, Lisa R.; Rubenstein, Lisa V.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA. [Lorenz, Karl A.; Rubenstein, Lisa V.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Goebel, Joy R.] Calif State Univ Long Beach, Dept Nursing, Long Beach, CA 90840 USA. RP Lorenz, KA (reprint author), Vet Adm Greater Angeles Healthcare Syst, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90064 USA. EM karl.lorenz@med.va.gov OI Cohen, Angela B./0000-0002-0620-1909 FU Veterans Administration Health Services Research and Development IIR [03-150] FX Veterans Administration Health Services Research and Development IIR 03-150. NR 23 TC 43 Z9 46 U1 2 U2 11 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD MAY-JUN PY 2009 VL 22 IS 3 BP 291 EP 298 DI 10.3122/jabfm.2009.03.080162 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 443VR UT WOS:000265939400010 PM 19429735 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI OBSTRUCTIVE SLEEP APNEA Response SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter ID ATRIAL-FIBRILLATION; PREVALENCE; ATHEROMAS; RISK C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD MAY PY 2009 VL 140 IS 5 BP 515 EP 516 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 445JS UT WOS:000266047700005 ER PT J AU Bloom, HG Ahmed, I Alessi, CA Ancoli-Israel, S Buysse, DJ Kryger, MH Phillips, BA Thorpy, MJ Vitiello, MV Zee, PC AF Bloom, Harrison G. Ahmed, Imran Alessi, Cathy A. Ancoli-Israel, Sonia Buysse, Daniel J. Kryger, Meir H. Phillips, Barbara A. Thorpy, Michael J. Vitiello, Michael V. Zee, Phyllis C. TI Evidence-Based Recommendations for the Assessment and Management of Sleep Disorders in Older Persons SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Review ID RESTLESS-LEGS-SYNDROME; NURSING-HOME RESIDENTS; POSITIVE AIRWAY PRESSURE; EXCESSIVE DAYTIME SLEEPINESS; BRIGHT-LIGHT THERAPY; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; PERIODIC LIMB MOVEMENTS; COMMUNITY-DWELLING ADULTS; CHEYNE-STOKES RESPIRATION AB Sleep-related disorders are most prevalent in the older adult population. A high prevalence of medical and psychosocial comorbidities and the frequent use of multiple medications, rather than aging per se, are major reasons for this. A major concern, often underappreciated and underaddressed by clinicians, is the strong bidirectional relationship between sleep disorders and serious medical problems in older adults. Hypertension, depression, cardiovascular disease, and cerebrovascular disease are examples of diseases that are more likely to develop in individuals with sleep disorders. Conversely, individuals with any of these diseases are at a higher risk of developing sleep disorders. The goals of this article are to help guide clinicians in their general understanding of sleep problems in older persons, examine specific sleep disorders that occur in older persons, and suggest evidence- and expert-based recommendations for the assessment and treatment of sleep disorders in older persons. No such recommendations are available to help clinicians in their daily patient care practices. The four sections in the beginning of the article are titled, Background and Significance, General Review of Sleep, Recommendations Development, and General Approach to Detecting Sleep Disorders in an Ambulatory Setting. These are followed by overviews of specific sleep disorders: Insomnia, Sleep Apnea, Restless Legs Syndrome, Circadian Rhythm Sleep Disorders, Parasomnias, Hypersomnias, and Sleep Disorders in Long-Term Care Settings. Evidence- and expert-based recommendations, developed by a group of sleep and clinical experts, are presented after each sleep disorder. C1 [Bloom, Harrison G.] Int Longev Ctr USA, New York, NY 10028 USA. [Bloom, Harrison G.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY USA. [Ahmed, Imran; Vitiello, Michael V.] Albert Einstein Coll Med, New York, NY USA. [Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Alessi, Cathy A.] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Buysse, Daniel J.] Univ Pittsburgh, Sch Med, Neurosci Clin & Translat Ctr, Pittsburgh, PA USA. [Kryger, Meir H.] Gaylord Hosp, Gaylord Sleep Ctr, Wallingford, CT USA. [Kryger, Meir H.] Univ Connecticut, Sch Med, Dept Med, Farmington, CT USA. [Phillips, Barbara A.] Natl Sleep Fdn, Washington, DC USA. [Phillips, Barbara A.] Univ Kentucky, Coll Med, Lexington, KY USA. [Thorpy, Michael J.] Montefiore Med Ctr, Ctr Sleep Wake Disorders, Bronx, NY 10467 USA. [Vitiello, Michael V.] Univ Washington, Seattle, WA 98195 USA. [Zee, Phyllis C.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. RP Bloom, HG (reprint author), Int Longev Ctr USA, 60 E 86th St, New York, NY 10028 USA. EM HarrisonB@ilcusa.org OI Vitiello, Michael/0000-0002-9776-0473 FU NIA NIH HHS [R01 AG008415, R01 AG008415-17] NR 293 TC 130 Z9 135 U1 5 U2 38 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2009 VL 57 IS 5 BP 761 EP 789 DI 10.1111/j.1532-5415.2009.02220.x PG 29 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 440OP UT WOS:000265709900001 PM 19484833 ER PT J AU Marson, DC Martin, RC Wadley, V Griffith, HR Snyder, S Goode, PS Kinney, FC Nicholas, AP Steele, T Anderson, B Zamrini, E Raman, R Bartolucci, A Harrell, LE AF Marson, Daniel C. Martin, Roy C. Wadley, Virginia Griffith, H. Randall Snyder, Scott Goode, Patricia S. Kinney, F. Cleveland Nicholas, Anthony P. Steele, Terri Anderson, Britt Zamrini, Edward Raman, Rema Bartolucci, Alfred Harrell, Lindy E. TI Clinical Interview Assessment of Financial Capacity in Older Adults with Mild Cognitive Impairment and Alzheimer's Disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE financial capacity; competency; clinical assessment; mild cognitive impairment; Alzheimer's disease ID DECISION-MAKING CAPACITY; PROTOTYPE-INSTRUMENT; ELDERLY PERSONS; COMPETENCE; ABILITIES; DEMENTIA; CONSENT; CONSISTENCY; JUDGMENTS AB To investigate financial capacity in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) using a clinician interview approach. Cross-sectional. Tertiary care medical center. Healthy older adults (n=75) and patients with amnestic MCI (n=58), mild AD (n=97), and moderate AD (n=31). The investigators and five study physicians developed a conceptually based, semistructured clinical interview for evaluating seven core financial domains and overall financial capacity (Semi-Structured Clinical Interview for Financial Capacity; SCIFC). For each participant, a physician made capacity judgments (capable, marginally capable, or incapable) for each financial domain and for overall capacity. Study physicians made more than 11,000 capacity judgments across the study sample (N=261). Very good interrater agreement was obtained for the SCIFC judgments. Increasing proportions of marginal and incapable judgment ratings were associated with increasing disease severity across the four study groups. For overall financial capacity, 95% of physician judgments for older controls were rated as capable, compared with 82% for patients with MCI, 26% for patients with mild AD, and 4% for patients with moderate AD. Physicians and other clinicians can reliably evaluate financial capacity in cognitively impaired older adults using a relatively brief, semistructured clinical interview. Patients with MCI have mild impairment in financial capacity, those with mild AD have emerging global impairment, and those with moderate AD have advanced global impairment. Patients with MCI and their families should proactively engage in financial and legal planning, given these patients' risk of developing AD and accelerated loss of financial abilities. C1 [Marson, Daniel C.; Martin, Roy C.; Wadley, Virginia; Griffith, H. Randall; Kinney, F. Cleveland; Nicholas, Anthony P.; Bartolucci, Alfred; Harrell, Lindy E.] Univ Alabama, Dept Neurol, Alzheimers Dis Res Ctr, Birmingham, AL 35294 USA. [Wadley, Virginia; Goode, Patricia S.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham, AL 35294 USA. [Snyder, Scott] Univ Alabama, Dept Educ, Birmingham, AL 35294 USA. [Kinney, F. Cleveland] Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA. [Bartolucci, Alfred] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Goode, Patricia S.; Harrell, Lindy E.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Anderson, Britt] Univ Waterloo, Dept Psychol, Ctr Theoret Neurosci, Waterloo, ON N2L 3G1, Canada. [Zamrini, Edward] Univ Utah Hlth Sci, Dept Neurol, Salt Lake City, UT USA. [Raman, Rema] Univ Calif San Diego, Dept Family Med & Neurosci, San Diego, CA 92103 USA. RP Marson, DC (reprint author), Univ Alabama, Dept Neurol, Alzheimers Dis Res Ctr, SC 650, Birmingham, AL 35294 USA. EM dmarson@uab.edu FU National Institute of Mental Health [MH55247]; National Institute on Aging [AG024525, AG021927, P50AG16582] FX Sponsor's Role: The funding source had no role in the design or conduct of the study, data management or analysis, or manuscript preparation. NR 35 TC 34 Z9 34 U1 4 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2009 VL 57 IS 5 BP 806 EP 814 DI 10.1111/j.1532-5415.2009.02202.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 440OP UT WOS:000265709900004 PM 19453308 ER PT J AU Labossiere, R Hintzke, C Ileana, S AF Labossiere, Reginald Hintzke, Carrie Ileana, Soneru TI Hypercalcemia of Immobilization SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Letter ID BONE MASS; BED REST; ADAPTATION; RAT C1 [Labossiere, Reginald; Ileana, Soneru] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Labossiere, Reginald; Hintzke, Carrie; Ileana, Soneru] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Labossiere, R (reprint author), Loyola Univ, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. NR 11 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAY PY 2009 VL 10 IS 4 BP 284 EP 285 DI 10.1016/j.jamda.2009.02.015 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 453XJ UT WOS:000266645900017 PM 19426949 ER PT J AU Lesselroth, BJ Felder, RS Adams, SM Cauthers, PD Dorr, DA Wong, GJ Douglas, DM AF Lesselroth, Blake J. Felder, Robert S. Adams, Shawn M. Cauthers, Phillip D. Dorr, David A. Wong, Gordon J. Douglas, David M. TI Design and Implementation of a Medication Reconciliation Kiosk: the Automated Patient History Intake Device (APHID) SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID ERRORS AB Errors associated with medication documentation account for a substantial fraction of preventable medical errors. Hence, the Joint Commission has called for the adoption of reconciliation strategies at all United States healthcare institutions. Although studies suggest that reconciliation tools can reduce errors, it remains unclear how best to implement systems and processes that are reliable and sensitive to clinical workflow. The authors designed a primary care process that Supported reconciliation without compromising clinic efficiency. This manuscript describes the design and implementation of Automated Patient History Intake Device (APHID): ambulatory check-in kiosks that allow patients to review the names, dosage, frequency, and Pictures of their medications before their appointment. Medication lists are retrieved from the electronic health record and patient updates are captured and reviewed by providers during the clinic session. Results from the roll-in phase indicate the device is easy for patients to use and integrates well with clinic workflow. J Am Med Inform Assoc. 2009;16:300-304. DOI 10.1197/jamia.M2642. C1 [Lesselroth, Blake J.] Portland VA Med Ctr, Dept Hosp Specialty Med, Portland, OR 97239 USA. [Lesselroth, Blake J.; Felder, Robert S.; Adams, Shawn M.; Cauthers, Phillip D.; Dorr, David A.; Wong, Gordon J.] Portland VA Med Ctr, Portland Patient Safety Ctr Inquiry, Portland, OR 97239 USA. [Lesselroth, Blake J.; Felder, Robert S.; Cauthers, Phillip D.; Wong, Gordon J.; Douglas, David M.] Portland VA Med Ctr, Technol & Informat Management Sect, Portland, OR 97239 USA. [Lesselroth, Blake J.; Dorr, David A.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. RP Lesselroth, BJ (reprint author), Portland VA Med Ctr, Dept Hosp Specialty Med, Mail Code P3 MED,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Blake.Lesselroth@va.gov NR 9 TC 22 Z9 22 U1 0 U2 4 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY-JUN PY 2009 VL 16 IS 3 BP 300 EP 304 DI 10.1197/jamia.M2642 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 447DU UT WOS:000266172600009 PM 19261949 ER PT J AU Dux, KE Sage, RA Gocke, SP AF Dux, Katherine E. Sage, Ronald A. Gocke, Sean P. TI Pedal Presentation of Metastatic Invasive Squamous Cell Carcinoma of the Bladder SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION LA English DT Article ID FOOT; TUMORS; BONES; TOE AB Squamous cell carcinoma is a malignant tumor of the squamous epithelium and can occur in many different organs. We present a case of a 61-year-old veteran with metastatic squamous cell carcinoma of the bladder with distal metastasis to the middle phalanx of the fourth toe, which is a rare occurrence in the literature. (J Am Podiatr Med Assoc 99(3): 251-253, 2009) C1 [Dux, Katherine E.; Gocke, Sean P.] Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA. [Sage, Ronald A.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Orthoped Surg & Rehabil, Hines, IL 60141 USA. RP Dux, KE (reprint author), Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, 2160 S 1st Ave, Maywood, IL 60153 USA. EM kduxdpm@gmail.com NR 15 TC 0 Z9 0 U1 0 U2 0 PU AMER PODIATRIC MED ASSOC PI BETHESDA PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621 USA SN 8750-7315 J9 J AM PODIAT MED ASSN JI J. Am. Podiatr. Med. Assoc. PD MAY-JUN PY 2009 VL 99 IS 3 BP 251 EP 253 PG 3 WC Orthopedics SC Orthopedics GA 447UJ UT WOS:000266217000012 PM 19448178 ER PT J AU Madero, M Wassel, CL Peralta, CA Najjar, SS Sutton-Tyrrell, K Fried, L Canada, R Newman, A Shlipak, MG Sarnak, MJ AF Madero, Magdalena Wassel, Christina L. Peralta, Carmen A. Najjar, Samer S. Sutton-Tyrrell, Kim Fried, Linda Canada, Robert Newman, Anne Shlipak, Michael G. Sarnak, Mark J. CA Health ABC Study TI Cystatin C Associates with Arterial Stiffness in Older Adults SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the American-Society-of-Nephrology/Annual Renal Week CY NOV 14-19, 2006 CL San Diego, CA SP Amer Soc Nephrol ID PULSE-WAVE VELOCITY; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR EVENTS; RISK-FACTOR; CREATININE CLEARANCE; AORTIC STIFFNESS; MORTALITY; PRESSURE AB Large arteries commonly become stiff in kidney failure, but few studies have investigated arterial stiffness in earlier stages of kidney disease. We evaluated the association between kidney function and aortic pulse wave velocity (aPWV) and its potential modification by race, diabetes, or coronary heart disease in older adults. We measured aPWV in 2468 participants in the Health Aging and Body Composition (Health ABC) study; mean age was 73.7 yr, 40% were black, and 24% had diabetes. After categorizing kidney function into three groups on the basis of cystatin C level, multivariable analysis revealed that the medium and high cystatin C groups associated with a 5.3% (95% confidence interval 0.8 to 10.0%) and 8.0% (95% confidence interval 2.2 to 14.1%) higher aPWV than the low cystatin C group; however, chronic kidney disease, as defined by estimated GFR <60 ml/min per 1.73 m(2), did not significantly associate with aPWV. We did not identify interactions between cystatin C and race, diabetes, or coronary heart disease. In conclusion, stiffness of large arteries, a major risk factor for cardiovascular disease, may partially mediate the association between cystatin C and cardiovascular risk in older adults. C1 [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Dept Med, Boston, MA 02111 USA. [Madero, Magdalena] Inst Nacl Cardiol Ignacio Chavez Mexico City, Dept Nephrol, Mexico City, DF, Mexico. [Wassel, Christina L.; Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Wassel, Christina L.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Wassel, Christina L.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Najjar, Samer S.] NIA, NIH, Bethesda, MD 20892 USA. [Sutton-Tyrrell, Kim; Newman, Anne] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Fried, Linda] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Canada, Robert] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA. RP Sarnak, MJ (reprint author), Tufts Med Ctr, Div Nephrol, Dept Med, Box 391,800 Washington St, Boston, MA 02111 USA. EM msarnak@tuftsmedicalcenter.org RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU Intramural NIH HHS; NIA NIH HHS [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIDDK NIH HHS [K24 DK078204] NR 34 TC 34 Z9 37 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAY PY 2009 VL 20 IS 5 BP 1086 EP 1093 DI 10.1681/ASN.2008030318 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 444DE UT WOS:000265959800022 PM 19357259 ER PT J AU Twiss, C Kilpatrick, L Craske, M Buffington, CAT Ornitz, E Rodriguez, LV Mayer, EA Naliboff, BD AF Twiss, Christian Kilpatrick, Lisa Craske, Michelle Buffington, C. A. Tony Ornitz, Edward Rodriguez, Larissa V. Mayer, Emeran A. Naliboff, Bruce D. TI Increased Startle Responses in Interstitial Cystitis: Evidence for Central Hyperresponsiveness to Visceral Related Threat SO JOURNAL OF UROLOGY LA English DT Article DE cystitis; interstitial; sensory gating; startle reaction; reflex ID ANXIETY DISORDERS; PELVIC PAIN; FEAR; AMYGDALA; HYPERSENSITIVITY; INDEX; IBS AB Purpose: Hypersensitivity to visceral stimuli in interstitial cystitis/painful bladder syndrome may result from enhanced responsiveness of affective circuits (including the amygdala complex) and associated central pain amplification. Potentiation of the eyeblink startle reflex under threat is mediated by output from the amygdala complex and, therefore, represents a noninvasive marker to study group differences in responsiveness in this brain circuit. Materials and Methods: Acoustic startle responses were examined in female patients with interstitial cystitis/painful bladder syndrome (13) and healthy controls (16) during context threat (application of muscle stimulation electrodes to the lower abdomen overlying the bladder), and cued conditions for safety (no stimulation possible), anticipation and imminent threat of aversive abdominal stimulation over the bladder. Results: Patients showed significantly greater startle responses during nonimminent threat conditions (baseline, safe and anticipation periods) while both groups showed similar robust startle potentiation during the imminent threat condition. Higher rates of anxiety and depression symptoms in the patient group did not account for the group differences in startle reflex magnitude. Conclusions: Compared to controls, female patients with interstitial cystitis/painful bladder syndrome showed increased activation of a defensive emotional circuit in the context of a threat of abdominal pain. This pattern is similar to that previously reported in patients with anxiety disorders as well as those with irritable bowel syndrome. Since these circuits have an important role in central pain amplification related to affective and cognitive processes, these results support the hypothesis that the observed abnormality may be involved in the enhanced perception of bladder signals associated with interstitial cystitis/painful bladder syndrome. C1 [Kilpatrick, Lisa; Craske, Michelle; Buffington, C. A. Tony; Ornitz, Edward; Mayer, Emeran A.; Naliboff, Bruce D.] Univ Calif Los Angeles, Ctr Neurobiol Stress, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Kilpatrick, Lisa; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Ornitz, Edward; Mayer, Emeran A.; Naliboff, Bruce D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Twiss, Christian; Rodriguez, Larissa V.] Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Craske, Michelle] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90073 USA. [Naliboff, Bruce D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Buffington, C. A. Tony] Ohio State Univ, Dept Vet Clin Sci, Coll Vet Med, Columbus, OH 43210 USA. RP Naliboff, BD (reprint author), Univ Calif Los Angeles, Ctr Neurobiol Stress, David Geffen Sch Med, CURE Bld 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM naliboff@ucla.edu RI Buffington, Tony/B-7135-2009; Kilpatrick, Lisa/E-6995-2015 FU NCCIH NIH HHS [R24AT002681, R24 AT002681, R24 AT002681-04]; NIDDK NIH HHS [P50 DK064539, P50 DK064539-06, P50 DK64539]; NINR NIH HHS [NR007768, R01 NR007768, R01 NR007768-03] NR 27 TC 22 Z9 22 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD MAY PY 2009 VL 181 IS 5 BP 2127 EP 2133 DI 10.1016/j.juro.2009.01.025 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 431PJ UT WOS:000265074800056 PM 19286199 ER PT J AU Chang, CK Chuter, TAM Niemann, CU Shlipak, MG Cohen, MJ Reilly, LM Hiramoto, JS AF Chang, Catherine K. Chuter, Timothy A. M. Niemann, Claus U. Shlipak, Michael G. Cohen, Mitchell J. Reilly, Linda M. Hiramoto, Jade S. TI Systemic inflammation, coagulopathy, and acute renal insufficiency following endovascular thoracoabdominal aortic aneurysm repair SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; ZENITH STENT GRAFT; CYSTATIN-C; BIOLOGICAL RESPONSES; SURGERY; INJURY; REINTERVENTION; CREATININE; BIOMARKERS; FAILURE AB Objective: To characterize the inflammatory and coagulopathic response after endovascular thoracoabdominal aortic aneurysm (TAAA) repair and to evaluate the effect of the response on postoperative renal function. Methods. From July 2005 to June 2008, 42 patients underwent elective endovascular repair of a TAAA using custom designed multi-branched stent-grafts at a single academic institution. Four patients were excluded from the analysis. White blood cell count (WBC), platelet count, prothrombin time (PT), and creatinine were measured in all patients. In the last nine patients, interleukin-6 (IEL-6), protein C, Factor V, cl-dimers, cystatin C, and neutrophil gelatinase-associated lipocatin (NGAL) levels were also measured. Change in lab values were expressed as a percentage of baseline values. Results. The 30-day mortality rate was 5% (2/38). All patients (n = 38) had a higher WBC (mean +/- SD: 139 +/- 80%, P < .0001), lower platelet count (56 +/- 15%, P < .0001), and higher PT (median: 17%, Interquartile range (IQR) 12%-22%, P < .0001) after stent-graft insertion. Twelve of 38 patients (32%) developed postoperative acute renal insufficiency (>50% rise in creatinine). Patients with renal insufficiency had significantly larger changes in WBC (178 +/- 100% vs 121 +/- 64%, P = .04) and platelet count (64 +/- 17% vs 52 +/- 12%, P = .02) compared with those without renal insufficiency. All patients (n = 9) had significant increases in NGAL (182 +/- 115%, P = .008) after stent-graft insertion. Six of nine patients (67%) had increased cystatin C (35 +/- 43%, P = .04) after stent-graft insertion, with a greater rise in those with postoperative renal insufficiency (87 +/- 32% vs 8 +/- 13%, P = .02). IEL-6 levels were markedly increased in all patients (n = 9) after repair (9840 +/- 6160%, P = .008). Protein C (35 +/- 10%, P = .008) and Factor V levels (28 +/- 20%, P = .008) were uniformly decreased, while d-dimers were elevated after repair in all patients (310 +/- 213%, P = .008). Conclusions. Leukocytosis and thrombocytopenia were uniform following endovascular TAAA repair, and the severity of the response correlated with post-operative renal dysfunction. Elevation of a sensitive marker of renal injury (NGAL) suggests that renal injury may occur in all patients after stent-graft insertion. (J Vasc Surg 2009;49:1140-6.) C1 [Chang, Catherine K.; Chuter, Timothy A. M.; Reilly, Linda M.; Hiramoto, Jade S.] Univ Calif San Francisco, Div Vasc Surg, Dept Surg, San Francisco, CA 94143 USA. [Niemann, Claus U.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. [Niemann, Claus U.] Univ Calif San Francisco, Div Transplantat, Dept Surg, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. RP Hiramoto, JS (reprint author), Univ Calif San Francisco, Div Vasc Surg, Dept Surg, 400 Parnassus Ave,A-581, San Francisco, CA 94143 USA. EM Jade.Hiramoto@ucsfmedctr.org FU National Institutes of Health (NIH)/National Center for Research Resources (NCRR)/OD University of California, Sail Francisco (UCSF)-Clinical and Translational Science Institute (CTSI) [KL2 RR024130]; NIH [K08 GM-085689]; Hellman Award; Research Evaluation and Allocation Committee, San Francisco, CA; Foundation of Anesthesia Research and Education; Foundation for Accelerated Vascular Research, San Francisco; American Heart Association FX This project was Supported by National Institutes of Health (NIH)/National Center for Research Resources (NCRR)/OD University of California, Sail Francisco (UCSF)-Clinical and Translational Science Institute (CTSI) Grant Number KL2 RR024130 (Dr Hiramoto) and NIH K08 GM-085689 (Dr Cohen). Its contents arc the responsibility of the authors and do not necessarily represent the official views of the NIH. This stud), was also supported in part by grants from the Hellman Award, Sail Francisco, CA (Dr Hiramoto); the Research Evaluation and Allocation Committee, San Francisco, CA (Dr Hirarnoto); the Foundation of Anesthesia Research and Education, Rochester, MN (Dr Niemann); the International Anesthesia Research Society, Cleveland, OH (Dr Niemann); the Foundation for Accelerated Vascular Research, San Francisco, CA (Drs Chang and Chuter); and the Established Investigator Award from the American Heart Association (Dr Shlipak). The Clinical-trials.gov number is: NCT00483249. NR 29 TC 33 Z9 36 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAY PY 2009 VL 49 IS 5 BP 1140 EP 1146 DI 10.1016/j.jvs.2008.11.102 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 441BQ UT WOS:000265744700009 PM 19394543 ER PT J AU Wheeler, S Bowen, JD Maynard, C Lowy, E Sun, HL Sales, AE Smith, NL Fihn, SD AF Wheeler, Stephanie Bowen, Jennie D. Maynard, Charles Lowy, Elliot Sun, Haili Sales, Anne E. Smith, Nicholas L. Fihn, Stephan D. TI Women Veterans and Outcomes after Acute Myocardial Infarction SO JOURNAL OF WOMENS HEALTH LA English DT Article ID ACUTE CORONARY SYNDROMES; HEALTH-CARE-SYSTEM; QUALITY-OF-CARE; SEX-DIFFERENCES; HOSPITAL DISCHARGE; ARTERY DISEASE; MEN; MANAGEMENT; MORTALITY; GENDER AB Background: Previous studies have shown that women have decreased survival and receive fewer cardiac procedures after acute myocardial infarction (AMI) compared with men, raising concerns for sexual bias in provision of care. The objective of this study is to describe clinical characteristics, treatment, and survival in women veterans compared with men after admission to VA hospitals for AMI. Methods: This is a retrospective inception cohort study using data drawn from the VA Cardiac Care Follow-up Clinical Study, describing patients admitted for AMI to VA hospitals from October 1, 2003 to March 31, 2005. Subjects were followed for 1 year. Results: There were 236 women and 13,259 men admitted during the study period to VA hospitals with AMI. Women were less likely to have a history of heart failure compared with men (18.2% of women vs. 27.2% of men, p = 0.002) and previous coronary artery bypass grafting (CABG) (11.4% of women vs. 19.6% of men, p=0.002). Diagnostic cardiac catheterization was similar in women and men (36.9% and 34.9%, p = 0.539). Crude in-hospital mortality was 4.2% for women and 7.6% for men (p=0.051). After adjusting for comorbidities and treatment variables, in-hospital mortality was not significantly different for women compared with men (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.60-1.12). Conclusions: Women veterans receive a level of care similar to men veterans for MI treated in VA hospitals. Differences in mortality between women and men were not significant and do not suggest that women fare worse. C1 [Wheeler, Stephanie; Bowen, Jennie D.; Maynard, Charles; Lowy, Elliot; Sun, Haili; Sales, Anne E.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, VA NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. [Maynard, Charles; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. RP Wheeler, S (reprint author), VA Puget Sound Hlth Care Syst, VA NW Hlth Serv Res & Dev Ctr Excellence, S-111-GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. EM stephanie.wheeler@med.va.gov RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814; Sales, Anne/0000-0001-9360-3334 NR 23 TC 2 Z9 2 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAY PY 2009 VL 18 IS 5 BP 613 EP 618 DI 10.1089/jwh.2008.1073 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 446DP UT WOS:000266100900003 PM 19392640 ER PT J AU Kuy, S AF Kuy, SreyRam TI Women Have Better Outcomes In Cholecystitis SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Kuy, SreyRam] Yale Univ, Sch Med, US Dept Vet Affairs, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA. [Kuy, SreyRam] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAY PY 2009 VL 18 IS 5 MA 30 BP 753 EP 753 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 446DP UT WOS:000266100900049 ER PT J AU Menefee, DS Gwynn, S Dao, TK Teng, E Graham, DP AF Menefee, Deleene S. Gwynn, Stacy Dao, Tam K. Teng, Ellen Graham, David P. TI Preliminary Examination of Correlates of Deployment Risk and Protective Factors and Mental Health Outcomes among OEF/OIF Women Veterans. SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Menefee, Deleene S.; Gwynn, Stacy; Dao, Tam K.; Teng, Ellen; Graham, David P.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Menefee, Deleene S.; Dao, Tam K.; Teng, Ellen; Graham, David P.] Baylor Coll Med, Menninger Dept Psychiat & Behav Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAY PY 2009 VL 18 IS 5 MA 33 BP 754 EP 754 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 446DP UT WOS:000266100900052 ER PT J AU Sugimoto, M Yamaoka, Y AF Sugimoto, Mitsushige Yamaoka, Yoshio TI Factors aside from Helicobacter pylori play an important role in the occurrence of peptic ulcer in dialysis patients Response SO KIDNEY INTERNATIONAL LA English DT Letter ID HEMODIALYSIS-PATIENTS C1 [Sugimoto, Mitsushige; Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Sugimoto, Mitsushige; Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. RP Sugimoto, M (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd,111D,Rm 3A-320, Houston, TX 77030 USA. EM sugimoto@bcm.tmc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAY PY 2009 VL 75 IS 10 BP 1115 EP 1115 DI 10.1038/ki.2009.27 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 439PS UT WOS:000265640100021 ER PT J AU Randolph, C Hilsabeck, R Kato, A Kharbanda, P Li, YY Mapelli, D Ravdin, LD Romero-Gomez, M Stracciari, A Weissenborn, K AF Randolph, Christopher Hilsabeck, Robin Kato, Ainobu Kharbanda, Parampreet Li, Yu-Yuan Mapelli, Daniela Ravdin, Lisa D. Romero-Gomez, Manuel Stracciari, Andrea Weissenborn, Karin TI Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines SO LIVER INTERNATIONAL LA English DT Review DE assessment; encephalopathy; hepatic; neuropsychological; outcome; psychometric ID QUALITY-OF-LIFE; PORTAL-SYSTEMIC ENCEPHALOPATHY; CRITICAL FLICKER FREQUENCY; LIVER-TRANSPLANTATION; REPEATABLE BATTERY; NONALCOHOLIC CIRRHOTICS; MAGNETIZATION-TRANSFER; CEREBRAL-DYSFUNCTION; PSYCHOMETRIC TESTS; GLUCOSE-METABOLISM AB Low-grade or minimal hepatic encephalopathy (MHE) is characterised by relatively mild neurocognitive impairments, and occurs in a substantial percentage of patients with liver disease. The presence of MHE is associated with a significant compromise of quality of life, is predictive of the onset of overt hepatic encephalopathy and is associated with a poorer prognosis for outcome. Early identification and treatment of MHE can improve quality of life and may prevent the onset of overt encephalopathy, but to date, there has been little agreement regarding the optimum method for detecting MHE. The International Society on Hepatic Encephalopathy and Nitrogen Metabolism convened a group of experts for the purpose of reviewing available data and making recommendations for a standardised approach for neuropsychological assessment of patients with liver disease who are at risk of MHE. Specific recommendations are presented, along with a proposed methodology for further refining these assessment procedures through prospective research. C1 [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA. [Hilsabeck, Robin] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Hilsabeck, Robin] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Kato, Ainobu] Iwate Med Univ, Dept Internal Med, Morioka, Iwate, Japan. [Kharbanda, Parampreet] Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh 160012, India. [Li, Yu-Yuan] First Municipal Peoples Hosp Guangzhou, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China. [Mapelli, Daniela] Univ Padua, Dept Gen Psychol, Padua, Italy. [Ravdin, Lisa D.] Weill Cornell Med Ctr, Dept Neurol, New York, NY USA. [Romero-Gomez, Manuel] Hosp Univ Valme, UGC Enfermedades Digestivas, Seville, Spain. [Stracciari, Andrea] St Orsola Marcello Malpighi Hosp, Dept Neurol, Bologna, Italy. [Weissenborn, Karin] Hannover Med Sch, Dept Neurol, D-30623 Hannover, Germany. RP Randolph, C (reprint author), 1 E Erie,Suite 355, Chicago, IL 60611 USA. EM crandol@lumc.edu RI Romero Gomez, Manuel/L-8030-2014; IBIS, DIGESTIVAS/O-1913-2015 OI MAPELLI, DANIELA/0000-0003-2168-1426 NR 70 TC 84 Z9 93 U1 3 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1478-3223 J9 LIVER INT JI Liver Int. PD MAY PY 2009 VL 29 IS 5 BP 629 EP 635 DI 10.1111/j.1478-3231.2009.02009.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 430UI UT WOS:000265014300003 PM 19302444 ER PT J AU Noworolski, SM Tien, PC Merriman, R Vigneron, DB Qayyum, A AF Noworolski, Susan M. Tien, Phyllis C. Merriman, Raphael Vigneron, Daniel B. Qayyum, Aliya TI Respiratory motion-corrected proton magnetic resonance spectroscopy of the liver SO MAGNETIC RESONANCE IMAGING LA English DT Article DE Spectroscopy; Liver; Steatosis; Nonalcoholic fatty liver disease; Respiration; Motion correction ID WOMENS INTERAGENCY HIV; CHRONIC HEPATITIS-C; IN-VIVO; NONALCOHOLIC STEATOHEPATITIS; MR SPECTROSCOPY; IMAGING DATA; SIGNAL LOSS; H-1; DISEASE; QUANTIFICATION AB Purpose: To develop a post-processing, respiratory-motion correction algorithm for magnetic resonance spectroscopy (MRS) of the liver and to determine the incidence and impact of respiratory motion in liver MRS. Materials and Methods: One hundred thirty-two subjects (27 healthy, 31 with nonalcoholic fatty liver disease and 74 HIV-infected with or without hepatitis C) were scanned with free breathing MRS at 1.5 T. Two spectral time series were acquired on an 8-ml single voxel using TR/TE=2500 ms/30 ms and (1) water suppression, 128 acquisitions, and (2) no water suppression, 8 acquisitions. Individual spectra were phased and frequency aligned to correct for intrallepatic motion. Next, water peaks more than 50% different from the median water peak area were identified and removed, and remaining spectra averaged to correct for presumed extrallepatic motion. Total CH(2)+CH(3) lipids to unsuppressed water ratios were compared before and after corrections. Results: Intrahepatic-motion correction increased the signal to noise ratio (S/N) in all cases (median=11-fold). Presumed extrahepatic motion was present in 41% (54/132) of the subjects. Its correction altered the lipids/water magnitude (magnitude change: median=2.6%, maximum=290%, and was >5% in 25% of these subjects). The incidence and effect of respiratory motion on lipids/water magnitude were similar among the three groups. Conclusion: Respiratory-motion correction of free breathing liver MRS greatly increased the S/N and, in a significant number of subjects, changed the lipids/water ratios, relevant for monitoring subjects. (C) 2009 Elsevier Inc. All rights reserved. C1 [Noworolski, Susan M.; Vigneron, Daniel B.; Qayyum, Aliya] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94107 USA. [Noworolski, Susan M.; Vigneron, Daniel B.] Univ Calif San Francisco, Grad Grp Bioengn, San Francisco, CA 94107 USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94107 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Merriman, Raphael] Calif Pacific Med Ctr, Dept Gastroenterol, San Francisco, CA USA. RP Noworolski, SM (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 185 Berry St,Suite 350, San Francisco, CA 94107 USA. EM sue@radiology.ucsf.edu FU NCRR NIH HHS [M01 RR000071, M01 RR000079, M01 RR000083, M01-RR-00071, M01-RR-00079, M01-RR-00083]; NIAID NIH HHS [K23 AI 66943, K23 AI066943, K23 AI066943-05, U01 AI 34993, U01 AI 31834, U01 AI 34989, U01 AI 34994, U01 AI 35004, U01 AI 42590, U01 AI031834, U01 AI034989, U01 AI034993, U01 AI034994, U01 AI035004, U01 AI042590]; NICHD NIH HHS [P01 HD 40543, P01 HD040543, P01 HD040543-019001, U01 HD 32632, U01 HD032632]; NIDDK NIH HHS [DK 074718-01, DK 061738-SI, R01 DK074718, R01 DK074718-01A1, U01 DK061738, U01 DK061738-03S1] NR 32 TC 16 Z9 16 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PD MAY PY 2009 VL 27 IS 4 BP 570 EP 576 DI 10.1016/j.mri.2008.08.008 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 435DL UT WOS:000265323800016 PM 18993007 ER PT J AU Regensteiner, JG Bauer, TA Reusch, JEB Quaife, RA Chen, MY Smith, SC Miller, TM Groves, BM Wolfel, EE AF Regensteiner, Judith G. Bauer, Timothy A. Reusch, Jane E. B. Quaife, Robert A. Chen, Marcus Y. Smith, Susan C. Miller, Tyler M. Groves, Bertron M. Wolfel, Eugene E. TI Cardiac Dysfunction during Exercise in Uncomplicated Type 2 Diabetes SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE PEAK OXYGEN CONSUMPTION; TYPE 2 DIABETES MELLITUS; PULMONARY CAPILLARY WEDGE PRESSURE; HEMODYNAMIC; MYOCARDIAL PERFUSION ID VENTRICULAR SYSTOLIC FUNCTION; SOCIETY-OF-ECHOCARDIOGRAPHY; CORONARY FLOW RESERVE; DOPPLER-ECHOCARDIOGRAPHY; DIASTOLIC DYSFUNCTION; MYOCARDIAL-PERFUSION; CARDIOMYOPATHY; MELLITUS; DISEASE; NOMENCLATURE AB REGENSTEINER, J. G., T. A. BAUER, J. E. REUSCH. R. A. QUAIFE, M. CHEN, S. C. SMITH, T. M. MILLER, B. M. GROVES, and E. E. WOLFEL. Cardiac Dysfunction during Exercise in Uncomplicated Type 2 Diabetes. Med. Sci. Sports Exerc., Vol. 41, No. 5, pp. 977-984, 2009. Purpose: Type 2 diabetes mellitus (T2DM) has been associated with reduced peak exercise capacity ((V) over dotO(2peak)). The causes of this impairment are not clearly established, but evidence Suggests that abnormalities in cardiac function play a significant role. We hypothesized that exercise would be associated with impaired cardiac function and hemodynamics in recently diagnosed T2DM, even in the absence of clinically evident cardiovascular complications. Methods: After baseline normal echocardiography screening, 10 premenopausal women with uncomplicated T2DM (average duration of diagnosed T2DM, 3.6 yr) and 10 healthy nondiabetic women of similar age, weight, and activity levels performed a peak cardiopulmonary exercise test while instrumented with all indwelling pulmonary artery catheter for assessing cardiac function. On separate days, technetium-99 sestamibi (cardolite) imaging was performed to assess myocardial perfusion at rest and peak exercise in seven T2DM and seven control patients. Results: Resting measures of cardiac hemodynamics were similar in T2DM and control Subjects. Absolute (V) over dotO(2peak) (mL.min(-1)) and peak cardiac output tended to be lower in T2DM than in control subjects but did not reach statistical significance. However, pulmonary capillary wedge pressure (PCWP) rose significantly more during exercise in T2DM than in controls (148% vs 109% increase at peak exercise, P<0.01). Normalized myocardial perfusion index was lower in persons with diabetes than in controls(11.0 +/- 3.5 x e(-9) vs 17.5 +/- 8.1 x e(-9), respectively, P < 0.05) and inversely related to peak exercise PCWP (R = -0.56, P < 0.05). Conclusions: Cardiac hemodynamics during graded exercise are altered in women with recently diagnosed T2DM as demonstrated by the disproportionate increase in PCWP at peak exercise compared with controls subjects. Cardiac abnormalities observed are potentially early signs of subclinical cardiac dysfunction associated with T2DM, which may precede the more greatly impaired cardiac function at rest and with exercise observed in longer established T2DM. C1 [Regensteiner, Judith G.] Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med,Hlth Sci Ctr, Aurora, CO 80045 USA. [Regensteiner, Judith G.; Quaife, Robert A.; Chen, Marcus Y.; Miller, Tyler M.; Groves, Bertron M.; Wolfel, Eugene E.] Univ Colorado, Div Cardiol, Dept Med, Aurora, CO 80045 USA. [Bauer, Timothy A.; Reusch, Jane E. B.] Univ Colorado, Div Endocrinol, Dept Med, Aurora, CO 80045 USA. [Regensteiner, Judith G.; Reusch, Jane E. B.] Ctr Womens Hlth Res, Aurora, CO USA. [Bauer, Timothy A.; Reusch, Jane E. B.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Regensteiner, JG (reprint author), Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med,Hlth Sci Ctr, B180,Acad Off Bldg A01,Rm 8221,12631 E 17th Ave, Aurora, CO 80045 USA. EM judy.regensteiner@uchsc.edu FU NIH [R55 DK53776, M01-RR00051]; VA merit review FX Results of the current study do not constitute endorsement by the ACSM. The authors are very grateful to the 20 participants for their participation. Funding support was provided to Dr. Regensteiner by NIH grant no. R55 DK53776 and by the General Clinical Research Center NIH grant no. M01-RR00051. Dr. Reusch is supported by VA merit review funding. The authors also thank the Medical and Nursing Staff of the Cardiac Catheterization Laboratory and the General Clinical Research Center who gave generously of their time for this study. The authors also thank Vermed, Inc., for their generous donation of ECG electrodes for all of our exercise studies. NR 36 TC 30 Z9 30 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2009 VL 41 IS 5 BP 977 EP 984 DI 10.1249/MSS.0b013e3181942051 PG 8 WC Sport Sciences SC Sport Sciences GA 435DS UT WOS:000265324500002 PM 19346991 ER PT J AU Littman, AJ Forsberg, CW Koepsell, TD AF Littman, Alyson J. Forsberg, Christopher W. Koepsell, Thomas D. TI Physical Activity in a National Sample of Veterans SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE EXERCISE; MODERATE; VIGOROUS; BEHAVIORAL RISK FACTORS SURVEILLANCE SYSTEM; EXERCISE MAINTENANCE ID OF-SPORTS-MEDICINE; CARDIOVASCULAR-DISEASE; DOSE-RESPONSE; PUBLIC-HEALTH; RECOMMENDATION AB LITTMAN, A, J., C, W, FORSBERG, and T, D, KOEPSELL, Physical Activity in a National Sample of Veterans. Med. Sci. Sports Exerc., Vol. 41, No. 5, pp. 1006-1013, 2009. Purpose: To describe and compare the prevalence of physical activity (PA) in relation to veteran status and use of Department of Veterans Affairs (VA) facilities. Methods: Data were obtained from the 2003 Behavioral Risk Factor Surveillance System surveys of US adults. Veteran status, VA health care use, and PA were determined in 245,564 adults. Individuals were classified as inactive, insufficiently active, or meeting recommendations for moderate or strenuous PA. To adjust for confounding, we used model-based direct adjustment and chi-square tests corrected for the survey design. Results: After adjusting for age and gender, the prevalence of inactivity was significantly lower (16.2% vs 20.5%), and meeting PA recommendations was significantly greater (46.0% vs 42.0%) in veterans than in nonveterans (P < 0.0001). Compared with veterans who did not obtain their health care from the VA, VA users were more likely to be inactive (20.8% vs 14.7%) and less likely to be insufficiently active (34.1% vs 38.2%) or meet recommendations (45.1% vs 47.1%; P < 0.0001). Differences in PA levels between veterans and nonveterans and between VA users and nonusers did not change substantially after additional adjustment for education, race/ethnicity, and smoking. Conclusion: Despite the high level of PA required of active duty military personnel, only a minority of veterans met PA recommendations, and the prevalence of inactivity was particularly high in VA users. These findings suggest a large potential to increase PA and improve health in VA users. C1 [Littman, Alyson J.] US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst 152E, Seattle, WA 98101 USA. [Littman, Alyson J.; Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Littman, AJ (reprint author), US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst 152E, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM alyson@u.washington.edu FU Office of Research and Development Cooperative Studies Program, Department of Veterans Affairs FX The authors have no conflicts of interest to report. NR 15 TC 21 Z9 21 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2009 VL 41 IS 5 BP 1006 EP 1013 DI 10.1249/MSS.0b013e3181943826 PG 8 WC Sport Sciences SC Sport Sciences GA 435DS UT WOS:000265324500006 PM 19346987 ER PT J AU Suffoletto, JA Hess, R AF Suffoletto, Jo-Anne Hess, Rachel TI Tapening versus cold turkey: symptoms versus successful discontinuation of menopausal hormone therapy SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; POSITION STATEMENT; SOCIETY; TRIAL C1 [Suffoletto, Jo-Anne] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hess, Rachel] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Hess, Rachel] Univ Pittsburgh, Dept Epidemiol, Ctr Res Hlth Care, Pittsburgh, PA 15261 USA. RP Suffoletto, JA (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. FU NIA NIH HHS [AG024254, K23 AG024254, K23 AG024254-05] NR 12 TC 5 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD MAY-JUN PY 2009 VL 16 IS 3 BP 436 EP 437 DI 10.1097/gme.0b013e3181a057db PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 443JG UT WOS:000265905400007 PM 19276996 ER PT J AU Nakano, T Inoue, I Seo, M Takahashi, S Komoda, T Katayama, S AF Nakano, Takanari Inoue, Ikuo Seo, Makoto Takahashi, Seiichiro Komoda, Tsugikazu Katayama, Shigehiro TI Acarbose attenuates postprandial hyperlipidemia: investigation in an intestinal absorptive cell model SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID LIPID-METABOLISM; TRIGLYCERIDE C1 [Nakano, Takanari; Seo, Makoto; Takahashi, Seiichiro; Komoda, Tsugikazu] Saitama Med Univ, Dept Biochem, Fac Med, Saitama 3500495, Japan. [Nakano, Takanari] Univ Calif Los Angeles, CURE, Los Angeles, CA 90073 USA. [Nakano, Takanari] W Los Angeles VA Med Ctr, BBRI, Los Angeles, CA 90073 USA. [Inoue, Ikuo; Katayama, Shigehiro] Saitama Med Univ, Dept Endocrinol & Diabet, Fac Med, Saitama 3500495, Japan. RP Nakano, T (reprint author), Saitama Med Univ, Dept Biochem, Fac Med, Saitama 3500495, Japan. EM nk.takanari@gmail.com NR 7 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD MAY PY 2009 VL 58 IS 5 BP 583 EP 585 DI 10.1016/j.metabol.2009.02.003 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 439YL UT WOS:000265663700001 PM 19375578 ER PT J AU Brochmann, EJ Behnam, K Murray, SS AF Brochmann, Elsa J. Behnam, Keyvan Murray, Samuel S. TI Bone morphogenetic protein-2 activity is regulated by secreted phosphoprotein-24 kd, an extracellular pseudoreceptor, the gene for which maps to a region of the human genome important for bone quality SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID VITAMIN-D-RECEPTOR; BAND ULTRASOUND ATTENUATION; X-RAY ABSORPTIOMETRY; QUANTITATIVE ULTRASOUND; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; OSTEOPOROTIC FRACTURES; BINDING PEPTIDE; ELDERLY-WOMEN; II RECEPTOR AB The material properties of bone are the sum of the complex and interrelated anabolic and catabolic processes that modulate formation and turnover. The 2q33-37 region of the human genome contains quantitative trait loci important in determining the broadband ultrasound attenuation (an index of trabecular microarchitecture, bone elasticity, and susceptibility to fracture) of the calcaneus, but no genes of significance to boric metabolism have been identified in this domain. Secreted phosphoprotein-24 kd (SPP24 or SPP2) is a novel and relatively poorly characterized growth hormone-regulated gene that maps to 2q37. The purpose of this review is to summarize the status of research related to spp24 and how it regulates bone morphogenetic protein (BMP) bioactivity in bone. SPP24 codes for an extracellular matrix protein that contains a high-affinity BMP-2-binding transforming growth factor-beta receptor 11 homology I loop similar to those identified in fetuin and the receptor itself. SPP24 is transcribed primarily in the liver and bone. High levels of spp24 (a hydroxyapatite-binding protein) arc found in bone, and small amounts are found in fetuin-mineral complexes. Full-length secretory spp24 inhibits ectopic bone formation, and overexpression of spp24 reduces murine bone mass and density. Spp24 is extremely labile to proteolysis, a process that regulates its bioactivity in vivo. For example, an 18.5-kd degradation product of spp24, designated spp 18,5, is pro-osteogenic. A synthetic cyclized Cys(1)-to-Cys(19) disulfide-bonded peptide (BMP binding peptide) corresponding to the transforming growth factor-beta receptor 11 homology 1 domain of spp24 and spp 18.5 binds BMP-2 and increases the rate and magnitude of BMP-2-mediated ectopic bone formation. Thus, the mechanism of action of spp 18.5 and spp24 may be to regulate the local bioavailability of BNIP cytokines. SPP24 is regulated by growth hormone and 3 major families of transcription factors (nuclear factor of activated T cells, CCAAT/enhancer-binding protein, Cut/Cux/CCAAT displacement protein) that regulate mesenchymal cell proliferation, embryonic patterning, and terminal differentiation. The gene contains at least 2 single nucleotide polymorphisms. Given its mechanism of action and sequence variability, SPP24 may be an interesting candidate for future studies of the genetic regulation of bone mass, particularly during periods of BMP-mediated endochondral bone growth, development, and fracture healing. Published by Elsevier Inc. C1 [Brochmann, Elsa J.; Murray, Samuel S.] Sepulveda Ambulatory Care Clin & Nursing Home, GRECC 11E, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. [Brochmann, Elsa J.; Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Behnam, Keyvan] Lanx, Broomfield, CO 80021 USA. RP Murray, SS (reprint author), Sepulveda Ambulatory Care Clin & Nursing Home, GRECC 11E, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. EM samuel.murray@med.va.gov FU Geriatric Research, Education, and Clinical Center of the VA Greater Los Angeles Healthcare System; Office of Research and Development, Department of Veterans Affairs; National Institutes of Health [5R21AR53259] FX Supported in part by the Geriatric Research, Education, and Clinical Center of the VA Greater Los Angeles Healthcare System; the Office of Research and Development, Department of Veterans Affairs; and the National Institutes of Health (5R21AR53259). The authors wish to thank Dr Matthew Beckman for his helpful discussion of the early observations of Sen, Walker, and Einarson. NR 60 TC 16 Z9 17 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD MAY PY 2009 VL 58 IS 5 BP 644 EP 650 DI 10.1016/j.metabol.2009.01.001 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 439YL UT WOS:000265663700010 PM 19375587 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI ACUTE KIDNEY INJURY Intravenous fluid to prevent contrast-induced AKI SO NATURE REVIEWS NEPHROLOGY LA English DT Editorial Material ID INDUCED NEPHROPATHY; SODIUM-BICARBONATE; CORONARY-ANGIOGRAPHY; N-ACETYLCYSTEINE; TRIAL; INTERVENTION; HYDRATION; CHLORIDE AB Trials that compared sodium bicarbonate and sodium chloride for the prevention of contrast-induced acute kidney injury have yielded highly conflicting results. the authors of a recent meta-analysis endeavored to provide a definitive assessment of the relative efficacy of these two intravenous fluids. C1 [Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, 111F-U,Room 7E 120,Univ Dr Div, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 8 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD MAY PY 2009 VL 5 IS 5 BP 256 EP 257 DI 10.1038/nrneph.2009.26 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 442QA UT WOS:000265854500007 PM 19384326 ER PT J AU Langbaum, JBS Chen, K Lee, W Reschke, C Bandy, D Fleisher, AS Alexander, GE Foster, NL Weiner, MW Koeppe, RA Jagust, WJ Reiman, EM AF Langbaum, Jessica B. S. Chen, Kewei Lee, Wendy Reschke, Cole Bandy, Dan Fleisher, Adam S. Alexander, Gene E. Foster, Norman L. Weiner, Michael W. Koeppe, Robert A. Jagust, William J. Reiman, Eric M. CA Alzheimer's Dis Neuroimaging Initi TI Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) SO NEUROIMAGE LA English DT Article DE Alzheimer's disease; MCI; MMSE; Positron emission tomography ID MILD COGNITIVE IMPAIRMENT; CEREBRAL GLUCOSE-METABOLISM; POSTERIOR CINGULATE CORTEX; PITTSBURGH COMPOUND-B; FDG-PET; APOLIPOPROTEIN-E; F-18-FDG PET; CLINICAL-DIAGNOSIS; DEMENTIA; MCI AB In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). The AD Neuroimaging Initiative (ADNI) is acquiring FDG PET, volumetric magnetic resonance imaging, and other biomarker measurements in a large longitudinal multi-center study of initially mildly affected probable AD (pAD) patients, amnestic mild cognitive impairment (aMCI) patients, who are at increased AD risk, and cognitively normal controls (NC), and we are responsible for analyzing the PET images using statistical parametric mapping (SPM). Here we compare baseline CMRgl measurements from 74 pAD patients and 142 aMCI patients to those from 82 NC, we correlate CMRgl with categorical and continuous measures of clinical disease severity, and we compare apolipoprotein E (APOE) epsilon 4 carriers to non-carriers in each of these subject groups. In comparison with NC, the pAD and aMCI groups each had significantly lower CMRgl bilaterally in posterior cingulate, precuneus, parietotemporal and frontal cortex. Similar reductions were observed when categories of disease severity or lower Mini-Mental State Exam (MMSE) scores were correlated with lower CMRgl. However, when analyses were restricted to the pAD patients, lower MMSE scores were significantly correlated with lower left frontal and temporal CMRgl. These findings from a large, multi-site study support previous single-site findings, supports the characteristic pattern of baseline CMRgl reductions in AD and aMCI patients, as well as preferential anterior CMRgl reductions after the onset of AD dementia. (C) 2009 Elsevier Inc. All rights reserved. C1 [Langbaum, Jessica B. S.; Chen, Kewei; Lee, Wendy; Reschke, Cole; Bandy, Dan; Fleisher, Adam S.; Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ 85006 USA. [Langbaum, Jessica B. S.; Chen, Kewei; Lee, Wendy; Reschke, Cole; Bandy, Dan; Fleisher, Adam S.; Reiman, Eric M.] Banner Good Samaritan PET Ctr, Phoenix, AZ USA. [Chen, Kewei] Arizona State Univ, Dept Math, Tempe, AZ 85287 USA. [Chen, Kewei] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA. [Alexander, Gene E.] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA. [Alexander, Gene E.] Univ Arizona, Evelyn F McKnight Brain Inst, Tucson, AZ 85721 USA. [Reiman, Eric M.] Univ Arizona, Dept Psychiat, Tucson, AZ USA. [Foster, Norman L.] Univ Utah, Ctr Alzheimers Care Imaging & Res, Salt Lake City, UT USA. [Foster, Norman L.] Univ Utah, Dept Neurol, Salt Lake City, UT USA. [Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Koeppe, Robert A.] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA. [Jagust, William J.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA USA. [Jagust, William J.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA USA. [Reiman, Eric M.] Translat Genom Res Inst, Neurogen Div, Phoenix, AZ USA. [Fleisher, Adam S.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Langbaum, Jessica B. S.; Chen, Kewei; Lee, Wendy; Reschke, Cole; Bandy, Dan; Fleisher, Adam S.; Alexander, Gene E.; Reiman, Eric M.] Arizona Alzheimers Consortium, Phoenix, AZ USA. RP Reiman, EM (reprint author), Banner Alzheimers Inst, 901 E Willetta St, Phoenix, AZ 85006 USA. EM eric.reiman@bannerhealth.com RI Scharre, Douglas/E-4030-2011; Chen, kewei/P-6304-2015 OI Chen, kewei/0000-0001-8497-3069 FU Alzheimer's Disease Neuroimaging Initiative (ADNI); NIH [U01 AG024904]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering (NIBIB); Pfizer Inc.; Wyeth Research; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Merck Co. Inc.; AstraZeneca AB; Novartis Pharmaceuticals Corporation; Eisai Global Clinical Development; Elan Corporation plc; Forest Laboratories; Institute for the Study of Aging; U.S. Food and Drug Administration FX Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; Principal Investigator: MichaelWeiner; NIH grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and through generous contributions from the following: Pfizer Inc., Wyeth Research, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck & Co. Inc., `AstraZeneca AB, Novartis Pharmaceuticals Corporation, Alzheimer's Association, Eisai Global Clinical Development, Elan Corporation plc, Forest Laboratories, and the Institute for the Study of Aging, with participation from the U.S. Food and Drug Administration. Industry partnerships are coordinated through the Foundation for the National Institutes of Health. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles. NR 56 TC 137 Z9 138 U1 3 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD MAY 1 PY 2009 VL 45 IS 4 BP 1107 EP 1116 DI 10.1016/j.neuroimage.2008.12.072 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 421SL UT WOS:000264378500007 PM 19349228 ER PT J AU Liu, LP Yenari, MA AF Liu, Liping Yenari, Midori A. TI Clinical application of therapeutic hypothermia in stroke SO NEUROLOGICAL RESEARCH LA English DT Article DE Temperature; heart; brain; cooling methods; combination ID TRANSIENT GLOBAL-ISCHEMIA; COMBINED POSTISCHEMIC HYPOTHERMIA; MILD RESUSCITATIVE HYPOTHERMIA; HOSPITAL CARDIAC-ARREST; MODERATE HYPOTHERMIA; COMATOSE SURVIVORS; FEASIBILITY; RATS; NEUROPROTECTION; TEMPERATURE AB Objective: Hypothermia has long been known to be a potent neuroprotectant. In this mini-review, we highlighted clinical experience that hypothermia protects the brain from cerebral injury. We discussed the clinical practice of hypothermia in ischemic stroke. Results: Multiple factors play a significant role in the mechanisms. Clinical application drew first from two clinical trials with comatose patients after cardiac arrest is attractive. The Australian and European study have led to renewed interest in these patients. More and more evidences bring the insight into its effects on cerebral ischemia. The type of cooling technique to be used, the duration of cooling and speed of rewarming appear to be key factors in determining whether hypothermia is effective in preventing or mitigating neurological injury. Although until now, there are no clear therapeutic standards of the parameters in therapeutic hypothermia, it is well accepted that cooling should be initiated as soon as possible. By combining hypothermia with other neuroprotectants, it may be possible to enhance protective effects, reduce side effects and lengthen the maximum time. Conclusion: In addition to its neuroprotective properties, hypothermia may extend the therapeutic window for other neuroprotective treatment. Thus, combination therapies with neuroprotective, anti-inflammatory and thrombolytic agents are likely to be investigated in the clinical setting in the future. [Neurol Res 2009; 31: 331-335] C1 [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Liu, Liping] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing 100050, Peoples R China. [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Yenari, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU NINDS NIH HHS [R01 NS040516, R01 NS040516-09] NR 33 TC 17 Z9 19 U1 1 U2 1 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 0161-6412 J9 NEUROL RES JI Neurol. Res. PD MAY PY 2009 VL 31 IS 4 BP 331 EP 335 DI 10.1179/174313209X444099 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 458KV UT WOS:000267020000002 PM 19508813 ER PT J AU Zhao, R Xiang, N Domann, FE Zhong, WX AF Zhao, Rui Xiang, Nong Domann, Fredrick E. Zhong, Weixiong TI Effects of Selenite and Genistein on G(2)/M Cell Cycle Arrest and Apoptosis in Human Prostate Cancer Cells SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID KINASE INHIBITOR GENISTEIN; CASPASE-MEDIATED APOPTOSIS; METHYLSELENINIC ACID; UNITED-STATES; IN-VITRO; PREVENTION; SELENOMETHIONINE; CHEMOPREVENTION; EXPRESSION; MORTALITY AB Combination of chemopreventive agents with distinct molectilar mechanisms is considered to offer a potential for enhancing cancer prevention efficacy while minimizing toxicity. Here we report two chemopreventive agents, selenite and genistein, that have synergistic effects on apoptosis, cell cycle arrest, and associated signaling pathways in p53-expressing LNCaP and p53-null PC3 prostate cancer cells. We show that selenite induced apoptosis only, whereas genistein induced both apoptosis and G(2)/M cell cycle arrest. Combination of these two agents exhibited enhanced effects, which were slightly greater in LNCaP than PC3 cells. Selenite or genistein alone upregulated protein levels of p53 in LNCaP cells only and p21(waf1) and Bax in both cell lines. Additionally, genistein inhibited AKT phosphorylation. Downregulation of AKT by siRNA caused apoptosis and G2/M cell cycle arrest and masked the effects of genistein. Treatment with insulin-like growth factor I (IGF-I) elevated levels of total and phosphorylated AKT and suppressed the effects of genistein. Neither downregulation of AKT nor IGF-I treatment altered the cellular effects of selenite. Our study demonstrates that selenium and genistein act via different molecular mechanisms and exhibit enhanced anticancer effects, suggesting that a combination of selenium and genistein may offer better efficacy and reduction of toxicity in prostate cancer prevention. C1 [Zhao, Rui; Xiang, Nong; Zhong, Weixiong] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Domann, Fredrick E.] Univ Iowa, Free Rad & Radiat Biol Grad Program, Iowa City, IA USA. [Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Zhong, WX (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA. EM wzhong3@wisc.edu OI Domann, Frederick/0000-0002-0489-2179 FU NCI NIH HHS [CA114281, CA73612,, R01 CA073612, R01 CA073612-09, R01 CA073612-10, R01 CA114281, R01 CA114281-03, R01 CA114281-04, R01 CA115438, R01 CA115438-02, R01 CA115438-03, R29 CA073612, R56 CA073612] NR 52 TC 44 Z9 48 U1 0 U2 4 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PD MAY-JUN PY 2009 VL 61 IS 3 BP 397 EP 407 DI 10.1080/01635580802582751 PG 11 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA 473WM UT WOS:000268242000014 PM 19373614 ER PT J AU Bautista, LE Casas, JP Herrera, VM Miranda, JJ Perel, P Pichardo, R Gonzalez, A Sanchez, JR Ferreccio, C Aguilera, X Silva, E Orostegui, M Gomez, LF Chirinos, JA Medina-Lezama, J Perez, CM Suarez, E Ortiz, AP Rosero, L Schapochnik, N Ortiz, Z Ferrante, D AF Bautista, L. E. Casas, J. P. Herrera, V. M. Miranda, J. J. Perel, P. Pichardo, R. Gonzalez, A. Sanchez, J. R. Ferreccio, C. Aguilera, X. Silva, E. Orostegui, M. Gomez, L. F. Chirinos, J. A. Medina-Lezama, J. Perez, C. M. Suarez, E. Ortiz, A. P. Rosero, L. Schapochnik, N. Ortiz, Z. Ferrante, D. CA Investigators Latin-American TI The Latin American Consortium of Studies in Obesity (LASO) SO OBESITY REVIEWS LA English DT Review DE Consortium; health surveys; Latin America; obesity; risk factors ID CORONARY-HEART-DISEASE; RISK-FACTORS; METABOLIC SYNDROME; NUTRITION TRANSITION; CARDIOVASCULAR RISK; DEVELOPING-WORLD; PREVALENCE; DETERMINANTS; PREDICTION; EXPERIENCE AB Current, high-quality data are needed to evaluate the health impact of the epidemic of obesity in Latin America. The Latin American Consortium of Studies of Obesity (LASO) has been established, with the objectives of (i) Accurately estimating the prevalence of obesity and its distribution by sociodemographic characteristics; (ii) Identifying ethnic, socioeconomic and behavioural determinants of obesity; (iii) Estimating the association between various anthropometric indicators or obesity and major cardiovascular risk factors and (iv) Quantifying the validity of standard definitions of the various indexes of obesity in Latin American population. To achieve these objectives, LASO makes use of individual data from existing studies. To date, the LASO consortium includes data from 11 studies from eight countries (Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Peru, Puerto Rico and Venezuela), including a total of 32 462 subjects. This article describes the overall organization of LASO, the individual studies involved and the overall strategy for data analysis. LASO will foster the development of collaborative obesity research among Latin American investigators. More important, results from LASO will be instrumental to inform health policies aiming to curtail the epidemic of obesity in the region. C1 [Bautista, L. E.; Herrera, V. M.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53726 USA. [Pichardo, R.; Gonzalez, A.] Inst Dominicano Cardiol, Santo Domingo, Dominican Rep. [Sanchez, J. R.] Inst nacl Salud, Ctr Nacl Alimentac & Nutr, Lima, Peru. [Ferreccio, C.] Pontificia Univ Catolica Chile, Dept Salud Publ, Santiago, Chile. [Aguilera, X.] Ministerio Salud Chile, Santiago, Chile. [Silva, E.] Univ Zulia, Fac Med, Inst Invest & Estudios Enfermedades Cardiovasc, Maracaibo 4011, Venezuela. [Orostegui, M.] Univ Ind Santander, Epidemiol Res Ctr, Cardiovasc Dis Epidemiol Observ, Bucaramanga, Colombia. [Gomez, L. F.] Fdn FES Social, Hlth Div, Bogota, Colombia. [Chirinos, J. A.] Univ Penn, Sch Med, Div Cardiol, Philadelphia, PA 19104 USA. [Medina-Lezama, J.] Santa Maria Catholic Univ, Arequipa, Peru. [Perez, C. M.; Suarez, E.; Ortiz, A. P.] Univ Puerto Rico, Dept Biostat & Epidemiol, Grad Sch Publ Hlth, San Juan, PR 00936 USA. [Rosero, L.] Univ Costa Rica, Ctr Ctr Amer Poblac, San Jose, Costa Rica. [Schapochnik, N.] Ministerio Salud Prov Tierra Fuego, Ushuaia, Argentina. [Ortiz, Z.] Acad Nacl Med Buenos Aires, Inst Invest Epidemiol, Buenos Aires, DF, Argentina. [Ferrante, D.] Ministerio Salud & Ambiente, Buenos Aires, DF, Argentina. [Casas, J. P.; Miranda, J. J.; Perel, P.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England. [Chirinos, J. A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Medina-Lezama, J.] Santa Maria Res Inst, Arequipa, Peru. RP Bautista, LE (reprint author), Univ Wisconsin, Dept Populat Hlth Sci, 610 Walnut St,703 WARF, Madison, WI 53726 USA. EM lebautista@wisc.edu RI Herrera, Victor/C-5602-2008; Miranda, J. Jaime/A-8482-2008; Aguilera, Ximena/D-9861-2014 OI Miranda, J. Jaime/0000-0002-4738-5468; Aguilera, Ximena/0000-0002-8153-6733 FU Ministerio de Salud de la Republica Argentina; Gobierno de la Provincia de Tierra del Fuego; Antartida e Islas del Atlantico Sur, Argentina; Ministerio de Salud, Chile; Secretaria Distrital de Salud de Bogota, Colombia; Secretaria de Salud Municipal de Bucaramanga; Secretaria Departamental de Salud de Santander, Colombia; Wellcome Trust Foundation [072406, GR074833MA]; Sociedad Dominicana de Cardiologia; Brystol Myers Squibb; Warners Lambert (Pfizer); Novartis; Merck Sharp Dohme and Magnachen International; Instituto Nacional de Salud, Lima, Peru; Instituto de Investigacion Santa Maria; Merck Sharp & Dohme Corporation; National Institutes of Health/National Center for Research Resources (NCRR/NIH) [G12RR03051, \P20RR011126]; Fondo Nacional de Ciencia, Tecnologia e Innovacion (FONACIT); Fundacion Venezolana de Hipertension Arterial (FUNDAHIPERTENSION) FX The 'Prueba de Validacion de la Encuesta Nacional de Factores de Riesgo' was funded by the Ministerio de Salud de la Republica Argentina and the Gobierno de la Provincia de Tierra del Fuego, Antartida e Islas del Atlantico Sur, Argentina. The 'Encuesta Nacional de Factores de Riesgo' was funded by the Ministerio de Salud de la Republica Argentina. The 'Encuesta Nacional de Salud 2003' was funded by the Ministerio de Salud, Chile. The 'Estudio CARMEN Santa Fe' was funded by the Secretaria Distrital de Salud de Bogota, Colombia. CARMEN-Bucaramanga was funded by the Secretaria de Salud Municipal de Bucaramanga and the Secretaria Departamental de Salud de Santander, Colombia. The 'Costa Rica: Estudio de Longevidad y Envejecimeinto Saludable (CRELES)' was funded by The Wellcome Trust Foundation, grant number 072406. The 'Estudio de Factores de Riesgo Cardiovascular en la Republica Dominicana (EFRICARD)' was funded by the Sociedad Dominicana de Cardiologia, Brystol Myers Squibb, Warners Lambert (Pfizer), Novartis, Merck Sharp Dohme and Magnachen International. The 'Encuesta Nacional de Indicadores Nutricionales, Bioquimicos, Socioeconomicos y Culturales Relacionados con las Enfermedades Cronico Degenerativas (ENINBSC-ECNT)' was funded by the Instituto Nacional de Salud, Lima, Peru. JJM and the 'PERU MIGRANT study' were supported by a Wellcome Trust Research Training Fellowship (GR074833MA). The study 'Prevalencia de Enfermedades Cardiovasculares y Factores de Riesgo Coronario en Arequipa (PREVENCION)' was partially supported by the Instituto de Investigacion Santa Maria. The study of the 'Prevalence of Metabolic Syndrome and its Individual Components in the adult population of the San Juan Metropolitan Area in Puerto Rico' was funded by an unrestricted grant from Merck Sharp & Dohme Corporation with additional support from the National Institutes of Health/National Center for Research Resources (NCRR/NIH) grant awards G12RR03051 and P20RR011126. The Zulia Coronary Heart Disease Risk Factor Study was funded by the Fondo Nacional de Ciencia, Tecnologia e Innovacion (FONACIT) and the Fundacion Venezolana de Hipertension Arterial (FUNDAHIPERTENSION). NR 44 TC 18 Z9 21 U1 3 U2 11 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1467-7881 J9 OBES REV JI Obes. Rev. PD MAY PY 2009 VL 10 IS 3 BP 364 EP 370 DI 10.1111/j.1467-789X.2009.00591.x PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 437UB UT WOS:000265511300015 PM 19438980 ER PT J AU Subak, LL Wing, R West, DS Franklin, F Vittinghoff, E Creasman, JM Richter, HE Myers, D Burgio, KL Gorin, AA Macer, J Kusek, JW Grady, D Investigators, P AF Subak, Leslee L. Wing, Rena West, Delia Smith Franklin, Frank Vittinghoff, Eric Creasman, Jennifer M. Richter, Hotly E. Myers, Deborah Burgio, Kathryn L. Gorin, Amy A. Macer, Judith Kusek, John W. Grady, Deborah Investigators, P. R. I. D. E. TI Weight Loss to Treat Urinary Incontinence in Overweight and Obese Women SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB Obesity is a strong risk factor for urinary incontinence. Although marked weight loss after bariatric surgery in morbidly obese women was associated in previous studies with a reduction in urinary incontinence, the overall evidence for a benefit of weight loss in obese women is inconclusive. In this randomized clinical trial, the Program to Reduce Incontinence by Diet and Exercise, the potential benefits of a behavioral weight-reduction intervention were compared with a structured educational program in 338 overweight and obese women with at least 10 urinary incontinence episodes per week. The study subjects were randomized to receive either an intensive 6-month weight-loss program that included diet, exercise, and behavior modification (intervention group, n = 226) or a structured education program consisting of general information about healthy eating, physical activity, and weight loss (control group, n = 112). The mean (+/- SD) age of the study subjects was 53 +/- 11 years. Body-mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. The primary study outcome was the change in the total number of self-reported incontinence episodes of any type (including stress and urge incontinence) recorded in a 7-day voiding diary at 6 months after randomization. At baseline, the mean BMI and the total number of incontinence episodes per week were the same in the intervention and control groups (BMI, 36 6 vs. 36 5, respectively; incontinence episodes, 24 18 vs. 24 16, respectively). At 6 months, the mean weight loss among women in the intervention group was 8.0% (7.8 kg), whereas the mean weight loss among women in the control group was 1.6% (1.5 kg) (P < .001). There was a greater decrease in total number of incontinence episodes per week in the intervention group at 6 months compared with the control group (intervention: 47.4% vs. control: 28.1%, P = 0.01). The frequency of stress incontinence episodes was reduced more in the intervention group (57.6%) than the control group (32.7%, P = 0.02). The frequency of episodes of urge incontinence was also decreased more in the intervention group (42.4% vs. 26.0%), but the difference was not statistically significant (P = 0.14). In comparison with the control group, a higher proportion of women in the intervention group reported a clinically meaningful reduction of at least 70% in the total weekly number of episodes of any type of incontinence (P < 0.001), stress-incontinence (P = 0.009), and urge-incontinence (P = 0.04). The investigators conclude from these findings that weight loss should be considered as a first-line treatment in overweight and obese women with incontinence. C1 [Subak, Leslee L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. Miriam Hosp, Providence, RI 02906 USA. Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR 72205 USA. Univ Alabama, Birmingham, AL USA. Ctr Geriatr Res Educ & Clin, Dept Vet Affairs, Birmingham, AL USA. Univ Connecticut, Storrs, CT USA. NIDDK, Bethesda, MD USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Subak, LL (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAY PY 2009 VL 64 IS 5 BP 317 EP 318 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 438OY UT WOS:000265566200019 ER PT J AU Morone, NE Karp, JF Lynch, CS Bost, JE El Khoudary, SR Weiner, DK AF Morone, Natalia E. Karp, Jordan F. Lynch, Cheryl S. Bost, James E. El Khoudary, Samar R. Weiner, Debra K. TI Impact of Chronic Musculoskeletal Pathology on Older Adults: A Study of Differences between Knee OA and Low Back Pain SO PAIN MEDICINE LA English DT Article DE Low Back Pain; Knee Pain; Physical Function; Psychosocial Factors ID PHYSICAL PERFORMANCE BATTERY; LOWER-EXTREMITY FUNCTION; SELF-RATED HEALTH; GAIT SPEED; PSYCHOLOGICAL-FACTORS; BODY-COMPOSITION; EFFICACY; DISABILITY; DEPRESSION; COMMUNITY AB The study aimed to compare the psychological and physical characteristics of older adults with knee osteoarthritis (OA) vs those of adults with chronic low back pain (CLBP) and to identify psychological and physical predictors of function as measured by gait speed. Secondary data analysis. Eighty-eight older adults with advanced knee OA and 200 with CLBP who had participated in separate randomized controlled trials were selected for this study. Inclusion criteria for both trials included age >= 65 and pain of at least moderate intensity that occurred daily or almost every day for at least the previous 3 months. Psychological constructs (catastrophizing, fear avoidance, self-efficacy, depression, affective distress) and physical measures (comorbid medical conditions, pain duration, pain severity, pain related interference, self-rated health) were obtained. Subjects with CLBP had slower gait (0.88 m/s vs 0.96 m/s, P = 0.002) and more comorbid conditions than subjects with knee pain (mean 3.36 vs 1.97, P < 0.001). All the psychological measures were significantly worse in the CLBP group except the Multidimensional Pain Inventory-Affective Distress score. Self-efficacy, pain severity, and medical comorbidity burden were associated with slower gait regardless of the location of the pain. Older adults with chronic pain may have distinct psychological and physical profiles that differentially impact gait speed. These findings suggest that not all pain conditions are the same in their psychological and physical characteristics and may need to be taken into consideration when developing treatment plans. C1 [Morone, Natalia E.; Lynch, Cheryl S.; Bost, James E.; El Khoudary, Samar R.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Karp, Jordan F.] Univ Pittsburgh, Dept Psychiat, Div Geriatr Med, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Div Geriatr Med, Pittsburgh, PA USA. [Lynch, Cheryl S.; Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [El Khoudary, Samar R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Morone, NE (reprint author), 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM moronene@upmc.edu OI El Khoudary Abushaban, Samar/0000-0003-2913-0821 FU National Center for Complementary and Alternative Medicine [R01AG018299, R21AG24288]; National Institute on Aging, National Institutes of Health; NIH Roadmap Multidisciplinary Clinical Research Career Development Award [1KL2RR024154-03, UL1RR024153, AG 021885-05]; National Center for Research Resources (NCRR) FX This research was supported by research grants (R01AG018299, R21AG24288) from the National Center for Complementary and Alternative Medicine and the National Institute on Aging, National Institutes of Health. During the time of this work, Drs. Morone and Karp were funded by the NIH Roadmap Multidisciplinary Clinical Research Career Development Award Grant (1KL2RR024154-03) from the NIH. This publication was also made possible by Grant Number UL1RR024153 from the National Center for Research Resources (NCRR), a component of the NIH and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Dr. Lynch was supported by grant T32 AG 021885-05 from the NIH. NR 41 TC 18 Z9 18 U1 1 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD MAY-JUN PY 2009 VL 10 IS 4 BP 693 EP 701 DI 10.1111/j.1526-4637.2009.00565.x PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 454JQ UT WOS:000266678600014 PM 19254337 ER PT J AU Fox, SA Heritage, J Stockdale, SE Asch, SM Duan, NH Reise, SP AF Fox, Sarah A. Heritage, John Stockdale, Susan E. Asch, Steven M. Duan, Naihua Reise, Steven P. TI Cancer screening adherence: Does physician-patient communication matter? SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Physician/patient communication; Cancer screening; Patient adherence ID COLORECTAL-CANCER; HEALTH COMMUNICATION; MEDICAL VISITS; UNITED-STATES; SELF-REPORTS; CARE; WOMEN; DISPARITIES; POPULATION; VALIDITY AB Objective: The objective of this study was to examine the separate contributions of patients and physicians to their communication regarding cancer screening. Methods: Research design and subjects: The authors conducted a cross-sectional analysis of survey data collected from 63 community-based primary care physicians and 904 of their female patients in Los Angeles. Results: Patients who perceived their physicians to be enthusiastic (at any level) in their discussions of mammography or fecal occult blood tests (FOBT) were significantly more likely to report a recent test than patients who reported no discussions. Conclusion: Physician discussions of cancer screening are important and effective even when, as in the case of mammography, screening rates are already high, or. as in the case of FOBT. rates have tended to remain low. The value of communication about screening should be taught and promoted to primary care physicians who serve as gatekeepers to screening. Practice implications: Those who train physicians in communication skills should take into account our finding that the communication style of physicians (e.g., enthusiasm for screening) was the only patient or physician variable that both influenced screening adherence and that could be taught. (C) 2009 Published by Elsevier Ireland Ltd. C1 [Fox, Sarah A.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Heritage, John] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90095 USA. [Stockdale, Susan E.] Univ Calif Los Angeles, Inst Neuropsychiat, Hlth Serv Res Ctr, Los Angeles, CA 90095 USA. [Duan, Naihua] Columbia Univ, New York State Psychiat Inst, Div Biostat, Dept Psychiat & Biostat, New York, NY 10032 USA. [Reise, Steven P.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Fox, SA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, VA Greater Los Angeles Healthcare Syst, Box 951736,911 Broxton, Los Angeles, CA 90095 USA. EM s.fox@ucla.edu FU National institutes of Health, National Cancer Institute [1 R01 CA61249] FX This work was supported by National institutes of Health, National Cancer Institute, Award No. 1 R01 CA61249 (SAF). The authors would like to acknowledge the extensive editing of the original draft by Jeanette Chung, PhD, American Medical Association, Chicago. NR 33 TC 22 Z9 22 U1 3 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD MAY PY 2009 VL 75 IS 2 BP 178 EP 184 DI 10.1016/j.pec.2008.09.010 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 437FH UT WOS:000265471500007 PM 19250793 ER PT J AU Cristian, A Greenwald, BD AF Cristian, Adrian Greenwald, Brian D. TI Fatigue Preface SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 [Cristian, Adrian] James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Bronx, NY 10468 USA. [Cristian, Adrian] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Greenwald, Brian D.] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA. RP Cristian, A (reprint author), James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, 3d-22,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM acristianmd@msn.com; brian.greenwald@mountsinai.org NR 1 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 J9 PHYS MED REHABIL CLI JI Phys. Med. Rehabil. Clin. N. Am. PD MAY PY 2009 VL 20 IS 2 BP XI EP XII DI 10.1016/j.pmr.2009.02.001 PG 2 WC Rehabilitation SC Rehabilitation GA 450KC UT WOS:000266398400002 PM 19389612 ER PT J AU Kalapatapu, RK Cristian, A AF Kalapatapu, Raj K. Cristian, Adrian TI Assessment of Fatigue in Adults with Disabilities SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Fatigue; Etiology; Adult; Rating scale; Assessment ID TRAUMATIC BRAIN-INJURY; CANCER-RELATED FATIGUE; FIBROMYALGIA IMPACT QUESTIONNAIRE; QUALITY-OF-LIFE; 1ST 2 YEARS; PRIMARY-CARE; MULTIPLE-SCLEROSIS; FAMILY-PRACTICE; VALIDATION; SYMPTOMS AB Fatigue is common among patients presenting to physicians. Fatigue can lead to serious public health consequences and may be caused by a vast array of etiologies. This article reviews the assessment of fatigue from the physical medicine and rehabilitation physician's perspective. The importance of a history and physical examination is emphasized, complemented by the use of laboratory studies. Rating scales used to assess fatigue from different etiologies are discussed, and patient-friendly Internet resources about fatigue are included. C1 [Kalapatapu, Raj K.] Mt Sinai Sch Med, New York, NY 10029 USA. [Cristian, Adrian] Mt Sinai Sch Med, Dept Rehabil Med, James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Kalapatapu, RK (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM rajkumar.kalapatapu@mssm.edu NR 67 TC 0 Z9 0 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 J9 PHYS MED REHABIL CLI JI Phys. Med. Rehabil. Clin. N. Am. PD MAY PY 2009 VL 20 IS 2 BP 313 EP + DI 10.1016/j.pmr.2008.12.001 PG 13 WC Rehabilitation SC Rehabilitation GA 450KC UT WOS:000266398400003 PM 19389613 ER PT J AU York, RM Perell-Gerson, KL Barr, M Durham, J Roper, JM AF York, Robyn M. Perell-Gerson, Karen L. Barr, Michele Durham, Jayson Roper, Janice M. TI Motor Learning of a Gait Pattern to Reduce Forefoot Plantar Pressures in Individuals with Diabetic Peripheral Neuropathy SO PM&R LA English DT Article AB Objective: To examine the role of visual feedback in the reduction of plantar pressures through teaching a "new" gait pattern to diabetic peripheral neuropathy subjects. Immediate, next day, and 1-week retention were studied to determine if motor pattern changes could occur. Design: Randomized controlled trial. Setting: VA Urban Healthcare System. Participants: Twenty-nine community-dwelling older adults with diabetic peripheral neuropathy volunteered. Interventions: Subjects were randomized into feedback and no-feedback groups. All subjects received instruction and 2 days of practice and returned for a 1-week retention test. Instruction to pull the leg forward from the hip to initiate swing rather than push off the ground with the foot while walking was given to all subjects. The feedback group received visual feedback regarding peak plantar pressures after each practice trial. The no-feedback group received no feedback. Main Outcome Measures: Peak plantar pressures in the forefoot region for immediate retention (retention 1), next day retention (retention 2), and long-term retention (1-week retention). Results: Peak plantar pressures were significantly (P < .01) reduced from baseline to retention 2 testing at the first metatarsal area in the feedback group. The feedback group walked significantly (P < .01) slower at retention 1 and 1-week testing compared with baseline. Conclusions: Individuals with diabetic peripheral neuropathy were unable to use a "new" strategy gait pattern to reduce peak plantar pressures long term (1 week). The use of visual feedback following the trial did not assist in the learning of a new walking pattern. C1 [York, Robyn M.; Perell-Gerson, Karen L.; Roper, Janice M.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [York, Robyn M.; Perell-Gerson, Karen L.; Barr, Michele] Calif State Univ Fullerton, Dept Kinesiol, Fullerton, CA 92634 USA. [Durham, Jayson] Space & Naval Warfare Syst Ctr, San Diego, CA USA. RP Perell-Gerson, KL (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. EM kperell@fullerton.edu FU VA Rehabilitation Research and Development Service [A2372K, A3117R] FX Supported by a Career Development Award (A2372K) from the VA Rehabilitation Research and Development Service to K.L.P.-G. and a grant (A3117R) from the VA Rehabilitation Research and Development Service to K.L.P.-G. and J.M.R. NR 22 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD MAY PY 2009 VL 1 IS 5 BP 434 EP 441 DI 10.1016/j.pmrj.2009.03.001 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA V24LI UT WOS:000208411500006 PM 19627930 ER PT J AU Wakchoure, S Swain, TM Hentunen, TA Bauskin, AR Brown, DA Breit, SN Vuopala, KS Harris, KW Selander, KS AF Wakchoure, Savita Swain, Telisha Millender Hentunen, Teuvo A. Bauskin, Asne R. Brown, David A. Breit, Samuel N. Vuopala, Katri S. Harris, Kevin W. Selander, Katri S. TI Expression of Macrophage Inhibitory Cytokine-1 in Prostate Cancer Bone Metastases Induces Osteoclast Activation and Weight Loss SO PROSTATE LA English DT Article DE MIC-1; prostate cancer; bone metastases ID TGF-BETA SUPERFAMILY; GROWTH-FACTOR-BETA; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; TUMOR-CELLS; MAP KINASE; IN-VITRO; MIC-1; SERUM; PROGRESSION AB BACKGROUND. Macrophage inhibitory cytokine-1 (MIC-1) belongs to the bone morphogenic protein/transforming growth factor-beta (BMP/TGF-beta) superfamily. Serum MIC-1 concentrations are elevated in patients with advanced prostate cancer. The effects of MIC-1 on prostate cancer bone metastases are unknown. METHODS. In vitro effects of MIC-1 on osteoblast differentiation and activity were analyzed with alkaline phosphatase and mineralization assays; osteoclast numbers were counted microscopically. MIC-1 effects on TLR9 expression were studied with Western blotting. Human Du-145 prostate cancer cells were stably transfected with a cDNA encoding for mature MIC-1 or with an empty vector. The in vivo growth characteristics of the characterized cells were studied with the intra-tibial model of bone metastasis. Tumor associated bone changes were viewed with X-rays, histology, and histomorphometry. Bone formation was assayed by measuring serum PINP. RESULTS. MIC-1 induced osteoblast differentiation and activity and osteoclast formation in vitro. These effects were independent of TLR9 expression, which was promoted by MIC-1. Both MIC-1 and control tumors induced mixed sclerotic/lytic bone lesions, but MIC-1 increased the osteolytic component of tumors. Osteoclast formation at the tumor-bone interface was significantly higher in the MIC-1 tumors, whereas bone formation was significantly higher in the control mice. At sacrifice, the mice bearing MIC-1 tumors were significantly lighter with significantly smaller tumors. CONCLUSIONS. MIC-1 up-regulates TLR9 expression in various cells. MIC-1 stimulates both osteoblast and osteoclast differentiation in vitro, independently of TLR9. MIC-1 over-expressing prostate cancer cells that grow in bone induce osteoclast formation and cachexia. Prostate 69: 652-661, 2009. (C) 2009 Wiley-Liss, Inc. C1 [Selander, Katri S.] Univ Alabama, Dept Med, Div Hematol Oncol, UAB, Birmingham, AL 35294 USA. [Hentunen, Teuvo A.] Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland. [Bauskin, Asne R.; Brown, David A.; Breit, Samuel N.] St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia. [Bauskin, Asne R.; Brown, David A.; Breit, Samuel N.] Univ New S Wales, Sydney, NSW, Australia. [Vuopala, Katri S.] Lapland Cent Hosp, Rovaniemi, Finland. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Selander, KS (reprint author), Univ Alabama, Dept Med, Div Hematol Oncol, UAB, WTI T558,1824 6th Ave S, Birmingham, AL 35294 USA. EM katri.selander@ccc.uab.edu FU National Health & Medical Research Council, Australia; New South Wales Health Research and Development Infrastructure; Department of Defense [W81XWH-05-1-0066] FX National Health & Medical Research Council, Australia; Grant sponsor: New South Wales Health Research and Development Infrastructure; Grant sponsor: Department of Defense; Grant number: W81XWH-05-1-0066. NR 52 TC 32 Z9 36 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD MAY 1 PY 2009 VL 69 IS 6 BP 652 EP 661 DI 10.1002/pros.20913 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 437YU UT WOS:000265523600009 PM 19152406 ER PT J AU Zhang, XY Zhou, DF Qi, LY Chen, S Cao, LY Chen, DC Xiu, MH Wang, F Wu, GY Lu, L Kosten, TA Kosten, TR AF Zhang, Xiang Yang Zhou, Dong Feng Qi, Ling Yan Chen, Song Cao, Lian Yuan Chen, Da Chun Xiu, Mei Hong Wang, Fan Wu, Gui Ying Lu, Lin Kosten, Therese A. Kosten, Thomas R. TI Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizophrenia; Immune; Cytokine; Oxidative stress; Antioxidant enzymes; Antipsychotic; Psychopathology ID NEUROLEPTIC-FREE SCHIZOPHRENIA; ANTIOXIDANT DEFENSE SYSTEM; FREE-RADICAL PATHOLOGY; IN-VITRO PRODUCTION; TRANSCRIPTION FACTOR; SERUM INTERLEUKIN-6; TARDIVE-DYSKINESIA; FATTY-ACIDS; CSF LEVELS; DRUG-FREE AB Both schizophrenia and oxidative stress have been associated with immune system abnormalities in interleukin-2 and -6 (IL-2; IL-6) and increases in superoxide dismutase (SOD) activity. These abnormalities may improve during antipsychotic drug treatment that reduces symptoms in schizophrenic patients. Subjects included 30 healthy controls (HC) and 78 schizophrenic (SCH) in-patients who were randomly assigned to 12 weeks of double-blind treatment with risperidone 6 mg/day or haloperidol 20 mg/day. Ratings using the Positive and Negative Syndrome Scale (PANSS) were correlated with blood SOD and serum IL-2 levels. SCH patients who were medication-free for 2 weeks had greater SOD, IL-2, and IL-6 levels than HC. At baseline, these SOD elevations were associated with higher PANSS total scores and the IL-2 elevations with lower PANSS positive symptom scores. The SOD and IL-2 levels in the SCH were also positively correlated. After treatment, PANSS positive symptoms and both SOD and IL-2 showed a significant decrease, but IL-6 showed no change. The SOD and IL-2 reductions were correlated with the reductions in PANSS total score, and SOD reductions also correlated with positive subscore reductions. Females showed these associations more strongly than males. Our results suggest that the dysregulation in the cytokine system and oxidative stress in patients with schizophrenia is implicated in clinical symptoms and is improved at least partially with antipsychotic treatment. The stronger associations in females deserve further study and confirmation. C1 [Zhang, Xiang Yang; Kosten, Thomas R.] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhou, Dong Feng] Peking Univ, Inst Mental Hlth, Beijing 100083, Peoples R China. [Zhang, Xiang Yang; Qi, Ling Yan; Chen, Song; Cao, Lian Yuan; Chen, Da Chun; Xiu, Mei Hong; Wang, Fan] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. [Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 10083, Peoples R China. RP Zhang, XY (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu FU Stanley Medical Institute Foundation [03T-459, 05T-726]; Mental Illness Research, Education and Clinical Center (MIRECC); National Institute on Drug Abuse [K05-DA0454, P50-DA18827] FX This study was funded by the Stanley Medical Institute Foundation (03T-459, 05T-726; XYZ), and the Department of Veterans Affairs, VISN 1, Mental Illness Research, Education and Clinical Center (MIRECC) and National Institute on Drug Abuse K05-DA0454 and P50-DA18827 (TRK). NR 55 TC 43 Z9 45 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD MAY PY 2009 VL 204 IS 1 BP 177 EP 184 DI 10.1007/s00213-008-1447-6 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 436AT UT WOS:000265385700017 PM 19139851 ER PT J AU Platt, AB Kuna, ST AF Platt, Alec B. Kuna, Samuel T. TI To Adhere or Not to Adhere-Patients Selectively Decide SO SLEEP LA English DT Editorial Material ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE SLEEP-APNEA; CARDIOVASCULAR OUTCOMES; MORTALITY; THERAPY; HYPOPNEA; TRIAL; RISK; MEN C1 [Kuna, Samuel T.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Platt, Alec B.] Reading Hosp Med Ctr, Reading, PA USA. [Platt, Alec B.] Resp Specialists LTD, Wyomissing, PA USA. [Kuna, Samuel T.] Univ Penn, Sch Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. RP Kuna, ST (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM skuna@mail.med.upenn.edu NR 15 TC 2 Z9 2 U1 0 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAY 1 PY 2009 VL 32 IS 5 BP 583 EP 584 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FS UT WOS:000265541900002 PM 19480222 ER PT J AU Rice, I Impink, B Niyonkuru, C Boninger, M AF Rice, I. Impink, B. Niyonkuru, C. Boninger, M. TI Manual wheelchair stroke characteristics during an extended period of propulsion SO SPINAL CORD LA English DT Article DE spinal cord injury; biomechanics; propulsion; fatigue; kinetics; wheelchair dynamometer ID MECHANICAL EFFICIENCY; PUSHRIM FORCES; KINETICS; USERS; BIOMECHANICS; FATIGUE; MOTION AB Study Design: Cross-sectional study. Objectives: The purpose of this study was to examine stroke characteristics of long-term manual wheelchair users during an extended manual wheelchair propulsion trial and the extent to which changes in propulsion biomechanics occurred. Setting: Human Engineering Research Laboratories, VA Rehabilitation Research and Development Center, VA Pittsburgh Healthcare Systems, Pittsburgh, PA, USA. Methods: Kinetic data were recorded from 21 subjects with paraplegia at four time points over the course of a 10-min propulsion trial at a steady state speed of 1.4 ms(-1). Upper extremity kinetic parameters were recorded using Smartwheels, force and torque sensing pushrims. Results: Subjects for propulsion biomechanics changed from early to late during the 10-min trial. Individuals displayed decreased maximum rate of rise of resultant force (P=0.0045) with a simultaneous increase in push time (P=0.043) and stroke time (P=0.023), whereas stroke frequency remained static. In addition, there was a decrease in out of plane moment application (P=0.032). Conclusion: Individuals seemed to naturally accommodate their propulsive stroke, using less injurious propulsion biomechanics over the course of a 10-minute trial on a dynamometer. The findings may have occurred as a result of both biomechanical compensations to a challenging propulsion trial and accommodation to propelling on a dynamometer. These results suggest that subjects may be capable of independently incorporating favorable biomechanical strategies to meet the demands of a challenging propulsion scenario. Spinal Cord (2009) 47, 413 - 417; doi:10.1038/sc.2008.139; published online 11 November 2008 C1 [Rice, I.] Univ Pittsburgh, Rehabil Sci Human Engn Res Lab, VA Pittsburgh Healthcare Syst, VA Rehabil Res & Dev Ctr,Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Rice, I.; Boninger, M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. [Impink, B.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15206 USA. [Boninger, M.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15206 USA. RP Rice, I (reprint author), Univ Pittsburgh, Rehabil Sci Human Engn Res Lab, VA Pittsburgh Healthcare Syst, VA Rehabil Res & Dev Ctr,Human Engn Res Labs, VA Pittsburgh 7180 Highland Dr 151R-1, Pittsburgh, PA 15206 USA. EM ricei@herlpitt.org OI Boninger, Michael/0000-0001-6966-919X FU Office of Research and Development; Rehabilitation Research and Development Service; Department of Veterans Affairs [B3142C] FX This study was supported by the Office of Research and Development, Rehabilitation Research and Development Service, Department of Veterans Affairs, Grant# B3142C'. NR 18 TC 9 Z9 9 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD MAY PY 2009 VL 47 IS 5 BP 413 EP 417 DI 10.1038/sc.2008.139 PG 5 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 443DM UT WOS:000265890400012 PM 19002155 ER PT J AU Ross, JS Halm, EA Bravata, DM AF Ross, Joseph S. Halm, Ethan A. Bravata, Dawn M. TI Use of Stroke Secondary Prevention Services Are There Disparities in Care? SO STROKE LA English DT Article DE health care; prevention; women and minorities; quality of care ID TRANSIENT ISCHEMIC ATTACK; PHYSICAL-ACTIVITY; RISK-FACTORS; HEALTH; BEHAVIORS; MORTALITY; OUTCOMES; DISEASE; CANCER AB Background and Purpose-The purpose of this study was to examine whether there are disparities in use of stroke secondary prevention services because disparities in stroke outcomes have been found among older adults, women, racial minorities, and within Stroke Belt states. Methods-Using the nationally-representative 2005 Behavior Risk Factor Surveillance System, we examined self-reported use of 11 stroke secondary prevention services queried in the survey. We used multivariable logistic regression to examine the association between service use and age, sex, race, and Stroke Belt state residence, controlling for other socio-demographic and health care access characteristics. Results-Among 11 862 adults with a history of stroke, 16% were 80 or older, 54% were women, 13% were non-Hispanic black, and 23% lived within a Stroke Belt state. Overall service use varied: 31% reported poststroke outpatient rehabilitation, 57% regular exercise, 66% smoking cessation counseling, and 91% current use of antihypertensive medications. Age 80 or older was not associated with lower use of any of the 11 services. Women were less likely to report poststroke outpatient rehabilitation and regular exercise when compared with men (probability values <= 0.005); there were no sex-based differences in use of the 9 other services. Blacks were less likely to report pneumococcal vaccination when compared with whites, but were more likely to report poststroke outpatient rehabilitation (probability values <= 0.005); there were no race-based differences in use of the 9 other services. Stroke Belt state residence was not associated with lower use of any of the 11 services. Conclusions-Use of many stroke secondary prevention services was suboptimal. We did not find consistent age, sex, racial, or Stroke Belt state residence disparities in care. (Stroke. 2009; 40: 1811-1819.) C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Bronx, NY USA. James J Peter VA Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA. James J Peter VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA. [Bravata, Dawn M.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA. Richard L Roudebush Vet Adm Med Ctr, HSR&D Ctr Excellence, Indianapolis, IN 46202 USA. RP Ross, JS (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM joseph.ross@mssm.edu FU NINDS NIH HHS [R01 NS056028-04, R01 NS056028-02, R01 NS056028-03, R01 NS056028, R01 NS056028-01A1] NR 26 TC 14 Z9 14 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAY PY 2009 VL 40 IS 5 BP 1811 EP 1819 DI 10.1161/STROKEAHA.108.539619 PG 9 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 438UB UT WOS:000265579800043 PM 19265044 ER PT J AU Parikh, NM Shah, DH Deswal, A Ashton, CM Agarwal, SJ Chen, H Johnson, M AF Parikh, N. M. Shah, D. H. Deswal, A. Ashton, C. M. Agarwal, S. J. Chen, H. Johnson, M. TI THE ASSOCIATION OF ASPIRIN USE ON RISK OF HOSPITALIZATION IN CHF PATIENTS TAKING ACE INHIBITORS: A RETROSPECTIVE ANALYSIS OF A NATIONAL COHORT OF VETERANS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Parikh, N. M.] Anal Grp Inc, Boston, MA USA. [Shah, D. H.] Abt Bio Pharma Solut Inc, Waltham, MA USA. [Deswal, A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Ashton, C. M.] Methodist Inst Technol Innovat & Educ, Houston, TX USA. [Agarwal, S. J.; Chen, H.; Johnson, M.] Univ Houston, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2009 VL 12 IS 3 BP A146 EP A146 DI 10.1016/S1098-3015(10)73792-X PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 433WO UT WOS:000265236700724 ER PT J AU Romeo, HE Tio, DL Taylor, AN AF Romeo, Horacio E. Tio, Delia L. Taylor, Anna N. TI Effects of superior cervical ganglionectomy on body temperature and on the lipopolysaccharide-induced febrile response in rats SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Fever; Superior cervical ganglionectomy; Biotelemetry; Lipopolysaccharide; Sprague-Dawley rat ID CORTICOTROPIN-RELEASING HORMONE; SUBMAXILLARY LYMPH-NODES; BROWN ADIPOSE-TISSUE; SYMPATHETIC NEURONS; BRAIN COMMUNICATION; LOCUS-COERULEUS; PITUITARY-GLAND; PREOPTIC AREA; NEUROENDOCRINE; HYPOTHALAMUS AB The involvement of the cervical sympathetic ganglia (SCG) on body temperature and during the occurrence of the induced febrile response was investigated in rats. Bilateral superior cervical gaglionectomy (SCGx) attenuated the daily dark-phase temperature compared to that of the sham-operated rats during the first 2 days post surgery. Body temperatures returned to pre-surgery levels by Day-3. Ten days after surgery, a febrile response was induced by lipopolysaccharide (LPS) immune challenge. SCGx significantly blunted the LPS-induced febrile response. These data suggest that obliteration of the cervical sympathetic peripheral innervation impairs the capability to produce an induced febrile response. (C) 2009 Elsevier B.V. All rights reserved. C1 [Romeo, Horacio E.] Univ Buenos Aires, Fac Med, Dept Fisiol, RA-2155 Buenos Aires, DF, Argentina. [Romeo, Horacio E.; Tio, Delia L.; Taylor, Anna N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Tio, Delia L.; Taylor, Anna N.] W Los Angeles Healthcare Ctr, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Romeo, HE (reprint author), Univ Buenos Aires, Fac Med, Dept Fisiol, 1121BA, RA-2155 Buenos Aires, DF, Argentina. EM hromeo@fmed.uba.ar FU National Institute of Dental and Craniofacial Research [DE016063-01] FX This work is supported by The National Institute of Dental and Craniofacial Research; Grant number: DE016063-01 (H.E. Romeo). NR 56 TC 3 Z9 3 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD APR 30 PY 2009 VL 209 IS 1-2 BP 81 EP 86 DI 10.1016/j.jneuroim.2009.01.027 PG 6 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 448ZG UT WOS:000266299900009 PM 19251325 ER PT J AU Sin, MLY Gau, V Liao, JC Haake, DA Wong, PK AF Sin, Mandy L. Y. Gau, Vincent Liao, Joseph C. Haake, David A. Wong, Pak Kin TI Active Manipulation of Quantum Dots using AC Electrokinetics SO JOURNAL OF PHYSICAL CHEMISTRY C LA English DT Article ID ELECTRIC-FIELDS; FLUID-FLOW; DNA; MICROELECTRODES; DIELECTROPHORESIS; NANOPARTICLES; ELECTROLYTES; BIOMOLECULES; NANOTUBES; BIOSENSOR AB The superior optical and electrical properties of quantum dot (QD) nanoparticles are being applied in a new generation of QD devices for microelectronic, nanophotonic, and biomedical systems. Research on integrated QD-based systems has been focused on passive manipulation of QDs including template-guided self-assembly, molecular scaffold-based assembly, and microbead-based assembly. However, little effort has been devoted to development of methods for active manipulation, such as positioning and concentration, of QDs. In this study, we show that 20 nm colloidal QDs can be effectively positioned and concentrated using a combination of dielectrophoresis (DEP) and AC electro-osmosis (ACEO). The long-range fluid motion generated by ACEO entrains QDs to the area near the electrode surface, which facilitates the trapping of QDs by DEP. A systematic investigation was performed to examine electrokinetic processes at different applied frequencies and voltages using a concentric electrode configuration. We demonstrate that QDs can be dynamically positioned with an electric field strength as small as 10 kV/m and define the operating parameters for increasing the concentration of colloidal QDs by 2 orders of magnitude within one minute. C1 [Sin, Mandy L. Y.; Wong, Pak Kin] Univ Arizona, Dept Aerosp & Mech Engn, Tucson, AZ 85721 USA. [Gau, Vincent] Genefluidics Inc, Monterey Pk, CA 91754 USA. [Liao, Joseph C.] Stanford Univ, Dept Urol, Stanford, CA 94305 USA. [Liao, Joseph C.] Stanford Univ, Bio X Program, Stanford, CA 94305 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90095 USA. [Wong, Pak Kin] Univ Arizona, Biomed Engn Interdisciplinary Program, Tucson, AZ 85721 USA. [Wong, Pak Kin] Univ Arizona, Inst Bio5, Tucson, AZ 85721 USA. RP Wong, PK (reprint author), Univ Arizona, Dept Aerosp & Mech Engn, Tucson, AZ 85721 USA. EM pak@email.arizona.edu RI Wong, Pak Kin/A-7974-2012; Liao, Joseph/J-5874-2015 OI Wong, Pak Kin/0000-0001-7388-2110; FU American Chemical Society Petroleum Research Fund [47507-G7]; Arizona Biomedical Research Commission; Arizona Research Laboratories Center for Insect Science [AI075565]; National Institute of Allergy and Infectious Disease [1U01AI082457-01]; Veterans Affairs RRD Merit Review [4872] FX The authors thank V. Constantino, C. S. Chen, and M. Junkin for technical assistance. This work was supported by the American Chemical Society Petroleum Research Fund (47507-G7), Arizona Biomedical Research Commission, Arizona Research Laboratories Center for Insect Science, Cooperative Agreement Award AI075565 (to D.A.H.) from the National Institute of Allergy and Infectious Disease (1U01AI082457-01), and Veterans Affairs RR&D Merit Review 4872 (to J.C.L.). NR 39 TC 22 Z9 22 U1 1 U2 14 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1932-7447 J9 J PHYS CHEM C JI J. Phys. Chem. C PD APR 23 PY 2009 VL 113 IS 16 BP 6561 EP 6565 DI 10.1021/jp9004423 PG 5 WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA 435ZV UT WOS:000265383300032 ER PT J AU Shekelle, PG AF Shekelle, Paul G. TI Supplementation with vitamin E or vitamin C did not differ from placebo for major cardiovascular events and mortality SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID PREVENTION; DISEASE; METAANALYSIS C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Shekelle, PG (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 4 TC 0 Z9 0 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 21 PY 2009 VL 150 IS 8 AR JC4-12 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 437AD UT WOS:000265457000027 PM 19391226 ER PT J AU Winkler, DD Schuermann, JP Cao, XH Holloway, SP Borchelt, DR Carroll, MC Proescher, JB Culotta, VC Hart, PJ AF Winkler, Duane D. Schuermann, Jonathan P. Cao, Xiaohang Holloway, Stephen P. Borchelt, David R. Carroll, Mark C. Proescher, Jody B. Culotta, Valeria C. Hart, P. John TI Structural and Biophysical Properties of the Pathogenic SOD1 Variant H46R/H48Q SO BIOCHEMISTRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; MOTOR-NEURON DEGENERATION; COPPER CHAPERONE CCS; CU,ZN-SUPEROXIDE DISMUTASE; TRANSGENIC MICE; BINDING-SITE; FAMILIAL ALS; IN-VITRO; DISULFIDE AB Over 100 mutations in the gene encoding human copper-zinc superoxide dismutase (SOD1) cause an inherited form of the fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS). Two pathogenic SOD1 mutations, His46Arg (H46R) and His48Gln (H48Q), affect residues that act as copper ligands in the wild type enzyme. Transgenic mice expressing a human SOD1 variant containing both mutations develop paralytic disease akin to ALS. Here we show that H46R/H48Q SOD1 possesses multiple characteristics that distinguish it from the wild type. These properties include the following: (1) an ablated copper-binding site, (2) a substantially weakened affinity for zinc, (3) a binding site for a calcium ion, (4) the ability to form stable heterocomplexes with the copper chaperone for SOD1 (CCS), and (5) compromised CCS-mediated oxidation of the intrasubunit disulfide bond in vivo. The results presented here, together with data on pathogenic SOD1 proteins coming from cell culture and transgenic mice, suggest that incomplete posttranslational modification of nascent SOD1 polypeptides via CCS may be a characteristic shared by familial ALS SOD1 mutants, leading to a population of destabilized, off-pathway folding intermediates that are toxic to motor neurons. C1 [Winkler, Duane D.; Schuermann, Jonathan P.; Cao, Xiaohang; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Winkler, Duane D.; Schuermann, Jonathan P.; Cao, Xiaohang; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Audie Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Borchelt, David R.] Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA. [Carroll, Mark C.; Proescher, Jody B.; Culotta, Valeria C.] Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu FU NIH-NINDS [R01-NS39112, P01-NS04913]; NIHGMS [GM50016]; JHU NIEHS center; American Foundation for Aging Research (AFAR).; NIH [T32AG021890-03]; NIEHS [ES 07141]; William and Ella Owens Medical Research Foundation; Judith and Jean Pape Adams Charitable Foundation FX This work was supported by grants NIH-NINDS R01-NS39112 (P.J.H.), P01-NS04913 (Joan S. Valentine, D.R.B., and P.J.H.), NIHGMS GM50016 (V.C.C.), and the JHU NIEHS center (V.C.C.). D.D.W. was supported in part by the American Foundation for Aging Research (AFAR). J.P.S. was supported by NIH T32AG021890-03. J.B.P. was supported by NIEHS training grant ES 07141. X.C. was supported in part by the William and Ella Owens Medical Research Foundation and the Judith and Jean Pape Adams Charitable Foundation. Support for the X-ray Crystallography Core Laboratory and the Center for Analytical Ultracentrifugation of Macromolecular Assemblies by the UTHSCSA Executive Research Committee and the San Antonio Cancer Institute is also gratefully acknowledged. NR 58 TC 18 Z9 18 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD APR 21 PY 2009 VL 48 IS 15 BP 3436 EP 3447 DI 10.1021/bi8021735 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 432YL UT WOS:000265170200020 PM 19227972 ER PT J AU Bohnen, NI Muller, MLTM Kuwabara, H Constantine, GM Studenski, SA AF Bohnen, N. I. Mueller, M. L. T. M. Kuwabara, H. Constantine, G. M. Studenski, S. A. TI Age-associated leukoaraiosis and cortical cholinergic deafferentation SO NEUROLOGY LA English DT Article ID WHITE-MATTER HYPERINTENSITIES; HUMAN-BRAIN; ACETYLCHOLINESTERASE ACTIVITY; PARKINSONS-DISEASE; ALZHEIMER-DISEASE; RATING-SCALE; IN-VIVO; DENERVATION; PATHWAYS; PERFORMANCE AB Objective: To investigate the relationship between age-associated MRI leukoaraiosis or white matter hyperintensities (WMH) and cortical acetylcholinesterase (AChE) activity. Background: One possible mechanism of cognitive decline in elderly individuals with leukoaraiosis is disruption of cholinergic fibers by strategically located white matter lesions. Periventricular lesions may have a higher chance of disrupting cholinergic projections compared with more superficial nonperiventricular white matter lesions because of anatomic proximity to the major cholinergic axonal projection bundles that originate from the basal forebrain. Methods: Community-dwelling, middle-aged and elderly subjects without dementia (mean age 71.0 +/- 9.2 years; 55-84 years; n = 18) underwent brain MRI and AChE PET imaging. The severity of periventricular and nonperiventricular WMH on fluid-attenuated inversion recovery MRI images was scored using the semiquantitative rating scale of Scheltens et al. [(11)C] methyl-4-piperidinyl propionate AChE PET imaging was used to assess cortical AChE activity. Age-corrected Spearman partial rank correlation coefficients were calculated. Results: The severity of periventricular (R = -0.52, p = 0.04) but not nonperiventricular (R = -0.20, not significant) WMH was inversely related to global cortical AChE activity. Regional cortical cholinergic effects of periventricular WMH were most significant for the occipital lobe (R = -0.58, p = 0.02). Conclusions: The presence of periventricular but not nonperiventricular white matter hyperintensities (WMH) is significantly associated with lower cortical cholinergic activity. These findings support a regionally specific disruption of cholinergic projection fibers by WMH. Neurology(R) 2009; 72: 1411-1416 C1 [Bohnen, N. I.; Mueller, M. L. T. M.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Radiol, Ann Arbor, MI 48105 USA. [Bohnen, N. I.; Mueller, M. L. T. M.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Neurol, Ann Arbor, MI 48105 USA. [Bohnen, N. I.] GRECC, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Kuwabara, H.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA. [Constantine, G. M.] Univ Pittsburgh, Dept Math & Stat, Pittsburgh, PA 15260 USA. [Studenski, S. A.] GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Studenski, S. A.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Dept Med, Pittsburgh, PA 15260 USA. RP Bohnen, NI (reprint author), Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Radiol, 24 Frank Lloyd Wright Dr,Box 362, Ann Arbor, MI 48105 USA. EM nbohnen@umich.edu RI Muller, Martijn/A-7205-2010 OI Muller, Martijn/0000-0002-1133-7202 FU Department of Veterans Affairs and National Institute on Aging [AG023641, AG024827] FX Supported by the Department of Veterans Affairs and National Institute on Aging grants AG023641 and AG024827. NR 31 TC 14 Z9 20 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 21 PY 2009 VL 72 IS 16 BP 1411 EP 1416 DI 10.1212/WNL.0b013e3181a187c6 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 436DV UT WOS:000265393700008 PM 19380700 ER PT J AU Egede, LE Frueh, CB Richardson, LK Acierno, R Mauldin, PD Knapp, RG Lejuez, C AF Egede, Leonard E. Frueh, Christopher B. Richardson, Lisa K. Acierno, Ronald Mauldin, Patrick D. Knapp, Rebecca G. Lejuez, Carl TI Rationale and design: telepsychology service delivery for depressed elderly veterans SO TRIALS LA English DT Article ID BEHAVIORAL ACTIVATION TREATMENT; POSTTRAUMATIC-STRESS-DISORDER; LONGITUDINAL PSYCHIATRIC DATA; RANDOM REGRESSION-MODELS; SAMPLE-SIZE FORMULAS; QUALITY-OF-LIFE; ESTABLISH EQUIVALENCE; RANDOMIZED-TRIAL; CLINICAL-TRIALS; NULL HYPOTHESIS AB Background: Older adults who live in rural areas experience significant disparities in health status and access to mental health care. "Telepsychology," (also referred to as " telepsychiatry," or " telemental health") represents a potential strategy towards addressing this longstanding problem. Older adults may benefit from telepsychology due to its: (1) utility to address existing problematic access to care for rural residents; (2) capacity to reduce stigma associated with traditional mental health care; and (3) utility to overcome significant age-related problems in ambulation and transportation. Moreover, preliminary evidence indicates that telepsychiatry programs are often less expensive for patients, and reduce travel time, travel costs, and time off from work. Thus, telepsychology may provide a cost-efficient solution to access-to-care problems in rural areas. Methods: We describe an ongoing four-year prospective, randomized clinical trial comparing the effectiveness of an empirically supported treatment for major depressive disorder, Behavioral Activation, delivered either via in-home videoconferencing technology ("Telepsychology") or traditional face-to-face services ("Same-Room"). Our hypothesis is that inhomeTelepsychology service delivery will be equally effective as the traditional mode (Same-Room). Two-hundred twenty-four (224) male and female elderly participants will be administered protocol-driven individual Behavioral Activation therapy for depression over an 8-week period; and subjects will be followed for 12-months to ascertain longer-term effects of the treatment on three outcomes domains: (1) clinical outcomes (symptom severity, social functioning); (2) process variables (patient satisfaction, treatment credibility, attendance, adherence, dropout); and (3) economic outcomes (cost and resource use). Discussion: Results from the proposed study will provide important insight into whether telepsychology service delivery is as effective as the traditional mode of service delivery, defined in terms of clinical, process, and economic outcomes, for elderly patients with depression residing in rural areas without adequate access to mental health services. Trial registration: National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier# NCT00324701). C1 [Egede, Leonard E.; Frueh, Christopher B.; Acierno, Ronald; Mauldin, Patrick D.; Knapp, Rebecca G.; Lejuez, Carl] Ralph H Johnson VAMC, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Egede, Leonard E.; Mauldin, Patrick D.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Frueh, Christopher B.] Baylor Coll Med, Menninger Clin, Houston, TX 77030 USA. [Frueh, Christopher B.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Frueh, Christopher B.; Richardson, Lisa K.; Acierno, Ronald] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Richardson, Lisa K.] Murdoch Univ, Sch Psychol, Perth, WA, Australia. [Mauldin, Patrick D.] Med Univ S Carolina, Dept Clin Pharm & Outcome Sci, Charleston, SC 29425 USA. [Knapp, Rebecca G.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Lejuez, Carl] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. RP Egede, LE (reprint author), Ralph H Johnson VAMC, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA. EM egedel@musc.edu; frueh@bcm.edu; l.richardson@murdoch.edu.au; acierno@musc.edu; mauldinp@musc.edu; knappr@musc.edu; clejuez@psyc.umd.edu FU Veterans Health Administration Health Services Research and Development program [IIR 04-421] FX The study was funded by grant # IIR 04-421 from the Veterans Health Administration Health Services Research and Development program. NR 89 TC 19 Z9 19 U1 4 U2 19 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD APR 20 PY 2009 VL 10 AR 22 DI 10.1186/1745-6215-10-22 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 452HS UT WOS:000266531600001 PM 19379517 ER PT J AU Kitagaki, H Cowart, LA Matmati, N Montefusco, D Gandy, J de Avalos, SV Novgorodo, SA Zheng, J Obeid, LM Hannun, YA AF Kitagaki, Hiroshi Cowart, L. Ashley Matmati, Nabil Montefusco, David Gandy, Jason de Avalos, Silvia Vaena Novgorodo, Sergei A. Zheng, Jim Obeid, Lina M. Hannun, Yusuf A. TI ISC1-dependent Metabolic Adaptation Reveals an Indispensable Role for Mitochondria in Induction of Nuclear Genes during the Diauxic Shift in Saccharomyces cerevisiae SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PHOSPHOSPHINGOLIPID-PHOSPHOLIPASE-C; SPHINGOLIPID BIOSYNTHESIS; RETROGRADE RESPONSE; LINKS METABOLISM; GENOME STABILITY; YEAST LONGEVITY; RTG2 PROTEIN; EXPRESSION; ACTIVATION; KINASE AB Growth of Saccharomyces cerevisiae following glucose depletion ( the diauxic shift) depends on a profound metabolic adaptation accompanied by a global reprogramming of gene expression. In this study, we provide evidence for a heretofore unsuspected role for Isc1p in mediating this reprogramming. Initial studies revealed that yeast cells deleted in ISC1, the gene encoding inositol sphingolipid phospholipase C, which resides in mitochondria in the post-diauxic phase, showed defective aerobic respiration in the post-diauxic phase but retained normal intrinsic mitochondrial functions, including intact mitochondrial DNA, normal oxygen consumption, and normal mitochondrial polarization. Microarray analysis revealed that the Delta isc1 strain failed to up-regulate genes required for nonfermentable carbon source metabolism during the diauxic shift, thus suggesting a mechanism for the defective supply of respiratory substrates into mitochondria in the post-diauxic phase. This defect in regulating nuclear gene induction in response to a defect in a mitochondrial enzyme raised the possibility that mitochondria may initiate diauxic shift-associated regulation of nucleus-encoded genes. This was established by demonstrating that in respiratory-deficient petite cells these genes failed to be upregulated across the diauxic shift in a manner similar to the Delta isc1 strain. Isc1p- and mitochondrial function-dependent genes significantly overlapped with Adr1p-, Snf1p-, and Cat8p-dependent genes, suggesting some functional link among these factors. However, the retrograde response was not activated in Delta isc1, suggesting that the response of Delta isc1 cannot be simply attributed to mitochondrial dysfunction. These results suggest a novel role for Isc1p in allowing the reprogramming of gene expression during the transition from anaerobic to aerobic metabolism. C1 [Kitagaki, Hiroshi; Cowart, L. Ashley; Matmati, Nabil; Montefusco, David; Gandy, Jason; de Avalos, Silvia Vaena; Zheng, Jim; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA. [Kitagaki, Hiroshi; Cowart, L. Ashley; Matmati, Nabil; Montefusco, David; Gandy, Jason; de Avalos, Silvia Vaena; Zheng, Jim; Hannun, Yusuf A.] Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA. [Novgorodo, Sergei A.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Cowart, L. Ashley; Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Kitagaki, Hiroshi] Saga Univ, Fac Agr, Saga 8408502, Japan. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA. EM hannun@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [GM43825, R01 AG016583]; Veterans Affairs Merit Award; Merit Review Entry Program Award; Department of Veterans Affairs, Office of Research and Development; Noda Institute for Scientific Research FX This work was supported, in whole or in part, by National Institutes of Health Grant GM43825 ( to Y. A. H.) and Grant R01 AG016583 ( to L. M. O.). This work was also supported by a Veterans Affairs Merit Award ( to L. M. O.), a Merit Review Entry Program Award ( to L. A. C.) from the Department of Veterans Affairs, Office of Research and Development, and in part by an NISR research grant from the Noda Institute for Scientific Research ( to H. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked " advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 45 TC 40 Z9 40 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 17 PY 2009 VL 284 IS 16 BP 10818 EP 10830 DI 10.1074/jbc.M805029200 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 431ZZ UT WOS:000265104600056 PM 19179331 ER PT J AU Viel, KR Ameri, A Abshire, TC Iyer, RV Watts, RG Lutcher, C Channell, C Cole, SA Fernstrom, KM Nakaya, S Kasper, CK Thompson, AR Almasy, L Howard, TE AF Viel, Kevin R. Ameri, Afshin Abshire, Thomas C. Iyer, Rathi V. Watts, Raymond G. Lutcher, Charles Channell, Cynthia Cole, Shelley A. Fernstrom, Karl M. Nakaya, Shelley Kasper, Carol K. Thompson, Arthur R. Almasy, Laura Howard, Tom E. TI Inhibitors of Factor VIII in Black Patients with Hemophilia SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the American-Society-of-Hematology CY DEC 09-12, 2006 CL Orlando, FL SP Amer Soc Hematol ID PREVIOUSLY UNTREATED PATIENTS; RECOMBINANT FACTOR-VIII; FACTOR-IX; GENETIC ASSOCIATION; AFRICAN-AMERICANS; UNITED-STATES; F8 GENE; MUTATIONS; RISK; INVERSION AB BACKGROUND Black patients with hemophilia A (factor VIII deficiency) are twice as likely as white patients to produce inhibitors against factor VIII proteins given as replacement therapy. There are six wild-type factor VIII proteins, designated H1 through H6, but only two (H1 and H2) match the recombinant factor VIII products used clinically. H1 and H2 are found in all racial groups and are the only factor VIII proteins found in the white population to date. H3, H4, and H5 have been found only in blacks. We hypothesized that mismatched factor VIII transfusions contribute to the high incidence of inhibitors among black patients. METHODS We sequenced the factor VIII gene (F8) in black patients with hemophilia A to identify causative mutations and the background haplotypes on which they reside. Results from previous Bethesda assays and information on the baseline severity of hemophilia, age at enrollment, and biologic relationships among study patients were obtained from review of the patients' medical charts. We used multivariable logistic regression to control for these potential confounders while testing for associations between F8 haplotype and the development of inhibitors. RESULTS Of the 78 black patients with hemophilia enrolled, 24% had an H3 or H4 background haplotype. The prevalence of inhibitors was higher among patients with either of these haplotypes than among patients with haplotype H1 or H2 (odds ratio, 3.6; 95% confidence interval, 1.1 to 12.3; P = 0.04), despite a similar spectrum of hemophilic mutations and degree of severity of illness in these two subgroups. CONCLUSIONS These preliminary results suggest that mismatched factor VIII replacement therapy may be a risk factor for the development of anti-factor VIII alloantibodies. C1 [Viel, Kevin R.; Cole, Shelley A.; Almasy, Laura] SW Fdn Biomed Res, San Antonio, TX 78284 USA. [Ameri, Afshin; Lutcher, Charles] Med Coll Georgia, Augusta, GA 30912 USA. [Abshire, Thomas C.; Channell, Cynthia; Fernstrom, Karl M.] Emory Univ, Atlanta, GA 30322 USA. [Iyer, Rathi V.] Univ Mississippi, Med Ctr, Jackson, MS USA. [Watts, Raymond G.] Univ Alabama, Birmingham, AL USA. [Nakaya, Shelley; Thompson, Arthur R.] Univ Washington, Seattle, WA 98195 USA. [Kasper, Carol K.; Howard, Tom E.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Kasper, Carol K.] Orthoped Hosp, Los Angeles, CA USA. [Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Howard, Tom E.] Greater Los Angeles Vet Affairs Hosp, Los Angeles, CA USA. RP Howard, TE (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, 11301 Wilshire Blvd,Bldg 500,Rm 12S4, Los Angeles, CA 90073 USA. EM tom.howard@va.gov FU NHLBI NIH HHS [HL-70751, HL-72533, K08 HL071130, K08 HL071130-06, R01 HL070751, R01 HL070751-07, R01 HL072533, R01 HL072533-05, HL-71130, HL-07109] NR 53 TC 106 Z9 111 U1 0 U2 6 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 16 PY 2009 VL 360 IS 16 BP 1618 EP 1627 DI 10.1056/NEJMoa075760 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 433BH UT WOS:000265178000006 PM 19369668 ER PT J AU Spiegel, BMR Farid, M Van Oijen, MGH Laine, L Howden, CW Esrailian, E AF Spiegel, B. M. R. Farid, M. Van Oijen, M. G. H. Laine, L. Howden, C. W. Esrailian, E. TI Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID HELICOBACTER-PYLORI INFECTION; PROTON PUMP INHIBITORS; PHYSICIANS PERCEPTIONS; NATIONAL-SURVEY; QUALITY; RISK; MANAGEMENT; DISORDERS; ENDOSCOPY; THERAPY AB Although 'best practice' guidelines for dyspepsia management have been disseminated, it remains unclear whether providers adhere to these guidelines. To compare adherence to 'best practice' guidelines among dyspepsia experts, community gastroenterologists and primary-care providers (PCPs). We administered a vignette survey to elicit knowledge and beliefs about dyspepsia including a set of 16 best practices, to three groups: (i) dyspepsia experts; (ii) community gastroenterologists and (iii) PCPs. The expert, community gastroenterologist and PCP groups endorsed 75%, 73% and 57% of best practices respectively. Gastroenterologists were more likely to adhere with guidelines than PCPs (P < 0.0001). PCPs were more likely to define dyspepsia incorrectly, overuse radiographic testing, delay endoscopy, treat empirically for Helciobacter pylori without confirmatory testing and avoid first-line proton pump inhibitors (PPIs). PCPs had more concerns about adverse events with PPIs [e.g. osteoporosis (P = 0.04), community-acquired pneumonia (P = 0.01)] and higher level of concern predicted lower guideline adherence (P = 0.04). Gastroenterologists are more likely than PCPs to comply with best practices in dyspepsia, although compliance remains incomplete in both groups. PCPs harbour more concerns regarding long-term PPI use and these concerns may affect therapeutic decision making. This suggests that best practices have not been uniformly adopted and persistent guideline-practice disconnects should be addressed. C1 [Spiegel, B. M. R.; Farid, M.; Esrailian, E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Spiegel, B. M. R.; Farid, M.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Spiegel, B. M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Spiegel, B. M. R.; Van Oijen, M. G. H.; Esrailian, E.] UCLA VA Ctr Outcomes Res & Educ, Los Angels, CA USA. [Van Oijen, M. G. H.] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, NL-6525 ED Nijmegen, Netherlands. [Laine, L.] Univ So Calif, Dept Gastroenterol, Keck Sch Med, Los Angels, CA USA. [Howden, C. W.] Northwestern Univ, Div Gastroenterol, Feinberg Sch Med, Chicago, IL 60611 USA. RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ulca.edu FU Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award [RCD 03-179-2]; AstraZeneca; Novartis; Amgen; Procter Gamble; TAP; Takeda; CURE Digestive Disease Research Center [NIH 2P30 DK 041301-17]; Nycomed FX Declaration of personal and funding interests: Dr Spiegel is supported by a Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award (RCD 03-179-2). Dr Spiegel has served as a consultant to TAP Pharmaceutical Products Inc, Takeda Pharmaceuticals of North America, Novartis, and AstraZeneca. He has received research funding from AstraZeneca, Novartis, Amgen, Procter & Gamble, TAP, Takeda, and AstraZeneca. Drs Esrailian and Spiegel are supported by the CURE Digestive Disease Research Center (NIH 2P30 DK 041301-17). Dr Howden has served as a consultant to TAP Pharmaceutical Products Inc., Takeda Pharmaceuticals of North America, Santarus, Otsuka, Novartis, Biovail, Extera Partners and KV Pharmaceuticals, as a speaker for AstraZeneca, Santarus and Otsuka, and has received research funding from AstraZeneca. Dr Laine has acted as a consultant for AstraZeneca, Eisai, Santarus, Horizon and Pozen, and has received research support from Takeda Pharmaceuticals and GSK. M. G. H. van Oijen is a consultant and has received grant support from AstraZeneca and Nycomed. The authors had complete authority over all aspects of the study, including development of the hypotheses and analysis plan, development of data collection instruments, collection of data, analysis and interpretation of data, and writing of the manuscript. NR 27 TC 15 Z9 15 U1 1 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD APR 15 PY 2009 VL 29 IS 8 BP 871 EP 881 DI 10.1111/j.1365-2036.2009.03935.x PG 11 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 421QC UT WOS:000264372400009 PM 19183152 ER PT J AU Parashar, S Katz, R Smith, NL Arnold, AM Vaccarino, V Wenger, NK Gottdiener, JS AF Parashar, Susmita Katz, Ronit Smith, Nicholas L. Arnold, Alice M. Vaccarino, Viola Wenger, Nanette K. Gottdiener, John S. TI Race, Gender, and Mortality in Adults >= 65 Years of Age With Incident Heart Failure (from the Cardiovascular Health Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; RACIAL-DIFFERENCES; UNITED-STATES; ELDERLY-PATIENTS; SEX-DIFFERENCES; HOSPITALIZATION; POPULATION; SURVIVAL; OUTCOMES; EPIDEMIOLOGY AB In patients with heart failure (HF), mortality is lower in women versus men. However, it is unknown whether the survival advantage in women compared with men is present in both whites and African Americans with HF. The inception cohort consisted of adults >= 65 years with incident HF after enrollment in the CHS, a prospective population-based study of cardiovascular disease. Of 5,888 CHS subjects, 1,264 developed new HF and were followed up for 3 years. Subjects were categorized into 4 race-gender groups, and Cox proportional hazard regression models were used to examine whether 3-year total and cardiovascular mortality differed among the 4 groups after adjusting for sociodemographic factors, co-morbidities, and treatment. A gender-race interaction was also tested for each outcome. In subjects with incident HF, African Americans had more hypertension and diabetes than whites, and white men had more coronary heart disease than other gender-race groups. Receipt of cardiovascular treatments among the 4 groups was similar. Mortality rates after HF were lower in women compared with men (for white women, African-American women, African-American men, and white men, total mortality was 35.5, 33.6, 44.4, and 40.5/100 person-years, and cardiovascular mortality was 18.4, 19.5, 20.2, and 22.7/100 person-years, respectively). After adjusting for covariates, women had a 15% to 20% lower risk of total and cardiovascular mortality compared with men, but there was no significant difference in outcome by race. The gender-race interaction for either outcome was not significant. In conclusion, in older adults with HF, women had significantly better survival than men irrespective of race, suggesting that gender-based survival differences may be more important than race-based differences. (C) 2009 Elsevier Inc. (Am J Cardiol 2009;103:1120-1127) C1 [Parashar, Susmita; Vaccarino, Viola; Wenger, Nanette K.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA. [Katz, Ronit; Smith, Nicholas L.; Arnold, Alice M.] Univ Washington, Dept Epidemiol, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98195 USA. [Smith, Nicholas L.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Gottdiener, John S.] Univ Maryland, Div Cardiol, Baltimore, MD 21201 USA. RP Parashar, S (reprint author), Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA. EM susmita.parashar@emory.edu FU National Heart, Lung, and Blood Institute, Bethesda, Maryland [N01-HC-35129, N01-HC45133, N01-HC-75150, N01-HC-85079, N01-HC-85086, N01 HC15103, N01 HC-55222, U01 HL080295]; National Institute of Neurological Disorders and Stroke. Bethesda, Maryland; American Heart Association, Dallas, Texas [0630084N]; National Center for Research Resources/ National Institutes of Health [1K23RR023171] FX This work was supported by contracts N01-HC-35129, N01-HC45133, N01-HC-75150. N01-HC-85079 through N01-HC-85086, N01 HC15103, N01 HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, with additional contribution from the National Institute of Neurological Disorders and Stroke. Bethesda, Maryland. Dr. Parashar was supported by Scientist Development Award 0630084N from the American Heart Association, Dallas, Texas, and Mentored Clinical Scientist Development Award 1K23RR023171 from the National Center for Research Resources/ National Institutes of Health. NR 30 TC 26 Z9 26 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2009 VL 103 IS 8 BP 1120 EP 1127 DI 10.1016/j.amjcard.2008.12.043 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 436RR UT WOS:000265433300014 PM 19361600 ER PT J AU McCarthy, JF Valenstein, M Kim, HM Ilgen, M Zivin, K Blow, FC AF McCarthy, John F. Valenstein, Marcia Kim, H. Myra Ilgen, Mark Zivin, Kara Blow, Frederic C. TI Suicide Mortality Among Patients Receiving Care in the Veterans Health Administration Health System SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE military medicine; mortality; suicide; veterans ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; WAR VETERANS; US VETERANS; GULF-WAR; AFFAIRS; RISK; WOMEN; OUTPATIENTS; DEPRESSION AB Understanding and reducing mortality from suicide among veterans is a national priority, particularly for individuals receiving care from the US Veterans Health Administration (VHA). This report examines suicide rates among VHA patients and compares them with rates in the general population. Suicide mortality was assessed in fiscal year 2001 for patients alive at the start of that fiscal year and with VHA use in fiscal years 2000-2001 (n = 4,692,034). Deaths from suicide were identified by using National Death Index data. General population rates were identified by use of the Web-based Injury Statistics Query and Reporting System. VHA rates were 43.13/100,000 person-years for men and 10.41/100,000 person-years for women. For male patients, the age-adjusted standardized mortality ratio was 1.66; for females, it was 1.87. Male patients aged 30-79 years had increased risks relative to men in the general population; standardized mortality ratios ranged from 2.56 (ages 30-39 years) to 1.33 (ages 70-79 years). Female patients aged 40-59 years had greater risks than did women in the general population, with standardized mortality ratios of 2.15 (ages 40-49 years) and 2.36 (ages 50-59 years). Findings offer heretofore unavailable comparison points for health systems. Prior to the conflicts in Afghanistan and Iraq and before recent VHA initiatives, rates were higher among VHA patients than in the general population. Female patients had particularly high relative risks. C1 [McCarthy, John F.; Valenstein, Marcia; Ilgen, Mark; Zivin, Kara; Blow, Frederic C.] Serious Mental Illness Treatment Res & Evaluat Ct, US Dept Vet Affairs, Ann Arbor, MI 48113 USA. [McCarthy, John F.; Valenstein, Marcia; Kim, H. Myra; Ilgen, Mark; Zivin, Kara; Blow, Frederic C.] Ctr Clin Management Res, US Dept Vet Affairs, Ann Arbor, MI USA. [McCarthy, John F.; Valenstein, Marcia; Kim, H. Myra; Ilgen, Mark; Zivin, Kara; Blow, Frederic C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP McCarthy, JF (reprint author), Serious Mental Illness Treatment Res & Evaluat Ct, US Dept Vet Affairs, POB 13017, Ann Arbor, MI 48113 USA. EM john.mccarthy2@va.gov NR 37 TC 117 Z9 117 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 15 PY 2009 VL 169 IS 8 BP 1033 EP 1038 DI 10.1093/aje/kwp010 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 425KH UT WOS:000264634900014 PM 19251753 ER PT J AU Lott, JP Iwashyna, TJ Christie, JD Asch, DA Kramer, AA Kahn, JM AF Lott, Jason P. Iwashyna, Theodore J. Christie, Jason D. Asch, David A. Kramer, Andrew A. Kahn, Jeremy M. TI Critical Illness Outcomes in Specialty versus General Intensive Care Units SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE critical care; health services; organization; intensive care unit; hospital mortality ID EVALUATION APACHE IV; EMERGENCY-DEPARTMENT; ILL PATIENTS; MECHANICAL VENTILATION; PATIENT OUTCOMES; BURNOUT SYNDROME; ACUTE PHYSIOLOGY; IMPACT; SERVICES; STATES AB Rationale: General intensive care units (ICUs) provide care across a wide range of diagnoses, whereas specialty ICUs provide diagnosis-specific care. Risk-adjusted outcome differences across such units are unknown. Objectives: To determine the association between specialty ICU care and the outcome of critical illness. Methods: We conducted a retrospective cohort study design analyzing patients admitted to 124 ICUs participating in the Acute Physiology and Chronic Health Evaluation IV from January 2002 to December 2005. We examined 84,182 patients admitted to specialty and general ICUs with an admitting diagnosis or procedure of acute coronary syndrome, ischemic stroke, intracranial hemorrhage, pneumonia, abdominal surgery, or coronary-artery bypass graft surgery. ICU type determined by a local data coordinator at each site. Patients were classified by admission to a general ICU, a diagnosis-appropriate ("ideal") specialty ICU, or a diagnosis-inappropriate ("non-ideal") specialty ICU. The primary outcomes were in-hospital mortality and ICU length of stay. Measurements and Main Results: After adjusting for important con-founders, there were no significant differences in risk-adjusted mortality between general versus ideal specialty ICUs for all conditions other than pneumonia. Risk-adjusted mortality was significantly greater for patients admitted to non-ideal specialty ICUs. There was no consistent effect of specialization on length of stay for all patients or for ICU survivors. Conclusions: Ideal specialty ICU care appears to offer no survival benefit over general ICU care for select common diagnoses. Non-ideal specialty ICU care (i.e., "boarding") is associated with increased risk-adjusted mortality. C1 [Christie, Jason D.; Kahn, Jeremy M.] Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Christie, Jason D.; Kahn, Jeremy M.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Iwashyna, Theodore J.] Univ Michigan, Sch Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA. [Iwashyna, Theodore J.; Asch, David A.; Kahn, Jeremy M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Kramer, Andrew A.] Cerner Corp, Vienna, VA USA. RP Kahn, JM (reprint author), Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, 723 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jmkahn@mail.med.upenn.edu OI Kramer, Andrew/0000-0002-5681-5781; Asch, David/0000-0002-7970-286X; Lott, Jason/0000-0002-4097-7225; Iwashyna, Theodore/0000-0002-4226-9310 NR 38 TC 40 Z9 41 U1 0 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 15 PY 2009 VL 179 IS 8 BP 676 EP 683 DI 10.1164/rccm.200808-1281OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 434BZ UT WOS:000265251500008 PM 19201923 ER PT J AU Taylor, WJ Shewchuk, R Saag, KG Schumacher, HR Singh, JA Grainger, R Edwards, NL Bardin, T Waltrip, RW Simon, LS Burgos-Vargas, R AF Taylor, W. J. Shewchuk, R. Saag, K. G. Schumacher, H. R., Jr. Singh, J. A. Grainger, R. Edwards, N. L. Bardin, T. Waltrip, R. W. Simon, L. S. Burgos-Vargas, R. TI Toward a Valid Definition of Gout Flare: Results of Consensus Exercises Using Delphi Methodology and Cognitive Mapping SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article ID CONTROLLED-TRIAL; TRIAMCINOLONE ACETONIDE; DOUBLE-BLIND; ARTHRITIS; INDOMETHACIN; ATTACKS; ETORICOXIB; HYPERURICEMIA; EFFICACY; THERAPY AB Objective. To identify, in people known to have gout, the testable, key components of a standard definition of gout flare for use in clinical research. Methods. Consensus methodology was used to identify key elements of a gout flare. Two Delphi exercises were conducted among different groups of rheumatologists. A cognitive mapping technique among 9 gout experts with hierarchical cluster analysis provided a framework to guide the panel discussion, which identified the final set of items that should be tested empirically. Results. From the Delphi exercises, 21 items were presented to the expert panel. Cluster analysis and multidimensional scaling showed that: these items clustered into 5 concepts (joint inflammation, severity of symptoms, stereotypical nature, pain, and gout archetype) distributed along 2 dimensions (objective to subjective features and general features to specific features of gout). Using this analysis, expert panel discussion generated a short list of potential features: joint swelling, joint tenderness, joint warmth, severity of pain, patient global assessment, time to maximum pain, time to complete resolution of pain, an acute-phase marker, and functional impact of the episode. Conclusion. A short list of features has been identified and now requires validation against a patient and physician-defined gout flare in order to determine the best combination of features. C1 [Taylor, W. J.] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Med, Wellington 6242, New Zealand. [Taylor, W. J.; Grainger, R.] Hutt Valley Dist Hlth Board, Wellington Reg Rheumatol Unit, Wellington, New Zealand. [Shewchuk, R.] Univ Alabama, Birmingham, AL USA. [Schumacher, H. R., Jr.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Schumacher, H. R., Jr.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Singh, J. A.] Univ Minnesota, Minneapolis, MN USA. [Singh, J. A.] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Grainger, R.] Malaghan Inst Med Res, Wellington, New Zealand. [Edwards, N. L.] Univ Florida, Gainesville, FL USA. [Bardin, T.] Hop Lariboisiere, F-75475 Paris, France. [Waltrip, R. W.] Savient Pharmaceut, E Brunswick, NJ USA. [Simon, L. S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Burgos-Vargas, R.] Univ Nacl Autonoma Mexico, Hosp Gen Mexico, Mexico City 04510, DF, Mexico. RP Taylor, WJ (reprint author), Univ Otago, Wellington Sch Med & Hlth Sci, Dept Med, POB 7343, Wellington 6242, New Zealand. EM will.taylor@otago.ac.nz RI Grainger, Rebecca/I-1866-2012 OI singh, jasvinder/0000-0003-3485-0006 FU American College of Rheumatology/European League Against Rheumatism; TAP; Savient FX Supported in part by an American College of Rheumatology/European League Against Rheumatism grant. Dr. Singh is recipient of investigator-initiated research grants from TAP and Savient for a different project. NR 25 TC 14 Z9 14 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD APR 15 PY 2009 VL 61 IS 4 BP 535 EP 543 DI 10.1002/art.24166 PG 9 WC Rheumatology SC Rheumatology GA 431AL UT WOS:000265033600018 PM 19333981 ER PT J AU New, AS Hazlett, E aan het Rot, M Liu, X Lazarus, S Goodman, M Zipursky, E Koenigsberg, HW Siever, LJ AF New, Antonia S. Hazlett, Erin aan het Rot, Marije Liu, Xun Lazarus, Sophie Goodman, Marianne Zipursky, Emma Koenigsberg, Harold W. Siever, Larry J. TI The Neuroscience of Alexithymia in Borderline Personality Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 64th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 14-16, 2009 CL Vancouver, CANADA SP Soc Biol Psychiat C1 [New, Antonia S.; Hazlett, Erin; aan het Rot, Marije; Liu, Xun; Lazarus, Sophie; Goodman, Marianne; Zipursky, Emma; Koenigsberg, Harold W.; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA. [New, Antonia S.; Goodman, Marianne; Koenigsberg, Harold W.] James J Peters VA Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. RI Liu, Xun/C-2400-2009 OI Liu, Xun/0000-0003-1366-8926 NR 0 TC 0 Z9 0 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 MA 13 BP 4S EP 4S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 432OS UT WOS:000265144200014 ER PT J AU Mathalon, DH Ford, JM Guglielmino, R Roach, BJ Gueorguieva, R Clapp, WC Teyler, TJ Cavus, I AF Mathalon, Daniel H. Ford, Judith M. Guglielmino, Robert Roach, Brian J. Gueorguieva, Ralitza Clapp, Wesley C. Teyler, Timothy J. Cavus, Idil TI Long-Term Potentiation of Visual Evoked Potentials is Impaired in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 64th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 14-16, 2009 CL Vancouver, CANADA SP Soc Biol Psychiat C1 [Mathalon, Daniel H.; Ford, Judith M.; Roach, Brian J.; Gueorguieva, Ralitza] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Ford, Judith M.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Guglielmino, Robert; Clapp, Wesley C.; Cavus, Idil] Yale Univ, New Haven, CT USA. [Roach, Brian J.] No Calif Inst Res & Educ, San Francisco, CA USA. [Teyler, Timothy J.] Univ Idaho, Moscow, ID 83843 USA. [Teyler, Timothy J.] Washington State Univ, Vcapp, Pullman, WA 99164 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 MA 41 BP 13S EP 13S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 432OS UT WOS:000265144200036 ER PT J AU Wynn, JK Crosby, S Nori, P Green, MF AF Wynn, Jonathan K. Crosby, Shelly Nori, Poorang Green, Michael F. TI Association Between Mismatch Negativity Deficits, Social Cognition and Functional Outcome in Schizoprhenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 64th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 14-16, 2009 CL Vancouver, CANADA SP Soc Biol Psychiat C1 [Wynn, Jonathan K.] VA Greater Los Angeles Healthcare Syst, Res & Dev, Los Angeles, CA USA. [Crosby, Shelly; Nori, Poorang; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 MA 176 BP 54S EP 54S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 432OS UT WOS:000265144200171 ER PT J AU Yao, J Dougherty, GG Keshavan, MS Montrose, DM Matson, WR McEvoy, J Kaddurah-Daouk, R Condray, R Reddy, RD AF Yao, Jeffrey Dougherty, George G. Keshavan, Matched S. Montrose, Debra M. Matson, Wayne R. McEvoy, Joseph Kaddurah-Daouk, Rima Condray, Ruth Reddy, Ravinder D. TI Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naive Patients with Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 64th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 14-16, 2009 CL Vancouver, CANADA SP Soc Biol Psychiat C1 [Yao, Jeffrey; Dougherty, George G.; Condray, Ruth] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey; Dougherty, George G.; Keshavan, Matched S.; Montrose, Debra M.; Condray, Ruth; Reddy, Ravinder D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Keshavan, Matched S.] Wayne State Univ, Dept Psychiat, Detroit, MI USA. [Matson, Wayne R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA. [McEvoy, Joseph; Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 MA 211 BP 65S EP 65S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 432OS UT WOS:000265144200205 ER PT J AU Koenigsberg, HW AF Koenigsberg, Harold W. TI Neural Network Sensitization and Habituation and Emotional Reactivity in Borderline and Avoidant Personality Disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 64th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 14-16, 2009 CL Vancouver, CANADA SP Soc Biol Psychiat C1 [Koenigsberg, Harold W.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Koenigsberg, Harold W.] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 MA 347 BP 104S EP 104S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 432OS UT WOS:000265144200336 ER PT J AU Vinogradov, S Deicken, R Ellman, LM Kern, DM Genevsky, A Poole, JH Kremen, W Schaefer, C Brown, AS AF Vinogradov, Sophia Deicken, Ray Ellman, Lauren M. Kern, David M. Genevsky, Alex Poole, John H. Kremen, William Schaefer, Catherine Brown, Alan S. TI The Interaction of Fetal Hypoxia and Prenatal infection in Schizophrenia: Investigating Effects of Concomitant Obstetric Complications SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 64th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 14-16, 2009 CL Vancouver, CANADA SP Soc Biol Psychiat C1 [Vinogradov, Sophia; Deicken, Ray] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ellman, Lauren M.; Kern, David M.; Brown, Alan S.] Columbia Univ, New York, NY USA. [Genevsky, Alex] San Francisco VA Med Ctr, San Francisco, CA USA. [Poole, John H.] Palo Alto VA, Palo Alto, CA USA. [Kremen, William] Univ Calif San Diego, San Diego, CA 92103 USA. [Kremen, William] Kaiser Permanente, Div Res, Res, Oakland, CA USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 SU S MA 629 BP 191S EP 192S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 432OS UT WOS:000265144200608 ER PT J AU Vinogradov, S Deicken, R Ellman, LM Kern, DM Cook, CL Poole, JH Kremen, W Schaefer, C Brown, AS AF Vinogradov, Sophia Deicken, Ray Ellman, Lauren M. Kern, David M. Cook, Colleen L. Poole, John H. Kremen, William Schaefer, Catherine Brown, Alan S. TI Fetal Hypoxia and Schizophrenia: A Longitudinal Case-Control Study of Cognitive and Brain Volumetric Outcomes SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 64th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 14-16, 2009 CL Vancouver, CANADA SP Soc Biol Psychiat C1 [Vinogradov, Sophia; Deicken, Ray] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ellman, Lauren M.; Kern, David M.; Brown, Alan S.] Columbia Univ, New York, NY USA. [Cook, Colleen L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Poole, John H.] Palo Alto VA, Palo Alto, CA USA. [Kremen, William] Univ Calif San Diego, San Diego, CA 92103 USA. [Schaefer, Catherine] Kaiser Permanente, Div Res, Res, Oakland, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 SU S MA 628 BP 191S EP 191S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 432OS UT WOS:000265144200607 ER PT J AU Crabbe, JC Metten, P Rhodes, JS Yu, CH Brown, LL Phillips, TJ Finn, DA AF Crabbe, John C. Metten, Pamela Rhodes, Justin S. Yu, Chia-Hua Brown, Lauren Lyon Phillips, Tamara J. Finn, Deborah A. TI A Line of Mice Selected for High Blood Ethanol Concentrations Shows Drinking in the Dark to Intoxication SO BIOLOGICAL PSYCHIATRY LA English DT Article DE DID; ethanol consumption; genetic animal models; HDID; intoxication; mouse; pharmacogenetics; selective breeding ID VOLUNTARY ALCOHOL-CONSUMPTION; C57BL/6J MICE; STRAIN DIFFERENCES; SCHEDULED ACCESS; LATERAL SEPTUM; ANIMAL-MODELS; GENETICS; RAT; SUSCEPTIBILITY; PERCEPTION AB Background: Many animal models of alcoholism have targeted aspects of excessive alcohol intake (abuse) and dependence. In the rodent, models aimed at increasing alcohol self-ad ministration have used genetic or environmental manipulations, or their combination. Strictly genetic manipulations (e.g., comparison of inbred strains or targeted mutants, selective breeding) have not yielded rat or mouse genotypes that will regularly and voluntarily drink alcohol to the point of intoxication. Although some behavioral manipulations (e.g., scheduling or limiting access to alcohol, adding a sweetener)will induce mice or rats to drink enough alcohol to become intoxicated, these typically require significant food or water restriction or a long time to develop. We report progress toward the development of a new genetic animal model for high levels of alcohol drinking. Methods: High Drinking in the Dark (HDID-1) mice have been selectively bred for high blood ethanol concentrations (BEC, ideally exceeding 100 mg%) resulting from the ingestion of a 20% alcohol solution. Results: After 11 generations of selection, more than 56% of the population now exceeds this BEC after a 4-hour drinking session in which a single bottle containing 20% ethanol is available. The dose of ethanol consumed also produced quantifiable signs of intoxication. Conclusions: These mice will be useful for mechanistic studies of the biological and genetic contributions to excessive drinking. C1 [Crabbe, John C.; Metten, Pamela; Yu, Chia-Hua; Brown, Lauren Lyon; Phillips, Tamara J.; Finn, Deborah A.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland, OR 97201 USA. [Crabbe, John C.; Metten, Pamela; Yu, Chia-Hua; Brown, Lauren Lyon; Phillips, Tamara J.; Finn, Deborah A.] VA Med Ctr, Portland, OR USA. [Rhodes, Justin S.] Univ Illinois, Beckman Inst, Dept Psychol, Urbana, IL USA. RP Crabbe, JC (reprint author), Portland VA Med Ctr, R&D 12,3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM crabbe@ohsu.edu FU National Institutes of Health and by the Department of Veterans Affairs [AA010760, AA013478, AA013519] FX These studies were conducted as part of the Integrative Neuroscience Initiative on Alcoholism of the National Institute on Alcohol Abuse and Alcoholism and were supported by Grant Nos. AA010760, AA013478, and AA013519 from the National Institutes of Health and by the Department of Veterans Affairs. We thank Andy Jade Cameron, Alex Henry, Katie Mordarski, Jason Schlumbohm, Michelle Sorensen, and Stephanie Spence for expert technical assistance. NR 36 TC 70 Z9 70 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2009 VL 65 IS 8 BP 662 EP 670 DI 10.1016/j.biopsych.2008.11.002 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 428OG UT WOS:000264857400005 PM 19095222 ER PT J AU Ohashi, E Kogai, T Kagechika, H Brent, GA AF Ohashi, Emi Kogai, Takahiko Kagechika, Hiroyuki Brent, Gregory A. TI Activation of the PI3 Kinase Pathway By Retinoic Acid Mediates Sodium/Iodide Symporter Induction and Iodide Transport in MCF-7 Breast Cancer Cells SO CANCER RESEARCH LA English DT Article ID RADIOIODIDE UPTAKE; NONGENOMIC ACTIONS; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; GENE-EXPRESSION; PROTEIN; NUCLEAR; DIFFERENTIATION; 3-KINASE; TARGET AB Iodide uptake in the thyroid and breast is mediated by the sodium/iodide symporter (NIS). NIS activation is used for radioiodide imaging and therapeutic ablation of thyroid carcinoma. NIS is expressed in >70% of breast cancers but at a level insufficient for radioiodine treatment. All-traps retinoic acid (tRA) induces NIS gene expression and functional iodide uptake in human breast cancer cell lines and mouse breast cancer models. tRA usually regulates gene expression by direct interaction of RA receptor (RAR) with a target gene, but it can also act through nongenomic pathways. We report a direct influence of tRA treatment on the phosphoinositide 3-kinase (PI3K) signal transduction pathway that mediates tRA-induced NIS expression in MCF-7 breast cancer cells. MCF-7 cells express all three RAR isoforms, alpha, beta, and gamma, and RXR alpha. We previously identified RAR beta and RXR alpha as important for NIS induction by tRA. Treatment with LY294002, the PI3K inhibitor, or p85 alpha knockdown with siRNA abolished tRA-induced NIS expression. Immunoprecipitation experiments and glutathione S-transferase pull-down assay showed a direct interaction between RAR beta 2, RXR alpha, and p85 alpha. RA also induced rapid activation of Akt in MCF-7 cells. Treatment with an Akt inhibitor or Akt knockdown with siRNA reduced NIS expression. These findings indicate that RA induction of NIS in MCF-7 cells is mediated, by rapid activation of the PI3K pathway and involves direct interaction with RAR and retinoid X receptor. Defining these mechanisms should lead to methods to further enhance NIS expression, as well as retinoid targets that influence growth and differentiation of breast cancer. [Cancer Res 2009;69(8):3443-50] C1 [Ohashi, Emi; Kogai, Takahiko; Brent, Gregory A.] Univ Calif Los Angeles, Mol Endocrinol Lab, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Dept Med, Los Angeles, CA 90073 USA. [Ohashi, Emi; Kogai, Takahiko; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Kagechika, Hiroyuki] Tokyo Med & Dent Univ, Sch Biomed Sci, Chiyoda Ku, Tokyo, Japan. RP Brent, GA (reprint author), Univ Calif Los Angeles, Mol Endocrinol Lab, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Dept Med, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu FU NIH [RO1 CA089364] FX Grant support: NIH RO1 CA089364 (GA Brent). NR 37 TC 32 Z9 34 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2009 VL 69 IS 8 BP 3443 EP 3450 DI 10.1158/0008-5472.CAN-08-3234 PG 8 WC Oncology SC Oncology GA 435AF UT WOS:000265314900028 PM 19351850 ER PT J AU Kahn, SE AF Kahn, Steven E. TI Glucose Control in Type 2 Diabetes Still Worthwhile and Worth Pursuing SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID CARDIOVASCULAR-DISEASE; AUTONOMIC NEUROPATHY; COMPLICATIONS; MELLITUS; HYPOGLYCEMIA; OUTCOMES C1 [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 NR 15 TC 9 Z9 9 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 15 PY 2009 VL 301 IS 15 BP 1590 EP 1592 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 432MH UT WOS:000265137900031 PM 19366780 ER PT J AU Castriotta, RJ Atanasov, S Wilde, MC Masel, BE Lai, JM Kuna, ST AF Castriotta, Richard J. Atanasov, Strahil Wilde, Mark C. Masel, Brent E. Lai, Jenny M. Kuna, Samuel T. TI Treatment of Sleep Disorders after Traumatic Brain Injury SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Trauma; brain injury; hypersomnia; sleep apnea; narcolepsy; sleep disorders; MSLT; continuous positive airway pressure ID EXCESSIVE DAYTIME SLEEPINESS; POSITIVE AIRWAY PRESSURE; APNEA-HYPOPNEA SYNDROME; MILD HEAD-INJURY; QUALITY-OF-LIFE; CPAP TREATMENT; RESIDUAL SLEEPINESS; DOUBLE-BLIND; MODAFINIL; PLACEBO AB Study Objectives: Determine whether treatment of sleep disorders identified in brain injured adults would result in resolution of those sleep disorders and improvement of symptoms and daytime function. Methods: Prospective evaluation of unselected traumatic brain injury patients with nocturnal polysomnography (NPSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS), and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ) before and after treatment with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA), modafinil (200 mg) for narcolepsy and posttraumatic hypersomnia (PTH), or pramipexole (0.375 mg) for periodic limb movements in sleep (PLMS). Setting: Three academic medical centers. Participants: Fifty-seven (57) adults >= 3 months post traumatic brain injury (TBI). Measurements And Results: Abnormal sleep studies were found in 22 subjects (39%), of whom 13 (23%) had OSA, 2 (3%) had PTH, 3 (5%) had narcolepsy, 4 (7%) had PLMS, and 12 had objective excessive daytime sleepiness with MSLT score < 10 minutes. Apneas, hypopneas, and snoring were eliminated by CPAP in OSA subjects, but there was no significant change in MSLT scores. Periodic limb movements were eliminated with pramipexole. One of 3 narcolepsy subjects and 1 of 2 PTH subjects had resolution of hypersomnia with modafinil. There was no significant change in FOSQ, POMS, or PVT results after treatment. Conclusions: Treatment of sleep disorders after TBI may result in polysomnographic resolution without change in sleepiness or neuropsychological function. C1 [Castriotta, Richard J.] Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, Houston, TX 77030 USA. [Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.] Mem Hermann Hosp Sleep Disorders Ctr, Houston, TX USA. [Atanasov, Strahil] Univ Texas Med Branch Galveston, Galveston, TX USA. [Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA. [Kuna, Samuel T.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Castriotta, RJ (reprint author), Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, 6431 Fannin St,MSB 1-274, Houston, TX 77030 USA. EM Richard.J.Castriotta@uth.tmc.edu RI Sanguansri, Luz/B-6630-2011 OI Sanguansri, Luz/0000-0003-1908-7604; Castriotta, Richard/0000-0003-3502-4558 NR 48 TC 40 Z9 40 U1 0 U2 7 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PD APR 15 PY 2009 VL 5 IS 2 BP 137 EP 144 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 499YN UT WOS:000270262900009 PM 19968047 ER PT J AU Ford, AC Chey, WD Talley, NJ Malhotra, A Spiegel, BMR Moayyedi, P AF Ford, Alexander C. Chey, William D. Talley, Nicholas J. Malhotra, Ashish Spiegel, Brennan M. R. Moayyedi, Paul TI Yield of Diagnostic Tests for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome Systematic Review and Meta-analysis SO ARCHIVES OF INTERNAL MEDICINE LA English DT Review ID ROME-II CRITERIA; COST-EFFECTIVENESS ANALYSIS; POPULATION-BASED COHORT; HEALTH-CARE SEEKING; GLUTEN-FREE DIET; GENERAL-POPULATION; SECONDARY CARE; PREVALENCE; DYSPEPSIA; RISK AB Background: Individuals with irritable bowel syndrome (IBS) report abdominal pain, bloating, and diarrhea, symptoms similar to those in celiac disease. Studies suggest that the prevalence of celiac disease is increased in individuals with IBS; however, evidence is conflicting, and current guidelines do not always recommend screening for celiac disease in these individuals. Methods: We conducted a systematic review and meta-analysis to estimate prevalence of celiac disease in unselected adults who met diagnostic criteria for IBS. MEDLINE (1950 to May 31, 2008) and EMBASE (1980 to May 31, 2008) were searched. Case series and case-control studies that used serologic tests for celiac disease were eligible for inclusion. Prevalence of positive serologic indications of celiac disease and biopsy-proved celiac disease were extracted and pooled for all studies and were compared between cases and controls using an odds ratio and 95% confidence interval. Results: Fourteen studies were identified comprising 4204 individuals, of whom 2278 (54%) met diagnostic criteria for IBS. Pooled prevalence of positive IgA-class antigliadin antibodies, either positive endomysial antibodies or tissue transglutaminase, and biopsy-proved celiac disease were 4.0% (95% confidence interval, 1.7-7.2), 1.63% (0.7-3.0), and 4.1% (1.9-7.0), respectively. Pooled odds ratios (95% confidence intervals) for positive IgA-class antigliadin antibodies, either positive endomysial antibodies or tissue transglutaminase, and biopsy-proved celiac disease in cases meeting diagnostic criteria for IBS compared with controls without IBS were 3.40 (1.62-7.13), 2.94 (1.36-6.35), and 4.34 (1.78-10.6). Conclusion: Prevalence of biopsy-proved celiac disease in cases meeting diagnostic criteria for IBS was more than 4-fold that in controls without IBS. C1 [Ford, Alexander C.; Moayyedi, Paul] McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada. [Chey, William D.] Univ Michigan, Med Ctr, Dept Med, Div Gastroenterol, Ann Arbor, MI 48109 USA. [Talley, Nicholas J.] Mayo Clin Florida, Dept Med, Jacksonville, FL USA. [Malhotra, Ashish] Mayo Clin Rochester, Div Gastroenterol & Hepatol, Rochester, MN USA. [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Sch Publ Hlth, VA Ctr Outcomes Res & Educ, Los Angeles, CA 90095 USA. RP Ford, AC (reprint author), McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada. EM alexf12399@yahoo.com RI Ford, Alexander/K-5491-2012; Talley, nicholas/D-5399-2013 OI Ford, Alexander/0000-0001-6371-4359; Talley, nicholas/0000-0003-2537-3092 FU American College of Gastroenterology FX This study was funded by the American College of Gastroenterology (Dr Moayyedi). NR 56 TC 126 Z9 129 U1 2 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 13 PY 2009 VL 169 IS 7 BP 651 EP 658 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 432AK UT WOS:000265105700002 PM 19364994 ER PT J AU Kalogeropoulos, A Georgiopoulou, V Kritchevsky, SB Psaty, BM Smith, NL Newman, AB Rodondi, N Satterfield, S Bauer, DC Bibbins-Domingo, K Smith, AL Wilson, PWF Vasan, RS Harris, TB Butler, J AF Kalogeropoulos, Andreas Georgiopoulou, Vasiliki Kritchevsky, Stephen B. Psaty, Bruce M. Smith, Nicholas L. Newman, Anne B. Rodondi, Nicolas Satterfield, Suzanne Bauer, Douglas C. Bibbins-Domingo, Kirsten Smith, Andrew L. Wilson, Peter W. F. Vasan, Ramachandran S. Harris, Tamara B. Butler, Javed TI Epidemiology of Incident Heart Failure in a Contemporary Elderly Cohort The Health, Aging, and Body Composition Study SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID RISK-FACTORS; SURVIVAL; POPULATION; PREVALENCE; PROGNOSIS; ASSOCIATION; COMMUNITY; TRENDS; ADULTS; DEATH AB Background: The race- and sex-specific epidemiology of incident heart failure (HF) among a contemporary elderly cohort are not well described. Methods: We studied 2934 participants without HF enrolled in the Health, Aging, and Body Composition Study (mean [SD] age, 73.6 [2.9] years; 47.9% men; 58.6% white; and 41.4% black) and assessed the incidence of HF, population-attributable risk (PAR) of independent risk factors for HF, and outcomes of incident HF. Results: During a median follow-up of 7.1 years, 258 participants (8.8%) developed HF (13.6 cases per 1000 person-years; 95% confidence interval, 12.1-15.4). Men and black participants were more likely to develop HF. No significant sex-based differences were observed in risk factors. Coronary heart disease (PAR, 23.9% for white participants and 29.5% for black participants) and uncontrolled blood pressure (PAR, 21.3% for white participants and 30.1% for black participants) carried the highest PAR in both races. Among black participants, 6 of 8 risk factors assessed (smoking, increased heart rate, coronary heart disease, left ventricular hypertrophy, uncontrolled blood pressure, and reduced glomerular filtration rate) had more than 5% higher PAR compared with that among white participants, leading to a higher overall proportion of HF attributable to modifiable risk factors in black participants vs white participants (67.8% vs 48.9%). Participants who developed HF had higher annual mortality (18.0% vs 2.7%). No racial difference in survival after HF was noted; however, rehospitalization rates were higher among black participants (62.1 vs 30.3 hospitalizations per 100 person-years, P <.001). Conclusions: Incident HF is common in older persons; a large proportion of HF risk is attributed to modifiable risk factors. Racial differences in risk factors for HF and in hospitalization rates after HF need to be considered in prevention and treatment efforts. C1 [Kalogeropoulos, Andreas; Georgiopoulou, Vasiliki; Smith, Nicholas L.; Wilson, Peter W. F.; Butler, Javed] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle VA Epidemiol Res & Informat Ctr, Seattle, WA USA. [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Rodondi, Nicolas] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland. [Satterfield, Suzanne] Univ Memphis, Dept Prevent Med, Memphis, TN 38152 USA. [Bauer, Douglas C.; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Vasan, Ramachandran S.] Boston Univ, Dept Med, Boston, MA 02215 USA. [Harris, Tamara B.] NIA, Geriatr Epidemiol Sect, NIH, Bethesda, MD 20892 USA. RP Butler, J (reprint author), Emory Univ, Emory Univ Hosp, Div Cardiol, 1365 Clifton Rd NE,Ste AT430, Atlanta, GA 30322 USA. EM javed.butler@emory.edu RI Kalogeropoulos, Andreas/A-9494-2009; Newman, Anne/C-6408-2013 OI Kalogeropoulos, Andreas/0000-0002-1284-429X; Newman, Anne/0000-0002-0106-1150; Ramachandran, Vasan/0000-0001-7357-5970 FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institutes of Health FX This study was supported in part by the Intramural Research Program of the National Institute on Aging and by grants N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 from the National Institute on Aging, National Institutes of Health. NR 36 TC 78 Z9 82 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 13 PY 2009 VL 169 IS 7 BP 708 EP 715 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 432AK UT WOS:000265105700010 PM 19365001 ER PT J AU Lohoff, FW Bloch, PJ Ferraro, TN Berrettini, WH Pettinati, HM Dackis, CA O'Brien, CP Kampman, KM Oslin, DW AF Lohoff, Falk W. Bloch, Paul J. Ferraro, Thomas N. Berrettini, Wade H. Pettinati, Helen M. Dackis, Charles A. O'Brien, Charles P. Kampman, Kyle M. Oslin, David W. TI Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence SO NEUROSCIENCE LETTERS LA English DT Article DE Addiction; Association study; Cocaine; Neurotrophic factor; Genetics; Substance abuse; ARMETL1 ID POPULATION-BASED SAMPLE; RECEPTOR GENE; TYROSINE-HYDROXYLASE; LINKAGE DISEQUILIBRIUM; AFRICAN-AMERICANS; ADMIXED POPULATIONS; ADMIXTURE DYNAMICS; GENOMIC CONTROL; DRUG-ADDICTION; NO ASSOCIATION AB Cocaine-induced neuroplasticity changes in the mesocorticolimbic dopamine systems are thought to be involved in the pathophysiology of cocaine dependence. Since neurotrophic factors have been observed to prevent/reverse and mimic cocaine-induced neurobiological changes in the brain, related genes are plausible candidates for susceptibility to cocaine dependence. The novel conserved dopamine neurotrophic factor protein (CDNF) promotes the survival, growth, and function of dopamine-specific neurons and is expressed in brain regions that undergo cocaine-induced neuroplasticity. In this study, we hypothesize that polymorphisms in the CDNF gene (CDNF/ARMETL1) contribute to increased risk for cocaine dependence. Cocaine dependent individuals (n = 351) and unaffected controls (n = 257) of African descent were ere genotyped for four single nucleotide polymorphisms (SNPs) in the CDNF gene (rs11259365, rs7094179, rs7900873. rs2278871). We observed no significant differences in allele, genotype, or haplotype frequencies between cases and controls for any of the tested SNPs. Our study suggests that there is no association between variants in the CDNF gene and cocaine dependence. However, additional studies using larger sample sizes, comprehensive SNP coverage, and clinically homogenous populations are necessary before confidently excluding CDNF as a significant genetic risk factor for cocaine dependence. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Lohoff, Falk W.] Univ Penn, Sch Med, Dept Psychiat, Ctr Neurobiol & Behav,Translat Res Labs, Philadelphia, PA 19104 USA. [Pettinati, Helen M.; Dackis, Charles A.; O'Brien, Charles P.; Kampman, Kyle M.; Oslin, David W.] Univ Penn, Sch Med, Dept Psychiat, Treatment Res Ctr, Philadelphia, PA 19104 USA. [Oslin, David W.] VISN 4 MIRECC, Vet Affairs Med Ctr, Philadelphia, PA USA. RP Lohoff, FW (reprint author), Univ Penn, Sch Med, Dept Psychiat, Ctr Neurobiol & Behav,Translat Res Labs, 125 S 31st St, Philadelphia, PA 19104 USA. EM lohoff@mail.med.upenn.edu RI Lohoff, Falk/M-7951-2016 FU Center for Neurobiology and Behavior; Department of Psychiatry, University of Pennsylvania; National Institutes of Health [K08MH080372]; NIDA [P60-051186]; Veterans Affairs Administration [P50-12756]; Tzedakah Foundation; Philip and Marcia Cohen FX This work was supported by the Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania. Financial support is gratefully acknowledged from National Institutes of Health grants K08MH080372 (F.W.L.), NIDA grants P60-051186 (C.P.O.) and P50-12756 (H.M.P), the VISN4 Mental Illness Research and Clinical Center grant from the Veterans Affairs Administration (D.W.O.), a grant from the Tzedakah Foundation (W.H.B.) and a grant from Philip and Marcia Cohen (W.H.B.). Most importantly, we thank the subjects who have participated in and contributed to these studies. NR 54 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD APR 10 PY 2009 VL 453 IS 3 BP 199 EP 203 DI 10.1016/j.neulet.2009.02.026 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 429UW UT WOS:000264946600016 PM 19429035 ER PT J AU Walter, LC Lindquist, K Nugent, S Schult, T Lee, SJ Casadei, MA Partin, MR AF Walter, Louise C. Lindquist, Karla Nugent, Sean Schult, Tammy Lee, Sei J. Casadei, Michele A. Partin, Melissa R. TI Impact of Age and Comorbidity on Colorectal Cancer Screening Among Older Veterans SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID FECAL-OCCULT-BLOOD; SERVICES TASK-FORCE; HEALTH-CARE-SYSTEM; PREVENTIVE SERVICES; MEDICARE BENEFICIARIES; ELDERLY-PATIENTS; UNITED-STATES; PROSTATE; AFFAIRS; QUALITY AB Background: The Veterans Health Administration, the American Cancer Society, and the American Geriatrics Society recommend colorectal cancer screening for older adults unless they are unlikely to live 5 years or have significant comorbidity that would preclude treatment. Objective: To determine whether colorectal cancer screening is targeted to healthy older patients and is avoided in older patients with severe comorbidity who have life expectancies of 5 years or less. Design: Cohort study. Setting: Veterans Affairs (VA) medical centers in Minneapolis, Minnesota; Durham, North Carolina; Portland, Oregon; and West Los Angeles, California, with linked national VA and Medicare administrative claims. Patients: 27 068 patients 70 years or older who had an outpatient visit at 1 of 4 VA medical centers in 2001 or 2002 and were due for screening. Measurements: The main outcome was receipt of fecal occult blood testing (FOBT), colonoscopy, sigmoidoscopy, or barium enema in 2001 or 2002, on the basis of national VA and Medicare claims. Charlson-Deyo comorbidity scores at the start of 2001 were used to stratify patients into 3 groups ranging from no comorbidity (score of 0) to severe comorbidity (score >= 4), and 5-year mortality was determined for each group. Results: 46% of patients were screened from 2001 through 2002. Only 47% of patients with no comorbidity were screened despite having life expectancies greater than 5 years (5-year mortality, 19%). Although the incidence of screening decreased with age and worsening comorbidity, it was still 41% for patients with severe comorbidity who had life expectancies less than 5 years (5-year mortality, 55%). The number of VA outpatient visits predicted screening independent of comorbidity, such that patients with severe comorbidity and 4 or more visits had screening rates similar to or higher than those of healthier patients with fewer visits. Limitations: Some tests may have been performed for nonscreening reasons. The generalizability of findings to persons who do not use the VA system is uncertain. Conclusion: Advancing age was inversely associated with colorectal cancer screening, whereas comorbidity was a weaker predictor. More attention to comorbidity is needed to better target screening to older patients with substantial life expectancies and avoid screening older patients with limited life expectancies. C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA. RP Walter, LC (reprint author), Vet Affairs Med Ctr 181G, 4150 Clement St, San Francisco, CA 94121 USA. EM louise.walter@ucsf.edu FU VA Health Services Research and Development [IIR-04-427]; Robert Wood Johnson Physician Faculty Scholar FX Grant Support: Dr. Walter is supported by VA Health Services Research and Development grant IIR-04-427 and is a Robert Wood Johnson Physician Faculty Scholar. Dr. Lee is a Hartford Geriatrics Health Outcomes Research Scholar. NR 54 TC 90 Z9 90 U1 2 U2 7 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 7 PY 2009 VL 150 IS 7 BP 465 EP + PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 432EZ UT WOS:000265117600004 PM 19349631 ER PT J AU Byne, W Hazlett, EA Buchsbaum, MS Kemether, E AF Byne, William Hazlett, Erin A. Buchsbaum, Monte S. Kemether, Eileen TI The thalamus and schizophrenia: current status of research SO ACTA NEUROPATHOLOGICA LA English DT Review DE Thalamus; Schizophrenia; Mediodorsal nucleus; Pulvinar; Anterior nucleus; Centromedian nucleus ID NEVER-MEDICATED SCHIZOPHRENICS; DOPAMINE-D-2 RECEPTOR-BINDING; LATERAL GENICULATE-NUCLEUS; POOR-OUTCOME SCHIZOPHRENIA; MEDIAL PREFRONTAL CORTEX; STROOP TASK-PERFORMANCE; VOXEL-BASED MORPHOMETRY; TOTAL NEURON NUMBER; ATAXIA TYPE-3 SCA3; MEDIODORSAL NUCLEUS AB The thalamus provides a nodal link for multiple functional circuits that are impaired in schizophrenia (SZ). Despite inconsistencies in the literature, a meta analysis suggests that the volume of the thalamus relative to that of the brain is decreased in SZ. Morphometric neuroimaging studies employing deformation, voxel-based and region of interest methodologies suggest that the volume deficit preferentially affects the thalamic regions containing the anterior and mediodorsal nuclei, and the pulvinar. Postmortem design-based stereological studies have produced mixed results regarding volume and neuronal deficits in these nuclei. This review examines those aspects of thalamic circuitry and function that suggest salience to SZ. Evidence for anomalies of thalamic structure and function obtained from postmortem and neuroimaging studies is then examined and directions for further research proposed. C1 [Byne, William] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. [Byne, William; Hazlett, Erin A.; Buchsbaum, Monte S.; Kemether, Eileen] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Byne, W (reprint author), James J Peters VA Med Ctr, Dept Psychiat, Res Bldg,Room 2F39, Bronx, NY 10468 USA. EM william.byne@mssm.edu FU veterans affairs VISN3 MI-RECC; VA merit award [MH66998, MH073911, MH60023]; Charles A. Dana Foundation ( FX Supported by the veterans affairs VISN3 MI-RECC, VA merit award (WB), MH66998 (WB), MH073911 (EAH), MH60023 (MSB) and a grant from the Charles A. Dana Foundation (MSB). NR 194 TC 83 Z9 85 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD APR PY 2009 VL 117 IS 4 BP 347 EP 368 DI 10.1007/s00401-008-0404-0 PG 22 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 418UF UT WOS:000264174200002 PM 18604544 ER PT J AU Smith, SM Gardner, KK Locke, J Zwart, SR AF Smith, Scott M. Gardner, Keri K. Locke, James Zwart, Sara R. TI Vitamin D supplementation during Antarctic winter SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID CELL-MEDIATED-IMMUNITY; SERUM-LEVELS; OLDER-ADULTS; D DEFICIENCY; 25-HYDROXYVITAMIN-D; DISEASE; OSTEOPOROSIS; POPULATION; PREVALENCE; WOMEN AB Background: Persons with limited exposure to ultraviolet B light, including space travelers, may not receive enough vitamin D. Recent studies indicate that optimal serum 25-hydroxyvitamin D [25(OH) D] should be >= 80 nmol/L. Objective: This study was designed to evaluate the effectiveness of 3 doses of vitamin D to raise and maintain 25(OH) D to a concentration.80 nmol/L in persons with limited ultraviolet B light exposure. Design: This was a 5-mo, prospective, randomized, double-blind study of vitamin D supplementation. It was conducted during winter in Antarctica at the McMurdo Station, when ultraviolet B radiation levels are essentially zero. The 55 subjects were randomly divided into 3 groups for vitamin D supplementation: 2000 IU/d (n = 18), 1000 IU/d (n = 19), and 400 IU/d (n = 18). An additional 7 subjects did not take supplements or took supplements of their own choosing. Blood samples were collected about every 2 mo during the winter. Results: About 5 mo after supplementation started, 25(OH)D increased to 71 +/- 23 nmol/L in the 2000-IU/d group, 63 +/- 25 nmol/L in the 1000-IU/d group, and 57 +/- 15 nmol/L in the 400-IU/d group and decreased to 34 +/- 12 nmol/L in the group not taking supplements. Conclusions: These data will enable us to provide space crews with evidence-based recommendations for vitamin D supplementation. The findings also have implications for other persons with limited ultraviolet light exposure, including polar workers and the elderly. Am J Clin Nutr 2009; 89:1092-8. C1 [Smith, Scott M.; Locke, James] NASA, Lyndon B Johnson Space Ctr, Space Life Sci Directorate, Houston, TX 77058 USA. [Gardner, Keri K.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Gardner, Keri K.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Zwart, Sara R.] Univ Space Res Assoc, Houston, TX USA. RP Smith, SM (reprint author), NASA, Lyndon B Johnson Space Ctr, Space Life Sci Directorate, Mail Code SK3,2101 NASA Pkwy, Houston, TX 77058 USA. EM scott.m.smith@nasa.gov FU NASA; National Science Foundation FX Supported by the NASA Human Research Program and made possible by the National Science Foundation. NR 46 TC 43 Z9 44 U1 0 U2 6 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD APR 1 PY 2009 VL 89 IS 4 BP 1092 EP 1098 DI 10.3945/ajcn.2008.27189 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 420WF UT WOS:000264319200016 PM 19225122 ER PT J AU Schnur, J Nguyen, S Divino, C Heimann, T Vidal, C AF Schnur, Jessica Nguyen, Scott Divino, Celia Heimann, Tomas Vidal, Claudia TI Coexisting Rectal and Urachal Carcinoma: A Case Report SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS LA English DT Article DE adenocarcinoma; rectal carcinoma; urachal carcinoma; urachus C1 [Schnur, Jessica; Nguyen, Scott; Divino, Celia; Heimann, Tomas; Vidal, Claudia] Mt Sinai Hosp, Dept Surg, New York, NY 10029 USA. [Schnur, Jessica; Nguyen, Scott; Divino, Celia; Heimann, Tomas; Vidal, Claudia] Mt Sinai Hosp, Dept Pathol, New York, NY 10029 USA. [Schnur, Jessica; Nguyen, Scott; Divino, Celia; Heimann, Tomas; Vidal, Claudia] Bronx Vet Affairs Med Ctr, Bronx, NY USA. RP Schnur, J (reprint author), Mt Sinai Hosp, Dept Surg, New York, NY 10029 USA. EM jessica.schnur@mssm.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-3732 J9 AM J CLIN ONCOL-CANC JI Am. J. Clin. Oncol.-Cancer Clin. Trials PD APR PY 2009 VL 32 IS 2 BP 220 EP 221 DI 10.1097/01.coc.0000230170.25322.cd PG 2 WC Oncology SC Oncology GA 431JF UT WOS:000265056900020 PM 19346817 ER PT J AU Satia, JA Littman, A Slatore, CG Galanko, JA White, E AF Satia, Jessie A. Littman, Alyson Slatore, Christopher G. Galanko, Joseph A. White, Emily TI Long-term Use of beta-Carotene, Retinol, Lycopene, and Lutein Supplements and Lung Cancer Risk: Results From the VITamins And Lifestyle (VITAL) Study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE beta carotene; carotenoids; cohort studies; dietary supplements; lung neoplasms; randomized controlled trials as topic; vitamins ID DIETARY CAROTENOIDS; WOMENS HEALTH; CARDIOVASCULAR-DISEASE; ALPHA-TOCOPHEROL; POOLED ANALYSIS; UNITED-STATES; COHORT; CONSUMPTION; NUTRITION; FRUIT AB High-dose beta-carotene supplementation in high-risk persons has been linked to increased lung cancer risk in clinical trials; whether effects are similar in the general population is unclear. The authors examined associations of supplemental beta-carotene, retinol, vitamin A, lutein, and lycopene with lung cancer risk among participants, aged 50-76 years, in the VITamins And Lifestyle (VITAL) cohort Study in Washington State. In 2000-2002, eligible persons (n = 77,126) completed a 24-page baseline questionnaire, including detailed questions about supplement use (duration, frequency, dose) during the previous 10 years from multivitamins and individual supplements/mixtures. Incident lung cancers (n = 521) through December 2005 were identified by linkage to the Surveillance, Epidemiology, and End Results cancer registry. Longer duration of use of individual beta-carotene, retinol, and lutein supplements (but not total 10-year average dose) was associated with statistically significantly elevated risk of total lung cancer and histologic cell types; for example, hazard ratio = 2.02, 95% confidence interval: 1.28, 3.17 for individual supplemental lutein with total lung cancer and hazard ratio = 3.22, 95% confidence interval: 1.29, 8.07 for individual beta-carotene with small-cell lung cancer for > 4 years versus no use. There was little evidence for effect modification by gender or smoking status. Long-term use of individual beta-carotene, retinol, and lutein supplements should not be recommended for lung cancer prevention, particularly among smokers. C1 [Satia, Jessie A.] Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA. [Satia, Jessie A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Satia, Jessie A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Satia, Jessie A.; Galanko, Joseph A.] Univ N Carolina, Div Digest Dis & Nutr, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA. [Littman, Alyson; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Littman, Alyson] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Slatore, Christopher G.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. RP Satia, JA (reprint author), Univ N Carolina, Dept Nutr, 2209 McGavran Greenberg Hall,CB 7461, Chapel Hill, NC 27599 USA. EM jsatia@unc.edu FU NCI NIH HHS [R03 CA119683, R03 CA119683-02] NR 41 TC 51 Z9 57 U1 0 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 1 PY 2009 VL 169 IS 7 BP 815 EP 828 DI 10.1093/aje/kwn409 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 421VX UT WOS:000264387500004 PM 19208726 ER PT J AU Singh, H Kadiyala, H Bhagwath, G Shethia, A El-Serag, H Walder, A Velez, ME Petersen, LA AF Singh, Hardeep Kadiyala, Himabindu Bhagwath, Gayathri Shethia, Anila El-Serag, Hashem Walder, Annette Velez, Maria E. Petersen, Laura A. TI Using a Multifaceted Approach to Improve the Follow-Up of Positive Fecal Occult Blood Test Results SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID COMPLETE DIAGNOSTIC EVALUATION; PRIMARY-CARE PHYSICIANS; ABNORMAL PAP-SMEARS; COLORECTAL-CANCER; PATIENT NAVIGATION; COLON EVALUATION; CONTROLLED-TRIAL; NATIONAL-SURVEY; TASK-FORCE; HEALTH AB OBJECTIVES : Inadequate follow-up of abnormal fecal occult blood test (FOBT) results occurs in several types of practice settings. Our institution implemented multifaceted quality improvement (QI) activities in 2004-2005 to improve follow-up of FOBT-positive results. Activities addressed precolonoscopy referral processes and system-level factors such as electronic communication, provider education, and feedback. We evaluated their effects on timeliness and appropriateness of positive-FOBT follow-up and identified factors that affect colonoscopy performance. METHODS: Retrospective electronic medical record review was used to determine outcomes before and after QI activities in a multispecialty ambulatory clinic of a tertiary care Veterans Affairs facility and its affiliated satellite clinics. From 1869 FOBT-positive cases, 800 were randomly selected from time periods before and after QI activities. Two reviewers used a pretested standardized data collection form to determine whether colonoscopy was appropriate or indicated based on predetermined criteria and if so, the timeliness of colonoscopy referral and performance before and after QI activities. RESULTS: In cases where a colonoscopy was indicated, the proportion of patients who received a timely colonoscopy referral and performance were significantly higher post-implementation (60.5% vs. 31.7%, P < 0.0001 and 11.4% vs. 3.4%, P = 0.0005). A significant decrease also resulted in median times to referral and performance (6 vs. 19 days, P < 0.0001 and 96.5 vs. 190 days, P < 0.0001) and in the proportion of positive-FOBT test results that had received no follow-up by the time of chart review (24.3% vs. 35.9%, P = 0.0045). Significant predictors of absence of the performance of an indicated colonoscopy included performance of a non-colonoscopy procedure such as barium enema or flexible sigmoidoscopy (OR = 16.9; 95% CI, 1.9-145.1), patient non-adherence (OR = 33.9; 95% CI, 17.3-66.6), not providing an appropriate provisional diagnosis on the consultation (OR = 17.9; 95% CI, 11.3-28.1), and gastroenterology service not rescheduling colonoscopies after an initial cancellation (OR = 11.0; 95% CI, 5.1-23.7). CONCLUSIONS: Multifaceted QI activities improved rates of timely colonoscopy referral and performance in an electronic medical record system. However, colonoscopy was not indicated in over one third of patients with positive FOBTs, raising concerns about current screening practices and the appropriate denominator used for performance measurement standards related to colon cancer screening. C1 [Singh, Hardeep; Petersen, Laura A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy & Qual Program, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. [Singh, Hardeep; Shethia, Anila; El-Serag, Hashem; Walder, Annette; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Singh, Hardeep; Petersen, Laura A.] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Kadiyala, Himabindu; Bhagwath, Gayathri] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Gen Med, Dept Med, Houston, TX 77030 USA. [El-Serag, Hashem; Velez, Maria E.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.tmc.edu FU NIH K23 career development award [K23CA125585]; Houston VA HSR&D Center of Excellence [HFP90-020]; Michael E. DeBakey Veterans Affairs Medical Center FX The study was supported by an NIH K23 career development award (K23CA125585) to Dr Singh, and in part by the Houston VA HSR&D Center of Excellence (HFP90-020) and the Michael E. DeBakey Veterans Affairs Medical Center. These sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manusc ript. NR 62 TC 32 Z9 32 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2009 VL 104 IS 4 BP 942 EP 952 DI 10.1038/ajg.2009.55 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 431AR UT WOS:000265034200023 PM 19293786 ER PT J AU Tabrizian, P Newell, P Reiter, BP Heimann, TM AF Tabrizian, Parissa Newell, Pippa Reiter, Bruce P. Heimann, Tomas M. TI Successful Multimodality Treatment for Hemosuccus Pancreaticus SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID GASTROINTESTINAL HEMORRHAGE; PSEUDOANEURYSMS; PSEUDOCYSTS; MANAGEMENT; DUCT C1 [Tabrizian, Parissa; Newell, Pippa; Heimann, Tomas M.] Mt Sinai Sch Med, Dept Surg, New York, NY 10029 USA. [Reiter, Bruce P.] James J Peters VA Med Ctr, Dept Radiol, New York, NY USA. RP Tabrizian, P (reprint author), Mt Sinai Sch Med, Dept Surg, 5 E 98th St,15th Floor, New York, NY 10029 USA. EM ptabrizian@hotmail.com NR 7 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2009 VL 104 IS 4 BP 1060 EP 1061 DI 10.1038/ajg.2009.33 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 431AR UT WOS:000265034200045 PM 19277028 ER PT J AU Federman, AD Safran, DG Keyhani, S Cole, H Halm, EA Siu, AL AF Federman, Alex D. Safran, Dana Gelb Keyhani, Salomeh Cole, Helen Halm, Ethan A. Siu, Albert L. TI Awareness of Pharmaceutical Cost-Assistance Programs Among Inner-City Seniors SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Article DE seniors; low income; pharmaceutical cost-assistance programs ID HEALTH LITERACY; MEDICARE; CARE; ASSOCIATION; OUTCOMES; BENEFIT; DISEASE; ACCESS; IMPACT AB Background: Lack of awareness may be a significant barrier to participation by low- and middle-income seniors in pharmaceutical cost-assistance programs. Objective: The goal Of this study was to determine whether older adults' awareness of 2 major state and federal pharmaceutical cost-assistance programs was associated with the seniors' ability to access and process information about assistance programs. Methods: Data were gathered from a cross-sectional study of independently living, English- or Spanish-speaking adults aged >= 60 years. Participants were interviewed in 30 community-based settings (19 apartment complexes and 11 senior centers) in New York, New York. The analysis focused on adults aged >= 65 years who lacked Medicaid coverage. multivariable logistic regression was used to model program awareness as a function of information access (family/social support, attendance at senior or community centers and places of worship, viewing of live health insurance presentations, instrumental activities of daily living, site of medical care, computer use, and having a proxy decision maker for health insurance matters) and information-processing ability (education level, English proficiency, health literacy, and cognitive function). The main outcome measure was awareness of New York's state pharmaceutical assistance program (Elderly Pharmaceutical Insurance Coverage [EPIC]) and the federal Medicare Part D low-income subsidy program (Extra Help). Results: A total of 269 patients were enrolled (mean [SD] age, 76.9 [7.5] years; 32.0% male; 39.9% white). Awareness of the programs differed widely: 77.3% knew of EPIC and 22.3% knew of Extra Help. In multivariable analysis, study participants were more likely to have heard of the EPIC program if they had attended a live presentation about health Insurance issues (adjusted odds ratio [AOR], 3.40; 95% CI, 1.20-9.61) and less likely if they received care in a clinic (AOR, 0.45; 95% CI, 0.23-0.92). Awareness of Extra Help in the multivariable models was more likely among Study participants who had viewed a live health insurance presentation (AOR, 3.35; 95% CI, 1.55-7.24) and less likely for those with inadequate health literacy (AOR, 0.15; 95% CI, 0.03-0.74). Conclusions: Viewing of live health insurance presentations and adequate health literacy were associated with greater awareness of important pharmaceutical cost-assistance programs in this study, in low-income, elderly individuals. The findings Suggest that use of live presentations, in addition to health literacy materials and messages, may be important strategies in promoting knowledge of and enrollment in state and federal pharmaceutical cost-assistance programs for low-income seniors. (Am J Geriatr Pharmacother. 2009;7:117-129) (C) 2009 Excerpta Medica Inc. C1 [Federman, Alex D.; Cole, Helen] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. [Safran, Dana Gelb] Tufts Univ New England Med Ctr, Hlth Inst, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Safran, Dana Gelb] Blue Cross & Blue Shield Massachusetts, Boston, MA USA. [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA. [Keyhani, Salomeh; Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA. [Siu, Albert L.] Bronx Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Siu, Albert L.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. RP Federman, AD (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, 1 Gustave L Levy Pl,Box 1087, New York, NY 10029 USA. EM alex.federman@mssm.edu FU National Institute on Aging [1K23AG028955-01]; VA Health Services Research and Development Service; Mount Sinai School of Medicine Alzheimer's Disease Research Center [NIH AG0051318] FX The authors thank Paul Hebert, PhD, for technical assistance with statistical procedures. NR 45 TC 2 Z9 2 U1 2 U2 8 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD APR PY 2009 VL 7 IS 2 BP 117 EP 129 DI 10.1016/j.amjopharm.2009.04.003 PG 13 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 440XY UT WOS:000265734200006 PM 19447364 ER PT J AU Ettenhofer, ML Hinkin, CH Castellon, SA Durvasula, R Ullman, J Lam, M Myers, H Wright, MJ Foley, J AF Ettenhofer, Mark L. Hinkin, Charles H. Castellon, Steven A. Durvasula, Ramani Ullman, Jodi Lam, Mona Myers, Hector Wright, Matthew J. Foley, Jessica TI Aging, Neurocognition, and Medication Adherence in HIV Infection SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the International-Neuropsychological-Society CY FEB 06-09, 2008 CL Waikoloa, HI SP Int Neuropsychol Soc DE HIV; AIDS; aging; cognition; medication adherence; executive functions ID ACTIVE ANTIRETROVIRAL THERAPY; MULTICENTER AIDS COHORT; NEUROPSYCHOLOGICAL PERFORMANCE; AGE; DEMENTIA; DISEASE; ADULTS; METAANALYSIS; ZIDOVUDINE; DISORDERS AB Objective: To evaluate the hypothesis that poor adherence to highly active antiretroviral treatment (HAART) would be more strongly related to cognitive impairment among older than among younger HIV-seropositive adults. Setting and Participants: A volunteer sample of 431 HIV-infected adult patients prescribed self-administered HAART was recruited from community agencies and university-affiliated infectious disease clinics in the Los Angeles area. Measurements: Neurocognitive measures included tests of attention, information processing speed, learning/memory, verbal fluency, motor functioning, and executive functioning. Medication adherence was measured using microchip-embedded pill bottle caps (Medication Event Monitoring System) and se report. Latent/structural analysis techniques were used to evaluate factor models of cognition and adherence. Results: Mean adherence rates were higher among older (>= 50 years) than younger (<50 years) HIV-positive adults. However, latent/structural modeling demonstrated that neurocognitive impairment was associated with poorer medication adherence among older participants only. When cognitive subdomains were examined individually, executive functioning, motor functioning, and processing speed were most strongly related to adherence in this age group. CD4 count and drug problems were also more strongly associated with adherence among older than younger adults. Conclusions: Older HIV-positive individuals with neurocognitive impairment or drug problems are at increased risk of suboptimal adherence to medication. Likewise, older adults may be especially vulnerable to immunological and neurocognitive dysfunction under conditions of suboptimal LOART adherence. These findings highlight the importance of optimizing medication adherence rates and evaluating neurocognition in the growing population of older HIV-infected patients. (Am J Geriatr Psychiatry 2009; 17:281-290) C1 [Ettenhofer, Mark L.] Univ Calif Los Angeles, Semel Inst, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Hinkin, Charles H.; Castellon, Steven A.; Lam, Mona] VA Greater Los Angeles Hlth Care Syst, Psychol Serv, Los Angeles, CA USA. [Durvasula, Ramani] Calif State Univ Los Angeles, Dept Psychol, Los Angeles, CA 90032 USA. [Ullman, Jodi] Calif State Univ San Bernardino, Dept Psychol & Human Dev, Los Angeles, CA USA. [Myers, Hector] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Ettenhofer, ML (reprint author), Univ Calif Los Angeles, Semel Inst, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza, Los Angeles, CA 90095 USA. EM MEttenhofer@mednct.ucla.edu FU NIDA NIH HHS [R01 DA013799-02, R01 DA013799, R01 DA013799-01A1, R01 DA013799-02S1, R01 DA013799-03, R01 DA013799-04, R01 DA13799]; NIMH NIH HHS [R01 MH058552, R01 MH058552-02, R01 MH058552-03, R01 MH058552-04, R01 MH058552-05, R01 MH58552, T32 MH019535, T32 MH019535-12, T32 MH019535-13, T32 MH019535-14, T32 MH019535-15, T32 MH019535-16, T32 MH019535-17, T32 MH19535] NR 40 TC 50 Z9 51 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD APR PY 2009 VL 17 IS 4 BP 281 EP 290 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 432QG UT WOS:000265148600004 PM 19307857 ER PT J AU Ramirez, P Al-Shahrouri, H Fanti, P Abboud, H Lorenzo, C Haffner, S AF Ramirez, Peter Al-Shahrouri, Hania Fanti, Paolo Abboud, Hanna Lorenzo, Carlos Haffner, Steven TI NMR IDENTIFIES ATHEROGENIC LIPOPROTEIN ABNORMALITIES IN EARLY DIABETIC NEPHROPATHY THAT ARE UNRECOGNIZED BY CONVENTIONAL ANALYSIS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAR 25-29, 2009 CL Nashville, TN SP Natl Kidney Fdn C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2009 VL 53 IS 4 MA 168 BP A64 EP A64 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 425JI UT WOS:000264632400193 ER PT J AU Naik, AD Woofter, AL Skinner, JM Abraham, NS AF Naik, Aanand D. Woofter, Aaron L. Skinner, Jessica M. Abraham, Neena S. TI Pharmaceutical Company Influence on Nonsteroidal Anti-Inflammatory Drug Prescribing Behaviors SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CONSENSUS PANEL; PHYSICIANS; QUALITY; OSTEOARTHRITIS; PRESCRIPTION; IMPROVEMENT; STRATEGIES; GUIDELINES; INHIBITORS; ADHERENCE AB Objectives: To describe the taxonomy of methods used by pharmaceutical companies to influence physicians' nonsteroidal anti-inflammatory drug (NSAID) prescribing behaviors and to elicit physicians' perceptions of and counterbalances to these influences. Study Design: In-depth interviews analyzed using the constant comparative method of qualitative data analysis. Methods: Qualitative interviews were conducted with physicians representing various clinical specialties. Interviews were transcribed and coded inductively using grounded theory. Recruitment was stopped at 25 participants after the attainment of thematic saturation, when no new concepts emerged from ongoing analysis of consecutive interviews. Results: Physicians described a variety of influences that shaped their NSAID prescribing behaviors, including detailing and direct contact with pharmaceutical representatives, requests from patients inspired by direct-to-consumer advertisements, and marketing during medical school and residency training. Physicians described practice guidelines, peer-reviewed evidence, and opinions of local physician experts as important counterweights to pharmaceutical company influence. Local physician experts interpreted and provided context for new clinical evidence, practice guidelines, and NSAID-related marketing. Conclusions: The social and communicative strategies used by pharmaceutical companies can be adapted to improve physicians' adoption of guidelines for safer NSAID prescribing. Communicative interactions between local experts and other physicians who prescribe NSAIDs may be the critical target for future interventions to promote safer NSAID prescribing. C1 [Naik, Aanand D.; Woofter, Aaron L.; Abraham, Neena S.] Michael E DeBakey Vet Affairs Med Ctr, Res & Dev Ctr Excellence, Gastroenterol Outcomes Geriatr Unit Hlth Serv, Houston, TX USA. [Woofter, Aaron L.] Duke Univ, Div Gastroenterol, Raleigh, NC USA. [Naik, Aanand D.; Skinner, Jessica M.; Abraham, Neena S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Naik, AD (reprint author), Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM anaik@bcm.tmc.edu FU Houston Center for Quality of Care & Utilization Studies; Houston Veterans Affairs Health Sciences Research and Development Center of Excellence [HFP90-020]; National Institute on Aging Career Development Award [5K23AG027144]; American Gastroenterological Association Foundation-Sucampo-Association of Specialty Professors Designated Research Award in Geriatric Gastroenterology; Department of Veterans Affairs [VA IIR 115-05] FX This study was supported by resources and use of facilities at the Houston Center for Quality of Care & Utilization Studies, Houston Veterans Affairs Health Sciences Research and Development Center of Excellence (HFP90-020). Dr Naik is supported by a National Institute on Aging Career Development Award (5K23AG027144). Dr Abraham is supported by an American Gastroenterological Association Foundation-Sucampo-Association of Specialty Professors Designated Research Award in Geriatric Gastroenterology and by a Merit Review Award from the Department of Veterans Affairs (VA IIR 115-05). No funding agencies had a role in the design and conduct of the study, analysis and interpretation of data, or preparation and approval of the manuscript. The views expressed herein are those of the authors and do not necessarily reflect those of the Department of Veterans Affairs or Baylor College of Medicine. NR 31 TC 4 Z9 4 U1 1 U2 4 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2009 VL 15 IS 4 BP E9 EP E15 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 433WS UT WOS:000265237100007 PM 19341315 ER PT J AU Chavez, AO Coletta, DK Kamath, S Cromack, DT Monroy, A Folli, F DeFronzo, RA Tripathy, D AF Chavez, Alberto O. Coletta, Dawn K. Kamath, Subhash Cromack, Douglas T. Monroy, Adriana Folli, Franco DeFronzo, Ralph A. Tripathy, Devjit TI Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE insulin sensitivity; adipokines; pathogenesis; type 2 diabetes mellitus ID DEPENDENT DIABETES-MELLITUS; SERUM RETINOL-BINDING-PROTEIN-4; METABOLIC SYNDROME; NONOBESE SUBJECTS; HUMAN OBESITY; VITAMIN-A; EXPRESSION; FAT; INFLAMMATION; SENSITIVITY AB Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, DeFronzo RA, Tripathy D. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. Am J Physiol Endocrinol Metab 296: E758-E764, 2009. First published February 3, 2009; doi:10.1152/ajpendo.90737.2008.-Retinol-binding protein-4 (RBP4), a novel protein secreted mainly by adipose tissue, has been associated with insulin resistance in obese subjects and in individuals with type 2 diabetes mellitus (T2DM). We examined the relationship between plasma RBP4 levels, expression of RBP4 in skeletal muscle and adipose tissue, and insulin sensitivity in Mexican Americans with varying degrees of obesity and glucose tolerance. Seventy-two subjects [16 lean normal-glucose-tolerant (NGT), 17 obese NGT, and 39 subjects with impaired fasting glucose/impaired glucose tolerance/T2DM] received an oral glucose tolerance test (OGTT) and euglycemic-hyperinsulinemic clamp. Insulin secretion was measured as insulinogenic index during OGTT. In a subset of subjects, hepatic glucose production was measured by 3-[(3)H] glucose infusion, biopsies of the vastus lateralis muscle and subcutaneous adipose tissue were obtained under basal conditions, and quantitative RT-PCR was performed to measure the RBP4 mRNA gene expression. Plasma RBP4 was significantly elevated in impaired glucose tolerance/T2DM compared with NGT lean or obese subjects. Plasma RBP4 levels correlated with 2-h glucose, triglycerides, and hemoglobin A(1c). There was no association between RBP4 levels and whole body insulin sensitivity measured with either the euglycemic insulin clamp or OGTT, basal hepatic glucose production rates, and the hepatic insulin resistance index. There was no correlation between plasma RBP4 levels and indexes of insulin secretion. RBP4 mRNA expression in skeletal muscle was similar in lean NGT subjects, obese NGT subjects, and T2DM subjects. There was no difference in RBP4 mRNA expression in adipose tissue between lean and obese NGT subjects or between NGT and T2DM individuals. Plasma RBP4 levels are elevated in T2DM and associated with impaired glucose tolerance, but not associated with obesity or insulin resistance or impaired insulin secretion in Mexican Americans. C1 [Chavez, Alberto O.; Coletta, Dawn K.; Kamath, Subhash; Cromack, Douglas T.; Monroy, Adriana; Folli, Franco; DeFronzo, Ralph A.; Tripathy, Devjit] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA. [Cromack, Douglas T.; DeFronzo, Ralph A.; Tripathy, Devjit] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Tripathy, D (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM tripathy@UTHSCSA.EDU RI Coletta, Dawn/G-6382-2016 OI folli, franco/0000-0001-9824-5222; Coletta, Dawn/0000-0001-5819-5152; Monroy, Adriana/0000-0001-6221-3763 NR 37 TC 21 Z9 21 U1 2 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD APR PY 2009 VL 296 IS 4 BP E758 EP E764 DI 10.1152/ajpendo.90737.2008 PG 7 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 423SB UT WOS:000264514900022 PM 19190263 ER PT J AU Zhang, JL Ling, YQ Tang, LP Luo, B Pollock, DM Fallon, MB AF Zhang, Junlan Ling, Yiqun Tang, Liping Luo, Bao Pollock, David M. Fallon, Michael B. TI Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-deficient rats SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE common bile duct ligation; endothelin-1; endothelial nitric oxide synthase; intravascular monocyte ID NITRIC-OXIDE SYNTHASE; BILE-DUCT LIGATION; ETB-RECEPTOR; HYPERTENSION; MODEL; VASODILATION; EXPRESSION; CIRRHOSIS; LIVER; ET-1 AB Experimental hepatopulmonary syndrome (HPS) after common bile duct ligation (CBDL) in rat is accompanied by increased lung vascular endothelial endothelin B (ET(B)) receptor expression and increased circulating levels of endothelin-1 (ET-1). The onset of HPS is hypothesized to be triggered by ET-1/ET(B) receptor activation of endothelial nitric oxide synthase (eNOS)-derived NO production in the pulmonary endothelium. However, whether functional pulmonary vascular ET(B) receptors are required for the development of experimental HPS is not defined. We evaluated the effects of vascular ET(B) receptor deficiency on the development of experimental HPS. The molecular and physiological alterations of HPS were compared in 2-wk CBDL wild-type and ET(B) receptor-deficient (transgenic sl/sl) rats. Relative to wild-type rats, basal hepatic and plasma ET-1 levels were elevated in sl/sl controls although, unlike wild-type animals circulating ET-1 levels, did not increase further after CBDL in sl/sl animals. In contrast to wild-type animals, ET(B) receptor-deficient rats did not develop increased Akt and eNOS expression and activation and did not develop gas exchange abnormalities of HPS after CBDL. There was a similar degree of pulmonary intravascular monocyte accumulation in both 2-wk CBDL sl/sl and wild-type animals. In conclusion, ET(B) receptor deficiency inhibits lung Akt/eNOS activation and prevents the onset of experimental HPS after CBDL. This effect is independent of inhibition of pulmonary intravascular monocyte accumulation. These results demonstrate that ET-1/ET(B) receptor signaling plays a key role in the initiation of experimental HPS. C1 [Zhang, Junlan; Ling, Yiqun; Tang, Liping; Luo, Bao; Fallon, Michael B.] Univ Alabama, Dept Internal Med, Ctr Liver, Birmingham, AL USA. [Tang, Liping; Luo, Bao; Fallon, Michael B.] Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL USA. [Pollock, David M.] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA. RP Zhang, JL (reprint author), Univ Texas Hlth Sci Ctr Houston, MSB 4-248,6431 Fannin St, Houston, TX 77030 USA. EM Junlan.Zhang@uth.tmc.edu FU AHA [0735468N]; NIH [DK0203] FX This work was supported by Grants AHA 0735468N (to J. Zhang) and NIH DK0203 (to M. B. Fallon). NR 29 TC 15 Z9 19 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD APR PY 2009 VL 296 IS 4 BP G704 EP G708 DI 10.1152/ajpgi.90627.2008 PG 5 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 426KE UT WOS:000264706400002 PM 19196949 ER PT J AU Primack, BA Douglas, EL Fine, MJ Dalton, MA AF Primack, Brian A. Douglas, Erika L. Fine, Michael J. Dalton, Madeline A. TI Exposure to Sexual Lyrics and Sexual Experience Among Urban Adolescents SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID POPULAR-MUSIC; BEHAVIOR; MEDIA; RISK; TELEVISION; WOMEN; INTERCOURSE; CHILDREN; VIOLENT; SCALE AB Background: Two thirds of all sexual references in Music are degrading in nature, yet it remains uncertain whether these references promote earlier sexual activity. The purpose of this study was to determine if exposure to lyrics describing degrading sex in popular music is independently associated with Sexual behavior in a cohort of urban adolescents. Methods: All ninth-grade health students at three large urban high schools completed in-school surveys in 2006 and 2007. Participants' exposure to lyrics describing degrading sex was computed with overall music exposure and content analyses of their favorite artists' songs. Outcomes included sexual intercourse and progression along a noncoital sexual continuum. Multivariable regression was used to assess independent associations between exposure to lyrics describing degrading sex and outcomes. Results: The 711 participants were exposed to 14.7 hours each week of songs with lyrics describing degrading sex (SD=17.0). Almost one third of participants (n=216) had previously been sexually active. Compared to those with the least exposure to lyrics describing degrading sex, those with the most exposure were more than twice as likely to have had sexual intercourse (OR=2.07; 95% CI=1.26, 3.41), even after adjusting for all covariates. Similarly, among those who had not had Sexual intercourse, those in the highest tertile of exposure to lyrics describing degrading sex were nearly twice as likely to have progressed along a noncoital sexual continuum (OR=1.88; 95% CI = 1.23, 2.88) compared to those ill the lowest tertile. Finally, the relationships between exposure to lyrics describing nondegrading sex and sexual outcomes were not significant. Conclusions: This study supports all association between exposure to lyrics describing degrading sex in popular music and early sexual experience among adolescents. C1 [Primack, Brian A.; Douglas, Erika L.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Dept Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.; Douglas, Erika L.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Sch Med, Div Adolescent Med, Dept Pediat, Pittsburgh, PA 15213 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Dalton, Madeline A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hood Ctr Children & Families,Dept Pediat, Hanover, NH 03756 USA. [Dalton, Madeline A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hood Ctr Children & Families,Community Hlth Res P, Hanover, NH 03756 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Dept Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu FU Robert Wood Johnson Foundation; National Cancer Institute [K07-CA114315]; Maurice Falk Foundation FX Dr. Primack is supported in part by a Physician Faculty Scholar Award from the Robert Wood Johnson Foundation; a career development award from the National Cancer Institute (K07-CA114315); and a grant from the Maurice Falk Foundation. The authors would like to thank Steven Martino, PhD, for his editorial input and his assistance with study design. Dr. Primack had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 38 TC 12 Z9 12 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2009 VL 36 IS 4 BP 317 EP 323 DI 10.1016/j.amepre.2008.11.011 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 422DP UT WOS:000264407700006 PM 19285196 ER PT J AU Zeber, JE Copeland, LA McCarthy, JF Bauer, MS Kilbourne, AM AF Zeber, John E. Copeland, Laurel A. McCarthy, John F. Bauer, Mark S. Kilbourne, Amy M. TI Perceived Access to General Medical and Psychiatric Care Among Veterans With Bipolar Disorder SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SERIOUS MENTAL-ILLNESS; HEALTH-SERVICES UTILIZATION; NATIONAL-COMORBIDITY-SURVEY; BEHAVIORAL-MODEL; VULNERABLE POPULATIONS; 12-MONTH PREVALENCE; SOCIAL SUPPORT; UNITED-STATES; OLDER-ADULTS; UNMET NEEDS AB Objectives. We examined associations between patient characteristics and self-reported difficulties in accessing mental health and general medical care services. Methods. Patients were recruited from the Continuous Improvement for Veterans in Care-Mood Disorders study. We used multivariable logistic regression analyses to assess whether predisposing (demographic characteristics), enabling (e.g., homelessness), or need (bipolar symptoms, substance abuse) factors were associated with difficulties in obtaining care, difficulties in locating specialty providers, and forgoing care because of cost. Results. Patients reported greater difficulty in accessing general medical services than in accessing psychiatric care. Individuals experiencing bipolar symptoms more frequently avoided psychiatric care because of cost (odds ratio (OR]=2.43) and perceived greater difficulties in accessing medical specialists (OR=2.06). Homeless individuals were more likely to report hospitalization barriers, whereas older and minority patients generally encountered fewer problems accessing treatment. Conclusions. Need and enabling factors were most influential in predicting self-reported difficulties in accessing care, subsequently interfering with treatment dynamics and jeopardizing clinical outcomes. Efforts in the Department of Veterans Affairs to expand mental health care access should be coupled with efforts to ensure adequate access to general medical services among patients with chronic mental illnesses. (Am J Public Health. 2009;99:720-727. doi:10.2105/AJPH.2007.131318) C1 [Zeber, John E.] S Texas Vet Hlth Care Syst, Vet Affairs HSR&D, San Antonio, TX 78229 USA. [Zeber, John E.; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [McCarthy, John F.; Kilbourne, Amy M.] VA Serious Mental Illness Treatment Res & Evaluat, Ann Arbor, MI USA. [McCarthy, John F.; Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Bauer, Mark S.] VA Med Ctr, Providence, RI USA. [Bauer, Mark S.] Harvard Univ, Dept Psychiat, Cambridge, MA 02138 USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst, Vet Affairs HSR&D, 7400 Merton Minter Blvd 11c6, San Antonio, TX 78229 USA. EM zeber@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs (VA); HSRD Service [IIR 02-283-2, 05-145] FX This study was supported through funds provided by the Department of Veterans Affairs (VA), HSR&D Service (Merit Review Investigator Initiated Research IIR 02-283-2, Merit Review Entry Program [MREP] Career Development Award HSR&D 02269). Laurel A. Cope-land received funding from the HSR&D Service (MREP Career Development Award 05-145). NR 59 TC 15 Z9 16 U1 0 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2009 VL 99 IS 4 BP 720 EP 727 DI 10.2105/AJPH.2007.131318 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 423RA UT WOS:000264512200025 PM 19150912 ER PT J AU Gross, RD Atwood, CW Ross, SB Olszewski, JW Eichhorn, KA AF Gross, Roxann Diez Atwood, Charles W., Jr. Ross, Sheryl B. Olszewski, Joan W. Eichhorn, Kimberly A. TI The Coordination of Breathing and Swallowing in Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE exacerbation; dysphagia; swallowing; deglutition; aspiration; pneumonia ID SUBGLOTTIC AIR-PRESSURE; PASSY-MUIR VALVE; BOLUS VOLUME; NORMAL ADULTS; RESPIRATORY PATTERNS; PHASE-RELATIONSHIPS; APNEA DURATION; SOLID FOOD; PHARYNGEAL; ASPIRATION AB Rationale. During deglutition, a strongly preferred exhale-swallow-exhale pattern has been shown in healthy adults. Disruption of this pattern can provoke prandial aspiration. Impaired coordination of breathing and swallowing has been measured in patients with chronic obstructive pulmonary disease (COPD) during the exacerbated state, but no reports describe the coordination of breathing and swallowing in stable patients with COPD during oral intake. Objectives: To test the hypothesis that persons with moderate to severe COPD would show disordered coordination of breathing and swallowing during oral intake when compared with a matched, healthy control group. Methods: This study used a prospective, repeated measures design using 25 subjects with COPD and 25 control subjects. Respiratory inductance plethysmography and nasal thermistry were used simultaneously to track respiratory signals. Submental surface EMG was used to mark the presence of each swallow within the respiratory cycle. Data were recorded while participants randomly and spontaneously swallowed solids and semi-solids. Measurements and Main Results: Logistic regression showed that participants with COPD swallowed solid food during inhalation more frequently than normal subjects (P = 0.002) and had a significantly higher rate of inhaling after swallowing semi-solid material (P < 0.001). Subjects with COPD also swallowed pudding at low VT significantly more often than they did the cookie (P = 0.006). Conversely, the control subjects swallowed cookie at low VT significantly more often than pudding (P = 0.034). Significant differences in deglutitive apnea durations were also found. Conclusions: Patients with COPD exhibit disrupted coordination of the respiratory cycle with deglutition. Disrupted breathing-swallowing coordination could increase the risk of aspiration in patients with advanced COPD and may contribute to exacerbations. C1 [Gross, Roxann Diez; Ross, Sheryl B.] Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Atwood, Charles W., Jr.] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA. [Olszewski, Joan W.] Henry Ford Hosp, Detroit, MI 48202 USA. RP Gross, RD (reprint author), Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM Grossrd@upmc.edu FU VA Research and Rehabilitation Merit Review Program FX Supported by the VA Research and Rehabilitation Merit Review Program. NR 51 TC 54 Z9 61 U1 0 U2 7 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 1 PY 2009 VL 179 IS 7 BP 559 EP 565 DI 10.1164/rccm.200807-1139OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 425UU UT WOS:000264663700008 PM 19151193 ER PT J AU Pa, J Boxer, A Chao, LL Gazzaley, A Freeman, K Kramer, J Miller, BL Weiner, MW Neuhaus, J Johnson, JK AF Pa, Judy Boxer, Adam Chao, Linda L. Gazzaley, Adam Freeman, Katie Kramer, Joel Miller, Bruce L. Weiner, Michael W. Neuhaus, John Johnson, Julene K. TI Clinical-Neuroimaging Characteristics of Dysexecutive Mild Cognitive Impairment SO ANNALS OF NEUROLOGY LA English DT Article ID VOXEL-BASED MORPHOMETRY; DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; VERBAL FLUENCY; DEMENTIA; ATROPHY; LESIONS; SUBTYPES AB Objective: Subgroups of mild cognitive impairment (MCI) have been proposed, but few studies have investigated the nonamnestic, single-domain subgroup of MCI. The goal of the study was to compare clinical and neuroimaging characteristics of two single-domain MCI subgroups: amnestic MCI and dysexecutive MCI. Methods: We compared the cognitive, functional, behavioral, and brain imaging characteristics of patients with amnestic MCI (n = 26), patients with dysexecutive MCI (n = 32), and age- and education-matched control subjects (n = 36) using analysis of variance and X 2 tests. We used voxel-based morphometry to examine group differences in brain magnetic resonance imaging atrophy patterns. Results: Patients with dysexecutive MCI had significantly lower scores on the majority of executive function tests, increased behavioral symptoms, and left prefrontal cortex atrophy on magnetic resonance imaging when compared with control subjects. In contrast, patients with amnestic MCI had significantly lower scores on tests of memory and a pattern of atrophy including bilateral hippocampi and entorhinal cortex, right inferior parietal cortex, and posterior cingulate gyrus when compared with control subjects. Interpretation: Overall, the clinical and neuroimaging findings provide support for two distinct single-domain subgroups of MCI., one involving executive function and the other involving memory. The brain imaging differences suggest that the two MCI subgroups have distinct patterns of brain atrophy. Ann Neurol 2009;65:414-423 C1 [Pa, Judy; Boxer, Adam; Chao, Linda L.; Gazzaley, Adam; Freeman, Katie; Kramer, Joel; Miller, Bruce L.; Weiner, Michael W.; Johnson, Julene K.] Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94117 USA. [Chao, Linda L.; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Neuhaus, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94117 USA. RP Johnson, JK (reprint author), Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, 350 Parnassus,Suite 905, San Francisco, CA 94117 USA. EM jjohnson@memory.ucsf.edu FU NIH [R01-AG022538, R01-AG010897, P50-AG0300601, K23-NS408855]; John D. French Foundation FX This work was supported by the NIH (National Institute on Aging, R01-AG022538 (JKJ), R01-AG010897 (MWW), P50-AG0300601 (BLM), K23-NS408855 (AB)) and John D. French Foundation (AB). NR 47 TC 47 Z9 48 U1 2 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 2009 VL 65 IS 4 BP 414 EP 423 DI 10.1002/ana.21591 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 439VT UT WOS:000265656200010 PM 19399879 ER PT J AU Cohen, ME Bilimoria, KY Ko, CY Richards, K Hall, BL AF Cohen, Mark E. Bilimoria, Karl Y. Ko, Clifford Y. Richards, Karen Hall, Bruce Lee TI Effect of Subjective Preoperative Variables on Risk-Adjusted Assessment of Hospital Morbidity and Mortality SO ANNALS OF SURGERY LA English DT Article ID PHYSICAL STATUS CLASSIFICATION; SURGICAL QUALITY IMPROVEMENT; ANAL ANASTOMOSIS SURGERY; LOGISTIC-REGRESSION; VASCULAR-SURGERY; PATIENT SAFETY; POUCH FAILURE; ANESTHESIOLOGISTS; CARE; QUANTIFICATION AB Objective: To examine the influence of American Society of Anesthesiologists Physical Status Classification (ASA) and preoperative Functional Health Status (FHS) variables on risk-adjusted estimates of surgical quality and to assess whether classifications are inflated at some hospitals. Background: ASA and FHS are influential in risk-adjusted comparisons of surgical quality. However, because ASA and FHS are subjective they can be inflated, making patients appear more ill than they actually are, and crediting hospitals for a sicker patient population. Methods: We identified 28,75 1 colorectal surgery patients at 170 hospitals participating in the American College of Surgeon's National Surgical Quality Improvement Program (ACS NSQIP) during 2006 to 2007. Logistic regression models were developed for morbidity and mortality with and without inclusion of ASA and FHS. Hospital quality rankings from the different models were compared. Results: Morbidity and mortality rates were 24.3% and 3.9%. respectively. Percents of patients in ASA classes I through V were 3.3%, 46.4%, 41.5%. 8.3%, and 0.7% and that were independent or partially or totally dependent were 89.2%, 7.2% and 3.6%, respectively. Models that included ASA and FHS exhibited slightly better fit (Hosmer-Lemshow statistic) and discrimination (c-statistic) than models without both these variables, though magnitudes of differences were consistent with chance. There was inconsistent evidence for improper assignment of ASA and FHS. Conclusions: The small improvements in model quality when both ASA and FHS are present versus absent, suggest that they make a unique contribution to assessing severity of preoperative risk. With little indication that these subjective variables are subject to an important level of institutional bias, it is appropriate that they be used to assess risk-adjusted surgical quality. Periodic monitoring for inappropriate inflation of ASA status is warranted. C1 [Cohen, Mark E.; Bilimoria, Karl Y.; Ko, Clifford Y.; Richards, Karen] Assoc Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce Lee] Univ Missouri, Ctr Hlth Policy, Columbia, MO USA. RP Cohen, ME (reprint author), Assoc Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St, Chicago, IL USA. EM markcohen@facs.org FU American College of Surgeons Clinical Scholars in Residence program FX KYB was supported by the American College of Surgeons Clinical Scholars in Residence program. NR 32 TC 29 Z9 29 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD APR PY 2009 VL 249 IS 4 BP 682 EP 689 DI 10.1097/SLA.0b013e31819eda21 PG 8 WC Surgery SC Surgery GA 429CT UT WOS:000264899100024 PM 19300217 ER PT J AU Ge, L Ratcliffe, M AF Ge, Liang Ratcliffe, Mark TI The Use of Computational Flow Modeling (CFD) to Determine the Effect of Left Ventricular Shape on Blood Flow in the Left Ventricle SO ANNALS OF THORACIC SURGERY LA English DT Editorial Material ID MAGNETIC-RESONANCE; ACTIVE CONTRACTION; CARDIAC-MUSCLE; MECHANICS; HEART C1 [Ge, Liang; Ratcliffe, Mark] San Francisco VA Med Ctr, VAMC Surg 112D, San Francisco, CA 94121 USA. RP Ratcliffe, M (reprint author), San Francisco VA Med Ctr, VAMC Surg 112D, 4150 Clement St, San Francisco, CA 94121 USA. EM mratcliffe@hotmail.com FU NHLBI NIH HHS [R01 HL063348] NR 11 TC 9 Z9 13 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2009 VL 87 IS 4 BP 993 EP 994 DI 10.1016/j.athoracsur.2009.02.045 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 423OQ UT WOS:000264506000001 PM 19324118 ER PT J AU Bakaeen, FG Dhaliwal, AS Chu, D Bozkurt, B Tsai, P LeMaire, SA Wall, MJ Coselli, JS Huh, J AF Bakaeen, Faisal G. Dhaliwal, Amandeep S. Chu, Danny Bozkurt, Biykem Tsai, Peter LeMaire, Scott A. Wall, Matthew J., Jr. Coselli, Joseph S. Huh, Joseph TI Does the Level of Experience of Residents Affect Outcomes of Coronary Artery Bypass Surgery? SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 55th Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 05-08, 2008 CL Austin, TX SP SE Thorac Surg Assoc ID CARDIAC-SURGERY; TRAIN RESIDENTS; OPERATING-ROOM; IMPACT; SAFETY; SUPERVISION; PERFORMANCE; SENIORITY; RISK AB Background. At our institution, coronary artery bypass grafting (CABG) operations are performed by staff surgeons or by first- or second-year cardiothoracic residents under the direct supervision of attending surgeons. We evaluated the influence of surgical seniority on outcomes. Methods. Using prospectively collected data from our departmental database, we identified all primary, isolated CABG operations (n = 1,042) performed between July 1997 and April 2007. Operations were then stratified according to the seniority of the primary surgeon: first-year cardiothoracic resident (CT1), second-year cardiothoracic resident (CT2), or staff surgeon. Data were examined for any association between seniority and surgical outcomes. Results. Staff, CT2, and CT1 surgeons performed 47 (4%), 610 (59%), and 385 (37%) cases, respectively. Efficiency was correlated with experience: for CT1, CT2, and staff surgeons, respectively, operative times averaged 345, 313, and 302 minutes; perfusion times averaged 118, 106, and 96 minutes; and cross-clamp times averaged 68, 58, and 57 minutes (p < 0.05 for all comparisons). The incidences of major morbidity (10.1%, 12.3%, 12.8%) and operative mortality (0.8%, 1.5%, 2.1%) were similar after operations performed by CT1, CT2, and staff surgeons, respectively (p > 0.15 for all). In univariate and multivariate analyses, the seniority of the primary surgeon did not independently predict morbidity or perioperative mortality. On follow-up (mean, 1,485 +/- 1,015 days), there was no significant difference in patient survival (log-rank, p = 0.64). Conclusions. Lower academic seniority was associated with longer CABG operative times but did not affect outcomes. Thus, training residents to perform CABG is safe and is characterized by progressive improvement in their technical efficiency. C1 [Bakaeen, Faisal G.] Ben Taub Gen Hosp, Dept Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr,Baylor Coll, Div Cardiothorac Surg,Dept Surg,Div Cardiol,Dept, Houston, TX 77030 USA. St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA. RP Bakaeen, FG (reprint author), Ben Taub Gen Hosp, Dept Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr,Baylor Coll, Div Cardiothorac Surg,Dept Surg,Div Cardiol,Dept, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM fbakaeen@bcm.edu NR 23 TC 39 Z9 39 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2009 VL 87 IS 4 BP 1127 EP 1134 DI 10.1016/j.athoracsur.2008.12.080 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 423OQ UT WOS:000264506000019 PM 19324138 ER PT J AU El-Deiry, MW Futran, ND McDowell, JA Weymuller, EA Yueh, B AF El-Deiry, Mark W. Futran, Neal D. McDowell, Jennifer A. Weymuller, Ernest A., Jr. Yueh, Bevan TI Influences and Predictors of Long-term Quality of Life in Head and Neck Cancer Survivors SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article; Proceedings Paper CT 7th International Conference on Head and Neck Cancer CY JUL 19-23, 2008 CL San Francisco, CA SP Amer Head & Neck Soc ID SQUAMOUS-CELL CARCINOMA; TOTAL LARYNGECTOMY; HEALTH-STATUS; CHEMORADIATION; COMORBIDITY; VALIDATION; SURGERY AB Objective: To examine the impact of clinical predictors (pretreatment variables) and other influences (treatment and posttreatment variables) on long-term quality of life (QOL) in patients treated for squamous cell carcinoma of the upper aerodigestive tract. We hypothesized that baseline QOL and comorbidity would be predictors of QOL 1 year after treatment. Design: Retrospective cohort study. Setting: Academic Medical Center in Seattle, Washington. Patients: Patients (N=173) with baseline (pretreatment) and 1-year posttreatment QOL data. Main Outcome Measure: Head and neck-specific QOL scores at 1 year after treatment (as measured by the University of Washington Quality of Life [UW-QOL] scale). Results: We identified strong relationships between 1-year UW-QOL scores and baseline UW-QOL scores (correlation coefficient [Pearson r]=0.58; P<.001) and pretreatment comorbidity (as measured by the Adult Comorbidity Evaluation scale) (Spearman rho=0.23; P<.001). T stage and N stage were also predictive. Although not a predictive variable, the presence of a gastrostomy tube at 1 year also strongly influenced 1-year UW-QOL scores. Patients with gastrostomy tubes had UW-QOL scores 11.5 points worse than those without (P<.001), when a 7-point difference is considered clinically significant. In predictive multivariate regression models, pretreatment QOL scores, comorbidity, and T stage had the strongest prognostic impact on 1-year UW-QOL scores. Conclusions: In bivariate analyses, the presence of a gastrostomy tube worsens UW-QOL scores at 1 year and requires further investigation. When considering predictive variables only, baseline QOL and comorbidity appear to have strong influences on posttreatment QOL and have greater impact than treatment modality. Greater attention to these baseline predictors should be given when counseling patients about long-term function after treatment. C1 [El-Deiry, Mark W.] Univ S Florida, Dept Otolaryngol Head & Neck Surg, Tampa, FL 33612 USA. [Futran, Neal D.; Weymuller, Ernest A., Jr.] Univ Washington, Seattle, WA 98195 USA. [Yueh, Bevan] Univ Minnesota, Minneapolis, MN USA. [McDowell, Jennifer A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. RP El-Deiry, MW (reprint author), Univ S Florida, Dept Otolaryngol Head & Neck Surg, 12901 Magnolia Ave, Tampa, FL 33612 USA. EM mark.eldeiry@moffitt.org OI Yueh, Bevan/0000-0003-1380-1053 NR 31 TC 38 Z9 38 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 2009 VL 135 IS 4 BP 380 EP 384 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 435ZD UT WOS:000265381100010 PM 19380361 ER PT J AU Hirsh, AT Turner, AP Ehde, DM Haselkorn, JK AF Hirsh, Adam T. Turner, Aaron P. Ehde, Dawn M. Haselkorn, Jodie K. TI Prevalence and Impact of Pain in Multiple Sclerosis: Physical and Psychologic Contributors SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Mental health; Multiple sclerosis; Pain; Rehabilitation ID DISABILITY; VETERANS; INTERFERENCE; SEVERITY; SAMPLE; SEX AB Hirsh AT, Turner AP, Elide DM, Haselkorn JK. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil 2009;90: 646-51. Objective: To characterize the prevalence and impact of pain in veterans with multiple sclerosis (MS) and to assess their association with demographic, biologic, and psychologic variables. Design: Cross-sectional cohort study linking computerized medical record information to mailed survey data. Setting: Veterans Health Administration (VHA). Participants: Sixty-four percent (2994/4685) of veterans with MS who received services in VRA and also returned Survey questionnaires. Interventions: Not applicable. Main Outcome Measures: Items assessing pain intensity, pain interference, and physical and mental health functioning. Results: Ninety-two percent of participants reported bodily pain within the prior 4 weeks, with 69% of the total sample indicating pain of moderate or higher intensity. Eighty-five percent indicated that pain caused functional interference during the past 4 weeks, with 71% of the total sample reporting pain-related interference that was moderate or greater. No significant sex or race differences emerged for the pain indices. A significant but modest relationship between increasing age and pain interference emerged (r=.05, P<.01); however, age was not significantly related to pain intensity. Multivariate regression analyses identified pain intensity (beta=.73), physical health functioning (beta=-07), and mental health functioning (beta=-.13) variables as significant, unique contributors to the prediction of pain interference. The interaction of pain intensity and physical functioning was also significant but of minimal effect size (beta=-.03). Conclusions: Pain is highly prevalent and causes substantial interference in the lives of veterans with MS. The functional impact of pain in veterans with MS is influenced by pain intensity, physical health, and emotional functioning. Clinical practice should take each of these domains into consideration and reflect a biopsychosocial conceptualization. C1 [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Vet Affairs Multiple Sclerosis Ctr Excellence W, Seattle, WA USA. [Hirsh, Adam T.; Turner, Aaron P.; Ehde, Dawn M.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov OI Turner, Aaron/0000-0001-6897-8003 FU Veterans Affairs Rehabilitation Research and Development Service Career Development Award [B4972W]; Veterans Affairs Center of Excellence in Substance Abuse Treatment and Education; Veterans Affairs Multiple Sclerosis Center of Excellence West; Veterans Affairs Office of Quality and Performance; National Institutes of Health [F31NS049675, IR011HD057916-01]; National Institute of Disability Research and Rehabilitation [H133B9031129]; Centers for Disease Control and Prevention [R01/DD000153-01]; National Multiple Sclerosis Society [PP1465] FX Supported by a Veterans Affairs Rehabilitation Research and Development Service Career Development Award (grant no. B4972W), Veterans Affairs Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Multiple Sclerosis Center of Excellence West, Veterans Affairs Office of Quality and Performance; National Institutes of Health (grant nos. F31NS049675, IR011HD057916-01). National Institute of Disability Research and Rehabilitation (grant no. H133B9031129), Centers for Disease Control and Prevention (grant no. R01/DD000153-01). and National Multiple Sclerosis Society (grant no. PP1465). NR 31 TC 24 Z9 24 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2009 VL 90 IS 4 BP 646 EP 651 DI 10.1016/j.apmr.2008.10.019 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 432TD UT WOS:000265156200016 PM 19345781 ER PT J AU Namjou, B Sestak, AL Armstrong, DL Zidovetzki, R Kelly, JA Jacob, N Ciobanu, V Kaufman, KM Ojwang, JO Ziegler, J Quismorio, FP Reiff, A Myones, BL Guthridge, JM Nath, SK Bruner, GR Mehrian-Shai, R Silverman, E Klein-Gitelman, M McCurdy, D Wagner-Weiner, L Nocton, JJ Putterman, C Bae, SC Kim, YJ Petri, M Reveille, JD Vyse, TJ Gilkeson, GS Kamen, DL Alarcon-Riquelme, ME Gaffney, PM Moser, KL Merrill, JT Scofield, RH James, JA Langefeld, CD Harley, JB Jacob, CO AF Namjou, Bahram Sestak, Andrea L. Armstrong, Don L. Zidovetzki, Raphael Kelly, Jennifer A. Jacob, Noam Ciobanu, Voicu Kaufman, Kenneth M. Ojwang, Joshua O. Ziegler, Julie Quismorio, Francesco P., Jr. Reiff, Andreas Myones, Barry L. Guthridge, Joel M. Nath, Swapan K. Bruner, Gall R. Mehrian-Shai, Ruth Silverman, Earl Klein-Gitelman, Marisa McCurdy, Deborah Wagner-Weiner, Linda Nocton, James J. Putterman, Chaim Bae, Sang-Cheol Kim, Yun Jung Petri, Michelle Reveille, John D. Vyse, Timothy J. Gilkeson, Gary S. Kamen, Diane L. Alarcon-Riquelme, Marta E. Gaffney, Patrick M. Moser, Kathy L. Merrill, Joan T. Scofield, R. Hal James, Judith A. Langefeld, Carl D. Harley, John B. Jacob, Chaim O. TI High-Density Genotyping of STAT4 Reveals Multiple Haplotypic Associations With Systemic Lupus Erythematosus in Different Racial Groups SO ARTHRITIS AND RHEUMATISM LA English DT Article ID GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; STAT4-DEFICIENT MICE; TARGETED DISRUPTION; SIGNALING PATHWAY; INTERFERON-ALPHA; RISK; INDUCTION; CELLS; IRF5 AB Objective. Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disorder, with complex etiology and a strong genetic component. Recently, gene products involved in the interferon pathway have been under intense investigation in terms of the pathogenesis of SLE. STAT-1 and STAT-4 are transcription factors that play key roles in the interferon and Th1 signaling pathways, making them attractive candidates for involvement in SLE susceptibility. Methods. Fifty-six single-nucleotide polymorphisms (SNPs) across STAT1 and STAT4 on chromosome 2 were genotyped using the Illumina platform, as part of an extensive association study in a large collection of 9,923 lupus patients and control subjects from different racial groups. DNA samples were obtained from the peripheral blood of patients with SLE and control subjects. Principal components analyses and population-based case-control association analyses were performed, and the P values, false discovery rate q values, and odds ratios with 95% confidence intervals were calculated. Results. We observed strong genetic associations with SLE and multiple SNPs located within STAT4 in different ethnic groups (Fisher's combined P = 7.02 x 10(-25)). In addition to strongly confirming the previously reported association in the third intronic region of this gene, we identified additional haplotypic association across STAT4 and, in particular, a common risk haplotype that is found in multiple racial groups. In contrast, only a relatively weak suggestive association was observed with STAT1, probably due to its proximity to STAT4. Conclusion. Our findings indicate that STAT4 is likely to be a crucial component in SLE pathogenesis in multiple racial groups. Knowledge of the functional effects of this association, when they are revealed, might improve our understanding of the disease and provide new therapeutic targets. C1 [Jacob, Chaim O.] Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Kaufman, Kenneth M.; Harley, John B.] Oklahoma Med Res Fdn, US Dept Vet Affairs, Med Ctr, Oklahoma City, OK 73104 USA. [Armstrong, Don L.; Zidovetzki, Raphael] Univ Calif Riverside, Riverside, CA 92521 USA. [Kaufman, Kenneth M.; Harley, John B.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Ziegler, Julie; Langefeld, Carl D.] Wake Forest Univ Hlth Sci, Winston Salem, NC USA. [Reiff, Andreas] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Myones, Barry L.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA. [Silverman, Earl] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Klein-Gitelman, Marisa] Childrens Mem Hosp, Chicago, IL 60614 USA. [Klein-Gitelman, Marisa] Northwestern Univ, Chicago, IL 60611 USA. [McCurdy, Deborah] Univ Calif Los Angeles, Los Angeles, CA USA. [Wagner-Weiner, Linda] LaRabida Hosp, Chicago, IL USA. [Wagner-Weiner, Linda] Univ Chicago, Chicago, IL 60637 USA. [Nocton, James J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Putterman, Chaim] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Bae, Sang-Cheol; Kim, Yun Jung] Hanyang Univ, Hosp Rheumat Dis, Seoul 133791, South Korea. [Petri, Michelle] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Reveille, John D.] Univ Texas Houston Hlth Sci Ctr, Houston, TX USA. [Vyse, Timothy J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England. [Kamen, Diane L.] Med Univ S Carolina, Charleston, SC 29425 USA. [Alarcon-Riquelme, Marta E.] Uppsala Univ, Uppsala, Sweden. RP Jacob, CO (reprint author), Univ So Calif, Sch Med, Dept Med, 2011 Zonal Ave,HMT 705, Los Angeles, CA 90033 USA. EM Jacob@usc.edu OI Armstrong, Don/0000-0002-4904-638X; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154 FU NIH [R01-AR-445650, AR-42460, RR-015577, AI-31584, AR-12253, AR-48940, DE-015223, RR-020143, AI-062629, AI-24717, AI-07633, AR-62277, P01-AR-49084, P60-AR-48095, T32-AR-07450, M01-RR00032]; Alliance for Lupus Research [52104]; Lupus Foundation of America; Alliance for Lupus Research; US Department of Veterans Affairs FX Supported in part by NIH grant R01-AR-445650 and the Alliance for Lupus Research (grant 52104) to Dr. Jacob. The Oklahoma Medical Research Foundation receives funding Support from the NIH (grants AR-42460, RR-015577, AI-31584, AR-12253, AR-48940, DE-015223, RR-020143, AI-062629, AI-24717, AI-07633, and AR-62277), the Lupus Foundation of America, the Alliance for Lupus Research, and the US Department of Veterans Affairs. The University of Alabama at Birmingham receives funding support from the NIH (grants P01-AR-49084, P60-AR-48095, T32-AR-07450, and M01-RR00032). NR 51 TC 54 Z9 56 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD APR PY 2009 VL 60 IS 4 BP 1085 EP 1095 DI 10.1002/art.24387 PG 11 WC Rheumatology SC Rheumatology GA 432RW UT WOS:000265152800022 PM 19333953 ER PT J AU Slatore, CG Au, DH Littman, AJ Satia, JA White, E AF Slatore, Christopher G. Au, David H. Littman, Alyson J. Satia, Jessie A. White, Emily TI Associaton of Nonsteroidal Anti-Inflammatory Drugs with Lung Cancer: Results from a Large Cohort Study SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID CYCLOOXYGENASE-2 EXPRESSION; RISK; CHEMOPREVENTION; DECREASES; AROMATASE; ASPIRIN; SMOKERS; KI-67; GENE AB Background: Lung cancer is the most common cause of cancer-related mortality. Smoking cessation is crucial to decrease risk, but additional prevention modalities are needed. The use of nonsteroidal anti-inflammatory drugs (NSAID) may be promising. Methods: The study was a prospective cohort of 77,125 men and women, ages 50 to 76 years, from Washington state recruited in 2000 to 2002 (the VITamin And Lifestyle study). Lung cancer cases were identified through the Seattle-Puget Sound Surveillance, Epidemiology and End Results cancer registry during 5 years of follow-up. Hazard ratios (HR) associated with 10-year average use of total NSAIDs (excluding low-dose aspirin) and specific categories of NSAIDs were calculated for total incident lung cancer and specific morphologies. Results: A total of 665 lung cancer cases were identified. After adjusting for smoking, age, gender, and acetaminophen use, there was a borderline-significant inverse trend with total NSAID use [>4.2 d/wk for >10 years versus none: HR, 0.82; 95% confidence interval (95% CI), 0.64-1.04; P for trend = 0.051. The association was strongest for adenocarcinoma (HR, 0.59; 95% CI, 0.37-0.94; P for trend = 0.01) and seemed to be limited to men (HR, 0.66; 95% CI, 0.47-0.92; P for trend = 0.01) and to long-term (>= 10 years) former smokers (HR, 0.65; 95% CI, 0.44-0.96; P for trend = 0.04). There were no appreciable differences by NSAID type. Conclusions: Total NSAID use was associated with a small reduced risk of lung cancer, which was strongest for adenocarcinoma, men, and long-term former smokers. These findings are supported by known lung carcinogenesis mechanisms and suggest that NSAIDS may be useful for chemoprevention. (Cancer Epidemiol Biomarkers Prev 2009;18(4):1203-7) C1 [Slatore, Christopher G.; Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Littman, Alyson J.; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Slatore, Christopher G.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Littman, Alyson J.] VA Puget Sound Hlth Care Syst, Epidemiol Res Informat Ctr, Seattle, WA USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. [Satia, Jessie A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Satia, Jessie A.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. RP Slatore, CG (reprint author), Univ Washington, Div Pulm & Crit Care Med, 1959 NE Pacific St, Seattle, WA 98195 USA. EM cslatore@u.washington.edu OI Slatore, Christopher/0000-0003-0958-8122 FU NIH [CA130328, CA74846, CA96556, CA119633] FX NIH grants CA130328 (C.G. Slatore), CA74846 (E. White), and CA96556 and CA119633 (J.A. Satia). NR 21 TC 37 Z9 38 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2009 VL 18 IS 4 BP 1203 EP 1207 DI 10.1158/1055-9965.EPI-08-1110 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 432HV UT WOS:000265125000024 PM 19293309 ER PT J AU Banez, LL Terris, MK Aronson, WJ Presti, JC Kane, CJ Amling, CL Freedland, SJ AF Banez, Lionel L. Terris, Martha K. Aronson, William J. Presti, Joseph C., Jr. Kane, Christopher J. Amling, Christopher L. Freedland, Stephen J. TI Race and Time from Diagnosis to Radical Prostatectomy: Does Equal Access Mean Equal Timely Access to the Operating Room?-Results from the SEARCH Database SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID CYP3A4 GENETIC VARIANT; AFRICAN-AMERICAN MEN; RACIAL-DIFFERENCES; UNITED-STATES; HEALTH-CARE; CANCER; IMPACT; DELAY; RISK; EPIDEMIOLOGY AB Background: African American men with prostate cancer are at higher risk for cancer-specific death than Caucasian men. We determine whether significant delays in management contribute to this disparity. We hypothesize that in an equal-access health care system, time interval from diagnosis to treatment would not differ by race. Methods: We identified 1,532 African American and Caucasian men who underwent radical prostatectomy (RP) from 1.988 to 2007 at one of four Veterans Affairs Medical Centers that comprise the Shared Equal-Access Regional Cancer Hospital (SEARCH) database with known biopsy date. We compared time from biopsy to RP between racial groups using linear regression adjusting for demographic and clinical variables. We analyzed risk of potential clinically relevant delays by determining odds of delays >90 and >180 days. Results: Median time interval from diagnosis to RP was 76 and 68 days for African Americans and Caucasian men, respectively (P = 0.004). After controlling for demographic and clinical variables, race was not associated with the time interval between diagnosis and RP (P = 0.09). Furthermore, race was not associated with increased risk of delays >90 (P = 0.45) or >180 days (P = 0.31). Conclusions: In a cohort of men undergoing RP in an equal-access setting, there was no significant difference between racial groups with regard to time interval from diagnosis to RP. Thus, equal-access includes equal timely access to the operating room. Given our previous finding of poorer outcomes among African Americans, treatment delays do not seem to explain these observations. Our findings need to be confirmed in patients electing other treatment modalities and in other practice settings. (Cancer Epiderniol Biomarkers Prev 2009;18(4):1208-12) C1 [Banez, Lionel L.; Freedland, Stephen J.] Duke Univ, Med Ctr, Div Urol Surg, Durham, NC 27710 USA. [Banez, Lionel L.; Freedland, Stephen J.] Duke Univ, Med Ctr, Dept Surg, Duke Prostate Ctr, Durham, NC 27710 USA. [Banez, Lionel L.; Freedland, Stephen J.] Duke Univ, Med Ctr, Urol Sect, Vet Affairs Med Ctr, Durham, NC 27710 USA. [Freedland, Stephen J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Los Angeles Sch Med, Dept Urol, Los Angeles, CA USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Kane, Christopher J.] Vet Affairs Med Ctr, Urol Sect, San Diego, CA 92161 USA. [Kane, Christopher J.] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA. [Amling, Christopher L.] Univ Alabama, Dept Urol, Birmingham, AL USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Div Urol Surg, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu FU Department of Veterans Affairs, the Duke University Department of Surgery; Division of Urology, Department of Defense Prostate Cancer Research Program, the American Urological Association Foundation/Astellas Rising Star in Urology Award; NIH Specialized Programs of Research Excellence [P50 CA58236]; the Georgia Cancer Coalition, NIH [R01CA100938, P50 CA92131-01A1] FX Department of Veterans Affairs, the Duke University Department of Surgery and Division of Urology, Department of Defense Prostate Cancer Research Program, the American Urological Association Foundation/Astellas Rising Star in Urology Award, NIH Specialized Programs of Research Excellence Grant P50 CA58236, the Georgia Cancer Coalition, NIH R01CA100938, and NIH Specialized Programs of Research Excellence Grant P50 CA92131-01A1. NR 25 TC 13 Z9 13 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2009 VL 18 IS 4 BP 1208 EP 1212 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 432HV UT WOS:000265125000025 PM 19336564 ER PT J AU Abdel-Kader, K Myaskovsky, L Karpov, I Shah, J Hess, R Dew, MA Unruh, M AF Abdel-Kader, Khaled Myaskovsky, Larissa Karpov, Irina Shah, Jay Hess, Rachel Dew, Mary Amanda Unruh, Mark TI Individual Quality of Life in Chronic Kidney Disease: Influence of Age and Dialysis Modality SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC-HEMODIALYSIS PATIENTS; RESPONSE SHIFT; SEIQOL-DW; RELATIVE IMPORTANCE; ADVANCED CANCER; ELDERLY-PEOPLE; UNITED-STATES; HEALTH; PATIENT; COHORT AB Background and objectives: Novel individualized quality-of-life (IQOL) measures permit patients with chronic kidney disease (CKD) to nominate unique areas of their lives that contribute to their well-being. This study assessed for differences in domains nominated by patients with CKD. We also examined the strength of association between (1) multidimensional health-related quality-of-life measures and IQOL and (2) psychosocial factors and IQOL. Design, setting, participants, & measurements: We performed a cross-sectional study of 151 patients who were undergoing peritoneal dialysis or hemodialysis or had stages 4 through 5 CKD. Patients completed the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQOL-DW), an instrument that assesses IQOL on the basis of patient-identified domains. Patients also completed health-related quality-of-life and psychosocial health measures. Results: Patients with CKD nominated many domains on the SEIQOL-DW, but family and health were the most common for all groups. Kidney disease was listed more frequently by peritoneal dialysis compared with hemodialysis patients or patients with CKD (31 versus 14 versus 5%, respectively). There were no significant differences in SEIQOL-DW scores between subgroups. SEIQOL-DW scores correlated with mental well-being and inversely correlated with chronic stress and depression. Conclusions: Patients with advanced CKD demonstrate compromised quality-of-life scores comparable to dialysis patients. IQOL measures provide unique information that may help guide interventions that are better tailored to address patients' concerns about their well-being. These findings also suggest that renal clinics should have staff available to address psychosocial aspects of patient well-being. C1 [Abdel-Kader, Khaled; Shah, Jay; Unruh, Mark] Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA 15261 USA. [Myaskovsky, Larissa; Hess, Rachel] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Karpov, Irina; Dew, Mary Amanda] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA. [Myaskovsky, Larissa] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Abdel-Kader, K (reprint author), Univ Pittsburgh, Renal Electrolyte Div, 355C Terrace St,A909 Scaife Hall, Pittsburgh, PA 15261 USA. EM abdelkaderk@upmc.edu OI Abdel-Kader, Khaled/0000-0002-6412-8498 FU Fresenius National Kidney Foundation Young Investigator; Paul Teschan Research; National Institutes of Health [DK66006, DK77785]; Ruth L. Kirschstein National Research Service Award Institutional Research Training [T32-DK061296] FX This work was supported by Fresenius National Kidney Foundation Young Investigator Grant, Paul Teschan Research Grant, National Institutes of Health grants DK66006 and DK77785 (M.U.), and Ruth L. Kirschstein National Research Service Award Institutional Research Training Grant T32-DK061296 (K.A.). NR 50 TC 29 Z9 29 U1 2 U2 13 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2009 VL 4 IS 4 BP 711 EP 718 DI 10.2215/CJN.05191008 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 429RN UT WOS:000264937900009 PM 19339411 ER PT J AU Desai, AA Bolus, R Nissenson, A Chertow, GM Bolus, S Solomon, MD Khawar, OS Talley, J Spiegel, BMR AF Desai, Amar A. Bolus, Roger Nissenson, Allen Chertow, Glenn M. Bolus, Sally Solomon, Matthew D. Khawar, Osman S. Talley, Jennifer Spiegel, Brennan M. R. TI Is there "Cherry Picking" in the ESRD Program? Perceptions from a Dialysis Provider Survey SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 40th Annual Meeting of the American-Society-of-Nephrology/Annual Renal Week CY OCT 31-NOV 05, 2007 CL San Francisco, CA SP Amer Soc Nephrol ID STAGE RENAL-DISEASE; PAY-FOR-PERFORMANCE; STANDARDIZED PATIENTS; CHART ABSTRACTION; NATIONAL-SURVEY; UNITED-STATES; QUALITY; CARE; PAYMENT; VIGNETTES AB Background and objectives: Changes in ESRD reimbursement policy, including proposed bundled payment, have raised concern that dialysis facilities may use "cherry picking" practices to attract a healthier, better insured, or more adherent patient population. Design, setting, participants, & measurements: As part of a national survey to measure beliefs about drivers of quality in dialysis, respondents were asked about their perceptions of cherry picking, including the frequency and effect of various cherry picking strategies on dialysis outcomes. We surveyed a random sample of 250 nurse members of the American Nephrology Nurses Association, 250 nephrologist members of the American Medical Association, 50 key opinion leaders, and 2000 physician members of the Renal Physicians Association. We tested hypothesized predictors of perception, including provider group, region, age, experience, and the main practice facility features. Results: Three-quarters of respondents reported that cherry picking occurred "sometimes" or "frequently." There were no differences in perceptions by provider or facility characteristics, insurance status, or health status. In multivariable regression, perceived cherry picking was 2.8- and 3.5-fold higher in the northeast and Midwest, respectively, versus the west. Among various cherry picking strategies, having a "low threshold to 'fire' chronic no-shows/late arrivers," and having a "low threshold to 'fire' for noncompliance with diet and meds" had the largest perceived association with outcomes. Conclusions: Under current reimbursement practices, dialysis caregivers perceive that cherry picking is common and important. An improved understanding of cherry picking practices, if evident, may help to protect vulnerable patients if reimbursement practices were to change. C1 [Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, David Geffen Sch Med, VA Ctr Outcomes Res & Educ,Dept Med, Los Angeles, CA 90073 USA. [Desai, Amar A.; Chertow, Glenn M.; Solomon, Matthew D.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90073 USA. [Desai, Amar A.] Stanford Univ, Ctr Hlth Policy & Primary Care Outcomes Res, Stanford, CA 94305 USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, David Geffen Sch Med, VA Ctr Outcomes Res & Educ,Dept Med, 11301 Wilshire Blvd,Bldg 115 Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU NIDDK NIH HHS [2P30 DK 041301-17, P30 DK041301-17, P30 DK041301] NR 22 TC 14 Z9 14 U1 1 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2009 VL 4 IS 4 BP 772 EP 777 DI 10.2215/CJN.05661108 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 429RN UT WOS:000264937900017 PM 19339407 ER PT J AU Wagner, JM AF Wagner, Julia M. TI Impact of a Dedicated IV Team SO CRITICAL CARE NURSE LA English DT Meeting Abstract C1 [Wagner, Julia M.] Denver VA Med Ctr, Eastern Colorado Hlth Care Syst, Denver, CO USA. EM julia.wagner@va.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 J9 CRIT CARE NURSE JI Crit. Care Nurse PD APR PY 2009 VL 29 IS 2 MA CS83 BP E12 EP E13 PG 2 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 427JB UT WOS:000264774500033 ER PT J AU Frei, CR Jaso, TC Mortensen, EM Restrepo, MI Raut, MK Oramasionwu, CU Ruiz, AD Makos, BR Ruiz, JL Attridge, RT Mody, SH Fisher, A Schein, JR AF Frei, C. R. Jaso, T. C. Mortensen, E. M. Restrepo, M. I. Raut, M. K. Oramasionwu, C. U. Ruiz, A. D. Makos, B. R. Ruiz, J. L. Attridge, R. T. Mody, S. H. Fisher, A. Schein, J. R. TI Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study SO CURRENT MEDICAL RESEARCH AND OPINION LA English DT Article; Proceedings Paper CT 43rd Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists CY DEC 07-11, 2008 CL Orlando, FL SP Amer Soc Hlth Syst Pharmacists DE Beta-lactam; Clinical practice guidelines; Community-acquired pneumonia; Fluoroquinolone; Length of stay; Macrolide ID BACTEREMIC PNEUMOCOCCAL PNEUMONIA; COMBINATION ANTIBIOTIC-THERAPY; LENGTH-OF-STAY; IN-HOSPITAL MORTALITY; ANTIMICROBIAL THERAPY; STREPTOCOCCUS-PNEUMONIAE; PROPENSITY SCORE; CONTROLLED-TRIAL; BETA-LACTAM; CARE AB Objective: The 2007 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines recommend that community-acquired pneumonia (CAP) patients admitted to hospital wards initially receive respiratory fluoroquinolone monotherapy or beta-lactam plus macrolide combination therapy. There is little evidence as to which regimen is preferred, or if differences in medical resource utilization exist between therapies. Thus, the authors compared length of hospital stay (LOS) and length of intravenous antibiotic therapy (LOIV) for patients who received initial levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily ('combination therapy'). Research design and methods: Adult hospital CAP cases from January 2005 to December 2007 were identified by principal discharge diagnosis code. Patients with a chest infiltrate and medical notes indicative of CAP were included. Direct intensive care unit admits and healthcare-associated cases were excluded. A propensity score technique was used to balance characteristics associated with initial antimicrobial therapy using multivariable regression to derive the scores. Propensity score categories, defined as propensity score quintiles, rather than propensity scores themselves, were used in the least squares regression model to assess the impact of LOS and LOIV. Results: A total of 495 patients from six hospitals met study criteria. Of these, 313 (63%) received levofloxacin and 182 (37%) received combination therapy. Groups were similar with respect to age, sex, most comorbidities, presenting signs and symptoms, and Pneumonia Severity Index (PSI) risk class. Patients on combination therapy were more likely to have heart failure and receive pre-admission antibiotics. Adjusted least squares mean (+/- SE) LOS and LOIV were shorter with levofloxacin versus combination therapy: LOS, 4.6 +/- 0.17 vs. 5.4 +/- 0.22 days, p<0.01; and LOIV, 3.6 +/- 0.17 vs. 4.8 +/- 0.21 days, p<0.01. Results for PSI risk class III or IV patients were: LOS, 5.0 +/- 0.30 vs. 5.9 +/- 0.37 days, p=0.07; and LOIV, 3.7 +/- 0.33 vs. 5.2 +/- 0.39 days, p<0.01. Due to the retrospective study design, limited sample size, and scope (single health-network), the authors encourage replication of this study in other data sources. Conclusions: Given the LOS and LOIV reductions of 0.8 and 1.2 days, respectively, utilization of levofloxacin 750 mg daily for CAP patients admitted to the medical floor has the potential to result in substantial cost savings for US hospitals. C1 [Frei, C. R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Frei, C. R.; Oramasionwu, C. U.; Ruiz, A. D.; Makos, B. R.; Ruiz, J. L.; Attridge, R. T.] Univ Texas Austin, Austin, TX 78712 USA. [Jaso, T. C.] Seton Family Hosp, Austin, TX USA. [Mortensen, E. M.; Restrepo, M. I.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Raut, M. K.; Mody, S. H.; Fisher, A.; Schein, J. R.] Ortho McNeil Janssen Sci Affairs LLC, Raritan, NJ USA. RP Frei, CR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Pharmacotherapy Educ & Res Ctr, 7703 Floyd Curl Dr,MSC 6220, San Antonio, TX 78229 USA. EM freic@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 NR 54 TC 10 Z9 13 U1 0 U2 5 PU LIBRAPHARM/INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND SN 0300-7995 J9 CURR MED RES OPIN JI Curr. Med. Res. Opin. PD APR PY 2009 VL 25 IS 4 BP 859 EP 868 DI 10.1185/03007990902779749 PG 10 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 444HC UT WOS:000265970300006 PM 19231913 ER PT J AU Nyendak, MR Lewinsohn, DA Lewinsohn, DM AF Nyendak, Melissa R. Lewinsohn, Deborah A. Lewinsohn, David M. TI New diagnostic methods for tuberculosis SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE diagnosis; immunological tests; molecular probes; tuberculosis ID ACID AMPLIFICATION TESTS; BLOOD INTERFERON-GAMMA; MEDIATED ISOTHERMAL AMPLIFICATION; DRUG-SUSCEPTIBILITY ASSAY; MULTIDRUG-RESISTANT TUBERCULOSIS; POLYMERASE-CHAIN-REACTION; ENZYME-LINKED IMMUNOSPOT; HIV-INFECTED PATIENTS; LINE PROBE ASSAY; CELL-BASED ASSAY AB Purpose of review During the last decade. laboratory tests for the detection of Mycobacterium tuberculosis (Mtb) have improved dramatically. Improvements in the ability to detect latent infection with Mtb. disease associated with Mtb, and strains resistant to commonly used antibiotics are reviewed. Recent findings Advances in the detection of Mtb include light-emitting diode fluorescence microscopy, nucleic acid amplification of Mtb and drug-resistant strains, and more rapid liquid culture with adjunct drug susceptibility testing. In the detection of latent tuberculosis infection, gamma release assays offer improved accuracy over the tuberculin skin test. interferon Summary The past 10 years have seen the most rapid growth in new diagnostics for Mtb in over a century. Although these tests offer improvements in the ability to detect Mtb, drug-resistant isolates. and those with latent tuberculosis infection, these improvements are counter-balanced by the need to deploy these tests in areas where Mtb burden is highest. C1 [Lewinsohn, David M.] Portland VA Med Ctr, Div Pulm & Crit Care Med, Pulmonary & CCM, Portland, OR 97239 USA. [Nyendak, Melissa R.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Div Pediat Infect Dis, Portland, OR 97201 USA. RP Lewinsohn, DM (reprint author), Portland VA Med Ctr, Div Pulm & Crit Care Med, Pulmonary & CCM, R&D 11,3710 SW US Vet Rd, Portland, OR 97239 USA. EM lewinsod@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 FU NIH/NCRR [5 KL2 RR024141-03]; NIH [N01-A1-400081, RO1 A1054474, RO1A148090] FX This work is funded by grants NIH/NCRR 5 KL2 RR024141-03 to Melissa R. Nyendak, NIH HHSN266200400081C (N01-A1-400081), RO1 A1054474 to Deborah A. Levvinsohn, and VA Merit Review Grant, Portland VA Medical Center, NIH HHSN266200400081C (N01-A1-400081). RO1A148090 to David M. Lewinsohn. NR 100 TC 39 Z9 42 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD APR PY 2009 VL 22 IS 2 BP 174 EP 182 DI 10.1097/QCO.0b013e3283262fe9 PG 9 WC Infectious Diseases SC Infectious Diseases GA 429YI UT WOS:000264955600014 PM 19283913 ER PT J AU Nery, FG Hatch, JP Nicoletti, MA Monkul, ES Najt, P Matsuo, K Cloninger, CR Soares, JC AF Nery, Fabiano G. Hatch, John P. Nicoletti, Mark A. Monkul, E. Serap Najt, Pablo Matsuo, Koji Cloninger, C. Robert Soares, Jair C. TI TEMPERAMENT AND CHARACTER TRAITS IN MAJOR DEPRESSIVE DISORDER: INFLUENCE OF MOOD STATE AND RECURRENCE OF EPISODES SO DEPRESSION AND ANXIETY LA English DT Article DE major depressive disorder; anxiety disorders; personality; temperament; character; psychopathology ID TRIDIMENSIONAL PERSONALITY QUESTIONNAIRE; BIPOLAR DISORDER; UNIPOLAR DEPRESSION; INVENTORY; DIMENSIONS; ANXIETY; OUTPATIENTS; ISSUES AB Background: The objective of this study was to compare personality traits between major depressive disorder (MDD) patients and healthy comparison subjects (HC) and examine if personality traits in patients are associated with specific clinical characteristics of the disorder. Methods: Sixty MDD patients (45 depressed, 15 remitted) were compared to 60 HC using the Temperament and Character Inventory. Analysis of covariance, with age and gender as covariates, was used to compare the mean Temperament and Character Inventory scores among the subject groups. Results: Depressed MDD patients scored significantly higher than HC on novelty seeking, harm avoidance, and self-transcendence and lower on reward dependence, self-directedness, and cooperativeness. Remitted MDD patients scored significantly lower than HC only on self-directedness. Comorbidity with anxiety disorder had a main effect only on harm avoidance. Harm avoidance was positively correlated with depression intensity and with number of episodes. Self-directedness bad an inverse correlation with depression intensity. Conclusions: MDD patients present a different personality profile from HC, and these differences are influenced by mood state and comorbid anxiety disorders. When considering patients who have been in remission for some time, the differences pertain to few personality dimensions. Cumulated number of depressive episodes may result in increased harm avoidance. Depression and Anxiety 26.382-388, 2009. (c) 2009 Wiky-Liss, Inc. C1 [Nicoletti, Mark A.; Soares, Jair C.] Univ N Carolina, Dept Psychiat, CERT BD, Sch Med, Chapel Hill, NC 27599 USA. [Nery, Fabiano G.; Hatch, John P.; Monkul, E. Serap; Najt, Pablo; Matsuo, Koji] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nery, Fabiano G.; Monkul, E. Serap; Najt, Pablo; Matsuo, Koji] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Nery, Fabiano G.] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. [Hatch, John P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. [Cloninger, C. Robert] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. RP Soares, JC (reprint author), Univ N Carolina, Dept Psychiat, CERT BD, Sch Med, 10616 Neurosci Hosp CB 7160, Chapel Hill, NC 27599 USA. EM jsoares@med.unc.edu RI Cloninger, Claude/F-5357-2012 OI Cloninger, Claude/0000-0003-3096-4807 FU UTHSCSA GCRC [M01-RR-01346]; NARSAD; Krus Endowed Chair in Psychiatry (UTHSCSA); Veterans Administration; American Foundation for Suicide Prevention (ASFP); [MH 01736]; [MH 068662] FX This research was partly supported by grants MH 01736, MH 068662, UTHSCSA GCRC (M01-RR-01346), NARSAD, the Krus Endowed Chair in Psychiatry (UTHSCSA), the Veterans Administration (VA Merit Review), and the American Foundation for Suicide Prevention (ASFP). The authors of this paper do not have any commercial associations that might pose a conflict of interest in connection with this article. NR 31 TC 37 Z9 38 U1 2 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD APR PY 2009 VL 26 IS 4 BP 382 EP 388 DI 10.1002/da.20478 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 430QD UT WOS:000265002700011 PM 19195006 ER PT J AU Zraika, S Hull, RL Udayasankar, J Aston-Mourney, K Subramanian, SL Kisilevsky, R Szarek, WA Kahn, SE AF Zraika, S. Hull, R. L. Udayasankar, J. Aston-Mourney, K. Subramanian, S. L. Kisilevsky, R. Szarek, W. A. Kahn, S. E. TI Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis SO DIABETOLOGIA LA English DT Article DE Beta cell apoptosis; IAPP; Insulin secretion; Islet amyloid; Oxidative stress ID FORMATION IN-VITRO; HUMAN AMYLIN; DIABETES-MELLITUS; INSULIN-SECRETION; GLUCOSE TOXICITY; MOUSE ISLETS; PROTEIN GLYCOSYLATION; TRANSGENIC MOUSE; POLYPEPTIDE IAPP; FIBRIL FORMATION AB Islet amyloid in type 2 diabetes contributes to loss of beta cell mass and function. Since islets are susceptible to oxidative stress-induced toxicity, we sought to determine whether islet amyloid formation is associated with induction of oxidative stress. Human islet amyloid polypeptide transgenic and non-transgenic mouse islets were cultured for 48 or 144 h with or without the antioxidant N-acetyl-l-cysteine (NAC) or the amyloid inhibitor Congo Red. Amyloid deposition, reactive oxygen species (ROS) production, beta cell apoptosis, and insulin secretion, content and mRNA were measured. After 48 h, amyloid deposition was associated with increased ROS levels and increased beta cell apoptosis, but no change in insulin secretion, content or mRNA levels. Antioxidant treatment prevented the rise in ROS, but did not prevent amyloid formation or beta cell apoptosis. In contrast, inhibition of amyloid formation prevented the induction of oxidative stress and beta cell apoptosis. After 144 h, amyloid deposition was further increased and was associated with increased ROS levels, increased beta cell apoptosis and decreased insulin content. At this time-point, antioxidant treatment and inhibition of amyloid formation were effective in reducing ROS levels, amyloid formation and beta cell apoptosis. Inhibition of amyloid formation also increased insulin content. Islet amyloid formation induces oxidative stress, which in the short term does not mediate beta cell apoptosis, but in the longer term may feed back to further exacerbate amyloid formation and contribute to beta cell apoptosis. C1 [Zraika, S.; Hull, R. L.; Udayasankar, J.; Aston-Mourney, K.; Subramanian, S. L.; Kahn, S. E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Zraika, S.; Hull, R. L.; Udayasankar, J.; Aston-Mourney, K.; Subramanian, S. L.; Kahn, S. E.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Kisilevsky, R.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada. [Kisilevsky, R.] Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada. [Szarek, W. A.] Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada. RP Zraika, S (reprint author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way 151, Seattle, WA 98108 USA. EM zraikas@u.washington.edu OI Aston-Mourney, Kathryn/0000-0003-1412-6715; Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 FU Department of Veterans Affairs; NIH [DK-75998, DK-17047, DK-74404]; Juvenile Diabetes Research Foundation; American Diabetes Association; Canadian Institutes for Health Research [MOP-3153]; Natural Sciences and Engineering Research Council of Canada; Institute for the Study of Aging FX We thank B. Barrow, R. Bhatti, T. Braddock, M. Cone, M. Peters, J. Teague, M. Watts and J. Willard for excellent technical support. This work was supported by research funding from the Department of Veterans Affairs and NIH grants DK-75998 and DK-17047. S. Zraika was supported by a Juvenile Diabetes Research Foundation Postdoctoral Fellowship and an American Diabetes Association Mentor-Based Fellowship. R. L. Hull was supported by NIH grant DK-74404. Preparation and development of WAS-406 was funded by the Canadian Institutes for Health Research grant MOP-3153, the Natural Sciences and Engineering Research Council of Canada and the Institute for the Study of Aging. NR 46 TC 89 Z9 90 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD APR PY 2009 VL 52 IS 4 BP 626 EP 635 DI 10.1007/s00125-008-1255-x PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 413IR UT WOS:000263787300012 PM 19148619 ER PT J AU Coletta, DK Sriwijitkamol, A Wajcberg, E Tantiwong, P Li, M Prentki, M Madiraju, M Jenkinson, CP Cersosimo, E Musi, N DeFronzo, RA AF Coletta, D. K. Sriwijitkamol, A. Wajcberg, E. Tantiwong, P. Li, M. Prentki, M. Madiraju, M. Jenkinson, C. P. Cersosimo, E. Musi, N. DeFronzo, R. A. TI Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial SO DIABETOLOGIA LA English DT Article DE Adiponectin; AMP kinase; Insulin sensitivity; Mitochondrial; Muscle; Pioglitazone ID TYPE-2 DIABETIC SUBJECTS; ACETYL-COA CARBOXYLASE; POLYCYSTIC-OVARY-SYNDROME; PLACEBO-CONTROLLED TRIAL; INSULIN SENSITIVITY; ADIPOSE-TISSUE; MALONYL-COA; GLOBULAR DOMAIN; GAMMA AGONISTS; RECEPTOR-GAMMA AB The molecular mechanisms by which thiazolidinediones improve insulin sensitivity in type 2 diabetes are not fully understood. We hypothesised that pioglitazone would activate the adenosine 5'-monophosphate-activated protein kinase (AMPK) pathway and increase the expression of genes involved in adiponectin signalling, NEFA oxidation and mitochondrial function in human skeletal muscle. A randomised, double-blind, parallel study was performed in 26 drug-naive type 2 diabetes patients treated with: (1) pioglitazone (n = 14) or (2) aggressive nutritional therapy (n = 12) to reduce HbA(1c) to levels observed in the pioglitazone-treated group. Participants were assigned randomly to treatment using a table of random numbers. Before and after 6 months, patients reported to the Clinical Research Center of the Texas Diabetes Institute for a vastus lateralis muscle biopsy followed by a 180 min euglycaemic-hyperinsulinaemic (80 mU m(-2) min(-1)) clamp. All patients in the pioglitazone (n = 14) or nutritional therapy (n = 12) group were included in the analysis. Pioglitazone significantly increased plasma adiponectin concentration by 79% and reduced fasting plasma NEFA by 35% (both p < 0.01). Following pioglitazone, insulin-stimulated glucose disposal increased by 30% (p < 0.01), and muscle AMPK and acetyl-CoA carboxylase (ACC) phosphorylation increased by 38% and 53%, respectively (p < 0.05). Pioglitazone increased mRNA levels for adiponectin receptor 1 and 2 genes (ADIPOR1, ADIPOR2), peroxisome proliferator-activated receptor gamma, coactivator 1 gene (PPARGC1) and multiple genes involved in mitochondrial function and fat oxidation. Despite a similar reduction in HbA(1c) and similar improvement in insulin sensitivity with nutritional therapy, there were no significant changes in muscle AMPK and ACC phosphorylation, or the expression of ADIPOR1, ADIPOR2, PPARGC1 and genes involved in mitochondrial function and fat oxidation. No adverse (or unexpected) effects or side effects were reported from the study. Pioglitazone increases plasma adiponectin levels, stimulates muscle AMPK signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation. These changes may represent an important cellular mechanism by which thiazolidinediones improve skeletal muscle insulin sensitivity. Trial registration: NCT 00816218 Funding: This trial was funded by National Institutes of Health Grant DK24092, VA Merit Award, GCRC Grant RR01346, Executive Research Committee Research Award from the University of Texas Health Science Center at San Antonio, American Diabetes Association Junior Faculty Award, American Heart Association National Scientist Development Grant, Takeda Pharmaceuticals North America Grant and Canadian Institute of Health Research Grant. C1 [Coletta, D. K.] Arizona State Univ, Coll Liberal Arts & Sci, Ctr Metab Biol, Tempe, AZ 85287 USA. [Sriwijitkamol, A.; Wajcberg, E.; Tantiwong, P.; Li, M.; Jenkinson, C. P.; Cersosimo, E.; Musi, N.; DeFronzo, R. A.] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA. [Sriwijitkamol, A.; Wajcberg, E.; Tantiwong, P.; Li, M.; Cersosimo, E.; Musi, N.; DeFronzo, R. A.] Texas Diabet Inst, San Antonio, TX USA. [Prentki, M.; Madiraju, M.] Univ Montreal, Dept Nutr, Mol Nutr Unit, Montreal, PQ H3C 3J7, Canada. [Prentki, M.; Madiraju, M.] Univ Montreal, Dept Biochem, Mol Nutr Unit, Montreal, PQ H3C 3J7, Canada. [Prentki, M.; Madiraju, M.] Univ Montreal, Montreal Diabet Res Ctr, Montreal, PQ H3C 3J7, Canada. [Prentki, M.; Madiraju, M.] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada. [Jenkinson, C. P.; DeFronzo, R. A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Coletta, DK (reprint author), Arizona State Univ, Coll Liberal Arts & Sci, Ctr Metab Biol, POB 873704, Tempe, AZ 85287 USA. EM Dawn.Coletta@asu.edu RI Coletta, Dawn/G-6382-2016 OI Coletta, Dawn/0000-0001-5819-5152 FU NIH [DK24092]; VA Merit Award; GCRC [RR01346]; University of Texas Health Science Center at San Antonio; American Diabetes Association Junior Faculty Award; American Heart Association National Scientist Development; Takeda Pharmaceuticals North America; Canadian Institute of Health Research FX This work was supported by NIH grant DK24092 ( R. A. DeFronzo), a VA Merit Award ( R. A. DeFronzo), GCRC grant RR01346, an Executive Research Committee Research Award from the University of Texas Health Science Center at San Antonio ( N. Musi), an American Diabetes Association Junior Faculty Award ( N. Musi), an American Heart Association National Scientist Development Grant ( D. K. Coletta), a grant from Takeda Pharmaceuticals North America and a grant from the Canadian Institute of Health Research ( M. Prentki). We thank all the patients who participated in the studies and the Texas Diabetes Institute nurses who helped to perform the studies. We thank N. Cyr for excellent technical assistance. NR 50 TC 52 Z9 56 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD APR PY 2009 VL 52 IS 4 BP 723 EP 732 DI 10.1007/s00125-008-1256-9 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 413IR UT WOS:000263787300023 PM 19169664 ER PT J AU Bilimoria, KY Bentrem, DJ Rock, CE Stewart, AK Ko, CY Halverson, A AF Bilimoria, Karl Y. Bentrem, David J. Rock, Colin E. Stewart, Andrew K. Ko, Clifford Y. Halverson, Amy TI Outcomes and Prognostic Factors for Squamous-Cell Carcinoma of the Anal Canal: Analysis of Patients From the National Cancer Data Base SO DISEASES OF THE COLON & RECTUM LA English DT Article DE Anal carcinoma; Surgery; Treatment; National Cancer Data Base; Staging; Disparities; Chemotherapy; Radiation ID EPIDERMOID CARCINOMA; RANDOMIZED-TRIAL; COMBINED THERAPY; RARE CANCER; HEALTH-CARE; RADIOTHERAPY; RADIATION; MITOMYCIN; SURVIVAL; RADIOCHEMOTHERAPY AB PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population. METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000). Univariate and multivariable methods were used to assess factors associated with survival. Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome. RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent). Overall five-year survival was 58.0 percent. The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663). On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >= 65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001). There was not a significant difference in survival by hospital type or year of diagnosis. CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal. C1 [Bilimoria, Karl Y.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Bentrem, David J.; Rock, Colin E.; Halverson, Amy] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Canc Programs, 633 N St Clair St,25th Floor, Chicago, IL 60611 USA. EM k-bilimori@northwestern.edu FU American College of Surgeons Clinical Scholars in Residence FX Dr. Bilimoria is supported by the American College of Surgeons Clinical Scholars in Residence program. NR 40 TC 53 Z9 55 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0012-3706 J9 DIS COLON RECTUM JI Dis. Colon Rectum PD APR PY 2009 VL 52 IS 4 BP 624 EP 631 DI 10.1007/DCR.0b013e31819eb7f0 PG 8 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 544GZ UT WOS:000273643900015 PM 19404066 ER PT J AU Cacciola, JS Koppenhaver, JM Alterman, AI Mckay, JR AF Cacciola, John S. Koppenhaver, Janelle M. Alterman, Arthur I. McKay, James R. TI Posttraumatic stress disorder and other psychopathology in substance abusing patients SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Posttraumatic stress disorder (PTSD); Alcohol dependence; Psychiatric comorbidity ID ADDICTION SEVERITY INDEX; STRUCTURED CLINICAL INTERVIEW; TEST-RETEST RELIABILITY; PSYCHIATRIC COMORBIDITY; COCAINE DEPENDENCE; PTSD; OUTCOMES; HISTORY; WOMEN AB Studies demonstrating greater problem severity in substance abuse patients with posttraumatic stress disorder (PTSD) versus those without have rarely considered other co-occurring psychiatric disorders. This study of 466 male veterans recently admitted to outpatient substance abuse treatment attempts to identify problems associated with PTSD versus those associated with other nonsubstance use Axis I disorders. Problem severity, particularly psychiatric. was examined across four groups of patients with substance use disorders (SUDs). Those with: 1, SUDs only (SU-Only); 2, PTSD, but no other Axis I disorders (SU + PTSID): 3, PTSD and other Axis I disorders (SU + PTSD + Axis 1): and 4, no PTSD, but other Axis I disorders (SU + other Axis 1). Results suggested a hierarchy of psychiatric, and to a lesser extent, other life problem severities associated with these diagnostic groupings. The most severe group was SU + PTSD + Axis 1, followed in decreasing severity by the SU + other Axis 1, SU + PTSD, and SU-Only groups. Additional analyses comparing the SU + PTSD + Axis I patients with a subgroup of Axis I patients with more than one Axis I disorder (SU + multiple Axis 1) revealed few group differences except for more lifetime suicide attempts and psychiatric hospitalizations in the SU + PTSD + Axis I group. The findings suggest that it is not PTSD per se, but the frequent co-occurrence of PTSD and other psychopathology that largely accounts for previously reported greater problem severity of SLID patients with PTSD. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Cacciola, John S.] Treatment Res Inst, Philadelphia, PA 19106 USA. [Cacciola, John S.; Koppenhaver, Janelle M.; Alterman, Arthur I.; McKay, James R.] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Ctr Studies Addict, Philadelphia, PA 19104 USA. RP Cacciola, JS (reprint author), Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mail W, Philadelphia, PA 19106 USA. EM jcacciola@tresearch.org FU NIDA [P60DA005186] FX Funding for this study was provided in part by NIDA Grant P60DA005186 (Charles P. O'Brien, PI); the NIDA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 37 TC 12 Z9 14 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2009 VL 101 IS 1-2 BP 27 EP 33 DI 10.1016/j.drugalcdep.2008.10.018 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 422KS UT WOS:000264427200005 PM 19062202 ER PT J AU Ma, RS Latif, R Davies, TF AF Ma, Risheng Latif, Rauf Davies, Terry F. TI Thyrotropin-Independent Induction of Thyroid Endoderm from Embryonic Stem Cells by Activin A SO ENDOCRINOLOGY LA English DT Article ID RECEPTOR MESSENGER-RNA; DEFINITIVE ENDODERM; IN-VITRO; DIFFERENTIATION; EXPRESSION; MOUSE; TSH; CULTURE AB To model the differentiation of thyroid epithelial cells, we examined embryoid bodies derived from undifferentiated murine embryonic stem cells treated with activin A to induce endoderm differentiation, the germ layer from which thyroid cells occur. The resulting endodermal cells were then further exposed to TSH and/or IGF-I for up to 21 d. Oct-4 and REX1 expression, required to sustain stem cell self-renewal and pluripotency, were appropriately down-regulated, whereas GATA-4, and alpha-fetoprotein, both endodermal-specific markers, increased as the embryonic stem cells were exposed to activin A. By d 5 culture, TSH receptor (TSHR) and sodium iodide symporter (NIS) gene and protein expression were markedly induced. Cells isolated by the fluorescence-activated cell sorter simultaneously expressed not only TSHR and NIS proteins but also PAX8 mRNA, an expression pattern unique to thyroid cells and expected in committed thyroid progenitor cells. Such expression continued until d 21 with no influence seen by the addition of TSH or IGF-I. The sequence of gene expression changes observed in these experiments demonstrated the emergence of definitive thyroid endoderm. The activin A induction of thyroid-specific markers, NIS and TSHR, occurred in the absence of TSH stimulation, and, therefore, the emergence of thyroid endoderm in vitro paralleled the emergence of thyroid cells in TSHR-knockout mice. Activin A is clearly a major regulator of thyroid endoderm. (Endocrinology 150: 1970-1975, 2009) C1 [Ma, Risheng; Latif, Rauf; Davies, Terry F.] James J Peters Vet Affairs Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, Bronx, NY 10468 USA. RP Ma, RS (reprint author), Vet Affairs Med Ctr, Room 2F-27,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM risheng.ma@mssm.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK069713]; Veteran Affairs Merit Award program; David Owen Segal Endowment [T32-DK007645-19] FX Supported in part by DK069713 from the National Institute of Diabetes and Digestive and Kidney Diseases, the Veteran Affairs Merit Award program (to T. F. D.), the David Owen Segal Endowment, and the T32-DK007645-19 Training Grant in Molecular and Cellular Endocrinology. NR 20 TC 22 Z9 23 U1 0 U2 7 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD APR PY 2009 VL 150 IS 4 BP 1970 EP 1975 DI 10.1210/en.2008-1374 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 422QN UT WOS:000264442900050 PM 19074581 ER PT J AU Hao, BH Clancy, CJ Cheng, SJ Raman, SB Iczkowski, KA Nguyen, MH AF Hao, Binghua Clancy, Cornelius J. Cheng, Shaoji Raman, Suresh B. Iczkowski, Kenneth A. Nguyen, M. Hong TI Candida albicans RFX2 Encodes a DNA Binding Protein Involved in DNA Damage Responses, Morphogenesis, and Virulence SO EUKARYOTIC CELL LA English DT Article ID CANDIDA-ALBICANS GENES; YEAST-HYPHA MORPHOGENESIS; HUMAN ORAL CANDIDOSIS; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; CHECKPOINT PATHWAYS; FUNGAL PATHOGEN; REPLICATION; EXPRESSION; TRANSCRIPTION AB We previously showed that Candida albicans orf19.4590, which we have renamed RFX2, expresses a protein that is reactive with antibodies in persons with candidiasis. In this study, we demonstrate that C. albicans RFX2 shares some functional redundancy with Saccharomyces cerevisiae RFX1. Complementation of an S. cerevisiae rfx1 mutant with C. albicans RFX2 partially restored UV susceptibility and the repression of DNA damage response genes. DNA damage- and UV-induced genes RAD6 and DDR48 were derepressed in a C. albicans rfx2 null mutant strain under basal conditions, and the mutant was significantly more resistant to UV irradiation, heat shock, and ethanol than wild-type strain SC5314. The rfx2 mutant was hyperfilamentous on solid media and constitutively expressed hypha-specific genes HWP1, ALS3, HYR1, ECE1, and CEK1. The mutant also demonstrated increased invasion of solid agar and significantly increased adherence to human buccal epithelial cells. During hematogenously disseminated candidiasis, mice infected with the mutant had a significantly delayed time to death compared to the wild type. During oropharyngeal candidiasis, mice infected with the mutant had significantly lower tissue burdens in the oral cavity and esophagus at 7 days and they were less likely to develop disseminated infections because of mucosal translocation. data demonstrate that C. albicans Rfx2p regulates DNA damage responses, morphogenesis, and virulence. C1 [Hao, Binghua; Clancy, Cornelius J.; Cheng, Shaoji; Raman, Suresh B.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15203 USA. [Clancy, Cornelius J.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Iczkowski, Kenneth A.] Univ Colorado, Dept Pathol, Denver, CO 80202 USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, 3550 Terrace St,Suite 871, Pittsburgh, PA 15203 USA. EM MHN5+@pitt.edu FU NIH Mycology Research Unit Program [5P01AI061537- 02]; VA Medical Research Service; University of Florida FX Research was funded by an NIH Mycology Research Unit Program Project Award (5P01AI061537- 02 to C. J. C. and M. H. N.) and supported by the VA Medical Research Service and the University of Florida. NR 56 TC 18 Z9 33 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1535-9778 J9 EUKARYOT CELL JI Eukaryot. Cell PD APR PY 2009 VL 8 IS 4 BP 627 EP 639 DI 10.1128/EC.00246-08 PG 13 WC Microbiology; Mycology SC Microbiology; Mycology GA 431DP UT WOS:000265041800023 PM 19252121 ER PT J AU Brouwer, IA Raitt, MH Dullemeijer, C Kraemer, DF Zock, PL Morris, C Katan, MB Connor, WE Camm, JA Schouten, EG McAnulty, J AF Brouwer, Ingeborg A. Raitt, Merritt H. Dullemeijer, Carla Kraemer, Dale F. Zock, Peter L. Morris, Cynthia Katan, Martijn B. Connor, William E. Camm, John A. Schouten, Evert G. McAnulty, John TI Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators SO EUROPEAN HEART JOURNAL LA English DT Article DE ICD; Arrhythmia; Fish oil; Omega-3 ID POLYUNSATURATED FATTY-ACIDS; REINFARCTION TRIAL DART; CORONARY-HEART-DISEASE; SUDDEN-DEATH; MYOCARDIAL-INFARCTION; RISK; SUPPLEMENTATION; METAANALYSIS; ARRHYTHMIAS; PREVENTION AB To determine the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator (ICD) patients by combining results from published trials. We searched in the Medline, EMBASE, and Cochrane databases and performed a meta-analysis on all three available trials on fish oil and ventricular arrhythmia. Furthermore, we pooled individual data of two of these randomized, double-blind, placebo-controlled trials (Raitt et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-2891 and Brouwer et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-2619). The main outcome was time to first confirmed ventricular fibrillation (VF) or ventricular tachycardia (VT) combined with death for the meta-analysis, and time to first spontaneous confirmed VF or VT for the pooled analysis. The meta-analysis (n = 1148) showed no convincing protective effect of fish oil (RR 0.90; 95% CI 0.67-1.22). The hazard ratio for the subgroup of patients with coronary artery disease at baseline (0.79; 0.60-1.06) tended towards a protective effect. The pooled analysis (n = 722) showed that time to appropriate ICD intervention was similar for fish oil and placebo treatment (log-rank P = 0.79). These findings do not support a protective effect of omega-3 PUFAs from fish oil on cardiac arrhythmia in all patients with an ICD. Current data neither prove nor disprove a beneficial or a detrimental effect for subgroups of patients with specific underlying pathologies. C1 [Brouwer, Ingeborg A.; Dullemeijer, Carla; Schouten, Evert G.] TI Food & Nutr, Wageningen, Netherlands. [Brouwer, Ingeborg A.] Vrije Univ Amsterdam, Inst Hlth Sci, NL-1081 HV Amsterdam, Netherlands. [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR USA. [Dullemeijer, Carla] Univ Wageningen & Res Ctr, Dept Human Nutr, Wageningen, Netherlands. [Kraemer, Dale F.; Morris, Cynthia] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Kraemer, Dale F.; Morris, Cynthia] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Kraemer, Dale F.] Oregon State Univ, Dept Pharm Practice, Portland, OR USA. [Zock, Peter L.] Unilever Food & Hlth Res Inst, Vlaardingen, Netherlands. [Connor, William E.] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol Metab & Clin Nutr, Portland, OR 97201 USA. [Camm, John A.] St George Hosp & Med Sch, London, England. [McAnulty, John] Good Samaritan Hosp, Portland, OR 97210 USA. RP Brouwer, IA (reprint author), TI Food & Nutr, Wageningen, Netherlands. EM ingeborg.brouwer@falw.vu.nl OI Raitt, Merritt/0000-0001-5638-7732 FU Wageningen Centre for Food Sciences (WCFS); National Institutes of Health [R01HL61682]; Public Health Service [5 M01 RROO334]; Top Institute Food and Nutrition; TI Food and Nutrition FX The SOFA study was funded by the Wageningen Centre for Food Sciences (WCFS) with an additional grant from the European Union (SEAFOODplus integrated project No. 506359). The Portland study was funded by the National Institutes of Health (grant R01HL61682), Public Health Service (grant 5 M01 RROO334), and Hoffman-LaRoche Inc. The meta- analysis and pooled analysis were funded by Top Institute Food and Nutrition. TI Food and Nutrition, formerly known as WCFS, is a public/private partnership. Partners are major Dutch food companies and research organizations. NR 26 TC 69 Z9 70 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD APR PY 2009 VL 30 IS 7 BP 820 EP 826 DI 10.1093/eurheartj/ehp003 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 428ZC UT WOS:000264889600017 PM 19196720 ER PT J AU Hussein, MRA Ali, HO Abdulwahed, SR Argoby, Y Tobeigei, FH AF Hussein, Mahmoud-Rezk A. Ali, Hayder O. Abdulwahed, Saad R. Argoby, Yahia Tobeigei, Faisal H. TI Calciphylaxis cutis: A case report and review of literature SO EXPERIMENTAL AND MOLECULAR PATHOLOGY LA English DT Article DE Kidney; Calciphylaxis; Skin ID RENAL-FAILURE; NECROSIS AB Calciphylaxis is a poorly understood syndrome of vascular calcification and skin necrosis. It affects 1-4% of the population with end stage renal disease (ESRD). Disorders implicated in the pathogenesis of calciphylaxis include chronic renal failure, hypercalcemia, hyperphosphatemia, an elevated calcium-phosphate product, and secondary hyperparathyroidism (Essary, L.R. and Wick, M.R. (2000) Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am. J. Clin. Pathol. 113, 280-287, Beitz, J.M. (2004) Calciphylaxis: an uncommon but potentially deadly form of skin necrosis. Am. J. Nurs. 104, 36-37.). Although these abnormalities are extremely common in-patients with ESRD, calciphylaxis is relatively rare. The mortality rate of calciphylaxis is about 60-80%. The leading cause of death is sepsis from necrotic skin lesions (Hitti, W. A., Papadimitriou, J.C., Bartlett, S. and Wali, R.K. (2007) Spontaneous cutaneous ulcers in a patient with a moderate degree of chronic kidney disease: a different spectrum of calciphylaxis. Scand. J. Urol. Nephrol. 1-3.). Here, we report a case of calciphylaxis in a 23-year-old female with past history of chronic renal failure, renal transplantation and intake of immunosuppressive drug. The relevant literature was discussed. (C) 2009 Elsevier Inc. All rights reserved. C1 [Abdulwahed, Saad R.] Al Azhar Univ, Dept Radiol, Assiut, Egypt. [Hussein, Mahmoud-Rezk A.] Univ Wisconsin, Sch Med, Madison, WI 53705 USA. [Hussein, Mahmoud-Rezk A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM mrcpath17@gmail.com NR 8 TC 10 Z9 10 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4800 J9 EXP MOL PATHOL JI Exp. Mol. Pathol. PD APR PY 2009 VL 86 IS 2 BP 134 EP 135 DI 10.1016/j.yexmp.2009.01.008 PG 2 WC Pathology SC Pathology GA 433KA UT WOS:000265201500010 PM 19348063 ER PT J AU Jang, YC Van Remmen, H AF Jang, Youngmok C. Van Remmen, Holly TI The mitochondrial theory of aging: Insight from transgenic and knockout mouse models SO EXPERIMENTAL GERONTOLOGY LA English DT Review DE Mitochondria; Mitochondrial theory of aging; Oxidative stress; Aging; Transgenic and knockout mouse models ID MANGANESE SUPEROXIDE-DISMUTASE; LIFE-SPAN; OXIDATIVE STRESS; DNA-DAMAGE; SKELETAL-MUSCLE; MICE; OVEREXPRESSION; MUTATIONS; BRAIN; RESTRICTION AB A substantial body of evidence has accumulated over the past 35 years in support of a role for oxidative damage to the mitochondrial respiratory chain and mitochondrial DNA in the determination of mammalian lifespan. The goal of this review is to provide a concise summary of recent studies using transgenic and knockout mouse models with altered expression of mitochondrial antioxidant enzymes (MnSOD (Sod2Tg and Sod2(+/-)), thioredoxin 2 (Trx2(+/-)), mitochondrial targeted catalase (mCAT) and mutant mice models that have been genetically manipulated to increase mitochondrial deletions or mutations (Poly(D257A/D257A) mutant mice) to examine the role of mitochondrial oxidative stress in aging. The majority of studies using these strategies do not support a clear role for mitochondrial oxidative stress or a vicious cycle of oxidative damage in the determination of lifespan in mice and furthermore do not support the free radical theory of aging. However, several key questions remain to be addressed and clearly more studies are required to fully understand the role of mitochondria in age-related disease and aging. (C) 2009 Elsevier Inc. All rights reserved. C1 [Jang, Youngmok C.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Jang, Youngmok C.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,MSC 7762, San Antonio, TX 78229 USA. EM vanremmen@uthscsa.edu NR 42 TC 99 Z9 101 U1 0 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD APR PY 2009 VL 44 IS 4 BP 256 EP 260 DI 10.1016/j.exger.2008.12.006 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 435JQ UT WOS:000265340600004 PM 19171187 ER PT J AU Sani, S Ostrem, JL Shimamoto, S Levesque, N Starr, PA AF Sani, Sepehr Ostrem, Jill L. Shimamoto, Shoichi Levesque, Nadja Starr, Philip A. TI Single unit "pauser" characteristics of the globus pallidus pars externa distinguish primary dystonia from secondary dystonia and Parkinson's disease SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Dystonia; Parkinson's disease; Neuronal pauses; Globus pallidus; Microelectrode recording ID DEEP BRAIN-STIMULATION; BASAL GANGLIA; FUNCTIONAL-ANATOMY; NEURONAL-ACTIVITY; GENERALIZED DYSTONIA; SUBTHALAMIC NUCLEUS; TECHNICAL APPROACH; DYT1 DYSTONIA; IN-VITRO; PALLIDOTOMY AB The presence of high frequency discharge neurons with long periods of silence or "pauses" in the globus pallidus pars externa (GPe) is a unique identifying feature of this nucleus. Prior studies have demonstrated that pause characteristics reflect synaptic inputs into GPe. We hypothesized that GPe pause characteristics should distinguish movement disorders whose basal ganglia network abnormalities are different. We examined Pause characteristics in 224 GPe units in patients with primary generalized dystonia, Parkinson's disease (PD), and secondary dystonia, undergoing single unit microelectrode recording for DBS placement in the awake state. Pauses in neuronal discharge Were identified using the Poisson surprise method. Mean pause length in primary dystonia (606.8373.3) was higher than in PD (557.4366.6) (p < 0.05). Interpause interval (IPI) was lower in primary dystonia (2331.63874.1) than PD (3646.45894.5) (p < 0.01), and mean pause frequency was higher in primary dystonia (0.140.10) than PD (0.070.12) (p < 0.01). Comparison of pause characteristics in primary versus secondary generalized dystonia revealed a significantly longer mean pause length in primary (606.8373.3) than in secondary dystonia (495.6236.5) (p < 0.01). IPI was shorter in primary (2331.6 +/- 3874.1) than in secondary dystonia (3484.5 +/- 3981.6) (p < 0.01). The results show that pause characteristics recorded in the awake human GPe distinguish primary dystonia from Parkinson's disease and secondary dystonia. The differences may reflect increased phasic input from striatal D2 receptor positive cells in primary dystonia, and are consistent with a recent model proposing that GPe provides capacity scaling for cortical input. (c) 2008 Elsevier Inc. All rights reserved. C1 [Sani, Sepehr; Ostrem, Jill L.; Shimamoto, Shoichi; Levesque, Nadja; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Sani, Sepehr; Ostrem, Jill L.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,Box 0445, San Francisco, CA 94143 USA. EM starrp@neurosurg.ucsf.edu FU NINDS NIH HHS [K08 NS002201, K08 NS002201-05] NR 38 TC 10 Z9 10 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 2009 VL 216 IS 2 BP 295 EP 299 DI 10.1016/j.expneurol.2008.12.006 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 424ZK UT WOS:000264606600008 PM 19146856 ER PT J AU Chen, YX Gelfond, J McManus, LM Shireman, PK AF Chen, Yongxin Gelfond, Jonathan McManus, Linda M. Shireman, Paula K. TI Reproducibility of miRNA Expression by Proliferating C2C12 Cells Using RT-PCR Array SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Chen, Yongxin; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 361.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621500126 ER PT J AU Gentile, NE McKlveen, JM Czambel, RK Karwoski, TE Rubin, RT Rhodes, ME AF Gentile, Natalie E. McKlveen, Jessica M. Czambel, R. Kenneth Karwoski, Tracy E. Rubin, Robert T. Rhodes, Michael E. TI Sexually Diergic Hypothalamic-Pituitary-Adrenal (HPA) Responses to Single-Dose Nicotine, Continuous Nicotine by Osmotic Mini-Pumps, and Nicotine Withdrawal by Single-Dose Mecamylamine in Rats SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Gentile, Natalie E.; McKlveen, Jessica M.; Rhodes, Michael E.] St Vincent Coll, Dept Biol, Latrobe, PA USA. [Czambel, R. Kenneth; Karwoski, Tracy E.] Allegheny Singer Res Inst, Neurosci Res Ctr, Pittsburgh, PA 15212 USA. [Rubin, Robert T.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Mental Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 941.10 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621504457 ER PT J AU Kendall, RT Lee, MH El-Shewy, HM Janech, MG Luttrell, DK Luttrell, LM AF Kendall, Ryan Thomas Lee, Mi-Hye El-Shewy, Hesham M. Janech, Michael G. Luttrell, Deirdre K. Luttrell, Louis M. TI Biased agonism reveals new G protein-independent AT1a receptor signals SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Kendall, Ryan Thomas; Lee, Mi-Hye; El-Shewy, Hesham M.; Janech, Michael G.; Luttrell, Deirdre K.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 880.5 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621502593 ER PT J AU Martinez, CO McManus, LM Shireman, PK AF Martinez, Carlo Obet McManus, Linda M. Shireman, Paula K. TI Kinetics of myogenic progenitor cell (MPC) expansion and bone marrow-derived cell recruitment in skeletal muscle regeneration SO FASEB JOURNAL LA English DT Meeting Abstract C1 [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 739.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621504294 ER PT J AU Shacka, JJ DeWitte, C Roth, KA Ness, JM AF Shacka, John J. DeWitte, Cary Roth, Kevin A. Ness, Jayne M. TI Regulation of Neuron Death in Neonatal Hypoxia-Ischemia SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Shacka, John J.; DeWitte, Cary; Roth, Kevin A.; Ness, Jayne M.] Univ Alabama Birmingham, Birmingham, AL USA. [Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 235.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621504363 ER PT J AU Soto-Pina, AE Kadapakkam, S Mehring, C Hinojosa-Laborde, C Strong, R AF Soto-Pina, Alexandra Estela Kadapakkam, Sheela Mehring, Cynthia Hinojosa-Laborde, Carmen Strong, Randy TI Role of adrenal medulla in dexamethasone-induced hypertension SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Soto-Pina, Alexandra Estela; Kadapakkam, Sheela; Mehring, Cynthia; Hinojosa-Laborde, Carmen; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Soto-Pina, Alexandra Estela; Kadapakkam, Sheela; Strong, Randy] S Texas Vet Hlth Care Network, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 969.14 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621504136 ER PT J AU Wey, MCY Fernandez, E Hinojosa-Laborde, C Strong, R AF Wey, Margaret Chia-Ying Fernandez, Elizabeth Hinojosa-Laborde, Carmen Strong, Randy TI Detoxification of Biogenic Aldehydes in Parkinsons Disease SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Wey, Margaret Chia-Ying; Fernandez, Elizabeth; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Wey, Margaret Chia-Ying; Fernandez, Elizabeth; Strong, Randy] S Texas Vet Hlth Care Network, GRECC, San Antonio, TX USA. [Hinojosa-Laborde, Carmen] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesiol, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 963.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621503424 ER PT J AU Wick, MJ Barr, EJ Wehling, CA Cool, CD Zamora, M Miller, YE Hersh, LB Voelkel, NF Dempsey, EC AF Wick, Marilee J. Barr, Erica J. Wehling, Carol A. Cool, Carlyne D. Zamora, Marty Miller, York E. Hersh, Louis B. Voelkel, Norbert F. Dempsey, Edward C. TI Lung neprilysin activity and expression are decreased in humans with COPD and pulmonary vascular remodeling SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Wick, Marilee J.; Barr, Erica J.; Dempsey, Edward C.] Univ Colorado Denver, CVP Res Lab, Aurora, CO USA. [Wick, Marilee J.; Cool, Carlyne D.; Zamora, Marty; Miller, York E.; Voelkel, Norbert F.] Univ Colorado Denver, Div Pulm, Aurora, CO USA. [Wehling, Carol A.; Miller, York E.; Dempsey, Edward C.] Denver VAMC, Denver, CO USA. [Hersh, Louis B.] Univ Kentucky, Lexington, KY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2009 VL 23 MA 770.3 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V27OC UT WOS:000208621500765 ER PT J AU El-Serag, HB Lagergren, J AF El-Serag, Hashem B. Lagergren, Jesper TI Alcohol Drinking and the Risk of Barrett's Esophagus and Esophageal Adenocarcinoma SO GASTROENTEROLOGY LA English DT Editorial Material ID GASTRIC CARDIA; REFLUX ESOPHAGITIS; CONSUMPTION; TOBACCO; CANCER C1 [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [El-Serag, Hashem B.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Lagergren, Jesper] Karolinska Inst, Dept Mol Med & Surg, Unit Esophageal & Gastr Res, Stockholm, Sweden. RP El-Serag, HB (reprint author), Baylor Coll Med, Dept Med, Gastroenterol Sect, 202 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu OI Lagergren, Jesper/0000-0002-5143-5448 FU NCI NIH HHS [R01 CA116845, R01 CA116845-03]; NIDDK NIH HHS [K24 DK078154, K24DK078154-03] NR 13 TC 8 Z9 9 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2009 VL 136 IS 4 BP 1155 EP 1157 DI 10.1053/j.gastro.2009.02.021 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 426OB UT WOS:000264716500010 PM 19236968 ER PT J AU Brades, S Svensson, CI Steinauer, J Pothoulakis, C Yaksh, TL Mayer, EA AF Brades, Sylvie Svensson, Camilla I. Steinauer, Joanne Pothoulakis, Charalabos Yaksh, Tony L. Mayer, Emeran A. TI Role of Spinal Microglia in Visceral Hyperalgesia and NK1R Up-Regulation in a Rat Model of Chronic Stress SO GASTROENTEROLOGY LA English DT Article ID NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; P38 MAPK; PROINFLAMMATORY CYTOKINES; MECHANICAL ALLODYNIA; GLIAL ACTIVATION; PATHOLOGICAL PAIN; NEUROPATHIC PAIN; GENE-EXPRESSION AB Background & Aims: Chronic psychological stress is associated with visceral hyperalgesia. and increased expression of spinal NK1 receptors (NK1Rs). We aimed to identify the role of spinal microglia in this process. Methods: Male Wistar rats were exposed to water avoidance (WA) or sham stress 1 hour each day for 10 days and given daily injections of minocycline, the p38 inhibitor SB203580, or saline. Phosphorylation levels of the kinase p38 (P-p38), the microglia marker OX42, NK1R, and I kappa B alpha were assessed by immunoblotting and/or immunostaining of spinal samples collected at day 11. The visceromotor response to colorectal. distention at baseline and following WA were also assayed in rats given injections of minocycline, SB203580, or vehicle. The effects of fractalkine were assessed on the visceromotor response in rats exposed to minocycline or vehicle. Results: P-p38 protein levels and immunoreactivity were increased in stressed rats and colocalized with OX42-positive cells and neurons in the dorsal horn. This increase was reversed by minocycline or SB203580 exposure. Stress-induced increased NK1R expression was blocked by minocycline but not SB203580. WA-induced decreased I kappa B alpha expression was blocked by minocycline and SB203580. WA-induced hyperalgesia was blocked by minocycline and SB203580 intrathecally. Fractalkine-induced hyperalgesia was blocked by minocycline. Conclusions: This is the first demonstration that stress-induced activation of spinal microglia has a key role in visceral hyperalgesia and associated spinal NKIR up-regulation. C1 [Brades, Sylvie] Univ Calif Los Angeles, Ctr Neuroblol Stress, VAGLAHS, Dept Med, Los Angeles, CA 90073 USA. [Brades, Sylvie; Mayer, Emeran A.] Univ Calif Los Angeles, Ctr Neuroblol Stress, Dept Physiol, Los Angeles, CA 90073 USA. [Pothoulakis, Charalabos] Univ Calif Los Angeles, Ctr Inflammatory Bowel Dis, Div Digest Dis, Los Angeles, CA 90073 USA. [Brades, Sylvie; Mayer, Emeran A.] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Svensson, Camilla I.] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden. [Steinauer, Joanne; Yaksh, Tony L.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA. RP Brades, S (reprint author), Univ Calif Los Angeles, Ctr Neuroblol Stress, VAGLAHS, Dept Med, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sbradesi@ucia.edu RI Yaksh, Tony/D-4119-2009; Svensson, Camilla/C-9511-2014 OI Svensson, Camilla/0000-0001-7980-4631 FU Arthritis Foundation Fellowship; [R21 DK071767]; [P50 DK64539]; [R24 AT00281]; [DK 48351]; [R01 NS16541]; [RO1 DA002110]; [RO1 DK 47343]; [PO1 DK 33506] FX Supported by grants R21 DK071767 (to S.B.), P50 DK64539 (to E.A.M.), R24 AT00281 (to E.A.M.), DK 48351 (to E.A.M.), R01 NS16541 (to T.L.Y.), RO1 DA002110 (to T.L.Y.), RO1 DK 47343 (to C.P.), and PO1 DK 33506 (to C.P.) and an Arthritis Foundation Fellowship (to C.I.S.). NR 43 TC 33 Z9 36 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2009 VL 136 IS 4 BP 1339 EP 1348 DI 10.1053/j.gastro.2008.12.044 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 426OB UT WOS:000264716500035 PM 19249394 ER PT J AU Bonham, VL Sellers, SL Gallagher, TH Frank, D Odunlami, AO Price, EG Cooper, LA AF Bonham, Vence L. Sellers, Sherrill L. Gallagher, Thomas H. Frank, Danielle Odunlami, Adebola O. Price, Eboni G. Cooper, Lisa A. TI Physicians' attitudes toward race, genetics, and clinical medicine SO GENETICS IN MEDICINE LA English DT Article DE clinical decision making; race; genetic variation; health disparities; physicians' attitudes ID PRIMARY-CARE PHYSICIANS; HEALTH DISPARITIES; HEART-FAILURE; BIOMEDICAL-RESEARCH; AFRICAN-AMERICAN; BLACK PATIENTS; GENOMICS; ASSOCIATION; ETHNICITY; CANCER AB Purpose: This qualitative study explored black and white general internists' attitudes about the relevance of race in clinical care; views of the relationships among race, genetics, and disease; and expectations about the future of genetics and health. Methods: We conducted 10 racially concordant focus groups of primary care physicians in five metropolitan areas in the United States. Ninety board certified or eligible general internists (50 self-identified whites and 40 self-identified blacks) participated in the study, Analysis included a two-stage independent review and adjudication process. Results: Both black and white physicians concluded that the race of the patient is medically relevant but did not agree upon why race is important in clinical decisions. They were reticent to make connections among race, genetics, and disease and asserted that genetics has a limited role in explaining racial differences in health. However, they were enthusiastic about the future of genomic medicine, believing that the main benefit will be the potential to improve the efficacy of commonly used drugs. Conclusions: Understanding the similarities and differences between black and white physicians' attitudes and beliefs about race, health and genetics is important for the translation of genomics to clinical care. Genet Med 2009:11(4): 279-286. C1 [Bonham, Vence L.; Odunlami, Adebola O.] NHGRI, Social & Behav Res Branch, NIH, Bethesda, MD 20892 USA. [Sellers, Sherrill L.] Univ Wisconsin, Sch Social Work, Madison, WI 53706 USA. [Sellers, Sherrill L.] Miami Univ, Dept Family Studies & Social Work, Oxford, OH 45056 USA. [Gallagher, Thomas H.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. [Gallagher, Thomas H.] Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA. [Frank, Danielle] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Price, Eboni G.] Tulane Univ, Hlth Sci Ctr, Sect Gen Internal Med & Geriatr, New Orleans, LA 70118 USA. [Cooper, Lisa A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA. RP Bonham, VL (reprint author), NHGRI, Social & Behav Res Branch, NIH, 31 Ctr Dr Room B1B55, Bethesda, MD 20892 USA. EM bonhamv@mail.nih.gov OI Price-Haywood, Eboni/0000-0003-2901-3852 FU National Human Genome Research Institute, National Institutes of Health FX The study was Supported (in part) by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. The authors thank Elizabeth M. Phillips and Sarah Knerr for their research assistance and Alan M. Guttmacher, MD, and Francis S. Collins, MD, PhD, (National Human Genome Research Institute) for their suggestions in preparing an early draft of this article. NR 40 TC 10 Z9 10 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD APR PY 2009 VL 11 IS 4 BP 279 EP 286 DI 10.1097/GIM.0b013e318195aaf4 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 435KT UT WOS:000265343500007 PM 19265721 ER PT J AU Werner, RM Konetzka, RT Kruse, GB AF Werner, Rachel M. Konetzka, R. Tamara Kruse, Gregory B. TI Impact of Public Reporting on Unreported Quality of Care SO HEALTH SERVICES RESEARCH LA English DT Article DE Quality of care; postacute care; nursing home quality; public reporting ID UNINTENDED CONSEQUENCES; PERFORMANCE; IMPROVEMENT; MDS AB The impact of quality improvement incentives on nontargeted care is unknown and some have expressed concern that such incentives may be harmful to nontargeted areas of care. Our objective is to examine the effect of publicly reporting quality information on unreported quality of care. The nursing home Minimum Data Set from 1999 to 2005 on all postacute care admissions. We studied 13,683 skilled nursing facilities and examined how unreported aspects of clinical care changed in response to changes in reported care after public reporting was initiated by the Centers for Medicare and Medicaid Services on their website, Nursing Home Compare, in 2002. We find that overall both unreported and reported care improved following the launch of public reporting. Improvements in unreported care were particularly large among facilities with high scores or that significantly improved on reported measures, whereas low-scoring facilities experienced no change or worsening of their unreported quality of care. Public reporting in the setting of postacute care had mixed effects on areas without public reporting, improving in high-ranking facilities, but worsening in low-ranking facilities. While the benefits of public reporting may extend beyond areas that are being directly measured, these initiatives may also widen the gap between high- and low-quality facilities. C1 [Werner, Rachel M.] Univ Penn, Ctr Hlth Equ Res & Promot, Leonard Davis Inst Hlth Econ, Div Gen Internal Med,Philadelphia VAMC,Sch Med, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Kruse, Gregory B.] Univ Penn, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@mail.med.upenn.edu FU Agency for Healthcare Research and Quality [R01 HS016478-01]; University Research Foundation of the University of Pennsylvania; VA HSR&D Career Development Award; Pennsylvania Department of Health FX Prior dissemination: This research was presented at AcademyHealth, Washington, DC, June 2008 and American Society of Health Economics, Durham NC, June 2008. NR 20 TC 37 Z9 37 U1 1 U2 7 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2009 VL 44 IS 2 BP 379 EP 398 DI 10.1111/j.1475-6773.2008.00915.x PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 418QV UT WOS:000264164400005 PM 19178586 ER PT J AU Byrne, MM Daw, CN Nelson, HA Urech, TH Pietz, K Petersen, LA AF Byrne, Margaret M. Daw, Christina N. Nelson, Harlan A. Urech, Tracy H. Pietz, Kenneth Petersen, Laura A. TI Method to Develop Health Care Peer Groups for Quality and Financial Comparisons Across Hospitals SO HEALTH SERVICES RESEARCH LA English DT Article DE Peer groups; cluster analysis; nearest neighbor; Euclidean distance; quality of care comparisons ID CLUSTER-ANALYSIS; PERFORMANCE; COST AB To develop and explore the characteristics of a novel "nearest neighbor" methodology for creating peer groups for health care facilities. Data were obtained from the Department of Veterans Affairs (VA) databases. Peer groups are developed by first calculating the multidimensional Euclidean distance between each of 133 VA medical centers based on 16 facility characteristics. Each medical center then serves as the center for its own peer group, and the nearest neighbor facilities in terms of Euclidean distance comprise the peer facilities. We explore the attributes and characteristics of the nearest neighbor peer groupings. In addition, we construct standard cluster analysis-derived peer groups and compare the characteristics of groupings from the two methodologies. The novel peer group methodology presented here results in groups where each medical center is at the center of its own peer group. Possible advantages over other peer group methodologies are that facilities are never on the "edge" of a group and group size-and thus group dispersion-is determined by the researcher. Peer groups with these characteristics may be more appealing to some researchers and administrators than standard cluster analysis and may thus strengthen organizational buy-in for financial and quality comparisons. C1 [Petersen, Laura A.] Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, Houston, TX 77030 USA. [Byrne, Margaret M.] Univ Miami, Dept Epidemiol & Publ Hlth, Miami, FL USA. [Daw, Christina N.; Urech, Tracy H.; Pietz, Kenneth] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Daw, Christina N.; Urech, Tracy H.; Pietz, Kenneth] Baylor Coll Med, Houston VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Nelson, Harlan A.] InVent Clin Inc, Indianapolis, IN USA. RP Petersen, LA (reprint author), Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM laurap@bcm.edu FU VA [XVA 33-097]; Houston VA HSR&D Center of Excellence [HFP90-020]; National Cancer Institute [K07 CA101812]; Robert Wood Johnson Foundation [045444]; American Heart Association [0540043N] FX Disclaimers: The views expressed are solely of the authors, and do not necessarily represent those of the VA. NR 25 TC 15 Z9 15 U1 1 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2009 VL 44 IS 2 BP 577 EP 592 DI 10.1111/j.1475-6773.2008.00916.x PG 16 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 418QV UT WOS:000264164400015 PM 19178585 ER PT J AU Essa, AS Kramer, JR Graham, DY Treiber, G AF Essa, Abdallah Said Kramer, Jennifer Rosenthal Graham, David Y. Treiber, Gerhard TI Meta-analysis: Four-Drug, Three-Antibiotic, Non-bismuth-Containing "Concomitant Therapy" Versus Triple Therapy for Helicobacter pylori Eradication SO HELICOBACTER LA English DT Article DE Helicobacter pylori; therapy; meta-analysis; amoxicillin; clarithromycin; nitroimidazole; proton pump inhibitor ID QUADRUPLE THERAPY; SEQUENTIAL THERAPY; CURE RATE; INFECTION; REGIMEN; CLARITHROMYCIN; AMOXICILLIN; METRONIDAZOLE; OMEPRAZOLE; MANAGEMENT AB Low success rates with triple therapy for Helicobacter pylori infections have prompted search for alternatives. In one, a proton-pump inhibitor (PPI) and amoxicillin was followed by the PPI plus clarithromycin and a nitroimidazole (sequential therapy); in another, these four drugs were given concomitantly (concomitant therapy). To compare concomitant therapy with standard triple therapy for H. pylori infection. By searching PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and abstracts of major gastrointestinal meeting, two independent reviewers systemically identified randomized controlled trials (RCT) comparing concomitant quadruple to standard triple therapies as well as studies reporting eradication rates of concomitant quadruple therapy in treatment of H. pylori. Pooled eradication rates and odds ratios (OR) with 95% confidence intervals (CI) were calculated, and univariable metaregression analysis for all extracted variables was conducted. We identified nine studies (10 treatment arms) including five qualifying RCTs (576 subjects) comparing concomitant (293 subjects, duration 3 to 5 days) and triple therapy (283 subjects, duration 5 to 10 days) and four other studies evaluating concomitant therapy (478 subjects, duration 3 to 7 days). Pooled estimates of the five RCTs showed superiority of concomitant therapy over triple therapy; with intention-to-treat) pooled OR of 2.86 (95% CI: 1.73-4.73) and per-protocol (PP) pooled OR of 3.52 (95% CI: 1.95-6.38). Considering all 10 treatment arms, the ITT eradication rate was 89.7% (95% CI: 86.8-92.1%) and PP was 92.9% (95% CI: 90.2-94.8%). Concomitant therapy appears to be an effective alternative to triple therapy and is less complex than sequential therapy. C1 [Essa, Abdallah Said; Kramer, Jennifer Rosenthal; Graham, David Y.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kramer, Jennifer Rosenthal] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Treiber, Gerhard] Saarland Univ Hosp, Dept Internal Med 2, Homburg, Germany. RP Graham, DY (reprint author), Vet Affairs Med Ctr 111D, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU Office of Research and Development Medical Research Service Department of Veterans Affairs [MRP05-315]; Public Health Service [DK56338]; Texas Medical Center Digestive Diseases Center; NIH; Services Research and Development Service; Egyptian government FX This material is based on the work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs and by Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center, and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the VA or NIH. In the last 3 years, Dr Graham has received small amounts of grant support and/or free drugs or urea breath tests from Meretek, Jannsen/Eisai, and TAP, and BioHit for investigator-initiated and completely investigator-controlled research. Dr Graham is a consultant for Novartis in relation to vaccine development for treatment or prevention of H. pylori infection. Dr Graham is also a paid consultant for Otsuka Pharmaceuticals and until July 2007 was a member of the Board of Directors of Meretek, Diagnostics, the manufacturer of the 13C-urea breath test. Dr Graham also receives royalties on the Baylor College of Medicine patent covering materials related to 13C-urea breath test. Dr Kramer is supported by an MREP Career Development Award from the Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs, grant number MRP05-315. Dr Essa was supported in part by a grant from the Egyptian government. NR 31 TC 122 Z9 130 U1 0 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD APR PY 2009 VL 14 IS 2 BP 109 EP 118 DI 10.1111/j.1523-5378.2009.00671.x PG 10 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 417IW UT WOS:000264070700005 PM 19298338 ER PT J AU Finan, KR Kilgore, ML Hawn, MT AF Finan, K. R. Kilgore, M. L. Hawn, M. T. TI Open suture versus mesh repair of primary incisional hernias: a cost-utility analysis SO HERNIA LA English DT Article DE Hernia; Ventral; Surgical mesh; Costs and cost analysis; Cost-benefit analysis; Decision support techniques ID RANDOMIZED CONTROLLED-TRIAL; OPEN VENTRAL HERNIORRHAPHY; TERM-FOLLOW-UP; RISK-FACTORS; POLYPROPYLENE MESH; WOUND-INFECTION; COMPLICATIONS; IMPROVEMENT; EXPERIENCE; RECURRENCE AB Despite 100,000 ventral hernia repairs (VHR) being performed annually, no gold standard for the technique exists. Mesh has been shown to decrease recurrence rates, yet, concerns of increased complications and costs prevent its systematic use. We examined the cost-effectiveness of open suture (OS) versus open mesh (OM) in primary VHR. A decision analysis model from the payer's perspective comparing OS to OM was constructed for calculating the total costs and cost-effectiveness. Probabilities for complications and outcomes were derived from the literature. The costs represented institutional fixed costs. The outcome measure of effectiveness was recurrence. One-way sensitivity analysis and a probabilistic analysis using Monte Carlo simulation were performed. OS was associated with a total cost of $16,355 (+/- 6,041) per repair, while OM was $16,947 (+/- 7,252). At 3-year follow-up, OM was the more effective treatment with 73.8% being recurrence-free, compared with 56.3% in the OS group. The incremental cost to prevent one recurrence by the placement of mesh was $1,878. OM became the less effective treatment strategy when the infection rate exceeded 35%. At a willingness to pay level of $5,500, OM was the more cost-effective treatment strategy. In subjects without contraindication to mesh placement, OM repair is the more effective surgical treatment for VHR, with a lower risk of recurrence at a small cost to the payer. C1 [Finan, K. R.; Hawn, M. T.] Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. [Kilgore, M. L.] Univ Alabama, Sch Publ Hlth, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA. [Hawn, M. T.] Birmingham Vet AVairs Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. RP Hawn, MT (reprint author), Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, KB 417,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mhawn@uab.edu FU Olympus America Inc FX We would like to thank Dr. Miguel Arguedas for his assistance in the decision modeling and Ms. Catherine Vick for her assistance in providing probabilities from the Veterans AVairs Medical Center ventral hernia repair study. K. R. Finan is a research fellow for the Department of Surgery supported by an educational grant funded by Olympus America Inc. This research was presented at the 2005 American College of Surgeons Clinical Congress, Surgical Forum in San Francisco, California, October 2005, and was awarded the Surgeons' Forum on Fundamental Surgical Problems Resident/ Fellow Excellence in Research Award. NR 31 TC 22 Z9 22 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1265-4906 J9 HERNIA JI Hernia PD APR PY 2009 VL 13 IS 2 BP 173 EP 182 DI 10.1007/s10029-008-0462-1 PG 10 WC Surgery SC Surgery GA 427WW UT WOS:000264810800010 PM 19142563 ER PT J AU Landsverk, ML Ruzzo, EK Mefford, HC Buysse, K Buchan, JG Eichler, EE Petty, EM Peterson, EA Knutzen, DM Barnett, K Farlow, MR Caress, J Parry, GJ Quan, D Gardner, KL Hong, M Simmons, Z Bird, TD Chance, PF Hannibal, MC AF Landsverk, Megan L. Ruzzo, Elizabeth K. Mefford, Heather C. Buysse, Karen Buchan, Jillian G. Eichler, Evan E. Petty, Elizabeth M. Peterson, Esther A. Knutzen, Dana M. Barnett, Karen Farlow, Martin R. Caress, Judy Parry, Gareth J. Quan, Dianna Gardner, Kathy L. Hong, Ming Simmons, Zachary Bird, Thomas D. Chance, Phillip F. Hannibal, Mark C. TI Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy SO HUMAN MOLECULAR GENETICS LA English DT Article ID BRACHIAL-PLEXUS NEUROPATHY; LDL RECEPTOR GENE; MAMMALIAN SEPTIN; CHROMOSOME 17Q25; HNA LOCUS; EXPRESSION; NEURITIS; PREDILECTION; MICROTUBULES; ORGANIZATION AB Hereditary neuralgic amyotrophy (HNA) is an autosomal dominant disorder associated with recurrent episodes of focal neuropathy primarily affecting the brachial plexus. Point mutations in the SEPT9 gene have been previously identified as the molecular basis of HNA in some pedigrees. However in many families, including those from North America demonstrating a genetic founder haplotype, no sequence mutations have been detected. We report an intragenic 38 Kb SEPT9 duplication that is linked to HNA in 12 North American families that share the common founder haplotype. Analysis of the breakpoints showed that the duplication is identical in all pedigrees, and molecular analysis revealed that the duplication includes the 645 bp exon in which previous HNA mutations were found. The SEPT9 transcript variants that span this duplication contain two in-frame repeats of this exon, and immunoblotting demonstrates larger molecular weight SEPT9 protein isoforms. This exon also encodes for a majority of the SEPT9 N-terminal proline rich region suggesting that this region plays a role in the pathogenesis of HNA. C1 [Landsverk, Megan L.; Ruzzo, Elizabeth K.; Knutzen, Dana M.; Barnett, Karen; Chance, Phillip F.; Hannibal, Mark C.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. [Mefford, Heather C.; Buysse, Karen; Eichler, Evan E.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA. [Chance, Phillip F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Chance, Phillip F.; Hannibal, Mark C.] Seattle Childrens Hosp, Seattle, WA 98105 USA. [Ruzzo, Elizabeth K.] Howard Hughes Med Inst, Seattle, WA 98195 USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Petty, Elizabeth M.; Peterson, Esther A.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48105 USA. [Farlow, Martin R.; Caress, Judy] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. [Parry, Gareth J.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA. [Quan, Dianna] Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. [Gardner, Kathy L.] Vet Adm Hosp, Dept Neurol, Pittsburgh, PA 15213 USA. [Gardner, Kathy L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA. [Hong, Ming] Grp Hlth Bellevue Med Ctr, Bellevue, WA 98004 USA. [Simmons, Zachary] Penn State Coll Med, Hershey Med Ctr, Dept Neurol, Hershey, PA 17033 USA. [Buysse, Karen] Univ Ghent, Ctr Med Genet, B-9000 Ghent, Belgium. RP Hannibal, MC (reprint author), HSB RR247,Box 356320,1959 NE Pacific St, Seattle, WA 98195 USA. EM mhanni@u.washington.edu FU National Institutes of Heath (NINDS) [NS38181] FX The work was supported by funds from the National Institutes of Heath (NINDS), (grant number NS38181 to P. F. C. and M.C.H.); The Neuropathy Association, New York, NY ( to P.F.C.); and the Allan and Phyllis Treuer Endowed Chair for Genetics and Development (to P.F.C.). NR 37 TC 12 Z9 12 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD APR 1 PY 2009 VL 18 IS 7 BP 1200 EP 1208 DI 10.1093/hmg/ddp014 PG 9 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 421XI UT WOS:000264391200003 PM 19139049 ER PT J AU Basile, JN AF Basile, J. N. TI Antihypertensive therapy, new-onset diabetes, and cardiovascular disease SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE LA English DT Review ID IMPAIRED GLUCOSE-TOLERANCE; RANDOMIZED CONTROLLED-TRIAL; RENIN-ANGIOTENSIN-SYSTEM; ANTI HYPERTENSIVE DRUGS; LIFE-STYLE INTERVENTION; PRESSURE LOWERING ARM; METABOLIC SYNDROME; CARDIAC OUTCOMES; FASTING GLUCOSE; BLOOD-PRESSURE AB Type 2 diabetes mellitus is a worldwide epidemic with considerable health and economic consequences. Diabetes is an important risk factor for cardiovascular disease, which is the leading cause of death in diabetic patients, and decreasing the incidence of diabetes may potentially reduce the burden of cardiovascular disease. This article discusses the clinical trial evidence for modalities associated with a reduction in the risk of new-onset diabetes, with a focus on the role of antihypertensive agents that block the renin-angiotensin system. Lifestyle interventions and the use of antidiabetic, anti-obesity, and lipid-lowering drugs are also reviewed. An unresolved question is whether decreasing the incidence of new-onset diabetes with non-pharmacologic or pharmacologic intervention will also lower the risk of cardiovascular disease. A large ongoing study is investigating whether the treatment with an oral antidiabetic drug or an angiotensin-receptor blocker will reduce the incidence of new-onset diabetes and cardiovascular disease in patients at high risk for developing diabetes. C1 [Basile, J. N.] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29403 USA. [Basile, J. N.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Basile, JN (reprint author), Ralph H Johnson VA Med Ctr, Primary Care Serv Line, 109 Bee St, Charleston, SC 29403 USA. EM jan.basile@va.gov FU Tanja Schub of Landmark Programs FX The author wishes to thank Tanja Schub of Landmark Programs for editorial support. NR 69 TC 7 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1368-5031 J9 INT J CLIN PRACT JI Int. J. Clin. Pract. PD APR PY 2009 VL 63 IS 4 BP 656 EP 666 DI 10.1111/j.1742-1241.2009.02009.x PG 11 WC Medicine, General & Internal; Pharmacology & Pharmacy SC General & Internal Medicine; Pharmacology & Pharmacy GA 419SX UT WOS:000264241100019 PM 19220522 ER PT J AU Cummings, DE AF Cummings, D. E. TI Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article; Proceedings Paper CT 9th and 10th Annual International Symposia of the Merck Frosst/CIHR Research Chair in Obesity CY NOV 15-16, 2007 CL Univ Laval, Quebec City, CANADA SP Merck Frost, CIHR HO Univ Laval DE diabetes; gastric bypass; bariatric surgery; ghrelin; GLP-1 ID DUODENAL-JEJUNAL BYPASS; GLUCAGON-LIKE PEPTIDE-1; GOTO-KAKIZAKI RATS; BETA-CELL FUNCTION; WEIGHT-LOSS; BARIATRIC SURGERY; HYPERINSULINEMIC HYPOGLYCEMIA; ILEAL TRANSPOSITION; RECURRENT HYPOGLYCEMIA; CIRCULATING GHRELIN AB Bariatric surgery is currently the most effective method to promote major, sustained weight loss. Roux-en-Y gastric bypass (RYGB), the most commonly performed bariatric operation, ameliorates virtually all obesity-related comorbid conditions, the most impressive being a dramatic resolution of type 2 diabetes mellitus (T2DM). After RYGB, 84% of patients with T2DM experience complete remission of this disease, and virtually all have improved glycemic control. Increasing evidence indicates that the impact of RYGB on T2DM cannot be explained by the effects of weight loss and reduced energy intake alone. Weight-independent antidiabetic actions of RYGB are apparent because of the very rapid resolution of T2DM ( before weight loss occurs), the greater improvement of glucose homeostasis after RYGB than after an equivalent weight loss from other means, and the occasional development of very late-onset, pancreatic beta-cell hyperfunction. Several mechanisms probably mediate the direct antidiabetic impact of RYGB, including enhanced nutrient stimulation of L-cell peptides ( for example, GLP-1) from the lower intestine, intriguing but still uncharacterized phenomena related to exclusion of the upper intestine from contact with ingested nutrients, compromised ghrelin secretion, and very probably other effects that have yet to be discovered. Research designed to prioritize these mechanisms and identify potential additional mechanisms promises to help optimize surgical design and might also reveal novel pharmaceutical targets for diabetes treatment. C1 [Cummings, D. E.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. [Cummings, D. E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Cummings, DE (reprint author), Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Box 358280,Mail Stop 111, Seattle, WA 98195 USA. EM davidec@u.washington.edu NR 50 TC 101 Z9 103 U1 2 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD APR PY 2009 VL 33 BP S33 EP S40 DI 10.1038/ijo.2009.15 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 435OR UT WOS:000265353700009 PM 19363506 ER PT J AU Kernisan, LP Lee, SJ Boscardin, WJ Landefeld, CS Dudley, RA AF Kernisan, Leslie P. Lee, Sei J. Boscardin, W. John Landefeld, C. Seth Dudley, R. Adams TI Association Between Hospital-Reported Leapfrog Safe Practices Scores and Inpatient Mortality SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID AORTIC-ANEURYSM REPAIR; QUALITY-OF-CARE; STANDARDS; RISK; SURGERY; VOLUME AB Context The Leapfrog Hospital Survey allows hospitals to self-report the steps they have taken toward implementing the Safe Practices for Better Healthcare endorsed by the National Quality Forum. The Leapfrog Group currently ranks hospital performance on the safe practices initiative by quartiles and presents this information to the public on its Web site. It is unknown how well a hospital's resulting Safe Practices Score (SPS) correlates with outcomes such as inpatient mortality. Objective To determine the relationship between hospitals' SPSs and risk-adjusted inpatient mortality rates. Design, Setting, and Participants Observational analysis of discharge data for all urban US hospitals completing the 2006 safe practices initiative and identifiable in the Nationwide Inpatient Sample. Leapfrog provided an SPS for each hospital as well as 3 alternative scores based on shorter versions of the original survey. Hierarchical logistic regression was used to determine the relationship between quartiles of SPS and risk-adjusted inpatient mortality, after adjusting for hospital discharge volume and teaching status. Subgroup analyses were performed using data from patients older than 65 years and patients with 5% or greater expected mortality risk. Main Outcome Measures Inpatient risk-adjusted mortality by quartiles of survey score. Results Of 1075 hospitals completing the 2006 Safe Practices Survey, 155 (14%) were identifiable in the National Inpatient Sample (1 772 064 discharges). Raw observed mortality in the primary sample was 2.09%. Fully adjusted mortality rates by quartile of SPS, from lowest to highest, were 1.97% (95% confidence interval [CI], 1.78%-2.18%), 2.04% (95% CI, 1.84%-2.25%), 1.96% (95% CI, 1.77%-2.16%), and 2.00% (95% CI, 1.80%-2.22%) (P=.99 for linear trend). Results were similar in the subgroup analyses. None of the 3 alternative survey scores was associated with risk-adjusted inpatient mortality, although P values for linear trends were lower (. 80, .20, and .11). Conclusion In this sample of hospitals that completed the 2006 Safe Practices Survey, survey scores were not significantly associated with risk-adjusted inpatient mortality. C1 [Dudley, R. Adams] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA. [Kernisan, Leslie P.; Lee, Sei J.; Boscardin, W. John; Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA. [Boscardin, W. John] Univ Calif San Francisco, Div Biostat, San Francisco, CA 94118 USA. [Kernisan, Leslie P.; Lee, Sei J.; Landefeld, C. Seth] San Francisco VA Med Ctr, Natl VA Qual Scholars Program, San Francisco, CA USA. [Lee, Sei J.; Boscardin, W. John; Landefeld, C. Seth] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. [Landefeld, C. Seth] Stanford Univ, Ctr Adv Study Behav Sci, Palo Alto, CA 94304 USA. RP Dudley, RA (reprint author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St,Ste 265, San Francisco, CA 94118 USA. EM adams.dudley@ucsf.edu FU National Institute on Aging, National Institutes of Health [2 T32 AG000212-16]; Robert Wood Johnson Foundation FX Funding/Support: This study was supported by the UCSF Division of Geriatrics, the UCSF Institute for Health Policy Studies, and the San Francisco VA Medical Center. Dr Kernisan was supported by T32 research fellowship grant 2 T32 AG000212-16 from the National Institute on Aging, National Institutes of Health, followed by a VA Quality Scholars fellowship. Dr Dudley's work was supported by a Robert Wood Johnson Foundation Investigator Award in Health Policy. This study was also supported by the Leapfrog Group, which provided its data at no cost. NR 30 TC 26 Z9 26 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 1 PY 2009 VL 301 IS 13 BP 1341 EP 1348 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 426LM UT WOS:000264709800023 PM 19336709 ER PT J AU Werner, RM McNutt, R AF Werner, Rachel M. McNutt, Robert TI A New Strategy to Improve Quality Rewarding Actions Rather Than Measures SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PERFORMANCE-MEASURES; MORTALITY; CARE C1 [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Sch Med, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [McNutt, Robert] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. RP Werner, RM (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, 423 Guardian Dr,1230 Blockley Hall, Philadelphia, PA 19104 USA. EM rwerner@mail.med.upenn.edu NR 13 TC 23 Z9 23 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 1 PY 2009 VL 301 IS 13 BP 1375 EP 1377 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 426LM UT WOS:000264709800028 PM 19336714 ER PT J AU Smith, MC Yamashita, TE Bryant, LL Hemphill, L Kutner, JS AF Smith, Marlaine C. Yamashita, Traci E. Bryant, Lucinda L. Hemphill, Linnea Kutner, Jean S. TI Providing Massage Therapy for People with Advanced Cancer: What to Expect SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID AROMATHERAPY MASSAGE; PAIN; CARE AB There is very little information in the literature to prepare massage therapists for what they might expect when they provide treatment to people with advanced cancer in hospice or palliative care. We report an analysis of a subset of data collected from a large multi-site clinical trial of the efficacy of massage therapy for people with advanced cancer. This is the first analysis of empirical data of patient presentation, massage treatment environment, and the characteristics of massage provided for this population. C1 [Smith, Marlaine C.] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Boca Raton, FL 33431 USA. [Yamashita, Traci E.] Univ Colorado, Denver Sch Med, Div Gen Internal Med, Denver, CO 80202 USA. [Bryant, Lucinda L.] Univ Colorado, Denver Sch Med, Dept Prevent Med & Biometr, Denver, CO 80202 USA. [Hemphill, Linnea] Denver Vet Affairs Med Ctr, Dept Nursing, Denver, CO USA. RP Smith, MC (reprint author), Florida Atlantic Univ, Christine E Lynn Coll Nursing, 777 Glades Rd, Boca Raton, FL 33431 USA. EM marlaine.smith@fau.edu FU National Institutes of Health/National Center for Complementary and Alternative Medicine [1R01AT01006-01A2]; Mendel/Asarch Lung Cancer Family Foundation FX This study was funded by grants from the National Institutes of Health/National Center for Complementary and Alternative Medicine (1R01AT01006-01A2) and the Mendel/Asarch Lung Cancer Family Foundation. We acknowledge Biotone (San Diego, CA) for their donation of massage cream for the study. We thank all the staff and volunteers from the hospices for their dedication and hard work, and the participants who gave their precious time. NR 19 TC 8 Z9 8 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD APR PY 2009 VL 15 IS 4 BP 367 EP 371 DI 10.1089/acm.2008.0391 PG 5 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 436MZ UT WOS:000265419500007 PM 19388858 ER PT J AU Belogrudov, GI AF Belogrudov, Grigory I. TI Recent advances in stucture-functional studies of mitochondrial factor B SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES LA English DT Article DE Factor B; Energy coupling; ATP synthase complex ID BOVINE HEART-MITOCHONDRIA; COUPLING FACTOR-B; ENERGY-LINKED FUNCTIONS; ATP SYNTHASE; OXIDATIVE-PHOSPHORYLATION; BEEF-HEART; SUBMITOCHONDRIAL PARTICLES; SUBUNIT-E; MEMBRANE; PURIFICATION AB Since the early studies on the resolution and reconstitution of the oxidative phosphorylation system from animal mitochondria, coupling factor B was recognized as an essential component of the machinery responsible for energy-driven ATP synthesis. At the phenomenological level, factor B was agreed to lie at the interface of energy transfer between the respiratory chain and the ATP synthase complex. However, biochemical characterization of the factor B polypeptide has proved difficult. It was not until 1990 that the N-terminal amino acid sequence of bovine mitochondrial factor B was reported, which followed, a decade later, by the report describing the amino acid sequence of full-length human factor B and its functional characterization. The present review summarizes the recent advances in structure-functional studies of factor B, including its recently determined crystal structure at 0.96 resolution. Ectopic expression of human factor B in cultured animal cells has unexpectedly revealed its role in shaping mitochondrial morphology. The supramolecular assembly of ATP synthase as dimer ribbons at highly curved apices of the mitochondrial cristae was recently suggested to optimize ATP synthesis under proton-limited conditions. We propose that the binding of the ATP synthase dimers with factor B tetramers could be a means to enhance the efficiency of the terminal step of oxidative phosphorylation in animal mitochondria. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Belogrudov, GI (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbelo@ucla.edu FU NIH [RO1 GM066085] FX I thank Dr. Youssef Hatefi on whose suggestion I started to work on the factor B project in his laboratory at The Scripps Research Institute in July 2000; my colleagues at the West Los Angeles VA Medical Center for their support and discussions; my outstanding collaborators Drs. John K. Lee and Robert M. Stroud, both of UCSF, on determination bovine factor B crystal structure. I am grateful to the late Professor Yuri A. Ovchinnikov in whose laboratory at the Shemyakin Institute of Bioorganic Chemistry, Moscow, in 1981 I, then a student, first encountered studies on mysterious factor B. This work was supported by NIH RO1 grant GM066085. NR 52 TC 10 Z9 12 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0145-479X J9 J BIOENERG BIOMEMBR JI J. Bioenerg. Biomembr. PD APR PY 2009 VL 41 IS 2 BP 137 EP 143 DI 10.1007/s10863-009-9210-1 PG 7 WC Biophysics; Cell Biology SC Biophysics; Cell Biology GA 460UH UT WOS:000267215700008 PM 19377834 ER PT J AU Liu, YP Seckin, H Izci, Y Du, ZW Yan, YP Baskaya, MK AF Liu, Yi-Ping Seckin, Hakan Izci, Yusuf Du, Zhong Wei Yan, Yi-Ping Baskaya, Mustafa K. TI Neuroprotective effects of mesenchymal stem cells derived from human embryonic stem cells in transient focal cerebral ischemia in rats SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE cerebral ischemia; human embryonic stem cells; mesenchymal stem cells; spontaneously hypertensive rats; stroke ID MARROW STROMAL CELLS; HUMAN SOMATIC-CELLS; BONE-MARROW; THERAPEUTIC BENEFIT; HUMAN FIBROBLASTS; DEFINED FACTORS; IN-VITRO; STROKE; DIFFERENTIATION; TRANSPLANTATION AB Embryonic mesenchymal stem cells (eMSCs) were first derived from human embryonic stem cells (hESCs) overexpressing green fluorescence protein (GFP). They expressed CD29, CD44, CD73, CD105, CD166 and nestin, but not CD34, CD45, CD106 SSEA-4 or Oct3/4. Twenty million eMSCs in 1 mL of phosphate-buffered saline (PBS) were injected into the femoral veins of spontaneously hypertensive rats after transient middle cerebral artery occlusion. The migration and differentiation of the eMSCs in the ischemic brain were analyzed. The results revealed that eMSCs migrated to the infarction region and differentiated into neurons, which were positive for beta-tubulin III, microtubule-associated protein 2 (MAP2), HuC, neurofilament and human nuclear antibody, and to vascular endothelial cells, which were positive for von Willebrand factor (vWF). The transplanted cells survived in the infarction region for at least 4 weeks. Adhesive removal function significantly improved in the first week after cell transplantation, and rotarod motor function significantly improved starting from the second week. The infarction volume in the eMSC group was significantly smaller than that in the PBS control group at 4 weeks after infusion. The results of this study show that when administered intravenously, eMSCs differentiated into neuronal and endothelial cells, reduced the infarction volume, and improved behavioral functional outcome significantly in transient focal cerebral ischemia. C1 [Liu, Yi-Ping; Seckin, Hakan; Izci, Yusuf; Yan, Yi-Ping; Baskaya, Mustafa K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA. [Du, Zhong Wei] Univ Wisconsin, Waisman Ctr, Madison, WI 53792 USA. [Baskaya, Mustafa K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Baskaya, MK (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Box 8660 Clin Sci Ctr K4,600 Highland Ave, Madison, WI 53792 USA. EM m.baskaya@neurosurg.wisc.edu NR 40 TC 36 Z9 39 U1 1 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD APR PY 2009 VL 29 IS 4 BP 780 EP 791 DI 10.1038/jcbfm.2009.1 PG 12 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 426XM UT WOS:000264741700013 PM 19209181 ER PT J AU Lee, CG Carr, MC Murdoch, SJ Mitchell, E Woods, NF Wener, MH Chandler, WL Boyko, EJ Brunzell, JD AF Lee, Christine G. Carr, Molly C. Murdoch, Susan J. Mitchell, Ellen Woods, Nancy F. Wener, Mark H. Chandler, Wayne L. Boyko, Edward J. Brunzell, John D. TI Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; HEALTHY POSTMENOPAUSAL WOMEN; HORMONE REPLACEMENT THERAPY; C-REACTIVE PROTEIN; SERUM-AMYLOID-A; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; FAT DISTRIBUTION; PLASMA-LEVELS; RISK-FACTORS AB Context: Postmenopausal women have greater visceral adiposity compared with premenopausal women. Adipokines are associated with increased adiposity, insulin resistance, and atherosclerosis. Objective: The objective of the study was to assess changes in adipokines and inflammatory markers through the menopausal transition and correlate them with changes in visceral adiposity. Design and Setting: This was a prospective cohort study of women through the menopausal transition conducted at the University of Washington. Participants: Sixty-nine healthy women were followed up longitudinally from premenopausal (aged 45-55 yr) to postmenopausal status (aged 49-60 yr). Outcome: On premenopausal and postmenopausal visits, fasting blood was drawn for adiponectin, leptin, serum amyloid A (SAA), C-reactive protein (CRP), monocyte-chemotactic protein-1, tissue plasminogen activator antigen (tPA), IL-6, and TNF-alpha. Body composition measures were assessed by body mass index, whole-body dual x-ray absorptiometry scan, and computed tomography scan of the abdomen at the lumbar 4-5 level. Results: Women had a statistically significant increase in SAA, tPA, monocyte-chemotactic protein-1, and adiponectin between the two measurement occasions (P = 0.04, P = 0.02, P = 0.001, and P < 0.001, respectively). The increase in intraabdominal fat was correlated positively with the change in SAA (r = 0.31, P = 0.02), CRP (r = 0.56, P < 0.001), tPA (r = 0.40, P = 0.002), and leptin (r = 0.41, P = 0.002) and negatively correlated with the change in adiponectin (r = -0.37, P = 0.005). After adjustment for change in sc abdominal fat, the correlation between change in CRP, tPA, leptin, and adiponectin remained significantly associated with change in intraabdominal fat. Conclusions: Women going through the menopausal transition have deleterious changes in inflammatory markers and adipokines that correlate with increased visceral adiposity. (J Clin Endocrinol Metab 94: 1104 - 1110, 2009) C1 [Lee, Christine G.; Carr, Molly C.; Murdoch, Susan J.; Brunzell, John D.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Med Ctr, Seattle, WA 98195 USA. [Mitchell, Ellen; Woods, Nancy F.] Univ Washington, Dept Family & Child Nursing, Seattle, WA 98195 USA. [Wener, Mark H.; Chandler, Wayne L.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Lee, CG (reprint author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Med Ctr, 1959 NE Pacific St,Box 356426, Seattle, WA 98195 USA. OI Boyko, Edward/0000-0002-3695-192X FU National Institutes of Health [HL30086, HL64322, NR04141, RR16067]; Bristol Myers Squibb Foundation; University of Washington Clinical Nutrition Research Unit [DK35816]; University of Washington General Clinical Research Center [M01-RR-00037]; University of Washington Diabetes Endocrinology Research Center; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK-17047] FX The authors thank Linda Floyd for her assistance with participant recruitment and management and Steve Hashimoto and Alegria Aquino-Albers for their technical expertise. We are indebted to the participants for their dedication and contribution to this study. Laboratory assays performed at the University of Washington were processed by Dr. Wayne Chandler and Dr. Mark Wener (Department of Laboratory Medicine) and the Clinical Nutrition Research Unit Core Laboratory. Adiponectin assays were performed in the laboratories of Dr. Peter J. Havel, D. V. M., Ph. D. (University of California, Davis, Department of Nutrition).; Address all correspondence and requests for reprints to: Christine G. Lee, M. D., Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, 1959 NE Pacific Street, Box 356426, Seattle, Washington 98195-4626.; This work was supported by National Institutes of Health Grants HL30086, HL64322, and NR04141, and K23 Grant RR16067 ( to M. C. C.) and a grant from the Bristol Myers Squibb Foundation. These studies were performed with the support of the University of Washington Clinical Nutrition Research Unit (DK35816), the University of Washington General Clinical Research Center (M01-RR-00037), and the University of Washington Diabetes Endocrinology Research Center, which is funded by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Grant P30 DK-17047.; Present address for M. C. C.: Wyeth Research, Collegeville, Pennsylvania.; Disclosure Summary: C. G. L., S.J.M., E. M., N.F.W., M. H. W., W. L. C., E.J.B., and J.D.B. have nothing to declare. M. C. C. worked on this study while employed at the University of Washington Medical Center. NR 36 TC 89 Z9 92 U1 2 U2 5 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2009 VL 94 IS 4 BP 1104 EP 1110 DI 10.1210/jc.2008-0701 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 432PB UT WOS:000265145100012 PM 19126626 ER PT J AU Mulligan, K Khatami, H Schwarz, JM Sakkas, GK DePaoli, AM Tai, VW Wen, MJ Lee, GA Grunfeld, C Schambelan, M AF Mulligan, Kathleen Khatami, Hootan Schwarz, Jean-Marc Sakkas, Giorgos K. DePaoli, Alex M. Tai, Viva W. Wen, Michael J. Lee, Grace A. Grunfeld, Carl Schambelan, Morris TI The Effects of Recombinant Human Leptin on Visceral Fat, Dyslipidemia, and Insulin Resistance in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy and Hypoleptinemia SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID HIV-INFECTED PATIENTS; HUMAN GROWTH-HORMONE; ISOTOPOMER DISTRIBUTION ANALYSIS; ADIPOSE-TISSUE; DIABETES-MELLITUS; CONTROLLED-TRIAL; GENERALIZED LIPODYSTROPHY; CONGENITAL LIPODYSTROPHY; ANTIRETROVIRAL THERAPY; REPLACEMENT THERAPY AB Context: Leptin deficiency is associated with dyslipidemia and insulin resistance in animals and humans with lipoatrophy; leptin replacement ameliorates these abnormalities. Objective: The objective of the study was to evaluate the effects of leptin therapy in lipoatrophic HIV-infected patients with dyslipidemia and hypoleptinemia. Design: This was a 6-month, open-label, proof-of-principle pilot study. Setting: Metabolicward studies were performed before and 3 and 6 months after leptin treatment. Participants: Participants included eight HIV-infected men with lipoatrophy, fasting triglycerides greater than 300 mg/dl, and serum leptin less than 3 ng/ml. Intervention: Recombinant human leptin was given by sc injection (0.01 mg/kg and 0.03 mg/kg twice daily for successive 3 month periods). Outcome Measures: Measuresincluded fat distribution by magnetic resonance imaging and dual-energy X-ray absorptiometry; fasting lipids; insulin sensitivity by euglycemic hyperinsulinemic clamp; endogenous glucose production, gluconeogenesis, glycogenolysis, and whole-body lipolysis by stable isotope tracer studies; oral glucose tolerance testing; liver fat by proton magnetic resonance spectroscopy; and safety. Results: Visceral fat decreased by 32%(P = 0.001) with no changes in peripheral fat. There were significant decreases in fasting total (15%, P = 0.012), direct low-density lipoprotein (20%, P = 0.002), and non-high-density lipoprotein (19%, P = 0.005) cholesterol. High-density lipoprotein cholesterol increased. Triglycerides, whole-body lipolysis, and free fatty acids decreased during fasting and hyperinsulinemia. Fasting insulin decreased. Endogenous glucose production decreased during fasting and hyperinsulinemia, providing evidence of improved hepatic insulin sensitivity. Leptin was well tolerated but decreased lean mass. Conclusions: Leptin treatment was associated with marked improvement in dyslipidemia. Hepatic insulin sensitivity improved and lipolysis decreased. Visceral fat decreased with no exacerbation of peripheral lipoatrophy. Results from this pilot study suggest that leptin warrants further study in patients with HIV-associated lipoatrophy. (J Clin Endocrinol Metab 94: 1137 - 1144, 2009) C1 [Mulligan, Kathleen; Khatami, Hootan; Schwarz, Jean-Marc; Sakkas, Giorgos K.; Tai, Viva W.; Wen, Michael J.; Schambelan, Morris] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Mulligan, Kathleen; Khatami, Hootan; Schwarz, Jean-Marc; Sakkas, Giorgos K.; Tai, Viva W.; Wen, Michael J.; Lee, Grace A.; Grunfeld, Carl; Schambelan, Morris] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Schwarz, Jean-Marc] Touro Univ, Dept Basic Sci, Vallejo, CA 94592 USA. [DePaoli, Alex M.] Amgen Inc, Thousand Oaks, CA 91320 USA. [Lee, Grace A.; Grunfeld, Carl] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Mulligan, K (reprint author), San Francisco Gen Hosp, Bldg 30,Room 3501K,1001 Potrero Ave, San Francisco, CA 94110 USA. EM kathleen.mulligan@ucsf.edu FU National Institutes of Health [DK63640, DK54615, DK66999, RR-00083]; University of California Universitywide AIDS Research Program [CF02-SF-302]; Amgen, Inc.; Amylin Pharmaceuticals, Inc. FX Disclosure Summary: H. K., J.-M. S., G. K. S., V. W. T., M.J.W., G. A. L., and C. G. have nothing to declare. K. M. and M. S. received consulting fees from Amgen Inc. and Amylin, Inc. M. S. received the drug used in this National Institutes of Health-funded study and a small research grant from Amgen; the latter was transferred to Amylin. A. M. D. was employed at Amgen Inc. at the time of this research. NR 47 TC 63 Z9 63 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2009 VL 94 IS 4 BP 1137 EP 1144 DI 10.1210/jc.2008-1588 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 432PB UT WOS:000265145100017 PM 19174500 ER PT J AU White, HK Petrie, CD Landschulz, W MacLean, D Taylor, A Lyles, K Wei, JY Hoffman, AR Salvatori, R Ettinger, MP Morey, MC Blackman, MR Merriam, GR AF White, Heidi K. Petrie, Charles D. Landschulz, William MacLean, David Taylor, Ann Lyles, Kenneth Wei, Jeanne Y. Hoffman, Andrew R. Salvatori, Roberto Ettinger, Mark P. Morey, Miriam C. Blackman, Marc R. Merriam, George R. CA Capromorelin Study Grp TI Effects of an Oral Growth Hormone Secretagogue in Older Adults SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID LOWER-EXTREMITY FUNCTION; PHYSICAL PERFORMANCE; BODY-COMPOSITION; FACTOR-I; INSULIN SENSITIVITY; ELDERLY-PEOPLE; MEN; DISABILITY; SECRETION; GHRELIN AB lContext: GH secretion declines with age, possibly contributing to reduced muscle mass, strength, and function. GH secretagogues (GHS) may increase muscle mass and physical performance. Objectives/Design: We conducted a randomized, double-masked, placebo-controlled, multicenter study to investigate the hormonal, body composition, and physical performance effects and the safety of the orally active GHS capromorelin in older adults with mild functional limitation. Intervention/Participants: A total of 395 men and women aged 65-84 yr were randomized for an intended 2 yr of treatment to four dosing groups (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day) or placebo. Although the study was terminated early according to predetermined treatment effect criteria, 315 subjects completed 6 months of treatment, and 284 completed 12 months. Results: A sustained dose-related rise in IGF-I concentrations occurred in all active treatment groups. Each capromorelin dose prompted a rise in peak nocturnal GH, which was greatest with the least frequent dosing. At 6 months, body weight increased 1.4 kg in subjects receiving capromorelin and decreased 0.2 kg in those receiving placebo (P = 0.006). Lean body mass increased 1.4 vs. 0.3 kg (P = 0.001), and tandem walk improved by 0.9 sec (P = 0.02) in the pooled treatment vs. placebo groups. By 12 months, stair climb also improved (P = 0.04). Adverse events included fatigue, insomnia, and small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance. Conclusions: In healthy older adults at risk for functional decline, administration of the oral GHS capromorelin may improve body composition and physical function. (J Clin Endocrinol Metab 94: 1198-1206, 2009) C1 [White, Heidi K.; Lyles, Kenneth; Morey, Miriam C.] Duke Univ, Sch Med, Durham, NC 27710 USA. [White, Heidi K.; Lyles, Kenneth; Morey, Miriam C.] Durham Vet Affairs VA Med Ctr, GRECC, Durham, NC 27710 USA. [Petrie, Charles D.] Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA. [Landschulz, William] Eli Lilly & Co, Endocrine Clin Res, Indianapolis, IN 46285 USA. [MacLean, David] Brown Univ, Sch Med, Providence, RI 02912 USA. [Taylor, Ann] Novartis, Cambridge, MA 02139 USA. [Wei, Jeanne Y.] Cent Arkansas Vet Affairs VA Healthcare Syst, GRECC, Little Rock, AR 72205 USA. [Wei, Jeanne Y.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Hoffman, Andrew R.] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Hoffman, Andrew R.] Stanford Univ, Palo Alto, CA 94304 USA. [Salvatori, Roberto] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA. [Ettinger, Mark P.] Radiant Res & Reg Osteoporosis Ctr, Stuart, FL 34996 USA. [Blackman, Marc R.] Washington DC VA Med Ctr, Washington, DC 20422 USA. [Merriam, George R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98493 USA. [Merriam, George R.] Univ Washington, Sch Med, Seattle, WA 98493 USA. [Merriam, George R.] Univ Washington, Sch Med, Tacoma, WA 98493 USA. [Merriam, George R.] VA Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. RP White, HK (reprint author), Duke Univ, Sch Med, Box 3003, Durham, NC 27710 USA. EM White031@mc.duke.edu FU Pfizer Global Research Development; Veterans Health Administration FX We thank Maria Fiatarone-Singh, Ph.D., who was instrumental in the planning of study entry criteria and physical performance endpoints developed in phase IIa studies that preceded this reported investigation. Other members of the Capromorelin Study Group were: Drs. William Hall, Robert Lang, Marco Pahor, William Pettit, Sherwyn L. Schwartz, Stuart Weiss, and Barbara Troupin. Clinical trial training support was provided by Kolette Fly, Al Kraska, and Nikos Kolivodiakos from Pfizer Global Research& Development. Statistical analysis and programming support was provided by Robert D. Chew, Ph.D., Chitra Lele, Shirsendu Sarkar, Urszula Masiukiewicz, and Andrea Flower from Pfizer Global Research & Development. The Duke Clinical Research Institute provided supervision and monitoring of five of the 12 research sites. We thank Colleen Carney, Ann Hill, Monica Kletke, Sheila Cole, and members of the Lake Worth, Florida, Radiant Research site for excellent support in the conduct of this protocol. We also gratefully acknowledge the contributions of the late Elizabeth C. Clipp, Ph.D., of Duke University.; Address all correspondence and requests for reprints to: Heidi K. White, M. D., M. H. S., Duke University School of Medicine, Box 3003, Durham, North Carolina 27710. E-mail: White031@mc.duke.edu.; This study was supported by Pfizer Global Research Development, which discovered and developed capromorelin, and by the Veterans Health Administration.; Trial Registration: Clinical Trials.gov Identifier: NCT00527046. Disclosure Summary: C. D. P. is employed by Pfizer and holds stock in the company. W. L., D. M., and A. T. were employed by Pfizer during this research study. H. K. W., K. L., J.Y.W., A. R. H., R. S., M. P. E., M. C. M., M. R. B., and G. R. M. received grant support for this research study from Pfizer, Inc. (October 1, 1999 to December 31, 2001). NR 49 TC 57 Z9 57 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2009 VL 94 IS 4 BP 1198 EP 1206 DI 10.1210/jc.2008-0632 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 432PB UT WOS:000265145100025 PM 19174493 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Hospitalization for Inflammatory Bowel Disease in the United States Between 1970 and 2004 SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE epidemiology; incidence; mortality; prevalence; time trends ID CROHNS-DISEASE; ULCERATIVE-COLITIS; PREVALENCE; TRENDS; RATES; EPIDEMIOLOGY; SURGERY; COUNTY AB Aim: The aim of the study was to use hospitalization data for the analysis of inflammatory bowel disease time trends in the United States. Methods: US hospital utilization data were available for individual years from 1970 to 2004 through the National Hospital Discharge Survey. Age-specific rates of hospitalization were Calculated for consecutive 5-year periods. Results: An increase in the rates of hospitalization for Crohn's disease was most pronounced in the age group 65+ followed by the age group 45 to 64. By contradistinction, the rates in the youngest age group 0 to 44 stayed largely unchanged. In ulcerative colitis, a significant increase in hospitalization rates was limited to the oldest age group, whereas the rates in the middle and young age group remained unchanged. Conclusions: Extrapolation of the current trends suggests that in the future the hospitalization for inflammatory bowel disease may start to level off. This may occur earlier and be more pronounced in younger age groups and patients with ulcerative colitis than Crohn's disease. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-G1,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 16 TC 16 Z9 16 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD APR PY 2009 VL 43 IS 4 BP 297 EP 300 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 439MM UT WOS:000265631200002 PM 18936713 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Waiting for Miracles SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Letter C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD APR PY 2009 VL 43 IS 4 BP 382 EP 383 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 439MM UT WOS:000265631200017 PM 19169151 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI Analysis of Recent Papers in Hypertension SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material C1 [Bloch, Michael J.] Univ Nevada, Div Cardiol, Div Gen Internal Med, Sch Med, Reno, NV 89557 USA. [Bloch, Michael J.] St Marys Reg Med Ctr, Risk Reduct Ctr, Reno, NV 89503 USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29403 USA. [Basile, Jan N.] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Bloch, MJ (reprint author), St Marys Reg Med Ctr, Risk Reduct Ctr, 645 N Arlington St,Suite 460, Reno, NV 89503 USA. EM mbloch@aol.com NR 1 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD APR PY 2009 VL 11 IS 4 BP 238 EP 240 DI 10.1111/j.1751-7176.2009.00105.x PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 432PM UT WOS:000265146200010 PM 19368588 ER PT J AU Lewis, DA Sweet, RA AF Lewis, David A. Sweet, Robert A. TI Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID DENDRITIC SPINE DENSITY; MISMATCH NEGATIVITY GENERATION; DORSOLATERAL PREFRONTAL CORTEX; PRIMARY AUDITORY-CORTEX; CORTICAL PYRAMIDAL NEURONS; MESSENGER-RNA EXPRESSION; O-METHYLTRANSFERASE COMT; NMDA RECEPTOR SUBUNITS; WORKING-MEMORY; GENE-EXPRESSION AB Schizophrenia is a severe disorder that disrupts the function of multiple brain systems, resulting in impaired social and occupational functioning. The etiology and pathogenesis of schizophrenia appear to involve the interplay of a potentially large number of genetic liabilities and adverse environmental events that disrupt brain developmental pathways. In this Review, we discuss a strategy for determining how particular common and core clinical features of the illness are associated with pathophysiology in certain circuits of the cerebral cortex. The identification of molecular alterations in these circuits is providing critical insights for the rational development of new therapeutic interventions. C1 [Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Lewis, DA (reprint author), Univ Pittsburgh, Dept Psychiat, W1651 Biomed Sci Tower,3811 Ohara St, Pittsburgh, PA 15213 USA. EM lewisda@upmc.edu RI Lewis, David/G-4053-2014 OI Lewis, David/0000-0002-3225-6778 FU National Institute of Mental Health [MH043784, MH045156, MH084053, MH071533] FX Cited work conducted by the authors was supported by NIH grants MH043784, MH045156, MH084053, and MH071533 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the NIH. The authors thank Mary Brady for preparation of the figures, Lindsay Karr for preparation of the manuscript, and Guillermo Gonzalez-Burgos and David Volk for helpful comments. NR 125 TC 116 Z9 118 U1 5 U2 16 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2009 VL 119 IS 4 BP 706 EP 716 DI 10.1172/JCI37335 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 428EF UT WOS:000264830100006 PM 19339762 ER PT J AU Insull, W Basile, JN Vo, AN Jiang, P Thakkar, R Padley, RJ AF Insull, William, Jr. Basile, Jan N. Vo, Anthony N. Jiang, Ping Thakkar, Roopal Padley, Robert J. TI Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study SO JOURNAL OF CLINICAL LIPIDOLOGY LA English DT Article DE Dyslipidemia; High-density lipoprotein; Niacin; PROBE; Statin ID CORONARY-HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; PLASMA LIPOPROTEIN(A); HDL CHOLESTEROL; DOUBLE-BLIND; PREVENTION; EVENTS; FRAMINGHAM; PROJECT; TRIALS AB BACKGROUND: Aggressive treatment of low-density lipoprotein cholesterol (LDL-C) fails to prevent most cardiovascular (CV) events. Concurrent treatment of LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) should be considered in patients with dyslipidemia. OBJECTIVE: The efficacy and safety of a proprietary niacin extended-release and simvastatin (NER/S) combination were compared to atorvastatin monotherapy in a Multicenter, Prospective, Randomized (3:2), Open-label. Blinded Endpoint (PROBE) study. METHODS: Following >= 4 weeks without lipid-modifying therapies, 193 patients with dyslipidemia were treated with NER/S (n = 114 1000/40 mg/day, weeks 1 to 4 2000/40 mg/day weeks 5 to 12) or atorvastatin (n = 79: 40 mg/day, weeks 1 to 12). RESULTS: Compared to atorvastatin, NER/S had a larger beneficial effect oil HDL-C (primary end point: 30.1 +/- 2.3% and 9.4 +/- 2.6%, respectively P <.001), TG (P =.02) and lipoprotein(a) (Lp[a]: P <.001), and similar effects on LDL-C and non-HDL-C. Two-thirds of patients treated with NER/S concurrently attained LDL-C (CV risk-adjusted goals), HDL-C (>= 40 mg/dL), and TG (< 150 mg/dL) targets, compared to one-third of patients treated with atorvastatin (P <.001). Flushing was the most common treatment-emergent adverse event (TEAE) (67.5% NER/S and 10.1% atorvastatin P <.001). Seventy-five percent Of flushing episodes were mild to moderate. More patients treated with NER/S discontinued due to TEAEs (21.1% and 3.8%; P <.001); the most common TEAE was flushing. CONCLUSION: Compared to atorvastatin, NER/S provided Superior improvements in HDL-C, TG. and Lp(a) and comparable improvements in non-HDL-C and LDL-C. Treatment with NER/S should be considered for patients with dyslipidemia requiring comprehensive lipid control. (c) 2009 National Lipid Association. All rights reserved. C1 [Insull, William, Jr.] Baylor Coll Med, Methodist Hosp, Lipid Res Clin, Houston, TX 77030 USA. [Basile, Jan N.] Ralph H Johnson Vet Aftairs Med Ctr, Charleston, SC USA. [Vo, Anthony N.] Long Beach Vet Affairs Med Ctr, Long Beach, CA USA. [Jiang, Ping; Thakkar, Roopal; Padley, Robert J.] Abbott, Abbott Pk, IL USA. RP Insull, W (reprint author), Baylor Coll Med, Methodist Hosp, Lipid Res Clin, 1790 Dryden Rd,Room 8-08, Houston, TX 77030 USA. EM winsull@bcm.edu FU Abbott; Abbott Laboratories [NCT00465088] FX Abbott is the financial sponsor of the SUPREME clinical trial. Abbott also provided financial support for a medical writer who provided editorial assistance during development of this work. Dr. Insull is a consultant for Abbott Laboratories (previously Kos Pharmaceuticals). Clinical Trials Identifier: NCT00465088. NR 30 TC 12 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-2874 J9 J CLIN LIPIDOL JI J. Clin. Lipidol. PD APR PY 2009 VL 3 IS 2 BP 109 EP 118 DI 10.1016/j.jacl.2009.02.009 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 464VU UT WOS:000267537400008 PM 21291800 ER PT J AU Ellis, MW Griffith, ME Jorgensen, JH Hospenthal, DR Mende, K Patterson, JE AF Ellis, Michael W. Griffith, Matthew E. Jorgensen, James H. Hospenthal, Duane R. Mende, Katrin Patterson, Jan E. TI Presence and Molecular Epidemiology of Virulence Factors in Methicillin-Resistant Staphylococcus aureus Strains Colonizing and Infecting Soldiers SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PANTON-VALENTINE LEUKOCIDIN; FIELD GEL-ELECTROPHORESIS; CATABOLIC MOBILE ELEMENT; NECROTIZING PNEUMONIA; NASAL CARRIAGE; UNITED-STATES; COLONIZATION; EMERGENCE; GENES; CLONE AB Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as an important cause of skin and soft-tissue infections (SSTI). The understanding of the molecular epidemiology and virulence of MRSA continues to expand. From January 2005 to December 2005, we screened soldiers for MRSA nasal colonization, administered a demographic questionnaire, and monitored them prospectively for SSTI. All MRSA isolates underwent molecular analysis, which included pulsed-filed gel electrophoresis (PFGE) and PCR for Panton-Valentine leukocidin (PVL), the arginine catabolic mobile element (ACME), and the staphylococcal cassette chromosome mec (SCCmec). Of the 3,447 soldiers screened, 134 (3.9%) had MRSA colonization. Of the 3,066 (89%) who completed the study, 39 developed culture-confirmed MRSA abscesses. Clone USA300 represented 53% of colonizing isolates but was responsible for 97% of the abscesses (P < 0.001). Unlike colonizing isolates, isolates positive for USA300, PVL, ACME, and type IV SCCmec were significantly associated with MRSA abscess isolates. As determined by multivariate analysis, risk factors for MRSA colonization were a history of SSTI and a history of hospitalization. Although various MRSA strains may colonize soldiers, USA300 is the most virulent when evaluated prospectively, and PVL, ACME, and type IV SCCmec are associated with these abscesses. C1 [Ellis, Michael W.; Griffith, Matthew E.; Hospenthal, Duane R.] Brooke Army Med Ctr, Dept Med Infect Dis, San Antonio, TX USA. [Jorgensen, James H.; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis, San Antonio, TX 78229 USA. [Ellis, Michael W.] Uniformed Serv Univ Hlth Sci, Dept Med Infect Dis, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. [Patterson, Jan E.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Ellis, MW (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med Infect Dis, Infect Dis Clin Res Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM michael.w.ellis@us.army.mil RI Valle, Ruben/A-7512-2013 NR 46 TC 25 Z9 26 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2009 VL 47 IS 4 BP 940 EP 945 DI 10.1128/JCM.02352-08 PG 6 WC Microbiology SC Microbiology GA 427RS UT WOS:000264797000011 PM 19213694 ER PT J AU Altshuler, LL Post, RM Hellemann, G Leverich, GS Nolen, WA Frye, MA Keck, PE Kupka, RW Grunze, H McElroy, SL Sugar, CA Suppes, T AF Altshuler, Lori L. Post, Robert M. Hellemann, Gerhard Leverich, Gabriele S. Nolen, Willem A. Frye, Mark A. Keck, Paul E., Jr. Kupka, Ralph W. Grunze, Heinz McElroy, Susan L. Sugar, Catherine A. Suppes, Trisha TI Impact of Antidepressant Continuation After Acute Positive or Partial Treatment Response for Bipolar Depression: A Blinded, Randomized Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID LITHIUM-CARBONATE; MOOD STABILIZERS; IMIPRAMINE; UNIPOLAR; ILLNESS; VENLAFAXINE; MANIA; DISCONTINUATION; COMBINATION; GUIDELINES AB Objective: To assess long-term outcome in bipolar disorder, subjects were prospectively followed after receiving acute treatment for bipolar depression. Method: Eighty-three outpatients with DSM-IV bipolar depression who were enrolled between March 1996 and November 2002 and were treated in a 10-week acute double-blind antidepressant treatment trial agreed to participate in a 1-year double-blind continuation of their medication. In the acute antidepressant treatment trial, subjects were treated with a mood stabilizer plus 1 of 3 randomly assigned antidepressants. Sixty-one subjects had attained an acute positive antidepressant response (50% improvement on the Inventory for Depressive Symptomatology [IDS] or 2-point improvement on the Clinical Global Impression for Bipolar Disorder [CGI-BP]) and 22 subjects achieved only acute partial improvement at the end of the 10-week acute trial. In the blinded continuation phase immediately following the acute trial, subjects continued on the same medications and were rated monthly for up to I year using the IDS, CGI-BP, and the Young Mania Rating scale. Results: At study endpoint, 42 (69%) of the 61 acute positive responders maintained positive response and 32 (53%) achieved remission. Compared to the acute positive responders, 6 (27%) of the 22 acute partial responders had achieved positive treatment response at study endpoint (p <.001). Eight acute positive responders (13%) and 5 acute partial responders (22%) developed mania. Conclusion: Patients who achieve a positive acute antidepressant response to 10 weeks of antidepressant treatment adjunctive to a mood stabilizer will probably maintain response with the same continued treatment. Patients who achieve only a partial acute antidepressant response are less likely to further improve when the same treatment is sustained. The switch rate into mania for patients being treated with an antidepressant adjunctive to a mood stabilizer is not higher than the reported rate for patients on mood stabilizer monotherapy. C1 [Altshuler, Lori L.] Univ Calif Los Angeles, Dept Psychiat, W Los Angeles Healthcare Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Altshuler, Lori L.; Hellemann, Gerhard] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Post, Robert M.; Leverich, Gabriele S.] Bipolar Collaborat Network, Bethesda, MD USA. [Post, Robert M.] George Washington Sch Med, Washington, DC USA. [Nolen, Willem A.] Univ Groningen, Dept Psychiat, Univ Med Ctr Groningen, Utrecht, Netherlands. [Kupka, Ralph W.] Altrech Inst Mental Hlth Care, Utrecht, Netherlands. [Frye, Mark A.] Mayo Coll Med, Genom Express & Neuropsychiat Evaluat Unit, Mayo Mood Disorder Clin & Res Program, Rochester, MN USA. [Keck, Paul E., Jr.; McElroy, Susan L.] Univ Cincinnati, Coll Med, Dept Psychiat, Psychopharmacol Res Program, Cincinnati, OH USA. [Keck, Paul E., Jr.; McElroy, Susan L.] HOPE, Frances Lindner Ctr, Cincinnati, OH USA. [Grunze, Heinz] Univ Munich, Dept Psychiat, D-80539 Munich, Germany. [Suppes, Trisha] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. RP Altshuler, LL (reprint author), 300 UCLA Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu RI Nolen, Willem/E-9006-2014 FU The Stanley Medical Research Institute; National Institute of Mental Health, Bethesda; Stanley Foundation Bipolar Network; GlaxoSmithKline, Philadelphia; Pfizer, New York, NY; Wyeth, Madison, NJ FX The authors gratefully acknowledge the support of The Stanley Medical Research Institute and the National Institute of Mental Health, Bethesda, Md., in the conduct of this research and the support of a grant from the Stanley Foundation Bipolar Network- (Dr Grunze). Drug and matching placebo were generously supplied by GlaxoSmithKline, Philadelphia, Pa. (bupropion); Pfizer, New York, NY (sertraline): and Wyeth, Madison, NJ (venlafaxine). NR 37 TC 35 Z9 35 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 2009 VL 70 IS 4 BP 450 EP 457 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 438IX UT WOS:000265550200002 PM 19358785 ER PT J AU Zisook, S Kasckow, JW Golshan, S Fellows, I Solorzano, E Lehman, D Mohamed, S Jeste, DV AF Zisook, Sidney Kasckow, John W. Golshan, Shahrokh Fellows, Ian Solorzano, Ellen Lehman, David Mohamed, Somaia Jeste, Dilip V. TI Citalopram Augmentation for Subsyndromal Symptoms of Depression in Middle-Aged and Older Outpatients With Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SEROTONIN REUPTAKE INHIBITOR; DOUBLE-BLIND; NEGATIVE SYMPTOMS; RATING-SCALE; CLINICAL-SIGNIFICANCE; FLUOXETINE; SUICIDE; PREVALENCE; VALIDATION; IMIPRAMINE AB Background: Subsyndromal symptoms of depression (SSD) in older outpatients with schizophrenia are common and clinically important. While many physicians prescribe antidepressants to patients with schizophrenia and schizoaffective disorder who have SSD, evidence for their effectiveness and safety has been meager. We describe a randomized placebo-controlled trial of citalopram in 198 patients. Method: Participants in this 2-site study, conducted from September 1, 200 1, to August 31, 2007, were men and women with DSM-IV schizophrenia or schizoaffective disorder who were 40 years of age or older and who met study criteria for SSD. Patients were randomly assigned to flexible-dose treatment with citalopram or placebo augmentation of their current antipsychotic medication. Analysis of covariance was used to compare improvement in scores on the Hamilton Rating Scale for Depression and Calgary Depression Rating Scale between treatment groups; secondary efficacy analyses compared improvement in several other dimensions of schizophrenia. Results: Augmentation with citalopram was significantly more effective than with placebo in improving depressive (p = .002) and negative (p = .049) symptoms, mental functioning (p = .000), and quality of life (p = .046). There were no significant differences between citalopram and placebo in suicidal ideation, positive symptoms, cognition, general medical health, physical functioning, or symptoms of movement disorders. No adverse events were more frequent in participants receiving citalopram than in those receiving placebo, and only 4 participants from each treatment group terminated early because of side effects. Conclusions: Subsyndromal symptoms of depression in middle aged and older patients with schizophrenia responded to treatment with citalopram with lessening of depressive symptoms and improved functioning and quality of life. It may be important for clinicians to identify and treat SSD in middle-aged and older patients with chronic schizophrenia. C1 [Zisook, Sidney; Golshan, Shahrokh; Fellows, Ian] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92161 USA. [Solorzano, Ellen; Lehman, David; Jeste, Dilip V.] Vet Affairs San Diego Hlth Care Syst, San Diego, CA USA. [Kasckow, John W.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Kasckow, John W.] MIRECC, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Mohamed, Somaia] MIRECC, VISN 1, Vet Affairs NE Program Evaluat Ctr, New Haven, CT USA. [Mohamed, Somaia] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Zisook, S (reprint author), Univ Calif San Diego, Dept Psychiat, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM szisook@ucsd.edu FU National Institute of Mental Health (NIMH) [RO-1 MH063931, MH66248, MH19934, P30 MH080002, R01 MH6398]; Department of Veterans Affairs FX This work was supported by National Institute of Mental Health (NIMH) grant RO-1 MH063931 Citalopram Augmentation of Older Patients with Schizophrenia (S. Zisook, principal investigator), and NIMH grants MH66248, MH19934, and P30 MH080002 and the Department of Veterans Affairs. Dr. Kasckow was supported by NIMH grant R01 MH6398, the VISN 4 MIRECC, and a VISN 4 Competitive Pilot Project Fund award. NR 50 TC 31 Z9 32 U1 1 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 2009 VL 70 IS 4 BP 562 EP 571 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 438IX UT WOS:000265550200013 PM 19192468 ER PT J AU Volpp, KG Troxel, A Long, J Ibrahaim, S Appleby, D Smith, J Jaskowiak, J Wang, P Holmes, JH Frosch, D Armstrong, K Helweg-Larsen, M Doshi, J Kumanyika, S Enge, K Townsend, R Joshi, N Kimmel, SE AF Volpp, K. G. Troxel, A. Long, J. Ibrahaim, S. Appleby, D. Smith, J. Jaskowiak, J. Wang, P. Holmes, J. H. Frosch, D. Armstrong, K. Helweg-Larsen, M. Doshi, J. Kumanyika, S. Enge, K. Townsend, R. Joshi, N. Kimmel, S. E. TI A RANDOMIZED CONTROLLED TRIAL OF COPAYMENT REDUCTIONS FOR BLOOD PRESSURE MEDICATION: THE COLLABORATION IN HYPERTENSION TO REDUCE DISPARITIES (CHORD) TRIAL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Volpp, K. G.; Troxel, A.; Long, J.; Armstrong, K.; Doshi, J.; Kimmel, S. E.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Volpp, K. G.; Long, J.; Armstrong, K.] Philadelphia Vet Affairs Med Ctr, CHERP, Philadelphia, PA USA. [Ibrahaim, S.] Vet Adm Hosp, CHERP, Pittsburgh, PA USA. [Smith, J.] Cheyney Univ, Cheyney, PA USA. [Frosch, D.] Univ Calif Los Angeles, Los Angeles, CA USA. [Helweg-Larsen, M.; Enge, K.] Dickinson Coll, Carlisle, PA 17013 USA. [Joshi, N.] Pinnacle Hlth, Harrisburg, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 9 EP 10 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000024 ER PT J AU Steinman, M Patil, S Kamat, P Knight, S AF Steinman, M. Patil, S. Kamat, P. Knight, S. TI A TAXONOMY OF REASONS FOR NOT PRESCRIBING GUIDELINE-RECOMMENDED MEDICATIONS: RESULTS FROM PHYSICIAN FOCUS GROUPS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Steinman, M.; Patil, S.; Kamat, P.; Knight, S.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 10 EP 11 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000027 ER PT J AU Gopal, RK Yamashita, TE Prochazka, AV AF Gopal, R. K. Yamashita, T. E. Prochazka, A. V. TI AMBULATORY CARE PROVIDERS' WORK ENVIRONMENT ASSOCIATED WITH POOR QUALITY OF CARE AND PROVIDER BURNOUT. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Gopal, R. K.; Prochazka, A. V.] Denver VAMC, Denver, CO USA. [Yamashita, T. E.] Univ Colorado, Sch Med, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 18 EP 19 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000048 ER PT J AU Paidisetty, S Broyles, LM Forman, SD Gordon, AJ AF Paidisetty, S. Broyles, L. M. Forman, S. D. Gordon, A. J. TI BUPRENORPHINE AND METHADONE OPIOID AGONIST THERAPY: DIFFERENCES IN PATIENT ENROLLMENT CHARACTERISTICS WITHIN A VA MEDICAL CENTER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Forman, S. D.; Gordon, A. J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 35 EP 36 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000095 ER PT J AU Dick, JF Wipf, JE Wilper, AP Smith, CS AF Dick, J. F. Wipf, J. E. Wilper, A. P. Smith, C. S. TI CAN RESIDENCY PROGRAM CURRICULA ENHANCE SELECTION OF PRIMARY CARE CAREERS? FACTORS AFFECTING PRIMARY CARE CAREER CHOICE IN ONE INTERNAL MEDICINE TRAINING PROGRAM. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Dick, J. F.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Wipf, J. E.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Wilper, A. P.; Smith, C. S.] Univ Washington, Boise VA Med Ctr, Boise, ID USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 37 EP 37 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000100 ER PT J AU Cohen, BE Ren, L Bertenthal, D Seal, KH AF Cohen, B. E. Ren, L. Bertenthal, D. Seal, K. H. TI CARDIAC RISK FACTORS IN IRAQ AND AFGHANISTAN VETERANS USING VA HEALTHCARE: ASSOCIATION WITH MENTAL HEALTH DIAGNOSES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Cohen, B. E.; Ren, L.; Bertenthal, D.; Seal, K. H.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 38 EP 38 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000102 ER PT J AU Volpp, K Konetzka, T Zhu, J Lindrooth, R AF Volpp, K. Konetzka, T. Zhu, J. Lindrooth, R. TI CHANGES OVER TIME IN HOSPITAL PROFITABILITY BY SERVICE LINE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Volpp, K.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, K.] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. [Konetzka, T.] Univ Chicago, Chicago, IL 60637 USA. [Zhu, J.] Univ Penn, Philadelphia, PA 19104 USA. [Lindrooth, R.] Med Univ S Carolina, Charleston, SC 29425 USA. RI Lindrooth, Richard/J-8607-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 40 EP 41 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000108 ER PT J AU Gordon, WJ Polansky, JM Boscardin, J Fung, K Steinman, M AF Gordon, W. J. Polansky, J. M. Boscardin, J. Fung, K. Steinman, M. TI CORONARY RISK ASSESSMENT BY POINT-BASED VS. EQUATION-BASED FRAMINGHAM MODELS: SIGNIFICANT IMPLICATIONS FOR CLINICAL CARE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Gordon, W. J.] Weill Cornell Med Coll, New York, NY USA. [Polansky, J. M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Boscardin, J.; Steinman, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fung, K.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 48 EP 49 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000128 ER PT J AU Singh, H Davis, T Khan, MM Thomas, EJ AF Singh, H. Davis, T. Khan, M. M. Thomas, E. J. TI DETECTION OF DIAGNOSTIC ERRORS USING ELECTRONIC HEALTH RECORDS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Singh, H.; Davis, T.; Khan, M. M.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Singh, H.; Davis, T.; Khan, M. M.] Baylor Coll Med, Houston, TX 77030 USA. [Thomas, E. J.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 53 EP 53 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000140 ER PT J AU Safford, MM Petersen, NJ Funkhouser, E Agee, BS Houston, TK AF Safford, M. M. Petersen, N. J. Funkhouser, E. Agee, B. S. Houston, T. K. TI DIMINISHING RETURNS: MORE BLOOD PRESSURE MEDICATIONS INCREASE CHANCES OF RUNNING OUT OF MEDICINE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Safford, M. M.; Funkhouser, E.] Univ Alabama, Birmingham, AL USA. [Petersen, N. J.] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Agee, B. S.; Houston, T. K.] Birmingham VA Med Ctr, Birmingham, AL USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 56 EP 56 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000150 ER PT J AU Hausmann, LR Mor, MK Geng, M Kresevic, D Grant, R Ibrahim, S AF Hausmann, L. R. Mor, M. K. Geng, M. Kresevic, D. Grant, R. Ibrahim, S. TI DISCRIMINATION IN HEALTH CARE AND PATIENT WILLINGNESS TO UNDERGO JOINT REPLACEMENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Hausmann, L. R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Mor, M. K.; Geng, M.; Ibrahim, S.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Mor, M. K.; Geng, M.; Ibrahim, S.] Univ Pittsburgh, Pittsburgh, PA USA. [Kresevic, D.; Grant, R.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Cleveland, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 57 EP 57 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000152 ER PT J AU Fihn, SD Rumsfeld, J Diehr, PH Mcdonell, M Stadius, M Gerrity, M Larsen, G Heidenreich, PA Bryson, C AF Fihn, S. D. Rumsfeld, J. Diehr, P. H. Mcdonell, M. Stadius, M. Gerrity, M. Larsen, G. Heidenreich, P. A. Bryson, C. TI EFFECT OF A COLLABORATIVE CARE INTERVENTION ON PATIENTS WITH ISCHEMIC HEART DISEASE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Fihn, S. D.] VA Off Qual & Performance, Seattle, WA USA. [Rumsfeld, J.] Eastern Colorado Hlth Care Syst, Denver, CO USA. [Diehr, P. H.] Univ Washington, Seattle, WA 98195 USA. [Mcdonell, M.; Stadius, M.; Bryson, C.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gerrity, M.; Larsen, G.] VA Portland, Portland, OR USA. [Heidenreich, P. A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 64 EP 64 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000171 ER PT J AU Prochazka, AV Fink, AS Henderson, W Bartenfeld, D Nyirenda, C AF Prochazka, A. V. Fink, A. S. Henderson, W. Bartenfeld, D. Nyirenda, C. TI EFFECT OF REPEAT BACK ON PATIENT PERCEPTIONS OF INFORMED CONSENT FOR SURGERY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Prochazka, A. V.] Denver VA Med Ctr, Denver, CO USA. [Fink, A. S.] Atlanta VAMC, Decatur, GA USA. [Henderson, W.; Nyirenda, C.] Univ Colorado Denver, Aurora, CO USA. [Bartenfeld, D.] Atlanta VAMC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 65 EP 66 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000176 ER PT J AU Kelley, AS Wenger, NS Sarkisian, CA AF Kelley, A. S. Wenger, N. S. Sarkisian, C. A. TI END OF LIFE PREFERENCES AND PLANNING AMONG OLDER LATINOS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Sarkisian, C. A.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 69 EP 69 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000187 ER PT J AU Bryson, CL Au, DH Blough, DK Fihn, SD Jackson, GL Piette, JD Maciejewski, ML Perkins, MW Sharp, ND Liu, C AF Bryson, C. L. Au, D. H. Blough, D. K. Fihn, S. D. Jackson, G. L. Piette, J. D. Maciejewski, M. L. Perkins, M. W. Sharp, N. D. Liu, C. TI FACILITY LEVEL VARIATION IN ADHERENCE TO ORAL DIABETES MEDICATIONS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Bryson, C. L.; Au, D. H.; Perkins, M. W.; Sharp, N. D.; Liu, C.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Blough, D. K.] Univ Washington, Seattle, WA 98195 USA. [Fihn, S. D.] VA Off Qual & Performance, Washington, DC USA. [Jackson, G. L.; Maciejewski, M. L.] Durham VA Med Ctr, Durham, NC USA. [Piette, J. D.] Univ Michigan, Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 73 EP 74 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000198 ER PT J AU Schiesser, R Espadas, D Petersen, LA Singh, H AF Schiesser, R. Espadas, D. Petersen, L. A. Singh, H. TI FOLLOW-UP OF ELECTRONIC CONSULTATION REQUESTS IN A MULTISPECIALTY OUTPATIENT CLINIC SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Espadas, D.] Michael E DeBakey Vet Affairs Med Ctr, Patient Safety Ctr Inquiry Improve Outpatient Saf, Houston HSR&D Ctr Excellence, Houston, TX USA. [Petersen, L. A.; Singh, H.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 77 EP 77 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000207 ER PT J AU Majesko, AA Boudreau, R Geng, M Kwoh, K Garvin, J Ibrahim, S AF Majesko, A. A. Boudreau, R. Geng, M. Kwoh, K. Garvin, J. Ibrahim, S. TI GENDER AND HIP/KNEE TOTAL ARTHROPLASTY: MORTALITY, COMPLICATIONS AND REVISION RATES IN THE STATE OF PENNSYLVANIA. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Majesko, A. A.] Univ Pittsburgh, VAPHS, Pittsburgh, PA USA. [Geng, M.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Garvin, J.] VA HSR&D Ctr Hlth Equity Res & Promot CHERP, Philadelphia, PA USA. [Ibrahim, S.] Vet Affairs Healthcare Syst Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 79 EP 80 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000214 ER PT J AU Seal, KH Cohen, B Ren, L Tarasovsky, G Burt, M Redden, N Abadjian, L AF Seal, K. H. Cohen, B. Ren, L. Tarasovsky, G. Burt, M. Redden, N. Abadjian, L. TI HIGH-RISK ALCOHOL USE AND SUBSTANCE MISUSE AMONG IRAQ AND AFGHANISTAN VETERANS: HIGH PREVALENCE AND ASSOCIATED MENTAL DISORDERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Seal, K. H.; Ren, L.; Tarasovsky, G.; Burt, M.; Redden, N.; Abadjian, L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 86 EP 86 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000232 ER PT J AU Bemben, W Gordon, AJ AF Bemben, W. Gordon, A. J. TI HOMELESS MEDICAL OUTREACH: A SYSTEMATIC NARRATIVE REVIEW AND CLIENT AND STAKEHOLDER PERCEPTIONS FOR IMPLEMENTATION IN ANCHORAGE ALASKA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Gordon, A. J.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 88 EP 88 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000237 ER PT J AU Korthuis, T Saha, S Moore, RD Cohn, JA Sharp, V Mccarty, D Beach, MC AF Korthuis, T. Saha, S. Moore, R. D. Cohn, J. A. Sharp, V. Mccarty, D. Beach, M. C. TI ILLICIT DRUG USE AND QUALITY OF PATIENT-PROVIDER COMMUNICATION IN HIV CLINICS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Korthuis, T.; Mccarty, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Moore, R. D.; Beach, M. C.] Johns Hopkins Univ, Baltimore, MD USA. [Cohn, J. A.] Wayne State Univ, Detroit, MI USA. [Sharp, V.] St Lukes Roosevelt Hosp, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 95 EP 96 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000257 ER PT J AU Mehta, K Fung, K Kistler, C Chang, A Walter, L AF Mehta, K. Fung, K. Kistler, C. Chang, A. Walter, L. TI IMPACT OF COGNITIVE IMPAIRMENT ON SCREENING MAMMOGRAPHY USE IN OLDER US WOMEN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Mehta, K.; Kistler, C.; Chang, A.; Walter, L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fung, K.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 98 EP 98 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000263 ER PT J AU Bautista, MK Garvan, CW Beyth, RJ Kwoh, K Harris, TB Nevitt, MC Shorr, RI AF Bautista, M. K. Garvan, C. W. Beyth, R. J. Kwoh, K. Harris, T. B. Nevitt, M. C. Shorr, R. I. TI LOW LITERACY PREDICTS UTILIZATION OF TOTAL KNEE ARTHROPLASTY IN OLDER ADULTS WITH KNEE PAIN: FINDINGS FROM THE HEALTH, AGING AND BODY COMPOSITION STUDY. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Bautista, M. K.; Beyth, R. J.; Shorr, R. I.] Univ Florida, Dept Aging, NF SGVHS GRECC, Gainesville, FL USA. [Garvan, C. W.] Univ Florida, Coll Educ, Gainesville, FL USA. [Kwoh, K.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Harris, T. B.] NIH, Chevy Chase, MD USA. [Nevitt, M. C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 117 EP 118 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000313 ER PT J AU Singh, H Hirani, K Kadiyala, H Rudomiotov, O Davis, T Khan, MM Wahls, T AF Singh, H. Hirani, K. Kadiyala, H. Rudomiotov, O. Davis, T. Khan, M. M. Wahls, T. TI LUNG CANCER DIAGNOSIS IN THE ERA OF ELECTRONIC MEDICAL RECORDS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Singh, H.; Davis, T.] Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D, Houston, TX USA. [Singh, H.; Davis, T.] Baylor Coll Med, Houston, TX 77030 USA. [Rudomiotov, O.; Wahls, T.] Iowa City Vet Adm Med Ctr, Iowa City, IA USA. [Rudomiotov, O.; Wahls, T.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 118 EP 119 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000315 ER PT J AU Krebs, EE Becker, WC Zerzan, J Mccoy, K Sutherland, J Bair, MJ AF Krebs, E. E. Becker, W. C. Zerzan, J. Mccoy, K. Sutherland, J. Bair, M. J. TI MORTALITY AMONG VA PATIENTS PRESCRIBED METHADONE AND MORPHINE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Krebs, E. E.; Mccoy, K.; Bair, M. J.] Roudebush VA Ctr Excellence Implementing Evidence, Indianapolis, IN USA. [Becker, W. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Zerzan, J.] Univ Colorado, Aurora, CO USA. [Sutherland, J.] Dartmouth Med Sch, Hanover, NH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 124 EP 125 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000332 ER PT J AU Salanitro, A Funkhouser, E Allison, JJ Halanych, JH Houston, TK Litaker, M Levine, DA Safford, MM AF Salanitro, A. Funkhouser, E. Allison, J. J. Halanych, J. H. Houston, T. K. Litaker, M. Levine, D. A. Safford, M. M. TI MULTIPLE UNCONTROLLED COMORBID CONDITIONS AND MEDICATION INTENSIFICATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Salanitro, A.; Houston, T. K.] Birmingham VA Med Ctr, Birmingham, AL USA. [Funkhouser, E.; Allison, J. J.; Halanych, J. H.; Litaker, M.; Safford, M. M.] Univ Alabama, Birmingham, AL USA. [Levine, D. A.] Ohio State Univ, Columbus, OH 43210 USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 125 EP 126 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000335 ER PT J AU Long, JA Lurie, N Escarce, J Montagnet, C Armstrong, K AF Long, J. A. Lurie, N. Escarce, J. Montagnet, C. Armstrong, K. TI NEIGHBORHOOD DISADVANTAGE, RACE, AND PROSTATE CANCER PRESENTATION, TREATMENT, AND MORTALITY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Long, J. A.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Lurie, N.] RAND, Arlington, VA USA. [Escarce, J.] RAND, Los Angeles, CA USA. [Montagnet, C.; Armstrong, K.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 126 EP 126 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000337 ER PT J AU Starrels, JL Becker, WC Li, X Weiner, MG Turner, BJ AF Starrels, J. L. Becker, W. C. Li, X. Weiner, M. G. Turner, B. J. TI OPIOID RISK MANAGEMENT IN A COHORT OF PRIMARY CARE PATIENTS WITH CHRONIC NON-CANCER PAIN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Starrels, J. L.; Li, X.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Becker, W. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Weiner, M. G.; Turner, B. J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 128 EP 128 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000341 ER PT J AU Pirraglia, PA Greenwald, D Welsh, D Kilbourne, A AF Pirraglia, P. A. Greenwald, D. Welsh, D. Kilbourne, A. TI ORGANIZATIONAL CHARACTERISTICS ASSOCIATED WITH CO-LOCATION OF GENERAL MEDICAL SERVICES IN MENTAL HEALTH PROGRAMS FOR VETERANS WITH SEVERE MENTAL ILLNESS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Pirraglia, P. A.] Providence VA Med Ctr, Providence, RI USA. [Greenwald, D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Welsh, D.; Kilbourne, A.] VA Natl Serious Mental Illness Treatment Res & Ev, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 129 EP 129 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000343 ER PT J AU Kelley, AS Ettner, SL Wenger, NS Sarkisian, CA AF Kelley, A. S. Ettner, S. L. Wenger, N. S. Sarkisian, C. A. TI PATIENT-LEVEL DETERMINANTS OF DYING IN THE HOSPITAL AMONG HRS DECEDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Sarkisian, C. A.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 135 EP 135 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000359 ER PT J AU Ling, B Hausmann, L Mor, MK Geng, M Ibrahim, S AF Ling, B. Hausmann, L. Mor, M. K. Geng, M. Ibrahim, S. TI PATIENT-PROVIDER COMMUNICATION AND INFORMED DECISION MAKING FOR PATIENTS WITH KNEE OR HIP OSTEOARTHRITIS IN THE ORTHOPEDIC SETTING WITHIN THE VA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Ling, B.; Hausmann, L.; Mor, M. K.; Geng, M.; Ibrahim, S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ling, B.; Hausmann, L.; Mor, M. K.; Geng, M.; Ibrahim, S.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 136 EP 136 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000361 ER PT J AU Cohen, BE Marmar, C Neylan, T Nelson, S Ali, S Whooley, MA AF Cohen, B. E. Marmar, C. Neylan, T. Nelson, S. Ali, S. Whooley, M. A. TI POST-TRAUMATIC STRESS DISORDER AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEART DISEASE: FINDINGS FROM THE HEART AND SOUL STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Cohen, B. E.; Marmar, C.; Neylan, T.; Nelson, S.; Ali, S.; Whooley, M. A.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 141 EP 141 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000375 ER PT J AU Harris, DP Chodosh, J Vassar, SD Vickrey, BG Shapiro, MF AF Harris, D. P. Chodosh, J. Vassar, S. D. Vickrey, B. G. Shapiro, M. F. TI PRIMARY CARE PROVIDERS' VIEW OF CHALLENGES AND REWARDS OF DEMENTIA CARE RELATIVE TO OTHER CONDITIONS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Vickrey, B. G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Chodosh, J.] Greater Los Angeles Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Los Angeles, CA USA. [Shapiro, M. F.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 146 EP 146 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000389 ER PT J AU Farmer, MF Yano, EM Sherman, S Mitchell, MN Riopelle, DD AF Farmer, M. F. Yano, E. M. Sherman, S. Mitchell, M. N. Riopelle, D. D. TI QUALITY IMPROVEMENT METHODS USED TO PROMOTE ADHERENCE TO GUIDELINES FOR SMOKING CESSATION TREATMENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Farmer, M. F.; Yano, E. M.; Mitchell, M. N.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Sherman, S.] NYU, Sch Med, New York, NY USA. [Riopelle, D. D.] VA Greater Los Angeles HSR&D Ctr Excellence, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 153 EP 153 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000406 ER PT J AU Saha, S Newman, P Morse, E AF Saha, S. Newman, P. Morse, E. TI RACE CONCORDANCE AND PATIENT DECISION-MAKING: A STUDY USING STANDARDIZED PHYSICIANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Newman, P.; Morse, E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 155 EP 155 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000411 ER PT J AU Sinha, S Schwartz, MD Ross, JS AF Sinha, S. Schwartz, M. D. Ross, J. S. TI SELF-REPORTED AND ACTUAL BETA-BLOCKER PRESCRIBING FOR HF PATIENTS: PHYSICIAN PREDICTORS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Sinha, S.] James J Peters VA Med Ctr, Bronx, NY USA. [Schwartz, M. D.] NYU, New York, NY USA. [Ross, J. S.] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 168 EP 168 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000448 ER PT J AU Starrels, JL Becker, WC Alford, DP Williams, AR Turner, BJ AF Starrels, J. L. Becker, W. C. Alford, D. P. Williams, A. R. Turner, B. J. TI SYSTEMATIC REVIEW: PREVALENCE AND EFFECTIVENESS OF IMPLEMENTING OPIOID TREATMENT AGREEMENTS FOR PRIMARY CARE PATIENTS WITH CHRONIC PAIN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Starrels, J. L.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Starrels, J. L.] Montefiore Med Ctr, Bronx, NY 10467 USA. [Becker, W. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Alford, D. P.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Williams, A. R.; Turner, B. J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 176 EP 176 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000469 ER PT J AU Nelson, K Lurie, N Escarce, J Taylor, L Lynne, M Fihn, SD AF Nelson, K. Lurie, N. Escarce, J. Taylor, L. Lynne, M. Fihn, S. D. TI THE IMPACT OF NEIGHBORHOOD ENVIRONMENT ON VETERAN HEALTH STATUS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Nelson, K.; Fihn, S. D.] Univ Washington, Seattle, WA 98195 USA. [Lurie, N.] RAND Corp, Arlington, VA USA. [Escarce, J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Taylor, L.; Lynne, M.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 186 EP 187 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000497 ER PT J AU Korthuis, T Saha, S Moore, RD Cohn, JA Sharp, V Mccarty, D Beach, MC AF Korthuis, T. Saha, S. Moore, R. D. Cohn, J. A. Sharp, V. Mccarty, D. Beach, M. C. TI UNHEALTHY ALCOHOL USE AND QUALITY OF PATIENT-PROVIDER COMMUNICATION IN HIV CLINICS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Korthuis, T.; Mccarty, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Moore, R. D.; Beach, M. C.] Johns Hopkins Univ, Baltimore, MD USA. [Cohn, J. A.] Wayne State Univ, Detroit, MI USA. [Sharp, V.] St Lukes Roosevelt Hosp, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 205 EP 205 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000545 ER PT J AU Salanitro, A Castiglioni, A Willett, LL Shewchuk, RM Qu, H Heudebert, GR Centor, RM AF Salanitro, A. Castiglioni, A. Willett, L. L. Shewchuk, R. M. Qu, H. Heudebert, G. R. Centor, R. M. TI USING COGNITIVE MAPPING TO IDENTIFY FACULTY PERSPECTIVES FOR SUCCESSFUL WARD ATTENDING ROUNDS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Castiglioni, A.] Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 209 EP 209 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000554 ER PT J AU Salanitro, A Estrada, CA Safford, MM Curry, W Houston, TK Williams, J Ovalle, F Allison, JJ AF Salanitro, A. Estrada, C. A. Safford, M. M. Curry, W. Houston, T. K. Williams, J. Ovalle, F. Allison, J. J. TI USING PATIENT COMPLEXITY TO INFORM PHYSICIAN PROFILES IN THE PAY-FOR-PERFORMANCE ERA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Salanitro, A.; Estrada, C. A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Safford, M. M.; Curry, W.; Houston, T. K.; Williams, J.; Ovalle, F.; Allison, J. J.] Univ Alabama, Birmingham, AL USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 211 EP 212 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000561 ER PT J AU Gellad, WF Lowe, JC Good, CB AF Gellad, W. F. Lowe, J. C. Good, C. B. TI VARIATION IN PRESCRIPTION DRUG SPENDING IN THE VA HEALTHCARE SYSTEM AND THE RELATIONSHIP TO QUALITY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Gellad, W. F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gellad, W. F.] RAND Hlth, Pittsburgh, PA USA. [Lowe, J. C.] VHA Pharm Benefits Management, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 213 EP 213 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000565 ER PT J AU Kim, AE Kamyab, K Zhu, J Volpp, K AF Kim, A. E. Kamyab, K. Zhu, J. Volpp, K. TI WHY ARE FINANCIAL INCENTIVES NOT EFFECTIVE AT INFLUENCING SOME SMOKERS TO QUIT? RESULTS FROM A PROCESS EVALUATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Kim, A. E.; Kamyab, K.] Res Triangle Inst, Res Triangle Pk, NC 27709 USA. [Zhu, J.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Volpp, K.] Univ Penn, Sch Med, Ctr Hlth Incent, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Volpp, K.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, K.] Philadelphia VA Med Cen, CHERP, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 219 EP 220 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000582 ER PT J AU Yano, EM Bean-Mayberry, B Ash, DR Canelo, IA Washington, DL AF Yano, E. M. Bean-Mayberry, B. Ash, D. Rose Canelo, I. A. Washington, D. L. TI WOMEN AND WAR: HOW ARE VETERANS HEALTH ADMINISTRATION (VA) FACILITIES ADAPTING TO THEIR CHANGING DEMOGRAPHICS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Yano, E. M.; Bean-Mayberry, B.; Ash, D. Rose; Canelo, I. A.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Washington, D. L.] VA Greater Los Angeles HSR&D Ctr Excellence, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 220 EP 221 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000584 ER PT J AU Bradley, SM Atanous, A Karani, R AF Bradley, S. M. Atanous, A. Karani, R. TI IMPACT OF A STUDENT-DIRECTED FALL RISK MODULE IN AMBULATORY GERIATRICS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Bradley, S. M.; Karani, R.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY USA. [Atanous, A.] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 229 EP 230 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000608 ER PT J AU Fung, PH Kolpakchi, AL Lu, L AF Fung, P. H. Kolpakchi, A. L. Lu, L. TI A LETHAL RASH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Fung, P. H.; Lu, L.] Baylor Coll Med, Houston, TX 77030 USA. [Kolpakchi, A. L.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 274 EP 275 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000724 ER PT J AU Kunkel, DC Cheng, ET AF Kunkel, D. C. Cheng, E. T. TI ASBESTOS: INSULATING YOU FROM THE CORRECT DIAGNOSIS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Kunkel, D. C.] Cedars Sinai Internal Med Residency Program, Los Angeles, CA USA. [Cheng, E. T.] Greater Los Angeles Vet Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 293 EP 293 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000774 ER PT J AU Helmer, D Kolpakchi, A AF Helmer, D. Kolpakchi, A. TI TO CARE FOR HIM WHO SHALL HAVE BORNE THE BATTLE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Helmer, D.; Kolpakchi, A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 369 EP 370 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000981 ER PT J AU Defonseka, AM Cheng, ET AF Defonseka, A. M. Cheng, E. T. TI UNEXPECTED FALLS: AN UNUSUAL MANIFESTATION OF HEPATIC ENCEPHALOPATHY TRIGGERED BY ANTI-VIRAL THERAPY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med C1 [Defonseka, A. M.; Cheng, E. T.] Greater Los Angeles Vet Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 SU 1 BP 371 EP 371 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 435ZI UT WOS:000265382000986 ER PT J AU Au, DH Bryson, CL Chien, JW Sun, HL Udris, EM Evans, LE Bradley, KA AF Au, David H. Bryson, Christopher L. Chien, Jason W. Sun, Haili Udris, Edmunds M. Evans, Laura E. Bradley, Katharine A. TI The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease Exacerbations SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; exacerbation; smoking cessation ID LUNG-FUNCTION; AIRWAY INFLAMMATION; COST-EFFECTIVENESS; HEALTH; COPD; SMOKERS; INTERVENTION; SYMPTOMS; SPUTUM; PREVENTION AB Smoking cessation has been demonstrated to reduce the rate of loss of lung function and mortality among patients with mild to moderate chronic obstructive pulmonary disease (COPD). There is a paucity of evidence about the effects of smoking cessation on the risk of COPD exacerbations. We sought to examine whether smoking status and the duration of abstinence from tobacco smoke is associated with a decreased risk of COPD exacerbations. We assessed current smoking status and duration of smoking abstinence by self-report. Our primary outcome was either an inpatient or outpatient COPD exacerbation. We used Cox regression to estimate the risk of COPD exacerbation associated with smoking status and duration of smoking cessation. We performed a cohort study of 23,971 veterans who were current and past smokers and had been seen in one of seven Department of Veterans Affairs (VA) primary care clinics throughout the US. In comparison to current smokers, ex-smokers had a significantly reduced risk of COPD exacerbation after adjusting for age, comorbidity, markers of COPD severity and socio-economic status (adjusted HR 0.78, 95% CI 0.75-0.87). The magnitude of the reduced risk was dependent on the duration of smoking abstinence (adjusted HR: quit < 1 year, 1.04; 95% CI 0.87-1.26; 1-5 years 0.93, 95% CI 0.79-1.08; 5-10 years 0.84, 95% CI 0.70-1.00; a parts per thousand yen10 years 0.65, 95% CI 0.58-0.74; linear trend < 0.001). Smoking cessation is associated with a reduced risk of COPD exacerbations, and the described reduction is dependent upon the duration of abstinence. C1 [Au, David H.; Bryson, Christopher L.; Sun, Haili; Udris, Edmunds M.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Au, David H.; Bryson, Christopher L.; Chien, Jason W.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Chien, Jason W.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Evans, Laura E.] NYU, Dept Med, New York, NY 10016 USA. RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way 152, Seattle, WA 98108 USA. EM dau@u.washington.edu FU Department of Veterans Affairs [IAC 05-206, IIR-99-376]; VA Career Development Award [RCS 03-177] FX David Au had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This study was funded by the Department of Veterans Affairs: IAC 05-206 and IIR-99-376. Dr. Bryson is funded by a VA Career Development Award (RCS 03-177). NR 37 TC 37 Z9 38 U1 3 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 IS 4 BP 457 EP 463 DI 10.1007/s11606-009-0907-y PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 423GJ UT WOS:000264484500003 PM 19194768 ER PT J AU Wong, MD Ettner, SL Boscardin, WJ Shapiro, MF AF Wong, Mitchell D. Ettner, Susan L. Boscardin, W. John Shapiro, Martin F. TI The Contribution of Cancer Incidence, Stage at Diagnosis and Survival to Racial Differences in Years of Life Expectancy SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE racial differences; cancer mortality; survival; life expectancy ID LOCALIZED PROSTATE-CANCER; BREAST-CANCER; COLORECTAL-CANCER; UNITED-STATES; LUNG-CANCER; ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; WHITE WOMEN; BLACK; MORTALITY AB African Americans have higher cancer mortality rates than whites. Understanding the relative contribution of cancer incidence, stage at diagnosis and survival after diagnosis to the racial gap in life expectancy has important implications for directing future health disparity interventions toward cancer prevention, screening and treatment. We estimated the degree to which higher cancer mortality among African Americans is due to higher incidence rates, later stage at diagnosis or worse survival after diagnosis. Stochastic model of cancer incidence and survival after diagnosis. Surveillance and Epidemiology End Result cancer registry and National Health Interview Survey data. Life expectancy if African Americans had the same cancer incidence, stage and survival after diagnosis as white adults. African-American men and women live 1.47 and 0.91 fewer years, respectively, than whites as the result of all cancers combined. Among men, racial differences in cancer incidence, stage at diagnosis and survival after diagnosis account for 1.12 (95% CI: 0.52 to 1.36), 0.17 (95% CI: -0.03 to 0.33) and 0.21 (95% CI: 0.05 to 0.34) years of the racial gap in life expectancy, respectively. Among women, incidence, stage and survival after diagnosis account for 0.41 (95% CI: -0.29 to 0.60), 0.26 (95% CI: -0.06 to 0.40) and 0.31 (95% CI: 0.05 to 0.40) years, respectively. Differences in stage had a smaller impact on the life expectancy gap compared with the impact of incidence. Differences in cancer survival after diagnosis had a significant impact for only two cancers-breast (0.14 years; 95% CI: 0.05 to 0.16) and prostate (0.05 years; 95% CI 0.01 to 0.09). In addition to breast and colorectal cancer screening, national efforts to reduce disparities in life expectancy should also target cancer prevention, perhaps through smoking cessation, and differences in survival after diagnosis among persons with breast and prostate cancer. C1 [Wong, Mitchell D.; Ettner, Susan L.; Shapiro, Martin F.] Univ Calif Los Angeles, Div GIM HSR, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Boscardin, W. John] San Francisco Vet Adm Med Ctr, Div Geriatr, San Francisco, CA USA. RP Wong, MD (reprint author), Univ Calif Los Angeles, Div GIM HSR, David Geffen Sch Med, 911 Broxton Ave,Suite 101, Los Angeles, CA 90024 USA. EM mitchellwong@mednet.ucla.edu OI Wong, Mitchell/0000-0002-4800-8410 FU National Institute on Aging [1K08AG/HS21616-05]; Pfizer Scholars Grant; National Institutes of Minority Health and Health Disparities [1P20MD000148-01] FX This work was supported by a K08 Mentored Scientist Award (1K08AG/HS21616-05) from the National Institute on Aging, a Pfizer Scholars Grant in Clinical Epidemiology and Doris Duke Charitable Foundation Clinical Scientist Development Award to Dr. Wong and the UCLA-Drew Project Export from the National Institutes of Minority Health and Health Disparities (1P20MD000148-01). NR 51 TC 15 Z9 15 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2009 VL 24 IS 4 BP 475 EP 481 DI 10.1007/s11606-009-0912-1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 423GJ UT WOS:000264484500006 PM 19189193 ER PT J AU Hsu, HC Wang, J Wu, Q Li, J Yang, P Li, H Mountz, JD AF Hsu, Hui-Chen Wang, John Wu, Qi Li, Jun Yang, PingAr Li, Hao Mountz, John D. TI Migration of marginal zone precursor B cells into the T-cell zone promoted by interferon-alpha induces a T-dependent germinal center response SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Hsu, Hui-Chen; Wang, John; Wu, Qi; Li, Jun; Yang, PingAr; Li, Hao; Mountz, John D.] Univ Alabama Birmingham, Med, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2009 VL 182 SU 1 MA 99.33 PG 1 WC Immunology SC Immunology GA V44QN UT WOS:000209763602071 ER PT J AU Salinthone, S Schillace, RV Yadav, V Marracci, G Bourdette, D Carr, DW AF Salinthone, Sonemany Schillace, Robynn V. Yadav, Vijayshree Marracci, Gail Bourdette, Dennis Carr, Daniel W. TI The natural antioxidant lipoic acid (LA) alters immune cell function: implications for multiple sclerosis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Salinthone, Sonemany; Schillace, Robynn V.; Marracci, Gail; Bourdette, Dennis; Carr, Daniel W.] Portland VA Med Ctr, Res & Dev, Portland, OR USA. [Salinthone, Sonemany; Schillace, Robynn V.; Yadav, Vijayshree; Marracci, Gail; Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2009 VL 182 SU 1 MA 50.3 PG 1 WC Immunology SC Immunology GA V44QN UT WOS:000209763601059 ER PT J AU Zhang, X Mathenia, J Reyes-Cortes, E Molano, I Gilkeson, G AF Zhang, Xian Mathenia, Jeremy Reyes-Cortes, Emmanuel Molano, Ivan Gilkeson, Gary TI Effects of expression Fli1 transcription factor on lupus disease development in NZM2410 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Zhang, Xian; Mathenia, Jeremy; Reyes-Cortes, Emmanuel; Molano, Ivan; Gilkeson, Gary] Med Univ South Carolina, Med, Charleston, SC USA. [Zhang, Xian; Gilkeson, Gary] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2009 VL 182 SU 1 PG 1 WC Immunology SC Immunology GA V44QN UT WOS:000209763602084 ER PT J AU Zuleger, CL Macklin, MD Pei, QL Newton, MA Albertini, MR AF Zuleger, Cindy L. Macklin, Michael D. Pei, Qinglin Newton, Michael A. Albertini, Mark R. TI Identification of in vivo 6-thioguanine-resistant T cells reactive to melanoma-associated antigens SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Zuleger, Cindy L.; Macklin, Michael D.; Newton, Michael A.; Albertini, Mark R.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA. [Pei, Qinglin; Newton, Michael A.] Univ Wisconsin, Sch Med & Publ Hlth, Stat, Madison, WI USA. [Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2009 VL 182 SU 1 MA 40.15 PG 2 WC Immunology SC Immunology GA V44QN UT WOS:000209763600243 ER PT J AU Bashir, MM Sharma, MR Werth, VP AF Bashir, Muhammad M. Sharma, Meena R. Werth, Victoria P. TI UVB and Proinflammatory Cytokines Synergistically Activate TNF-alpha Production in Keratinocytes through Enhanced Gene Transcription SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MESSENGER-RNA; HUMAN SKIN; ULTRAVIOLET-LIGHT; FACTOR PROMOTER; OVARIAN-CANCER; GROWTH-FACTOR; IN-VITRO; EXPRESSION AB UVB irradiation potently induces cytokines in the skin, including IL-1 alpha and tumor necrosis factor-alpha (TNF-alpha). The mechanism for TNF-alpha induction in UVB-irradiated keratinocytes is not clear. In this study, we explored the effects of UVB and cytokines, alone or in combination in human keratinocytes. Keratinocytes were sham-or UVB-irradiated with 30 mJ cm(-2), and then incubated in the absence or presence of IFN-alpha 2b, TNF-alpha, or IL-1 alpha. UVB and IL-1 alpha treatment synergistically enhanced TNF-alpha secretion and mRNA levels in human keratinocytes, similar to the findings reported previously in human fibroblasts. Exogenous recombinant TNF-alpha up-regulates its own mRNA level. However, addition of IFN-alpha 2b did not show any additive effect on TNF-alpha mRNA induction. To understand the regulation of TNF-alpha mRNA by UVB, with or without IL-1 alpha, we examined the transcription rate and half-life of TNF-alpha mRNA. Treatment of keratinocytes with IL-1 alpha or UVB alone increased TNF-alpha gene transcription 4- to 5-fold over sham treatment, and TNF-alpha gene transcription increased 11-fold in cells treated with UVB plus IL-1 alpha over sham. UVB with IL-1 alpha did not enhance the half-life of TNF-alpha mRNA over that seen with UVB alone. In conclusion, TNF-alpha expression in primary keratinocytes is upregulated transcriptionally by UVB and IL-1 alpha. C1 [Bashir, Muhammad M.; Sharma, Meena R.; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Bashir, Muhammad M.; Sharma, Meena R.; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Philadelphia VA Med Ctr, 2 Rhoads Pavil,36th & Spruce Sts, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [P30 AR057217-01, P30 AR057217] NR 52 TC 34 Z9 34 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2009 VL 129 IS 4 BP 994 EP 1001 DI 10.1038/jid.2008.332 PG 8 WC Dermatology SC Dermatology GA 430MW UT WOS:000264994200024 PM 19005488 ER PT J AU Braunstein, I Goodman, NG Rosenbach, M Okawa, J Kovarik, C Prak, ETL Werth, V AF Braunstein, I. Goodman, N. G. Rosenbach, M. Okawa, J. Kovarik, C. Prak, E. T. Luning Werth, V. TI Changes in the circulating leukocyte profile of subjects on lenalidomide for cutaneous lupus erythematosus SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the Society-of-Investigative-Dermatology CY MAY 06-09, 2009 CL Montreal, CANADA SP Soc Investigat Dematol C1 [Braunstein, I.; Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Braunstein, I.; Goodman, N. G.; Rosenbach, M.; Okawa, J.; Kovarik, C.; Prak, E. T. Luning; Werth, V.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2009 VL 129 MA 257 BP S43 EP S43 PG 1 WC Dermatology SC Dermatology GA 430MU UT WOS:000264994000255 ER PT J AU Chang, LM Schaffer, L Head, SR Werth, VP AF Chang, L. M. Schaffer, L. Head, S. R. Werth, V. P. TI The molecular basis for increased dermal content of hyaluronic acid and chondroitin sulfate in cutaneous lupus erythematosus SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the Society-of-Investigative-Dermatology CY MAY 06-09, 2009 CL Montreal, CANADA SP Soc Investigat Dematol C1 [Chang, L. M.; Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chang, L. M.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Schaffer, L.; Head, S. R.] Consortium Funct Glyc, La Jolla, CA USA. [Schaffer, L.; Head, S. R.] Scripps Res Inst, La Jolla, CA 92037 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2009 VL 129 MA 70 BP S12 EP S12 PG 1 WC Dermatology SC Dermatology GA 430MU UT WOS:000264994000071 ER PT J AU Chren, MM Torres, JS Stuart, SE Labrador, RJ Bertenthal, D Boscardin, WJ AF Chren, M. M. Torres, J. S. Stuart, S. E. Labrador, R. J. Bertenthal, D. Boscardin, W. J. TI Tumor recurrence after treatment of keratinocyte carcinoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the Society-of-Investigative-Dermatology CY MAY 06-09, 2009 CL Montreal, CANADA SP Soc Investigat Dematol C1 [Chren, M. M.; Boscardin, W. J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Chren, M. M.; Torres, J. S.; Stuart, S. E.; Labrador, R. J.; Bertenthal, D.; Boscardin, W. J.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2009 VL 129 MA 384 BP S64 EP S64 PG 1 WC Dermatology SC Dermatology GA 430MU UT WOS:000264994000384 ER PT J AU Katiyar, SK Katiyar, N Xu, H Meeran, SM AF Katiyar, S. K. Katiyar, N. Xu, H. Meeran, S. M. TI Interleukin-12-deficiency enhances 12-O-tetradecanoylphorbol-13-acetate-induced skin tumor promotion and malignant progression of papillomas to carcinomas in DMBA-initiated mouse skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the Society-of-Investigative-Dermatology CY MAY 06-09, 2009 CL Montreal, CANADA SP Soc Investigat Dematol C1 [Katiyar, S. K.; Katiyar, N.; Xu, H.; Meeran, S. M.] Univ Alabama, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2009 VL 129 MA 145 BP S25 EP S25 PG 1 WC Dermatology SC Dermatology GA 430MU UT WOS:000264994000145 ER PT J AU Meeran, SM Punathil, T Katiyar, S Elmets, CA Katiyar, SK AF Meeran, S. M. Punathil, T. Katiyar, S. Elmets, C. A. Katiyar, S. K. TI Inhibition of angiogenesis in UV-induced skin tumors by drinking green tea polyphenols requires IL-12 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the Society-of-Investigative-Dermatology CY MAY 06-09, 2009 CL Montreal, CANADA SP Soc Investigat Dematol C1 [Meeran, S. M.; Punathil, T.; Katiyar, S.; Elmets, C. A.; Katiyar, S. K.] Univ Alabama, Birmingham, AL USA. [Elmets, C. A.; Katiyar, S. K.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2009 VL 129 MA 752 BP S126 EP S126 PG 1 WC Dermatology SC Dermatology GA 430MU UT WOS:000264994000754 ER PT J AU Sharma, MR Werth, B LoMonico, J Werth, VP AF Sharma, M. R. Werth, B. LoMonico, J. Werth, V. P. TI Effect of Etanercept, TNF-alpha blocker on TNF-alpha-mediated photodamage/photoaging SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the Society-of-Investigative-Dermatology CY MAY 06-09, 2009 CL Montreal, CANADA SP Soc Investigat Dematol C1 [Sharma, M. R.; Werth, B.; LoMonico, J.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Sharma, M. R.; Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2009 VL 129 MA 773 BP S129 EP S129 PG 1 WC Dermatology SC Dermatology GA 430MU UT WOS:000264994000771 ER PT J AU Singh, H Fox, SA Petersen, NJ Shethia, A Street, RL AF Singh, Hardeep Fox, Sarah A. Petersen, Nancy J. Shethia, Anila Street, Richard L., Jr. TI Older Patients' Enthusiasm to Use Electronic Mail to Communicate With Their Physicians: Cross-Sectional Survey SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE Electronic mail; doctor-patient communication; Internet; doctor-patient relationship ID MEDICAL ENCOUNTER; HEALTH-CARE; EMAIL; INTERNET; DIVIDE; ACCESS AB Background: Recent evidence indicates increased access to and use of Internet and non-healthcare-related email by older patients. Because email adoption could potentially reduce some of the disparities faced by this age group, there is a need to understand factors determining older patients' enthusiasm to use email to communicate with their physicians. Electronic mail (email) represents a means of communication that, coupled with face-to-face communication, could enhance quality of care for older patients. Objective: Testa model to determine factors associated with older patients' enthusiasm to use email to communicate with their physicians. Methods: We conducted a secondary data analysis of survey data collected in 2003 for two large, longitudinal, randomized controlled trials. Logistic-regression models were used to model the dichotomous outcome of patient enthusiasm for using email to communicate with their physicians. Explanatory variables included demographic characteristics, health status, use of email with people other than their physician, characteristics of the physician-patient relationship, and physician enthusiasm to use email with patients. Results: Participants included a pooled sample of 4059 patients over 65 years of age and their respective physicians (n = 181) from community-based practices in Southern California. Although only 52 (1.3%) patient respondents reported that they communicated with their physician by email, about half (49.3%) expressed enthusiasm about the possibility of using it. Odds of being enthusiastic decreased with increased age (by 0.97 for each year over 66) but were significantly higher in African Americans (OR = 2.1, CI = 1.42 - 3.06), Hispanics (OR = 1.6, CI = 1.26 - 2.14) and men (OR = 1.3, CI = 1.1 - 1.5). A perception of better communication skills of their physician, lower quality of interaction with physician in traditional face-to-face encounters, and physician enthusiasm to use email with patients were significantly associated with an enthusiasm to use email. Patients who did not use email at all were less enthusiastic compared to those who used email for other reasons. Half of the physician respondents were not enthusiastic about communicating with patients using email. Conclusions: Despite perceived barriers such as limited access to the Internet, older patients seem to want to use email to communicate with their physicians. C1 [Singh, Hardeep; Petersen, Nancy J.; Shethia, Anila; Street, Richard L., Jr.] Michael E DeBakey VA Med Ctr, Ctr Excellence, Houston VA Hlth Serv Res & Dev HSR&D, Houston, TX 77030 USA. [Singh, Hardeep; Petersen, Nancy J.; Shethia, Anila; Street, Richard L., Jr.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Singh, Hardeep] Michael E DeBakey VA Med Ctr, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX USA. [Fox, Sarah A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Ctr Community Patnerships Hlth Promot, Los Angeles, CA 90095 USA. [Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu FU National Cancer Institute [RO1CA74322]; Houston VA HSR&D Center of Excellence [HFP90-020] FX The study was supported by a grant from the National Cancer Institute (NCI RO1CA74322) and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). These sources had no role in study design or execution, collection of data, writing the manuscript, or the decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 29 TC 30 Z9 30 U1 4 U2 8 PU JOURNAL MEDICAL INTERNET RESEARCH PI TORONTO PA TORONTO GENERAL HOSPITAL, R FRASER ELLIOTT BLDG, 4TH FL, R 4S435, 190 ELIZABETH ST, TORONTO, ON M5G 2C4, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD APR-JUN PY 2009 VL 11 IS 2 AR e18 DI 10.2196/jmir.1143 PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 556YT UT WOS:000274632700004 PM 19632972 ER PT J AU Hasman, H Pachucki, CT Unal, A Nguyen, D Devlin, T Peeples, ME Kwilas, SA AF Hasman, Hatice Pachucki, Constance T. Unal, Arife Nguyen, Diep Devlin, Troy Peeples, Mark E. Kwilas, Steven A. TI Aetiology of influenza-like illness in adults includes parainfluenzavirus type 4 SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID RESPIRATORY-SYNCYTIAL-VIRUS; REVERSE TRANSCRIPTION-PCR; CLINICAL-SAMPLES; HUMAN METAPNEUMOVIRUS; PEDIATRIC-PATIENTS; INFECTIONS; IDENTIFICATION; DIAGNOSIS; CHILDREN; ASSAYS AB Influenza viruses cause significant morbidity and mortality in adults each winter. At the same time, other respiratory viruses circulate and cause respiratory illness with influenza-like symptoms. Human respiratory syncytial virus (HRSV), human parainfluenza viruses (HPIV) and human metapneumovirus have all been associated with morbidity and mortality in adults, including nosocomial infections. This study evaluated 154 respiratory specimens collected from adults with influenza-like/acute respiratory illness (ILI) seen at the Edward Hines Jr VA Hospital, Hines, IL, USA, during two successive winters, 1998-1999 and 1999-2000. The samples were tested for ten viruses in two nested multiplex RT-PCRs. One to three respiratory viruses were detected in 68% of the samples. As expected, influenza A virus (FLU-A) infections were most common (50% of the samples), followed by HRSV-A (16%). Surprisingly, HPIV-4 infections (5.8%) were the third most prevalent. Mixed infections were also relatively common (11%). When present, HPIV infections were approximately three times more likely to be included in a mixed infection than FLU-A or HRSV. Mixed infections and HPIV-4 are likely to be missed using rapid diagnostic tests. This study confirms that ILI in adults and the elderly can be caused by HRSV and HPIVs, including HPIV-4, which co-circulate with FLU-A. C1 [Hasman, Hatice; Peeples, Mark E.] Rush Univ, Coll Med, Dept Immunol & Microbiol, Chicago, IL 60612 USA. [Hasman, Hatice] Sisli Etfal Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey. [Pachucki, Constance T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Med, Infect Dis Sect, Hines, IL 60141 USA. [Nguyen, Diep; Devlin, Troy] Rush Univ, Coll Hlth Sci, Dept Med Technol, Chicago, IL 60612 USA. [Peeples, Mark E.; Kwilas, Steven A.] Rush Univ, Grad Coll, Div Immunol, Chicago, IL 60612 USA. [Unal, Arife; Peeples, Mark E.; Kwilas, Steven A.] Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Sect Vaccines & Immun,Res Inst,Dept Pediat, Columbus, OH 43205 USA. RP Peeples, ME (reprint author), Rush Univ, Coll Med, Dept Immunol & Microbiol, 1653 W Congress Pkwy, Chicago, IL 60612 USA. EM mark.peeples@nationwidechildrens.org FU National Institutes of Health (NIH), USA [A1047213] FX We thank the Clinical Microbiology Laboratory at the Rush University Medical Center; Richard Compans, Peter Collins, Robert Lamb, Guy Boivin and Dean Erdman for the standard viruses; Barbara Newton, Stephanie Downing and Anumeha Gupta for their excellent technical help; Doug Salamon and Amy Leber for helpful discussions; and Mayte Coiras for helpful discussions and reagents. This work was supported by National Institutes of Health (NIH), USA, grant A1047213. NR 26 TC 20 Z9 20 U1 0 U2 0 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD APR PY 2009 VL 58 IS 4 BP 408 EP 413 DI 10.1099/jmm.0.006098-0 PG 6 WC Microbiology SC Microbiology GA 429GJ UT WOS:000264908600004 PM 19273634 ER PT J AU Kleinschmidt-DeMasters, BK Cummings, TJ Hulette, CM Morgenlander, JC Corboy, JR AF Kleinschmidt-DeMasters, Bette Kay Cummings, Thomas J. Hulette, Christine M. Morgenlander, Joel C. Corboy, John R. TI Adult Cases of Leukoencephalopathy, Cerebral Calcifications, and Cysts: Expanding the Spectrum of the Disorder SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Angiomatous malformation; Cerebral calcification; Cerebroretinal microangiopathy; Leukoencephalopathy; Pilocytic astrocytoma; Rosenthal fibers; Vasculitis; Vasculopathy ID CEREBRORETINAL MICROANGIOPATHY; BRAIN AB Leukoencephalopathy with cerebral calcifications and cysts (LCC) was first reported in children who developed cognitive decline and variable extrapyramidal, cerebellar, and pyramidal signs.. with or without seizures. Leukoencephalopathy with cerebral calcifications and cysts is characterized by progressive formation of brain cysts that can generate a mass effect simulating a neoplasm. Retinal changes that overlap with Coats disease, a microangiopathy with retinal telangiectasias and exudates, may also Occur. We and others have reported LCC cases in adults. Neuroimaging shows diffuse leukoencephalopathy, multifocal calcifications especially of deep gray and white matter, multifocal enhancement, and variably sized cysts that may require surgical decompression. Biopsies adjacent to cysts have shown angiomatous and/or severely hyalinized blood vessels surrounded by myelin loss and gliosis, calcifications, and Rosenthal fibers. We report 2 additional adult-onset cases of LCC. Case I is a 40-year-old mail who developed neurological symptoms and cirrhosis and died of acute gastrointestinal bleeding, fie had numerous retinal microinfarcts at autopsy. Case 2 is a 55-year-old woman who was found by chance to have LCC; one and a half years later, her Course remains benign. These cases expand the spectrum Of adult-onset LCC, the etiology of which is unknown. C1 [Kleinschmidt-DeMasters, Bette Kay] Univ Colorado, Dept Pathol, Aurora, CO USA. [Kleinschmidt-DeMasters, Bette Kay; Corboy, John R.] Univ Colorado, Dept Pathol, Aurora, CO USA. [Kleinschmidt-DeMasters, Bette Kay] Univ Colorado, Dept Neurosurg, Aurora, CO USA. [Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Cummings, Thomas J.; Hulette, Christine M.] Duke Univ Hlth Syst, Dept Pathol, Durham, NC USA. [Morgenlander, Joel C.] Duke Univ Hlth Syst, Dept Med Neurol, Durham, NC USA. RP Kleinschmidt-DeMasters, BK (reprint author), UCDHSC, Dept Surg Pathol, Mail Stop B216,12631 E 17th Ave, Aurora, CO 80045 USA. EM bk.demasters@ucdenver.edu NR 13 TC 17 Z9 20 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD APR PY 2009 VL 68 IS 4 BP 432 EP 439 PG 8 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 427VT UT WOS:000264807900010 PM 19287308 ER PT J AU Harris, AHS Humphreys, K Bowe, T Kivlahan, DR Finney, JW AF Harris, Alex H. S. Humphreys, Keith Bowe, Thomas Kivlahan, Daniel R. Finney, John W. TI Measuring the quality of substance use disorder treatment: Evaluating the validity of the Department of Veterans Affairs continuity of care performance measure SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Health care delivery; Substance use disorder services; Veterans; Performance measures; Standards of quality; Continuity of care; Continuing care ID ADDICTION SEVERITY INDEX; PATTERN-MIXTURE MODELS; MISSING DATA; FOLLOW-UP; ABUSE TREATMENT; TREATMENT OUTCOMES; CHANGE SCORES; INDICATORS; REGRESSION; RETENTION AB This study examined the patient- and facility-level associations between the continuity of care performance measure adopted by the Department of Veterans Affairs (VA) and improvements in self-administered Addiction Severity Index (ASI) composites and other indicators of problematic substance use. Up to 50 patients from each of a nationally representative sample of 109 VA substance use disorder (SUD) treatment programs at 73 VA facilities were assessed at intake and posttreatment. The continuity of care performance measure specifies that patients should receive at least two SUD outpatient visits in each of the three consecutive 30-day periods after they qualify as new SUD patients. In analyses adjusting for baseline characteristics, meeting the continuity of care performance measure was not associated with patient-level improvements in the ASI alcohol or drug composites, days of alcohol intoxication, or days of substance-related problems. Facility-level rates of continuity of care were negatively associated with improvements in ASI alcohol and drug composites. The continuity of care performance measure derived from prior patient-level evidence did not discriminate facility-level performance as predicted. Translating research into process-of-care quality measures requires postconstruction validation. Published by Elsevier Inc. C1 [Harris, Alex H. S.; Humphreys, Keith; Bowe, Thomas; Finney, John W.] Dept Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Harris, Alex H. S.; Humphreys, Keith; Bowe, Thomas; Finney, John W.] Stanford Univ, Sch Med, Menlo Pk, CA 94025 USA. [Kivlahan, Daniel R.] Univ Washington, Sch Med, Seattle, WA 98108 USA. [Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Qual Enhancement Res Initiat, Subst Use Disorder Ctr, Seattle, WA 98108 USA. RP Harris, AHS (reprint author), Dept Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd,MPD 152, Menlo Pk, CA 94025 USA. EM alexander.harris2@va.gov NR 47 TC 23 Z9 23 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD APR PY 2009 VL 36 IS 3 BP 294 EP 305 DI 10.1016/j.jsat.2008.05.011 PG 12 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 423QE UT WOS:000264510000006 PM 18835678 ER PT J AU Schnelle, JF Simmons, SF Beuscher, L Peterson, EN Habermann, R Leung, F AF Schnelle, John F. Simmons, Sandra F. Beuscher, Linda Peterson, Emily N. Habermann, Ralf Leung, Felix TI Prevalence of Constipation Symptoms in Fecally Incontinent Nursing Home Residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE Constipation; fecal incontinence; nursing home ID MANAGEMENT AB To determine the prevalence of constipation symptoms and the effects of a brief toileting assistance trial on constipation in a sample of fecally incontinent nursing home (NH) residents. Observational study. Five NHs. One hundred eleven fecally incontinent NH residents. Research staff measured bowel movement frequency every 2 hours for 10 days. The following week, residents were offered toileting assistance every 2 hours for 2 days to determine resident straining, time required for a bowel movement, and resident perceptions of feeling empty after a bowel movement. Constipation data were abstracted from the medical record. The frequency of bowel movements during usual NH care was low (mean=0.32 per person per day), and most episodes were incontinent. The frequency of bowel movements increased significantly, to 0.82 per person per day, and most episodes were continent during the 2 days that research staff provided toileting assistance. Eleven percent of residents showed evidence of straining, and 21% of the time after a continent bowel movement, residents reported not feeling empty. Five percent of participants had medical record or Minimum Data Set documentation indicative of constipation symptoms. Low rates of bowel movements during the day that are potentially indicative of constipation were immediately improved during a 2-day trial of toileting assistance in approximately 68% of the residents, although other symptoms of constipation remained in a subset of residents who increased toileting frequency. C1 [Schnelle, John F.; Simmons, Sandra F.; Beuscher, Linda; Peterson, Emily N.] Vanderbilt Univ, Div Gen Internal Med & Publ Hlth, Ctr Qual Aging, Sch Med, Nashville, TN 37232 USA. [Beuscher, Linda] Vanderbilt Univ, Sch Nursing, Nashville, TN 37232 USA. [Habermann, Ralf] Vanderbilt Univ, Div Gen Internal Med & Publ Hlth, Vanderbilt Senior Care ACE Unit, Nashville, TN 37232 USA. [Schnelle, John F.; Simmons, Sandra F.] Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN 37212 USA. [Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Schnelle, JF (reprint author), Vanderbilt Univ, Med Ctr, 1161 21st Ave S,S-1121 Med Ctr N, Nashville, TN 37232 USA. EM John.Schnelle@vanderbilt.edu FU National Institutes of Health (NIH), [RO1 AG023555]; NIH FX This research was supported by Grant RO1 AG023555 from the National Institutes of Health (NIH), John F. Schnelle, Principal Investigator. We extend thanks to the following valuable research team members: Roberta McCord, Sonia Meador, Clayton Ellis, and Christie Young.; Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.; Author Contributions: Dr. Schnelle was the principle investigator and took primary lead in the development of all aspects of the paper listed under ths category. The other authors contributed to writing, data analysis, conceptualization, or all three.; Sponsor's Role: NIH who funded and approved the trial. NR 14 TC 10 Z9 10 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2009 VL 57 IS 4 BP 647 EP 652 DI 10.1111/j.1532-5415.2009.02215.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 428WT UT WOS:000264883500009 PM 19392956 ER PT J AU Weinstein, AM Barton, C Ross, L Kramer, JH Yaffe, K AF Weinstein, Andrea M. Barton, Cynthia Ross, Leslie Kramer, Joel H. Yaffe, Kristine TI Treatment Practices of Mild Cognitive Impairment in California Alzheimer's Disease Centers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 60th Annual Meeting of the American-Academy-of-Neurology CY APR 12-19, 2008 CL Chicago, IL SP Amer Acad Neurol DE Alzheimer's disease; mild cognitive impairment; aging; medications; cholinesterase inhibitors ID RANDOMIZED CONTROLLED-TRIAL; VASCULAR DEMENTIA; VITAMIN-E; DIAGNOSIS; DECLINE; SUPPLEMENTATION; HOMOCYSTEINE; PREVALENCE; DONEPEZIL; CRITERIA AB To examine "real world" treatments for patients with mild cognitive impairment (MCI). Cross-sectional. California Department of Public Health Alzheimer's Disease (AD) Research Centers of California. Five hundred seventy-eight patients diagnosed with MCI. All patients underwent comprehensive neurological and neuropsychological evaluations. Logistic regression models were used to determine patient characteristics associated with use of anti-AD medications, statins, antioxidants, and folic acid. One hundred sixty-six patients (28.7%) were taking anti-AD medications; use was associated with greater functional impairment, higher education, MCI subtype, and older age (P <.05 for all). Two hundred fifty-two patients (43.6%) were taking statins; use was associated with diabetes mellitus, hypertension, myocardial infarct, male sex, and MCI subtype (P <.05 for all). One hundred fifteen patients (19.9%) were taking antioxidants; use was associated with higher education and diabetes mellitus and varied according to site (P <.05 for all). Thirty-seven patients (6.4%) were taking folic acid; use was associated with nonwhite race, male sex, and greater functional impairment (P <.05 for all). This study suggests that patients with MCI are frequently being treated with "off label" cholinesterase inhibitors and memantine, as well as other possible cognition-enhancing drugs. Further investigation of the effect of treatment patterns on the clinical course of MCI is needed. C1 [Weinstein, Andrea M.; Barton, Cynthia; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Weinstein, Andrea M.] No Calif Inst Res & Educ, San Francisco, CA USA. [Barton, Cynthia; Ross, Leslie; Kramer, Joel H.; Yaffe, Kristine] Univ Calif San Francisco, Sch Nursing, Dept Psychiat, San Francisco, CA 94121 USA. [Barton, Cynthia; Ross, Leslie; Kramer, Joel H.; Yaffe, Kristine] Univ Calif San Francisco, Sch Nursing, Dept Neurol, San Francisco, CA 94121 USA. [Barton, Cynthia; Ross, Leslie; Kramer, Joel H.; Yaffe, Kristine] Univ Calif San Francisco, Sch Nursing, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Nursing, Inst Hlth & Aging, San Francisco, CA 94121 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Sch Nursing, Dept Psychiat, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu FU NIA NIH HHS [K24 AG031155, K24 AG031155-01, 1K24AG031155-01] NR 30 TC 19 Z9 19 U1 0 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2009 VL 57 IS 4 BP 686 EP 690 DI 10.1111/j.1532-5415.2009.02200.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 428WT UT WOS:000264883500016 PM 19392962 ER PT J AU Siever, LJ Weinstein, LN AF Siever, Larry J. Weinstein, Lissa N. TI THE NEUROBIOLOGY OF PERSONALITY DISORDERS: IMPLICATIONS FOR PSYCHOANALYSIS SO JOURNAL OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION LA English DT Review ID SOCIAL ANXIETY DISORDER; POSITRON-EMISSION-TOMOGRAPHY; VISUOSPATIAL WORKING-MEMORY; C/T PROMOTER POLYMORPHISMS; DRD4 GENE POLYMORPHISM; MONOAMINE-OXIDASE-A; SCHIZOTYPAL-PERSONALITY; BORDERLINE PERSONALITY; ATTACHMENT DISORGANIZATION; IMPULSIVE AGGRESSION AB As advances in neuroscience have furthered our understanding of the role of brain circuitry, genetics, stress, and neuromodulators in the regulation of normal behavior and in the pathogenesis of psychopathology, an increasing appreciation of the role of neurobiology in individual differences in personality and their pathology in personality disorders has emerged. Individual differences in the regulation and organization of cognitive processes, affective reactivity, impulse/action patterns, and anxiety may in the extreme provide susceptibilities to personality disorders such as borderline and schizotypal personality disorder. A low threshold for impulsive aggression, as observed in borderline and antisocial personality disorders, may be related to excessive amygdala reactivity, reduced prefrontal inhibition, and diminished serotonergic facilitation of prefrontal controls. Affective instability may be mediated by excessive limbic reactivity in gabaminergic/glutamatergic/cholinergic circuits, resulting in an increased sensitivity or reactivity to environmental emotional stimuli as in borderline personality disorder and other cluster B personality disorders. Disturbances in cognitive organization and information processing may contribute to the detachment, desynchrony with the environment, and cognitive/perceptional distortions of cluster A or schizophrenia spectrum personality disorders. A low threshold for anxiety may contribute to the avoidant, dependent, and compulsive behaviors observed in cluster C personality disorders. These alterations in critical regulatory domains will influence how representations of self and others are internalized. Aspects of neurobiological functioning themselves become cognized through the medium of figurative language into an ongoing narrative of the self, one that can be transformed through the analytic process, allowing for the modulation of genetic/biological thresholds. C1 [Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Siever, Larry J.] VISN 3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Weinstein, Lissa N.] CUNY City Coll, Doctoral Program Clin Psychol, New York, NY USA. RP Siever, LJ (reprint author), Dept Psychiat OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM larry.siever@va.gov FU NCRR NIH HHS [M01-RR-00071]; NIMH NIH HHS [MH56140] NR 140 TC 24 Z9 25 U1 5 U2 24 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-0651 J9 J AM PSYCHOANAL ASS JI J. Am. Psychoanal. Assoc. PD APR PY 2009 VL 57 IS 2 BP 361 EP 398 DI 10.1177/0003065109333502 PG 38 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA 458DM UT WOS:000266994400005 PM 19516057 ER PT J AU Fried, L AF Fried, Linda TI Are We Ready to Screen the General Population for Microalbuminuria? SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR OUTCOMES; DIABETIC NEPHROPATHY; COST-EFFECTIVENESS; PREVENTION; RAMIPRIL; EVENTS; PROTEINURIA; INHIBITION; FOSINOPRIL C1 [Fried, Linda] Univ Pittsburgh, Dept Med, Sch Med, Renal Sect,VA Pittsburgh Healthcare Syst,Renal El, Pittsburgh, PA 15240 USA. [Fried, Linda] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Fried, L (reprint author), Univ Pittsburgh, Dept Med, Sch Med, Renal Sect,VA Pittsburgh Healthcare Syst,Renal El, Univ Dr, Pittsburgh, PA 15240 USA. EM linda.fried@va.gov NR 15 TC 22 Z9 27 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD APR PY 2009 VL 20 IS 4 BP 686 EP 688 DI 10.1681/ASN.2009020147 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 428ER UT WOS:000264831300004 PM 19279125 ER PT J AU Slatore, CG Au, DH Hollingworth, W AF Slatore, Christopher G. Au, David H. Hollingworth, William TI Cost-Effectiveness of a Smoking Cessation Program Implemented at the Time of Surgery for Lung Cancer SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Cost-effectiveness; QALY; Smoking cessation program; Non-small cell lung cancer ID QUALITY-OF-LIFE; RANDOMIZED CLINICAL-TRIAL; PULMONARY COMPLICATIONS; POSTOPERATIVE COMPLICATIONS; SURGICAL-PATIENTS; SURVIVAL; INTERVENTION; RESECTION; STAGE; GUIDELINES AB Background: Many patients are active smokers at the time of a diagnosis Of Surgically resectable lung cancer. Perioperative smoking cessation is associated with improved survival, but the cost-effectiveness of a smoking cessation program initiated immediately before surgery is unknown. Methods: We developed a decision analytic Markov model to evaluate the incremental cost-effectiveness of a formal smoking cessation program. The parameter estimates were taken from the available literature. The model included the cost and effectiveness of the smoking cessation program, cost and incidence of perioperative complications, postoperative mortality, and utility measured in quality adjusted life years (QALY). Dollars per QALY and life year were calculated and one-way sensitivity analyses were performed. Results: The cost/QALY and cost/life year were $16,415 and $45,629 at 1 year after surgery and $2609 and $2703 at 5 years, respectively. Most sensitivity analyses showed the 1 year postsurgery cost/QALY estimates were less than $50,000, and all were less than $12,000 at 5 years. Cost-effectiveness estimates were most sensitive to the frequency of perioperative complications and the estimated short-term utility estimates. Conclusion: A smoking cessation program initiated before Surgical lung resection is cost-effective at both I and 5 years postsurgery. Providers should encourage patients who are still smoking to engage in formal smoking cessation programs. C1 [Slatore, Christopher G.; Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Slatore, Christopher G.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Hollingworth, William] Univ Bristol, Dept Social Med, Bristol, Avon, England. RP Slatore, CG (reprint author), 1959 NE Pacific St,Campus Box 356522, Seattle, WA 98195 USA. EM cslatore@u.washington.edu OI Slatore, Christopher/0000-0003-0958-8122 FU National Institutes of Health [CA130328] FX This work was performed at Health Services Research and Development, VA Puget Sound Health Care System, Seattle, WA. Dr. Slatore was funded by the National Institutes of Health (CA130328) for his work on a separate project. NR 41 TC 15 Z9 15 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD APR PY 2009 VL 4 IS 4 BP 499 EP 504 PG 6 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 425BD UT WOS:000264611100010 PM 19204575 ER PT J AU Hanlon, JT Boudreau, RM Roumani, YF Newman, AB Ruby, CM Wright, RM Hilmer, SN Shorr, RI Bauer, DC Simonsick, EM Studenski, SA AF Hanlon, Joseph T. Boudreau, Robert M. Roumani, Yazan F. Newman, Anne B. Ruby, Christine M. Wright, Rollin M. Hilmer, Sarah N. Shorr, Ronald I. Bauer, Douglas C. Simonsick, Eleanor M. Studenski, Stephanie A. CA Health ABC Study TI Number and Dosage of Central Nervous System Medications on Recurrent Falls in Community Elders: The Health, Aging and Body Composition Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Aged; Falls; Central nervous system medications ID OLDER-ADULTS; PEOPLE; DRUGS; RISK; HOME; METAANALYSIS; ANALGESICS; WITHDRAWAL; CONSENSUS; EUROPE AB Few studies have examined the risk of multiple or high doses of combined central nervous system (CNS) medication use for recurrent falls in the elderly. The study objective was to evaluate whether multiple- or high-dose CNS medication use in older adults was associated with a higher risk of recurrent (>= 2) falls. This longitudinal cohort study included 3,055 participants from the Health, Aging and Body Composition study who were well functioning at baseline. CNS medication use (benzodiazepine and opioid receptor agonists, antipsychotics, antidepressants) was determined annually (except Year 4) during in-person interviews. The number and summated standard daily doses (SDDs; low, medium, and high) of CNS medications were computed. Falls 1 year later were ascertained annually for 5 years. For a period of 5 years, as many as 24.1% of CNS medication users took 2+ agents annually, whereas as no more than 18.9% of CNS medication users took high doses annually (3+ SDDs). Yearly, as many as 9.7% of participants reported recurrent falls. Multivariable Generalized Estimating Equation analyses showed that multiple CNS medication users compared with never users had an increased risk of sustaining 2+ falls (adjusted odds ratio [OR] 1.95; 95% confidence interval [CI] 1.35-2.81). Those taking high (3+) CNS SDDs also exhibited an increased risk of 2+ falls (adjusted OR 2.89; 95% CI 1.96-4.25). Higher total daily doses of CNS medications were associated with recurrent falls. Further studies are needed to determine the impact of reducing the number of CNS medications and/or dosage on recurrent falls. C1 [Hanlon, Joseph T.; Roumani, Yazan F.; Newman, Anne B.; Wright, Rollin M.; Studenski, Stephanie A.] Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Ruby, Christine M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Studenski, Stephanie A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Geriatr Res Educ, Pittsburgh, PA USA. [Hanlon, Joseph T.; Studenski, Stephanie A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Clin, Pittsburgh, PA USA. [Boudreau, Robert M.; Newman, Anne B.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Hilmer, Sarah N.] Royal N Shore Hosp, St Leonards, NSW, Australia. [Hilmer, Sarah N.] Univ Sydney, Sydney, NSW 2006, Australia. [Shorr, Ronald I.] N Florida S Georgia Vet Hlth Syst Geriatr Res Edu, Gainesville, FL USA. [Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Sch Med, Dept Geriatr Med, Kaufman Med Bldg,Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA. EM hanlonj@dom.pitt.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Hilmer, Sarah/0000-0002-5970-1501; Boudreau, Robert/0000-0003-0162-5187 FU National Institute of Aging [R01AG027017, P30AG024827, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institutes of Health FX This study was primarily supported by National Institute of Aging grants (R01AG027017; P30AG024827, N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106). This research was supported in part by the Intramural Research program of the National Institutes of Health, National Institute on Aging. NR 39 TC 63 Z9 64 U1 2 U2 4 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2009 VL 64 IS 4 BP 492 EP 498 DI 10.1093/gerona/gln043 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 421XD UT WOS:000264390700011 PM 19196642 ER PT J AU Teerlink, JR Metra, M Felker, GM Ponikowski, P Voors, AA Weatherley, BD Marmor, A Katz, A Grzybowski, J Unemori, E Teichman, SL Cotter, G AF Teerlink, John R. Metra, Marco Felker, G. Michael Ponikowski, Piotr Voors, Adriaan A. Weatherley, Beth Davison Marmor, Alon Katz, Amos Grzybowski, Jacek Unemori, Elaine Teichman, Sam L. Cotter, Gad TI Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study SO LANCET LA English DT Article ID RENAL VASODILATION; CONSCIOUS RATS; PREGNANCY HORMONE; CLINICAL-TRIALS; PEPTIDE; HYPERFILTRATION; HEMODYNAMICS; ANTAGONIST; ENDOTHELIN; TEZOSENTAN AB Background Most patients admitted for acute heart failure have normal or increase blood pressure. Relaxin is a natural human peptide that affects multiple vascular control pathways, suggesting potential mechanisms of benefit for such patients. We assessed the dose response of relaxin's effect on symptom relief, other clinical outcomes, and safety. Methods In a placebo-controlled, parallel-group, dose-ranging study, 234 patients with acute heart failure, dyspnoea, congestion on chest radiograph, and increased brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, mild-to-moderate renal insufficiency, and systolic blood pressure greater than 125 mm Hg were recruited from 54 sites in eight countries and enrolled within 16 h of presentation. Patients were randomly assigned, in a double-blind manner via a telephone-based interactive voice response system, to standard care plus 48-h intravenous infusion Of placebo (n=62) or relaxin 10 mu g/kg (n=40), 30 mu g/kg (n=43), 100 mu g/kg (n=39), or 250 mu g/kg (n=50) per day. Several clinical endpoints were explored to assess whether intravenous relaxin should be pursued in larger studies of acute heart failure, to identify an optimum dose, and to help to assess endpoint selection and power calculations. Analysis was by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT00520806. Findings In the modified intention-to-treat population, 61 patients were assessed in the placebo group, 40 in the relaxin 10 mu g/kg per day group, 42 in the relaxin 30 mu g/kg per day group, 37 in the relaxin 100 mu g/kg per day group, and 49 in the relaxin 250 mu g/kg per day group. Dyspnoea improved with relaxin 30 mu g/kg compared with placebo, as assessed by Likert scale (17 of 42 patients [40%] moderately or markedly improved at 6 h, 12 h, and 24 h vs 14 of 61 [23%]; p=0.044) and visual analogue scale through day 14 (8214 mmxh [SD 87121 vs 4622 mmxh [90031; p=0.053). Length of stay was 10.2 days (SD 6.1) for relaxin-treated patients versus 12.0 days (7.3) for those given placebo, and days alive out of hospital were 47.9 (10.1) versus 44.2 (14.2). Cardiovascular death or readmission due to heart or renal failure at day 60 was reduced with relaxin (2.6% [95% Cl 0.4-16.8] vs 17.2% [9.6-29.6]; p=0.053). The number of serious adverse events was similar between groups. Interpretation When given to patients with acute heart failure and normal-to-increased blood pressure, relaxin was associated with favourable relief of dyspnoea and other clinical outcomes, with acceptable safety. C1 [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Metra, Marco] Univ Brescia, Dept Expt & Appl Sci, Sect Cardiovasc Dis, Brescia, Italy. [Felker, G. Michael] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Ponikowski, Piotr] Med Univ, Mil Hosp, Dept Cardiol, Dept Hlth Sci, Wroclaw, Poland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands. [Weatherley, Beth Davison; Cotter, Gad] Momentum Res, Durham, NC USA. [Marmor, Alon] Ziv Med Ctr, Inst Heart, Safed, Israel. [Katz, Amos] Barzilai Govt Hosp, Dept Cardiol, Ashqelon, Israel. [Grzybowski, Jacek] Inst Cardiol, Dept Gen Cardiol, Warsaw, Poland. [Unemori, Elaine; Teichman, Sam L.] Corthera, San Mateo, CA USA. RP Teerlink, JR (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol 111C,4150 Clemet St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu RI Katz, Amos/E-6261-2011; Teerlink, John/D-2986-2012; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568 FU Corthera (USA) FX The Pre-RELAX-AHF study is supported by Corthera (USA). NR 29 TC 207 Z9 218 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD APR-MAY PY 2009 VL 373 IS 9673 BP 1429 EP 1439 DI 10.1016/S0140-6736(09)60622-X PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 437QL UT WOS:000265501900031 PM 19329178 ER PT J AU Marzetti, E Carter, CS Wohlgemuth, SE Lees, HA Giovannini, S Anderson, B Quinn, LS Leeuwenburgh, C AF Marzetti, Emanuele Carter, Christy S. Wohlgemuth, Stephanie E. Lees, Hazel A. Giovannini, Silvia Anderson, Barbara Quinn, LeBris S. Leeuwenburgh, Christiaan TI Changes in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restriction SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE Sarcopenia; Interleukin-15; Tumor necrosis factor-alpha; Calorie restriction; Apoptosis ID NECROSIS-FACTOR-ALPHA; X-LINKED INHIBITOR; TUMOR-BEARING RATS; SKELETAL-MUSCLE; TNF-ALPHA; AGED RATS; INTERLEUKIN-15 PROTECTS; PHYSICAL PERFORMANCE; DNA FRAGMENTATION; SOLEUS MUSCLE AB TNF-alpha-mediated apoptosis is enhanced in aged rodent muscles, suggesting that this pathway may be involved in sarcopenia. Interleukin-15 (IL-15), a muscle-derived anabolic cytokine, mitigates muscle wasting and apoptosis in cachectic rats. This effect is thought to occur through inhibition of TNF-alpha-triggered apoptosis. We investigated IL-15 signaling and the TNF-a-mediated pathway of apoptosis in the gastrocnemius muscle of Fischer344xBrown Norway rats across the ages of 8, 18, 29 and 37 months, in relation to life-long calorie restriction (CR, 40% calorie intake reduction). Aging caused loss of muscle mass and increased apoptotic DNA fragmentation, which were mitigated by CR. Protein levels of IL-15 and mRNA abundance of IL-15 receptor a-chain decreased in senescent ad libitum (AL) fed rats, but were maintained in CR rodents. Elevations of TNF-alpha, TNF-receptor 1, cleaved caspase-8 and -3 were observed at advanced age in AL rats. These changes were prevented or mitigated by CR. Our results indicate that aging is associated with decreased IL-15 signaling in rat gastrocnemius muscle, which may contribute to sarcopenia partly through enhanced TNF-a-mediated apoptosis. Preservation of IL-15 signaling by CR may therefore represent a further mechanism contributing to the anti-aging effect of this dietary intervention in skeletal muscle. Published by Elsevier Ireland Ltd. C1 [Marzetti, Emanuele; Carter, Christy S.; Wohlgemuth, Stephanie E.; Lees, Hazel A.; Giovannini, Silvia; Leeuwenburgh, Christiaan] Univ Florida, Dept Aging & Geriatr Res, Inst Aging, Div Biol Aging, Gainesville, FL 32610 USA. [Marzetti, Emanuele; Giovannini, Silvia] Univ Cattolica Sacro Cuore, Dept Gerontol Geriatr & Physiat, I-00168 Rome, Italy. [Carter, Christy S.] Malcom Randall Vet Affairs Med Ctr, GRECC, Gainesville, FL 32608 USA. [Anderson, Barbara; Quinn, LeBris S.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. [Anderson, Barbara; Quinn, LeBris S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Marzetti, E (reprint author), Univ Florida, Dept Aging & Geriatr Res, Inst Aging, Div Biol Aging, 1600 SW Archer Rd,Room P1-09,POB 100143, Gainesville, FL 32610 USA. EM emarzetti@aging.ufl.edu; cleeuwen@aging.ufl.edu RI Carter, Christy/E-6630-2011; Marzetti, Emanuele/A-9430-2010; Giovannini, Silvia/J-2955-2012 OI Marzetti, Emanuele/0000-0001-9567-6983; Giovannini, Silvia/0000-0001-9125-752X FU USDA Cooperative State Research, Education, and Extension Service Animal Growth and Nutrient Utilization Program [2005-35206-15264]; Department of Veterans Affairs; University of Florida Institute; Claude D. Pepper Older Americans Independence Center [1 P30 AG028740]; [NIA R01-AG17994]; [AG21042]; [NIH R01-AG024526-02]; [NIH R01-AG024136] FX This research was supported by grants to CL (NIA R01-AG17994 and AG21042), CC (NIH R01-AG024526-02) and LQ (NIH R01-AG024136 and National Research Initiative Competitive Grant 2005-35206-15264 from the USDA Cooperative State Research, Education, and Extension Service Animal Growth and Nutrient Utilization Program), and by the Department of Veterans Affairs. EM, SW and HL are supported by the University of Florida Institute on Aging and Claude D. Pepper Older Americans Independence Center (1 P30 AG028740). The authors wish to thank Dr. Michael Daniels for assisting with the statistical analysis, and Drs. Tim Hofer and Stephane Servais for their critical input in the conduct of the study. NR 64 TC 49 Z9 51 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD APR PY 2009 VL 130 IS 4 BP 272 EP 280 DI 10.1016/j.mad.2008.12.008 PG 9 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 423RF UT WOS:000264512700010 PM 19396981 ER PT J AU Thorpe, CT Bryson, CL Maciejewski, ML Bosworth, HB AF Thorpe, Carolyn T. Bryson, Chris L. Maciejewski, Mathew L. Bosworth, Hayden B. TI Medication Acquisition and Self-Reported Adherence in Veterans With Hypertension SO MEDICAL CARE LA English DT Article; Proceedings Paper CT AcademyHealth Annual Research Meeting CY JUN 08-10, 2008 CL Washington, DC DE medication acquisition; refill adherence; self-report; hypertension ID BLOOD-PRESSURE CONTROL; HEALTH-CARE-SYSTEM; REFILL ADHERENCE; PHARMACY RECORDS; OLDER-ADULTS; THERAPY; ASSOCIATION; PERSISTENCE; VALIDATION; VALIDITY AB Objectives: To examine factors associated with oversupply and undersupply of antihypertensive medication, and examine evidence for medication acquisition as distinct from self-reported adherence. Research Design: Analysis of pharmacy refill records, medical charts, and in-person interviews. Subjects: Five hundred sixty-two male veterans with hypertension enrolled in a randomized controlled trial to improve BP control. Measures: Patients were classified as having undersupply (<0.80), appropriate supply (>= 0.80 and <= 1.20), or oversupply (>1.20) of antihypertensive medication in the 90 days before trial enrollment based on the ReComp algorithm. Determination of BP control was based on clinic measurements at enrollment. Demographic, clinical, psychosocial, and behavioral factors relevant to medication-taking behavior and BP were assessed at enrollment. Results: Twenty-three percent of the patients had undersupply, 47% had appropriate Supply, and 30% had oversupply of antihypertensive medication. Multinomial logistic regression revealed that using fewer classes of antihypertensive medications and greater perceived adherence barriers were independently associated with greater likelihood of undersupply. Current employment was associated with decreased likelihood of oversupply, and greater comorbidity and being married were associated with increased likelihood of oversupply. Agreement between ReComp and self-reported adherence was poor (kappa = 0.19 P < 0.001). Undersupply, oversupply, and self-reported nonadherence were all independently associated with decreased likelihood of BP control after adjusting for each other and patient factors. Conclusions: Antihypertensive oversupply was common and may arise front different circumstances than Undersupply. Measures of medication acquisition and self-reported adherence appear to provide distinct, complementary information about patients' medication-taking behavior. C1 [Thorpe, Carolyn T.] Univ Wisconsin, Dept Populat Hlth Sci, Hlth Innovat Program, Madison, WI 53792 USA. [Bryson, Chris L.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev NW Ctr Excellence, Seattle, WA USA. [Bryson, Chris L.] Univ Washington, Dept Med, Seattle, WA USA. [Maciejewski, Mathew L.; Bosworth, Hayden B.] Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Maciejewski, Mathew L.; Bosworth, Hayden B.] Duke Univ, Dept Med, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Ctr Aging & Human Dev, Durham, NC USA. RP Thorpe, CT (reprint author), Univ Wisconsin, Dept Populat Hlth Sci, Hlth Innovat Program, E5-724 CSC,600 Highland Ave, Madison, WI 53792 USA. EM cthorpe@wisc.edu NR 49 TC 30 Z9 30 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2009 VL 47 IS 4 BP 474 EP 481 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 425ER UT WOS:000264620300014 PM 19330891 ER PT J AU Bokhour, BG Pugh, MJ Rao, JK Avetisyan, R Berlowitz, DR Kazis, LE AF Bokhour, Barbara G. Pugh, Mary Jo Rao, Jaya K. Avetisyan, Ruzan Berlowitz, Dan R. Kazis, Lewis E. TI Improving Methods for Measuring Quality of Care A Patient-Centered Approach in Chronic Disease SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article; Proceedings Paper CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med DE quality indicators; patient-centered care; chronic disease; epilepsy; qualitative methods ID HEALTH-CARE; PATIENTS PERSPECTIVE; EPILEPSY; INTERVENTIONS; PERCEPTIONS; DEPRESSION; IMPACT; VIEWS; AGREE AB As health care systems seek to provide patient-centered care as a cornerstone of quality, how to measure this aspect of quality has become a concern. Previous development of quality indicators for treating individual chronic disease has rarely included patient perspectives on quality of care. Using epilepsy as an exemplar, the authors sought to develop an approach to measuring patient-centered quality of care. They conducted six focus groups with adults with epilepsy. Using qualitative methods, the authors initially identified 10 patient-generated quality indicators, 5 of which were subsequently rated, along with literature-based quality indicators, by an expert panel using a modified RAND appropriateness methodology. The authors discuss similarities and differences in aspects of care patients and providers value as essential for good quality. The process presented in this article may serve as a model for incorporating patient perceptions of quality into the future development of quality indicators for chronic diseases. C1 [Bokhour, Barbara G.; Berlowitz, Dan R.; Kazis, Lewis E.] Edith Nourse Rogers Mem Vet Aff Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Bokhour, Barbara G.; Avetisyan, Ruzan; Berlowitz, Dan R.; Kazis, Lewis E.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Pugh, Mary Jo] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat Implementat Ctr, Res Enhancement Award Program, San Antonio, TX USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Rao, Jaya K.] Ctr Dis Control & Prevent, Healthy Aging Program, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Rao, Jaya K.] Emory Univ, Sch Med, Atlanta, GA USA. RP Bokhour, BG (reprint author), Edith Nourse Rogers Mem Vet Aff Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. OI Bokhour, Barbara/0000-0001-8238-0745; Kazis, Lewis/0000-0003-1800-5849 FU PHS HHS [ASPH S3492] NR 45 TC 15 Z9 15 U1 2 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 J9 MED CARE RES REV JI Med. Care Res. Rev. PD APR PY 2009 VL 66 IS 2 BP 147 EP 166 DI 10.1177/1077558708327174 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 420JD UT WOS:000264284700002 PM 19074307 ER PT J AU Iqbal, N Cardillo, S Volger, S Bloedon, LT Anderson, RA Boston, R Szapary, PO AF Iqbal, Nayyar Cardillo, Serena Volger, Sheri Bloedon, LeAnne T. Anderson, Richard A. Boston, Raymond Szapary, Philippe O. TI Chromium Picolinate Does Not Improve Key Features of Metabolic Syndrome in Obese Nondiabetic Adults SO METABOLIC SYNDROME AND RELATED DISORDERS LA English DT Article CT 66th Annual Meeting of the American-Diabetes-Association CY JUN 09-13, 2006 CL Washington, DC SP Amer Diabet Assoc ID INSULIN SENSITIVITY; GLUCOSE-METABOLISM; BODY-WEIGHT; OLDER MEN; SUPPLEMENTATION; METAANALYSIS; CHOLESTEROL; PARAMETERS; NONOBESE; HEALTHY AB Background: The use of chromium-containing dietary supplements is widespread among patients with type 2 diabetes. Chromium's effects in patients at high risk for developing diabetes, especially those with metabolic syndrome, is unknown. The objective of this study was to determine the effects of chromium picolinate (CrPic) on glucose metabolism in patients with metabolic syndrome. Method: A double-blind, placebo-controlled, randomized trial was conducted at a U. S. academic medical center. Sixty three patients with National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)-defined metabolic syndrome were included. The primary end point was a change in the insulin sensitivity index derived from a frequently sampled intravenous glucose tolerance test. Prespecified secondary end points included changes in other measurements of glucose metabolism, oxidative stress, fasting serum lipids, and high sensitivity C-reactive protein. Results: After 16 weeks of CrPic treatment, there was no significant change in insulin sensitivity index between groups (P = 0.14). However, CrPic increased acute insulin response to glucose (P = 0.02). CrPic had no significant effect on other measures of glucose metabolism, body weight, serum lipids, or measures of inflammation and oxidative stress. Conclusion: CrPic at 1000 mu g/day does not improve key features of the metabolic syndrome in obese nondiabetic patients. C1 [Szapary, Philippe O.] Univ Penn Hlth Syst, Philadelphia Heart Inst, Div Gen Internal Med, Inst Translat Med & Therapeut,CRIP,Dept Med, Philadelphia, PA 19104 USA. [Iqbal, Nayyar; Cardillo, Serena] Univ Penn Hlth Syst, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA. [Volger, Sheri; Bloedon, LeAnne T.; Szapary, Philippe O.] Univ Penn Hlth Syst, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Iqbal, Nayyar] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Boston, Raymond] Univ Penn, Sch Vet Med, Dept Clin Studies, Biostat Sect,New Bolton Ctr, Kennett Sq, PA 19348 USA. [Anderson, Richard A.] USDA, Beltsville Human Nutr Res Ctr, Beltsville, MD 20705 USA. RP Szapary, PO (reprint author), Univ Penn Hlth Syst, Philadelphia Heart Inst, Div Gen Internal Med, Inst Translat Med & Therapeut,CRIP,Dept Med, Suite 2A,39th & Market St, Philadelphia, PA 19104 USA. EM philippe.szapary@uphs.upenn.edu OI volger, sheri/0000-0002-1689-1173 FU NCCIH NIH HHS [K-23 AT-00058]; NCRR NIH HHS [M01-RR00040]; NIDDK NIH HHS [R21DK067241] NR 31 TC 33 Z9 35 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-4196 J9 METAB SYNDR RELAT D JI Metab. Syndr. Relat. Disord. PD APR PY 2009 VL 7 IS 2 BP 143 EP 150 DI 10.1089/met.2008.0048 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 438XP UT WOS:000265589900010 PM 19422140 ER PT J AU Pamir, N McMillen, TS Li, YI Lai, CM Wong, H LeBoeuf, RC AF Pamir, Nathalie McMillen, Timothy S. Li, Yu-I Lai, Ching-Mei Wong, Howard LeBoeuf, Renee C. TI Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID DIET-INDUCED OBESITY; HIGH-FAT-DIET; PLASMA TRIGLYCERIDE CONCENTRATIONS; LDL PARTICLE-SIZE; INSULIN-RESISTANCE; LIPOPROTEIN-LIPASE; RICH LIPOPROTEINS; LEPTIN RESISTANCE; SEXUAL-DIMORPHISM; C57BL/6J MICE AB Apolipoprotein As (APOA5) is expressed primarily in the liver and modulates plasma triglyceride levels in mice and humans. Mice overexpressing APOA5 exhibit reduced plasma trigglyceride levels. Because there is a tight association between plasma triglyceride concentration and traits of the metabolic syndrome, we used transgenic mice overexprcssing human APOA5 to test the concept that these Mice would be protected from diet-induced obesity and insulin resistance. Male and female transgenic and wild-type mice on the FVB/N genetic background were fed standard rodent chow or a diet rich in fat and sucrose for 18 weeks, during which time clinical phenotypes associated with obesity and glucose homeostasis were measured. We found that APOA5 transgenic (A5tg) mice were resistant to diet-induced changes in plasma triglyceride but not total cholesterol levels. Body weights were similar between the genotypes for females and males, although male A5tg mice showed a modest but significant increase in the relative size of inguinal fat pads. Although male A5tg mice showed a significantly increased ratio of plasma glucose to insulin, profiles Of glucose clearance as evaluated after injections of glucose or insulin failed to reveal any differences between genotypes, Overall, our data showed that there was no advantage to responses to diet-induced obesity with chronic reduction of plasma triglyceride levels as mediated by overexpression of APOA5. (C) 2009 Elsevier Inc. All rights reserved. C1 [Pamir, Nathalie; McMillen, Timothy S.; Li, Yu-I; LeBoeuf, Renee C.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Lai, Ching-Mei; Wong, Howard] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Lai, Ching-Mei; Wong, Howard] Vet Adm Greater Los Angeles Healthcare Syst, Lipid Res Lab, Los Angeles, CA USA. RP LeBoeuf, RC (reprint author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. EM leboeuf@u.washington.edu RI Pamir, Nathalie/H-5234-2013 OI LI, YU-I/0000-0002-9888-1541 FU National Institutes of Health [RO1 DK063159]; VA Merit Review Grant (HW) FX This work was supported by grants from the National Institutes of Health (RO1 DK063159 [RCL]) and a VA Merit Review Grant (HW). NR 51 TC 13 Z9 14 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD APR PY 2009 VL 58 IS 4 BP 560 EP 567 DI 10.1016/j.metabol.2008.11.018 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 429QV UT WOS:000264936100020 PM 19303979 ER PT J AU Jensen, BC Swigart, PM Simpson, PC AF Jensen, Brian C. Swigart, Philip M. Simpson, Paul C. TI Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY LA English DT Article DE Alpha-1-adrenoceptor; Antibodies; Subtypes ID BLOOD-PRESSURE; KNOCKOUT; ALPHA-1D; ARTERIES; MICE AB Commercial antibodies are used widely to quantify and localize the alpha 1-adrenergic receptor (AR) subtypes, alpha 1A, alpha 1B, and alpha 1D. We tested ten antibodies, from abcam and Santa Cruz, using western blot with heart and brain tissue from wild-type (WT) mice and mice with systemic knockout (KO) of one or all three subtypes. We found that none of the antibodies detected a band in WT that was absent in the appropriate KO or in the KO that was null for all alpha 1-ARs (ABDKO). We conclude that the antibodies we tested are not specific for alpha 1-ARs. These results raise caution with prior studies using these reagents. For now, competition radioligand binding is the only reliable approach to quantify the alpha 1-AR subtype proteins. Receptor protein localization remains a challenge. C1 [Jensen, Brian C.; Swigart, Philip M.; Simpson, Paul C.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. [Jensen, Brian C.; Swigart, Philip M.; Simpson, Paul C.] San Francisco VA Med Ctr, Res Serv, San Francisco, CA 94121 USA. [Jensen, Brian C.] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. [Simpson, Paul C.] Univ Calif San Francisco, Dept Med, Inst Cardiovasc Res, San Francisco, CA 94143 USA. RP Simpson, PC (reprint author), San Francisco VA Med Ctr, Cardiol Sect, 111-C-8,4150 Clement St, San Francisco, CA 94121 USA. EM paul.simpson@ucsf.edu FU United States Department of Veterans Affairs Research Service; NIH; GlaxoSmithKline Research Foundation FX We appreciate the support of the United States Department of Veterans Affairs Research Service, the NIH, and the GlaxoSmithKline Research Foundation. NR 10 TC 86 Z9 86 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0028-1298 J9 N-S ARCH PHARMACOL JI Naunyn-Schmiedebergs Arch. Pharmacol. PD APR PY 2009 VL 379 IS 4 BP 409 EP 412 DI 10.1007/s00210-008-0368-6 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 423KF UT WOS:000264494500011 PM 18989658 ER PT J AU Haroutunian, V Katsel, P Schmeidler, J AF Haroutunian, Vahram Katsel, Pavel Schmeidler, James TI Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia SO NEUROBIOLOGY OF AGING LA English DT Article DE Gene expression; Microarray; Alzheimer's disease; Dementia; Cerebral cortex; Hippocampus ID GENE-EXPRESSION; STEREOLOGIC ANALYSIS; ENTORHINAL CORTEX; ELDERLY SUBJECTS; MICROARRAY; SCHIZOPHRENIA; PLAQUES; TANGLES; CA1; NORMALIZATION AB This study determined (a) the association between stages of Alzheimer's disease (AD) and overall gene expression change, and (b) brain regions of greatest vulnerability to transcriptional change as the disease progressed. Fifteen cerebrocortical sites and the hippocampus were examined in persons with either no cognitive impairment or neuropathology, or with only AD-associated lesions. Cases were stratified into groups of 7 19 based on the degree of cognitive impairment (clinical dementia rating scale, CDR); neurofibrillary tangle distribution and severity (Braak staging) or density of cerebrocortical neuritic plaque (NP; grouping by NP density). Transcriptional change was assessed by Affymetrix U 133 mRNA microarray analysis. The results suggested that (a) gene expression changes in the temporal and prefrontal cortices tire more closely related to disease severity than other regions examined; (b) more genes are down-regulated at,my given disease severity stage than up-regulated; (c) the degree of gene expression change in a given regions depends oil the disease severity classification scheme used; and (d) the classification of cases by CDR provides a more orderly gradient of gene expression change in most brain regions than Braak staging or NP grouping. (C) 2007 Elsevier Inc. All rights reserved. C1 [Haroutunian, Vahram; Katsel, Pavel; Schmeidler, James] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, MIRECC, Bronx, NY 10468 USA. RP Haroutunian, V (reprint author), Bronx VA Med Ctr, 4F-33B,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu FU [AG02219] FX Supported by AG02219 (VH). NR 50 TC 29 Z9 27 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2009 VL 30 IS 4 BP 561 EP 573 DI 10.1016/j.neurobiolaging.2007.07.021 PG 13 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 424PT UT WOS:000264579500012 PM 17845826 ER PT J AU Yaffe, K Lindquist, K Sen, S Cauley, J Ferrell, R Penninx, B Harris, T Li, RL Cummings, SR AF Yaffe, Kristine Lindquist, Karla Sen, Saunak Cauley, Jane Ferrell, Robert Penninx, Brenda Harris, Tamara Li, Rongling Cummings, Steven R. CA Hlth ABC Study TI Estrogen receptor genotype and risk of cognitive impairment in elders: Findings from the Health ABC study SO NEUROBIOLOGY OF AGING LA English DT Article DE Estrogen; Dementia; Genetics; Aging ID ALPHA GENE POLYMORPHISMS; SPORADIC ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; POSTMENOPAUSAL WOMEN; CAUCASIAN WOMEN; MESSENGER-RNA; HUMAN BRAIN; ASSOCIATION; BETA; ESR1 AB Objective: To determine whether variants in the estrogen receptors 1 (alpha) and 2 (beta) (ESR1 and ESR2) genes are associated with cognitive impairment in non-demented elderly men and women. Background: Several single nucleotide polymorphisms (SNPs) on ESR1 and ESR2 genes have been associated with a range of hormone sensitive diseases such as breast cancer and osteoporosis. Genetic variations in ESR may also influence cognitive aging but are less studied, especially among men. Methods: We studied 2527 participants enrolled in an ongoing prospective study of community-dwelling elders. Four SNPs from ESR1 and four from ESR2 were analyzed. We measured cognitive function with the Modified Mini-Mental Status Examination (3MS) at baseline and biannually cognitive impairment was defined as it decline of live or more points over 4 years. We calculated odds of developing cognitive impairment across SNPS using gender-stratified logistic regression and adjusted analyses for age, education, baseline 3MS score and in addition for race. Results: One thousand three hundred and forty-three women (mean age 73.4) and 1184 men (mean age 73.7) comprised Our cohort. Among women, after multivariate adjustment, two of the ESR1 SNPs (rs8179176, rs9340799) and two of the ESR2 SNPs (rs1256065, rs1256030) were associated with likelihood of developing cognitive impairment., although the association for rs8179176 was of trend level significance. In men, one of the ESR1 SNPs (rs729524) and two of the ESR2 (rs1255998, rs1256030) were associated with cognitive impairment. Further adjustment for race attenuated the results somewhat. There was no association between any ESR SNP and level of bioavailable estradiol but testosterone level did vary among two of the SNPs (p < 0.05). Conclusion: We found that among non-demented Community elders, several SNPs in the ESR1 and ESR2 genes were associated with risk of developing cognitive impairment. These findings suggest that estrogen receptor genetic variants may play it role in cognitive aging. (C) 2007 Elsevier Inc. All rights reserved. C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat & Neurol, Sch Med, San Francisco, CA 94121 USA. [Yaffe, Kristine; Sen, Saunak] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Lindquist, Karla] Univ Calif San Francisco, Dept Geriatr, Sch Med, San Francisco, CA 94121 USA. [Yaffe, Kristine; Sen, Saunak] San Francisco VA Med Ctr, San Francisco, CA USA. [Cauley, Jane] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Ferrell, Robert] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA. [Penninx, Brenda] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, EMGO Inst, Amsterdam, Netherlands. [Harris, Tamara] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Li, Rongling] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Ctr Genom & Bioinformat, Memphis, TN 38163 USA. [Cummings, Steven R.] San Francisco Coordinating Ctr, San Francisco, CA USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat & Neurol, Sch Med, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM Kristine.yaffe@uesf.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU NIH, National Institute on Aging; [N01-AG-6-2101]; [N01-AG-6-2103]; [N01-AG6-2106]; [R01-AG021918] FX Funded by N01-AG-6-2101, N01-AG-6-2103, N01-AG6-2106 and R01-AG021918. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. NR 31 TC 37 Z9 38 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2009 VL 30 IS 4 BP 607 EP 614 DI 10.1016/j.neurobiolaging.2007.08.003 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 424PT UT WOS:000264579500016 PM 17889406 ER PT J AU Lim, DA Larson, PS AF Lim, Daniel A. Larson, Paul S. TI Intraoperative MRI in Functional Neurosurgery Preface SO NEUROSURGERY CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 [Lim, Daniel A.] San Francisco VA Med Ctr, Neurosurg Sect, Surg Serv, Dept Vet Affairs, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. RP Lim, DA (reprint author), San Francisco VA Med Ctr, Neurosurg Sect, Surg Serv, Dept Vet Affairs, 4150 Clement St, San Francisco, CA 94121 USA. EM LimD@neurosurg.ucsf.edu; LarsonP@neurosurg.ucsf.edu OI Lim, Daniel/0000-0001-7221-3425 NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1042-3680 J9 NEUROSURG CLIN N AM JI Neurosurg. Clin. N. Am. PD APR PY 2009 VL 20 IS 2 BP XI EP XI DI 10.1016/j.nec.2009.04.014 PG 1 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 480HM UT WOS:000268724500001 PM 19555874 ER PT J AU Roskom, J Swistowski, A Zeng, XM Lim, DA AF Roskom, Joshua Swistowski, Andrzej Zeng, Xianmin Lim, Daniel A. TI Future Directions: Use of Interventional MRI for Cell-Based Therapy of Parkinson Disease SO NEUROSURGERY CLINICS OF NORTH AMERICA LA English DT Article DE Embryonic stem cells; Induced pluripotent stem cells; Cell transplantation; Parkinson's disease; Dopamine neurons; Interventional MRI ID EMBRYONIC STEM-CELLS; DOPAMINE NEURONS; IN-VITRO; ELECTROPHYSIOLOGICAL GUIDANCE; NIGRAL TRANSPLANTS; LEVODOPA THERAPY; TECHNICAL NOTE; DIFFERENTIATION; GENERATION; IMPLANTATION AB Transplantation of neural cells for the treatment of neurologic disorders has garnered much attention and considerable enthusiasm from patients and physicians alike. Cell-based therapies have been proposed for a wide range of central nervous system pathologies ranging from stroke and trauma to demyelinating disorders and neurodegenerative diseases. Notably, cell transplantation for Parkinson disease (PD) has become even more attractive with the rapid advances in derivation of dopaminergic neurons from human embryonic stem cells. This article briefly reviews some of the relevant issues regarding the transplantation of cells for treatment of PD and hypothesizes how interventional MRI may be useful to optimize the surgical delivery of cells for PD and other central nervous system disorders. C1 [Lim, Daniel A.] San Francisco VA Med Ctr, Neurosurg Sect, Dept Vet Affairs, Surg Serv, San Francisco, CA 94121 USA. [Lim, Daniel A.] Dept Vet Affairs, San Francisco Vet Affairs Med Ctr, Surg Serv, Neurosurg Sect, San Francisco, CA 94121 USA. [Roskom, Joshua] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Swistowski, Andrzej] Buck Inst Age Res, Novato, CA 94945 USA. [Zeng, Xianmin] Buck Inst Age Res, N Bay Calif Inst Regenerat Med, Shared Res Lab Stem Cells & Aging, Novato, CA 94945 USA. RP Lim, DA (reprint author), San Francisco VA Med Ctr, Neurosurg Sect, Dept Vet Affairs, Surg Serv, 4150 Clement St, San Francisco, CA 94121 USA. EM limd@neurosurg.ucsf.edu OI Lim, Daniel/0000-0001-7221-3425 NR 46 TC 4 Z9 4 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1042-3680 J9 NEUROSURG CLIN N AM JI Neurosurg. Clin. N. Am. PD APR PY 2009 VL 20 IS 2 BP 225 EP + DI 10.1016/j.nec.2009.04.005 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 480HM UT WOS:000268724500012 PM 19555884 ER PT J AU Thompson, K AF Thompson, Kerry TI Transplantation of GABA-Producing Cells for Seizure Control in Models of Temporal Lobe Epilepsy SO NEUROTHERAPEUTICS LA English DT Article CT 4th Workshop on New Horizons in the Development of Antiepileptic Drugs CY MAR 05-07, 2008 CL Dublin, IRELAND DE GABA; cell transplantation; temporal lobe epilepsy; seizures; genetic engineering ID GLUTAMIC-ACID DECARBOXYLASE; NEURAL PROGENITOR CELLS; EMBRYONIC STEM-CELLS; ADENOSINE-RELEASING CELLS; FETAL GABAERGIC NEURONS; PARKINSONS-DISEASE; DENTATE GYRUS; KINDLING EPILEPSY; STATUS EPILEPTICUS; INTRANIGRAL TRANSPLANTS AB A high percentage of patients with temporal lobe epilepsy (TLE) are refractory to conventional pharmacotherapy. The progressive neurodegenerative processes associated with a lifetime of uncontrolled seizures mandate the development of alternative approaches to treat this disease. Transplantation of inhibitory cells has been suggested as a potential therapeutic strategy to achieve seizure suppression in humans with intractable TLE. Preclinical investigations over 20 years have demonstrated that multiple cell types from several sources can produce anticonvulsant, and antiepileptogenic, effects in animal models of TLE. Transplanting GABA-producing cells, in particular, has been shown to reduce seizures in several well-established models. This review addresses experimentation using different sources of transplantable GABAergic cells, highlighting progress with fetal tissue, neural cell lines, and stem cells. Regardless of the source of the GABAergic cells used in seizure studies, common challenges have emerged. Several variables influence the anticonvulsant potential of GABA-producing cells. For example, tissue availability, graft survival, immunogenicity, tumorigenicity, and varying levels of cell migration, differentiation, and integration into functional circuits and the microenvironment provided by sclerotic tissue all contribute to the efficacy of transplanted cells. The challenge of understanding how all of these variables work in concert, in a disease process that has no well-established etiology, suggests that there is still much basic research to be done before rational cell-based therapies can be developed for TLE. C1 [Thompson, Kerry] Occidental Coll, Dept Biol, Los Angeles, CA 90041 USA. [Thompson, Kerry] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90012 USA. RP Thompson, K (reprint author), Occidental Coll, Dept Biol, 1600 Campus Rd, Los Angeles, CA 90041 USA. EM kthompson@oxy.edu NR 108 TC 24 Z9 25 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-7213 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD APR PY 2009 VL 6 IS 2 BP 284 EP 294 PG 11 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 425TL UT WOS:000264659900010 PM 19332321 ER PT J AU Wadden, TA West, DS Neiberg, RH Wing, RR Ryan, DH Johnson, KC Foreyt, JP Hill, JO Trence, DL Vitolins, MZ AF Wadden, Thomas A. West, Delia S. Neiberg, Rebecca H. Wing, Rena R. Ryan, Donna H. Johnson, Karen C. Foreyt, John P. Hill, James O. Trence, Dace L. Vitolins, Mara Z. CA Look AHEAD Res Grp TI One-year Weight Losses in the Look AHEAD Study: Factors Associated With Success SO OBESITY LA English DT Article ID RESTING ENERGY-EXPENDITURE; TERM DIETARY INTERVENTION; PLACEBO-CONTROLLED TRIAL; AFRICAN-AMERICAN; OBESE-PATIENTS; WHITE WOMEN; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; BODY-COMPOSITION; CONTROL PROGRAM AB This report provides a further analysis of the first year weight losses in the Look AHEAD (Action for Health in Diabetes) study and identifies factors associated with success. Participants were a total of 5,145 men and women with type 2 diabetes who were recruited at 16 sites and randomly assigned to an intensive lifestyle intervention (ILI) or a control condition, Diabetes Support and Education (DSE). During year 1, participants in ILI received comprehensive diet and physical activity counseling in a total of 42 group and individual sessions, compared with three educational sessions for DSE participants. As reported previously, at the end of the year, ILI participants lost 8.6% of initial weight, compared to 0.7% for DSE (P < 0.001). Within the ILI group, all racial/ethnic groups achieved clinically significant weight losses (>5.5%), although there were significant differences among groups. For the year, ILI participants attended an average of 35.4 treatment sessions and reported exercising a mean of 136.6 min/week and consuming a total of 360.9 meal replacement products. Greater self-reported physical activity was the strongest correlate of weight loss, followed by treatment attendance and consumption of meal replacements. The use of orlistat, during the second half of the year, increased weight loss only marginally in those ILI participants who had lost <5% of initial weight during the first 6 months and chose to take the medication thereafter as a toolbox option. The lifestyle intervention was clinically effective in all subsets of an ethnically and demographically diverse population. C1 [Wadden, Thomas A.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [West, Delia S.] Univ Arkansas Med Sci, Fay W Boozman Coll Publ Hlth, Dept Hlth Behav & Hlth Educ, Little Rock, AR 72205 USA. [Neiberg, Rebecca H.] Wake Forest Univ, Dept Biostat Sci, Winston Salem, NC 27109 USA. [Wing, Rena R.] Miriam Hosp, Providence, RI 02906 USA. [Wing, Rena R.] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Ryan, Donna H.] Pennington Biomed Res Ctr, Dept Clin Res, Baton Rouge, LA USA. [Johnson, Karen C.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Foreyt, John P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Hill, James O.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA. [Trence, Dace L.] Univ Washington, Dept Endocrinol, Washington, DC USA. [Trence, Dace L.] VA Puget Sound Hlth Care Syst, Washington, DC USA. [Look AHEAD Res Grp] Wake Forest Univ, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. RP Wadden, TA (reprint author), Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. EM Wadden@mail.med.upenn.edu FU National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992, DK 046204]; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; Centers for Disease Control and Prevention; Johns Hopkins Medical Institutions [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee [M01RR0021140]; University of Pittsburgh [M01RR00005644]; University of Washington/VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs [M01RR01346] FX This study is supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (M01RR000056 44) and NIH grant (DK 046204); and the University of Washington/VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center (M01RR01346). The following organizations have committed to make major contributions to Look AHEAD: Federal Express; Health Management Resources; Johnson & Johnson, LifeScan Inc.; OptifastNovartis Nutrition; Roche Pharmaceuticals; Ross Product Division of Abbott Laboratories; Slim-Fast Foods Company; and Unilever. NR 39 TC 204 Z9 209 U1 4 U2 21 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD APR PY 2009 VL 17 IS 4 BP 713 EP 722 DI 10.1038/oby.2008.637 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 425TA UT WOS:000264658800023 PM 19180071 ER PT J AU Paramsothy, P Lin, YS Kernic, MA Foster-Schubert, KE AF Paramsothy, Pathmaja Lin, Yvonne S. Kernic, Mary A. Foster-Schubert, Karen E. TI Interpregnancy Weight Gain and Cesarean Delivery Risk in Women With a History of Gestational Diabetes SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID ADVERSE PREGNANCY OUTCOMES; VENOUS THROMBOEMBOLISM; MATERNAL MORTALITY; PLACENTA PREVIA; OBESITY; SECTION; COMPLICATIONS AB OBJECTIVE: Along with the rising prevalence of obesity, rates of gestational diabetes mellitus (GDM) and associated adverse outcomes also have increased. We conducted a population-based, retrospective cohort study to assess the association of weight gain between pregnancies with cesarean delivery for the subsequent pregnancy among women with a history of GDM. METHODS: Using linked birth-certificate data for women with at least two singleton births in Washington State during the period from 1992-2005, we identified 2,753 women with GDM who delivered vaginally at the baseline pregnancy (first pregnancy on record). The interpregnancy weight change (subsequent-baseline prepregnancy weight) for each woman was calculated and assigned to one of three categories: weight loss (more than 10 lb), weight stable (10 lb), or weight gain (more than 10 lb). Multiple logistic regression was used to calculate the risk (odds ratio [OR]) of cesarean delivery at the subsequent pregnancy among the weight-gain and weight-loss groups relative to the weight-stable category. RESULTS: Among 2,581 eligible women, 10.9% lost more than 10 lb between pregnancies, 54.0% were weight-stable, and 35.1% gained more than 10 lb. Women who gained more than 10 lb had an adjusted OR for subsequent cesarean delivery of 1.70 (95% confidence interval [CI] 1.16-2.49, 9.7% of women who gained weight), whereas the adjusted OR for women who lost weight was 0.55 (95% CI 0.28-1.10, 4.7% of women who lost weight). CONCLUSION: Women with a history of GDM who gained more than 10 lb between pregnancies are at increased risk of future cesarean delivery. Appropriate weight management among women with a history of GDM may result in decreased cesarean delivery rates along with decreases in associated excess risks and costs. (Obstet Gynecol 2009;113:817-23) C1 Univ Washington, Dept Internal Med, Div Cardiol, Dept Pharmaceut, Seattle, WA 98195 USA. Univ Washington, Dept Internal Med, Div Cardiol, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Internal Med, Div Endocrinol, Seattle, WA 98195 USA. RP Foster-Schubert, KE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Endocrinol 111, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kfoster@u.washington.edu FU National Center for Research Resources [1KL2RR025015-01]; National Institutes of Health (NIH); NIH Roadmap for Medical Research FX Supported by grant number 1KL2RR025015-01 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research (P.P., YS.L., K.E.F-S.). NR 21 TC 8 Z9 8 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2009 VL 113 IS 4 BP 817 EP 823 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 424PG UT WOS:000264578000009 PM 19305325 ER PT J AU Cheng, EM Giaconi, JA Coleman, AL Lee, BL Weinreb, RN Newberry, SJ Suttorp, MJ Schonlau, M Fingeret, M Gupta, N Hitchings, RA Jampel, HD Lewis, TL Miglior, S Mills, RP Pfeiffer, N Topouzis, F Samuelson, TW AF Cheng, Eric M. Giaconi, JoAnn A. Coleman, Anne L. Lee, Brian L. Weinreb, Robert N. Newberry, Sydne J. Suttorp, Marika J. Schonlau, Matthias Fingeret, Murray Gupta, Neeru Hitchings, Roger A. Jampel, Henry D. Lewis, Thomas L. Miglior, Stefano Mills, Richard P. Pfeiffer, Norbert Topouzis, Fotis Samuelson, Thomas W. TI For Which Glaucoma Suspects Is It Appropriate to Initiate Treatment? SO OPHTHALMOLOGY LA English DT Article ID OPEN-ANGLE GLAUCOMA; OCULAR HYPERTENSION; CORONARY REVASCULARIZATION; PHYSICIAN RATINGS; LIFE-EXPECTANCY; PANEL; SPECIALTY; UNDERUSE; CANCER AB Objective: Because uncertainty exists about which glaucoma suspects should be treated, this study sought to identify the glaucoma suspects who an expert panel could agree would be appropriate or inappropriate to treat. Design: The RAND/UCLA appropriateness method, a well-established procedure to synthesize the scientific literature with expert opinion to resolve uncertainty on a health topic. Participants: Eleven-member panel composed of recognized international leaders in the field of glaucoma. Methods: Based on a systematic review of the literature on potentially important factors to consider when deciding to initiate treatment, more than 1000 scenarios of glaucoma suspects initially were created. The panel formally rated the appropriateness of initiating treatment for glaucoma suspects through a 2-round modified Delphi method, a technique that preserves the confidentiality of individual panelists' ratings but allows panelists to compare their own ratings with those of the entire panel. Main Outcome Measures: Final ratings for scenarios were categorized as appropriate, uncertain, or inappropriate to treat according to typical prespecified statistical criteria previously used in projects using the RAND/UCLA appropriateness method. Tools were developed to help clinicians to approximate the panel ratings of glaucoma suspects. Results: The panel chose age, life expectancy, intraocular pressure (IOP), central corneal thickness, cup-to-disc ratio, disc size, and family history as the variables to consider when deciding whether to treat glaucoma suspects. Permutations of these variables created 1800 unique scenarios. The panel rated 587 (33%) scenarios as appropriate, 585 (33%) as uncertain, and 628 (35%) as inappropriate for treatment initiation. Analysis of variance determined that IOP had greater impact than any other variable on panel ratings. A point system was created with 96% sensitivity and 93% specificity for predicting panel ratings of appropriateness for a glaucoma suspect. Conclusions: An expert panel can reach agreement on the appropriateness and inappropriateness of treatment for glaucoma suspects. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 116:710-716 (C) 2009 by the American Academy of Ophthalmology. C1 [Cheng, Eric M.; Giaconi, JoAnn A.; Coleman, Anne L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Weinreb, Robert N.] Univ Calif San Diego, Hamilton Glaucoma Ctr, San Diego, CA 92103 USA. [Weinreb, Robert N.] Shiley Eye Ctr, La Jolla, CA USA. [Fingeret, Murray] St Albans VA Hosp, St Albans, NY USA. [Gupta, Neeru] Univ Toronto, St Michaels Hosp, Carter Wing, Toronto, ON M5B 1W8, Canada. [Hitchings, Roger A.] Moorfields Eye Hosp, London, England. [Jampel, Henry D.] Johns Hopkins Univ, Baltimore, MD USA. [Lewis, Thomas L.] Penn Coll Optometry, Elkins Pk, PA USA. [Miglior, Stefano] Policlin Monza, Clin Oculist, Monza, MI, Italy. [Mills, Richard P.] Swedish Med Ctr, Seattle, WA USA. [Pfeiffer, Norbert] Johannes Gutenberg Univ Mainz, Univ Augenklin, Mainz, Germany. [Topouzis, Fotis] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece. [Samuelson, Thomas W.] Minnesota Eye Consultants PA, Minneapolis, MN USA. RP Cheng, EM (reprint author), VA Greater Los Angeles Healthcare Syst, B 500,ML127, Los Angeles, CA 90073 USA. EM eric.cheng@va.gov FU Pfizer, Inc., New York, New York; National Institute of Neurological Disorders and Stroke (NINDS, Washington, DC) [K23NS058571] FX Supported by Pfizer, Inc., New York, New York. Dr. Cheng is also supported by a Career Development Award, K23NS058571, from National Institute of Neurological Disorders and Stroke (NINDS, Washington, DC). NR 19 TC 7 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD APR PY 2009 VL 116 IS 4 BP 710 EP 716 DI 10.1016/j.ophtha.2008.12.065 PG 7 WC Ophthalmology SC Ophthalmology GA 427YI UT WOS:000264814600016 ER PT J AU Grady, D Cauley, JA Stock, JL Cox, DA Mitlak, BH Song, JL Cummings, SR AF Grady, Deborah Cauley, Jane A. Stock, John L. Cox, David A. Mitlak, Bruce H. Song, Jingli Cummings, Steven R. TI EFFECT OF RALOXIFENE ON ALL-CAUSE MORTALITY ACROSS CLINICAL TRIALS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT 8th International Symposium on Osteoporosis - Translating Research into Clinical Practice CY APR 01-09, 2009 CL Washington, DC C1 [Grady, Deborah; Cummings, Steven R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. [Cummings, Steven R.] CPMC Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA. [Cauley, Jane A.] Univ Pittsburgh, Pittsburgh, PA USA. [Stock, John L.; Cox, David A.; Mitlak, Bruce H.; Song, Jingli] Eli Lilly & Co, Indianapolis, IN 46285 USA. RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI ARTINGTON PA ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP, GUILDFORD, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD APR PY 2009 VL 20 BP S206 EP S207 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 536AF UT WOS:000273012900032 ER PT J AU Jaffe, E AF Jaffe, Emily TI Regulating Complexity SO PAIN MEDICINE LA English DT Editorial Material C1 Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15260 USA. RP Jaffe, E (reprint author), Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15260 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD APR PY 2009 VL 10 IS 3 BP 429 EP 431 DI 10.1111/j.1526-4637.2009.00585.x PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 431QI UT WOS:000265077500001 PM 19425206 ER PT J AU Becker, WC Fiellin, DA Gallagher, RM Barth, KS Ross, JT Oslin, DW AF Becker, William C. Fiellin, David A. Gallagher, Rollin M. Barth, Kelly S. Ross, Jennifer T. Oslin, David W. TI The Association Between Chronic Pain and Prescription Drug Abuse in Veterans SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Prescription Drug Abuse; Multivariable Analysis ID NONMEDICAL USE; UNITED-STATES; SUBSTANCE USE; OPIOID ANALGESICS; USE DISORDERS; RISK-FACTORS; MEDICAL USE; US ADULTS; DEPENDENCE; ADDICTION AB We sought to investigate the association between chronic pain and self-reported prescription drug abuse in a large cohort of patients referred from primary care for a behavioral health assessment. We performed a cross-sectional analysis of responses to a telephone assessment administered to patients referred for a behavioral health evaluation between April 25, 2005 and October 31, 2007. We conducted descriptive statistics and investigated multivariable associations. Multivariable analyses included age, gender, race, financial status, employment, current smoking, drinking problem, past-year illicit drug use, depression, and chronic pain. Veterans referred from primary care (N = 6,377). Mean age of the sample was 56.5 years with a range of 19-97. The majority of respondents was white, unmarried, and was unemployed. Nearly 5% of the sample reported past 6-month prescription drug abuse. On multivariable analysis, younger age, possible depression (odds ratio [OR] 1.9; 1.3-2.8), probable depression (OR 2.4; 1.6-3.4), smoking (OR 1.4; 1.1-1.8), illicit drug use (OR 2.8; 2.2-3.7), and chronic pain (OR 1.9; 1.4-2.5) were associated with prescription drug abuse. We have identified specific variables associated with self-reported prescription drug abuse in primary care patients. Chronic pain is associated both with an indication for prescribing opioids and with abuse of prescription medications. Clinicians are encouraged to follow treatment algorithms when managing patients with chronic pain as a method for reducing misuse. C1 [Becker, William C.; Gallagher, Rollin M.; Ross, Jennifer T.; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, MIRECC, VISN4, Philadelphia, PA USA. [Barth, Kelly S.] Univ Penn, Sch Med, Dept Psychiat, Ctr Study Addict, Philadelphia, PA 19104 USA. [Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Becker, WC (reprint author), Philadelphia VAMC, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM William.Becker4@va.gov OI Becker, William/0000-0002-0788-1467; Fiellin, David/0000-0002-4006-010X NR 27 TC 29 Z9 29 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD APR PY 2009 VL 10 IS 3 BP 531 EP 536 DI 10.1111/j.1526-4637.2009.00584.x PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 431QI UT WOS:000265077500015 PM 19425211 ER PT J AU Grotzke, JE Harriff, MJ Siler, AC Nolt, D Delepine, J Lewinsohn, DA Lewinsohn, DM AF Grotzke, Jeff E. Harriff, Melanie J. Siler, Anne C. Nolt, Dawn Delepine, Jacob Lewinsohn, Deborah A. Lewinsohn, David M. TI The Mycobacterium tuberculosis Phagosome Is a HLA-I Processing Competent Organelle SO PLOS PATHOGENS LA English DT Article ID CD8(+) T-LYMPHOCYTES; ANTIGEN PRESENTATION; EXOGENOUS ANTIGENS; CROSS-PRESENTATION; DENDRITIC CELLS; INFECTED-CELLS; PEPTIDE; PATHWAY; TAP; MACROPHAGES AB Mycobacterium tuberculosis (Mtb) resides in a long-lived phagosomal compartment that resists maturation. The manner by which Mtb antigens are processed and presented on MHC Class I molecules is poorly understood. Using human dendritic cells and IFN-gamma release by CD8(+) T cell clones, we examined the processing and presentation pathway for two Mtb-derived antigens, each presented by a distinct HLA-I allele (HLA-Ia versus HLA-Ib). Presentation of both antigens is blocked by the retrotranslocation inhibitor exotoxin A. Inhibitor studies demonstrate that, after reaching the cytosol, both antigens require proteasomal degradation and TAP transport, but differ in the requirement for ER-golgi egress and new protein synthesis. Specifically, presentation by HLA-B8 but not HLA-E requires newly synthesized HLA-I and transport through the ER-golgi. Phenotypic analysis of the Mtb phagosome by flow organellometry revealed the presence of Class I and loading accessory molecules, including TAP and PDI. Furthermore, loaded HLA-I: peptide complexes are present within the Mtb phagosome, with a pronounced bias towards HLA-E: peptide complexes. In addition, protein analysis also reveals that HLA-E is enriched within the Mtb phagosome compared to HLA-A2. Together, these data suggest that the phagosome, through acquisition of ER-localized machinery and as a site of HLA-I loading, plays a vital role in the presentation of Mtb-derived antigens, similar to that described for presentation of latex bead-associated antigens. This is, to our knowledge, the first description of this presentation pathway for an intracellular pathogen. Moreover, these data suggest that HLA-E may play a unique role in the presentation of phagosomal antigens. C1 [Grotzke, Jeff E.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Harriff, Melanie J.; Siler, Anne C.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Dept Med, Portland VA Med Ctr, Portland, OR 97201 USA. [Nolt, Dawn; Delepine, Jacob; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Div Infect Dis, Dept Pediat, Portland, OR 97201 USA. RP Grotzke, JE (reprint author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. EM lewinsod@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 FU NIH [R01AI048090]; VA Merit Review Grant; Portland VA Medical Center FX This research was supported by NIH grant R01AI048090, VA Merit Review Grant, and the Portland VA Medical Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 33 Z9 33 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD APR PY 2009 VL 5 IS 4 AR e1000374 DI 10.1371/journal.ppat.1000374 PG 13 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 447UC UT WOS:000266216300018 PM 19360129 ER PT J AU Crilly, JF Caine, ED Lamberti, JS Brown, T Friedman, B AF Crilly, John F. Caine, Eric D. Lamberti, J. Steven Brown, Theodore Friedman, Bruce TI Mental Health Services Use and Symptom Prevalence in a Cohort of Adults on Probation SO PSYCHIATRIC SERVICES LA English DT Article ID ILLNESS AB Objective: This study examined the prevalence of mental disorder symptoms among adult probationers and the probability of mental health service use. Methods: Data from the 2001 National Household Survey on Drug Abuse were used to obtain information on adults reporting mental disorder symptoms who had been on probation within the past year and those who had not. Results: Twenty-seven percent of probationers (N=311 of 1,168) and 17% of nonprobationers (N=5,830 of 34,230) had mental disorder symptoms. Mental health service use was reported by 23% of both groups. Compared with persons who had not been on probation, probationers were more likely to report psychosis, mania, and post-traumatic stress disorder; both groups were as likely to report depression. Conclusions: The prevalence of mental disorder symptoms did not differ by probation status. However, the type and distribution of symptoms were significantly different in the two groups. These are important considerations when planning for service connection with mental health providers. (Psychiatric Services 60: 542-544, 2009) C1 [Crilly, John F.; Caine, Eric D.; Lamberti, J. Steven; Friedman, Bruce] Univ Rochester, Dept Psychiat, Rochester, NY 14642 USA. [Friedman, Bruce] Univ Rochester, Dept Community Prevent Med, Rochester, NY 14642 USA. [Crilly, John F.; Brown, Theodore] US Dept Vet Affairs, VA Healthcare Network Upstate New York VISN2, Ctr Excellence Canandaigua, Canandaigua, NY USA. RP Crilly, JF (reprint author), Univ Rochester, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA. EM john_crilly@urmc.rochester.edu FU National Institute of Mental Health [P20-MH071897] FX The writing of this brief report was supported in part by grant P20-MH071897 ( principal investigator, Dr. Caine) from the National Institute of Mental Health. This brief report draws on a portion of Dr. Crilly's dissertation, completed under the supervision of Dr. Friedman and coauthors. NR 9 TC 8 Z9 8 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2009 VL 60 IS 4 BP 542 EP 544 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 427QJ UT WOS:000264793500021 PM 19339332 ER PT J AU Horan, WP Nuechterlein, KH Wynn, JK Lee, J Castelli, F Green, MF AF Horan, W. P. Nuechterlein, K. H. Wynn, J. K. Lee, J. Castelli, F. Green, M. F. TI Disturbances in the spontaneous attribution of social meaning in schizophrenia SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Anthropomorphizing; mentalizing; schizophrenia; social cognition; theory of mind ID HIGHER-FUNCTIONING AUTISM; PSYCHIATRIC RATING-SCALE; INTENTIONAL MOVEMENT; ASPERGER-SYNDROME; BRAIN MECHANISMS; MIND; PERCEPTION; CAUSALITY; PEOPLE; MOTION AB Background. Schizophrenia patients show disturbances on a range of tasks that assess mentalizing or 'Theory of Mind' (ToM). However, these tasks are often developmentally inappropriate, make large demands on verbal abilities and explicit problem-solving skills, and involve after-the-fact reflection as opposed to spontaneous mentalizing. Method. To address these limitations, 55 clinically stable schizophrenia out-patients and 44 healthy controls completed a validated Animations Task designed to assess spontaneous attributions of social meaning to ambiguous abstract visual stimuli. In this paradigm, 12 animations depict two geometric shapes 'interacting' with each other in three conditions: (1) ToM interactions that elicit attributions of mental states to the agents, (2) Goal-Directed (GD) interactions that elicit attributions of simple actions, and (3) Random scenes in which no interaction occurs. Verbal descriptions of each animation are rated for the degree of Intentionality attributed to the agents and for accuracy. Results. Patients had lower Intentionality ratings than controls for ToM and GD scenes but the groups did not significantly differ for Random scenes. The descriptions of the patients less closely matched the situations intended by the developers of the task. Within the schizophrenia group, performance on the Animations Task showed minimal associations with clinical symptoms. Conclusions. Patients demonstrated disturbances in the spontaneous attribution of mental states to abstract visual stimuli that normally evoke such attributions. Hence, in addition to previously established impairment on mentalizing tasks that require logical inferences about others' mental states, individuals with schizophrenia show disturbances in implicit aspects of mentalizing. C1 [Green, M. F.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Castelli, F.] CALTECH, Pasadena, CA 91125 USA. RP Horan, WP (reprint author), 300 UCLA Med Plaza,Suite 2240, Los Angeles, CA 90095 USA. EM horan@ucla.edu RI Lee, Junghee/C-5226-2014; Wynn, Jonathan/H-3749-2014 OI Lee, Junghee/0000-0001-9567-8700; Wynn, Jonathan/0000-0002-1763-8540 FU NARSAD [MH43292, MH65707]; National Institute of Mental Health [MH14584]; Department of Veterans Affairs FX This research was supported by a NARSAD Young Investigator Award (W. P. Horan), by research grants MH43292 and MH65707 (PI: M. F. Green) and Institutional NRSA MH14584 (PI: K. H. Nuechterlein) from the National Institute of Mental Health, and by the Department of Veterans Affairs VISN 22 MIRECC. We thank Tamara A. Russell for helpful consultation during the planning of this study, and Shelly M. Crosby, Kelly Tillery, Karina Shokat-Fadai, Joseph Ventura, and Sarah Wilson for their contributions to this project. NR 54 TC 23 Z9 23 U1 2 U2 13 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD APR PY 2009 VL 39 IS 4 BP 635 EP 643 DI 10.1017/S0033291708003838 PG 9 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 426EO UT WOS:000264691000010 PM 18606048 ER PT J AU Kern, RS Green, MF Fiske, AP Kee, KS Lee, J Sergi, MJ Horan, WP Subotnik, KL Sugar, CA Nuechterlein, KH AF Kern, R. S. Green, M. F. Fiske, A. P. Kee, K. S. Lee, J. Sergi, M. J. Horan, W. P. Subotnik, K. L. Sugar, C. A. Nuechterlein, K. H. TI Theory of mind deficits for processing counterfactual information in persons with chronic schizophrenia SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Counterfactual information; deception; sarcasm; schizophrenia; theory of mind ID TRAUMATIC BRAIN-INJURY; SOCIAL-PERCEPTION; MENTALIZING ABILITY; PEOPLE; COMPREHENSION; REMISSION; COMMUNICATION; PRAGMATICS; INFERENCE; VALIDITY AB Background. Interpersonal communication problems are common among persons with schizophrenia and may be linked, in part, to deficits in theory of mind (ToM), the ability to accurately perceive the attitudes, beliefs and intentions of others. Particular difficulties might be expected in the processing of counterfactual information such as sarcasm or lies. Method. The present study included 50 schizophrenia or schizo-affective out-patients and 44 demographically comparable healthy adults who were administered Part III of The Awareness of Social Inference Test (TASIT; a measure assessing comprehension of sarcasm Versus lies) as well as measures of positive and negative symptoms and community functioning. Results. TASIT data were analyzed using a 2 (group: patients versus healthy adults) x 2 (condition: sarcasm versus lie) repeated-measures ANOVA. The results show significant effects for group, condition, and the group x condition interaction. Compared to controls, patients performed significantly worse on sarcasm but not lie scenes. Within-group contrasts showed that patients performed significantly worse on sarcasm versus lie scenes; controls performed comparably on both. In patients, performance on TASIT showed a significant correlation with positive, but not negative, symptoms. The group and interaction effects remained significant when rerun with a subset of patients with low-level positive symptoms. The findings for a relationship between TASIT performance and community functioning were essentially negative. Conclusions. The findings replicate a prior demonstration of difficulty in the comprehension of sarcasm using a different test, but are not consistent with previous studies showing global ToM deficits in schizophrenia. C1 [Kern, R. S.; Green, M. F.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.; Subotnik, K. L.; Nuechterlein, K. H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA. [Kern, R. S.; Green, M. F.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.] Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, VISN 22, Los Angeles, CA USA. [Fiske, A. P.] Univ Calif Los Angeles, Dept Anthropol, Ctr Culture Brain & Dev, Los Angeles, CA 90024 USA. [Fiske, A. P.] Univ Calif Los Angeles, Ctr Behav Evolut & Culture, Los Angeles, CA 90024 USA. [Kee, K. S.] Calif State Univ, Channel Isl, CA USA. [Sergi, M. J.] Calif State Univ Northridge, Northridge, CA 91330 USA. [Nuechterlein, K. H.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Psychol, Los Angeles, CA 90024 USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Syst MIRECC 210, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU NIMH [P50 MH 66586] FX We thank the patients for their participation in the project, and Mike DeGroot, Robin Kite, Jeff Nishii, and Samantha Swain for their help in the data collection. The project was supported by an NIMH Center grant to K.H.N. (P50 MH 66586). NR 56 TC 42 Z9 42 U1 3 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD APR PY 2009 VL 39 IS 4 BP 645 EP 654 DI 10.1017/S0033291708003966 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 426EO UT WOS:000264691000011 PM 18694537 ER PT J AU Caska, CM Hendrickson, BE Wong, MH Ali, S Neylan, T Whooley, MA AF Caska, Catherine M. Hendrickson, Bethany E. Wong, Michelle H. Ali, Sadia Neylan, Thomas Whooley, Mary A. TI Anger Expression and Sleep Quality in Patients With Coronary Heart Disease: Findings From the Heart and Soul Study SO PSYCHOSOMATIC MEDICINE LA English DT Article DE anger expression; sleep quality; coronary heart disease ID CORTICOTROPIN-RELEASING HORMONE; POSTTRAUMATIC-STRESS-DISORDER; C-REACTIVE PROTEIN; BLOOD-PRESSURE; ATHEROSCLEROSIS RISK; CARDIOVASCULAR CONSEQUENCES; PERSEVERATIVE COGNITION; MYOCARDIAL-INFARCTION; CHRONIC ILLNESS; WHITE MALES AB Objective: To evaluate if anger expression affects sleep quality in patients with coronary heart disease (CHD). Research has indicated that poor sleep quality independently predicts adverse outcomes in patients with CHID. Risk factors for poor sleep quality include older age, socioeconomic factors, medical comorbidities, lack of exercise, and depression. Methods: We sought to examine the association of anger expression with sleep quality in 1020 outpatients with CHD from the Heart and Soul Study. We assessed anger-in, anger-out, and anger temperament, using the Spielberger State-Trait Anger Expression Inventory 2, and measured sleep quality, using items from the Cardiovascular Health Study and Pittsburgh Sleep Quality Index. We used multivariate analysis of variance to examine the association between anger expression and sleep quality, adjusting for potential confounding variables. Results: Each standard deviation (SD) increase in anger-in was associated with an 80% greater odds of poor sleep quality (odds ratio (OR)=1.8, 95% Confidence Interval (CI)=1.6-2.1; p<.0001). This association remained strong after adjusting for demographics, comorbidities, lifestyle factors, medications, cardiac function, depressive symptoms, anger-out, and anger temperament (adjusted OR=1.4, 95% CI=1.5-1.7; p=.001). In the same model, each SD increase in anger-out was associated with a 21% decreased odds of poor sleep quality (OR=0.79,95% CI=0.64-0.98; p=.03). Anger temperament was not independently associated with sleep quality. Conclusions: Anger suppression is associated with poor sleep quality in patients with CHD. Whether modifying anger expression can improve sleep quality or reduce cardiovascular morbidity and mortality deserves further study. C1 [Caska, Catherine M.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. [Hendrickson, Bethany E.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Wong, Michelle H.; Ali, Sadia; Neylan, Thomas; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA USA. [Neylan, Thomas] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Caska, CM (reprint author), Univ Utah, Dept Psychol, 380 S 1530 E,Room 502, Salt Lake City, UT 84112 USA. EM cmcaska@gmail.com FU Department of Veterans Affairs (Epidemiology Merit Review Program); National Heart, Lung and Blood Institute [R01 HI-079235]; Robert Wood Johnson Foundation; American Federation for Aging Research; Ischemia Research and Education Foundation; Nancy Kirwan Heart Research Fund FX Supported by grants from the Department of Veterans Affairs (Epidemiology Merit Review Program), the National Heart, Lung and Blood Institute (Grant R01 HI-079235), the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), the Ischemia Research and Education Foundation, and the Nancy Kirwan Heart Research Fund. None of these funding sources had any role in the collection of data, interpretation of results, or preparation of this manuscript. All funding was received by M.A.W. NR 63 TC 17 Z9 18 U1 3 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2009 VL 71 IS 3 BP 280 EP 285 DI 10.1097/PSY.0b013e31819b6a08 PG 6 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 434NQ UT WOS:000265281800005 PM 19251866 ER PT J AU Walker, RN Heuberger, RA AF Walker, Renee N. Heuberger, Roschelle A. TI Predictive Equations for Energy Needs for the Critically Ill SO RESPIRATORY CARE LA English DT Review DE indirect calorimetry; energy needs; prediction equations; mechanical ventilation; critical illness; nutrition support; review ID INTENSIVE-CARE-UNIT; RESTING METABOLIC-RATE; NUTRITIONAL SUPPORT; CRITICAL ILLNESS; ICU PATIENTS; INFLAMMATORY RESPONSE; HOSPITALIZED-PATIENTS; PARENTERAL-NUTRITION; INDIRECT CALORIMETRY; REFEEDING SYNDROME AB Nutrition may affect clinical outcomes in critically ill patients, and providing either more or fewer calories than the patient needs can adversely affect outcomes. Calorie need fluctuates substantially over the course of critical illness, and nutrition delivery is often influenced by: the risk of refeeding syndrome; a hypocaloric feeding regimen; lack of feeding access; intolerance of feeding; and feeding-delay for procedures. Lean body mass is the strongest determinant of resting energy expenditure, but age, sex, medications, and metabolic stress also influence the calorie requirement. Indirect calorimetry is the accepted standard for determining calorie requirement, but is unavailable or unaffordable in many centers. Moreover, indirect calorimetry is not infallible and care must be taken when interpreting the results. In the absence of calorimetry, clinicians use equations and clinical judgment to estimate calorie need. We reviewed 7 equations (American College of Chest Physicians, Harris-Benedict, Ireton-Jones 1992 and 1997, Penn State 1998 and 2003, Swinamer 1990) and their prediction accuracy. Understanding an equation's reference population and using the equation with similar patients are essential for the equation to perform similarly. Prediction accuracy among equations is rarely within 10% of the measured energy expenditure; however, in the absence of indirect calorimetry, a prediction equation is the best alternative. C1 [Walker, Renee N.] Michael E DeBakey Vet Affairs Med Ctr, Nutr Serv, Houston, TX 77030 USA. [Walker, Renee N.] Michael E DeBakey Vet Affairs Med Ctr, Food Serv, Houston, TX 77030 USA. [Heuberger, Roschelle A.] Cent Michigan Univ, Dept Human Environm Studies, Mt Pleasant, MI 48859 USA. RP Walker, RN (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Nutr Serv, 2002 Holcombe Blvd,Room 4A-340, Houston, TX 77030 USA. EM renee.walker2@va.gov NR 99 TC 37 Z9 41 U1 0 U2 5 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD APR PY 2009 VL 54 IS 4 BP 509 EP 521 PG 13 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 431PL UT WOS:000265075000014 PM 19327188 ER PT J AU Taylor, L Zhou, XH AF Taylor, Leslie Zhou, Xiao-Hua TI RELAXING LATENT IGNORABILITY IN THE ITT ANALYSIS OF RANDOMIZED STUDIES WITH MISSING DATA AND NONCOMPLIANCE SO STATISTICA SINICA LA English DT Article DE Causal inference; complier average causal effect; encouragement design study; flu shots; latent ignorability; missing data; noncompliance ID INSTRUMENTAL VARIABLES; CAUSAL INFERENCE; IDENTIFICATION AB In this paper we consider the problem in causal inference of estimating the local complier average causal effect (CACE) parameter in the setting of a randomized clinical trial with a binary outcome, cross-over noncompliance, and unintentional missing data on the responses. We focus oil the development of a moment estimator that relaxes the assumption of latent ignorability and incorporates sensitivity parameters that represent the relationship between potential outcomes and associated potential response indicators. If conclusions are insensitive over a range of logically possible values of the sensitivity parameters, then the number of interpretations of the data is reduced, and causal conclusions are more defensible. We illustrate our methods using a randomized encouragerne lit design study oil the effectiveness of an influenza vaccine. C1 [Taylor, Leslie] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Taylor, L (reprint author), Univ Washington, Dept Biostat, F-600 Hlth Sci Bldg,1705 NE Pacific St, Seattle, WA 98195 USA. EM taylorl@u.washington.edu; azhou@u.washington.edu NR 13 TC 1 Z9 1 U1 0 U2 1 PU STATISTICA SINICA PI TAIPEI PA C/O DR H C HO, INST STATISTICAL SCIENCE, ACADEMIA SINICA, TAIPEI 115, TAIWAN SN 1017-0405 J9 STAT SINICA JI Stat. Sin. PD APR PY 2009 VL 19 IS 2 BP 749 EP 764 PG 16 WC Statistics & Probability SC Mathematics GA 437EK UT WOS:000265469000019 ER PT J AU Cheng, EM Cohen, SN Lee, ML Vassar, SD Chen, AY AF Cheng, Eric M. Cohen, Stanley N. Lee, Martin L. Vassar, Stefanie D. Chen, Alex Y. TI No Improvement In Overall Use of Antiplatelet or Antithrombotic Agents Among United States Stroke Survivors from 2000-2005. SO STROKE LA English DT Meeting Abstract CT American-Association-International-Stroke Conference 2009 CY FEB 17-20, 2009 CL San Diego, CA SP Amer Assoc Int Stroke C1 [Cheng, Eric M.; Lee, Martin L.; Vassar, Stefanie D.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cohen, Stanley N.] Univ Nevada, Sch Med, Las Vegas, NV 89154 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD APR PY 2009 VL 40 IS 4 BP E263 EP E263 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 426LJ UT WOS:000264709500730 ER PT J AU Gopaldas, RR Atluri, PV Blaustein, AS Bakaeen, FG Huh, J Chu, D AF Gopaldas, Raja R. Atluri, Prasad V. Blaustein, Alvin S. Bakaeen, Faisal G. Huh, Joseph Chu, Danny TI Papillary Fibroelastoma of the Aortic Valve Operative Approaches upon Incidental Discovery SO TEXAS HEART INSTITUTE JOURNAL LA English DT Article DE Aortic valve/pathology/surgery/utrasonography; cardiac surgical procedures/methods; echocardiography, transesophageal; fibroma/complications/pathology/surgery/ultrasonography; heart neoplasms/diagnosis/pathology/surgery/therapy/ultrasonography ID ECHOCARDIOGRAPHIC CHARACTERISTICS; EXCISION AB Papillary fibroelastomas are the most common benign neoplasms of the cardiac valvular structures, and they are being recognized more frequently because of higher-resolution imaging technology Papillary fibroelastomas are associated with substantial complications that are secondary to systemic embolism. Incidentally discovered papillary fibroelastomas are treated on the basis of their size, mobility, and associated comorbidities and symptoms. Surgical resection should be offered to all patients who have symptoms and to asymptomatic patients who have pedunculated lesions or tumors larger than 1 cm in diameter Valve-sparing excision produces good long-term results in most instances. Herein, we present the case of a patient who was scheduled for elective myocardial revasculanzation and in whom an aortic valve papillary fibroelastoma was discovered incidentally during routine intraoperative transesophageal echocardiography. The timely recognition of this asymptomatic tumor enabled a modified operative approach: the patient underwent myocardial revascularization with concomitant valve-sparing resection of the tumor We discuss the pathophysiology of fibroelastomas of the aortic valve and operative approaches to the management of these tumors when they are discovered incidentally. (Tex Heart Inst J 2009,36(2):160-3) C1 [Gopaldas, Raja R.; Bakaeen, Faisal G.; Huh, Joseph; Chu, Danny] Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, Houston, TX 77030 USA. [Atluri, Prasad V.] Michael E DeBakey Vet Affairs Med Ctr, Dept Anesthesia, Houston, TX 77030 USA. [Blaustein, Alvin S.] Michael E DeBakey Vet Affairs Med Ctr, Div Cardiol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Chu, D (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM dchumd@gmail.com NR 19 TC 18 Z9 18 U1 0 U2 0 PU TEXAS HEART INST PI HOUSTON PA PO BOX 20345, HOUSTON, TX 77225-0345 USA SN 0730-2347 J9 TEX HEART I J JI Tex. Heart Inst. J. PD APR PY 2009 VL 36 IS 2 BP 160 EP 163 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 435GL UT WOS:000265331800019 PM 19436815 ER PT J AU Bhattacharya, D Ansari, IH Striker, R AF Bhattacharya, Dipankar Ansari, Israrul H. Striker, Rob TI The flaviviral methyltransferase is a substrate of Casein Kinase 1 SO VIRUS RESEARCH LA English DT Article DE Casein Kinase 1; Phosphorylation; Methyltransferase; RNA cap; Flavivirus ID PHOSPHORYLATION; PROTEINS; SEQUENCE; NS5; CK1; HYPERPHOSPHORYLATION; DETERMINANTS; METHYLATIONS; INHIBITORS; FAMILY AB Serine/Threonine phosphorylation of the nonstructural protein 5 (NS5) is a conserved feature of flaviviruses, but the identity and function(s) of the responsible kinase(s) remain unknown. Serine 56 in the methyltransferase domain of NS5 can be phosphorylated intracellularly, is conserved in all flaviviruses, and is a critical residue in the catalytic mechanism. A negative charge at this residue inactivates the 2'-0 methyltransferase activity necessary to form a 5' cap structure of the viral RNA. Here we show pharmacologic inhibition of Casein Kinase 1 (CK1) suppresses yellow fever virus (YFV) production. We also demonstrate the alpha isoform of Casein Kinase I (CK1 alpha), a kinase previously identified as phosphorylating Hepatitis C Virus NS5A protein, also phosphorylates serine 56 of YFV methyltransferase. Overall these results suggest CK1 activity can influence flaviviral replication. Published by Elsevier B.V. C1 [Bhattacharya, Dipankar; Ansari, Israrul H.; Striker, Rob] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Striker, Rob] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. RP Striker, R (reprint author), Univ Wisconsin, Dept Med, 1550 Linden Dr, Madison, WI 53706 USA. EM rtstriker@wisc.edu FU NIH/NIAID Regional Center of Excellence for Biodefense; Emerging Infectious Diseases Research (RCE) Program; Region V 'Great Lakes' RCE [U54-AI057153]; Wisconsin Partnership Fund for a Healthy Future FX This work was sponsored by the NIH/NIAID Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) Program. The authors wish to acknowledge membership within and support from the Region V 'Great Lakes' RCE (NIH award U54-AI057153). We thank the UW Madison Biotechnology Mass Spectrometry facility and the Human Proteomics Mass Spectrometry Facility supported by the "The Wisconsin Partnership Fund for a Healthy Future" for technical assistance, Laura Hogan for editorial suggestions and Richard Kuhn for the anti NS3 YFV antibody. NR 24 TC 10 Z9 10 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD APR PY 2009 VL 141 IS 1 BP 101 EP 104 DI 10.1016/j.virusres.2009.01.002 PG 4 WC Virology SC Virology GA 430MJ UT WOS:000264992900013 PM 19185594 ER PT J AU Yang, LD Belaguli, N Berger, DH AF Yang, Linda Belaguli, Narasimhaswamy Berger, David H. TI MicroRNA and Colorectal Cancer SO WORLD JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT Molecular Surgeon Symposium on Personalized Genomic Medicine and Surgery CY APR 12, 2008 CL Baylor Coll Med, Houston, TX HO Baylor Coll Med ID CHRONIC LYMPHOCYTIC-LEUKEMIA; COLON-CANCER; CAENORHABDITIS-ELEGANS; REGULATED MICRORNA; RNA-INTERFERENCE; BURKITT-LYMPHOMA; NUCLEAR EXPORT; GENE; EXPRESSION; CELLS AB MicroRNAs are small 19 to 22 nucleotide sequences of RNA that participate in the regulation of cell differentiation, cell cycle progression, and apoptosis. MicroRNAs act much like small interfering RNA, annealing with RISC, to cleave messenger RNA, and microRNAs exert translational inhibition that is incompletely understood. They are important factors in tumorigenesis and have been the subject of research in many types of cancers, including colon cancer. MicroRNAs may be abnormally down-regulated or up-regulated in colon-cancer tissue. Artificial dysregulation of certain microRNAs will trigger tumorigenesis or apoptosis depending on which microRNA is manipulated. Although the natural mechanisms for the dysregulation of microRNAs is still largely unknown, one theory tested in colon cancers proposes that DNA hypermethylation leads to down-regulation of certain microRNAs. Specific microRNA expression patterns help characterize specific cancers and may be used as a prognostication factor and in following patient response to 5-fluorouracil chemotherapy. This article reviews the existing literature pertaining to the study of microRNA in colorectal cancer. C1 [Yang, Linda; Belaguli, Narasimhaswamy; Berger, David H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. RP Berger, DH (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, 112OCL,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dhb@bcm.tmc.edu FU NCI NIH HHS [R13 CA132572] NR 65 TC 72 Z9 77 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD APR PY 2009 VL 33 IS 4 BP 638 EP 646 DI 10.1007/s00268-008-9865-5 PG 9 WC Surgery SC Surgery GA 419FW UT WOS:000264205600005 PM 19123024 ER PT J AU Sergi, MJ Fiske, AP Horan, WP Kern, RS Kee, KS Subotnik, KL Nuechterlein, KH Green, MF AF Sergi, Mark J. Fiske, Alan P. Horan, William P. Kern, Robert S. Kee, Kimmy S. Subotnik, Kenneth L. Nuechterlein, Keith H. Green, Michael F. TI Development of a measure of relationship perception in schizophrenia SO PSYCHIATRY RESEARCH LA English DT Article DE Schizophrenia; Relationship perception; Relationships Across Domains; Social cognition; Relational models theory; Community functioning ID SOCIAL-PERCEPTION; NEUROCOGNITIVE DEFICITS; MODELS THEORY; COGNITION; RECOGNITION; PERFORMANCE; MEDIATOR; ERRORS; TESTS; FORMS AB Relationships Across Domains (RAD) is a new measure of competence in relationship perception that may be used to assess clinically stable persons with schizophrenia and healthy persons. The structure and content of the RAD are grounded in relational models theory, a well-validated theory of social relations. The 75-item RAD contains 25 vignettes and can be administered in approximately 35 min. The RAD requires participants to implicitly identify the relational model of a dyad described in a brief vignette and infer how the members of the dyad are likely to behave in three other social contexts. The RAD demonstrated good internal consistency in schizophrenia outpatients and healthy participants matched to the outpatients in age and education. The schizophrenia outpatients performed more poorly on the RAD than two healthy comparison groups, supporting the ability of the RAD to discriminate between clinical and non-clinical populations. The schizophrenia patients' performance on the RAD was moderately related to reading ability and several domains of community functioning. (c) 2008 Elsevier Ireland Ltd. All fights reserved. C1 [Sergi, Mark J.] Calif State Univ Northridge, Dept Psychol, Northridge, CA 91330 USA. [Sergi, Mark J.; Horan, William P.; Kern, Robert S.; Kee, Kimmy S.; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fiske, Alan P.] Univ Calif Los Angeles, Dept Anthropol, Ctr Culture Brain & Dev, Los Angeles, CA USA. [Fiske, Alan P.] Univ Calif Los Angeles, Ctr Behav Evolut & Culture, Los Angeles, CA USA. [Horan, William P.; Kern, Robert S.; Kee, Kimmy S.; Subotnik, Kenneth L.; Nuechterlein, Keith H.; Green, Michael F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Kee, Kimmy S.] Calif State Univ Channel Isl, Psychol Program, Camarillo, CA USA. [Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA. RP Sergi, MJ (reprint author), Calif State Univ Northridge, Dept Psychol, 18111 Nordhoff St, Northridge, CA 91330 USA. EM mark.sergi@csun.edu FU National Institute of Mental Health Translational Research Center [MH66286]; National Institute of Mental Health [MH43292, MH65707]; Department of Veterans Affairs VISN-22 Mental Illness Research Education Clinical Center FX This research was supported by the National Institute of Mental Health Translational Research Center (MH66286; Keith H. Nuechterlein, Director), Dr. Green's grants from the National Institute of Mental Health (MH43292 and MH65707), and the Department of Veterans Affairs VISN-22 Mental Illness Research Education Clinical Center. The authors thank Jim Mintz, Ph.D., of the UCLA Sernel Neuropsychiatric Institute Biostatistical Core for his consultation regarding the construction of Relationships Across Domains. The authors thank Nicholas Haslam, Ph.D., for his advice on the development of the RAD and his comments on an earlier version of this paper. The authors also thank Karen Cornelius, Psy.D., Shauna Davidson, M.A., Mark McGee, B.A., and Poorang Nori, B.A., for their assistance with the recruitment of participants and/or the collection and coding of data. NR 40 TC 16 Z9 17 U1 2 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAR 31 PY 2009 VL 166 IS 1 BP 54 EP 62 DI 10.1016/j.psychres.2008.03.010 PG 9 WC Psychiatry SC Psychiatry GA 425CT UT WOS:000264615300007 PM 19193447 ER PT J AU Haley, RW Spence, JS Carmack, PS Gunst, RF Schucany, WR Petty, F Devous, MD Bonte, FJ Trivedi, MH AF Haley, Robert W. Spence, Jeffrey S. Carmack, Patrick S. Gunst, Richard F. Schucany, William R. Petty, Frederick Devous, Michael D., Sr. Bonte, Frederick J. Trivedi, Madhukar H. TI Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Tomography, emission-computed, single-photon; Physostigmine; Brain diseases; Regional blood flow; Persian Gulf syndrome; Veterans ID CEREBRAL BLOOD-FLOW; US ARMY VETERANS; FUNCTIONAL STATUS; MR SPECTROSCOPY; CASE-DEFINITION; SARIN; PHYSOSTIGMINE; EXPOSURE; ILLNESS; TALAIRACH AB Several case definitions of chronic illness in veterans of the 1991 Persian Gulf War have been linked epidemiologically with environmental exposure to cholinesterase-inhibiting chemicals, which cause chronic changes in cholinergic receptors in animal models. Twenty-one chronically ill Gulf War veterans (5 with symptom complex 1, 11 with complex 2, and 5 with complex 3) and 17 age-, sex- and education-matched controls, underwent an 99mTc-HMPAO-SPECT brain scan following infusion of saline and >48 h later a second scan following infusion of physostigmine in saline. From each SPECT image mean normalized regional cerebral blood flow (nrCBF) from 39 small blocks of correlated voxels were extracted with geostatistical spatial modeling from eight deep gray matter structures in each hemisphere. Baseline nrCBF in symptom complex 2 was lower than controls throughout deep structures. The change in nrCBF after physostigmine (challenge minus baseline) was negative in complexes I and 3 and controls but positive in complex 2 in some structures. Since effects were opposite in different groups, no finding typified the entire patient sample. A hold-out discriminant model of nrCBF from 17 deep brain blocks predicted membership in the clinical groups with sensitivity of 0.95 and specificity of 0.82. Gulf War-associated chronic encephalopathy in a subset of veterans may be due to neuronal dysfunction, including abnormal cholinergic response, in deep brain structures. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Haley, Robert W.; Spence, Jeffrey S.; Carmack, Patrick S.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Epidemiol, Dallas, TX 75390 USA. [Haley, Robert W.; Spence, Jeffrey S.; Carmack, Patrick S.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Spence, Jeffrey S.; Carmack, Patrick S.; Gunst, Richard F.; Schucany, William R.] So Methodist Univ, Dept Stat Sci, Dallas, TX 75275 USA. [Petty, Frederick; Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Petty, Frederick] US Dept Vet Affairs, Med Ctr, Dallas, TX USA. [Devous, Michael D., Sr.; Bonte, Frederick J.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Nucl Med Ctr, Dallas, TX 75390 USA. RP Haley, RW (reprint author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Epidemiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM Robert.Haley@UTSouthwestern.edu RI Haley, Robert/P-9026-2014 OI Haley, Robert/0000-0001-8849-9579 NR 59 TC 19 Z9 21 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD MAR 31 PY 2009 VL 171 IS 3 BP 207 EP 220 DI 10.1016/j.pscychresns.2008.05.004 PG 14 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 426HG UT WOS:000264698000007 PM 19230625 ER PT J AU Turenius, CI Htut, MM Prodon, DA Ebersole, PL Ngo, PT Lara, RN Wilczynski, JL Stanley, BG AF Turenius, Christine I. Htut, Myat M. Prodon, Daniel A. Ebersole, Priscilla L. Ngo, Phuong T. Lara, Raul N. Wilczynski, Jennifer L. Stanley, B. Glenn TI GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation SO BRAIN RESEARCH LA English DT Article DE GABA; Receptor; Feeding; Suppression; Lateral hypothalamus; Rat ID D-ASPARTIC ACID; ELICITS FEEDING-BEHAVIOR; NUCLEUS-ACCUMBENS SHELL; RAT HYPOTHALAMUS; FOOD-INTAKE; REVERSE MICRODIALYSIS; NEURONS; GLUTAMATE; MUSCIMOL; SYSTEMS AB In the lateral hypothalamus (LH), the inhibitory amino acid neurotransmitter, GABA, has had a long-standing presumptive role as an inhibitor of food intake. However, minimal investigation has been focused on GABA, especially as compared to the attention received by many peptide transmitters. To begin to address this deficiency in the understanding of the role of GABA in the LH and feeding, we report that antagonism of GABA(A) receptors in the rat LH elicits feeding, consistent with previous findings, and provide evidence for the behavioral selectivity of this effect. We extend previous findings that activation of LH GABA(A) receptors suppresses feeding, in particular by showing that night-time and deprivation-induced eating are dramatically suppressed. Finally, we show that chronic activation, but not blockade, of the LH GABA(A) receptors leads to a reduction in 24 h food intake with concomitant body weight loss. These data collectively suggest that activation of GABA(A) receptors plays a fundamental role in controlling food intake and body weight, a role that has previously been somewhat underestimated. Published by Elsevier B.V. C1 [Turenius, Christine I.; Stanley, B. Glenn] Univ Calif Riverside, Interdept Neurosci Grad Program, Riverside, CA 92521 USA. [Htut, Myat M.; Prodon, Daniel A.; Ebersole, Priscilla L.; Ngo, Phuong T.; Lara, Raul N.; Wilczynski, Jennifer L.; Stanley, B. Glenn] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA. [Stanley, B. Glenn] Univ Calif Riverside, Dept Psychol, Riverside, CA 92521 USA. RP Turenius, CI (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM turenius@u.washington.edu NR 51 TC 24 Z9 24 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD MAR 25 PY 2009 VL 1262 BP 16 EP 24 DI 10.1016/j.brainres.2009.01.016 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 429XY UT WOS:000264954600003 PM 19401161 ER PT J AU Dobscha, SK Corson, K Perrin, NA Hanson, GC Leibowitz, RQ Doak, MN Dickinson, KC Sullivan, MD Gerrity, MS AF Dobscha, Steven K. Corson, Kathryn Perrin, Nancy A. Hanson, Ginger C. Leibowitz, Ruth Q. Doak, Melanie N. Dickinson, Kathryn C. Sullivan, Mark D. Gerrity, Martha S. TI Collaborative Care for Chronic Pain in Primary Care A Cluster Randomized Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CHRONIC NONCANCER PAIN; CLINICALLY IMPORTANT DIFFERENCE; IMPROVING PRIMARY-CARE; LOW-BACK-PAIN; DEPRESSION CARE; OUTCOME MEASURES; CHRONIC ILLNESS; SCREENING-TEST; HEALTH-STATUS; MANAGEMENT AB Context Chronic pain is common in primary care patients and is associated with distress, disability, and increased health care use. Objective To assess whether a collaborative intervention can improve chronic pain related outcomes, including comorbid depression severity, in a Department of Veterans Affairs primary care setting. Design, Setting, and Participants Cluster randomized controlled trial of a collaborative care assistance with pain treatment intervention vs treatment as usual at 5 primary care clinics of 1 Department of Veterans Affairs Medical Center. Forty-two primary care clinicians were randomized to the assistance with pain treatment intervention group or the treatment as usual group. The 401 patients had musculoskeletal pain diagnoses, moderate or greater pain intensity, and disability lasting 12 weeks or longer and were assigned to the same treatment groups as their clinicians. Recruitment occurred from January 2006 to January 2007 and follow-up concluded in January 2008. Intervention Assistance with pain treatment included a 2-session clinician education program, patient assessment, education and activation, symptom monitoring, feedback and recommendations to clinicians, and facilitation of specialty care. Main Outcome Measures Changes over 12 months in pain-related disability (Roland-Morris Disability Questionnaire, range of 0-24), pain intensity (Chronic Pain Grade [CPG] Pain Intensity subscale, range of 0-100), and depression (Patient Health Questionnaire 9 [PHQ-9], range of 0-27), measured as beta coefficients (difference in slopes in points per month). Results Intervention patients had a mean (SD) of 10.6 (4.5) contacts with the assistance with pain treatment team. Compared with the patients receiving treatment as usual, intervention patients showed greater improvements in pain-related disability (Roland-Morris Disability Questionnaire beta, -0.101 [95% confidence interval {CI}, -0.163 to -0.040]; P=.004 and CPG Pain Intensity subscale beta, -0.270 [95% CI, -0.480 to -0.061]; P=.01). Among patients with baseline depression (PHQ-9 score >= 10), there was greater improvement in depression severity in patients receiving the intervention compared with patients receiving treatment as usual (PHQ-9 beta, -0.177 [95% CI, -0.295 to -0.060]; P=.003). The differences in scores between baseline and 12 months for the assistance with pain treatment intervention group and the treatment as usual group, respectively, were -1.4 vs -0.2 for the Roland-Morris Disability Questionnaire, -4.7 vs -0.6 for the CPG Pain Intensity subscale, and -3.7 vs -1.2 for PHQ-9. Conclusion The assistance with pain treatment collaborative intervention resulted in modest but statistically significant improvement in a variety of outcome measures. Trial Registration clinicaltrials.gov Identifier: NCT00129480 C1 [Dobscha, Steven K.; Corson, Kathryn; Leibowitz, Ruth Q.; Dickinson, Kathryn C.; Gerrity, Martha S.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA. [Doak, Melanie N.] Portland VA Med Ctr, Div Primary Care, Portland, OR 97239 USA. [Gerrity, Martha S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97239 USA. [Dobscha, Steven K.; Corson, Kathryn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Doak, Melanie N.; Gerrity, Martha S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Perrin, Nancy A.; Hanson, Ginger C.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Sullivan, Mark D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM steven.dobscha@va.gov FU Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service [PMI 03-195, REA 06-174]; Greenwall Foundation FX Funding/Support: This research was supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Projects PMI 03-195 and REA 06-174. Some research team members received training on chronic pain communication skills developed with a grant from the Greenwall Foundation. NR 67 TC 130 Z9 131 U1 5 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 25 PY 2009 VL 301 IS 12 BP 1242 EP 1252 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 423JO UT WOS:000264492800024 PM 19318652 ER PT J AU Sinha, S Subramanian, S Miller, L Proctor, TM Roberts, C Burrows, GG Vandenbark, AA Offner, H AF Sinha, Sushmita Subramanian, Sandhya Miller, Lisa Proctor, Thomas M. Roberts, Chris Burrows, Gregory G. Vandenbark, Arthur A. Offner, Halina TI Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand SO JOURNAL OF NEUROSCIENCE LA English DT Article ID PROTEOLIPID PROTEIN; DENDRITIC CELLS; TRANSGENIC MICE; SJL MICE; INTERLEUKIN-10; PEPTIDE; MECHANISMS; TOLERANCE; SCLEROSIS; DESIGN AB Recombinant T-cell receptor ligands (RTLs) can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in an antigen-specific manner, and are currently in clinical trials for treatment of subjects with multiple sclerosis (MS). Antigen specificity of RTL raises the question as to whether this treatment would be successful in MS patients where target antigens are unknown. Using spinal cord homogenate or combinations of two different peptides to induce disease, we found that treatment with single RTL could reverse EAE as long as targeted T-cells were present. Therapy with three different RTLs each caused a significant reduction in IL-17 and increases in IL-10 and IL-13 in peptide-activated splenocytes, reduced proliferation of both cognate and bystander specificities of lymph node cells, and reduced inflammatory lesions and secreted IL-17 and IL-2 from peptide-activated spinal cord cells. These results show that treatment with single RTLs can induce a cytokine switch in cognate T-cells that inhibits both the target and bystander T-cells, providing new evidence for the potential applicability of RTL therapy in MS. C1 [Sinha, Sushmita; Subramanian, Sandhya; Miller, Lisa; Proctor, Thomas M.; Roberts, Chris; Vandenbark, Arthur A.; Offner, Halina] Vet Affairs Med Ctr, Portland, OR 97239 USA. [Sinha, Sushmita; Subramanian, Sandhya; Miller, Lisa; Roberts, Chris; Burrows, Gregory G.; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Burrows, Gregory G.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Proctor, Thomas M.; Burrows, Gregory G.; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Tykeson Multiple Sclerosis Res Lab, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU National Multiple Sclerosis Society; National Multiple Sclerosis Society Postdoctoral Fellowship [FG1749-A-1, RG3794A, RG3468]; National Institutes of Health [NS47661, AI43960, NS41965, NS46877] FX Dr. Sinha is a Postdoctoral Fellow of the National Multiple Sclerosis Society, and this work was supported in part by National Multiple Sclerosis Society Postdoctoral Fellowship FG1749-A-1 and Grants RG3794A and RG3468; National Institutes of Health Grants NS47661, AI43960, NS41965, and NS46877; The Nancy Davis MS Center Without Walls; and the Biomedical Laboratory R&D Service, Department of Veterans Affairs. We thank Eva Niehaus for assistance in preparing the manuscript. NR 22 TC 22 Z9 23 U1 0 U2 1 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAR 25 PY 2009 VL 29 IS 12 BP 3816 EP 3823 DI 10.1523/JNEUROSCI.5812-08.2009 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 424DE UT WOS:000264544900016 PM 19321778 ER PT J AU Chirinos, JA Franklin, SS Townsend, RR Raij, L AF Chirinos, Julio A. Franklin, Stanley S. Townsend, Raymond R. Raij, Leopoldo TI Body Mass Index and Hypertension Hemodynamic Subtypes in the Adult US Population SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID PULSE-WAVE VELOCITY; ISOLATED SYSTOLIC HYPERTENSION; INCREASED ARTERIAL STIFFNESS; NUTRITION EXAMINATION SURVEY; CORONARY-HEART-DISEASE; METABOLIC SYNDROME; AORTIC STIFFNESS; BLOOD-PRESSURE; INDEPENDENT PREDICTOR; CARDIOVASCULAR MORTALITY AB Background: Obesity produces various hemodynamic abnormalities that may impact hypertension subtypes. Similarly, the study of hypertension subtypes provides important information regarding the relative importance of hemodynamic abnormalities contributing to obesity-related hypertension. Methods: Cross-sectional analysis of adults enrolled in the Third National Health and Nutrition Examination Survey (NHANES III) (n= 16 545) and NHANES 1999-2004 (n= 12 137). We examined the relationship between body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) and the risk of hypertension and hemodynamic subtypes: isolated systolic hypertension (ISH), isolated diastolic hypertension (IDH), and systodiastolic hypertension (SDH). Results: In NHANES 1999-2004, the odds ratio (OR) for hypertension for every 5-unit increase in BMI was 1.45 (95% confidence interval [CI], 1.39-1.52) (P <.001). However, the magnitude of the relative increase in the odds of hypertension was higher among younger adults. Among patients with hypertension, increasing BMI was a significant predictor of IDH or SDH (OR for IDH or SDH, 1.04; 95% CI, 1.02-1.06) (P <.001), as opposed to ISH. Isolated systolic hypertension represented a minority of hypertension cases in obese men (38.9%; 95% CI, 30.9-47.6) but remained the most prevalent type in obese women (62.1%; 95% CI, 52.4%-71.0%) (P <.001), despite a significant relative decrease in the frequency of ISH with increasing BMI in both sexes. Findings in NHANES III were very similar. Conclusions: Isolated diastolic hypertension and SDH account for most cases of obesity-related hypertension, suggesting that determinants of mean arterial pressure account for the major burden of obesity-related hypertension in US adult men. These findings should be considered in the design of clinical trials and therapeutic strategies for obesity-related hypertension. Further studies should assess determinants of mean arterial pressure in obesity and the role of sex in the pathogenesis of obesity-related hypertension. C1 [Chirinos, Julio A.] Philadelphia Vet Affairs Med Ctr, Div Cardiol, Dept Med, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Univ Penn, Sch Med, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA. [Townsend, Raymond R.] Univ Penn, Sch Med, Dept Med, Div Nephrol, Philadelphia, PA 19104 USA. [Franklin, Stanley S.] Univ Calif Irvine, Heart Dis Prevent Program, Irvine, CA 92717 USA. [Raij, Leopoldo] Univ Miami, Miller Sch Med, Dept Med, Div Cardiol, Miami, FL 33136 USA. [Raij, Leopoldo] Miami Vet Affairs Med Ctr, Miami, FL USA. RP Chirinos, JA (reprint author), Philadelphia Vet Affairs Med Ctr, Div Cardiol, Dept Med, 8B111,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu FU Cardiodynamics Inc; Atcor Medical Inc FX Dr Chirinos has received minor research support from Cardiodynamics Inc and Atcor Medical Inc, companies that manufacture devices for noninvasive hemodynamic measurements. NR 56 TC 22 Z9 24 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 23 PY 2009 VL 169 IS 6 BP 580 EP 586 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 423HO UT WOS:000264487600008 PM 19307521 ER PT J AU Brice, SE Alford, CW Cowart, LA AF Brice, Sarah E. Alford, Charlene W. Cowart, L. Ashley TI Modulation of Sphingolipid Metabolism by the Phosphatidylinositol-4-phosphate Phosphatase Sac1p through Regulation of Phosphatidylinositol in Saccharomyces cerevisiae SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID DOMAIN PROTEINS SLM1; DE-NOVO; HEAT-STRESS; SERINE PALMITOYLTRANSFERASE; ACTIN CYTOSKELETON; LIPID PHOSPHATASE; FREE SPHINGOSINE; PLASMA-MEMBRANE; DISTINCT ROLES; YEAST AB Sphingolipids and phosphoinositides both play signaling roles in Saccharomyces cerevisiae. Although previous data indicate independent functions for these two classes of lipids, recent genetic studies have suggested interactions between phosphatidylinositol (PtdIns) phosphate effectors and sphingolipid biosynthetic enzymes. The present study was undertaken to further define the effects of phosphatidylinositol 4-phosphate (PtdIns(4)P) metabolism on cell sphingolipid metabolism. The data presented indicate that deletion of SAC1, a gene encoding a PtdIns(4) P phosphatase, increased levels of most sphingolipid species, including sphingoid bases, sphingoid base phosphates, and phytoceramide. In contrast, sac1 Delta dramatically reduced inositol phosphosphingolipids, which result from the addition of a PtdIns-derived phosphoinositol head group to ceramides through Aur1p. Deletion of SAC1 decreased PtdIns dramatically in both steady-state and pulse labeling studies, suggesting that the observed effects on sphingolipids may result from modulation of the availability of PtdIns as a substrate for Aur1p. Supporting this hypothesis, acute attenuation of PtdIns(4) P production through Stt4p immediately increased PtdIns and subsequently reduced sphingoid bases. This reduction was overcome by the inhibition of Aur1p. Moreover, modulation of sphingoid bases through perturbation of PtdIns(4) P metabolism initiated sphingolipid-dependent biological effects, supporting the biological relevance for this route of regulating sphingolipids. These findings suggest that, in addition to potential signaling effects of PtdInsP effectors on sphingolipid metabolism, PtdIns kinases may exert substantial effects on cell sphingolipid profiles at a metabolic level through modulation of PtdIns available as a substrate for complex sphingolipid synthesis. C1 [Brice, Sarah E.; Alford, Charlene W.; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM cowartl@musc.edu FU Centers of Biomedical Research Excellence in lipidomics and pathobiology at the Medical University of South Carolina FX This work was supported in part by the Centers of Biomedical Research Excellence in lipidomics and pathobiology at the Medical University of South Carolina NR 48 TC 38 Z9 40 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 20 PY 2009 VL 284 IS 12 BP 7588 EP 7596 DI 10.1074/jbc.M808325200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 419CB UT WOS:000264195600021 PM 19139096 ER PT J AU Goebel, M Stengel, A Wang, LX Lambrecht, NWG Tache, Y AF Goebel, Miriam Stengel, Andreas Wang, Lixin Lambrecht, Nils W. G. Tache, Yvette TI Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei SO NEUROSCIENCE LETTERS LA English DT Article DE Brain; Spinal cord; Immunohistochemistry; mRNA expression; Nucleobindin-2; Rat ID PARAVENTRICULAR NUCLEUS; SATIETY MOLECULE; FOS EXPRESSION; HYPOTHALAMUS; NEURONS; NUCLEOBINDIN-2; VASOPRESSIN; OXYTOCIN; RELEASE; PAIN AB Nesfatin-1 is one of the peptide products of posttranslational processing of the nucleobindin-2 (NUCB2) gene, suggested to have physiological relevance to suppress food intake and body weight gain in rats. Nesfatin-1-immunoreactive cells have been found in distinct nuclei in the rat brain related to circuitries regulating food intake. Here, we report novel yet undescribed localization of NUCB2/nesfatin-1 at the mRNA and protein level in the rat central nervous system. Immunohistochemical staining revealed the localization of NUCB2/nesfatin-1 in the piriform and insular cortex, endopiriform nucleus, nucleus accumbens, lateral septum, bed nucleus of stria terminalis, central amygdaloid nucleus, medial preoptic area, dorsal raphe nucleus, ambiguus nucleus, ventrolateral medulla and gigantocellular reticular nucleus, as well as Purkinje-cells of the cerebellum. In the spinal cord, nesfatin-1 immunoreactivity (IR) was found in both sympathetic and parasympathetic preganglionic neuronal groups and in the dorsal area X from lower thoracic to sacral segments. The immunohistochemical results were confirmed by RT-PCR in the central amygdaloid nucleus, nucleus accumbens, cerebellum and lumbar spinal cord microdissected by punch technique. The features and distributions of nesfatin-1 IR and mRNA expression in the brain and spinal cord suggest that NUCB2/nesfatin-1 could play a wider role in autonomic regulation of visceral-endocrine functions besides food intake. Published by Elsevier Ireland Ltd. C1 [Goebel, Miriam; Stengel, Andreas; Wang, Lixin; Lambrecht, Nils W. G.; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Ctr Neurovisceral Sci & Womens Hlth, Ctr Neurobiol Stress,Digest Dis Div,Dept Med,Davi, Los Angeles, CA USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, Cure Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu OI Lambrecht, Nils/0000-0002-1275-1384 FU German Research Foundation [1718/1-1, STE 1765/1-1]; VA Research Career Scientist Award, Department of Veterans Affairs Merit Award [NIHDK 33061, DK-41301] FX This work was supported by German Research Foundation grant GO 1718/1-1 (M.G.), grant STE 1765/1-1 (A.S.) and the VA Research Career Scientist Award, Department of Veterans Affairs Merit Award (Y.T.), NIHDK 33061 (Y.T.) and Center grant DK-41301 (Animal Core, Y.T.). We are grateful to Mrs. Honghui Liang for her excellent technical support. NR 25 TC 92 Z9 98 U1 2 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD MAR 20 PY 2009 VL 452 IS 3 BP 241 EP 246 DI 10.1016/j.neulet.2009.01.064 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 425QZ UT WOS:000264653500006 PM 19348732 ER PT J AU Brown, CJ Roth, DL Allman, RM Sawyer, P Ritchie, CS Roseman, JM AF Brown, Cynthia J. Roth, David L. Allman, Richard M. Sawyer, Patricia Ritchie, Christine S. Roseman, Jeffrey M. TI Trajectories of Life-Space Mobility After Hospitalization SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID OLDER PATIENTS; FUNCTIONAL DECLINE; MULTICOMPONENT INTERVENTION; RANDOMIZED-TRIAL; NATURAL-HISTORY; HEART-FAILURE; ACUTE-CARE; OUTCOMES; DELIRIUM; ADULTS AB Background: Life space is a measure of where a person goes, the frequency of going there, and the dependency in getting there. It may be a more accurate measure of mobility in older adults because it reflects participation in society as well as physical ability. Objective: To assess effects of hospitalization on life space in older adults, and to compare life-space trajectories associated with surgical and nonsurgical hospitalizations. Design: Prospective observational study. Setting: Central Alabama. Participants: 687 community-dwelling Medicare beneficiaries at least 65 years of age with surgical (n = 44), nonsurgical (n = 167), or no (n = 476) hospitalizations. Measurements: Life-Space Assessment (LSA) scores before and after hospitalization (range, 0 to 120; higher scores reflect greater mobility). Results: Mean age of participants was 74.6 years (SD, 6.3). Fifty percent were black, and 46% were male. Before hospitalization, adjusted LSA scores were similar in participants with surgical and nonsurgical admissions. Life-space assessment scores decreased in both groups immediately after hospitalization; however, participants with surgical hospitalizations had a greater decrease in scores (12.1 more points [95% CI, 3.6 to 20.7 points]; P = 0.005) than those with nonsurgical hospitalizations. However, participants with surgical hospitalizations recovered more rapidly over time (gain of 4.7 more points [CI, 2.0 to 7.4 points] per ln [week after discharge]; P < 0.001). Score recovery for participants with nonsurgical hospitalizations did not significantly differ from the null (average recovery, 0.7 points [CI,-0.6 to 1.9 points] per ln [week after discharge]). Limitation: Life space immediately before and after hospitalization was self-reported, often after hospital discharge. Conclusion: Hospitalization decreases life space in older adults. Surgical hospitalizations are associated with immediate marked life-space declines followed by rapid recovery, in contrast to nonsurgical hospitalizations, which are associated with more modest immediate declines and little evidence of recovery after several years of follow-up. C1 Birmingham & Atlanta Vet Affairs Geriatr Res, Birmingham, AL USA. Ctr Clin, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. RP Brown, CJ (reprint author), Birmingham Vet Affairs Med Ctr, 11G,700 S 19th St, Birmingham, AL 35233 USA. EM cbrown@aging.uab.edu; droth@uab.edu FU National Institute on Aging [R01 AG015062]; Veterans Affairs Research Career Development Award [E4-3842VA]; John A. Hartford Foundation FX Grant Support: By a Veterans Affairs Research Career Development Award (E4-3842VA) (Dr. Brown) and a John A. Hartford Foundation-funded Southeast Center of Excellence in Geriatric Medicine Special Fellows grant (Dr. Brown). The UAB Study of Aging is funded through a grant from the National Institute on Aging (R01 AG015062). NR 40 TC 59 Z9 59 U1 2 U2 6 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 17 PY 2009 VL 150 IS 6 BP 372 EP W67 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 423AJ UT WOS:000264468500002 PM 19293070 ER PT J AU Lee, TA Pickard, AS Au, DH AF Lee, Todd A. Pickard, A. Simon Au, David H. TI How Much Did Biases in the Study of Chronic Obstructive Pulmonary Disease Medications and Mortality Affect the Outcome? Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID RACIAL-DIFFERENCES; HEALTH C1 [Lee, Todd A.] Edward Hines Jr VA Hosp, Hines, IL 60141 USA. [Pickard, A. Simon] Univ Illinois, Chicago, IL 60637 USA. [Au, David H.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98174 USA. RP Lee, TA (reprint author), Edward Hines Jr VA Hosp, Hines, IL 60141 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 17 PY 2009 VL 150 IS 6 BP 426 EP 427 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 423AJ UT WOS:000264468500015 ER PT J AU Bautista, LE Herrera, VM Casas, JP Miranda, J Perel, P Pichardo, R Gonzalez, A Sanchez, JR Ferreccio, C Aguilera, X Silva, E Orostegui, M Gomez, LF Chirinos, JA Medina-Lezama, J Perez, CM Suarez, E Ortiz, AP Rosero, L Schapochnik, N Ortiz, Z Ferrante, D Diaz, M AF Bautista, Leonelo E. Herrera, Victor M. Casas, Juan P. Miranda, Jaime Perel, Pablo Pichardo, Rafael Gonzalez, Angel Sanchez, Jose R. Ferreccio, Catterina Aguilera, Ximena Silva, Egle Orostegui, Myriam Gomez, Luis F. Chirinos, Julio A. Medina-Lezama, Josefina Perez, Cynthia M. Suarez, Erick Ortiz, Ana P. Rosero, Luis Schapochnik, Norberto Ortiz, Zulma Ferrante, Daniel Diaz, Margarita TI Obesity and Blood Pressure: Ethnicity Does Matter SO CIRCULATION LA English DT Meeting Abstract CT Joint Nutrition, Physical Activity and Metabolism Conference/49th Cardiovascular Disease Epidemiology and Prevention of the American-Heart-Association CY MAR 10-14, 2009 CL Palm Harbor, FL SP Amer Heart Assoc C1 [Bautista, Leonelo E.; Herrera, Victor M.] Univ Wisconsin, Madison, WI USA. [Casas, Juan P.; Miranda, Jaime; Perel, Pablo] London Sch Hyg & Trop Med, London WC1, England. [Pichardo, Rafael; Gonzalez, Angel] Inst Dominicano Cardiol, Santo Domingo, Dominican Rep. [Sanchez, Jose R.] Ctr Nacl Alimentac & Nutr, Inst Nacl Salud, Lima, Peru. [Ferreccio, Catterina] Pontificia Univ Catolica Chile, Santiago, Chile. [Aguilera, Ximena] Minist Salud Chile, Santiago, Chile. [Silva, Egle] Univ Zulia, Fac Med, Inst Invest & Estudios Enfermedades Cardiovasc, Maracaibo 4011, Venezuela. [Orostegui, Myriam] Univ Ind Santander, Epidemiol Rsch Ctr, Fac Dis Epidemiol Observ, Bucaramanga, Colombia. [Gomez, Luis F.] Fdn FES Social, Bogota, Colombia. [Chirinos, Julio A.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Medina-Lezama, Josefina] Santa Maria Catholic Univ, Arequipa, Peru. [Medina-Lezama, Josefina] Santa Maria Rsch Inst, Arequipa, Peru. [Perez, Cynthia M.; Suarez, Erick; Ortiz, Ana P.] Univ Puerto Rico, Grad Sch Publ Hlth, San Juan, PR 00936 USA. [Rosero, Luis] Univ Costa Rica, Ctr Cntramericano Poblac, San Jose, Costa Rica. [Schapochnik, Norberto] Minist Salud Prov Tierra Del Fuego, Tierra Del Fuego, Argentina. [Ortiz, Zulma] Acad Nacl Med Buenos Aires, Inst Invest Epidemiol, Buenos Aires, DF, Argentina. [Ferrante, Daniel] Minist Salud & Ambiente, Buenos Aires, DF, Argentina. [Diaz, Margarita] Med Acad, Ctr Invest, Montevideo, Uruguay. RI Herrera, Victor/C-5602-2008; Miranda, J. Jaime/A-8482-2008 OI Miranda, J. Jaime/0000-0002-4738-5468 NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 17 PY 2009 VL 119 IS 10 BP E346 EP E346 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 419TX UT WOS:000264243700365 ER PT J AU Herrera, VM Casas, JP Miranda, J Perel, P Pichardo, R Gonzalez, A Sanchez, JR Ferreccio, C Aguilera, X Silva, E Orostegui, M Gomez, LF Chirinos, JA Medina-Lezama, J Perez, CM Suarez, E Ortiz, AP Rosero, L Schapochnik, N Ortiz, Z Ferrante, D Diaz, M Bautista, LE AF Herrera, Victor M. Casas, Juan P. Miranda, Jaime Perel, Pablo Pichardo, Rafael Gonzalez, Angel Sanchez, Jose R. Ferreccio, Catterina Aguilera, Ximena Silva, Egle Orostegui, Myriam Gomez, Luis F. Chirinos, Julio A. Medina-Lezama, Josefina Perez, Cynthia M. Suarez, Erick Ortiz, Ana P. Rosero, Luis Schapochnik, Norberto Ortiz, Zulma Ferrante, Daniel Diaz, Margarita Bautista, Leonelo E. TI Ethnic and Gender-Specific Effects of Fasting Glucose on Hypertension SO CIRCULATION LA English DT Meeting Abstract CT Joint Nutrition, Physical Activity and Metabolism Conference/49th Cardiovascular Disease Epidemiology and Prevention of the American-Heart-Association CY MAR 10-14, 2009 CL Palm Harbor, FL SP Amer Heart Assoc C1 [Herrera, Victor M.; Bautista, Leonelo E.] Univ Wisconsin, Madison, WI USA. [Casas, Juan P.; Miranda, Jaime; Perel, Pablo] London Sch Hyg & Trop Med, London WC1, England. [Pichardo, Rafael; Gonzalez, Angel] Inst Dominicano Cardiol, Santo Domingo, Dominican Rep. [Sanchez, Jose R.] Inst Nacl Salud, Ctr Nacl Alimentac & Nutr, Lima, Peru. [Ferreccio, Catterina] Pontificia Univ Catolica Chile, Santiago, Chile. [Aguilera, Ximena] Minist Salud Chile, Santiago, Chile. [Silva, Egle] Univ Zulia, Fac Med, Inst Invest & Estudios Enfermedades Cardiovac, Maracaibo 4011, Venezuela. [Orostegui, Myriam] Univ Ind Santander, Epidemiol Rsch Cntr, Cardiovasc Dis Epidemiol Observ, Bucaramanga, Colombia. [Gomez, Luis F.] Fdn FES Social, Hlth Div, Bogota, Colombia. [Chirinos, Julio A.] Univ Penn, Philadelphia VA Med Cntr, Philadelphia, PA 19104 USA. [Medina-Lezama, Josefina] Santa Maria Catholic Univ, Arequipa, Peru. [Medina-Lezama, Josefina] Santa Maria Rsch Inst, Arequipa, Peru. [Perez, Cynthia M.; Suarez, Erick; Ortiz, Ana P.] Univ Puerto Rico, Grad Sch Publ Hlth, Med Sci Campus, San Juan, PR 00936 USA. [Rosero, Luis] Univ Costa Rica, Cntr Cntramer Poblac, San Jose, Costa Rica. [Schapochnik, Norberto] Minist Salud Prov Tierra Fuego, Tierra Del Fuego, Argentina. [Ortiz, Zulma] Acad Nacl Med Buenos Aires, Inst Invest Epidemiol, Buenos Aires, DF, Argentina. [Ferrante, Daniel] Minist Salud Ambiente, Buenos Aires, DF, Argentina. [Diaz, Margarita] Med Acad, Ctr Invest, Montevideo, Uruguay. RI Herrera, Victor/C-5602-2008; Miranda, J. Jaime/A-8482-2008 OI Miranda, J. Jaime/0000-0002-4738-5468 NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 17 PY 2009 VL 119 IS 10 BP E364 EP E365 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 419TX UT WOS:000264243700448 ER PT J AU Kottgen, A Glazer, NL Dehghan, A Hwang, SJ Katz, R Li, M Yang, Q Kao, WHL Coresh, J Shlipak, MG Witteman, J Fox, CS AF Kottgen, Anna Glazer, Nicole L. Dehghan, Abbas Hwang, Shih-Jen Katz, Ronit Li, Man Yang, Qiong Kao, Wen Hong Linda Coresh, Josef Shlipak, Michael G. Witteman, Jacqueline Fox, Caroline S. TI Genome-Wide Association Study of Chronic Kidney Disease and Related Traits in 19,877 Participants in 4 Population-Based Studies Identifies Common Genetic Variants Conferring Disease Risk SO CIRCULATION LA English DT Meeting Abstract CT Joint Nutrition, Physical Activity and Metabolism Conference/49th Cardiovascular Disease Epidemiology and Prevention of the American-Heart-Association CY MAR 10-14, 2009 CL Palm Harbor, FL SP Amer Heart Assoc C1 [Kottgen, Anna; Li, Man; Kao, Wen Hong Linda; Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Glazer, Nicole L.; Katz, Ronit] Univ Washington, Seattle, WA 98195 USA. [Dehghan, Abbas; Witteman, Jacqueline] Erasmus MC, Rotterdam, Netherlands. [Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Yang, Qiong] Boston Univ, Boston, MA 02215 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. RI Yang, Qiong/G-5438-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 17 PY 2009 VL 119 IS 10 BP E283 EP E283 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 419TX UT WOS:000264243700072 ER PT J AU Brilakis, ES Lichtenwalter, C de Lemos, JA Roesle, M Obel, O Haagen, D Saeed, B Gadiparthi, C Bissett, JK Sachdeva, R Voudris, VV Karyofillis, P Kar, B Rossen, J Fasseas, P Berger, P Banerjee, S AF Brilakis, Emmanouil S. Lichtenwalter, Christopher de Lemos, James A. Roesle, Michele Obel, Owen Haagen, Donald Saeed, Bilal Gadiparthi, Chiranjeevi Bissett, Joseph K. Sachdeva, Rajesh Voudris, Vassilios V. Karyofillis, Panagiotis Kar, Biswajit Rossen, James Fasseas, Panayotis Berger, Peter Banerjee, Subhash TI A Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions The SOS (Stenting Of Saphenous Vein Grafts) Trial SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE bare-metal stents; coronary artery bypass graft surgery; drug-eluting stents; outcomes; percutaneous coronary intervention; saphenous vein grafts ID LONG-TERM OUTCOMES; FOLLOW-UP; INTERVENTION; IMPLANTATION; DISEASE AB Objectives The aim of this study was to compare the frequency of angiographic restenosis and clinical events between a paclitaxel-eluting stent (PES) and a similar bare-metal stent (BMS) in saphenous vein graft (SVG) lesions. Background There are conflicting and mostly retrospective data on outcomes after drug-eluting stent implantation in SVGs. Methods Patients requiring SVG lesion stenting were randomized to BMS or PES. The primary study end point was binary in-segment restenosis at 12-month follow-up quantitative coronary angiography. Secondary end points included death, myocardial infarction, ischemia-driven target vessel and lesion revascularization, and target vessel failure. Results Eighty patients with 112 lesions in 88 SVGs were randomized to a BMS (39 patients, 43 grafts, 55 lesions) or PES (41 patients, 45 grafts, 57 lesions). Binary angiographic restenosis occurred in 51% of the BMS-treated lesions versus 9% of the PES-treated lesions (relative risk: 0.18; 95% confidence interval [CI]: 0.07 to 0.48, p < 0.0001). During a median follow-up of 1.5 years the PES patients had less target lesion revascularization (28% vs. 5%, hazard ratio: 0.38; 95% CI: 0.15 to 0.74, p = 0.003) and target vessel failure (46% vs. 22%, hazard ratio: 0.65; 95% CI: 0.42 to 0.96, p = 0.03), a trend toward less target vessel revascularization (31% vs. 15%, hazard ratio: 0.66; 95% CI: 0.39 to 1.05, p = 0.08) and myocardial infarction (31% vs. 15%, hazard ratio: 0.67; 95% CI: 0.40 to 1.08, p = 0.10), and similar mortality (5% vs. 12%, hazard ratio: 1.56; 95% CI: 0.72 to 4.11, p = 0.27). Conclusions In SVG lesions, PES are associated with lower rates of angiographic restenosis and target vessel failure than BMS. (The SOS [Stenting of Saphenous Vein Grafts] Randomized-Controlled Trial; NCT00247208) (J Am Coll Cardiol 2009; 53: 919-28) (C) 2009 by the American College of Cardiology Foundation C1 [Brilakis, Emmanouil S.; Lichtenwalter, Christopher; de Lemos, James A.; Roesle, Michele; Obel, Owen; Haagen, Donald; Gadiparthi, Chiranjeevi; Banerjee, Subhash] Vet Affairs N Texas Healtchcare Syst, Dallas, TX USA. [Brilakis, Emmanouil S.; Lichtenwalter, Christopher; de Lemos, James A.; Obel, Owen; Gadiparthi, Chiranjeevi; Banerjee, Subhash] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Saeed, Bilal] Univ Toledo, Dept Internal Med, Toledo, OH 43606 USA. [Bissett, Joseph K.; Sachdeva, Rajesh] Cent Arkansas Vet Hlthcare Syst, Little Rock, AR USA. [Bissett, Joseph K.; Sachdeva, Rajesh] Univ Arkansas Med Sci, Little Rock, AR USA. [Voudris, Vassilios V.; Karyofillis, Panagiotis] Onassis Cariac Surg Ctr, Athens, Greece. [Kar, Biswajit] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Rossen, James] Iowa City Vet Affairs Med Ctr, Iowa City, IA USA. [Fasseas, Panayotis] Wheaton Franciscan Med Grp, Racine, WI USA. [Berger, Peter] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA. RP Brilakis, ES (reprint author), Dallas VA Med Ctr 111A, 4500 S Lancaster Rd, Dallas, TX 75216 USA. EM esbrilakis@yahoo.com RI Brilakis, Emmanouil/B-5282-2009 OI Sachdeva, Rajesh/0000-0002-7729-6247; Brilakis, Emmanouil/0000-0001-9416-9701 NR 25 TC 119 Z9 126 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 17 PY 2009 VL 53 IS 11 BP 919 EP 928 DI 10.1016/j.jacc.2008.11.029 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 417GX UT WOS:000264065600002 PM 19281920 ER PT J AU Jacobs, ET Ahnen, DJ Ashbeck, EL Baron, JA Greenberg, ER Lance, P Lieberman, DA McKeown-Eyssen, G Schatzkin, A Thompson, PA Martinez, ME AF Jacobs, Elizabeth T. Ahnen, Dennis J. Ashbeck, Erin L. Baron, John A. Greenberg, E. Robert Lance, Peter Lieberman, David A. McKeown-Eyssen, Gail Schatzkin, Arthur Thompson, Patricia A. Martinez, Maria Elena TI Association Between Body Mass Index and Colorectal Neoplasia at Follow-Up Colonoscopy: A Pooling Study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE adenoma; body mass index; colorectal neoplasms; meta-analysis as topic; neoplasms; second primary; recurrence ID COLON-CANCER RISK; WOMEN UNITED-STATES; PHYSICAL-ACTIVITY; WAIST CIRCUMFERENCE; ADENOMA RECURRENCE; METABOLIC SYNDROME; RECTAL-CANCER; WEIGHT-GAIN; OBESITY; MEN AB A direct relation between body mass index (BMI) and risk of colorectal adenomas and cancer has been reported, but few studies have had adequate sample size for conducting stratified analyses by sex, family history, colorectal subsite, or features of metachronous lesions. Data from 8,213 participants in 7 prospective studies of metachronous colorectal adenomas were pooled to assess whether the association between BMI and metachronous neoplasia varied by these factors. A statistically significant direct association between BMI and the odds of nonadvanced adenomas (P(trend) < 0.001) was observed, while the relation for advanced adenomas was of marginal significance (P(trend) < 0.07). In sex-stratified analyses, obesity was statistically significantly associated with the odds of any metachronous lesion among men (odds ratio = 1.36, 95% confidence interval: 1.17, 1.58) but not among women (odds ratio = 1.10, 95% confidence interval: 0.89, 1.37). The associations with BMI appeared to be limited to proximal neoplasia, with statistically significant results for BMI and proximal (P(trend) < 0.001), but not distal (P(trend) < 0.85), neoplasia. Exploratory analyses indicated that BMI was significantly related to most histologic characteristics of metachronous adenomas among men but not among women. Our results provide further support for the association between BMI and metachronous colorectal adenomas, particularly among men, thereby indicating that body size may affect colorectal carcinogenesis at comparatively early stages. C1 [Jacobs, Elizabeth T.] Univ Arizona, Arizona Canc Ctr, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85724 USA. [Ahnen, Dennis J.] Denver VA Med Ctr, Denver, CO USA. [Ahnen, Dennis J.] Univ Colorado, Denver, CO 80202 USA. [Baron, John A.; Greenberg, E. Robert] Dartmouth Med Sch, Sect Biostat & Epidemiol, Lebanon, NH USA. [Greenberg, E. Robert] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Lance, Peter] Univ Arizona, Coll Med, Tucson, AZ 85724 USA. [Lieberman, David A.] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA. [Lieberman, David A.] Portland VA Med Ctr, Portland, OR USA. [McKeown-Eyssen, Gail] Univ Toronto, Dalla Lana Sch Publ Heath, Toronto, ON, Canada. [McKeown-Eyssen, Gail] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada. [Schatzkin, Arthur] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Thompson, Patricia A.] Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA. RP Jacobs, ET (reprint author), Univ Arizona, Arizona Canc Ctr, Mel & Enid Zuckerman Coll Publ Hlth, POB 245024, Tucson, AZ 85724 USA. EM jacobse@u.arizona.edu RI Lance, Peter/I-2196-2014 OI Lance, Peter/0000-0003-2944-1881 FU National Cancer Institute [CA-41108, CA-23074, CA95060, CA37287, CA23108, CA 59005, CA 26852]; K07 Career Development Award [CA106269]; Cooperative Studies Program; Department of Veterans Affairs FX This work was supported by the National Cancer Institute ( grants CA-41108, CA-23074, CA95060, CA37287, CA37287, CA23108, CA 59005, and CA 26852). Dr. Jacobs is supported by a K07 Career Development Award ( grant CA106269) from the National Cancer Institute. Funding for the Veterans Affairs Study was supported by the Cooperative Studies Program, Department of Veterans Affairs. Conflict of interest: none declared. NR 52 TC 40 Z9 42 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 15 PY 2009 VL 169 IS 6 BP 657 EP 666 DI 10.1093/aje/kwn401 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 413ZT UT WOS:000263834400002 PM 19147743 ER PT J AU Peralta, CA Katz, R Madero, M Sarnak, M Kramer, H Criqui, MH Shlipak, MG AF Peralta, Carmen A. Katz, Ronit Madero, Magdalena Sarnak, Mark Kramer, Holly Criqui, Michael H. Shlipak, Michael G. TI The Differential Association of Kidney Dysfunction With Small and Large Arterial Elasticity The Multiethnic Study of Atherosclerosis SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE albuminuria; cystatin C; elasticity; kidney; kidney diseases ID PULSE-WAVE VELOCITY; GLOMERULAR-FILTRATION-RATE; AORTIC STIFFNESS; CARDIOVASCULAR MORTALITY; CREATININE CLEARANCE; SERUM CREATININE; CONTOUR ANALYSIS; RENAL-FUNCTION; NORMAL VALUES; DISEASE AB Vascular remodeling may be a mechanism linking chronic kidney disease to cardiovascular disease. Whether early kidney dysfunction is associated with small and large arterial remodeling is not well understood. Using multivariable linear regression, back-transforming beta-coefficients to relative difference, the authors studied the association of cystatin C, creatinine-based estimated glomerular filtration rate (GFR), and albuminuria with small (SAE) and large (LAE) arterial elasticity and aortic distensibility among 6,282 participants in the Multiethnic Study of Atherosclerosis at baseline (2000-2002). Compared with the lowest quintile, higher quintiles of cystatin C were incrementally associated with lower SAE: third quintile relative difference = -5% (95% confidence interval (CI): -8, -2); fourth quintile relative difference = -10% (95% CI: -13, -8); and highest quintile relative difference = -16% (95% CI: -20, -12). By use of creatinine, the association was observed only among those with chronic kidney disease (estimated GFR, < 60 mL/minute/1.73 m(2)): relative difference = -9% (95% CI: -13, -4). Albuminuria was significantly associated with lower SAE: relative difference = -6% (95% CI: -10, -1). Cystatin C was associated with lower LAE only at the highest quintile (relative difference = -3%, 95% CI: -6, 0) compared with the lowest quintile. By use of creatinine, chronic kidney disease was not independently associated with LAE (P = 0.912). Cystatin C, estimated GFR, and albuminuria were not associated with aortic distensibility (P = 0.26, 0.48, 0.45). Early kidney dysfunction is significantly associated with decreased arterial elasticity in smaller arteries and, to a lesser degree, in larger arteries. C1 [Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. [Katz, Ronit] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Katz, Ronit] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Madero, Magdalena; Sarnak, Mark] Tufts Univ New England Med Ctr, Dept Med, Boston, MA USA. [Kramer, Holly] Loyola Univ, Med Ctr, Dept Prevent Med, Maywood, IL 60153 USA. [Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med & Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA 94124 USA. RP Peralta, CA (reprint author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94124 USA. EM carmenalicia.peralta@ucsf.edu OI Kramer, Holly/0000-0002-6374-837X FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95165, N01-HC-95169]; Clinical Scientist in Nephrology Program from the American Kidney Fund; National Center for Research Resources [KL2 RR024130]; American Heart Association Established Investigator Award FX This work was supported by contracts N01-HC-95159 through N01-HC-95165 and by contract N01-HC-95169 from the National Heart, Lung, and Blood Institute. This work was also funded by the Clinical Scientist in Nephrology Program from the American Kidney Fund and by the National Center for Research Resources (KL2 RR024130 to C. A. P.), as well as by an American Heart Association Established Investigator Award to M. S. NR 32 TC 22 Z9 22 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 15 PY 2009 VL 169 IS 6 BP 740 EP 748 DI 10.1093/aje/kwn392 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 413ZT UT WOS:000263834400011 PM 19131564 ER PT J AU Mani, G Feldman, MD Oh, S Agrawal, CM AF Mani, Gopinath Feldman, Marc D. Oh, Sunho Agrawal, C. Mauli TI Surface modification of cobalt-chromium-tungsten-nickel alloy using octadecyltrichlorosilanes SO APPLIED SURFACE SCIENCE LA English DT Article DE Biomaterials surfaces; Cobalt-chromium alloys; Self-assembled monolayers; Silanes ID SELF-ASSEMBLED MONOLAYERS; ATOMIC-FORCE MICROSCOPY; NATIVE-OXIDE SURFACE; ALKYLSILOXANE MONOLAYERS; TITANIUM SURFACES; INFRARED-SPECTROSCOPY; EXTERNAL REFLECTION; ORGANIC MONOLAYERS; THERMAL-STABILITY; IMPLANT MATERIALS AB Cobalt-chromium (Co-Cr) alloys have been extensively used for medical implants because of their excellent mechanical properties, corrosion resistance, and biocompatibility. This first time study reports the formation and stability of self-assembled monolayers (SAMs) on a Co-Cr-W-Ni alloy. SAMs of octadecyltrichlorosilanes (OTS) were coated on sputtered Co-Cr-W-Ni alloy thin film and bulk Co-Cr W-Ni alloy. OTS SAM coated alloy specimens were characterized using contact angle goniometry, Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), and atomic force microscopy (AFM). Contact angle analysis and FTIR suggested that ordered monolayers were coated on both sputtered and bulk alloy. XPS suggested the selective dissolution of cobalt from the alloy during the formation of OTS SAM. The bonding between the alloy and the OTS SAM was mainly attributed to Si-O-Cr and Si-O-W covalent bonds and a smaller contribution from Si-O-Co bonds. AFM images showed the distribution of islands of monolayers coated on the alloy. The height of monolayers in majority of the islands was closer to the theoretical length of fully extended OTS molecules oriented perpendicular to the surface. The stability of OTS SAM was investigated in tris-buffered saline at 37 degrees C for up to 7 days. Contact angle, FTIR, and XPS collectively confirmed that the monolayers remain ordered and bound to the alloy surface under this condition. This study shows that Co-Cr alloys can be surface modified using SAMs for potential biomedical applications. (C) 2009 Elsevier B. V. All rights reserved. C1 [Mani, Gopinath; Feldman, Marc D.; Oh, Sunho; Agrawal, C. Mauli] Univ Texas San Antonio, Dept Biomed Engn, San Antonio, TX 78249 USA. [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Feldman, Marc D.] Dept Vet Affairs S Texas Hlth Care Syst, San Antonio, TX 78229 USA. RP Agrawal, CM (reprint author), Univ Texas San Antonio, Dept Biomed Engn, 1 UTSA Circle, San Antonio, TX 78249 USA. EM Mauli.Agrawal@utsa.edu FU South Texas Technology Management FX We are grateful to Sparc POC grant program sponsored by South Texas Technology Management for financial support. NR 80 TC 37 Z9 38 U1 1 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-4332 J9 APPL SURF SCI JI Appl. Surf. Sci. PD MAR 15 PY 2009 VL 255 IS 11 BP 5961 EP 5970 DI 10.1016/j.apsusc.2009.01.046 PG 10 WC Chemistry, Physical; Materials Science, Coatings & Films; Physics, Applied; Physics, Condensed Matter SC Chemistry; Materials Science; Physics GA 414VR UT WOS:000263893800058 ER PT J AU Braithwaite, RS Roberts, MS Goetz, MB Gibert, CL Rodriguez-Barradas, MC Nucifora, K Justice, AC AF Braithwaite, R. Scott Roberts, Mark S. Goetz, Matthew Bidwell Gibert, Cynthia L. Rodriguez-Barradas, Maria C. Nucifora, Kimberly Justice, Amy C. TI Do Benefits of Earlier Antiretroviral Treatment Initiation Outweigh Harms for Individuals at Risk for Poor Adherence? SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HIV; INFECTION; TRANSMISSION; VETERANS; OUTCOMES AB Clinicians may defer antiretroviral treatment for patients with suboptimal adherence. We used a validated computer simulation of HIV disease progression to compare alternative treatment thresholds for patients with suboptimal adherence. Earlier treatment increased life expectancy across a wide adherence range (50%-100% of doses taken). Delaying treatment for patients with suboptimal adherence may not always be appropriate. C1 [Braithwaite, R. Scott; Nucifora, Kimberly; Justice, Amy C.] Yale Univ, Dept Med, Gen Internal Med Sect, West Haven, CT USA. [Braithwaite, R. Scott; Nucifora, Kimberly; Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Roberts, Mark S.] Univ Pittsburgh, Sch Med, Dept Med, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA USA. [Roberts, Mark S.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Infect Dis Sect, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gibert, Cynthia L.] George Washington Univ, Dept Med, Infect Dis Sect, Washington, DC USA. [Gibert, Cynthia L.] Vet Affairs Med Ctr, Infect Dis Sect, Washington, DC 20422 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Braithwaite, RS (reprint author), 950 Campbell Ave,11ACSLG, New Haven, CT 06516 USA. EM ronald.braithwaite@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU National Institute of Alcohol Abuse and Alcoholism [K23 AA14483-01]; Archimedes; Monogram Biosciences FX Potential conflicts of interest. M. S. R. has received an unrestricted research grant from and consults for Archimedes. M. B. G. has received an honorarium and consultancy fees from Monogram Biosciences. R. S. B. is a methodological consultant for United BioSource. All other authors: no conflicts. NR 12 TC 19 Z9 19 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2009 VL 48 IS 6 BP 822 EP 826 DI 10.1086/596768 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 415QI UT WOS:000263949000020 PM 19210173 ER PT J AU Suzuki, T Miyamoto, H Nakahari, T Inoue, I Suemoto, T Jiang, B Hirota, Y Itohara, S Saido, TC Tsumoto, T Sawamoto, K Hensch, TK Delgado-Escueta, AV Yamakawa, K AF Suzuki, Toshimitsu Miyamoto, Hiroyuki Nakahari, Takashi Inoue, Ikuyo Suemoto, Takahiro Jiang, Bin Hirota, Yuki Itohara, Shigeyoshi Saido, Takaomi C. Tsumoto, Tadaharu Sawamoto, Kazunobu Hensch, Takao K. Delgado-Escueta, Antonio V. Yamakawa, Kazuhiro TI Efhc1 deficiency causes spontaneous myoclonus and increased seizure susceptibility SO HUMAN MOLECULAR GENETICS LA English DT Article ID POTASSIUM CHANNEL GENE; FEBRILE SEIZURES; SODIUM-CHANNEL; EPILEPSY; MUTATIONS; CILIA; SCN1A; MICE; GAMMA-2-SUBUNIT; NEUROGENESIS AB Mutations in EFHC1 gene have been previously reported in patients with epilepsies, including those with juvenile myoclonic epilepsy. Myoclonin1, also known as mRib72-1, is encoded by the mouse Efhc1 gene. Myoclonin1 is dominantly expressed in embryonic choroid plexus, post-natal ependymal cilia, tracheal cilia and sperm flagella. In this study, we generated viable Efhc1-deficient mice. Most of the mice were normal in outward appearance, and both sexes were found to be fertile. However, the ventricles of the brains were significantly enlarged in the null mutants, but not in the heterozygotes. Although the ciliary structure was found intact, the ciliary beating frequency was significantly reduced in null mutants. In adult stages, both the heterozygous and null mutants developed frequent spontaneous myoclonus. Furthermore, the threshold of seizures induced by pentylenetetrazol was significantly reduced in both heterozygous and null mutants. These observations seem to further suggest that decrease or loss of function of myoclonin1 may be the molecular basis for epilepsies caused by EFHC1 mutations. C1 [Suzuki, Toshimitsu; Inoue, Ikuyo; Yamakawa, Kazuhiro] RIKEN, Neurogenet Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan. [Miyamoto, Hiroyuki; Hensch, Takao K.] RIKEN, Lab Neuronal Circuit Dev, Brain Sci Inst, Wako, Saitama 3510198, Japan. [Suemoto, Takahiro; Saido, Takaomi C.] RIKEN, Lab Proteolyt Neurosci, Brain Sci Inst, Wako, Saitama 3510198, Japan. [Jiang, Bin; Tsumoto, Tadaharu] RIKEN, Tsumoto Res Unit, Brain Sci Inst, Wako, Saitama 3510198, Japan. [Itohara, Shigeyoshi] RIKEN, Lab Behav Genet, Brain Sci Inst, Wako, Saitama 3510198, Japan. [Suzuki, Toshimitsu] RIKEN, Special Postdoctoral Researchers Program, Brain Sci Inst, Wako, Saitama 3510198, Japan. [Nakahari, Takashi] Osaka Med Coll, Dept Physiol, Osaka 5698686, Japan. [Hirota, Yuki; Sawamoto, Kazunobu] Nagoya City Univ, Grad Sch Med Sci, Inst Mol Med, Dept Dev & Regenerat Biol, Nagoya, Aichi 4678601, Japan. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Comprehens Epilepsy Program, Epilepsy Genetics Lab, Los Angeles, CA 90073 USA. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Comprehens Epilepsy Program, Genom Labs, Los Angeles, CA 90073 USA. [Delgado-Escueta, Antonio V.] VA GLAHS W Los Angeles, Los Angeles, CA 90073 USA. RP Yamakawa, K (reprint author), RIKEN, Neurogenet Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan. EM yamakawa@brain.riken.jp RI Itohara, Shigeyoshi/I-8769-2012; Yamakawa, Kazuhiro/N-5050-2015 OI Itohara, Shigeyoshi/0000-0002-2410-9989; Delgado-Escueta, Antonio V./0000-0002-1581-6999; Sawamoto, Kazunobu/0000-0003-1984-5129 FU Ministry of Education, Culture, Sports, Science and Technology of Japan; RIKEN FX This work was supported in part by a grant from RIKEN Brain Science Institute (K.Y.), from the Ministry of Education, Culture, Sports, Science and Technology of Japan ( T. S.) and from RIKEN Special Postdoctoral Researchers Program ( T. S.). NR 35 TC 39 Z9 39 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAR 15 PY 2009 VL 18 IS 6 BP 1099 EP 1109 DI 10.1093/hmg/ddp006 PG 11 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 413XT UT WOS:000263828100011 PM 19147686 ER PT J AU Han, SZ Kim-Howard, X Deshmukh, H Kamatani, Y Viswanathan, P Guthridge, JM Thomas, K Kaufman, KM Ojwang, J Rojas-Villarraga, A Baca, V Orozco, L Rhodes, B Choi, CB Gregersen, PK Merrill, JT James, JA Gaffney, PM Moser, KL Jacob, CO Kimberly, RP Harley, JB Bae, SC Anaya, JM Alarcon-Riquelme, ME Matsuda, K Vyse, TJ Nath, SK AF Han, Shizhong Kim-Howard, Xana Deshmukh, Harshal Kamatani, Yoichiro Viswanathan, Parvathi Guthridge, Joel M. Thomas, Kenaz Kaufman, Kenneth M. Ojwang, Joshua Rojas-Villarraga, Adriana Baca, Vicente Orozco, Lorena Rhodes, Benjamin Choi, Chan-Bum Gregersen, Peter K. Merrill, Joan T. James, Judith A. Gaffney, Patrick M. Moser, Kathy L. Jacob, Chaim O. Kimberly, Robert P. Harley, John B. Bae, Sang-Choel Anaya, Juan-Manuel Alarcon-Riquelme, Marta E. Matsuda, Koichi Vyse, Timothy J. Nath, Swapan K. TI Evaluation of imputation-based association in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE) SO HUMAN MOLECULAR GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; REVISED CRITERIA; GENOTYPE DATA; CLASSIFICATION; POLYMORPHISM; DISEASES; TDT AB We recently identified a novel non-synonymous variant, rs1143679, at exon 3 of the ITGAM gene associated with systemic lupus erythematosus (SLE) susceptibility in European-Americans (EAs) and African-Americans. Using genome-wide association approach, three other studies also independently reported an association between SLE susceptibility and ITGAM or ITGAM-ITGAX region. The primary objectives of this study are to assess whether single or multiple causal variants from the same gene or any nearby gene(s) are involved in SLE susceptibility and to confirm a robust ITGAM association across nine independent data sets (n = 8211). First, we confirmed our previously reported association of rs1143679 (risk allele 'A') with SLE in EAs (P = 1.0 x 10(-8)) and Hispanic-Americans (P = 2.9 x 10(-5)). Secondly, using a comprehensive imputation-based association test, we found that ITGAM is one of the major non-human leukocyte antigen susceptibility genes for SLE, and the strongest association for EA is the same coding variant rs1143679 (log(10)Bayes factor=20, P = 6.17 x 10(-24)). Thirdly, we determined the robustness of rs1143679 association with SLE across three additional case-control samples, including UK (P = 6.2 x 10(-8)), Colombian (P = 3.6 x 10(-7)), Mexican (P = 0.002), as well as two independent sets of trios from UK (P(TDT) = 1.4 x 10(-5)) and Mexico (P(TDT) = 0.015). A meta-analysis combing all independent data sets greatly reinforces the association (P(meta) = 7.1 x 10(-50), odds ratio = 1.83, 95% confidence interval = 1.69-1.98, n = 10 046). However, this ITGAM association was not observed in the Korean or Japanese samples, in which rs1143679 is monomorphic for the non-risk allele (G). Taken together along with our earlier findings, these results demonstrate that the coding variant, rs1143679, best explains the ITGAM-SLE association, especially in European- and African-derived populations, but not in Asian populations. C1 [Han, Shizhong; Kim-Howard, Xana; Deshmukh, Harshal; Viswanathan, Parvathi; Nath, Swapan K.] Oklahoma Med Res Fdn, Genet Epidemiol Unit, Oklahoma City, OK 73104 USA. [Han, Shizhong; Kim-Howard, Xana; Deshmukh, Harshal; Viswanathan, Parvathi; Kaufman, Kenneth M.; Ojwang, Joshua; Gaffney, Patrick M.; Moser, Kathy L.; Harley, John B.; Anaya, Juan-Manuel; Nath, Swapan K.] Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. [Guthridge, Joel M.; James, Judith A.] Oklahoma Med Res Fdn, Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Kamatani, Yoichiro; Matsuda, Koichi] Univ Tokyo, Inst Med Sci, Tokyo, Japan. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Rojas-Villarraga, Adriana; Anaya, Juan-Manuel] Rosario Univ, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Baca, Vicente] Pediat Hosp, IMSS, Dept Rheumatol, Ctr Med Nacl Siglo 21, Mexico City, DF, Mexico. [Orozco, Lorena] Inst Nacl Med Genom, Mexico City, DF, Mexico. [Rhodes, Benjamin; Vyse, Timothy J.] Hammersmith Hosp, Imperial Coll, Rheumatol Sect, London, England. [Choi, Chan-Bum; Bae, Sang-Choel] Hosp Rheumat Dis, Seoul, South Korea. [Gregersen, Peter K.] Feinstein Inst Med Res, Manhasset, NY USA. [James, Judith A.; Harley, John B.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. [Nath, Swapan K.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK USA. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Kimberly, Robert P.] Univ Alabama, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Alarcon-Riquelme, Marta E.] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Uppsala, Sweden. RP Nath, SK (reprint author), Oklahoma Med Res Fdn, Genet Epidemiol Unit, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM swapan-nath@omrf.org RI Han, Shizhong/E-4084-2010; Han, Shizhong/H-5785-2011; Kamatani, Yoichiro/N-5513-2015; Rojas-Villarraga, Adriana/J-2404-2016; Anaya, Juan-Manuel/J-1960-2016 OI Rojas-Villarraga, Adriana/0000-0003-3145-2440; Matsuda, Koichi/0000-0001-7292-2686; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392 FU NCRR NIH HHS [RR020143]; NIAID NIH HHS [AI063622, AI24717]; NIAMS NIH HHS [AR043274, AR048940, AR049084, AR053483, AR42460, AR445650, P30 AR053483]; Wellcome Trust NR 31 TC 61 Z9 61 U1 0 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAR 15 PY 2009 VL 18 IS 6 BP 1171 EP 1180 DI 10.1093/hmg/ddp007 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 413XT UT WOS:000263828100018 PM 19129174 ER PT J AU Raj, SM Choo, KE Noorizan, AM Lee, YY Graham, DY AF Raj, S. Mahendra Choo, Keng Ee Noorizan, A. Majid Lee, Yeong Yeh Graham, David Y. TI Evidence against Helicobacter pylori Being Related to Childhood Asthma SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID EASTERN PENINSULAR MALAYSIA; LOW-PREVALENCE; INFECTION C1 [Raj, S. Mahendra] Pantai Med Ctr, Kuala Lumpur 59100, Malaysia. [Choo, Keng Ee; Noorizan, A. Majid; Lee, Yeong Yeh] Univ Sains Malaysia, Sch Med Sci, Kota Baharu, Kelantan, Malaysia. [Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. RP Raj, SM (reprint author), Pantai Med Ctr, 8 Jalan Bukit Pantai, Kuala Lumpur 59100, Malaysia. EM hemani@streamyx.com RI Lee, Yeong Yeh/G-2470-2010 OI Lee, Yeong Yeh/0000-0002-6486-7717; Abdul Majid, Noorizan/0000-0002-5618-9637 NR 7 TC 11 Z9 11 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2009 VL 199 IS 6 BP 914 EP 915 DI 10.1086/597066 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 411UU UT WOS:000263677900022 PM 19434934 ER PT J AU Pamuklar, Z Federico, L Liu, SY Umezu-Goto, M Dong, AP Panchatcharam, M Fulerson, Z Berdyshev, E Natarajan, V Fang, XJ Van Meeteren, LA Moolenaar, WH Mills, GB Morris, AJ Smyth, SS AF Pamuklar, Zehra Federico, Lorenzo Liu, Shuying Umezu-Goto, Makiko Dong, Anping Panchatcharam, Manikandan Fulerson, Zachary Berdyshev, Evgeny Natarajan, Viswanathan Fang, Xianjun Van Meeteren, Laurens A. Moolenaar, Wouter H. Mills, Gordon B. Morris, Andrew J. Smyth, Susan S. TI Autotaxin/Lysopholipase D and Lysophosphatidic Acid Regulate Murine Hemostasis and Thrombosis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; PLATELET SHAPE CHANGE; MYOSIN LIGHT-CHAIN; GLANZMANN THROMBASTHENIA; LYSOPHOSPHOLIPASE-D; AUTOTAXIN; RECEPTORS; ACTIVATION; MICE; PHOSPHORYLATION AB The lipid mediator lysophosphatidic acid (LPA) is a potent regulator of vascular cell function in vitro, but its physiologic role in the cardiovasculature is largely unexplored. To address the role of LPA in regulating platelet function and thrombosis, we investigated the effects of LPA on isolated murine platelets. Although LPA activates platelets from the majority of human donors, we found that treatment of isolated murine platelets with physiologic concentrations of LPA attenuated agonist-induced aggregation. Transgenic overexpression of autotaxin/lysophospholipase D (Enpp2), the enzyme necessary for production of the bulk of biologically active LPA in plasma, elevated circulating LPA levels and induced a bleeding diathesis and attenuation of thrombosis in mice. Intravascular administration of exogenous LPA recapitulated the prolonged bleeding time observed in Enpp2-Tg mice. Enpp2(+/-) mice, which have similar to 50% normal plasma LPA levels, were more prone to thrombosis. Plasma autotaxin associated with platelets during aggregation and concentrated in arterial thrombus, and activated but not resting platelets bound recombinant autotaxin/lysoPLD in an integrin-dependent manner. These results identify a novel pathway in which LPA production by autotaxin/lysoPLD regulates murine hemostasis and thrombosis and suggest that binding of autotaxin/lysoPLD to activated platelets may provide a mechanism to localize LPA production. C1 [Pamuklar, Zehra; Federico, Lorenzo; Dong, Anping; Panchatcharam, Manikandan; Fulerson, Zachary; Morris, Andrew J.; Smyth, Susan S.] Gill Heart Inst, Div Cardiovasc Med, Lexington, KY USA. [Federico, Lorenzo; Smyth, Susan S.] Univ Kentucky, Dept Pharmacol, Lexington, KY 40536 USA. [Morris, Andrew J.] Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA. [Liu, Shuying; Umezu-Goto, Makiko; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA. [Berdyshev, Evgeny; Natarajan, Viswanathan] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Fang, Xianjun] Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA. [Van Meeteren, Laurens A.; Moolenaar, Wouter H.] Netherlands Canc Inst, Div Cellular Biochem, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands. [Smyth, Susan S.] US Dept Vet Affairs, Med Ctr, Lexington, KY 40511 USA. RP Smyth, SS (reprint author), Gill Heart Inst, Div Cardiovasc Med, 900 S Limestone St,326 CTW Bldg, Lexington, KY USA. EM SusanSmyth@uky.edu RI van Meeteren, Laurens/A-9890-2008; Morris, Andrew/B-7869-2010 OI van Meeteren, Laurens/0000-0001-9885-0668; Panchatcharam, Manikandan/0000-0002-7691-8948 FU National Institutes of Health [HL070304, HL078663, HL074219, CA096496, GM050388, HL79396, P30 CA16672, PO1 CA64602] FX This work was supported, in whole or in part, by National Institutes of Health Grants HL070304, HL078663, and HL074219 ( to S. S. S.), CA096496 and GM050388 to A. J. M.), HL79396 ( to V. N.), and P30 CA16672 and PO1 CA64602 ( to G. B. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 48 TC 74 Z9 75 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 13 PY 2009 VL 284 IS 11 BP 7385 EP 7394 DI 10.1074/jbc.M807820200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 415FF UT WOS:000263919000084 PM 19139100 ER PT J AU Maddox, TM Ross, C Ho, PM Magid, D Rumsfeld, JS AF Maddox, Thomas M. Ross, Colleen Ho, P. Michael Magid, David Rumsfeld, John S. TI Impaired heart rate recovery is associated with new-onset atrial fibrillation: a prospective cohort study SO BMC CARDIOVASCULAR DISORDERS LA English DT Article ID TREADMILL EXERCISE SCORE; RISK-FACTORS; CHRONOTROPIC RESPONSE; PROGNOSTIC VALUE; MORTALITY; PREDICTOR; DISEASE; DYSFUNCTION; PREVALENCE; MANAGEMENT AB Background: Autonomic dysfunction appears to play a significant role in the development of atrial fibrillation (AF), and impaired heart rate recovery (HRR) during exercise treadmill testing (ETT) is a known marker for autonomic dysfunction. However, whether impaired HRR is associated with incident AF is unknown. We studied the association of impaired HRR with the development of incident AF, after controlling for demographic and clinical confounders. Methods: We studied 8236 patients referred for ETT between 2001 and 2004, and without a prior history of AF. Patients were categorized by normal or impaired HRR on ETT. The primary outcome was the development of AF. Cox proportional hazards modeling was used to control for demographic and clinical characteristics. Secondary analyses exploring a continuous relationship between impaired HRR and AF, and exploring interactions between cardiac medication use, HRR, and AF were also conducted. Results: After adjustment, patients with impaired HRR were more likely to develop AF than patients with normal HRR (HR 1.43, 95% confidence interval (CI) 1.06, 1.93). In addition, there was a linear trend between impaired HRR and AF (HR 1.05 for each decreasing BPM in HRR, 95% CI 0.99, 1.11). No interactions between cardiac medications, HRR, and AF were noted. Conclusion: Patients with impaired HRR on ETT were more likely to develop new-onset AF, as compared to patients with normal HRR. These findings support the hypothesis that autonomic dysfunction mediates the development of AF, and suggest that interventions known to improve HRR, such as exercise training, may delay or prevent AF. C1 [Maddox, Thomas M.; Ho, P. Michael; Rumsfeld, John S.] Denver VAMC, Cardiol Sect, Denver, CO USA. [Maddox, Thomas M.; Ho, P. Michael; Rumsfeld, John S.] Univ Colorado Denver, Dept Med Cardiol, Denver, CO USA. [Ross, Colleen; Magid, David] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. RP Maddox, TM (reprint author), Denver VAMC, Cardiol Sect, Denver, CO USA. EM thomas.maddox@va.gov; colleen.ross@kp.org; michael.ho@va.gov; david.j.magid@kp.org; john.rumsfeld@va.gov FU Institute for Health Research, Kaiser Permanente Colorado FX Funding for the cohort creation and analysis came from the Institute for Health Research, Kaiser Permanente Colorado. NR 28 TC 5 Z9 6 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2261 J9 BMC CARDIOVASC DISOR JI BMC Cardiovasc. Disord. PD MAR 12 PY 2009 VL 9 AR 11 DI 10.1186/1471-2261-9-11 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 457HT UT WOS:000266919800001 PM 19284627 ER PT J AU Schillace, RV Miller, CL Pisenti, N Grotzke, JE Swarbrick, GM Lewinsohn, DM Carr, DW AF Schillace, Robynn V. Miller, Casey L. Pisenti, Neal Grotzke, Jeff E. Swarbrick, Gwendolyn M. Lewinsohn, David M. Carr, Daniel W. TI A-Kinase Anchoring in Dendritic Cells Is Required for Antigen Presentation SO PLOS ONE LA English DT Article AB Background: Dendritic cells (DC) are the most potent antigen presenting cells (APC) of the immune system. Prostaglandin E-2, cyclic AMP, and protein kinase A (PKA) have all been shown to regulate DC maturation and activity. In other cells, the ability of these molecules to convey their signals has been shown to be dependent on A-kinase anchoring proteins (AKAPs). Here we present evidence for the existence and functional importance of AKAPs in human DC. Methodology/Principal Findings: Using immunofluorescence and/or western analyses we identify AKAP79, AKAP149, AKAP95, AKAP LBC and Ezrin. We also demonstrate by western analysis that expression of AKAP79, AKAP149 and RII are upregulated with DC differentiation and maturation. We establish the functional importance of PKA anchoring in multiple aspects of DC biology using the anchoring inhibitor peptides Ht31 and AKAP-IS. Incubation of protein or peptide antigen loaded DC with Ht31 or AKAP-IS results in a 30-50% decrease in antigen presentation as measured by IFN-gamma production from antigen specific CD4(+) T cells. Incubation of LPS treated DC with Ht31 results in 80% inhibition of TNF-alpha and IL-10 production. Ht31 slightly decreases the expression of CD18 and CD11a and CD11b, slightly increases the basal expression of CD83, dramatically decreases the LPS stimulated expression of CD40, CD80 and CD83, and significantly increases the expression of the chemokine receptor CCR7. Conclusions: These experiments represent the first evidence for the functional importance of PKA anchoring in multiple aspects of DC biology. C1 [Schillace, Robynn V.; Miller, Casey L.; Pisenti, Neal; Lewinsohn, David M.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. [Schillace, Robynn V.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Grotzke, Jeff E.] Oregon Hlth & Sci Univ, Dept Microbiol & Mol Immunol, Portland, OR 97201 USA. [Swarbrick, Gwendolyn M.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Pulmonary Med, Portland, OR 97201 USA. [Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97201 USA. RP Schillace, RV (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. EM carrd@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research & Development Service FX This research was supported by Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research & Development Service (DWC). VA Merit Review. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 10 Z9 12 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 11 PY 2009 VL 4 IS 3 AR e4807 DI 10.1371/journal.pone.0004807 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 437OF UT WOS:000265496100024 PM 19277197 ER PT J AU Boylston, WH Venkatachalam, K Prabhu, SD Valente, AJ Chandrasekar, B AF Boylston, William H. Venkatachalam, Kaliyamurthi Prabhu, Sumanth D. Valente, Anthony J. Chandrasekar, Bysani TI Neutralization of Interleukin (IL)-18 Ameliorates Ischemia/Reperfusion-Induced Myocardial Injury SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A310 EP A311 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864201287 ER PT J AU Dash, R Chan, T Yamada, M Paningbatan, M Myagmar, BE Swigart, PM Yang, PC Simpson, PC AF Dash, Rajesh Chan, Trevor Yamada, Mayumi Paningbatan, Marietta Myagmar, Bat-Erdene Swigart, Philip M. Yang, Phillip C. Simpson, Paul C., Jr. TI Magnetic Resonance Imaging With Targeted Iron-Oxide Labeling Detects Differential Cardiac Cell Survival After Doxorubicin and Myocardial Infarction in Culture and In Vivo SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 San Francisco VA Med Ctr, San Francisco, CA USA. Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A304 EP A304 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864201261 ER PT J AU Klein, AJ Kim, MS Westfall, JM Masoudi, FA Rumsfeld, JS Carroll, JD Jaynes, CL Messenger, JC AF Klein, Andrew J. Kim, Michael S. Westfall, John M. Masoudi, Frederick A. Rumsfeld, John S. Carroll, John D. Jaynes, Cathy L. Messenger, John C. TI Medical Simulation Training to Improve Acute Myocardial Infarction Care for Rural Hospitals SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 Univ Colorado Denver, Aurora, CO USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A401 EP A401 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864201663 ER PT J AU Maddox, T Ho, PM Roe, M Dai, D Tsai, T Rumsfeld, JS AF Maddox, Thomas Ho, P. Michael Roe, Matthew Dai, David Tsai, Tom Rumsfeld, John S. TI Secondary Prevention Therapies Among Patients With Non-Obstructive CAD: Insights From the NCDR Cath-PCI Registry SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 Denver VAMC, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A468 EP A468 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864201937 ER PT J AU Maddox, T Ho, PM Wang, TY Ou, FS Tsai, T Wiviott, SD Rumsfeld, JS AF Maddox, Thomas Ho, P. Michael Wang, Tracy Y. Ou, Fang-Shu Tsai, Tom Wiviott, Stephen D. Rumsfeld, John S. TI Clopidogrel Use Among Medically-Managed NSTEMI Patients: Insights From the NCDR ACTION Registry - GWTG SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 Denver VAMC, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A374 EP A374 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864201552 ER PT J AU Schwartz, GG Draznin, B Reusch, JEB Leitner, JW Lu, L Xu, Y Greyson, CR Wang, CCL AF Schwartz, Gregory G. Draznin, Boris Reusch, Jane E. B. Leitner, J. Wayne Lu, Li Xu, Ya Greyson, Clifford R. Wang, Cecilia C. L. TI Insulin-Stimulated PI 3-Kinase Activity Is Blunted, but Akt Pphosphorylation Is Preserved in Aortas of Pigs With Diet-Induced Obesity SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado Denver, Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A435 EP A435 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864201806 ER PT J AU Sweeney, AW Hage, F Aqel, R Phillips, G Perry, G Zogbi, G Calhoun, D AF Sweeney, Aaron W. Hage, Fadi Aqel, Raed Phillips, George Perry, Gilbert Zogbi, Gilbert Calhoun, David TI Percutaneous Renal Artery Revascularization versus Medical Therapy for Renal Artery Stenosis: A Prospective Randomized Trial SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 Univ Alabama, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A87 EP A87 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864200361 ER PT J AU Tsai, TT Ho, PM Carroll, NM Shetterly, SM Xu, S Powers, JD Go, AS Margolis, K Magid, DJ AF Tsai, Thomas T. Ho, P. Michael Carroll, Nikki M. Shetterly, Susan M. Xu, Stanley Powers, J. David Go, Alan S. Margolis, Karen Magid, David J. TI Two Year Outcomes Following Off-Label Use of Drug-Eluting Stents in the Real-World: Insights from the HMO Research Network-Stent Registry (HMORN-Stent) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 BP A16 EP A16 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864200065 ER PT J AU Venkatachalam, K Boylston, WH Bailey, SR Chandrasekar, B AF Venkatachalam, Kaliyamurthi Boylston, William H. Bailey, Steven R. Chandrasekar, Bysani TI AMPK Activation Blocks Interleukin-18-Mediated IKK/NF-B/PTEN Activation and Endothelial Cell Death SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 58th Annual Scientific Session of the American-College-of-Cardiology CY MAR 28-31, 2009 CL Orlando, FL SP Amer Coll Cardiol C1 S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 10 PY 2009 VL 53 IS 10 SU 1 BP A430 EP A430 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 414LD UT WOS:000263864201786 ER PT J AU Ganzini, L Goy, ER Dobscha, SK AF Ganzini, Linda Goy, Elizabeth R. Dobscha, Steven K. TI Oregonians' Reasons for Requesting Physician Aid in Dying SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID MENTAL STATUS QUESTIONNAIRE; TERMINALLY-ILL PATIENTS; ASSISTED SUICIDE; HASTENED DEATH; DESIRE; EXPERIENCES; EUTHANASIA; ATTITUDES; CANCER AB Background: Oregon is the only US jurisdiction with a legal process, the Oregon Death with Dignity Act, that allows terminally ill patients to obtain physician aid in dying ( PAD). Methods: Fifty-six Oregonians who either requested PAD or contacted a PAD advocacy organization completed a survey indicating the importance of 29 reasons for their interest in PAD on a scale where 1 was not important and 5 was very important; 28% of people referred from the PAD advocacy organization enrolled in the study. Results: Forty-one patients died by the end of the study; 18 received a prescription for medication under the Oregon Death with Dignity Act, and 9 died by lethal dose of medication. The most important reasons for requesting PAD, all with median scores of 5, were wanting to control the circumstances of death and die at home; loss of independence; and concerns about future pain, poor quality of life, and inability to care for one's self. All physical symptoms (eg, pain, dyspnea, and fatigue) at the time of the interview were rated as unimportant (median score, 1), but concerns about physical symptoms in the future were rated at a median score of 3 or higher. Lack of social support and depressed mood were rated as unimportant reasons for requesting PAD. Conclusions: At the time they express initial interest in PAD, Oregonians are motivated by worries about future physical discomfort and losses of autonomy and function. When confronted with a request for PAD, health care providers should first work to bolster the patient's sense of control and to educate and reassure the patient regarding management of future symptoms. C1 Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Hlth Serv Res & Dev Serv, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Res Serv, Mail Code R&D 66,POB 1034, Portland, OR 97239 USA. EM Linda.Ganzini@va.gov FU Department of Veterans' Affairs Health Services Research and Development Service FX This study was supported by a grant from the Northwest Health Foundation and Career Development Awards from the Department of Veterans' Affairs Health Services Research and Development Service (Drs Goy and Dobscha). NR 22 TC 42 Z9 43 U1 4 U2 19 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 9 PY 2009 VL 169 IS 5 BP 489 EP 492 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 416EX UT WOS:000263989500010 PM 19273779 ER PT J AU Habib, SL AF Habib, Samy L. TI Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients SO MOLECULAR CANCER LA English DT Article ID TUBEROUS SCLEROSIS COMPLEX; 3-KINASE/AKT PATHWAY; KIDNEY TUMORS; RENAL TUMORS; OGG1; PROTEIN; REPAIR; GENE; EXPRESSION; CARCINOGENESIS AB Background: The tuberous sclerosis complex (TSC) is caused by defects in one of two tumor suppressor genes, TSC-1 or TSC-2. TSC-2 gene encodes tuberin, a protein involved in the pathogenesis of kidney tumors, both angiomyolipomas and renal cell carcinomas. Loss of heterozygosity at the 8-oxoG-DNA glycosylase (OGG1) allele is found in human kidney clear cell carcinoma identifying loss of OGG1 function as a possible contributor to tumorigenesis in the kidney. Tuberin regulates OGG1 through the transcription factor NF-YA in cultured cells. The purpose of this study is to determine the effect of tuberin-deficiency on OGG1 protein and mRNA levels as well as on 8-oxodG levels in kidney tumors from patients with TSC. In addition we evaluated the phophorylation level of downstream targets of mTOR, phospho-S70K, in kidney tumor tissue from TSC patients. Results: Kidney angiomyolipoma tissue from TSC patients expresses significant levels of phophotuberin and low levels of tuberin compared to control kidney tissue. The increase in tuberin phosphorylation and the decrease tuberin expression are associated with decrease in OGG1 protein and mRNA levels in tumor samples compared to normal kidney samples. The decrease OGG1 expression is also associated with significant decrease in the transcription factor, NF-YA, expression in tumor samples compared to normal tissues. In addition, the levels of 8-oxodG are 4-fold higher in tumors compared to control samples. The significant increase of phospho-tuberin expression is associated with increase phosphorylation of S6K in tumor samples compared to controls. Cyclin D1 expression is also 3-fold higher in increase in the tumor tissues compared to normal kidney tissues. Conclusion: These data indicate that tuberin deficiency in angiomyolipoma enhances mTOR activation by phosphorylation of S6K and downregulation of protein and mRNA expression of OGG1 resulted in accumulation of oxidized DNA in patients with TSC. These data suggest that tuberin and OGG1 are important proteins in the pathogenesis of angiomyolipoma in TSC patients. C1 [Habib, Samy L.] S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Habib, SL (reprint author), S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. EM habib@uthscsa.edu FU NIH [P50DK061597]; NIDDK; George M. O'Brien Development and Feasibility Project; American Diabetes Association Research Grant; New Investigator Award from the South Texas Veterans Healthcare System FX The author would like to acknowledge the Morphology Core, George O'Brien Kidney Center for help with fluorescence microscopy (P50DK061597 NIH, NIDDK). Dr. H. E. Abboud for reading the manuscript. This work is supported in part by George M. O'Brien Development and Feasibility Project, American Diabetes Association Research Grant and a New Investigator Award from the South Texas Veterans Healthcare System ( to S. L. H.). NR 30 TC 8 Z9 8 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD MAR 5 PY 2009 VL 8 AR 13 DI 10.1186/1476-4598-8-13 PG 10 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 424WZ UT WOS:000264600300001 PM 19265534 ER PT J AU Ho, PM Maddox, TM Wang, L Fihn, SD Jesse, RL Peterson, ED Rumsfeld, JS AF Ho, P. Michael Maddox, Thomas M. Wang, Li Fihn, Stephan D. Jesse, Robert L. Peterson, Eric D. Rumsfeld, John S. TI Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; OF-FUNCTION POLYMORPHISM; MEDICATION NONADHERENCE; ANTIPLATELET ACTION; TRIAL; ATORVASTATIN; THERAPY; ASPIRIN; RESISTANCE; REGRESSION AB Context Prior mechanistic studies reported that omeprazole decreases the platelet inhibitory effects of clopidogrel, yet the clinical significance of these findings is not clear. Objective To assess outcomes of patients taking clopidogrel with or without a proton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS). Design, Setting, and Patients Retrospective cohort study of 8205 patients with ACS taking clopidogrel after discharge from 127 Veterans Affairs hospitals between October 1, 2003, and January 31, 2006. Vital status information was available for all patients through September 30, 2006. Main Outcome Measures All-cause mortality or rehospitalization for ACS. Results Of 8205 patients taking clopidogrel after discharge, 63.9% (n = 5244) were prescribed PPI at discharge, during follow-up, or both and 36.1% (n = 2961) were not prescribed PPI. Death or rehospitalization for ACS occurred in 20.8% (n = 615) of patients taking clopidogrel without PPI and 29.8% (n = 1561) of patients taking clopidogrel plus PPI. In multivariable analyses, use of clopidogrel plus PPI was associated with an increased risk of death or rehospitalization for ACS compared with use of clopidogrel without PPI ( adjusted odds ratio [AOR], 1.25; 95% confidence interval [CI], 1.11-1.41). Among patients taking clopidogrel after hospital discharge and prescribed PPI at any point during follow-up (n = 5244), periods of use of clopidogrel plus PPI ( compared with periods of use of clopidogrel without PPI) were associated with a higher risk of death or rehospitalization for ACS (adjusted hazard ratio, 1.27; 95% CI, 1.10-1.46). In analyses of secondary outcomes, patients taking clopidogrel plus PPI had a higher risk of hospitalizations for recurrent ACS compared with patients taking clopidogrel without PPI (14.6% vs 6.9%; AOR, 1.86 [ 95% CI, 1.57-2.20]) and revascularization procedures (15.5% vs 11.9%; AOR, 1.49 [ 95% CI, 1.30-1.71]), but not for all-cause mortality (19.9% vs 16.6%; AOR, 0.91 [ 95% CI, 0.80-1.05]). The association between use of clopidogrel plus PPI and increased risk of adverse outcomes also was consistent using a nested case-control study design (AOR, 1.32; 95% CI, 1.14-1.54). In addition, use of PPI without clopidogrel was not associated with death or rehospitalization for ACS among patients not taking clopidogrel after hospital discharge (n = 6450) ( AOR, 0.98; 95% CI, 0.85-1.13). Conclusion Concomitant use of clopidogrel and PPI after hospital discharge for ACS was associated with an increased risk of adverse outcomes than use of clopidogrel without PPI, suggesting that use of PPI may be associated with attenuation of benefits of clopidogrel after ACS. C1 [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Wang, Li; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fihn, Stephan D.; Jesse, Robert L.] VA Cent Off, Washington, DC USA. [Jesse, Robert L.] Richmond VA Med Ctr, Richmond, VA USA. [Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA. RP Ho, PM (reprint author), Dept Cardiol 111B, 1055 Clermont St, Denver, CO 80220 USA. EM michael.ho@va.gov FU Quality Enhancement Research Initiative of the US Department of Veterans Affairs; VA Health Services Research and Development Career Development Award; National Institute on Aging and from an Agency for Healthcare Research and Quality Center for Education and Research on Therapeutics [RO1] FX This study was supported by the Quality Enhancement Research Initiative of the US Department of Veterans Affairs. Dr Ho is supported by VA Health Services Research and Development Career Development Award. Dr Peterson is supported by an RO1 grant from the National Institute on Aging and from an Agency for Healthcare Research and Quality Center for Education and Research on Therapeutics. NR 34 TC 590 Z9 648 U1 2 U2 26 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 4 PY 2009 VL 301 IS 9 BP 937 EP 944 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 413HQ UT WOS:000263784600023 PM 19258584 ER PT J AU Spertus, JA Jones, PG Masoudi, FA Rumsfeld, JS Krumholz, HM AF Spertus, John A. Jones, Philip G. Masoudi, Frederick A. Rumsfeld, John S. Krumholz, Harlan M. TI Factors Associated With Racial Differences in Myocardial Infarction Outcomes SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID QUALITY-OF-LIFE; CORONARY-ARTERY-DISEASE; HEALTH-STATUS; PROPENSITY-SCORE; CLINICAL-TRIALS; HEART-FAILURE; PRIMARY-CARE; END-POINTS; RACE; REVASCULARIZATION AB Background: Little information is available about factors associated with racial differences across a broad spectrum of post-myocardial infarction outcomes, including patients' symptoms and quality of life. Objective: To determine racial differences in mortality, rehospitalization, angina, and quality of life after myocardial infarction and identify the factors associated with these differences. Design: Prospective cohort study. Setting: 10 hospitals in the United States. Patients: 1849 patients who had myocardial infarction, 28% of whom were black. Measurements: Demographic, economic, clinical, psychosocial, and treatment characteristics and outcomes were prospectively collected. Outcomes included time to 2-year all-cause mortality, 1-year rehospitalization, and Seattle Angina Questionnaire-assessed angina and quality of life. Results: Black patients had higher unadjusted mortality (19.9% vs. 9.3%; P < 0.001) and rehospitalization rates (45.4% vs. 40.4%; P = 0.130), more angina (28.0% vs. 17.8%; P < 0.001), and worse mean quality of life (80.6 [SD, 22.5] vs. 85.9 [SD, 17.2]; P < 0.001). After adjustment for patient characteristics, black patients trended toward greater mortality (hazard ratio, 1.29 [95% CI, 0.92 to 1.81]; P = 0.142), fewer rehospitalizations (hazard ratio, 0.82 [CI, 0.66 to 1.02]; P = 0.071), and higher likelihood of angina at 1 year (odds ratio, 1.41 [CI, 1.03 to 1.94]; P = 0.032) but similar quality of life (mean difference, -0.6 [CI, -3.4 to 2.2]). Adjustment for site of care further attenuated mortality differences (hazard ratio, 1.04 [CI, 0.71 to 1.52]; P = 0.84). Adjustment for treatments had minimal effect on any association. Limitation: Residual confounding and missing data may have introduced bias. Conclusion: Although black patients with myocardial infarction have worse outcomes than white patients, these differences did not persist after adjustment for patient factors and site of care. Further adjustment for treatments received minimally influenced observed differences. Strategies that focus on improving baseline cardiac risk and hospital factors may do more than treatment-focused strategies to attenuate racial differences in myocardial infarction outcomes. C1 [Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Univ Missouri, Kansas City, MO 64110 USA. Univ Colorado, Denver Hlth Med Ctr, Hlth Sci Ctr, Denver, CO 80202 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Yale New Haven Med Ctr, New Haven, CT 06504 USA. Yale Univ, Sch Med, New Haven, CT USA. RP Spertus, JA (reprint author), St Lukes Hosp, Mid Amer Heart Inst, 4401 Wornall Rd,5th Floor, Kansas City, MO 64111 USA. EM Spertusj@umkc.edu FU The National Heart, Lung, and Blood Institute; Cardiac Dysfunction and Disease; CV Therapeutics; Cardiovascular Outcomes FX Funding: The National Heart, Lung, and Blood Institute Specialized Center of Clinically Oriented Research in Cardiac Dysfunction and Disease, CV Therapeutics, and Cardiovascular Outcomes. NR 55 TC 29 Z9 29 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 3 PY 2009 VL 150 IS 5 BP 314 EP + PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 417CC UT WOS:000264051700003 PM 19258559 ER PT J AU Bourdette, D Simon, J AF Bourdette, Dennis Simon, Jack TI The radiologically isolated syndrome Is it very early multiple sclerosis? SO NEUROLOGY LA English DT Editorial Material ID DIAGNOSTIC-CRITERIA C1 [Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Simon, Jack] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA. [Bourdette, Dennis; Simon, Jack] Portland VA Med Ctr, Portland, OR USA. RP Bourdette, D (reprint author), Oregon Hlth & Sci Univ, Dept Neurol L226, Portland, OR 97239 USA. EM bourdett@ohsu.edu NR 10 TC 13 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR 3 PY 2009 VL 72 IS 9 BP 780 EP 781 DI 10.1212/01.wnl.0000337255.89622.ce PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 413CZ UT WOS:000263771800001 PM 19073944 ER PT J AU Perez, VI Buffenstein, R Masamsetti, V Leonard, S Salmon, AB Mele, J Andziak, B Yang, T Edrey, Y Friguet, B Ward, W Richardson, A Chaudhuri, A AF Perez, Viviana I. Buffenstein, Rochelle Masamsetti, Venkata Leonard, Shanique Salmon, Adam B. Mele, James Andziak, Blazej Yang, Ting Edrey, Yael Friguet, Bertrand Ward, Walter Richardson, Arlan Chaudhuri, Asish TI Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE cysteine oxidation; Heterocephalus glaber; mechanisms of aging; proteasome activity; protein homeostasis ID AGE-RELATED-CHANGES; HYDROGEN-PEROXIDE; DISULFIDE BONDS; LIFE-SPAN; MICE; PROTEASOME; METABOLISM; EXPLAIN; THIOREDOXIN; REDUCTION AB The widely accepted oxidative stress theory of aging postulates that aging results from accumulation of oxidative damage. Surprisingly, data from the longest-living rodent known, naked molerats [MRs; mass 35 g; maximum lifespan (MLSP) > 28.3 years], when compared with mice (MLSP 3.5 years) exhibit higher levels of lipid peroxidation, protein carbonylation, and DNA oxidative damage even at a young age. We hypothesize that age-related changes in protein structural stability, oxidation, and degradation are abrogated over the lifespan of the MR. We performed a comprehensive study of oxidation states of protein cysteines [both reversible (sulfenic, disulfide) and indirectly irreversible (sulfinic/sulfonic acids)] in liver from young and old C57BL/6 mice (6 and 28 months) and MRs (2 and >24 years). Furthermore, we compared interspecific differences in urea-induced protein unfolding and ubiquitination and proteasomal activity. Compared with data from young mice, young MRs have 1.6 times as much free protein thiol groups and similar amounts of reversible oxidative damage to cysteine. In addition, they show less urea-induced protein unfolding, less protein ubiquitination, and higher proteasome activity. Mice show a significant age-related increase in cysteine oxidation and higher levels of ubiquitination. In contrast, none of these parameters were significantly altered over 2 decades in MRs. Clearly MRs have markedly attenuated age-related accrual of oxidation damage to thiol groups and age-associated up-regulation of homeostatic proteolytic activity. These pivotal mechanistic interspecies differences may contribute to the divergent aging profiles and strongly implicate maintenance of protein stability and integrity in successful aging. C1 [Perez, Viviana I.; Buffenstein, Rochelle; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Buffenstein, Rochelle; Mele, James; Ward, Walter] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Perez, Viviana I.; Buffenstein, Rochelle; Masamsetti, Venkata; Leonard, Shanique; Salmon, Adam B.; Mele, James; Ward, Walter; Richardson, Arlan; Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Richardson, Arlan; Chaudhuri, Asish] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. [Friguet, Bertrand] Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, EA 3106, IFR 117, F-75251 Paris 05, France. [Buffenstein, Rochelle; Andziak, Blazej; Yang, Ting; Edrey, Yael] CUNY, Grad Sch, Dept Biol, New York, NY 10016 USA. RP Buffenstein, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM buffenstein@uthscsa.edu; chaudhuria@uthscsa.edu FU American Federation for Aging Research (V.I.P.); National Institutes of Health/National Institute on Aging [K07 AG025063 04, AG-022891, AG025362, AG23843, R37 AG26557] FX This work was supported by the American Federation for Aging Research (V.I.P.), and National Institutes of Health/National Institute on Aging Grants K07 AG025063 04 (to A.C.), AG-022891 (to R.B.), AG025362 (to W.W.), AG23843 (to A.R.), and R37 AG26557 (to A.R. and A.C.). NR 43 TC 165 Z9 168 U1 1 U2 41 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 3 PY 2009 VL 106 IS 9 BP 3059 EP 3064 DI 10.1073/pnas.0809620106 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 414DM UT WOS:000263844100018 PM 19223593 ER PT J AU Keene, CD Chang, RC Leverenz, JB Kopyov, O Perlman, S Hevner, R Born, DE Bird, TD Montine, TJ AF Keene, C. Dirk Chang, Rubens C. Leverenz, James B. Kopyov, Oleg Perlman, Susan Hevner, Robert F. Born, Donald E. Bird, Thomas D. Montine, Thomas J. TI A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions SO ACTA NEUROPATHOLOGICA LA English DT Article DE Huntington's disease; Human fetal neural transplantation; Graft survival and differentiation; Transplant overgrowth; Peripheral nerve co-graft ID AUTOLOGOUS ADRENAL-MEDULLA; PARKINSONS-DISEASE; INTRASTRIATAL COGRAFTS; PERIPHERAL-NERVE; FOLLOW-UP; ALLOGRAFTS; PATHOLOGY; SAFETY; NEUROTRANSPLANTATION; STRIATUM AB Transplantation of human fetal neural tissue into adult neostriatum is an experimental therapy for Huntington's disease (HD). Here we describe a patient with HD who received ten intrastriatal human fetal neural transplants and, at one site, an autologous sural nerve co-graft. Although initially clinically stable, she developed worsening asymmetric upper motor neuron symptoms in addition to progression of HD, and ultimately died 121 months post transplantation. Eight neural transplants, up to 2.9 cm, and three ependymal cysts, up to 2.0 cm, were identified. The autologous sural nerve co-graft was found adjacent to the largest mass lesion, which, along with the ependymal cyst, exhibited pronounced mass effect on the internal capsules bilaterally. Grafts were composed of neurons and glia embedded in disorganized neuropil; robust Y chromosome labeling was present in a subset of grafts and cysts. The graft-host border was discrete, and there was no evidence of graft rejection or HD pathologic changes within donor neurons. This report, for the first time, highlights the potential for graft overgrowth in a patient receiving fetal neural transplantation. C1 [Keene, C. Dirk; Chang, Rubens C.; Hevner, Robert F.; Born, Donald E.; Montine, Thomas J.] Univ Washington, Med Ctr, Harborview Med Ctr, Dept Pathol,Div Neuropathol, Seattle, WA 98104 USA. [Leverenz, James B.; Bird, Thomas D.] Univ Washington, Med Ctr, Dept Neurol, VA Puget Sound Hlth Care Syst, Seattle, WA 98104 USA. [Hevner, Robert F.] Univ Washington, Med Ctr, Dept Neurosurg, Seattle Childrens Hosp, Seattle, WA 98104 USA. [Hevner, Robert F.] Reg Med Ctr, Seattle, WA 98104 USA. [Kopyov, Oleg] St Johns Reg Med Ctr, Inst Neurosci, Oxnard, CA 93030 USA. [Perlman, Susan] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. RP Keene, CD (reprint author), Univ Washington, Med Ctr, Harborview Med Ctr, Dept Pathol,Div Neuropathol, Box 359791, Seattle, WA 98104 USA. EM cdkeene@u.washington.edu RI Keene, Christopher/N-1806-2015 FU NIA NIH HHS [5T32-AG000238, P50 AG005136, P50 AG005136-25, P50-AG005136, T32 AG000238] NR 27 TC 42 Z9 45 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD MAR PY 2009 VL 117 IS 3 BP 329 EP 338 DI 10.1007/s00401-008-0465-0 PG 10 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 409YA UT WOS:000263540500010 PM 19057918 ER PT J AU Silverman, JM Beeri, MS Schmeidler, J Rosendorff, C Angelo, G Mavris, RS Grossman, HT Elder, GA Carrion-Baralt, J West, R AF Silverman, Jeremy M. Beeri, Michal Schnaider Schmeidler, James Rosendorff, Clive Angelo, Gary Mavris, Rizalina S. Grossman, Hillel T. Elder, Gregory A. Carrion-Baralt, Jose West, Rebecca TI C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects SO AGE AND AGEING LA English DT Letter ID COGNITIVE DECLINE; METABOLIC SYNDROME; ALZHEIMER-DISEASE; RISK; AGE; INFLAMMATION; MORTALITY; DEMENTIA; MARKERS; WOMEN C1 [Silverman, Jeremy M.; Beeri, Michal Schnaider; Schmeidler, James; Angelo, Gary; Grossman, Hillel T.; Elder, Gregory A.; Carrion-Baralt, Jose; West, Rebecca] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Silverman, Jeremy M.; Rosendorff, Clive; Mavris, Rizalina S.; Grossman, Hillel T.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. RP Silverman, JM (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. EM jeremy.silverman@mssm.edu FU NIA NIH HHS [K01 AG023515, P01-AG02219, P50-AG05138] NR 27 TC 16 Z9 16 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0002-0729 J9 AGE AGEING JI Age Ageing PD MAR PY 2009 VL 38 IS 2 BP 237 EP 241 DI 10.1093/ageing/afn278 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 410UD UT WOS:000263602900021 PM 19147740 ER PT J AU Scibelli, AC Phillips, TJ AF Scibelli, Angela C. Phillips, Tamara J. TI Combined Scopolamine and Ethanol Treatment Results in a Locomotor Stimulant Response Suggestive of Synergism That is Not Blocked by Dopamine Receptor Antagonists SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Dopamine; Ethanol; Locomotor Activity; Muscarinic Receptor; Selected Line ID CONDITIONED PLACE PREFERENCE; SUBTYPE-SPECIFIC ANTIBODIES; QUANTITATIVE TRAIT LOCUS; SLOW MOUSE LINES; MUSCARINIC ACETYLCHOLINE; NUCLEUS-ACCUMBENS; REVERSE SELECTION; GENETIC INFLUENCE; KNOCKOUT MICE; TREATED RATS AB Muscarinic acetylcholine receptors (mAChRs) are well positioned to mediate ethanol's stimulant effects. To investigate this possibility, we examined the effects of scopolamine, a receptor subtype nonselective mAChR antagonist, on ethanol-induced stimulation in genotypes highly sensitive to this effect of ethanol. We also investigated whether the dopamine D1-like receptor antagonist, SCH-23390 or the dopamine D2-like receptor antagonist, haloperidol, could block the extreme stimulant response found following co-administration of scopolamine and ethanol. Scopolamine (0, 0.0625, 0.125, 0.25, or 0.5 mg/kg) was given 10 minutes prior to saline or ethanol (0.75 to 2 g/kg) to female FAST (Experiment I) or DBA/2J (Experiment II) mice that were then tested for locomotion for 30 minutes. In Experiments III and IV, respectively, SCH-23390 (0, 0.015, or 0.03 mg/kg) was given 10 minutes prior, and haloperidol (0, 0.08, or 0.16 mg/kg) was given 2 minutes prior, to scopolamine (0 or 0.5 mg/kg), followed 10 minutes later by saline or ethanol (1.5 g/kg) and female DBA/2J mice were tested for locomotion for 30 minutes. FAST and DBA/2J mice displayed a robust enhancement of the locomotor effects of ethanol following pretreatment with scopolamine that was suggestive of synergism. SCH-23390 had no effect on the response to the scopolamine + ethanol drug combination, nor did it attenuate ethanol- or scopolamine-induced locomotor activity. Haloperidol, while attenuating the effects of ethanol, was not able to block the effects of scopolamine or the robust response to the scopolamine-ethanol drug combination. These results suggest that while muscarinic receptor antagonism robustly enhances acute locomotor stimulation to ethanol, dopamine receptors are not involved in the super-additive interaction of scopolamine and ethanol treatment. They also suggest that in addition to cautions regarding the use of alcohol when scopolamine is clinically prescribed due to enhanced sedative effects, enhanced stimulation may also be a concern. C1 [Scibelli, Angela C.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. [Scibelli, Angela C.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR USA. RP Phillips, TJ (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, 3710 SW US Vet Hosp Rd,R&D-32, Portland, OR 97239 USA. EM phillipt@ohsu.edu FU National Institute on Alcohol Abuse and Alcoholism [P60AA010760]; National Institute on Drug Abuse [T32DA07262]; Department of Veterans Affairs FX This work was supported by a National Institute on Alcohol Abuse and Alcoholism grant P60AA010760, a grant from the National Institute on Drug Abuse T32DA07262, and a grant from the Department of Veterans Affairs. NR 77 TC 6 Z9 7 U1 1 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAR PY 2009 VL 33 IS 3 BP 435 EP 447 DI 10.1111/j.1530-0277.2008.00854.x PG 13 WC Substance Abuse SC Substance Abuse GA 409PN UT WOS:000263518400007 PM 19120057 ER PT J AU Decker, C Ahmad, H Moreng, KL Maddox, TM Reid, KJ Jones, PG Spertus, JA AF Decker, Carole Ahmad, Homaa Moreng, Kate Louise Maddox, Thomas M. Reid, Kimberly J. Jones, Philip G. Spertus, John A. TI Risk factor management after myocardial infarction: Reported adherence and outcomes SO AMERICAN HEART JOURNAL LA English DT Article ID CORONARY-ARTERY-DISEASE; CARDIAC REHABILITATION; LIFE-STYLE; SECONDARY PREVENTION; HEALTH-STATUS; CARE; MEDICATION; VALIDITY; THERAPY; QUALITY AB Background Providing patients with documented discharge instructions is a performance measure of health care quality. It is not well known how often cardiac patients comply with the list of instructions or what their association is with health status outcomes after an acute myocardial infarction. Methods Acute myocardial infarction patients (N = 2,498) were prospectively enrolled into a 19-center study and asked, at I month, if they had recalled receiving instructions at discharge on any of the 13 secondary prevention behaviors (eg, exercise, medications, diet, and smoking). Adherence, defined as the percentage of relevant activities patients reported adhering to at 1 month, was grouped into 4 categories: poor (0%-49%), partial (50%-74%), careful (75%-99%), and very careful (100%). Results A total of 2,046 patients completed 1-month interviews and received instruction on at least 1 risk factor management (RFM) behavior. Very careful adherence at I-month was reported most frequently with "taking medications as prescribed" (94%). In multivariable-adjusted models, patients who reported being poorly adherent were 58% more likely to report angina at I year as compared with those who very carefully followed RFM (relative risk 1.58, 95% CI 1.05-2.37). There was no independent association between RFM behavior and quality of life, physical functioning, rehospitalization, or mortality. Conclusions There is substantial variation in the types of RFM to which acute myocardial infarction patients adhere. In aggregate, stronger adherence was associated with less angina at I year. More research is needed to understand adherence patterns and its association with outcomes. (Am Heart J 2009; 157:556-62.) C1 [Decker, Carole; Reid, Kimberly J.; Jones, Philip G.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Decker, Carole; Moreng, Kate Louise; Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA. [Ahmad, Homaa] Univ Chicago Hosp, Cardiol Sect, Chicago, IL 60637 USA. [Maddox, Thomas M.] Univ Colorado, Hlth Sci Ctr, Denver VAMC, Denver, CO USA. RP Decker, C (reprint author), St Lukes Hosp, Mid Amer Heart Inst, 4401 Warnall Rd, Kansas City, MO 64111 USA. EM cldecker@saint-lukes.org NR 32 TC 9 Z9 9 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAR PY 2009 VL 157 IS 3 BP 556 EP 562 DI 10.1016/j.ahj.2008.11.022 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 419JD UT WOS:000264214700023 PM 19249428 ER PT J AU Harris, B Hwang, U Lee, WS Richardson, LD AF Harris, Ben Hwang, Ula Lee, Won S. Richardson, Lynne D. TI Disparities in use of computed tomography for patients presenting with headache SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article CT Research Forum of the American-College-of-Emergency-Physicians CY OCT 08-09, 2007 CL Seattle, WA SP Amer Coll Emergency Phys ID EMERGENCY-DEPARTMENT; SUBARACHNOID HEMORRHAGE; ETHNIC DISPARITIES; HEALTH-CARE; CHEST-PAIN; STROKE; GENDER; RACE AB Objective: Headache is a common presenting complaint in the emergency department (ED). Physicians may choose to screen for causes of headache using computed tomography (CT). It is not known whether patient characteristics influence this decision. This study sought to identify patient demographic factors associated with CT evaluation for adult patients with headache. Methods: This study used a retrospective cohort review at an academic, urban ED. Study eligibility was based on chief complaint of headache and final diagnosis of the same. Detailed demographic (age, sex, race/ethnicity, insurance) and clinical (Emergency Severity Index [ESI], Charlson comorbidity score, pain score) data were abstracted from the ED medical record. The main outcome studied was whether a head CT was part of clinical evaluation. Results: One hundred fifty-five patients were reviewed. Mean age was 42 years (SD, +/- 18 years); 75% female, 17% white, 41% black, and 33% Hispanic; 73% were insured; mean ESI was 3.06 (SD, +/- 0.64); and Charlson score was 0.60 (SD, +/- 1.55). Thirty-seven percent of patients underwent head CT. In multivariable analyses, patients were more likely to undergo head CT if they had greater acuity (ESI :! 3; odds ratio [OR], 5.11; P < .01) but were less likely to undergo head CT if they were black (OR, 0.21; P < .01) when adjusting for each other as well as older age, sex, comorbidity, insurance status, and history of migraine. Conclusion: In this study, patients who were black were significantly less likely to undergo head CT during their ED evaluation for headache, independent of clinical and demographic factors. Published by Elsevier Inc. C1 [Harris, Ben; Hwang, Ula; Richardson, Lynne D.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. [Hwang, Ula] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Lee, Won S.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. EM ulahwang@yahoo.com FU NHLBI NIH HHS [R01 HL073387, R01 HL073387-03] NR 20 TC 9 Z9 10 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD MAR PY 2009 VL 27 IS 3 BP 333 EP 336 DI 10.1016/j.ajem.2008.03.041 PG 4 WC Emergency Medicine SC Emergency Medicine GA 432SN UT WOS:000265154500014 PM 19328379 ER PT J AU Ramsey, PJ Shaib, YH Graham, DY AF Ramsey, Peter J. Shaib, Yasser H. Graham, David Y. TI Appropriate Use or Overutilization of the CORI Database? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter C1 [Ramsey, Peter J.; Shaib, Yasser H.; Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Coll Med, Dept Med, Houston, TX 77030 USA. [Ramsey, Peter J.; Shaib, Yasser H.; Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Coll Med, Dept Med, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu NR 5 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2009 VL 104 IS 3 BP 785 EP 786 DI 10.1038/ajg.2008.113 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 416KS UT WOS:000264005600041 PM 19209169 ER PT J AU Campa, OM Melrose, RJ Harwood, DG Mandelkern, MA Sultzer, DL Walston, AK AF Campa, Olivia M. Melrose, Rebecca J. Harwood, Dylan G. Mandelkern, Mark A. Sultzer, David L. Walston, Amy K. TI Depressive Symptoms and Regional Cortical Metabolism in Patients with Alzheimer's Disease: An FDG-PET Study SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Melrose, Rebecca J.; Harwood, Dylan G.; Sultzer, David L.; Walston, Amy K.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Mandelkern, Mark A.] Univ Calif Los Angeles, Dept Phys, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2009 VL 17 IS 3 SU 1 BP A73 EP A73 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YW UT WOS:000207905900087 ER PT J AU Dunn, LB Feil, D Meeks, T Misra, S AF Dunn, Laura B. Feil, Denise Meeks, Thomas Misra, Sahana TI Tough Love: Ways to Make the Difficult Decisions When Caring for Dementia Patients SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Dunn, Laura B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Feil, Denise] Univ Calif Los Angeles, W Los Angeles VA, Los Angeles, CA USA. [Meeks, Thomas] Univ Calif San Diego, San Diego, CA 92103 USA. [Misra, Sahana] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2009 VL 17 IS 3 SU 1 BP A12 EP A12 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YW UT WOS:000207905900005 ER PT J AU Kasckow, J Brown, C Bensasi, S Houck, P Thomas, S Ford, A Reynolds, C AF Kasckow, John Brown, Charlotte Bensasi, Salem Houck, Patty Thomas, Stephen Ford, Angela Reynolds, Charles TI Racial Preferences for Participation in a Depression Prevention Research Intervention SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Brown, Charlotte; Bensasi, Salem; Reynolds, Charles] Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Houck, Patty] UPMC Hlth Syst, Pittsburgh, PA USA. [Thomas, Stephen; Ford, Angela] Ctr Minor Hlth, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2009 VL 17 IS 3 SU 1 BP A65 EP A66 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YW UT WOS:000207905900074 ER PT J AU Lanouette, NM Kaskow, JW Fellows, I Patterson, TL Golshan, S Zisook, S AF Lanouette, Nicole M. Kaskow, John W. Fellows, Ian Patterson, Thomas L. Golshan, Shahrokh Zisook, Sidney TI Subsyndromal Depressive Symptoms in Schizophrenia: Effect of Treatment Response on Functional Outcomes SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Lanouette, Nicole M.; Fellows, Ian; Patterson, Thomas L.; Golshan, Shahrokh; Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA. [Kaskow, John W.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kaskow, John W.] Univ Pittsburgh, Pittsburgh, PA USA. [Fellows, Ian; Golshan, Shahrokh; Zisook, Sidney] VA San Diego Hlth Care Syst, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2009 VL 17 IS 3 SU 1 BP A128 EP A129 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YW UT WOS:000207905900182 ER PT J AU Melrose, RJ Harwood, DG Campa, O Mandelkern, MA Bussel, N Sultzer, DL AF Melrose, Rebecca J. Harwood, Dylan G. Campa, Olivia Mandelkern, Mark A. Bussel, Natalya Sultzer, David L. TI Neurobiological Correlates of Instrumental Activities of Daily Living in Alzheimer's Disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Melrose, Rebecca J.; Harwood, Dylan G.; Campa, Olivia; Bussel, Natalya; Sultzer, David L.] Univ Calif Los Angeles, VA Greater Healthcare Syst, Los Angeles, CA USA. [Melrose, Rebecca J.; Harwood, Dylan G.; Sultzer, David L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Mandelkern, Mark A.] Univ Calif Irvine, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2009 VL 17 IS 3 SU 1 BP A82 EP A82 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YW UT WOS:000207905900101 ER PT J AU Sultzer, DL Davis, SM Tariot, PN Dagerman, KS Lebowitz, BD Lyketsos, CG Rosenheck, RA Hsiao, JK Lieberman, JA Schneider, LS AF Sultzer, David L. Davis, Sonia M. Tariot, Pierre N. Dagerman, Karen S. Lebowitz, Barry D. Lyketsos, Constantine G. Rosenheck, Robert A. Hsiao, John K. Lieberman, Jeffrey A. Schneider, Lon S. TI Antipsychotic Medication Treatment Response in Alzheimer's Disease (CATIE-AD): Patient Symptoms, Function, and Life Quality, and Caregiver Well-being SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Sultzer, David L.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Sultzer, David L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Davis, Sonia M.] Quintiles, Res Triangle Pk, NC USA. [Tariot, Pierre N.] Banner Alzheimers Inst, Phoenix, AZ USA. [Dagerman, Karen S.] USC, Dept Psychiat, Keck Sch Med, Los Angeles, CA USA. [Lebowitz, Barry D.] UCSD, Div Geriatr Psychiat, La Jolla, CA USA. [Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD USA. [Rosenheck, Robert A.] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA. [Hsiao, John K.] NIMH, Bethesda, MD 20892 USA. [Lieberman, Jeffrey A.] Columbia Univ, New York, NY USA. [Schneider, Lon S.] USC, Dept Psychiat, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2009 VL 17 IS 3 SU 1 BP A74 EP A75 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YW UT WOS:000207905900090 ER PT J AU Kooienga, L Fried, L Scragg, R Kendrick, J Smits, G Chonchol, M AF Kooienga, Laura Fried, Linda Scragg, Robert Kendrick, Jessica Smits, Gerard Chonchol, Michel TI The Effect of Combined Calcium and Vitamin D(3) Supplementation on Serum Intact Parathyroid Hormone in Moderate CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Vitamin D(3); chronic kidney disease; secondary hyperparathyroidism ID CHRONIC KIDNEY-DISEASE; BONE-MINERAL DENSITY; SECONDARY HYPERPARATHYROIDISM; D DEFICIENCY; HEMODIALYSIS-PATIENTS; CALCIDIOL DEFICIENCY; ERGOCALCIFEROL; PARICALCITOL; PREVALENCE; WOMEN AB Background: Studies addressing the effects of vitamin D(3) supplementation on secondary hyperparathyroidism in patients with moderate chronic kidney disease are scarce. Study Design: Post hoc analysis of the randomized clinical trial Vitamin D, Calcium, Lyon Study II (DECALYOS II) to assess effects according to baseline estimated glomerular filtration rate (eGFR). Setting & Participants: Multicenter, randomized, double-blinded, placebo-controlled study of 639 elderly women randomly assigned to calcium-vitamin D(3) fixed combination; calcium plus vitamin D(3) separate combination, or placebo. Interventions: Placebo or calcium (1,200 mg) and vitamin D(3) (800 IU) in fixed or separate combination. Outcomes & Measurements: Proportion of participants with a mean decrease in intact parathyroid hormone (iPTH) level of 30% or greater. eGFR was calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) Study equation and categorized as 60 or greater, 45 to 59, and less than 45 mL/min/1.73 m(2). Results: 610 participants had an eGFR at baseline: 288 (47.2%), 222 (36.4%), and 100 (16.4%) were in each decreasing eGFR category. Across decreasing eGFR groups, 88%, 86%, and 89% had 25-hydroxyvitamin D (25[OH]D) levels less than 15 ng/mL at baseline. On treatment, similar improvements in the proportion of participants achieving 25(OH)D levels greater than 30 ng/mL at 6 months were seen in all kidney function groups (43%, 49%, and 41%, respectively). Active regimens versus placebo increased mean 25(OH)D levels from baseline in all eGFR groups at all times (P < 0.001 for all). The proportion with a 30% or greater decrease in iPTH level at 6 months was 50% in all eGFR groups on treatment versus 6% to 9% for placebo (P < 0.001 for all). The effects of the intervention on iPTH levels did not differ according to baseline eGFR (interaction P > 0.1 for all times). Limitations: This study included only elderly white women. Conclusion: Vitamin D3 was effective in increasing 25(OH)D and decreasing iPTH levels in patients with moderate chronic kidney disease. C1 [Kooienga, Laura; Kendrick, Jessica; Smits, Gerard; Chonchol, Michel] Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Denver, CO 80262 USA. [Fried, Linda] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Scragg, Robert] Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand. RP Chonchol, M (reprint author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Box C-280, Denver, CO 80262 USA. EM michel.chonchol@uchsc.edu OI Scragg, Robert/0000-0003-0013-2620 NR 30 TC 26 Z9 29 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2009 VL 53 IS 3 BP 408 EP 416 DI 10.1053/j.ajkd.2008.09.020 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 414DJ UT WOS:000263843800010 PM 19185400 ER PT J AU Ta, S Goldzweig, C Juzba, M Lee, M Wenger, N Yano, EM Asch, S AF Ta, Sony Goldzweig, Caroline Juzba, Michael Lee, Martin Wenger, Neil Yano, Elizabeth M. Asch, Steve TI Addressing Physician Concerns About Performance Profiling: Experience With a Local Veterans Affairs Quality Evaluation Program SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE veterans' administration; diabetes mellitus; quality of care; clinical performance ID HEALTH-CARE FACILITIES; PAY-FOR-PERFORMANCE; DIABETES CARE; OF-CARE; CHRONIC DISEASE; DISPARITIES; MELLITUS AB The Authors investigated the addition of novel quality indicators, patient risk adjustment, and simple statistics in an ongoing clinician feedback initiative that profiles diabetes care for 13 Veterans Affairs (VA) clinics. Data were extracted from a computerized database for calendar years 2004 to 2005. Performance was assessed with 4 monitoring measures, 3 intermediate outcomes, and 3 appropriate treatment measures. Attainment rates for each indicator were calculated by clinic. The effect of risk adjustment and the significance of clinic performance variation were determined with multivariate logistic models. Analysis of the 10 quality measures revealed lower attainment and greater clinic-level variation for the less familiar indicators. Statistically significant performance variations were detected among clinics, with several being of a clinically important magnitude. Risk adjustment did not substantially change performance. The addition of clinically relevant quality measures and simple statistics appeared to enhance the characterization of performance by this profiling program. (Am J Med Qual 2009;24:123-131) C1 [Ta, Sony; Wenger, Neil] Univ Calif Los Angeles, Dept Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90096 USA. [Goldzweig, Caroline; Lee, Martin; Yano, Elizabeth M.; Asch, Steve] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Juzba, Michael] Long Beach VA Healthcare Syst, Long Beach, CA USA. RP Ta, S (reprint author), Univ Calif Los Angeles, Dept Gen Internal Med & Hlth Serv Res, 911 Broxton Ave,3rd Floor, Los Angeles, CA 90096 USA. EM sonyta@med-net.ucla.edu FU VA Health Services Research and Development Center of Excellence for the Study of Healthcare Provider Behavior; National Research Service Award [T32HP19001]; University of California Los Angeles Department of General Internal Medicine and Health Services Research FX Dr Ta and Dr Wenger are with the UCLA Department of General Internal Medicine. and Health Services Research, Los Angeles, CA; Dr Goldzweig, Dr Lee, Dr Yano, and Dr Asch are with the Greater Los Angeles VA Healthcare System, Los Angeles, CA; and Dr Juzba is with the Long Beach VA Healthcare System, Long Beach, CA. This research was funded by a local grant from the VA Health Services Research and Development Center of Excellence for the Study of Healthcare Provider Behavior, and by a National Research Service Award grant (T32HP19001) from the University of California Los Angeles Department of General Internal Medicine and Health Services Research. The authors' have no financial interests involving this research and this work was not supported by any commercial entity. The views expressed in this article are those of the authors and do not necessarily represent the views of the organizations with which they are affiliated. Corresponding author Sony Ta, MD, MPH, UCLA Department of General Internal Medicine and Health Services Research, 911 Broxton Avenue, 3rd Floor, Los Angeles, CA 90096 (email: sonyta@mednet.ucla.edu). NR 25 TC 2 Z9 2 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 J9 AM J MED QUAL JI Am. J. Med. Qual. PD MAR-APR PY 2009 VL 24 IS 2 BP 123 EP 131 DI 10.1177/1062860608330828 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 423KJ UT WOS:000264494900005 PM 19228893 ER PT J AU Dempsey, EC Wick, MJ Karoor, V Barr, EJ Tallman, DW Wehling, CA Walchak, SJ Laudi, S Le, M Oka, M Majka, S Cool, CD Fagan, KA Klemm, DJ Hersh, LB Gerard, NP Gerard, C Miller, YE AF Dempsey, Edward C. Wick, Marilee J. Karoor, Vijaya Barr, Erica J. Tallman, Dustin W. Wehling, Carol A. Walchak, Sandra J. Laudi, Sven Le, Mysan Oka, Masahiko Majka, Susan Cool, Carlyne D. Fagan, Karen A. Klemm, Dwight J. Hersh, Louis B. Gerard, Norma P. Gerard, Craig Miller, York E. TI Neprilysin Null Mice Develop Exaggerated Pulmonary Vascular Remodeling in Response to Chronic Hypoxia SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID PROTEIN-KINASE-C; ANGIOTENSIN-CONVERTING ENZYME; NEUROENDOCRINE CELL SYSTEM; ENDOPEPTIDASE EC 3.4.24.11; SMOOTH-MUSCLE-CELLS; NEUTRAL ENDOPEPTIDASE; ENDOCRINE-CELLS; BRONCHOPULMONARY DYSPLASIA; VASOPEPTIDASE INHIBITORS; ARTERIAL-HYPERTENSION AB Neprilysin is a transmembrane metalloendopeptidase that degrades neuropeptides that are important for both growth and contraction. In addition to promoting carcinogenesis, decreased levels of neprilysin increases inflammation and neuroendocrine cell hyperplasia, which may predispose to vascular remodeling. Early pharmacological studies showed a decrease in chronic hypoxic pulmonary hypertension with neprilysin inhibition. We used a genetic approach to test the alternate hypothesis that neprilysin depletion increases chronic hypoxic pulmonary hypertension. Loss of neprilysin had no effect on baseline airway or alveolar wall architecture, vessel density, cardiac function, hematocrit, or other relevant peptidases. Only lung neuroendocrine cell hyperplasia and a subtle neuropeptide imbalance were found. After chronic hypoxia, neprilysin-null mice exhibited exaggerated pulmonary hypertension and striking increases in muscularization of distal vessels. Subtle thickening of proximal media/adventitia not typically seen in mice was also detected. In contrast, adaptive right ventricular hypertrophy was less than anticipated. Hypoxic wild-type pulmonary vessels displayed close temporal and spatial relationships between decreased neprilysin and increased cell growth. Smooth muscle cells from neprilysin-null pulmonary arteries had increased proliferation compared with controls, which was decreased by neprilysin replacement. These data suggest that neprilysin may be protective against chronic hypoxic pulmonary hypertension in the lung, at least in part by attenuating the growth of smooth muscle cells. Lung-targeted strategies to increase neprilysin levels could have therapeutic benefits in the treatment of this disorder. (Am J Pathol 2009, 174:782-796; DOI: 10.2353/ajpath.2009.080345) C1 [Dempsey, Edward C.; Wick, Marilee J.; Karoor, Vijaya; Barr, Erica J.; Tallman, Dustin W.; Walchak, Sandra J.; Oka, Masahiko; Majka, Susan; Fagan, Karen A.; Klemm, Dwight J.; Hersh, Louis B.] Univ Colorado Denver & Hlth Sci Ctr, Cardiovasc Pulm Res Lab, Denver, CO USA. [Laudi, Sven] Univ Colorado Denver & Hlth Sci Ctr, Dept Anesthesiol, Denver, CO 80202 USA. [Cool, Carlyne D.] Univ Colorado Denver & Hlth Sci Ctr, Dept Pathol, Denver, CO 80202 USA. [Dempsey, Edward C.; Wick, Marilee J.; Barr, Erica J.; Wehling, Carol A.; Le, Mysan; Klemm, Dwight J.; Miller, York E.] Denver VA Med Ctr, Pulm & Crit Care Sect, Denver, CO USA. [Cool, Carlyne D.] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA. [Hersh, Louis B.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Gerard, Norma P.; Gerard, Craig] Childrens Hosp, Dept Pediat, Div Pulm, Boston, MA USA. [Dempsey, Edward C.] Univ Colorado Denver & Hlth Sci Ctr, Univ Colorado Canc Ctr, Denver, CO USA. RP Dempsey, EC (reprint author), Univ Colorado Denver, Cardiovasc Pulm Res Lab, B-133,12700 E 19th Ave, Aurora, CO 80046 USA. EM edward.dempsey@ucdenver.edu FU National Heart Lung and Blood Institute PPG [HL14985, RO-1, HL078927] FX Supported by grants from the National Heart Lung and Blood Institute PPG #HL14985 and RO-1 #HL078927 to E.C.D. NR 71 TC 24 Z9 24 U1 0 U2 4 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2009 VL 174 IS 3 BP 782 EP 796 DI 10.2353/ajpath.2009.080345 PG 15 WC Pathology SC Pathology GA 410XW UT WOS:000263612600008 PM 19234135 ER PT J AU Blevins, JE Morton, GJ Williams, DL Caldwell, DW Bastian, LS Wisse, BE Schwartz, MW Baskin, DG AF Blevins, James E. Morton, Gregory J. Williams, Diana L. Caldwell, David W. Bastian, Lloyd S. Wisse, Brent E. Schwartz, Michael W. Baskin, Denis G. TI Forebrain melanocortin signaling enhances the hindbrain satiety response to CCK-8 SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE paraventricular nucleus; retrograde tracer; cholecystokinin ID MELANOCYTE-STIMULATING HORMONE; CORTICOTROPIN-RELEASING HORMONE; AGOUTI-RELATED PROTEIN; REDUCES FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; LEPTIN ACTION; MEAL SIZE; FEEDING INHIBITION; AREA POSTREMA; RECEPTOR AB Blevins JE, Morton GJ, Williams DL, Caldwell DW, Bastian LS, Wisse BE, Schwartz MW, Baskin DG. Forebrain melanocortin signaling enhances the hindbrain satiety response to CCK-8. Am J Physiol Regul Integr Comp Physiol 296: R476-R484, 2009. First published December 24, 2008; doi:10.1152/ajpregu.90544.2008. Melanocortin 4 receptors (MC4R) are hypothesized to mediate the central nervous system actions of leptin to enhance the satiety effects of cholecystokinin (CCK). To further elucidate this mechanism, we confirmed that peripheral administration of CCK-8 is less effective in producing this effect in MC4R-deficient mice ( MC4R(-/-)). Whereas intraperitoneal (ip) CCK-8 at 0.75 nmol/kg lean body mass (lbm) suppressed food intake in wild-type mice, CCK-8 doses of 7.5 nmol/kg lbm were required to attenuate food intake in MC4R(-/-) mice. To determine whether melanocortin signaling in the hypothalamic paraventricular nucleus (PVN) participates in regulating this CCK satiety response, we administered the MC3/MC4R antagonist, SHU9119, into the PVN of rats before ip CCK-8 administration. PVN administration of SHU9119 attenuated the ability of CCK-8 to reduce 30-min food intake by 20%. To determine whether MC4R are expressed by PVN neurons that project directly to hindbrain nuclei involved in the satiety response to ip CCK-8, the retrograde tracer fluorescent cholera toxin subunit B was injected into the nucleus tractus solitarius (NTS) of the hindbrain. After 4 days, labeled PVN neurons were collected by laser capture microdissection and found to express MC4R mRNA by quantitative RT-PCR analysis. These data provide evidence for a neuroanatomical link between hypothalamic melanocortin signaling in the PVN and NTS neurons that regulate food intake. These findings highlight the contribution of melanocortin signaling in the PVN toward regulating the satiety effects of CCK-8 while acknowledging that melanocortin-dependent pathways in other brain regions and/or melanocortin-independent mechanisms are also important in this mechanism. C1 [Blevins, James E.; Caldwell, David W.; Bastian, Lloyd S.; Baskin, Denis G.] VA Puget Sound Hlth Care Syst, Off Res & Dev, Dept Vet Affairs Med Ctr, Med Res Serv, Seattle, WA 98108 USA. [Blevins, James E.; Morton, Gregory J.; Williams, Diana L.; Wisse, Brent E.; Schwartz, Michael W.; Baskin, Denis G.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Baskin, Denis G.] Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA. RP Blevins, JE (reprint author), VA Puget Sound Hlth Care Syst, Off Res & Dev, Dept Vet Affairs Med Ctr, Med Res Serv, Mail stop S-151,1660 S Columbian Way, Seattle, WA 98108 USA. EM jeblevin@u.washington.edu RI Schwartz, Michael/H-9950-2012; Williams, Diana/C-1699-2014 OI Williams, Diana/0000-0002-3548-7440 FU University of Washington; CNRU; NIH [DK-17047, P30DK-035816, P30 DK-017047-31, P30 DK017047 -31689, P30 DK-035816, PO1 DK-068384] FX This material is based on work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs including the VA Career Development Program, Merit Review Research Program, Research Enhancement Award Program, and Career Scientist Program. D. G. Baskin is the recipient of a Department of Veterans Affairs Senior Research Career Scientist Award at the VA Puget Sound Health Care System. The research was also supported by the biomedical research core programs,particularly the Cellular and Molecular Imaging Core of the National Institutes of Health (NIH) Diabetes Endocrinology Research Center and NIH CNRU at the University of Washington. Grant support for the research was provided by a Pilot and Feasibility grant from the University of Washington CNRU and NIH Grants DK-17047, P30DK-035816, P30 DK-017047 -31, P30 DK017047 -31689, P30 DK-035816, and PO1 DK-068384. NR 53 TC 41 Z9 42 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD MAR PY 2009 VL 296 IS 3 BP R476 EP R484 DI 10.1152/ajpregu.90544.2008 PG 9 WC Physiology SC Physiology GA 412ST UT WOS:000263745200002 PM 19109369 ER PT J AU Vagin, O Kraut, JA Sachs, G AF Vagin, Olga Kraut, Jeffrey A. Sachs, George TI Role of N-glycosylation in trafficking of apical membrane proteins in epithelia SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Review DE apical sorting; apical membrane retention; H-K-ATPase beta-subunit; lectin ID DARBY CANINE KIDNEY; INFLUENZA-VIRUS HEMAGGLUTININ; H,K-ATPASE BETA-SUBUNIT; POLARIZED MDCK CELLS; L-TYPE LECTINS; PLASMA-MEMBRANE; LIPID RAFTS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; TRANSMEMBRANE DOMAIN AB Vagin O, Kraut JA, Sachs G. Role of N-glycosylation in trafficking of apical membrane proteins in epithelia. Am J Physiol Renal Physiol 296: F459-F469, 2009. First published October 29, 2008; doi: 10.1152/ajprenal.90340.2008.- Polarized distribution of plasma membrane transporters and receptors in epithelia is essential for vectorial functions of epithelia. This polarity is maintained by sorting of membrane proteins into apical or basolateral transport containers in the trans-Golgi network and/or endosomes followed by their delivery to the appropriate plasma membrane domains. Sorting depends on the recognition of sorting signals in proteins by specific sorting machinery. In the present review, we summarize experimental evidence for and against the hypothesis that N-glycans attached to the membrane proteins can act as apical sorting signals. Furthermore, we discuss the roles of N-glycans in the apical sorting event per se and their contribution to folding and quality control of glycoproteins in the endoplasmic reticulum or retention of glycoproteins in the plasma membrane. Finally, we review existing hypotheses on the mechanism of apical sorting and discuss the potential roles of the lectins, VIP36 and galectin-3, as putative apical sorting receptors. C1 [Vagin, Olga; Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Vagin, Olga; Kraut, Jeffrey A.; Sachs, George] Univ Calif Los Angeles, Membrane Biol Lab, Los Angeles, CA 90073 USA. [Kraut, Jeffrey A.] Vet Adm Greater Los Angeles Hlth Care Syst, Div Nephrol, Los Angeles, CA USA. RP Vagin, O (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Bldg 113,Rm 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM olgav@ucla.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK-077149, DK-58333, DK-053642] FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-077149, DK-58333, and DK-053642. Downloaded from ajprenal. physiology. org on February 23, 2009 NR 95 TC 77 Z9 79 U1 0 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAR PY 2009 VL 296 IS 3 BP F459 EP F469 DI 10.1152/ajprenal.90340.2008 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 410CB UT WOS:000263552400001 PM 18971212 ER PT J AU Rongey, CA Kanwal, F Hoang, T Gifford, AL Asch, SM AF Rongey, Catherine A. Kanwal, Fasiha Hoang, Tuyen Gifford, Allen L. Asch, Steven M. TI Viral RNA Testing in Hepatitis C Antibody-Positive Veterans SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID INJECTION-DRUG USERS; VIRUS-INFECTION; UNITED-STATES; ANTIVIRAL THERAPY; PLUS RIBAVIRIN; LIVER FIBROSIS; CIRRHOSIS; AMINOTRANSFERASE; MULTICENTER; ELIGIBILITY AB Background: Chronic hepatitis C virus (HCV) infection affects approximately 1.3% of the U.S. population. As up to 30% of HCV-antibody (anti-HCV)-positive patients leave negative HCV ribonucleic acid (RNA), indicating resolution of infection, VA (Veterans Affairs) guidelines recommend RNA testing on all anti-HCV-positive patients. As HCV RNA testing is a prequel to treatment, perceived eligibility for treatment may influence the decision to order an RNA test. This study was designed to determine the patient and healthcare facility factors associated with patient receipt of HCV RNA testing. Methods: Two logistic regression analyses were conducted in anti-HCV-positive patients, including the entire sample and then on a subsample excluding sites with routine HCV RNA testing policies, using data stored in the VA Southern California Network data warehouse. Significant patient- and site-level predictors of patient receipt of HCV RNA testing were determined. Results: Of the 13,257 antibody-positive patients, 76% received HCV RNA testing. Excluding sites with routine HCV RNA testing, patients aged >65 years (RR=0.79) and illicit drug users (RR=0.94) were significantly less likely to receive HCV RNA testing. Patients with abnormal transaminases (RR=1.14), presence of non-HCV hepatitis (RR=1.08), or decompensated liver disease (RR=1.22) were significantly more likely to receive HCV RNA testing. Conclusions: Without policies for routine RNA testing, patients with hepatitic C who either are aged >65 years or are illicit: drug users are less likely to be tested. Also, patient receipt of RNA testing becomes dependent on clinical cites of hepatic decompensation or inflammation. The results Support the implementation of routine RNA testing for anti-HCV-positive patients. C1 [Rongey, Catherine A.] Univ Calif Los Angeles, Robert Wood Johnson Clin Schloars Program, Los Angeles, CA 90024 USA. [Kanwal, Fasiha] Univ Calif Los Angeles, Ctr Outcomes Res & Educ, Los Angeles, CA 90024 USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA 90095 USA. [Rongey, Catherine A.; Hoang, Tuyen; Asch, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Rongey, Catherine A.] Univ So Calif, Div Gastroenterol, Los Angeles, CA 90033 USA. [Kanwal, Fasiha] St Louis Univ, Div Gastroenterol, St Louis, MO 63103 USA. [Gifford, Allen L.] Boston Univ, Dept Internal Med, Boston, MA 02215 USA. RP Rongey, CA (reprint author), Univ So Calif, Dept Med, GI Liver Div, Sch Med, 1200 N State St,LAC Room 12-137, Los Angeles, CA 90033 USA. EM rongey@usc.edu FU VA HIV-Hepatitis Quality Enhancement Research Initiative FX Dr. Rongey is supported by the Robert Wood Johnson Clinical Scholars and Foundation. This research was also supported by the VA HIV-Hepatitis Quality Enhancement Research Initiative. NR 28 TC 14 Z9 14 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2009 VL 36 IS 3 BP 235 EP 238 DI 10.1016/j.amepre.2008.10.013 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 409XE UT WOS:000263538300007 PM 19162434 ER PT J AU Tamashiro, E Xiong, GX Anselmo-Lima, WT Kreindler, JL Palmer, JN Cohen, NA AF Tamashiro, Edwin Xiong, Guoxiang Anselmo-Lima, Wilma T. Kreindler, James L. Palmer, James N. Cohen, Noam A. TI Cigarette smoke exposure impairs respiratory epithelial ciliogenesis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article; Proceedings Paper CT 54th Annual Fall Meeting of the American-Rhinologic-Society CY SEP 20, 2008 CL Chicago, IL SP Amer Rhinol Soc DE Cigarette; cilia; ciliogenesis; concentrate; rhinosinusitis; tobacco; transepithelial resistance ID ENDOSCOPIC SINUS SURGERY; RAT TRACHEAL EPITHELIUM; LIQUID INTERFACE CULTURES; CILIARY BEAT FREQUENCY; NECROSIS-FACTOR-ALPHA; CHRONIC RHINOSINUSITIS; MECHANICAL INJURY; OXYGEN RADICALS; TOBACCO-SMOKE; EX-SMOKERS AB Background: Cigarette smoke exposure is considered an important negative prognostic factor for chronic rhinosinusitis (CRS) patients. However, there is no clear mechanistic evidence implicating cigarette smoke exposure in the poor clinical evolution of the disease or in the maintenance of the inflammatory state characterizing CRS. This study aimed to evaluate the effects of cigarette smoke exposure on respiratory cilia differentiation. Methods: Monse nasal septal epithelium cultures grown at an air-liquid interface were used as a model of respiratory epithelium. After 5 days of cell growth, cultures were exposed to air on the apical surface. Additionally, cigarette smoke condensate (CSC; the particulate phase of tobacco smoke) or cigarette smoke extract (CSE; the volatile phase) Were diluted in the basolateral compartment in different concentrations. After 15 days of continuous exposure, scanning electron microscopy and immunofluorescence for type IV tubulin were used to determine presence and maturation of cilia. Transepithelial resistance was also recorded to evaluate confluence and physiological barrier integrity. Results: CSC and CSE impair ciliogenesis in a dose-dependent manner with notable effects in concentrations higher than 30 mu g/mL, yielding >70% nonciliation and shorter cilia compared With control. No statistical difference on transepithelial resistance was evident. Conclusion: CSC and CSE exposure negatively impacts ciliogenesis of respiratory cells at concentrations not effecting transepithelial resistance. The impairment on ciliogenesis reduce the mucociliary clearance apparatuts after injury and/or infection and may explain the poor response to therapy for CRS patients exposed to tobacco smoke. C1 [Palmer, James N.; Cohen, Noam A.] Univ Penn Hlth Syst, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA USA. [Palmer, James N.; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Dept Surg, Philadelphia, PA USA. [Tamashiro, Edwin; Anselmo-Lima, Wilma T.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Ophthalmol Otorhinolaryngol & Head & Neck Su, BR-05508 Sao Paulo, Brazil. [Xiong, Guoxiang; Kreindler, James L.] Univ Penn Hlth Syst, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Div Rhinol, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM cohenn@uphs.upenn.edu RI Tamashiro, Edwin/C-5062-2012 OI Tamashiro, Edwin/0000-0002-3153-6292; Cohen, Noam/0000-0002-9462-3932 NR 45 TC 53 Z9 53 U1 2 U2 39 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AMJ RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD MAR-APR PY 2009 VL 23 IS 2 BP 117 EP 122 DI 10.2500/ajra.2009.23.3280 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 431IV UT WOS:000265055900001 PM 19401033 ER PT J AU Bannerman, DD Rinaldi, M Vinyard, BT Laihia, J Leino, L AF Bannerman, Douglas D. Rinaldi, Manuela Vinyard, Bryan T. Laihia, Jarmo Leino, Lasse TI Effects of intramammary infusion of cis-urocanic acid on mastitis-associated inflammation and tissue injury in dairy cows SO AMERICAN JOURNAL OF VETERINARY RESEARCH LA English DT Article ID BETA-D-GLUCOSAMINIDASE; ENDOTOXIN-INDUCED MASTITIS; EPITHELIAL-CELL DAMAGE; NECROSIS-FACTOR-ALPHA; BOVINE MAMMARY-GLAND; ESCHERICHIA-COLI; CLINICAL MASTITIS; LACTATE-DEHYDROGENASE; STAPHYLOCOCCUS-AUREUS; BACTERIAL LIPOPOLYSACCHARIDE AB Objective-To evaluate the effects of cis-urocanic acid (cis-UCA) on mammary gland (MG) inflammation and injury associated with Escherichia coli-induced mastitis in dairy cows. Animals-12 lactating dairy cows (36 MGs). Procedures-At 7-week intervals, a different MG in each cow was experimentally inoculated with E coli. At 6-hour intervals from 6 to 36 hours after inoculation, the inoculated MG in each cow was infused with 40 mL of saline (0.9% NaCl) solution, 12.5mM cis-UCA, or 25mM cis-UCA (4 cows/group); ultimately, each cow received each treatment. Immediately prior to and at various time points after inoculation and treatment, milk samples were collected. Bacterial CFUs, somatic cell counts (SCCs), N-acetyl-beta-D-glucosaminidase (NAGase) and lactate dehydrogenase (LDH) activities, and concentrations of bovine serum albumin, tumor necrosis factor-alpha, and cis-UCA were quantified in each milk sample. Results-Compared with findings in saline solution-treated MGs, NAGase and LDH activities in milk samples from cis-UCA-treated MGs were lower. Cis-UCA had no effect on milk SCCs and milk concentrations of bovine serum albumin and tumor necrosis factor-alpha. Furthermore, cis-UCA had no adverse effect on bacterial clearance; CFUS of E coli in MGs treated with saline solution or cis-UCA were equivalent. Conclusions and Clinical Relevance-In cows, milk NAGase and LDH activities were both lower in E coli-infected MGs infused with cis-UCA than in those infused with saline solution, which suggests that cis-UCA reduced mastitis-associated tissue damage. Furthermore, these data indicated that therapeutic concentrations of cis-UCA in milk can be achieved via intramammary infusion. (Am J Vet Res 2009,-70:373-382) C1 [Bannerman, Douglas D.; Rinaldi, Manuela] ARS, Bovine Funct Genom Lab, USDA, BARC E, Beltsville, MD 20705 USA. [Vinyard, Bryan T.] ARS, Biometr Consulting Serv, USDA, BARC W, Beltsville, MD 20705 USA. [Laihia, Jarmo; Leino, Lasse] BioCis Pharma Ltd, Turku 20520, Finland. RP Bannerman, DD (reprint author), US Dept Vet Affairs, Off Res Oversight, 810 Vermont Ave NW 10R, Washington, DC 20420 USA. NR 72 TC 8 Z9 9 U1 0 U2 4 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0002-9645 J9 AM J VET RES JI Am. J. Vet. Res. PD MAR PY 2009 VL 70 IS 3 BP 373 EP 382 PG 10 WC Veterinary Sciences SC Veterinary Sciences GA 419FL UT WOS:000264204400009 PM 19254150 ER PT J AU Saxena, S AF Saxena, Shashank TI The ASA Difficult Airway Algorithm: Is It Time to Include Video Laryngoscopy and Discourage Blind and Multiple Intubation Attempts in the Nonemergency Pathway? SO ANESTHESIA AND ANALGESIA LA English DT Letter ID CLOSED CLAIMS ANALYSIS; MANAGEMENT C1 Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Saxena, S (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. EM saxenas@anes.npmc.edu NR 7 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAR PY 2009 VL 108 IS 3 BP 1052 EP 1052 DI 10.1213/ane.0b013e31819341e4 PG 1 WC Anesthesiology SC Anesthesiology GA 409WU UT WOS:000263537300077 PM 19224832 ER PT J AU Lee, C Gianos, M Klaustermeyer, WB AF Lee, Christina Gianos, Mary Klaustermeyer, William B. TI Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Review ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CARBOPLATIN-HYPERSENSITIVITY; L-ASPARAGINASE; ESCHERICHIA-COLI; IDIOSYNCRATIC REACTIONS; RAPID DESENSITIZATION; FLUID RETENTION; OVARIAN-CANCER; BREAST-CANCER; OXALIPLATIN AB Objectives: To review clinical hypersensitivity reactions related to common cancer chemotherapy agents and to discuss potential management strategies. Data Sources: PubMed searches were performed for articles published from 1970 to 2008 regarding hypersensitivity to cancer chemotherapy and related agents using the keywords hypersensitivity, allergy, chemotherapy, platinums, taxanes, asparaginase, epipodophyllotoxins, and procarbazine. Retrieved articles were surveyed for additional citations. Study Selection: Articles were reviewed for relevance to the subject matter, and the most pertinent articles were included in this review. Results: Hypersensitivity reactions are commonly associated with the use of certain cancer chemotherapy drugs, including platinums, taxanes, asparaginase, procarbazine, and epipodophyllotoxins. Platinum agents (cisplatin, carboplatin, oxaliplatin) are associated with IgE-mediated hypersensitivity reactions, and skin testing may be indicated. Taxane (paclitaxel, docetaxel)-related reactions are generally non-IgE mediated, and premedication with corticosteroids and antihistamines is usually effective. Asparaginase has a high rate of hypersensitivity reactions that are likely IgE mediated or related to complement activation. Skin testing has been recommended but has not been validated for asparaginase. Procarbazine reactions call be IgE mediated but are also associated with a type III reaction manifested by pulmonary toxicity and cutaneous reactions. Hypersensitivity reactions related to epipodophyllotoxins may involve both immunologic and nonimmunologic factors that may be avoided with a slow infusion and premedication. Conclusion: With the increasing use of cancer chemotherapy agents, hypersensitivity reactions are commonly encountered. Knowledge of the presentations of these reactions and management options give the treating physician the means to make all informed decision of how best to proceed. C1 [Lee, Christina; Gianos, Mary; Klaustermeyer, William B.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Allergy & Immunol 111R, Los Angeles, CA 90024 USA. RP Lee, C (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Allergy & Immunol 111R, 11301 Wilshire Blvd, Los Angeles, CA 90024 USA. EM christina.h.lee@hotmail.com NR 79 TC 60 Z9 64 U1 0 U2 16 PU AMER COLL ALLERGY ASTHMA IMMUNOLOGY PI ARLINGTON HTS PA 85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD MAR PY 2009 VL 102 IS 3 BP 179 EP 187 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 420GM UT WOS:000264277000003 PM 19354063 ER PT J AU Pollack, CV Varon, J Garrison, NA Ebrahimi, R Dunbar, L Peacock, WF AF Pollack, Charles V. Varon, Joseph Garrison, Norman A. Ebrahimi, Ramin Dunbar, Lala Peacock, W. Frank TI Clevidipine, an Intravenous Dihydropyridine Calcium Channel Blocker, Is Safe and Effective for the Treatment of Patients With Acute Severe Hypertension SO ANNALS OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Scientific Assembly of the American-College-of-Emergency-Physicians CY OCT 18-19, 2007 CL Seattle, WA SP Amer Coll Emergency Phys ID BLOOD-PRESSURE; HEALTHY-VOLUNTEERS; MANAGEMENT; ANTAGONIST; CRISES; EMERGENCIES; EFFICACY; SURGERY AB Study objective: We assess the safety and efficacy of intravenous clevidipine for treating patients with acute severe increase in blood pressure by using prespecified, non-weight-based titration dosing, with continuous maintenance infusion for 18 hours or longer. Methods: Prospective, open-label, single-arm evaluation of patients aged 18 years or older and presenting in the emergency department or ICU with severe hypertension (systolic blood pressure >180 mm Hg and/or diastolic blood pressure >115 mm Hg) and treated with clevidipine to achieve a predetermined, patient-specific systolic blood pressure target range. Clevidipine was initiated at 2 mg per hour and titrated as needed in doubling increments every 3 minutes to a maximum of 32 mg per hour, during 30 minutes, and then continued for a total duration of 18 to 96 hours. Results: Study patients Commonly presented with both acute hypertension and end-organ injury; 81% (102/126) had demonstrable end-organ injury at baseline. Within 30 minutes of starting clevidipine, 88.9% (104/117) of patients achieved target range. Median time to target range was 10.9 minutes. No concomitant intravenous antihypertensives were needed in 92.3% (108/117) of patients receiving 18 hours or more of clevidipine infusion. Clevidipine was well tolerated with successful transition to oral antihypertensive therapy after infusion to a defined blood pressure target in 91.3% (115/126) of patients. Conclusion: Clevidipine, dosed in a non-weight-based manner, was safe and effective in a cohort of patients with severe hypertension at a Starting dose of 2 mg per hour, followed by simple titration during 18 hours or more of continuous infusion. Patients were effectively managed via simple blood pressure cuff monitoring throughout. (Ann Emerg Med. 2009;53:329-338.] C1 [Pollack, Charles V.] Univ Penn, Dept Emergency Med, Penn Hosp, Philadelphia, PA 19107 USA. [Varon, Joseph] Univ Texas Med Sch, Univ Texas Hlth Sci Ctr Houston, St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA. Univ Texas Med Branch Galveston, Galveston, TX USA. [Garrison, Norman A.] Jackson Hosp, Montgomery, AL USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA USA. [Ebrahimi, Ramin] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Dunbar, Lala] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Peacock, W. Frank] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44106 USA. RP Pollack, CV (reprint author), Univ Penn, Dept Emergency Med, Penn Hosp, 800 Spruce St,2 Pine E, Philadelphia, PA 19107 USA. EM pollackc@pahosp.com OI Varon, Joseph/0000-0002-7622-9974 NR 26 TC 31 Z9 34 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD MAR PY 2009 VL 53 IS 3 BP 329 EP 338 DI 10.1016/j.annemergmed.2008.04.025 PG 10 WC Emergency Medicine SC Emergency Medicine GA 422VK UT WOS:000264455600008 PM 18534716 ER PT J AU Kwo, EC Kamat, P Steinman, MA AF Kwo, Elizabeth C. Kamat, Priya Steinman, Michael A. TI Physician Use of Brand Versus Generic Drug Names in 1993-1994 and 2003-2004 SO ANNALS OF PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 02-06, 2007 CL Seattle, WA SP Amer Geriatr Soc DE brand names; generic names; pharmaceutical industry ID POTENTIAL SAVINGS; MEDICATION USE; TRADE NAMES; PHARMACEUTICALS; SUBSTITUTION; BENEFIT AB BACKGROUND: Physicians often refer to drugs by their brand names, which can result in brand name drugs being dispensed even when bioequivalent generic alternatives are available. As a result, use of brand-name terminology may result in increased drug costs. OBJECTIVE: To evaluate how often physicians use brand and generic names of drugs, how the use of terminology changes over time, and factors associated with this change. METHODS: This was a serial cross-sectional study using data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey in 1993/1994 and 2003/2004. Over the 4 study years, data were collected on 376,383 subjects. Using forms completed by physicians that described medication regimens, we determined the proportion of drug names that were recorded using brand vs nonproprietary (ie, generic) terminology. RESULTS: In 1993/1994, the 25 most commonly mentioned drugs were referred to by their brand names a median of 89% of the time. Over the ensuing decade, use of brand-name terminology decreased by a median of 11%. Drugs that first faced generic competition within 10 years of the baseline study year had large declines in brand-name use (43-58% decline), whereas drugs that first faced generic competition more than 10 years before or after the baseline study year had minimal change in brand-name use (2-3% decline; p = 0.02 for difference in rate of decline among drug groups). Year of drug introduction, baseline rate of brand-name use, clinical setting, and national region were not associated with reductions in brand-name use. CONCLUSIONS: Brand-name terminology is commonly used and decreases over time with the introduction of generic competition. Interventions that standardize medication-naming practices may hasten this decline and increase use of nonproprietary terminology in medicine. C1 [Kamat, Priya; Steinman, Michael A.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, No Calif Inst Res & Educ, San Francisco, CA 94121 USA. [Kwo, Elizabeth C.] Univ Calif San Francisco, Aging Res Program, San Francisco, CA 94143 USA. [Kwo, Elizabeth C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Steinman, MA (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, No Calif Inst Res & Educ, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu RI Mendoza, Elvia/A-9361-2012 NR 35 TC 6 Z9 6 U1 0 U2 3 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAR PY 2009 VL 43 IS 3 BP 459 EP 468 DI 10.1345/aph.1L502 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 419IK UT WOS:000264212700007 PM 19261956 ER PT J AU Pivtoraiko, VN Stone, SL Roth, KA Shacka, JJ AF Pivtoraiko, Violetta N. Stone, Sara L. Roth, Kevin A. Shacka, John J. TI Oxidative Stress and Autophagy in the Regulation of Lysosome-Dependent Neuron Death SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID CATHEPSIN-D DEFICIENCY; MOUSE PERITONEAL-MACROPHAGES; SPORADIC ALZHEIMERS-DISEASE; LIPID-PEROXIDATION PRODUCTS; CULTURED RAT HEPATOCYTES; AMYLOID-BETA-PROTEIN; AGE-RELATED-CHANGES; INDUCED CELL-DEATH; INDUCED APOPTOSIS; HYDROGEN-PEROXIDE AB Lysosomes critically regulate the pH-dependent catabolism of extracellular and intracellular macromolecules delivered from the endocytic/heterophagy and autophagy pathways, respectively. The importance of lysosomes to cell survival is underscored not only by their unique ability effectively to degrade metalloproteins and oxidatively damaged macromolecules, but also by the distinct potential for induction of both caspase-dependent and -independent cell death with a compromise in the integrity of lysosome function. Oxidative stress and free radical damage play a principal role in cell death induced by lysosome dysfunction and may be linked to several upstream and downstream stimuli, including alterations in the autophagy degradation pathway, inhibition of lysosome enzyme function, and lysosome membrane damage. Neurons are sensitive to lysosome dysfunction, and the contribution of oxidative stress and free radical damage to lysosome dysfunction may contribute to the etiology of neurodegenerative disease. This review provides a broad overview of lysosome function and explores the contribution of oxidative stress and autophagy to lysosome dysfunction-induced neuron death. Putative signaling pathways that either induce lysosome dysfunction or result from lysosome dysfunction or both, and the role of oxidative stress, free radical damage, and lysosome dysfunction in pediatric lysosomal storage disorders (neuronal ceroid lipofuscinoses or NCL/Batten disease) and in Alzheimer's disease are emphasized. Antioxid. Redox Signal. 11, 481-496. C1 [Pivtoraiko, Violetta N.; Stone, Sara L.; Roth, Kevin A.; Shacka, John J.] Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. [Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Shacka, JJ (reprint author), SC 843A,1530 3rd Ave S, Birmingham, AL 35294 USA. EM shacka@uab.edu OI Roth, Kevin/0000-0002-0643-995X FU National Institutes of Health [NS35107, NS41962]; UAB Alzheimer's Disease Research Center; Birmingham VA Medical Center FX We thank Angela Schmeckebier and Barry Bailey for expert technical assistance in preparation of the manuscript. We also thank the UAB Neuroscience Core Facilities (NS47466 and NS57098) for technical assistance. This work is supported by grants from the National Institutes of Health (NS35107 and NS41962), a pilot grant from the UAB Alzheimer's Disease Research Center, and a VISN7 Career Development Award from the Birmingham VA Medical Center. NR 174 TC 46 Z9 47 U1 1 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD MAR PY 2009 VL 11 IS 3 BP 481 EP 496 DI 10.1089/ars.2008.2263 PG 16 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 399VD UT WOS:000262826500008 PM 18764739 ER PT J AU Goldstein, G AF Goldstein, Gerald TI Neuropsychology in New York City (1930-1960)(dagger) SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Editorial Material C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst 151R, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM ggold@nb.net NR 18 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAR PY 2009 VL 24 IS 2 BP 137 EP 143 DI 10.1093/arclin/acp023 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA 454TL UT WOS:000266705500002 PM 19435732 ER PT J AU Hilsabeck, RC Sutker, PB AF Hilsabeck, Robin C. Sutker, Patricia B. TI Using an Implicit Memory Task to Estimate Premorbid Memory SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Premorbid IQ; Premorbid cognitive functioning; Dementia; Brain injury; Mild cognitive impairment ID ALZHEIMERS-DISEASE; ABILITY; PERFORMANCE; INTELLIGENCE; TESTS; INFORMATION; VALIDATION; EXPLICIT; SAMPLE; AGE AB Clinicians are often asked to determine if significant memory loss has occurred. Clinical judgment figures prominently in making these determinations, because there is no accepted, objective method for estimating premorbid memory. Two studies were designed to explore the utility of an implicit memory task, Anagrams Solutions, for estimating premorbid memory ability. A secondary goal was to identify predictors of immediate and delayed memory measured by the Repeatable Battery for the Assessment of Neuropsychological Status using selected intellectual (IQ) and demographic variables. Participants in both studies were administered the implicit memory task, explicit memory measures, and IQ estimate. Results revealed that Anagrams Solutions was not a useful estimate of premorbid memory and that a combination of IQ and demographic variables accounted for 24-31% of the variance in measured memory performances. Findings point to the need for caution in interpreting scores on these variables as valid estimates of premorbid memory functioning. C1 [Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.; Sutker, Patricia B.] Texas Tech Univ Hlth Sci Ctr, Lubbock, TX 79430 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM robin.hilsabeck@va.gov FU National Academy of Neuropsychology Clinical Research; Research and Education Center at Carillon Senior Living Campus FX This research was supported by grants from the National Academy of Neuropsychology Clinical Research Grants Program, and The Research and Education Center at Carillon Senior Living Campus. NR 42 TC 3 Z9 3 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAR PY 2009 VL 24 IS 2 BP 179 EP 191 DI 10.1093/arclin/acp024 PG 13 WC Psychology, Clinical; Psychology SC Psychology GA 454TL UT WOS:000266705500006 PM 19435733 ER PT J AU Markland, AD Gerety, MB Goode, PS Kraus, SR Cornell, J Hazuda, HP AF Markland, Alayne D. Gerety, Meghan B. Goode, Patricia S. Kraus, Stephen R. Cornell, John Hazuda, Helen P. TI Urinary incontinence in community-dwelling older Mexican American and European American women SO ARCHIVES OF GERONTOLOGY AND GERIATRICS LA English DT Article DE Urinary incontinence; Fecal incontinence; Epidemiology of urinary incontinence; Risk factors ID AFRICAN-AMERICAN; NATURAL-HISTORY; HISPANIC WOMEN; RISK-FACTORS; PREVALENCE; HEALTH; WHITE; EPIDEMIOLOGY; DEPRESSION; SEVERITY AB The aim was to measure prevalence and correlates of urinary incontinence in community-dwelling Mexican American (MA) and European American (EA) women from a cross-sectional analysis of baseline data from a longitudinal cohort. Participants were MA and EA women, aged 65 years and older, in the San Antonio Longitudinal Study of Aging (SALSA), of whom 421 (97.4%) responded to the question "How often do you have difficulty holding your urine until you can get to a toilet." Measurements included sociodemographic, functional, cognitive, psychosocial, and clinical status variables derived from bilingual interviews and performance-based tests. Urinary incontinence prevalence was 36.6% (n = 154). MA women reported less incontinence than did EAs (29% versus 45%, p = 0.001). in multivariable analyses in MA women, urinary incontinence correlated with the presence of fecal incontinence (OR 4.0, 95% CI 1.1-14.0) and more dependency in activities of daily living (1.4, 1.1-1.8) after controlling for significant sociodemographic factors. In EA women, only age >75 (4.2, 1.4-12.4) was associated with urinary incontinence. MA women were less likely to report incontinence compared to EAs, despite MAs having increased number of children, less education, higher BMI, and more diabetes. Further research is needed to evaluate risk factors for urinary incontinence among MA women. Published by Elsevier Ireland Ltd. C1 [Markland, Alayne D.; Goode, Patricia S.] Univ Alabama, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Div Gerontol & Geriatr Med,Dept Med, Birmingham Vet Affairs Med Ctr,VAMC GRECC, Birmingham, AL 35294 USA. [Gerety, Meghan B.] New Mexico VA Healthcare Syst, Dept Vet Affairs, Albuquerque, NM 87108 USA. [Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Kraus, Stephen R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Gerety, Meghan B.; Cornell, John] S Texas Vet Hlth Care Adm, San Antonio, TX 78229 USA. [Gerety, Meghan B.; Cornell, John] Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Markland, AD (reprint author), Univ Alabama, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Div Gerontol & Geriatr Med,Dept Med, Birmingham Vet Affairs Med Ctr,VAMC GRECC, 11-G Room 8221,1350 3rd Ave S, Birmingham, AL 35294 USA. EM amarkland@aging.uab.edu OI Markland, Alayne/0000-0002-6567-6744 FU National Institute of Aging [RO1 AG 10444, 16518] FX Work supported by National Institute of Aging Grants RO1 AG 10444 and 16518. The authors would like to thank Kathryn L. Burgio, PhD, for reviewing the manuscript. NR 33 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-4943 J9 ARCH GERONTOL GERIAT JI Arch. Gerontol. Geriatr. PD MAR-APR PY 2009 VL 48 IS 2 BP 232 EP 237 DI 10.1016/j.archger.2008.01.013 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 411IK UT WOS:000263642800022 PM 18313155 ER PT J AU Yaffe, K Weston, AL Blackwell, T Krueger, KA AF Yaffe, Kristine Weston, Andrea L. Blackwell, Terri Krueger, Kathryn A. TI The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women SO ARCHIVES OF NEUROLOGY LA English DT Article ID VASCULAR RISK-FACTORS; BODY-MASS INDEX; ALZHEIMER-DISEASE; BLOOD-PRESSURE; DEMENTIA; DECLINE; POPULATION; OBESITY; ADULTS; OSTEOPOROSIS AB Background: Several studies support a role for cardiovascular risk factors in cognitive aging. The metabolic syndrome, a constellation of cardiovascular risk factors, is common in elderly people. A growing but conflicting body of literature suggests that the metabolic syndrome may be associated with cognitive impairment. Objective: To investigate the association between the metabolic syndrome and its components and incident cognitive impairment in older women. Design: We prospectively determined if the metabolic syndrome and its components were associated with a 4-year risk of developing cognitive impairment (dementia, mild cognitive impairment, or low global cognitive test score). Setting: The study was conducted at 180 clinical centers in 25 countries. Participants: A total of 4895 older women (mean age, 66.2 years) with osteoporosis who were part of an ancillary study to determine clinically relevant cognitive impairment were included in this study. These women were free of baseline cognitive impairment and had metabolic syndrome component measures. Main Outcome Measures: Clinically significant cognitive impairment was defined to include women with clinically adjudicated dementia or MCI and women who had a Short Blessed test score greater than 6 (consistent with impairment), but whose cases were not clinically adjudicated. Logistic regression analysis was used to examine the association between presence of the metabolic syndrome and development of clinically significant cognitive impairment. Results: A total of 497 women (10.2%) had the metabolic syndrome and, of these, 36 (7.2%) developed cognitive impairment compared with 181 (of 4398 or 4.1%) without the syndrome (age-adjusted odds ratio, 1.66; 95% confidence interval, 1.14-2.41). The mean (SD) number of metabolic syndrome components for all women was 1.0 (1.1); 518 women (10.6%) were obese, 895 (18.3%) had hypertriglyceridemia, 1200 (24.5%) had low high-density lipoprotein cholesterol levels, 1944 (39.7%) had high blood pressure, and 381 (7.8%) had high fasting blood glucose levels. There was a 23.0% age-adjusted increase in the risk of developing cognitive impairment (odds ratio, 1.23; 95% confidence interval, 1.09-1.39) per unit increase in the number of components. Further multivariable adjustment somewhat reduced the effect. Conclusion: We found an association between the metabolic syndrome and the number of components and risk of developing cognitive impairment in older women. Additional studies are needed to determine if screening and close management of these at-risk elderly women would diminish the incidence of cognitive impairment. C1 [Yaffe, Kristine; Weston, Andrea L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Yaffe, Kristine; Weston, Andrea L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Blackwell, Terri] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Krueger, Kathryn A.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Campus Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM Kristine.yaffe@ucsf.edu FU National Institute on Aging [AG031155]; Eli Lilly and Company FX DrYaffe is supported in part by National Institute on Aging grant AG031155. Dr Krueger receives a full salary from Eli Lilly and Company. Ms Blackwell receives partial salary support from Eli Lilly and Company. The parent trial was funded by Eli Lilly and Company. NR 36 TC 106 Z9 110 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2009 VL 66 IS 3 BP 324 EP 328 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 416EY UT WOS:000263989600007 PM 19273750 ER PT J AU Qin, WP Haroutunian, V Katsel, P Cardozo, CP Ho, L Buxbaum, JD Pasinetti, GM AF Qin, Weiping Haroutunian, Vahram Katsel, Pavel Cardozo, Christopher P. Ho, Lap Buxbaum, Joseph D. Pasinetti, Giulio M. TI PGC-1 alpha Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia SO ARCHIVES OF NEUROLOGY LA English DT Article ID CEREBRAL GLUCOSE-METABOLISM; ENERGY-METABOLISM; GENE-EXPRESSION; HEPATIC GLUCONEOGENESIS; AMYLOID NEUROPATHOLOGY; CALORIE RESTRICTION; TRANSCRIPTIONAL COACTIVATOR; COGNITIVE DECLINE; INSULIN-RECEPTOR; TRANSGENIC MICE AB Objectives: To explore mechanisms through which altered peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) expression may influence Alzheimer disease (AD) amyloid neuropathology and to test the hypothesis that promotion of PGC-1 alpha expression in neurons might be developed as a novel therapeutic strategy in AD. Design: Case-control. Patients: Human postmortem brain (hippocampal formation) samples from AD cases and age-matched non-AD cases. Results: Using genome-wide complementary DNA microarray analysis, we found that PGC-1 alpha messenger RNA expression was significantly decreased as a function of progression of clinical dementia in the AD brain. Following confirmatory real-time polymerase chain reaction assay, we continued to explore the role of PGC-1 alpha in clinical dementia and found that PGC-1 alpha protein content was negatively associated with both AD-type neuritic plaque pathology and beta-amyloid (A beta)(X-42) contents. Moreover, we found that the predicted elevation of amyloidogenic A beta(1-42) and A beta(1-40) peptide accumulation in embryonic cortico-hippocampal neurons derived from Tg2576 AD mice under hyperglycemic conditions (glucose level, 182-273 mg/dL) coincided with a dose-dependent attenuation in PGC-1 alpha expression. Most importantly, we found that the reconstitution of exogenous PGC-1 alpha expression in Tg2576 neurons attenuated the hyperglycemic-mediated beta-amyloidogenesis through mechanisms involving the promotion of the "nonamyloidogenic" alpha-secretase processing of amyloid precursor protein through the attenuation of the forkheadlike transcription factor 1 (FoxO3a) expression. Conclusion: Therapeutic preservation of neuronal PGC-1 alpha expression promotes the nonamyloidogenic processing of amyloid precursor protein precluding the generation of amyloidogenic A beta peptides. C1 [Qin, Weiping; Haroutunian, Vahram; Katsel, Pavel; Buxbaum, Joseph D.; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Ho, Lap; Buxbaum, Joseph D.; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Ho, Lap; Pasinetti, Giulio M.] Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Ho, Lap; Pasinetti, Giulio M.] James J Peters VA Med Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Qin, Weiping/0000-0002-5763-5846 FU Atkins Foundation; National Institutes of Health [AG14766]; Dana Foundation for Brain Research Initiative, Merit Review; Department of Veterans Affairs Rehabilitation Research and Development Service [B4162C] FX These studies were supported by the Dr Robert C. Atkins Foundation, National Institutes of Health grant AG14766, the Dana Foundation for Brain Research Initiative, Merit Review (Dr Pasinetti), and grant B4162C from the Department of Veterans Affairs Rehabilitation Research and Development Service. NR 60 TC 126 Z9 126 U1 3 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0003-9942 EI 1538-3687 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2009 VL 66 IS 3 BP 352 EP 361 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 416EY UT WOS:000263989600011 PM 19273754 ER PT J AU Turner, AP Kivlahan, DR Haselkorn, JK AF Turner, Aaron P. Kivlahan, Daniel R. Haselkorn, Jodie K. TI Exercise and Quality of Life Among People With Multiple Sclerosis: Looking Beyond Physical Functioning to Mental Health and Participation in Life SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Exercise; Health status; Mental health; Multiple sclerosis; Quality of life; Rehabilitation ID RANDOMIZED CONTROLLED-TRIAL; LOW-BACK-PAIN; WAR VETERANS ILLNESSES; AEROBIC EXERCISE; UNITED-STATES; OUTPATIENT REHABILITATION; BEHAVIORAL ACTIVATION; DEPRESSIVE SYMPTOMS; ACTIVITY LEVEL; DISABILITY AB Objective: To describe the prevalence of exercise in a national sample of veterans with multiple sclerosis (MS) and the association of exercise with quality of life, including physical health, mental health, and participation restriction. Design: Cross-sectional cohort study linking computerized medical records to mailed survey data from 1999. Setting: Veterans Health Administration. Participants: Veterans with MS (N=2995; 86.5% men) who received services in the Veterans Health Administration and returned survey questionnaires. Interventions: Not applicable. Main Outcome Measures: Demographic information, Veteran RAND 36-Item Health Survey (VR-36), self-reported exercise frequency. Results: Among all survey respondents with MS, only 28.6% (95% confidence interval, 26.9-30.2) endorsed any exercise. In adjusted logistic regression, exercise was associated with younger age, more education, living alone, lower levels of bodily pain, and higher body mass index. After adjusting for demographic variables and medical comorbidities, exercise was associated with better physical and mental health. People who exercised reported they had better social functioning and better role functioning (participation in life despite physical and emotional difficulties). Conclusions: Exercise in veterans with MS is uncommon. In the context of chronic illness care, the identification of exercise patterns and promotion of physical activity may represent an important opportunity to improve mental health and quality of life among people with MS. Intervention should address factors associated with lower rates of exercise including age. education, and pain. C1 [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov OI Turner, Aaron/0000-0001-6897-8003 FU Department of Veterans Affairs Rehabilitation Research; Development Service Career Development Award [B4927W] FX Supported by Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award (grant no. B4927W). Veterans Affairs Center of Excellence in Substance Abuse Treatment and Education, the Veterans Affairs Multiple Sclerosis Center of Excellence West. and the Veterans Affairs Office of Quality and Performance. NR 73 TC 36 Z9 36 U1 4 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2009 VL 90 IS 3 BP 420 EP 428 DI 10.1016/j.apmr.2008.09.558 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 421YW UT WOS:000264395200008 PM 19254606 ER PT J AU Weaver, FM Burns, SP Evans, CT Rapacki, LM Goldstein, B Hammond, MC AF Weaver, Frances M. Burns, Stephen P. Evans, Charlesnika T. Rapacki, Lauren M. Goldstein, Barry Hammond, Margaret C. TI Provider Perspectives on Soldiers With New Spinal Cord Injuries Returning From Iraq and Afghanistan SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Health personnel; Rehabilitation; Spinal cord injuries; Veterans ID TRAUMATIC BRAIN-INJURY; COMBAT; WAR; REHABILITATION; CASUALTIES; RISK AB Objective: The military conflicts in Iraq and Afghanistan have resulted in many soldiers returning with serious combat injuries, including spinal cord injuries (SCIs). The purpose of this study was to query providers regarding any unique problems or needs in a cohort of these soldiers treated in Veterans Health Administration (VHA) SCI Centers. Design: Semi structured questionnaire. Setting: Seventeen VHA SCI Centers. Participants: Thirty-eight providers, including physicians, nurses, therapists, social workers, and psychologists who volunteered to return completed questionnaires. Interventions: Not applicable. Main Outcome Measures: Identification of medical and psychosocial issues, rehabilitation delays, therapy and vocational needs, social support, and discharge planning. Results: Providers identified several injuries and conditions beyond SCI that were experienced by these soldiers including fractures, pressure ulcers, traumatic brain injuries, posttraumatic stress disorder, and resistant infections. Rehabilitation was often delayed because these problems needed to be addressed first. Soldiers' family and friends provide considerable support. Vocational needs include use of technology, especially computers; education; and participation in sports. Although most return to the community after discharge, many soldiers are still active duty, and some return to military base housing. Conclusions: Combat soldiers returning with SCI often have additional medical and psychosocial problems that require appropriate and timely intervention. They have strong support from family and friends and are motivated to integrate back into the community after discharge. C1 [Weaver, Frances M.; Evans, Charlesnika T.; Rapacki, Lauren M.] Edward Hines Jr VA Hosp, Ctr Complex Chron Care, Hines, IL 60141 USA. [Weaver, Frances M.; Evans, Charlesnika T.; Rapacki, Lauren M.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. [Weaver, Frances M.; Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Weaver, Frances M.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA. [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA. [Goldstein, Barry; Hammond, Margaret C.] Dept Vet Affairs, Spinal Cord Injury & Disorders Serv, Seattle, WA USA. RP Weaver, FM (reprint author), VA Hosp, 5000 S 5th Ave 151H, Hines, IL 60141 USA. EM Frances.Weaver@va.gov FU Spinal Cord Injury Quality Enhancement Research Initiative (QUERI) in the Department of Veterans Affairs [SC198-001] FX Supported by the Spinal Cord Injury Quality Enhancement Research Initiative (QUERI) in the Department of Veterans Affairs (grant no. SC198-001). NR 14 TC 24 Z9 25 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2009 VL 90 IS 3 BP 517 EP 521 DI 10.1016/j.apmr.2008.09.560 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 421YW UT WOS:000264395200023 PM 19254621 ER PT J AU Gordon, AT Land, RM AF Gordon, Assaf T. Land, Rebekah M. TI Transtibial Prosthesis Suspension Failure During Skydiving Freefall: A Case Report SO ASSISTIVE TECHNOLOGY LA English DT Article DE failure; prosthesis; skydiving; suspension system; transtibial amputation AB This report describes the unusual case of an everyday-use prosthesis suspension system failure during the freefall phase of a skydiving jump. The case individual was a 53-year-old male with a left transtibial amputation secondary to trauma. He used his everyday prosthesis, a transtibial endoskeleton with push-button, plunger-releasing, pin-locking silicon liner suction suspension and a neoprene knee suspension sleeve, for a standard recreational tandem skydive. Within seconds of exiting the plane, the suspension systems failed, resulting in the complete prosthesis floating away. Several factors may have led to suspension system failure, including an inadequate seal and material design of the knee suspension sleeve and liner, lack of auxiliary suspension mechanisms, and lack of a safety cover overlying the push-button release mechanism. This is the first report, to our knowledge, to discuss prosthetic issues specifically related to skydiving. While amputees are to be encouraged to participate in this extreme sport, special modifications to everyday components may be necessary to reduce the possibility of prosthesis failure during freefall, parachute deployment, and landing. C1 [Gordon, Assaf T.] Univ Calif Los Angeles, Dept Phys Med & Rehabil, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Land, Rebekah M.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, Pittsburgh, PA 15213 USA. RP Gordon, AT (reprint author), Capital Spine Ctr, 2800 Shirlington Rd,Suite 102, Arlington, VA 22206 USA. EM gordonat@gmail.com NR 6 TC 1 Z9 1 U1 0 U2 3 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD SPR PY 2009 VL 21 IS 1 BP 25 EP 27 DI 10.1080/10400430902945827 PG 3 WC Rehabilitation SC Rehabilitation GA 521XZ UT WOS:000271961200003 PM 19719060 ER PT J AU Cohen, LJ Fitzgerald, SG Lane, S Boninger, ML Minkel, J McCue, M AF Cohen, Laura J. Fitzgerald, Shirley G. Lane, Suzanne Boninger, Michael L. Minkel, Jean McCue, Michael TI Validation of the Seating and Mobility Script Concordance Test SO ASSISTIVE TECHNOLOGY LA English DT Article DE clinical competence; educational measurement; professional practice; rehabilitation; validation ID DIAGNOSTIC KNOWLEDGE; CAPACITY AB The purpose of this study was to develop the scoring system for the Seating and Mobility Script Concordance Test (SMSCT), obtain and appraise internal and external structure evidence, and assess the validity of the SMSCT. The SMSCT purpose is to provide a method for testing knowledge of seating and mobility prescription. A sample of 106 therapists and 15 spinal cord injury experts contributed to the development of the scoring system. Validity evidence was obtained using 15 seating and mobility experts, 10 orthopedic experts, and 66 therapists with varying levels of seating and mobility expertise. Proxy measures of clinical expertise were used for external validity evidence since no criterion measures exist. The SMSCT was found to differentiate between seating and mobility experts' and orthopedic experts' intervention subtest scores (p = 0.04). The proxy measure of clinical expertise, seating and mobility hours/week, was found to predict SMSCT intervention scores (p = 0.002). The internal structure of the SMSCT may include evidence of reduced item performance but satisfactory convergent and discriminate evidence by construct definition. Although the SMSCT may be a promising approach for measuring seating and mobility expertise, limitations exist in the corrected content. Future application of the SMSCT should only be used after further development of the tool occurs. C1 [Cohen, Laura J.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA. [Fitzgerald, Shirley G.] James A Haley Tampa VA, Tampa, FL USA. [Lane, Suzanne] Univ Pittsburgh, Sch Educ, Dept Educ Psychol, Pittsburgh, PA 15260 USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15260 USA. [Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Minkel, Jean] Minkel Consulting, New Windsor, NY USA. [McCue, Michael] Univ Pittsburgh, Dept Rehabil Sci & Technol, Sch Hlth & Rehabil Sci, Pittsburgh, PA 15260 USA. RP Fitzgerald, SG (reprint author), HSR&D REAP, 8900 Grand Oak Circle 118 M, Tampa, FL 33637 USA. EM Shirley.Fitzgerald@va.gov OI Boninger, Michael/0000-0001-6966-919X NR 19 TC 1 Z9 1 U1 0 U2 2 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD SPR PY 2009 VL 21 IS 1 BP 47 EP 56 DI 10.1080/10400430902945546 PG 10 WC Rehabilitation SC Rehabilitation GA 521XZ UT WOS:000271961200006 PM 19719063 ER PT J AU Nery, FG Chen, HH Hatch, JP Nicoletti, MA Brambilla, P Sassi, RB Mallinger, AG Keshavan, MS Soares, JC AF Nery, Fabiano G. Chen, Hua-Hsuan Hatch, John P. Nicoletti, Mark A. Brambilla, Paolo Sassi, Roberto B. Mallinger, Alan G. Keshavan, Matcheri S. Soares, Jair C. TI Orbitofrontal cortex gray matter volumes in bipolar disorder patients: a region-of-interest MRI study SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; magnetic resonance imaging; neuronal plasticity; prefrontal cortex; region-of-interest; stress ID VOXEL-BASED MORPHOMETRY; VENTRAL PREFRONTAL CORTEX; MAJOR DEPRESSION; ANATOMICAL MRI; ANTERIOR CINGULATE; DECISION-MAKING; ABNORMALITIES; SCHIZOPHRENIA; MANIA; HIPPOCAMPUS AB Objectives: Functional and postmortem studies suggest that the orbitofrontal cortex (OFC) is involved in the pathophysiology of bipolar disorder (BD). This anatomical magnetic resonance imaging (MRI) study examined whether BD patients have smaller OFC gray matter volumes compared to healthy comparison subjects (HC). Methods: Twenty-eight BD patients were compared to 28 age- and gender-matched HC. Subjects underwent a 1.5T MRI with 3D spoiled gradient recalled acquisition. Total OFC and medial and lateral subdivisions were manually traced by a blinded examiner. Images were segmented and gray matter volumes were calculated using an automated method. Results: Analysis of covariance, with intracranial volume as covariate, showed that BD patients and HC did not differ in gray matter volumes of total OFC or its subdivisions. However, total OFC gray matter volume was significantly smaller in depressed patients (n = 10) compared to euthymic patients (n = 18). Moreover, total OFC gray matter volumes were inversely correlated with depressive symptom intensity, as assessed by the Hamilton Depression Rating Scale. OFC gray matter volumes were not related to lithium treatment, age at disease onset, number of episodes, or family history of mood disorders. Conclusions: Our results suggest that abnormal OFC gray matter volumes are not a pervasive characteristic of BD, but may be associated with specific clinical features of the disorder. C1 [Nery, Fabiano G.; Hatch, John P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [Nery, Fabiano G.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Chen, Hua-Hsuan] Univ Cincinnati, Dept Radiol, Cincinnati, OH USA. [Hatch, John P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. [Nicoletti, Mark A.; Soares, Jair C.] Univ N Carolina, Sch Med, Dept Psychiat, CERT BD, Chapel Hill, NC USA. [Brambilla, Paolo] Univ Udine, Sect Psychiat, Dept Pathol & Expt & Clin Med, I-33100 Udine, Italy. [Brambilla, Paolo] Sci Inst IRCCS E Medea, Udine, Italy. [Sassi, Roberto B.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Mallinger, Alan G.] NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA. [Keshavan, Matcheri S.] Wayne State Sch Med, Dept Psychiat & Behav Sci, Detroit, MI USA. [Nery, Fabiano G.] Univ Sao Paulo, Sch Med, Bipolar Disorder Res Grp, Inst Psychiat,Dept Psychiat, BR-04503010 Sao Paulo, Brazil. RP Nery, FG (reprint author), Univ Sao Paulo, Sch Med, Bipolar Disorder Res Grp, Inst Psychiat,Dept Psychiat, Rua Dr Ovidio Pires Campos, BR-04503010 Sao Paulo, Brazil. EM fabiano_nery@hotmail.com RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NARSAD; Veterans Affairs; Krus Endowed Chair in Psychiatry; [MH 68766]; [MH 068662]; [RR 20571] FX This research was partly supported by MH 68766, MH 068662, RR 20571, NARSAD, Veterans Affairs (Merit Review), and the Krus Endowed Chair in Psychiatry. The views expressed in this paper do not necessarily reflect those of the NIH or the federal government. NR 53 TC 28 Z9 28 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD MAR PY 2009 VL 11 IS 2 BP 145 EP 153 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 433DT UT WOS:000265185200004 PM 19267697 ER PT J AU Gee, JR Jarrard, DF Bruskewitz, RC Moon, TD Hedican, SP Leverson, GE Nakada, SY Messing, EM AF Gee, Jason R. Jarrard, David F. Bruskewitz, Reginald C. Moon, Timothy D. Hedican, Sean P. Leverson, Glen E. Nakada, Stephen Y. Messing, Edward M. TI Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-GuErin SO BJU INTERNATIONAL LA English DT Article DE bladder cancer; chemoprevention; aspirin; nonsteroidal anti-inflammatory drugs; BCG ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSITIONAL-CELL CARCINOMA; URINARY-BLADDER; PREVENTION; INHIBITORS; COX-2 AB To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-GuErin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms. In all, 43 patients with carcinoma in situ (CIS) and/or high-grade papillary bladder cancer were treated with intravesical BCG. Patients were stratified according to whether they took cardioprotective aspirin after treatment, and Kaplan-Meier curves of RFS were compared by log-rank analysis. Multivariable analysis was used for potentially confounding factors, including maintenance BCG, the presence of CIS, and smoking status. Of patients taking cardioprotective aspirin, the 5-year RFS rate was 64.3%, compared with 26.9% for patients not taking aspirin, with a significantly higher RFS by univariable log rank analysis (P = 0.03). Even after adjusting for the other factors by multivariable analysis, aspirin seems to affect recurrence (hazard ratio 0.179, P = 0.001). Maintenance BCG (hazard ratio 0.233, P = 0.02) and smoking history (hazard ratio 3.199, P = 0.05) also significantly affected recurrence. There was a significantly higher RFS rate in patients taking cardioprotective aspirin after intravesical BCG therapy for bladder cancer. The results of this study support the further investigation of aspirin and other NSAIDs as preventive agents in patients being treated for superficial bladder cancer. C1 [Gee, Jason R.; Jarrard, David F.; Bruskewitz, Reginald C.; Moon, Timothy D.; Hedican, Sean P.; Leverson, Glen E.; Nakada, Stephen Y.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Urol, Madison, WI 53792 USA. [Gee, Jason R.; Moon, Timothy D.] William S Middleton Mem Vet Adm Med Ctr, Dept Urol, Madison, WI USA. [Messing, Edward M.] Univ Rochester, Sch Med & Dent, Dept Urol, Rochester, NY 14642 USA. RP Gee, JR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Urol, Clin Sci Ctr G5-342,600 Highland Ave, Madison, WI 53792 USA. EM Gee@urology.wisc.edu FU Cook; Fujirabio, DiagnoCure FX Financial disclosures: Cook (S.Y.N.); Fujirabio, DiagnoCure (E.M.M). NR 14 TC 14 Z9 15 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-4096 J9 BJU INT JI BJU Int. PD MAR PY 2009 VL 103 IS 6 BP 736 EP 739 DI 10.1111/j.1464-410X.2008.08123.x PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 410TD UT WOS:000263600300006 PM 19007364 ER PT J AU Gore, JL Lai, J Setodji, CM Litwin, MS Saigal, CS AF Gore, John L. Lai, Julie Setodji, Claude M. Litwin, Mark S. Saigal, Christopher S. CA Urologic Dis Amer Project TI Mortality Increases When Radical Cystectomy Is Delayed More Than 12 Weeks Results From a Surveillance, Epidemiology, and End Results-Medicare Analysis SO CANCER LA English DT Article DE bladder cancer; radical cystectomy; survival; access to care ID BLADDER-CANCER; MUSCLE INVASION; DIAGNOSIS; VOLUME; CARCINOMA; DATABASE; SURGERY AB BACKGROUND: Single-institution series have documented the adverse impact of a 12-week delay between resection of muscle-invasive bladder cancer and radical cystectomy. These data are derived from tertiary centers, in which referral populations may confound outcomes. The authors sought to examine the survival impact of a delay in radical cystectomy using nationally representative data. METHODS: From the linked Surveillance, Epidemiology, and End Results-Medicare dataset, the authors identified subjects with stage II transitional cell carcinoma (TCC) of the bladder who underwent radical cystectomy between 1992 and 2001. They examined delays of 8, 12, and 24 weeks and incorporated these delay cutoffs into multivariate Cox proportional hazards survival models. Covariates included age, race/ethnicity, marital status, Charlson comorbidity index, and cancer grade. RESULTS: The authors identified 441 subjects with stage II TCC who underwent cystectomy during the study period. Compared with immediate surgery (ie, within 4-8 weeks of transurethral resection), longer time to cystectomy increased the risk of both disease-specific and overall mortality (hazard ratio [HR], 2.0; P < .01 and HR, 1.6; P < .01, respectively, for those delayed 12-24 weeks: HR, 2.0; P < .01 for disease-specific and overall death among those delayed beyond 24 weeks 1 year after diagnosis). Covariates associated with overall mortality included older age (HR, 1.04; P < .01) and comorbidity (HR, 2.0 for Charlson >= 3 vs Charlson 0-1; P < .01). CONCLUSIONS: Delay in definitive surgical treatment beyond 12 weeks conferred an increased risk of disease-specific and all-cause mortality among subjects with stage II bladder cancer. Cancer 2009;115:988-96. (c) 2009 American Cancer Society. C1 [Gore, John L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gore, John L.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Gore, John L.; Litwin, Mark S.; Saigal, Christopher S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Lai, Julie; Setodji, Claude M.; Litwin, Mark S.; Saigal, Christopher S.] RAND Corp, Santa Monica, CA USA. RP Gore, JL (reprint author), 911 Broxton Ave,3rd Floor, Los Angeles, CA 90024 USA. EM jgore@mednet.ucla.edu OI Gore, John/0000-0002-2847-5062 FU National Institute of Diabetes and Digestive and Kidney Diseases [NO1-DK-7-0003] FX Source of funding: National Institute of Diabetes and Digestive and Kidney Diseases NO1-DK-7-0003. NR 19 TC 86 Z9 88 U1 1 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD MAR 1 PY 2009 VL 115 IS 5 BP 988 EP 996 DI 10.1002/cncr.24052 PG 9 WC Oncology SC Oncology GA 410QQ UT WOS:000263593500010 PM 19142878 ER PT J AU Okino, ST Pookot, D Basak, S Dahiya, R AF Okino, Steven T. Pookot, Deepa Basak, Shashwati Dahiya, Rajvir TI Toxic and Chemopreventive Ligands Preferentially Activate Distinct Aryl Hydrocarbon Receptor Pathways: Implications for Cancer Prevention SO CANCER PREVENTION RESEARCH LA English DT Article ID MAMMARY-TUMOR GROWTH; PROSTATE-CANCER; BREAST-CANCER; IN-VIVO; INHIBITION; INDUCTION; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; INDOLE-3-CARBINOL; CELLS; 3,3'-DIINDOLYLMETHANE AB The aryl hydrocarbon receptor (AhR) is a ligand-activated regulatory protein that controls estrogen action through two distinct pathways. In one pathway, AhR acts as a transcription factor that induces the expression of the CYP1 family of estrogen-metabolizing genes; in the other pathway, AhR initiates the degradation of the estrogen receptor and suppresses estrogen signaling. The AhR ligand 3,3'-diindolylmethane (DIM) is a beneficial dietary constituent that prevents breast tumors in rodents and is associated with decreased breast cancer risk in humans. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a toxic AhR ligand that is implicated in birth defects, infertility, and cancer. We analyzed MCF-7 cells to gain insight into how two AhR ligands can exert such fundamentally different health effects. We find that DIM and TCDD have differing abilities to activate the distinct AhR-controlled pathways. TCDD strongly induces AhR-dependent CYP1 gene expression, whereas DIM is a relatively weak CYP1 inducer. DIM strongly inhibits estrogen receptor-alpha expression and estrogen signaling, whereas TCDD has a notably weaker effect on these processes. Small interfering RNA knockdown of AhR confirms that the effects of DIM and TCDD are indeed AhR dependent. Our findings reveal that DIM and TCDD each elicit a unique pattern of change in pathways that control estrogen action; such patterns may determine if an AhR ligand has beneficial or adverse health effects. C1 [Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, 4150 Clement St 112F, San Francisco, CA 94121 USA. EM Rdahiya@urology.ucsf.edu FU NCI NIH HHS [R01CA101844, R01CA108612, R01CA111470]; NIA NIH HHS [R01AG21418]; NIDDK NIH HHS [T32DK07790] NR 39 TC 27 Z9 32 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD MAR PY 2009 VL 2 IS 3 BP 251 EP 256 DI 10.1158/1940-6207.CAPR-08-0146 PG 6 WC Oncology SC Oncology GA 420MT UT WOS:000264294600010 PM 19223575 ER PT J AU Meeran, SM Vaid, M Punathil, T Katiyar, SK AF Meeran, Syed M. Vaid, Mudit Punathil, Thejass Katiyar, Santosh K. TI Dietary grape seed proanthocyanidins inhibit 12-O-tetradecanoyl phorbol-13-acetate-caused skin tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated mouse skin, which is associated with the inhibition of inflammatory responses SO CARCINOGENESIS LA English DT Article ID TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; INDUCED OXIDATIVE STRESS; SKH-1 HAIRLESS MICE; NF-KAPPA-B; GREEN TEA; CARCINOMA-CELLS; CANCER; CARCINOGENESIS; ACTIVATION; PHOTOCARCINOGENESIS AB Grape seed proanthocyanidins (GSPs) possess anticarcinogenic activities. Here, we assessed the effects of dietary GSPs on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumor promotion in 7,12-dimethylbenz[a]anthracene (DMBA)-initiated mouse skin. Administration of dietary GSPs (0.2 and 0.5%, wt/wt) supplemented with control AIN76A diet resulted in significant inhibition of TPA-induced skin tumor promotion in C3H/HeN mice. The mice treated with GSPs developed a significantly lower tumor burden in terms of the percentage of mice with tumors (P < 0.05), total number of tumors per group (P < 0.01, n = 20) and total tumor volume per tumor-bearing mouse (P < 0.01-0.001) as compared with the mice that received the control diet. GSPs also delayed the malignant progression of papillomas into carcinomas. As TPA-induced inflammatory responses are used routinely as markers of skin tumor promotion, we assessed the effect of GSPs on biomarkers of TPA-induced inflammation. Immunohistochemical analysis and western blotting revealed that GSPs significantly inhibited expression of cyclooxygenase-2 (COX-2), prostaglandin E(2) (PGE(2)) and markers of proliferation (proliferating cell nuclear antigen and cyclin D1) in both the DMBA-initiated/TPA-promoted mouse skin and skin tumors. In short-term experiments in which the mouse skin was treated with acute or multiple TPA applications, we found that dietary GSPs inhibited TPA-induced edema, hyperplasia, leukocytes infiltration, myeloperoxidase, COX-2 expression and PGE(2) production in the mouse skin. The inhibitory effect of GSPs was also observed against other structurally different skin tumor promoter-induced inflammation in the skin. Together, our results show that dietary GSPs inhibit chemical carcinogenesis in mouse skin and that the inhibition of skin tumorigenesis by GSPs is associated with the inhibition of inflammatory responses caused by tumor promoters. C1 [Meeran, Syed M.; Vaid, Mudit; Punathil, Thejass; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award FX Veterans Administration Merit Review Award to S. K. K. NR 32 TC 39 Z9 39 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD MAR PY 2009 VL 30 IS 3 BP 520 EP 528 DI 10.1093/carcin/bgp019 PG 9 WC Oncology SC Oncology GA 415OW UT WOS:000263944500019 PM 19158151 ER PT J AU Dorfman, TA Aqel, R AF Dorfman, Todd A. Aqel, Raed TI Regional Pericarditis: A Review of the Pericardial Manifestations of Acute Myocardial Infarction SO CLINICAL CARDIOLOGY LA English DT Review DE regional pericarditis; infarction-associated pericarditis; pericardial effusion ID ELECTROCARDIOGRAPHIC DIAGNOSIS; INVOLVEMENT; EFFUSION AB Regional pericarditis has been described in several settings, but occurs most frequently after transmural myocardial infarction. White the diagnosis remains elusive, it Must be considered in all patients with recurrent chest pain following acute myocardial infarction (AMI). Pericarditis classically presents with positional chest pain, a pericardial friction rub, diffuse ST-segment elevation, and PR depression, but regional ECG changes associated with infarction-associated pericarditis sometimes exist. Given the magnitude and frequency of AMI, it is imperative to be aware of the myriad of pericardial manifestations of myocardial injury. An illustrative case and a comprehensive review of the literature will be provided. C1 [Aqel, Raed] Birmingham Vet Affair Med Ctr, Div Cardiovasc Dis, Birmingham, AL 35233 USA. [Dorfman, Todd A.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. RP Aqel, R (reprint author), Birmingham Vet Affair Med Ctr, Div Cardiovasc Dis, 700 19th St S, Birmingham, AL 35233 USA. EM RaedAqel@med.va.gov NR 15 TC 10 Z9 10 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0160-9289 J9 CLIN CARDIOL JI Clin. Cardiol. PD MAR PY 2009 VL 32 IS 3 BP 115 EP 120 DI 10.1002/clc.20444 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 422ZG UT WOS:000264465600002 PM 19301285 ER PT J AU Yoshida, A Isomoto, H Hisatsune, J Nakayama, M Nakashima, Y Matsushima, K Mizuta, Y Hayashi, T Yamaoka, Y Azuma, T Moss, J Hirayama, T Kohno, S AF Yoshida, Akira Isomoto, Hajime Hisatsune, Junzo Nakayama, Masaaki Nakashima, Yujiro Matsushima, Kayoko Mizuta, Yohei Hayashi, Tomayoshi Yamaoka, Yoshio Azuma, Takeshi Moss, Joel Hirayama, Toshiya Kohno, Shigeru TI Enhanced expression of CCL20 in human Helicobacter pylori-associated gastritis SO CLINICAL IMMUNOLOGY LA English DT Article DE CC chemokine ligand 20; CC chemokine receptor 6; H. pylori; Dendritic cells; cag pathogenicity island ID INFLAMMATORY-BOWEL-DISEASE; MATURE DENDRITIC CELLS; EPITHELIAL-CELLS; CHEMOKINES; RECRUITMENT; INFECTION; MIP-3-BETA; ACTIVATION; CCL19 AB CC chemokine ligand 20 (CCL20) attracts CC chemokine receptor 6 (CCR6)-expressing cells. Using endoscopic biopsies taken from the gastric antrum of 42 subjects infected with H. pylori and 42 uninfected subjects, mucosal CCL20 mRNA and protein levels were measured by real-time polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. CCL19 mRNA and protein levels, as well as CCL21 mRNA levels, were also measured. The CCL20 mRNA and protein levels were significantly elevated in H. pylori-positive patients and substantially decreased after successful eradication. CCL19 and CCL21 expression levels were comparable in the H. pylori-infected and the uninfected groups. The CCL20 concentrations correlated with the degree of chronic gastritis. Immunohistochemistry and the in vitro infection assay showed that CCL20 was principally produced by the gastric epithelium. CCR6-expressing cells, including CD45RO(+) memory T lymphocytes and fascin(+)-CD1a(+) immature dendritic cells, infiltrated close to the CCL20-expressing epithelial cells. The CCL20/CCR6 interaction may be involved in the development of H. pylori-associated gastritis. (C) 2008 Elsevier Inc. All rights reserved. C1 [Yoshida, Akira; Isomoto, Hajime; Nakashima, Yujiro; Matsushima, Kayoko; Mizuta, Yohei; Kohno, Shigeru] Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 8528501, Japan. [Hisatsune, Junzo; Nakayama, Masaaki; Hirayama, Toshiya] Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528501, Japan. [Hayashi, Tomayoshi] Nagasaki Univ, Sch Med, Dept Pathol, Nagasaki 8528501, Japan. [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX USA. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Azuma, Takeshi] Kobe Univ, Sch Med, Dept Gastroenterol, Kobe, Hyogo 650, Japan. [Moss, Joel] NHLBI, Translat Med Branch, NIH, Bethesda, MD 20892 USA. RP Isomoto, H (reprint author), Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 8528501, Japan. EM hajimei2002@yahoo.co.jp FU intramural research program; NIH; NHLBI FX J Moss was supported by the intramural research program, NIH, NHLBI. NR 25 TC 16 Z9 17 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD MAR PY 2009 VL 130 IS 3 BP 290 EP 297 DI 10.1016/j.clim.2008.09.016 PG 8 WC Immunology SC Immunology GA 409UD UT WOS:000263530400008 PM 19006683 ER PT J AU Chiao, EY AF Chiao, Elizabeth Y. TI Duration of Anal Human Papillomavirus Infection among Immunocompetent Women: Clues to Anal Cancer Epidemiology and Possible Prevention Strategies SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID SQUAMOUS INTRAEPITHELIAL LESIONS; RISK-FACTORS; PREVALENCE; ACQUISITION; ETIOLOGY; COHORT C1 [Chiao, Elizabeth Y.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Chiao, Elizabeth Y.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA. RP Chiao, EY (reprint author), Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM echiao@bcm.edu FU NCI NIH HHS [K23CA124318] NR 13 TC 1 Z9 1 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2009 VL 48 IS 5 BP 547 EP 549 DI 10.1086/596759 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 403DE UT WOS:000263061700003 PM 19191637 ER PT J AU Koo, HL Koo, DC Musher, DM DuPont, HL AF Koo, Hoonmo L. Koo, Diana C. Musher, Daniel M. DuPont, Herbert L. TI Antimotility Agents for the Treatment of Clostridium difficile Diarrhea and Colitis SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID COMPLICATING PSEUDOMEMBRANOUS ENTEROCOLITIS; DOUBLE-BLIND TRIAL; TOXIC MEGACOLON; TRAVELERS DIARRHEA; UNITED-STATES; BISMUTH SUBSALICYLATE; SYMPTOMATIC TREATMENT; LOMOTIL THERAPY; GUINEA PIGS; LOPERAMIDE AB Antimotility agent use for the treatment of Clostridium difficile infection (CDI) is discouraged. We reviewed the literature and unpublished postmarketing surveillance reports regarding antimotility treatment of CDI. Twenty reports met inclusion criteria, describing 55 patients with CDI who were exposed to antimotility agents. All studies were case reports or series, with the exception of 1 retrospective review. Nineteen patients (35%) improved, with clinical resolution. Nine patients (16%) died, and 27 patients (49%) had unknown outcomes. Seventeen patients (31%) with CDI developed colonic dilation; 5 of these patients with severe CDI died. However, all patients who experienced complications or died were given antimotility agents alone initially, without an appropriate antibiotic. Twenty-three patients who received metronidazole or vancomycin coadministered with the antimotility agent experienced no complications. Evidence supporting the hypothesis that worsened outcomes are associated with antimotility therapy of CDI is lacking. Further study of the role of antimotility agents in providing symptomatic relief and reducing environmental contamination with infectious stool may be warranted. C1 [Koo, Hoonmo L.; Musher, Daniel M.; DuPont, Herbert L.] Baylor Coll Med, Div Infect Dis, Dept Med, Houston, TX 77030 USA. [Koo, Hoonmo L.; Koo, Diana C.; DuPont, Herbert L.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [DuPont, Herbert L.] Univ Texas Houston, Sch Med, Houston, TX USA. [Musher, Daniel M.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [DuPont, Herbert L.] St Lukes Episcopal Hosp, Houston, TX 77030 USA. RP Koo, HL (reprint author), Baylor Coll Med, Div Infect Dis, Dept Med, 1 Baylor Plaza,BCM 286,N1319, Houston, TX 77030 USA. EM koo@bcm.tmc.edu NR 65 TC 28 Z9 29 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2009 VL 48 IS 5 BP 598 EP 605 DI 10.1086/596711 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 403DE UT WOS:000263061700012 PM 19191646 ER PT J AU Gunzler, SA Pavel, M Koudelka, C Carlson, NE Nutt, JG AF Gunzler, Steven A. Pavel, Misha Koudelka, Caroline Carlson, Nichole E. Nutt, John G. TI Foot-Tapping Rate as an Objective Outcome Measure for Parkinson Disease Clinical Trials SO CLINICAL NEUROPHARMACOLOGY LA English DT Review DE foot tapping; finger tapping; Parkinson disease; motor fluctuation; apomorphine ID DURATION RESPONSE; APOMORPHINE; RELIABILITY; LEVODOPA AB Objectives: To explore foot-tapping rate as a reliable and a valid measure of motor function in Parkinson disease (PD). Methods: We present data from a randomized, single-blind, outpatient study and a randomized, double-blind, placebo-control led, crossover, inpatient study. Fifty PD subjects completed the outpatient Study. A Unified Parkinson Disease Rating Scale motor score was determined for each subject. Subsequently, finger tapping, alternate (between 2 pedals) and repetitive (on I pedal) foot-tapping rates, and gait were measured. Thirteen PD subjects completed the inpatient study. Each subject received a daily infusion of high-dose apomorphine (APO), low-dose APO, and placebo in random order over 3 days. In this subanalysis, we compared variance and reliability of the finger- and the foot-tapping techniques during the placebo day and compared the validity of these outcome measures to detect improvement in parkinsonism during high-dose APO infusion. Results: Alternate foot tapping was reliable (interclass correlation on the placebo inpatient day, 84%). Only foot tapping detected improvement in parkinsonism with high-dose APO treatment (a measure of validity). In the outpatient study, there was a significant correlation between alternate and repetitive tapping with finger tapping (R-2 = 0.28 and 0.23, respectively) and Unified Parkinson Disease Rating Scale motor score (R-2 = 0.09 and 0.08), but only alternate tapping correlated with gait (R-2 = 0.16). Conclusions: Alternate foot tapping was equally reliable but more valid than finger tapping. Alternate foot tapping correlated better did existing PD Outcome measures than did repetitive foot tapping. Foot tapping may be a useful outcome measure for determination of dopaminergic medication effect in PD clinical trials. C1 [Gunzler, Steven A.; Nutt, John G.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. [Gunzler, Steven A.] Oregon Hlth & Sci Univ, Parkinson Ctr Oregon, Portland, OR 97201 USA. [Pavel, Misha] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. [Koudelka, Caroline] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA. [Carlson, Nichole E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97201 USA. RP Gunzler, SA (reprint author), Univ Hosp Case Med Ctr, Neurol Inst, Movement Disorders Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM Steven.Gunzler@UHhospitals.org FU Portland VA Medical Center; PHS [UL1 RR024140-01]; National Institutes of Health [R01 NS021062-20] FX This work was supported by the Parkinson Disease Research, Education, and Clinical Center at the Portland VA Medical Center; the Oregon Clinical and Translational Research Institute at Oregon Health and Sciences University (supported in pail by PHS grant, UL1 RR024140-01); and a National Institutes of Health grant, R01 NS021062-20. Britannia Pharmaceuticals provided apomorphine. NR 19 TC 4 Z9 6 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-5664 J9 CLIN NEUROPHARMACOL JI Clin. Neuropharmacol. PD MAR-APR PY 2009 VL 32 IS 2 BP 97 EP 102 DI 10.1097/WNF.0b013e3181684c22 PG 6 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 428ID UT WOS:000264840300009 PM 18978495 ER PT J AU Goudreau, KA AF Goudreau, Kelly A. TI What Clinical Nurse Specialists Need to Know About the Consensus Model for Advanced Practice Registered Nurse Regulation SO CLINICAL NURSE SPECIALIST LA English DT Editorial Material C1 Portland VA Med Ctr, Portland, OR USA. RP Goudreau, KA (reprint author), Portland VA Med Ctr, Portland, OR USA. NR 4 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2009 VL 23 IS 2 BP 50 EP 51 PG 2 WC Nursing SC Nursing GA 413OZ UT WOS:000263803700002 PM 19225281 ER PT J AU Filley, CM Kozora, E Brown, MS Miller, DE West, SG Arciniegas, DB Grimm, A Zhang, LN AF Filley, Christopher M. Kozora, Elizabeth Brown, Mark S. Miller, David E. West, Sterling G. Arciniegas, David B. Grimm, Alex Zhang, Lening TI White Matter Microstructure and Cognition in Non-neuropsychiatric Systemic Lupus Erythematosus SO COGNITIVE AND BEHAVIORAL NEUROLOGY LA English DT Article DE lupus; white matter; choline; MRS; MRI ID MAGNETIC-RESONANCE SPECTROSCOPY; NEUROLOGIC RATING-SCALE; PROTON MR SPECTROSCOPY; MULTIPLE-SCLEROSIS; BRAIN-LESIONS; ABNORMALITIES; DYSFUNCTION; DISEASE; DAMAGE AB Objective: This Study examined white matter (WM) structural and metabolic alterations in relation to Cognition in patients with non-neuropsychiatric systemic lupus erythematosus (non-NPSLE). Background: SLE can produce cognitive impairment even without overt neuropsychiatric features, but the pathogenesis of this dysfunction is not well understood. Our preliminary study of non-NPSLE found evidence correlating cognitive impairment with increased choline/creatine (Ch/Cr) in frontal lobe WM. Methods: Subjects included 60 non-NPSLE patients and 24 controls. Magnetic resonance imaging and magnetic resonance spectroscopy were performed, and a battery of neuropsychologic tests was administered. Structural and metabolic measures were analyzed and correlated with neuropsychologic data. Results: No significant differences were found in total brain, gray matter, and WM Volumes, or in frontal WM N-acetylaspartate/Cr, but the non-NPSLE group had significantly increased Ch/Cr in frontal WM. A WM cognitive score (WMCS) that included the Paced Auditory Serial Addition Task, Letter Fluency, and Animal Naming was found to correlate with total WM volume, and lower WMCS correlated with higher left frontal WM Ch/Cr. Conclusions: Non-NPSLE patients had frontal WM metabolic changes that correlated with cognitive impairment, whereas no cerebral atrophy or WM axonal damage was evident. These data confirm and extend our previous observations Supporting the role of microstructural WM changes in the cognitive impairment of non-NPSLE patients. The data also Suggest that the WMCS may be sensitive to cognitive dysfunction from myelin damage that develops before axonal injury. C1 [Filley, Christopher M.; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. [Filley, Christopher M.; Kozora, Elizabeth; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. [Brown, Mark S.; Miller, David E.; Grimm, Alex] Univ Colorado, Sch Med, Dept Radiol, Denver, CO USA. [West, Sterling G.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA. [Kozora, Elizabeth; Zhang, Lening] Natl Jewish Med & Res Ctr, Denver, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Filley, CM (reprint author), 12631 E 17th Ave,POB 6511, Aurora, CO 80045 USA. EM christopher.filley@uchsc.edu FU National Institute of Musculoskelctal and Skin Diseases [ROI AR049152-02] FX Supported by the National Institute of Musculoskelctal and Skin Diseases grant ROI AR049152-02). NR 40 TC 22 Z9 24 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1543-3633 J9 COGN BEHAV NEUROL JI Cogn. Behav. Neurol. PD MAR PY 2009 VL 22 IS 1 BP 38 EP 44 PG 7 WC Behavioral Sciences; Clinical Neurology SC Behavioral Sciences; Neurosciences & Neurology GA 426IV UT WOS:000264702100004 PM 19372769 ER PT J AU Cavusoglu, E Ruwende, C Chopra, V Yanamadala, S Eng, C Pinsky, DJ Marmur, JD AF Cavusoglu, Erdal Ruwende, Cyril Chopra, Vineet Yanamadala, Sunitha Eng, Calvin Pinsky, David J. Marmur, Jonathan D. TI Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography SO CORONARY ARTERY DISEASE LA English DT Article DE acute coronary syndrome; asymmetric dimethylarginine; biomarker; myocardial infarction; nitric oxide; prognosis ID NITRIC-OXIDE SYNTHESIS; ASYMMETRIC DIMETHYLARGININE; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; UNSTABLE ANGINA; MYOCARDIAL-INFARCTION; INDEPENDENT PREDICTOR; EVENTS; MORTALITY; DISEASE AB Background Nitric oxide (NO) is produced from L-arginine by NO synthase and is an important molecule with antiatherogenic properties. Asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of endothelial NO synthase. As such, it has been associated with endothelial dysfunction and elevated circulating levels of ADMA have been found in patients with cardiovascular risk factors. In addition, high baseline plasma levels of ADMA have been shown to be an independent predictor of adverse outcomes in a variety of patient populations. However, there are very limited data in patients with acute coronary syndromes (ACS). Methods This study investigated the long-term prognostic significance of baseline plasma ADMA levels in a well-characterized cohort of 193 men with ACS who were referred for coronary angiography. All patients were followed up prospectively for the development of vascular outcomes. Results After controlling for a variety of baseline variables (including established biomarkers such as high-sensitivity C-reactive protein and fibrinogen), plasma ADMA levels (analyzed as the upper tertile of baseline values compared with the lower two tertiles) were a strong and independent predictor of each of the individual endpoints of all-cause mortality [hazard ratio (HR): 2.45, 95% confidence interval (Cl): 1.08-5.57; P=0.03251 and myocardial infarction (H R: 2.28, 95% Cl: 1.14-4.57; P=0.0204) when using a Cox proportional hazards model. In addition, baseline ADMA values were also an independent predictor of the composite outcome of all-cause mortality, fatal or nonfatal myocardial infarction, or stroke (HR: 1.81, 95% Cl: 1.01-3.25; P=0.0482). Conclusion These data show that elevated baseline levels of ADMA are a strong and independent predictor of cardiovascular outcomes (including mortality) in patients with ACS. Coron Artery Dis 20:112-117 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Cavusoglu, Erdal; Marmur, Jonathan D.] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. [Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA. [Ruwende, Cyril; Yanamadala, Sunitha; Pinsky, David J.] Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, 450 Clarkson Ave,Box 1257, Brooklyn, NY 11203 USA. EM ECavusoglu@aol.com NR 25 TC 20 Z9 22 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-6928 J9 CORONARY ARTERY DIS JI Coronary Artery Dis. PD MAR PY 2009 VL 20 IS 2 BP 112 EP 117 DI 10.1097/MCA.0b013e328323982f PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 432UK UT WOS:000265159500005 PM 19240644 ER PT J AU Camhi, SL Mercado, AF Morrison, RS Du, DL Platt, DM August, GI Nelson, JE AF Camhi, Sharon L. Mercado, Alice F. Morrison, R. Sean Du, Qingling Platt, David M. August, Gary I. Nelson, Judith E. TI Deciding in the dark: Advance directives and continuation of treatment in chronic critical illness SO CRITICAL CARE MEDICINE LA English DT Article DE prolonged mechanical ventilation; prolonged critical illness; do not resuscitate; decision making; withholding treatment; withdrawing treatment ID END-OF-LIFE; PROLONGED MECHANICAL VENTILATION; INTENSIVE-CARE-UNIT; ARTIFICIAL NUTRITION; DECISION-MAKING; ILL PATIENT; PHYSICIANS ATTITUDES; CATASTROPHIC ILLNESS; SUSTAINING TREATMENT; WITHDRAWAL AB Objective: Chronic critical illness is a devastating syndrome for which treatment offers limited clinical benefit but imposes heavy burdens on patients, families, clinicians, and the health care system. We studied the availability of advance directives and appropriate surrogates to guide decisions about life-sustaining treatment for the chronically critically ill and the extent and timing of treatment limitation. Design: Prospective cohort study. Setting: Respiratory Care Unit (RCU) in a large, tertiary, urban, university-affiliated, hospital. Patients: Two hundred three chronically critically ill adults transferred to RCU after tracheotomy for failure to wean from mechanical ventilation in the intensive care unit. Interventions. None. Measurements and Main Results: We interviewed RCU care-givers and reviewed patient records to identify proxy appointments, living wills, or oral statements of treatment preferences, resuscitation directives, and withholding/withdrawal of mechanical ventilation, nutrition, hydration, renal replacement and vaso-pressors. Forty-three of 203 patients (21.2%) appointed a proxy and 33 (16.2%) expressed preferences in advance directives. Do not resuscitate directives were given for 71 patients (35.0%). Treatment was limited for 39 patients (19.2%). Variables significantly associated with treatment limitation were proxy appointment prior to study entry (time of tracheotomy/RCU transfer) (odds ratio = 6.7, 95% confidence interval [CI], 2.3-20.0, p = 0.0006) and palliative care consultation in the RCU (OR = 40.9, 95% Cl, 13.1-127.4, p < 0.0001). Median (interquartile range) time to first treatment limitation was 39 (31.0-45.0) days after hospital admission and 13 (8.0-29.0) days after RCU admission. For patients dying after treatment limitation, median time from first limitation to death ranged from 3 days for mechanical ventilation and hydration to 7 days for renal replacement. Conclusions. Most chronically critically ill patients fail to designate a surrogate decision-maker or express preferences regarding life-sustaining treatments. Despite burdensome symptoms and poor outcomes, limitation of such treatments was rare and occurred late, when patients were near death. Opportunities exist to improve communication and decision-making in chronic critical illness. (Crit Care Med 2009; 37:919-925) C1 [Camhi, Sharon L.] VA Pittsburgh Hlth Care Syst, Div Pulm & Crit Care Med, Pittsburgh, PA USA. [Mercado, Alice F.; Platt, David M.; August, Gary I.; Nelson, Judith E.] Mt Sinai Sch Med, Div Pulm Crit Care & Sleep Med, New York, NY USA. [Morrison, R. Sean; Du, Qingling; Nelson, Judith E.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Morrison, R. Sean; Du, Qingling; Nelson, Judith E.] Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Adult Dev, New York, NY USA. [Morrison, R. Sean] Bronx VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Camhi, SL (reprint author), VA Pittsburgh Hlth Care Syst, Div Pulm & Crit Care Med, Pittsburgh, PA USA. EM sharon.camhi@va.gov FU NIA NIH HHS [K02 AG024476, K02 AG024476-01, K24 AG022345, K24 AG022345-01, R01 AG021172, R01 AG021172-02, R01 AG21172] NR 55 TC 43 Z9 44 U1 4 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2009 VL 37 IS 3 BP 919 EP 925 DI 10.1097/CCM.0b01361819613ce PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 413FW UT WOS:000263779300016 PM 19237897 ER PT J AU Matioc, AA Arndt, G Jofee, A AF Matioc, Adrian A. Arndt, George Jofee, Aaron TI The critical airway: The difficult airway in the adult critical care SO CRITICAL CARE MEDICINE LA English DT Letter ID TRACHEAL INTUBATION C1 [Matioc, Adrian A.] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. [Arndt, George] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI USA. [Jofee, Aaron] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA. RP Matioc, AA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. NR 5 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2009 VL 37 IS 3 BP 1175 EP 1176 DI 10.1097/CCM.0b013e3181986ec0 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 413FW UT WOS:000263779300079 PM 19237959 ER PT J AU Kirkpatrick, DP Dransfield, MT AF Kirkpatrick, deNay P. Dransfield, Mark T. TI Racial and sex differences in chronic obstructive pulmonary disease susceptibility, diagnosis, and treatment SO CURRENT OPINION IN PULMONARY MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; disparities; race; sex ID HOME-OXYGEN-THERAPY; LUNG-FUNCTION; GENDER-DIFFERENCES; SMOKING-CESSATION; AFRICAN-AMERICAN; COPD; EMPHYSEMA; MORTALITY; CAPACITY; PATTERNS AB Purpose of review Chronic obstructive pulmonary disease (COPD) is an increasing cause of morbidity and mortality worldwide. Although COPD has historically been considered a disease of white male smokers, it now clearly impacts both sexes and all races, with mortality rising fastest in women and African-Americans. Given the scarcity of data about non-African-American minorities, this review will focus on the disparities in COPD susceptibility, diagnosis, and treatment between men and women and between African-Americans and whites. Recent findings Although the changing epidemiology of COPD in part reflects the changing epidemiology of cigarette smoking, there are data suggesting that women and African Americans may be particularly susceptible to tobacco smoke and that the diagnosis, treatment, and natural history of the disease are influenced by race and sex. Summary The possibility that sex or race or both, may influence COPD susceptibility and progression is of critical importance, and may mean that the potential future impact of the disease has been underestimated. Unfortunately, our understanding of these differences and the efficacy of standard COPD treatments in women and minorities remains limited by the low enrolment in clinical trials. C1 [Kirkpatrick, deNay P.; Dransfield, Mark T.] Univ Alabama, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Dransfield, MT (reprint author), 422 THT,1900 Univ Blvd, Birmingham, AL 35294 USA. EM mdransfield99@msn.com NR 43 TC 11 Z9 11 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5287 J9 CURR OPIN PULM MED JI Curr. Opin. Pulm. Med. PD MAR PY 2009 VL 15 IS 2 BP 100 EP 104 DI 10.1097/MCP.0b013e3283232825 PG 5 WC Respiratory System SC Respiratory System GA 420HU UT WOS:000264280700004 PM 19532023 ER PT J AU Hage, FG AlJaroudi, W Pajaro, O Nanda, NC Aqel, RA AF Hage, Fadi G. AlJaroudi, Wael Pajaro, Octavio Nanda, Navin C. Aqel, Raed A. TI Alcohol Septal Ablation in a Young Patient after Aortic Valve Replacement SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE alcohol septal ablation; hypertrophic cardiomyopathy; aortic stenosis; aortic valve prosthesis ID OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY; ECHOCARDIOGRAPHY; DIAGNOSIS; THROMBOSIS; DISEASE AB A 38-year-old male presented with heart failure symptoms and was diagnosed with aortic valve endocarditis and underlying aortic stenosis in the absence of concentric hypertrophy or bicuspid aortic valve and underwent aortic valve replacement but continued to have symptoms which were then attributed to hypertrophic cardiomyopathy with dynamic left ventricular outflow tract obstruction. He was determined to be unsuitable for myomectomy and underwent successful alcohol septal ablation using transthoracic echocardiographic Doppler and continuous wave velocity monitoring without requiring to cross the aortic valve or to perform transatrial septostomy and left ventricular pressure monitoring. When crossing the aortic valve is a relative or absolute contraindication like in our index case, continuous Doppler velocity recording is a safe and effective alternative approach to monitor the outflow gradient while performing alcohol septal ablation. (ECHOCARDIOGRAPHY, Volume 26, March 2009) C1 [Hage, Fadi G.; AlJaroudi, Wael; Nanda, Navin C.; Aqel, Raed A.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.; AlJaroudi, Wael; Aqel, Raed A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Pajaro, Octavio] Univ Alabama, Div Cardiothorac Surg, Birmingham, AL USA. RP Aqel, RA (reprint author), BDB 383,1530 3rd Ave, Birmingham, AL 35294 USA. EM raed.aqel@med.va.gov OI Hage, Fadi/0000-0002-1397-4942 NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0742-2822 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD MAR PY 2009 VL 26 IS 3 BP 291 EP 294 DI 10.1111/j.1540-8175.2008.00818.x PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 428VQ UT WOS:000264879900009 PM 19175777 ER PT J AU Levine, DA Allison, JJ Cherrington, A Richman, J Scarinci, IC Houston, TK AF Levine, Deborah A. Allison, Jeroan J. Cherrington, Andrea Richman, Joshua Scarinci, Isabel C. Houston, Thomas K. TI DISPARITIES IN SELF-MONITORING OF BLOOD GLUCOSE AMONG LOW-INCOME ETHNIC MINORITY POPULATIONS WITH DIABETES, UNITED STATES SO ETHNICITY & DISEASE LA English DT Article DE Diabetes Mellitus; Self-care; Healthcare Disparities; Minority Health; Income ID HEALTH-CARE ACCESS; GLYCEMIC CONTROL; MANAGED CARE; ADULTS; OUTCOMES; SERVICES; BARRIERS; HMO AB Background: In adults with insulin-treated diabetes, self-monitoring of blood glucose (SMBG) rates may be lower in minority or low-income populations, but the effect of income on racial/ethnic differences in SMBG is unknown. Methods: We assessed whether racial/ethnic differences in SMBG vary by income among adults with insulin-treated diabetes by using Behavioral Risk Factor Surveillance System data from 2000 through 2004. We measured the prevalence of SMBG at least once per day among 16,630 adults aged >= 19 years with insulin-treated diabetes. Results: At incomes >=$20,000, Hispanics and non-Hispanic Blacks reported similar but lower SMBG rates than did non-Hispanic Whites (78%, 77%, 85%; P <= .01). However, among those with income <$20,000, Hispanics performed SMBG substantially less than did Blacks or Whites (65%, 79%, 85%; P <= .01). Racial/ethnic differences in SMBG persisted after adjustment for age, sex, education, health insurance, health status, survey period, and diabetes measures. Receipt of diabetes education varied significantly by race/ethnicity in the income <$20,000 group only (Hispanics 49%, Blacks 64%, Whites 62%; P < .001). Low-income Hispanics with limited English proficiency had lower SMBG and diabetes education rates than did those with English proficiency (61% vs 79% and 44% vs 58%, respectively). Conclusions: Among US adults with insulin-treated diabetes, Hispanics and Blacks performed daily SMBG less frequently than did Whites. Stratification by income revealed a disparity gradient in the income <$20,000 group: SMBG rates decreased from Whites to Blacks to Hispanics. Low-income Hispanics with limited English proficiency are at greater risk for reduced SMBG than are those proficient in English. (Ethn Dis. 2009;19:97-103) C1 [Levine, Deborah A.] Ohio State Univ, Div Gen Internal Med, Coll Med, Columbus, OH 43210 USA. [Levine, Deborah A.] Ohio State Univ, Div Hlth Serv Management & Policy, Coll Publ Hlth, Columbus, OH 43210 USA. [Levine, Deborah A.; Allison, Jeroan J.; Cherrington, Andrea; Richman, Joshua; Scarinci, Isabel C.; Houston, Thomas K.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Houston, Thomas K.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. RP Levine, DA (reprint author), Ohio State Univ, Div Gen Internal Med, Coll Med, 466 Cunz Hall,1841 Neil Ave, Columbus, OH 43210 USA. EM dlevine@cph.osu.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 NR 23 TC 27 Z9 27 U1 2 U2 6 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2009 VL 19 IS 2 BP 97 EP 103 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 455OB UT WOS:000266769300001 PM 19537217 ER PT J AU Shacter, HE Shea, JA Akhabue, E Sablani, N Long, JA AF Shacter, Hannah E. Shea, Judy A. Akhabue, Ehimare Sablani, Naveen Long, Judith A. TI A QUALITATIVE EVALUATION OF RACIAL DISPARITIES IN GLUCOSE CONTROL SO ETHNICITY & DISEASE LA English DT Article DE Diabetes Mellitus; African Americans; Blood Glucose; Health Status Disparities; Veterans ID TYPE-2 DIABETES-MELLITUS; AFRICAN-AMERICAN WOMEN; HEALTH-CARE SETTINGS; GLYCEMIC CONTROL; OF-CARE; SELF-MANAGEMENT; MICROVASCULAR COMPLICATIONS; SOCIOECONOMIC POSITION; VETERANS; ADULTS AB Objective: Type 2 diabetes is more prevalent and severe among African Americans than among Whites. To elucidate barriers to glucose control that are unique to African Americans with poor glucose control we conducted a qualitative study among veterans with diabetes in an academic Veterans Affairs medical center. Methods: We enrolled African American and White veterans with diabetes; participants' glucose control was described as well controlled or poorly controlled, and groups were organized on the basis of ethnicity and glucose control. Discussions were conducted by using modified nominal group technique to define factors that aided or hindered glucose control. Results: Well-controlled groups similarly reported that self-care, health care, and psychosocial factors were important in controlling glucose. Although poorly controlled African Americans cited self-care as important, they also noted difficulty following self-care practices and the interference of psychosocial factors with glucose control. Poorly controlled Whites were similar. Uniquely, poorly controlled African Americans were less likely to report positive healthcare experiences; their barriers were related to poor access and poor relationships with providers. Conclusions: Poorly controlled African Americans endorsed healthy self-care behaviors but found it difficult to follow through. interventions targeting the management of stress, depression, mood, and temptation, as well as improved access to and communication with providers may help these patients better manage their glucose and minimize disparities in diabetes outcomes. (Ethn Dis. 2009;19:121-127) C1 [Shacter, Hannah E.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Shea, Judy A.; Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Shea, Judy A.; Akhabue, Ehimare; Long, Judith A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Sablani, Naveen] Univ Penn, Leonard Davis Inst Hlth Econ, SUMR Program, Philadelphia, PA 19104 USA. RP Long, JA (reprint author), 1201 Blockley,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jalong@mail.med.upenn.edu FU CHERP VISN 4 Competitive Pilot Research Program FX This study was supported by the CHERP VISN 4 Competitive Pilot Research Program. NR 41 TC 9 Z9 9 U1 2 U2 3 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2009 VL 19 IS 2 BP 121 EP 127 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 455OB UT WOS:000266769300005 PM 19537221 ER PT J AU Ellis, C Zhao, YM Egede, LE AF Ellis, Charles Zhao, Yumin Egede, Leonard E. TI RACIAL/ETHNIC DIFFERENCES IN STROKE MORTALITY IN VETERANS SO ETHNICITY & DISEASE LA English DT Article DE Stroke; Mortality; Race/Ethnicity; Veterans ID SOCIOECONOMIC-STATUS; CEREBRAL INFARCTION; RACIAL-DIFFERENCES; HEART-DISEASE; UNITED-STATES; RACE; DISPARITIES; BLACKS; CARE; MEN AB Objective: We examined racial-ethnic differences in all-cause mortality after stroke in a cohort of veterans living in the southeastern United States. Methods: Data on a cohort of 4115 veterans with a diagnosis of stroke were analyzed. The cohort included veterans who classified themselves as non-Hispanic White, non-Hispanic Black, or Other. All veterans had a diagnosis of ischemic or hemorrhagic stroke. All subjects were seen in Veterans Affairs facilities in the Charleston, South Carolina area and were followed from January 1, 2000 to December 31, 2006. Cox proportional hazards regression models were used to compare survival times by race/ethnicity, adjusting for relevant covariates. Results: In 38 months of follow-up, 1232 veterans in the cohort died. Compared with non-Hispanic White veterans, Black veterans were approximate to 20% more likely to die, and other ethnicities were approximate to 20% less likely to die in the unadjusted model. In the adjusted model, the White-Black disparity increased somewhat, and the disparity between Whites and other ethnicities was somewhat attenuated. Age, coronary heart disease, cancer, and Charlson co-morbidity index > 2 were also associated with higher mortality. Conclusions: Non-Hispanic Black veterans with a history of stroke in the southeastern United States had significantly higher mortality than did Non-Hispanic White veterans and veterans of other ethnicities, even after adjusting for relevant covariates. (Ethn Dis. 2009;19:161-165) C1 [Ellis, Charles] Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA. [Zhao, Yumin; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Ellis, Charles; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA REAP, Charleston, SC USA. RP Ellis, C (reprint author), Med Univ S Carolina, Dept Hlth Profess, 151-B Rutledge Ave, Charleston, SC 29425 USA. EM ellisc@musc.edu NR 30 TC 6 Z9 6 U1 0 U2 0 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2009 VL 19 IS 2 BP 161 EP 165 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 455OB UT WOS:000266769300011 PM 19537227 ER PT J AU Shimazaki, K Chan, AM Moniz, RJ Wadehra, M Nagy, A Coulam, CP Mareninov, S Lepin, EM Wu, AM Kelly, KA Braun, J Gordon, LK AF Shimazaki, Kaori Chan, Ann M. Moniz, Raymond J. Wadehra, Madhuri Nagy, Agnes Coulam, Catherine P. Mareninov, Sergey Lepin, Eric M. Wu, Anna M. Kelly, Kathleen A. Braun, Jonathan Gordon, Lynn K. TI Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY LA English DT Article DE Chlamydia muridarum; epithelial membrane protein 2 (EMP2); infection; antibody therapy ID TRACHOMATIS INFECTION; HEPARAN-SULFATE; TRACT INFECTION; SURFACE EXPRESSION; FIELD TRIAL; CELLS; MICE; VACCINE; MOUSE; GLYCOSAMINOGLYCAN AB New methods are needed to eradicate or prevent Chlamydia trachomatis infections. Blockade of epithelial membrane protein 2 (EMP2) by genetic silencing or neutralizing polyclonal antibody reduced chlamydial infectivity in vitro. This study tests the prediction that recombinant anti-EMP2 diabody could reduce early chlamydial infection of the genital tract in vivo. In a murine infection model, pretreatment with anti-EMP2 diabody, as compared with control diabody, significantly reduced bacterial load, tissue production of inflammatory cytokines, recruitment of polymorphonuclear leukocytes, and local tissue inflammation. These findings support EMP2 as a potential preventative and therapeutic target for genital chlamydial infection. C1 [Gordon, Lynn K.] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Gordon, Lynn K.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Shimazaki, Kaori; Braun, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA. [Chan, Ann M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol Sci, Los Angeles, CA 90095 USA. [Moniz, Raymond J.; Wadehra, Madhuri; Nagy, Agnes; Coulam, Catherine P.; Mareninov, Sergey; Kelly, Kathleen A.; Braun, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lepin, Eric M.; Wu, Anna M.; Braun, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. RP Gordon, LK (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM lgordon@ucla.edu OI Braun, Jonathan/0000-0003-1646-2974 FU NIH [CA86306, CA009120, 2-T32-AI-07323, AI026328, CA016042]; Iris Cantor Foundation; Giannini Family Foundation; Oppenheimer Family Foundation FX This work was supported by NIH CA86306 (A.M.W., J.B.), CA009120 (M.W.), 2-T32-AI-07323 (K.S.), AI026328 (K.K.), and CA016042 (UCLA Jonsson Comprehensive Cancer Center flow cytometry core); Iris Cantor Foundation (M.W.); the Giannini Family Foundation (M.W.); the Oppenheimer Family Foundation Grant - Center for the Prevention of Eye Disease (L.K.G., J.B.); and Richard and Barbara Braun. We are grateful to Dr Harlan Caldwell for gift of reagent (anti-Chlamydia lipopolysaccharide mouse antibody) and also thank Dr Wei Bo for helpful comments. NR 40 TC 4 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0928-8244 J9 FEMS IMMUNOL MED MIC JI FEMS Immunol. Med. Microbiol. PD MAR PY 2009 VL 55 IS 2 BP 240 EP 249 DI 10.1111/j.1574-695X.2008.00525.x PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 404EM UT WOS:000263133600016 PM 19159428 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI How to choose a job after a GI fellowship (weighing family and city life against salary and research) SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material C1 Portland VA Med Ctr, Dept Gastroenterol, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, Portland, OR USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2009 VL 69 IS 3 BP 526 EP 529 DI 10.1016/j.gie.2008.11.053 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 416NF UT WOS:000264012100020 PM 19231493 ER PT J AU El Hajj, II Khalid, A Schoedel, KE Abu-Ehmagd, KM McGrath, KM Fasanella, KE AF El Hajj, Ihab I. Khalid, Asif Schoedel, Karen E. Abu-Ehmagd, Kareem M. McGrath, Kevin M. Fasanella, Kenneth E. TI EUS-guided FNA diagnosis of primary splenic lymphoma SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID FINE-NEEDLE-ASPIRATION; ENDOSCOPIC ULTRASOUND; VEIN-THROMBOSIS; NATURAL-HISTORY; BIOPSY; SPLEEN C1 [El Hajj, Ihab I.; Khalid, Asif; McGrath, Kevin M.; Fasanella, Kenneth E.] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA 15213 USA. [Schoedel, Karen E.] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA 15213 USA. [Abu-Ehmagd, Kareem M.] Univ Pittsburgh, Dept Surg, Med Ctr, Pittsburgh, PA 15213 USA. [Khalid, Asif] VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. RP Fasanella, KE (reprint author), Univ Pittsburgh, Dept Med, Med Ctr, 200 Lothrop St,Mezzanine Level 2,C Wing, Pittsburgh, PA 15213 USA. RI Fasanella, Kenneth/I-2781-2012 NR 12 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2009 VL 69 IS 3 BP 585 EP 588 DI 10.1016/j.gie.2008.04.058 PN 1 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 416NF UT WOS:000264012100040 PM 19012888 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI How to overbook procedures in the endoscopy unit SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID NON-ATTENDANCE RATE; OUTPATIENT ENDOSCOPY; NONATTENDANCE; APPOINTMENTS; PATIENT AB Background: Because nonattendance of outpatients scheduled for GI endoscopy is unavoidable, a frequently recommended Solution involves overbooking patient appointments. Objective: To provide a set of numerical guidelines of how to overbook patients scheduled for endoscopy. Design: Cost-benefit analysis using stochastic modeling to estimate the total number of endoscopy appointments (including overbooking) that maximize the expected benefit from endoscopy. Patients: Subjects schecluled for GI endoscopy. Main Outcome Measurements: The number of endoscopies that should be scheduled under various scenarios of patient attendance rates, the number of available endoscopy slots, and the cost impact of missed appointments. Results: Overbooking can increase the expected benefit but never quite reaches the benefit that would be achieved, if all patients were perfectly reliable in meeting their scheduled appointments. The expected benefit of overbooking always comes to lie between the low benefit without overbooking and the high benefit associated with perfectly reliable patients. The less reliable the patient population, the more overbooking needs to take place. Overbooking should also expand with a decreasing cost impact of overbooked endoscopies. Overbooking is most beneficial in large endoscopy units. This article provides a table with a large set of numerical examples for different scenarios of overbooking that cover endoscopy units of diverse sizes and patient attendance rates. Limitations: The analysis does not take into account individual patient characteristics that may affect attendance rates. Conclusion: This analysis yields a set of estimates for overbooking that can be readily applied to a large variety of endocscopic units. (Gastrointest Endosc 2009;69:710-5.) C1 Portland VA Med Ctr, Dept Gastroenterol, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. NR 17 TC 5 Z9 5 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2009 VL 69 IS 3 BP 710 EP 715 DI 10.1016/j.gie.2008.09.052 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 416NG UT WOS:000264012200018 PM 19251015 ER PT J AU Mummidi, S Bonello, GB Ahuja, SK AF Mummidi, S. Bonello, G. B. Ahuja, S. K. TI Confirmation of differential binding of Interferon Regulatory Factor-1 (IRF-1) to the functional and HIV disease-influencing-2578 A/G polymorphism in CCL2 SO GENES AND IMMUNITY LA English DT Letter ID EXPRESSION; PROMOTER C1 [Mummidi, S.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Mummidi, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA. EM mummidi@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 NR 5 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD MAR PY 2009 VL 10 IS 2 BP 197 EP 198 DI 10.1038/gene.2008.75 PG 2 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 415AD UT WOS:000263905800013 PM 18923432 ER PT J AU Odinokova, IV Sung, KF Mareninova, OA Hermann, K Evtodienko, Y Andreyev, A Gukovsky, I Gukovskaya, AS AF Odinokova, I. V. Sung, K-F Mareninova, O. A. Hermann, K. Evtodienko, Y. Andreyev, A. Gukovsky, I. Gukovskaya, A. S. TI Mechanisms regulating cytochrome c release in pancreatic mitochondria SO GUT LA English DT Article ID PERMEABILITY TRANSITION PORE; OXYGEN SPECIES PRODUCTION; CELL-DEATH; ACINAR-CELLS; BRAIN MITOCHONDRIA; OXIDATIVE STRESS; MEMBRANE PERMEABILIZATION; ENZYME ACTIVATION; FREE-RADICALS; APOPTOSIS AB Background: Mechanisms of acinar cell death in pancreatitis are poorly understood. Cytochrome c release is a central event in apoptosis in pancreatitis. Here, we assessed the regulation of pancreatic cytochrome c release by Ca(2+), mitochondrial membrane potential (Delta Psi m), and reactive oxygen species (ROS), the signals involved in acute pancreatitis. We used both isolated rat pancreatic mitochondria and intact acinar cells hyper-stimulated with cholecystokinin-8 (CCK-8; in vitro model of acute pancreatitis). Results: Micromolar amounts of Ca(2+) depolarised isolated pancreatic mitochondria through a mechanism different from the "classical'' (ie, liver) mitochondrial permeability transition pore (mPTP). In contrast with liver, Ca(2+)-induced mPTP opening caused a dramatic decrease in ROS and was not associated with pancreatic mitochondria swelling. Importantly, we found that Ca(2+)-induced depolarisation inhibited cytochrome c release from pancreatic mitochondria, due to blockade of ROS production. As a result, Ca(2+) exerted two opposite effects on cytochrome c release: Ca(2+) per se stimulated the release, whereas Ca(2+)-induced depolarisation inhibited it. This dual effect caused a non-monotonous dose-dependence of cytochrome c release on Ca(2+). In intact acinar cells, cytochrome c release, caspase activation and apoptosis were all stimulated by ROS and Ca(2+), and inhibited by depolarisation, corroborating the findings on isolated pancreatic mitochondria. Conclusions: These data implicate ROS as a key mediator of CCK-induced apoptotic responses. The results indicate a major role for mitochondria in the effects of Ca(2+) and ROS on acinar cell death. They suggest that the extent of apoptosis in pancreatitis is regulated by the interplay between ROS, Delta Psi m and Ca(2+). Stabilising mitochondria against loss of Delta Psi m may represent a strategy to mitigate the severity of pancreatitis. C1 [Gukovskaya, A. S.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Dept Med,David Geffen Sch Med, Los Angeles, CA 90073 USA. [Odinokova, I. V.; Evtodienko, Y.] Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Russia. [Sung, K-F] Chang Gung Mem Hosp, Dept Hepatogastroenterol, Taipei 10591, Taiwan. [Andreyev, A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA. RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Dept Med,David Geffen Sch Med, 11301 Wilshire Blvd,Blg 258,Rm 40, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU NIH [DK059936]; Foundation Designated Research Scholar Award in Pancreatitis; Hirshberg Foundation FX This study was supported by NIH grant DK059936 (to ASG), an AGA Foundation Designated Research Scholar Award in Pancreatitis (to OAM) and by the Hirshberg Foundation. NR 66 TC 33 Z9 34 U1 0 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD MAR PY 2009 VL 58 IS 3 BP 431 EP 442 DI 10.1136/gut.2007.147207 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 406CZ UT WOS:000263273900022 PM 18596195 ER PT J AU Goldzweig, CL Towfigh, A Maglione, M Shekelle, PG AF Goldzweig, Caroline Lubick Towfigh, Ali Maglione, Margaret Shekelle, Paul G. TI Costs And Benefits Of Health Information Technology: New Trends From The Literature SO HEALTH AFFAIRS LA English DT Article; Proceedings Paper CT 15th Princeton Conference on Can Payment and Other Innovations Improve the Quality and Value of Health Care CY MAY 27-28, 2008 CL Princeton, NJ SP Council Hlth Care Econ & Policy AB To understand what is new in health information technology ( IT), we updated a systematic review of health IT with studies published during 2004-2007. From 4,683 titles, 179 met inclusion criteria. We identified a proliferation of patient-focused applications although little formal evaluation in this area; more descriptions of commercial electronic health records (EHRs) and health IT systems designed to run independently from EHRs; and proportionately fewer relevant studies from the health IT leaders. Accelerating the adoption of health IT will require greater public-private partnerships, new policies to address the misalignment of financial incentives, and a more robust evidence base regarding IT implementation. [Health Affairs 28, no. 2 (2009): w282-w293 (published online 27 January 2009; 10.1377/hlthaff.28.2.w282)] C1 [Goldzweig, Caroline Lubick; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst Calif, Los Angeles, CA USA. [Maglione, Margaret; Shekelle, Paul G.] RAND, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. RP Goldzweig, CL (reprint author), VA Greater Los Angeles Healthcare Syst Calif, Los Angeles, CA USA. EM caroline.goldzweig@va.gov NR 3 TC 124 Z9 126 U1 2 U2 14 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAR-APR PY 2009 VL 28 IS 2 BP W282 EP W293 DI 10.1377/hlthaff.28.2.w282 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 422RJ UT WOS:000264445100083 PM 19174390 ER PT J AU Sarkar, U Ali, S Whooley, MA AF Sarkar, Urmimala Ali, Sadia Whooley, Mary A. TI Self-Efficacy as a Marker of Cardiac Function and Predictor of Heart Failure Hospitalization and Mortality in Patients With Stable Coronary Heart Disease: Findings From the Heart and Soul Study SO HEALTH PSYCHOLOGY LA English DT Article DE self-efficacy; heart failure; epidemiology ID HEALTH-CARE UTILIZATION; DEPRESSIVE SYMPTOMS; ARTERY-DISEASE; MEDICATION ADHERENCE; PULMONARY-DISEASE; CONTROLLED-TRIAL; MANAGEMENT; INTERVENTION; ASSOCIATION; BEHAVIORS AB Objective: The authors sought to evaluate the association of self-efficacy with objective measures of cardiac function, subsequent hospitalization for heart failure (HF), and all-cause mortality. Design: Observational cohort of ambulatory patients with stable CHD. The authors measured self-efficacy using a published, validated, 5-item summative scale, the Sullivan Self-Efficacy to Maintain Function Scale. The authors also performed a cardiac assessment, including an exercise treadmill test with stress echocardiography. Main Outcome Measures: Hospitalizations for HF, as determined by blinded review of medical records, and all-cause mortality, with adjustment for demographics, medical history, medication use, depressive symptoms, and social support. Results: Of the 1,024 predominately male, older CHD patients, 1013 (99%) were available for follow-up, 124 (12%) were hospitalized for HF, and 235 (23%) died during 4.3 years of follow-up. Mean cardiac self-efficacy score was 9.7 (SD 4.5, range 0-20), corresponding to responses between "not at all confident" and "somewhat confident" for ability to maintain function. Lower self-efficacy predicted subsequent HF hospitalization (OR per SD decrease = 1.4, p = .0006), and all-cause mortality (OR per SD decrease = 1.4, p < .0001). After adjustment, the association of cardiac self-efficacy with both HF hospitalization and mortality was explained by worse baseline cardiac function. Conclusion: Among patients with CHD, self-efficacy was a reasonable proxy for predicting HF hospitalizations. The increased risk of HF associated with lower baseline self-efficacy was explained by worse cardiac function. These findings indicate that measuring cardiac self-efficacy provides a rapid and potentially useful assessment of cardiac function among outpatients with CHD. C1 [Sarkar, Urmimala; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [Ali, Sadia; Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. RP Sarkar, U (reprint author), Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Box 1732, San Francisco, CA 94143 USA. EM urmimalasarkar@yahoo.com FU National Research Service Awards [1 T32 HP19025]; Department of Veterans Affairs; Robert Wood Johnson Foundation; American Federation for Aging Research; Ischemia Research and Education Foundation; Nancy Kirwan Heart Research Fund FX Urmimala Sarkar is supported by National Research Service Awards Grant No. 1 T32 HP19025. This work was supported by grants from the Department of Veterans Affairs (Epidemiology Merit Review Program), the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), the Ischemia Research and Education Foundation, and the Nancy Kirwan Heart Research Fund. None of these funding sources had any role in the collection of data, interpretation of results, or preparation of this article. NR 44 TC 37 Z9 40 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 J9 HEALTH PSYCHOL JI Health Psychol. PD MAR PY 2009 VL 28 IS 2 BP 166 EP 173 DI 10.1037/a0013146 PG 8 WC Psychology, Clinical; Psychology SC Psychology GA 420YY UT WOS:000264326300004 PM 19290708 ER PT J AU Farmer, SA Kirkpatrick, JN Heidenreich, PA Curtis, JP Wang, YF Groeneveld, PW AF Farmer, Steven A. Kirkpatrick, James N. Heidenreich, Paul A. Curtis, Jeptha P. Wang, Yongfei Groeneveld, Peter W. TI Ethnic and racial disparities in cardiac resynchronization therapy SO HEART RHYTHM LA English DT Article DE Registry; Heart failure; Pacemaker; Epidemiology; Implantable cardioverter-defibrillator ID ACUTE MYOCARDIAL-INFARCTION; CORONARY REVASCULARIZATION PROCEDURES; HEART-FAILURE; SOCIOECONOMIC-STATUS; FUTURE; CARE; UNDERUSE; OUTCOMES; RACE; SEX AB BACKGROUND Racial/ethnic differences in the use of cardiac resynchronization therapy with defibrillator (CRT-D) may result from underprovision or overprovision relative to published guidelines. OBJECTIVE The purpose of this study was to examine the National Cardiovascular Data Registry (NCDR) ICD Registry for ethnic/racial differences in use of CRT-D. METHODS We studied white, black, and Hispanic patients who received either an implantable cardioverter-defibrillator (ICD) or CRT-D between January 2005 and April 2007. Two multivariate Logistic regression models were fit with the following outcome variables: (1) receipt of either ICD or CRT-D and (2) receipt of CRT-D outside of published guidelines. RESULTS Of 108,341 registry participants, 22,205 met inclusion criteria for the first analysis and 27,165 met criteria for the second analysis. Multivariate analysis indicated CRT-eligible black (odds ratio [OR] 0.84; 95% confidence interval [CI], 0.75-0.95; P <.004) and Hispanic (OR 0.83; 95% CI, 0.71-0.99; P <.033) patients were less likely to receive CRT-D than were white patients. A substantial proportion of patients received CRT-D outside of published guidelines, although black (OR 1.18; 95% CI, 1.02-1.36; P = .001) and Hispanic (OR 1.17; 95% CI, 1.02-1.36; P = .03) patients were more likely to meet all. three eligibility criteria. CONCLUSION Black and Hispanic patients who were eligible for CRT-D were less Likely to receive therapy compared with white patients. Conversely, in the context of widespread out-of-guideline use of CRT-D, black and Hispanic patients were more likely to meet established criteria. Our findings suggest systematic racial/ethnic differences in the treatment of patients with advanced heart failure. C1 [Farmer, Steven A.; Kirkpatrick, James N.] Univ Penn, Sch Med, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA. [Heidenreich, Paul A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Heidenreich, Paul A.] Stanford Univ, Sch Med, Dept Med, Div Cardiovasc, Stanford, CA 94305 USA. [Curtis, Jeptha P.; Wang, Yongfei] Yale Univ, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA. [Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. RP Farmer, SA (reprint author), Hosp Univ Penn, Div Cardiovasc, 3400 Spruce St,9 Gates, Philadelphia, PA 19104 USA. EM Steven.Farmer@uphs.upenn.edu OI Heidenreich, Paul/0000-0001-7730-8490 FU American College of Cardiology/National Cardiovascular Data Registry; Research Career Development Award FX This research was supported by the American College of Cardiology/National Cardiovascular Data Registry. Dr. Groeneveld was supported by a Research Career Development Award from the Department of Veterans Affairs. NR 33 TC 39 Z9 39 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD MAR PY 2009 VL 6 IS 3 BP 325 EP 331 DI 10.1016/j.hrthm.2008.12.018 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 419OE UT WOS:000264228100007 PM 19251206 ER PT J AU Jenkins, TC McCollister, BD Sharma, R McFann, KK Madinger, NE Barron, M Bessesen, M Price, CS Burman, WJ AF Jenkins, Timothy C. McCollister, Bruce D. Sharma, Rohini McFann, Kim K. Madinger, Nancy E. Barron, Michelle Bessesen, Mary Price, Connie S. Burman, William J. TI Epidemiology of Healthcare-Associated Bloodstream Infection Caused by USA300 Strains of Methicillin-Resistant Staphylococcus aureus in 3 Affiliated Hospitals SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID PANTON-VALENTINE LEUKOCIDIN; FIELD GEL-ELECTROPHORESIS; UNITED-STATES; EMERGENCE; PNEUMONIA; CLONE; DISEASE; GENES AB OBJECTIVE. To describe the epidemiology of bloodstream infection caused by USA300 strains of methicillin-resistant Staphylococcus aureus (MRSA), which are traditionally associated with cases of community-acquired infection, in the healthcare setting. DESIGN. Retrospective cohort study. SETTING. Three academically affiliated hospitals in Denver, Colorado. METHODS. Review of cases of S. aureus bloodstream infection during the period from 2003 through 2007. Polymerase chain reaction was used to identify MRSA USA300 isolates. RESULTS. A total of 330 cases of MRSA bloodstream infection occurred during the study period, of which 286 (87%) were healthcare-associated. The rates of methicillin resistance among the S. aureus isolates recovered did not vary during the study period and were similar among the 3 hospitals. However, the percentages of cases of healthcare-associated MRSA bloodstream infection due to USA300 strains varied substantially among the 3 hospitals: 62%, 19%, and 36% (P <.001) for community-onset cases and 33%, 3%, and 33% (P = .005) for hospital-onset cases, in hospitals A, B, and C, respectively. In addition, the number of cases of healthcare-associated MRSA bloodstream infection caused by USA300 strains increased during the study period at 2 of the 3 hospitals. At each hospital, USA300 strains were most common among cases of community-associated infection and were least common among cases of hospital-onset infection. Admission to hospital A (a safety-net hospital), injection drug use, and human immunodeficiency virus infection were independent risk factors for healthcare-associated MRSA bloodstream infection due to USA300 strains. CONCLUSIONS. The prevalence of USA300 strains among cases of healthcare-associated MRSA bloodstream infection varied dramatically among geographically clustered hospitals. USA300 strains are replacing traditional healthcare-related strains of MRSA in some healthcare settings. Our data suggest that the prevalence of USA300 strains in the community is the dominant factor affecting the prevalence of this strain type in the healthcare setting. C1 [Jenkins, Timothy C.; Price, Connie S.; Burman, William J.] Univ Colorado, Div Infect Dis, Denver Hlth, Denver, CO 80202 USA. [Jenkins, Timothy C.; McCollister, Bruce D.; Sharma, Rohini; McFann, Kim K.; Madinger, Nancy E.; Barron, Michelle; Bessesen, Mary; Price, Connie S.; Burman, William J.] Univ Colorado, Dept Med, Div Infect Dis, Denver, CO 80202 USA. [Bessesen, Mary] Denver Vet Affairs Med Ctr, Div Infect Dis, Denver, CO USA. RP Jenkins, TC (reprint author), Denver Hlth Med Ctr, 660 Bannock St, Denver, CO 80204 USA. EM timothy.jenkins@dhha.org OI Bessesen, Mary/0000-0001-9305-1293 FU Division of Infectious Diseases at the University of Colorado Denver FX Financial support. We were supported by the Division of Infectious Diseases at the University of Colorado Denver. NR 21 TC 33 Z9 33 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAR PY 2009 VL 30 IS 3 BP 233 EP 241 DI 10.1086/595963 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 406XL UT WOS:000263328100005 PM 19199535 ER PT J AU McBride, AJA Cerqueira, GM Suchard, MA Moreira, AN Zuerner, RL Reis, MG Haake, DA Ko, AI Dellagostin, OA AF McBride, Alan J. A. Cerqueira, Gustavo M. Suchard, Marc A. Moreira, Angela N. Zuerner, Richard L. Reis, Mitermayer G. Haake, David A. Ko, Albert I. Dellagostin, Odir A. TI Genetic diversity of the Leptospiral immunoglobulin-like (Lig) genes in pathogenic Leptospira spp. SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Leptospirosis; Lig; Pathogenesis; Molecular evolution; Sequence analysis ID SURFACE-EXPOSED LIPOPROTEIN; OUTER-MEMBRANE PROTEIN; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; NUCLEOTIDE-SEQUENCES; MAMMALIAN INFECTION; PROTECTIVE IMMUNITY; BINDING PROTEIN; URBAN EPIDEMIC; HAMSTER MODEL AB Recent serologic, immunoprotection, and pathogenesis studies identified the Lig proteins as key virulence determinants in interactions of leptospiral pathogens with the mammalian host. We examined the sequence variation and recombination patterns of ligA, ligB, and ligC among 10 pathogenic strains from five Leptospira species. All strains were found to have intact ligB genes and genetic drift accounting for most of the ligB genetic diversity observed. The ligA gene was found exclusively in L. interrogans and L. kirschneri strains, and was created from ligB by a two-step partial gene duplication process. The aminoterminal domain of LigB and the LigA paralog were essentially identical (98.5 +/- 0.8% mean identity) in strains with both genes. Like ligB, ligC gene variation also followed phylogenetic patterns, suggesting an early gene duplication event. However, ligC is a pseudogene in several strains, suggesting that LigC is not essential for virulence. Two ligB genes and one ligC gene had mosaic compositions and evidence for recombination events between related Leptospira species was also found for some ligA genes. In conclusion, the results presented here indicate that Lig diversity has important ramifications for the selection of Lig polypeptides for use in diagnosis and as vaccine candidates. This sequence information will aid the identification of highly conserved regions within the Lig proteins and improve upon the performance characteristics of the Lig proteins in diagnostic assays and in subunit vaccine formulations with the potential to confer heterologous protection. (C) 2008 Elsevier B.V. All rights reserved. C1 [McBride, Alan J. A.; Reis, Mitermayer G.; Ko, Albert I.] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil. [Cerqueira, Gustavo M.; Moreira, Angela N.; Dellagostin, Odir A.] Univ Fed Pelotas, Ctr Biotecnol, Pelotas, RS, Brazil. [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Suchard, Marc A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA. [Zuerner, Richard L.] USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Ko, Albert I.] Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, New York, NY 10021 USA. RP Dellagostin, OA (reprint author), Univ Fed Pelotas, Ctr Biotecnol, Pelotas, RS, Brazil. EM odir@ufpel.edu.br RI Dellagostin, Odir/C-2331-2009; Vacinas, Inct/J-9431-2013; Cerqueira, Gustavo/B-7180-2015; Ko, Albert/P-2343-2015; McBride, Alan/D-4106-2012 OI Dellagostin, Odir/0000-0003-2803-4088; Cerqueira, Gustavo/0000-0002-3029-6899; Ko, Albert/0000-0001-9023-2339; McBride, Alan/0000-0001-9682-540X FU Bio-Manguinhos; Oswaldo Cruz Foundation; Brazilian Ministry of Health [09224-7]; Brazilian National Research Council [01.06.0298.00 3773/2005, 420067/2005, 554788/2006, 473006/2006-5]; Public Health Service [AI-34431]; National Institute of Allergy and Infectious Diseases [R01 AI034431]; VA Medical Research Funds; Fogarty International Center [D43 TW00919]; National Institutes of Health; Alfred P. Sloane Research Fellowship; John Simon Guggenheim Memorial Fellowship FX This work was supported by Bio-Manguinhos, Oswaldo Cruz Foundation, Brazilian Ministry of Health (grant 09224-7), Brazilian National Research Council (grants 01.06.0298.00 3773/2005, 420067/2005, 554788/2006 and 473006/2006-5); Public Health Service grants AI-34431 (to D.A.H.) and R01 AI034431 (to A.I.K.) from the National Institute of Allergy and Infectious Diseases, the VA Medical Research Funds(to D.A.H.) and grant D43 TW00919 (to A.I.K.) from the Fogarty International Center, National Institutes of Health. M.A.S. is supported by an Alfred P. Sloane Research Fellowship and a John Simon Guggenheim Memorial Fellowship. NR 67 TC 33 Z9 35 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD MAR PY 2009 VL 9 IS 2 BP 196 EP 205 DI 10.1016/j.meegid.2008.10.012 PG 10 WC Infectious Diseases SC Infectious Diseases GA 417BL UT WOS:000264049400006 PM 19028604 ER PT J AU Gerding, DN AF Gerding, Dale N. TI Clostridium difficile 30 years on: what has, or has not, changed and why? SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Article; Proceedings Paper CT Conference on New Views on Clostridium Difficile Infections CY SEP 26-27, 2008 CL Leipzig, GERMANY SP Int Soc Chemotherapy DE Clostridium difficile; Pseudomembranous colitis; Antibiotic-associated diarrhoea; Clindamycin colitis; Animal models; Toxins A and B; Binary toxin ID CLINDAMYCIN-ASSOCIATED COLITIS; POLYMERASE-CHAIN-REACTION; PLACEBO-CONTROLLED TRIAL; SERUM ANTIBODY-RESPONSE; TOXIN-A; PSEUDOMEMBRANOUS COLITIS; ORAL VANCOMYCIN; DIARRHEA; HAMSTERS; INFECTION AB The report of clindamycin-associated colitis in 1974 by Tedesco et al. [Ann Intern Med 81: 429 33] stimulated an intense search for the cause of this severe complication of antibiotic use. The search culminated in early 1978 in the publication of a series of papers within 3 months that identified the causative agent as Clostridium difficile and its accompanying toxins. Thirty years later we are in the midst of a resurgence of C. difficile infection (CDI) in North America and Europe that is greater than ever previously reported and for which morbidity and mortality appear to be higher than ever seen in the past. The purpose of this review is to highlight the discoveries of the past 30 years that, in my view, have brought us to our current level of understanding of the pathogenesis, prevention and treatment of CDI, and to suggest why a disease thought to be managed so well 30 years ago could now be causing more morbidity and mortality than ever before. In the 21st century the focus should be on better understanding the relationship between the C. difficile organism and the host at the mucosal level, so that biotherapeutic and vaccine strategies for the prevention of CDI can be developed. (C) 2009 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved. C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Div Infect Dis, Maywood, IL USA. RP Gerding, DN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, 5000 S 5th Ave,Bldg 1,Room C344, Hines, IL 60141 USA. EM dale.gerding2@va.gov NR 91 TC 31 Z9 31 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD MAR PY 2009 VL 33 BP S2 EP S8 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 438OL UT WOS:000265564900002 PM 19303564 ER PT J AU Johnson, S AF Johnson, Stuart TI Recurrent Clostridium difficile infection: causality and therapeutic approaches SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Article; Proceedings Paper CT Conference on New Views on Clostridium Difficile Infections CY SEP 26-27, 2008 CL Leipzig, GERMANY SP Int Soc Chemotherapy DE Clostridium difficile; Diarrhoea; Recurrence ID ANTIBODY-RESPONSE; TOXIN-A; GAMMA-GLOBULIN; DIARRHEA; COLITIS; DISEASE; VANCOMYCIN; RIFAXIMIN; METRONIDAZOLE; COLONIZATION AB Recurrent diarrhoea after successful treatment of the primary episode is a common complication of Clostridium difficile infection (CDI) and may be increasing in frequency. Evidence suggests that persistent alterations in the indigenous bowel. ora and failure to mount an effective antibody response to C. difficile toxins are the main mechanisms whereby recurrent CDIs occur. Treatment of the first recurrence with the same agent used for the treatment of the primary episode is reasonable, but a different approach is needed for patients with multiple CDI recurrences. Prolonged, repeated courses of metronidazole are discouraged, but a practical first option in these patients is to use tapered-dose oral vancomycin followed by a pulsed-dose regimen. Other potential options include probiotic approaches, restoration of the normal. ora, immunological approaches, toxin-binding approaches, and serial therapy with vancomycin followed by rifaximin. Randomised studies including a sufficient numbers of patients have not yet been conducted for the treatment of recurrent CDI and are needed to help guide the formulation of effective recommendations. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. C1 [Johnson, Stuart] Loyola Univ Chicago, Div Infect Dis, Stritch Sch Med, Maywood, IL 60153 USA. [Johnson, Stuart] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Med Serv, Hines, IL 60141 USA. RP Johnson, S (reprint author), Loyola Univ Chicago, Div Infect Dis, Stritch Sch Med, 2160 S 1st Ave,Fahey Ctr Bldg 54,Room 149, Maywood, IL 60153 USA. EM sjohnson@lumc.edu NR 39 TC 26 Z9 26 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD MAR PY 2009 VL 33 BP S33 EP S36 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 438OL UT WOS:000265564900008 PM 19303567 ER PT J AU Merrigan, MM Sambol, SP Johnson, S Gerding, DN AF Merrigan, Michelle M. Sambol, Susan P. Johnson, Stuart Gerding, Dale N. TI New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C-difficile during daily ampicillin or ceftriaxone administration SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Article; Proceedings Paper CT Conference on New Views on Clostridium Difficile Infections CY SEP 26-27, 2008 CL Leipzig, GERMANY SP Int Soc Chemotherapy DE Clostridium difficile; Pseudomembranous colitis; Antibiotic-associated diarrhoea; Ceftriaxone; Hamster model; Ampicillin ID HAMSTERS; CLINDAMYCIN; STRAIN; RISK; PREVENTION; DIARRHEA; DISEASE; TOXIN AB Non-toxigenic strains of Clostridium difficile are highly effective in preventing toxigenic C. difficile infection in hamsters when given following a single dose of an antimicrobial agent. The goal of this study was to determine the ability of non-toxigenic C. difficile to colonise hamsters during administration of an antibiotic to which the organisms are resistant ceftriaxone and an antibiotic to which they are susceptible ampicillin and to determine if non-toxigenic colonisation is protective against toxigenic strain challenge. Groups of four or five hamsters were administered daily ceftriaxone 60 mg/kg/d intraperitoneally or ampicillin 60 mg/kg/d orally for 5 days. Three non-toxigenic strains of C. difficile, M3, M23, and T7 (MICs 96 128 mg/L) were each given orally at a dose of 1 x 10(6) spores to groups of five animals 3 h after the first dose of ceftriaxone. All animals were colonised successfully by day 3 of the study and when challenged with 1 x 10(6) spores of toxigenic strain J9 (MIC > 256 mg/L) on day 3 all animals survived, whereas the control animal given ceftriaxone, but not non-toxigenic C. difficile, died within 48 h of challenge. When groups of four hamsters were given ampicillin, administration of non-toxigenic strain M3 (MIC 2 mg/L) or toxigenic strain J9 (MIC 0.75 mg/L) at 1 x 10(6) spores did not result in any colonisation or infection of the animals until day 8, 3 days after the last ampicillin dose. A protection study was designed by giving M3 spores to groups of five animals daily for 5 days beginning on day 1, 3, or 5 of ampicillin. Toxigenic challenge was given with J9 spores on day 3 of each M3 regimen. M3 colonised all animals by day 8 and none became infected with J9. Colonisation by non-toxigenic C. difficile is an effective prevention strategy during antibiotic administration of ceftriaxone or ampicillin, but multiple-day administration is required for ampicillin and colonisation does not occur until several days after the drug is discontinued. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. C1 [Merrigan, Michelle M.; Sambol, Susan P.; Johnson, Stuart; Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Johnson, Stuart; Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Div Infect Dis, Maywood, IL USA. RP Gerding, DN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, 5000 S 5th Ave,Bldg 1,Room C344, Hines, IL 60141 USA. EM dale.gerding2@va.gov NR 12 TC 30 Z9 30 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD MAR PY 2009 VL 33 BP S46 EP S50 PG 5 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 438OL UT WOS:000265564900011 PM 19303570 ER PT J AU Goetz, MB Leduc, R Kostman, JR Labriola, AM Lie, Y Weidler, J Coakley, E Bates, M Luskin-Hawk, R AF Goetz, Matthew Bidwell Leduc, Robert Kostman, Jay R. Labriola, Ann M. Lie, Yolanda Weidler, Jodi Coakley, Eoin Bates, Michael Luskin-Hawk, Roberta CA Long-Term Monitoring Study CPCRA TI Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 47th Interscience Conference on Antimicrobial Agents and Chemotherapy CY SEP 17-20, 2007 CL Chicago, IL DE tropism; HIV receptors; natural history; progression; prognosis ID HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; ANTIRETROVIRAL THERAPY; CLINICAL PROGRESSION; HOMOSEXUAL-MEN; CELL DEPLETION; T-CELLS; TYPE-1; AIDS; USAGE AB Objective: To assess the effect of HIV coreceptor tropism (CRT) on the relative risk of progression to a composite outcome of CD4(+) Count <= 350 cells per microliter, treatment initiation, or death. Methods: CRT assays were performed after Study Closure in baseline samples obtained from enrollees in a prospectively monitored cohort of treatment-naive adults with >= 450 CD4(+) cells per microliter and >= 1000 HIV-1 RNA copies per milliliter. Results: Dual/mixed (D/M) and R5 CRT were detected in 32 and 282 patients, respectively. The baseline CD4(+) count (617 versus 694 cells/mu L(-1) P = 0.05) differed in patients with D/M versus R5 CRT. Otherwise, baseline laboratory characteristics were similar. The relative risk of progression to the composite end point was 2.15 (P = 0.002) for D/M versus R5 CRT, 2.07 per 1.0 log(10) higher viral load (P < 0.001) and 0.87 per 50 cells per microliter higher CD4(+) cell count (P < 0.001). The effect of DIM CRT was also significant in separate analyses of time to initiation of antiretroviral therapy or CD4(+) cell count <= 350 cells per microliter. Conclusions: Untreated patients with D/M rather than R5 CRT had a faster rate of disease progression, whether assessed by a composite outcome of time to CD4(+) count <= 350 cells per microliter, treatment initiation, or death or by separate analyses of time to CD4(+) count <= 350 cells per microliter or treatment initiation. C1 [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Dept Med, Los Angeles, CA 90073 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Leduc, Robert] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Kostman, Jay R.] Univ Penn Hlth Syst, Presbyterian Med Ctr, Dept Med, Philadelphia, PA USA. [Labriola, Ann M.] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Lie, Yolanda; Weidler, Jodi; Coakley, Eoin; Bates, Michael] Monogram Biosci, San Francisco, CA USA. [Luskin-Hawk, Roberta] St Joseph Hosp, Dept Med, Chicago, IL USA. RP Goetz, MB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM matthew.gowtz@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU NIAID NIH HHS [U01 AI46362, U01AI042170, U01 AI068641, U01 AI042170, R44 AI050321, R44AI050321, U01 AI046362, R44 AI050321-04, R44 AI050321-03A1] NR 56 TC 36 Z9 39 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2009 VL 50 IS 3 BP 259 EP 266 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 415FX UT WOS:000263920800003 PM 19194318 ER PT J AU Gros, DF Antony, MM McCabe, RE Swinson, RP AF Gros, Daniel F. Antony, Martin M. McCabe, Randi E. Swinson, Richard P. TI Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Irritable bowel syndrome; Anxiety disorders; Depression; Comorbidity ID FUNCTIONAL GASTROINTESTINAL DISORDERS; PANIC DISORDER; PSYCHOMETRIC PROPERTIES; STRESS SCALES; COMORBIDITY; PREVALENCE; COMMUNITY; RELIABILITY; DISEASE; SAMPLE AB High rates of irritable bowel syndrome (IBS) symptoms have been reported in individuals diagnosed with anxiety and depressive disorders. However, most studies have investigated these relations in a single disorder, rather than a heterogeneous group of patients, thereby not allowing for comparisons across anxiety disorders and depression, or for considering the effects of comorbidity. Thus, the present study investigated the symptoms of IBS in a diverse group of patients (N = 357) by administering questionnaires and a diagnostic interview. A high frequency of IBS symptoms was found in patients with panic disorder, generalized anxiety disorder, and major depressive disorder. However, the frequency of IBS symptoms in patients with social anxiety disorder, specific phobia, and obsessive-compulsive disorder was comparable to rates found in community samples. In addition, anxiety sensitivity and illness attitudes and intrusiveness were predictive of elevated IBS symptomatology. Together, these findings emphasize the role physiological symptoms of anxiety and worry in the co-occurrence of the anxiety disorders and IBS. Published by Elsevier Ltd. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv, Charleston, SC 29410 USA. [Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Gros, Daniel F.; Antony, Martin M.; McCabe, Randi E.; Swinson, Richard P.] St Josephs Healthcare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. [Antony, Martin M.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. [Antony, Martin M.; McCabe, Randi E.; Swinson, Richard P.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv, 109 Bee St, Charleston, SC 29410 USA. EM grosd@musc.edu RI Antony, Martin/K-1991-2012 OI Antony, Martin/0000-0002-3508-377X NR 49 TC 67 Z9 70 U1 7 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD MAR PY 2009 VL 23 IS 2 BP 290 EP 296 DI 10.1016/j.janxdis.2008.08.004 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 407CH UT WOS:000263340700019 PM 18819774 ER PT J AU Xie, AL Skatrud, JB Barczi, SR Reichmuth, K Morgan, BJ Mont, S Dempsey, JA AF Xie, Ailiang Skatrud, James B. Barczi, Steven R. Reichmuth, Kevin Morgan, Barbara J. Mont, Sara Dempsey, Jerome A. TI Influence of cerebral blood flow on breathing stability SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE Pa(CO2); apnea ID CONGESTIVE-HEART-FAILURE; RABBIT CAROTID-BODY; SLEEP-APNEA; VENTILATORY RESPONSE; CARDIAC-FAILURE; CARBON-DIOXIDE; CYCLOOXYGENASE INHIBITORS; GRADED REDUCTION; INDOMETHACIN; HUMANS AB Xie A, Skatrud JB, Barczi SR, Reichmuth K, Morgan BJ, Mont S, Dempsey JA. Influence of cerebral blood flow on breathing stability. J Appl Physiol 106: 850-856, 2009. First published December 31, 2008; doi:10.1152/japplphysiol. 90914.2008.-Our previous work showed a diminished cerebral blood flow (CBF) response to changes in Pa(CO2) in congestive heart failure patients with central sleep apnea compared with those without apnea. Since the regulation of CBF serves to minimize oscillations in H(+) and PCO(2) at the site of the central chemoreceptors, it may play an important role in maintaining breathing stability. We hypothesized that an attenuated cerebrovascular reactivity to changes in Pa(CO2) would narrow the difference between the eupneic Pa(CO2) and the apneic threshold Pa(CO2) (Delta Pa(CO2)), known as the CO(2) reserve, thereby making the subjects more susceptible to apnea. Accordingly, in seven normal subjects, we used indomethacin (Indo; 100 mg by mouth) sufficient to reduce the CBF response to CO(2) by similar to 25% below control. The CO(2) reserve was estimated during non-rapid eye movement (NREM) sleep. The apnea threshold was determined, both with and without Indo, in NREM sleep, in a random order using a ventilator in pressure support mode to gradually reduce Pa(CO2) until apnea occurred. RESULTS: Indo significantly reduced the CO(2) reserve required to produce apnea from 6.3 +/- 0.5 to 4.4 +/- 0.7 mmHg (P = 0.01) and increased the slope of the ventilation decrease in response to hypocapnic inhibition below eupnea ( control vs. Indo: 1.06 +/- 0.10 vs. 1.61 +/- 0.27 l (.) min(-1) (.) mmHg(-1), P < 0.05). We conclude that reductions in the normal cerebral vascular response to hypocapnia will increase the susceptibility to apneas and breathing instability during sleep. C1 [Skatrud, James B.; Barczi, Steven R.] William S Middleton Mem Vet Adm Med Ctr, Genet Res Educ & Clin Ctr, Madison, WI USA. [Xie, Ailiang; Skatrud, James B.; Barczi, Steven R.; Reichmuth, Kevin; Mont, Sara] Univ Wisconsin, Dept Med, Madison, WI USA. [Dempsey, Jerome A.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Morgan, Barbara J.] Univ Wisconsin, Dept Orthoped & Rehabil, Madison, WI USA. RP Xie, AL (reprint author), William S Middleton Vet Hosp, Pulm Physiol Lab, 2500 Overlook Terrace, Madison, WI 53705 USA. EM axie@facstaff.wisc.edu FU Veterans Affairs Research Service, National Heart, Lung, and Blood Institute, and American Lung Association of Wisconsin FX This work was supported by the Veterans Affairs Research Service, National Heart, Lung, and Blood Institute, and American Lung Association of Wisconsin. NR 54 TC 36 Z9 38 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAR PY 2009 VL 106 IS 3 BP 850 EP 856 DI 10.1152/japplphysiol.90914.2008 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 412IY UT WOS:000263719700015 PM 19118158 ER PT J AU Abramowitz, JS Moore, EL Braddock, AE Harrington, DL AF Abramowitz, Jonathan S. Moore, Elizabeth L. Braddock, Autumn E. Harrington, Diana L. TI Self-help cognitive-behavioral therapy with minimal therapist contact for social phobia: A controlled trial SO JOURNAL OF BEHAVIOR THERAPY AND EXPERIMENTAL PSYCHIATRY LA English DT Article DE Social phobia; Bibliotherapy; Self-help; Cognitive-behavioral therapy; Anxiety ID VALIDATION; DISORDER; SCALE AB Due to treatment accessibility and cost issues, interest in self-help programs (e.g., bibliotherapy, telehealth) for common psychological disorders is growing. Research supporting the efficacy of such a program for social anxiety, however, is limited. The present study examined the efficacy of an 8-week self-directed cognitive behavioral treatment with minimal therapist involvement for social phobia based on a widely available self-help book. Twenty-one adults with social phobia initially received either treatment (i.e. assigned readings in the workbook with limited therapist contact) OF were wait-listed. Wait-listed patients eventually received the same self-directed treatment. Results revealed that the self-help/minimal therapist contact treatment was superior to wait-list on most Outcome measures. Across the entire sample, reductions in social anxiety, global severity, general anxiety, and depression were observed at posttest and 3-month follow-up. These findings provide preliminary support for using this self-help workbook for individuals with mild to moderate social anxiety in conjunction with infrequent therapist visits to reinforce the treatment principles. Study limitations and future directions are discussed. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Abramowitz, Jonathan S.] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA. [Abramowitz, Jonathan S.; Moore, Elizabeth L.; Braddock, Autumn E.] Mayo Clin, Rochester, MN USA. [Moore, Elizabeth L.] Inst Living, Hartford, CT USA. [Braddock, Autumn E.] VA Greater Los Angels, Los Angeles, CA USA. RP Abramowitz, JS (reprint author), Univ N Carolina, Dept Psychol, CB 2370 Davie Hall, Chapel Hill, NC 27599 USA. EM jabramowitz@unc.edu NR 19 TC 17 Z9 18 U1 4 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7916 J9 J BEHAV THER EXP PSY JI J. Behav. Ther. Exp. Psychiatry PD MAR PY 2009 VL 40 IS 1 BP 98 EP 105 DI 10.1016/j.jbtep.2008.04.004 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 398TC UT WOS:000262753400009 PM 18514614 ER PT J AU Glaister, BC Schoen, JA Orendurff, MS Klute, GK AF Glaister, Brian C. Schoen, Jason A. Orendurff, Michael S. Klute, Glenn K. TI A Mechanical Model of the Human Ankle in the Transverse Plane During Straight Walking: Implications for Prosthetic Design SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE gait analysis; legged locomotion; physiological models; prosthetics; torsion; viscosity ID TIME AB In order to protect sensitive residual limb soft tissues, lower limb prostheses need to control torsional loads during gait. To assist with the design of a torsional prosthesis, this paper used simple mechanical elements to model the behavior of the human ankle in the transverse plane during straight walking. Motion capture data were collected from ten able-bodied subjects walking straight ahead at self-selected walking speeds. Gait cycle data were separated into four distinct states, and passive torsional springs and dampers were chosen to model the behavior in each state. Since prosthetic design is facilitated by simplicity, it was desirable to investigate if elastic behavior could account for the physiological ankle moment and include viscous behavior only if necessary to account for the inadequacies of the spring model. In all four states, a springlike behavior was able to account for most of the physiological ankle moments, rendering the use of a damper unnecessary. In State 1, a quadratic torsional spring was chosen to model the behavior, while linear torsional springs were chosen for States 2-4. A prosthetic system that actively changes stiffness could be able to replicate the physiological behavior of the human ankle in the transverse plane. The results of this study will contribute to the mechanical design and control of a biomimetic torsional prosthesis for lower limb amputees. C1 [Glaister, Brian C.; Klute, Glenn K.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Glaister, Brian C.; Schoen, Jason A.; Klute, Glenn K.] VA Puget Sound Hlth Care Syst, VA Ctr Excellence Limb Loss Prevent & Prosthet En, Seattle, WA 98108 USA. [Orendurff, Michael S.] Texas Scottish Rite Hosp Children, Movement Sci Lab, Dallas, TX 75219 USA. [Klute, Glenn K.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. RP Glaister, BC (reprint author), Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. EM bglaiste@u.washington.edu FU Department of Veterans Affairs [A2661C, A3611I] FX This work was funded in part by the Department of Veterans Affairs Grant Nos. A2661C and A3611I. The authors wish to thank Greta Bernatz and Elizabeth Huff for assistance with data collection. NR 13 TC 3 Z9 3 U1 3 U2 12 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD MAR PY 2009 VL 131 IS 3 AR 034501 DI 10.1115/1.3005153 PG 5 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 432MG UT WOS:000265137800013 PM 19154072 ER PT J AU Ix, JH Wassel, CL Bauer, DC Toroian, D Tylavsky, FA Cauley, JA Harris, TB Price, PA Cummings, SR Shlipak, MG AF Ix, Joachim H. Wassel, Christina L. Bauer, Douglas C. Toroian, Damon Tylavsky, Frances A. Cauley, Jane A. Harris, Tamara B. Price, Paul A. Cummings, Steven R. Shlipak, Michael G. CA Hlth ABC Study TI Fetuin-A and BMD in Older Persons: The Health Aging and Body Composition (Health ABC) Study SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE fetuin-A; BMD; elderly ID ALPHA-2 HS-GLYCOPROTEIN; VASCULAR CALCIFICATION; HUMAN-BONE; SERUM; DISEASE; PROTEIN; MINERALIZATION; ASSOCIATION; INHIBITION; MATRIX AB Fetuin-A is a hepatic secretory protein that promotes bone mineralization in vitro. Whether fetuin-A levels are associated with BMD in humans is unknown. The Health Aging and Body Composition study enrolled 3075 well-functioning black and white persons 70-79 yr of age and measured BMD. This cross-sectional study measured serum fetuin-A using ELISA among a random sample of 508 participants within sex and race strata. Multivariate linear regression analysis evaluated the associations of fetuin-A with BMD. Among women (n = 257), higher fetuin-A levels were significantly associated with higher total hip (p = 0.02), lumbar spine (p = 0.03), and whole body BMD (p = 0.01) in models adjusted for age, race, diabetes, alcohol and tobacco use, physical activity, body mass index, C-reactive protein levels, calcium supplement, and estrogen use. For example, each SD (0.38 g/liter) higher level of fetuin-A was associated with 0.0.16 g/cm(2) higher total hip area] BMD. The association was of similar magnitude and direction for femoral neck BMD but did not reach statistical significance (p = 0.11). In contrast, among men (n = 251), fetuin-A had no significant associations with total hip (p = 0.79), lumbar spine (p = 0.35), whole body (p = 0.46), or femoral neck BMD (p = 0.54) in multivariable models. We conclude that higher fetuin-A levels are independently associated with higher BMD among well-functioning community-dwelling older women but not older men. Future studies should evaluate whether fetuin-A may refine fracture risk assessment in older women. C1 [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92161 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA. [Wassel, Christina L.] Univ Minnesota, Dept Epidemiol & Community Hlth, Minneapolis, MN USA. [Wassel, Christina L.; Bauer, Douglas C.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med & Epidemiol & Biostat, San Francisco, CA 94143 USA. [Toroian, Damon; Price, Paul A.] Univ Calif San Diego, Div Biol Sci, San Diego, CA 92161 USA. [Tylavsky, Frances A.] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Cummings, Steven R.] Calif Pacific Med Ctr, Dept Med, San Francisco, CA USA. [Cummings, Steven R.] San Francisco Coordinating Ctr, San Francisco, CA USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Med Sect, San Francisco, CA USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU American Diabetes Association (ADA); Atlantic Philanthropies; John A. Hartford Foundation; ASP; American Heart Association Fellow to Faculty Transition Award (JHI) [N01-AG-6-2101, N01-AG-6-2103, N01-AG6-2106]; Intramural Research Program from the National Institutes on Aging (NIA) FX The authors thank the other investigators, the staff, and the participants of the Health ABC stud), for valuable contributions and Dr Elsa Strotmeyer for her critical review of the manuscript. This Study was supported by an American Diabetes Association (ADA)-ASP Young Investigator Innovation Award in Geriatric Endocrinology sponsored by the Atlantic Philanthropies, ADA, the John A. Hartford Foundation, and ASP, an American Heart Association Fellow to Faculty Transition Award (JHI), and Contracts N01-AG-6-2101. N01-AG-6-2103, and N01-AG6-2106 and an Intramural Research Program from the National Institutes on Aging (NIA). The funding sources NR 41 TC 21 Z9 21 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAR PY 2009 VL 24 IS 3 BP 514 EP 521 DI 10.1359/JBMR.081017 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 410JA UT WOS:000263572100015 PM 19016589 ER PT J AU Guy, TS Brzezinski, M Stechert, MM Tseng, E AF Guy, T. Sloane Brzezinski, Marek Stechert, Martin M. Tseng, Elaine TI Robotic Mammary Artery Harvest and Anastomotic Device Allows Minimally Invasive Mitral Valve Repair and Coronary Bypass SO JOURNAL OF CARDIAC SURGERY LA English DT Article ID SURGERY AB We report the case of a 60-year-old man requiring combined mitral valve repair and coronary artery bypass grafting. A unique minimally invasive approach was used combining robotic internal mammary artery harvesting, partial lower sternotomy, and single vessel coronary artery bypass grafting using an automated distal coronary artery anastomotic device. Issues in approaching the commonly encountered patient with mitral valve disease and coronary artery disease using minimally invasive techniques are discussed. (J Card Surg 2009;24:170-172). C1 [Guy, T. Sloane; Tseng, Elaine] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94121 USA. [Brzezinski, Marek; Stechert, Martin M.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. RP Guy, TS (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, 4150 Clement St, San Francisco, CA 94121 USA. EM sloane.guy@va.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0886-0440 J9 J CARDIAC SURG JI J. Card. Surg. PD MAR PY 2009 VL 24 IS 2 BP 170 EP 172 DI 10.1111/j.1540-8191.2008.00709.x PG 3 WC Cardiac & Cardiovascular Systems; Surgery SC Cardiovascular System & Cardiology; Surgery GA 412AC UT WOS:000263694600016 PM 18778296 ER PT J AU Noygorodov, SA Gudz, TI AF Noygorodov, Sergei A. Gudz, Tatyana I. TI Ceramide and Mitochondria in Ischemia/Reperfusion SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Review DE apoptosis; mitochondria; ceramide synthase; LASS (Cer-S); sphingomyelinase; cytochrome c; Bax; PP2A; cathepsin D; Bcl-2 ID CYTOCHROME-C RELEASE; FOCAL CEREBRAL-ISCHEMIA; PERMEABILITY TRANSITION PORE; ISCHEMIC/REPERFUSED RAT-HEART; LONGEVITY ASSURANCE GENES; ACTIVATED PROTEIN-KINASES; PROGRAMMED CELL-DEATH; ACUTE-RENAL-FAILURE; JURKAT T-CELLS; INDUCED APOPTOSIS AB A hallmark of tissue injury in various models of ischemia/reperfusion (IR) is mitochondrial dysfunction and the release of mitochondrial proapoptotic proteins leading to cell death. Although IR-induced mitochondrial injury has been extensively Studied and key mitochondrial functions affected by IR are chiefly characterized, the nature of the molecule that causes loss of mitochondrial integrity and function remains obscure. It has become increasingly clear that ceramide, a membrane sphingolipid and a key mediator of cell stress responses, could play a critical role in IR-induced mitochondrial damage. Emerging data point to excessive ceramide accumulation in tissue and, specifically, ill mitochondria after IR. Exogenously added to isolated mitochondria, ceramide could mimic sonic of the mitochondrial dysfunctions Occurring ill IR. The recent identification and characterization of major enzymes in ceramide synthesis is expected to contribute to the understanding of molecular mechanisms of ceramide involvement in mitochondrial damage in IR. This review will examine the experimental evidence supporting the important role of ceramide in mitochondrial dysfunction in IR to highlight potential targets for pharmacological manipulation of ceramide levels. C1 [Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Noygorodov, Sergei A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Noygorodov, Sergei A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Gudz, Tatyana I.] Ralph H Johnson Vet Aftairs Med Ctr, Charleston, SC 29425 USA. RP Gudz, TI (reprint author), Med Univ S Carolina, Dept Neurosci, 114 Doughty St, Charleston, SC 29425 USA. EM gudz@musc.edu FU NIH/NCCR [P20 RR 17677-04]; VA Merit award; NIH [AG16583] FX Supported by the NIH/NCCR COBRE in Lipidomics and Pathobiology P20 RR 17677-04 (T. I. Gudz), VA Merit award (T. I. Gudz). and S. A. Novgorodov was supported by NIH grant AG16583. NR 179 TC 0 Z9 0 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD MAR PY 2009 VL 53 IS 3 BP 198 EP 208 PG 11 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 430TI UT WOS:000265011100003 ER PT J AU Matioc, AA AF Matioc, Adrian A. TI Use of the Arndt airway exchanger catheter set with the Larygneal Mask Airway Supreme SO JOURNAL OF CLINICAL ANESTHESIA LA English DT Letter ID INTUBATION C1 Univ Wisconsin Hosp & Clin, Anesthesiol Serv, William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. RP Matioc, AA (reprint author), Univ Wisconsin Hosp & Clin, Anesthesiol Serv, William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. EM adrian.matioc@va.gov NR 3 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0952-8180 J9 J CLIN ANESTH JI J. Clin. Anesth. PD MAR PY 2009 VL 21 IS 2 BP 152 EP 153 DI 10.1016/j.jclinane.2008.08.010 PG 2 WC Anesthesiology SC Anesthesiology GA 432LC UT WOS:000265133500019 PM 19329027 ER PT J AU Brambilla, DJ Matsumoto, AM Araujo, AB McKinlay, JB AF Brambilla, Donald J. Matsumoto, Alvin M. Araujo, Andre B. McKinlay, John B. TI The Effect of Diurnal Variation on Clinical Measurement of Serum Testosterone and Other Sex Hormone Levels in Men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CIRCADIAN-RHYTHMS; DEHYDROEPIANDROSTERONE-SULFATE; PLASMA TESTOSTERONE; LUTEINIZING-HORMONE; BOUND TESTOSTERONE; HEALTHY-YOUNG; CORTISOL; MALES; SHBG; FSH AB Context: Although diurnal variation of testosterone and other hormones in men has been well documented, the effect of this variation on sampling during typical clinic hours has not been examined. Objective: Our objective was to examine temporal variation in serum testosterone and five other hormones in men over normal clinic hours. Design: Blood samples were collected at six separate visits, three morning visits 1-3 d apart and three afternoon visits 1-3 d apart. Setting and Participants: In Boston, MA, 66 men participated, 30-80 yr of age, randomly selected from the Boston Area Community Health Survey who completed at least five visits. Main Outcome Measures: The age-specific ratio of hormone level at times ranging from 0801-1600 h to hormone level at 0800 h was calculated. Ratios were calculated from parameter estimates obtained from cosinor models. Results: In men 30-40 yr old, testosterone levels were 20-25% lower at 1600 h than at 0800 h. The difference declined with age, with a 10% difference at 70 yr. 17 men with at least one of three measurements less than 300 ng/dl (10.4 nmol/liter) after 1200 h had normal testosterone levels at all three visits before 1200 h (five of eight men 30-47 yr old, four of nine men 66-80 yr old). Much lower levels of diurnal variation were found for dihydrotestosterone, SHBG, LH, FSH, and estradiol at all ages. Conclusions: Our results support the recommendation of restricting testosterone measurements to morning hours in both young and older men. Limited diurnal variation in other hormones indicates that sampling through the day is appropriate. (J Clin Endocrinol Metab 94: 907-913, 2009) C1 [Araujo, Andre B.; McKinlay, John B.] New England Res Inst, Watertown, MA 02472 USA. [Brambilla, Donald J.] Res Triangle Inst, Rockville, MD 20852 USA. [Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA. [Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Araujo, AB (reprint author), New England Res Inst, 9 Galen St, Watertown, MA 02472 USA. EM aaraujo@neriscience.com RI Perez , Claudio Alejandro/F-8310-2010 OI Perez , Claudio Alejandro/0000-0001-9688-184X FU National Institute on Aging of the National Institutes of Health [AG23027] FX This study was supported by Grant AG23027 from the National Institute on Aging of the National Institutes of Health. NR 21 TC 120 Z9 122 U1 0 U2 6 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2009 VL 94 IS 3 BP 907 EP 913 DI 10.1210/jc.2008-1902 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 416QN UT WOS:000264020700030 PM 19088162 ER PT J AU Sugimoto, M Wu, JY Abudayyeh, S Hoffman, J Brahem, H Al-Khatib, K Yamaoka, Y Graham, DY AF Sugimoto, Mitsushige Wu, Jeng-Yih Abudayyeh, Suhaib Hoffman, Jill Brahem, Hajer Al-Khatib, Khaldun Yamaoka, Yoshio Graham, David Y. TI Unreliability of Results of PCR Detection of Helicobacter pylori in Clinical or Environmental Samples SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID POLYMERASE-CHAIN-REACTION; IN-SITU HYBRIDIZATION; DENTAL PLAQUE; ORAL-CAVITY; CLARITHROMYCIN RESISTANCE; ERADICATION THERAPY; BIOPSY SPECIMENS; RAPID DETECTION; HIGH PREVALENCE; NESTED PCR AB The aim of this study was to compare published Helicobacter pylori primer pairs for their ability to reliably detect H. pylori in gastric biopsy specimens and salivary samples. Detection limits of the 26 PCR primer pairs previously described for detection of H. pylori DNA in clinical samples were determined. Sensitivity and specificity were determined using primers with detection limits of < 100 CFU/ml using 50 H. pylori-positive and -negative (by concordance by culture and histology) coded gastric biopsy specimens. These results were then confirmed with gastric biopsy specimens and saliva from patients with confirmed H. pylori status. Five of the twenty-six previously reported primer pairs (HP64-f/HP64-r, HP1/HP2, EHC-U/EHC-L, VAG-F/VAG-R, and ICT37/ICT38) had detection limits of < 100 CFU/ml in the presence of gastric tissue. None had 100% specificity or sensitivity; all produced false-positive results. The HP64-f/HP64-r for ureA and HP1/HP2 for 16S rRNA individually had sensitivities and specificities of > 90% with gastric biopsy specimens. No combinations of primer pairs improved the results. Using these five primer pairs, 54% of the positive saliva samples were determined to be false positive; both the HP64-f/HP64-r and the HP1/HP2 sets produced false positives with saliva. We conclude that clinicians should not rely on results using current PCR primers alone to decide the H. pylori status of an individual patient or as a basis for treatment decisions. The results of studies based on PCR identification of H. pylori in environmental samples should be viewed with caution. Possibly, specific primers sets can be identified based on the presence of multiple putative virulence factor genes. C1 [Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320,111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU Office of Research and Development Medical Research Service Department of Veterans Affairs; Public Health Service [DK56338]; NIH [DK62813] FX This material is based upon work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs and by Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases Center. In the last 3 years, D.Y.G. has received small amounts of grant support and/or free drugs or urea breath tests from Meretek, Jannsen/Eisai, and TAP, and BioHit for investigator- initiated and completely investigator-controlled research. D. Y. G. is a consultant for Novartis in relation to vaccine development for treatment or prevention of H. pylori infection. D. Y. G. is also a paid consultant for Otsuka Pharmaceuticals and until July 2007 was member of the Board of Directors of Meretek Diagnostics, the manufacturer of the 13C- urea breath test. D. Y. G. also receives royalties on the Baylor College of Medicine patent covering materials related to 13C-urea breath test. Y. Y. is supported in part by a grant from the NIH (DK62813). NR 57 TC 27 Z9 29 U1 2 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2009 VL 47 IS 3 BP 738 EP 742 DI 10.1128/JCM.01563-08 PG 5 WC Microbiology SC Microbiology GA 413UU UT WOS:000263818800033 PM 19129407 ER PT J AU Mahlen, SD Clarridge, JE AF Mahlen, Steven D. Clarridge, Jill E., III TI Oral Abscess Caused by Campylobacter rectus: Case Report and Literature Review SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID WOLINELLA-RECTA; PERIODONTITIS LESIONS; GEN-NOV; GINGIVITIS; MICROBIOTA; INFECTIONS; GRACILIS; HEALTH; BONE AB Campylobacter rectus was isolated under routine anaerobic conditions (no additional hydrogen gas in the atmosphere) from an oral, nonperiodontal abscess from a patient with gastroesophageal adenocarcinoma. We report the first case of a palate abscess caused by C. rectus and review the literature and atmospheric requirements of this organism. C1 [Clarridge, Jill E., III] Vet Affairs Puget Sound Hlth Care Syst, Pathol & Lab Serv, Seattle, WA 98108 USA. [Mahlen, Steven D.; Clarridge, Jill E., III] Univ Washington, Dept Lab Med, USA, Seattle, WA 98195 USA. RP Clarridge, JE (reprint author), VA PSHCS, Pathol & Lab Serv 113, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Jill.clarridge@va.gov NR 21 TC 11 Z9 11 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2009 VL 47 IS 3 BP 848 EP 851 DI 10.1128/JCM.01590-08 PG 4 WC Microbiology SC Microbiology GA 413UU UT WOS:000263818800060 PM 19109480 ER PT J AU Szegedi, A Jansen, WT van Willigenburg, APP van der Meulen, E Stassen, HH Thase, ME AF Szegedi, Armin Jansen, Wim T. van Willigenburg, Arjen P. P. van der Meulen, Egbert Stassen, Hans H. Thase, Michael E. TI Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID STAR-ASTERISK-D; ANTIDEPRESSANT ACTION; TREATMENT RESPONSE; DRUG RESPONSE; DELAYED-ONSET; FLUOXETINE; GUIDELINES; PAROXETINE; SERTRALINE; TITRATION AB Objective: New evidence indicates that treatment response can be predicted with high sensitivity after 2 weeks of treatment. Here, we assess whether early improvement with antidepressant treatment predicts treatment outcome in patients with major depressive disorder (MDD). Data Sources: Forty-one clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients (all-treated population, N = 6907; intent-to-treat population, N = 6562) with MDD (DSM-III-R or DSM-IV Criteria) were examined for early improvement (>= 20% score reduction from baseline on the 17-item Hamilton Rating Scale for Depression [HAM-D-17] within 2 weeks of treatment) and its relationship to treatment outcome. Study Selection: Data were obtained from a systematic search of single- or double-blind clinical trials (clinical trials database, Organon, a part of Schering-Plough Corporation, Oss, The Netherlands). All included trials (a total of 41) employed antidepressant treatment for more than 4 weeks and a maximum of 8 weeks. The studies ranged from March 1982 to December 2003. Trials were excluded if there were no HAM-D-17 ratings available, no diagnosis of MDD, or if the study was not blinded. Trials were also excluded if HAM-D-17 assessments were not available at week 2, week 4. and at least once beyond week 4. Data Synthesis: Early improvement predicted stable response and stable remission with high sensitivity (>= 81% and >= 87%, respectively). Studies utilizing rapid titration vs. slow titration of mirtazapine demonstrated improved sensitivity for stable responders (98%, [95% CI = 93% to 100%] vs. 91% [95% CI = 89% to 93%]) and stable remitters (100%, [95% CI = 92% to 100%] vs. 93% [95% CI = 91% to 95%]). Negative predictive values for stable responders and stable remitters were much higher (range = 82%-100%) than positive predictive values (range = 19%-60%). Conclusions: These results indicate that early improvement with antidepressant medication can predict subsequent treatment outcome with high sensitivity in patients with major depressive disorder. The high negative predictive values indicate little chance of stable response or stable remission in the absence of improvement within 2 weeks. A lack of improvement during the first 2 weeks of therapy may indicate that changes in depression management should be considered earlier than conventionally thought. C1 [Szegedi, Armin; van Willigenburg, Arjen P. P.] Organon, Roseland, NJ USA. [Stassen, Hans H.] Psychiat Univ Hosp, Zurich, Switzerland. [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. RP Szegedi, A (reprint author), Schering Plough Res Inst, Global Clin Res CNS, 56 Livingston Ave, Roseland, NJ 07068 USA. EM armin.szegedi@spcorp.com RI Szegedi, Armin/M-9184-2016 OI Szegedi, Armin/0000-0001-6487-4071 FU Organon FX Financial support for this report was provided by an unrestricted educational grant from Organon, a part of Schering-Plough Corporation. NR 34 TC 135 Z9 147 U1 0 U2 14 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAR PY 2009 VL 70 IS 3 BP 344 EP 353 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 426VC UT WOS:000264735200006 PM 19254516 ER PT J AU Nwasuruba, C Osuagwu, C Bae, S Singh, KP Egede, LE AF Nwasuruba, Chiagozie Osuagwu, Christie Bae, Sejong Singh, Karan P. Egede, Leonard E. TI Racial differences in diabetes self-management and quality of care in Texas SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Diabetes; Race; Ethnicity; Self-management; Survey research ID HEALTH-INSURANCE COVERAGE; RISK-FACTOR SURVEY; UNITED-STATES; RACIAL/ETHNIC DIFFERENCES; BLOOD-GLUCOSE; EXCESS MORTALITY; ADULTS; POPULATION; INDIVIDUALS; RELIABILITY AB Aim: To assess racial/ethnic differences in diabetes self-management behaviors and quality of care in Texas. Methods: This cross-sectional study assessed self-management behaviors and quality of care in 1720 adults with diabetes in the 2002-2004 Texas Behavioral Risk Factor Surveillance Survey. Multiple logistic regression models were used for assessing the independent association between race/ethnicity, self-management behaviors, and quality of care variables controlling for covariates. SAS (SAS Institute Inc, 2002-2003) was used for statistical analysis. Results: Eighteen percent of Hispanics, 14% of Blacks, and 10% of Whites reported never performing home glucose testing. Seventeen percent of Hispanics, 11% of Blacks, and 10% of Whites reported never doing home foot exam. Thirty-two percent of Hispanics, 21% of Blacks, and 16% of Whites did not have an A1C test in the prior 12 months. Twelve percent of Hispanics, 10% of Blacks, and 6% of Whites did not have a dilated eye exam in the prior 12 months. Fifty-four percent of Whites, 42% of Blacks, and 40% of Hispanics received a flu shot. Forty-nine percent of Whites, 30% of Blacks, and 26% of Hispanics received a pneumonia shot. In adjusted models, Hispanics were more likely to be sedentary (OR, 1.64; 95% CI, 1.08-2.49) compared to Whites. Blacks did not differ significantly from Whites (OR, 1.46; 95% CI, 0.92-2.34). Hispanics (OR, 1.61; 95% CI, 1.01-2.57) and Blacks (OR, 1.83; 95% CI, 1.10-3.03) were more likely to get an annual foot exam by a provider compared to Whites. Hispanics (OR, 0.54; 95% CI, 0.34-0.85) and Blacks (OR, 0.58; 95% CI, 0.35-0.98) were less likely to get a pneumonia shot compared to Whites. Conclusions: Hispanics have poorer access to care and poorer health status compared to Whites or Blacks. Controlling for socioeconomic and access to care variables eliminated disparities in self-management but did not eliminate disparities in quality of diabetes care. (C) 2009 Elsevier Inc. All rights reserved. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA TREP, Charleston, SC USA. [Bae, Sejong; Singh, Karan P.] Univ N Texas, Hlth Sci Ctr, Dept Biostat, Ft Worth, TX USA. [Osuagwu, Christie] Univ Texas Hlth Ctr Tyler, Dept Emergency Med, Tyler, TX USA. [Nwasuruba, Chiagozie] Univ Texas Hlth Ctr Tyler, Dept Med, Tyler, TX USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institutes of Health: National Center for Minority Health and Health Disparities [1R24 MD 535-1] FX We would like to acknowledge the East Texas Project EXPORT center. The East Texas Project EXPORT Center is funded by the National Institutes of Health: National Center for Minority Health and Health Disparities (Grant #1R24 MD 535-1). NR 31 TC 26 Z9 26 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAR-APR PY 2009 VL 23 IS 2 BP 112 EP 118 DI 10.1016/j.jdiacomp.2007.11.005 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 414TE UT WOS:000263887300006 PM 18413179 ER PT J AU Reiter, MJ Harsch, M Lung, TH Munneke, D Kim, MH Shalaby, A AF Reiter, Michael J. Harsch, Manya Lung, Te-Hsin Munneke, Dave Kim, Michael H. Shalaby, Alaa CA Vitatron AFm Registry Investigator TI Influence of structural heart disease on characteristics of atrial fibrillation recurrence in patients with dual-chamber pacemakers SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article DE Atrial fibrillation; Structural heart disease; Epidemiology; Cardiac pacing ID PREVENTION; STROKE; IMPLANTATION; RISK; DDDR; TACHYARRHYTHMIAS; DEVICE AB Aims: The aim of the study was to prospectively examine the influence of structural heart disease (SHD) and sinus node dysfunction (SND) on the frequency and duration of atrial fibrillation (AF) episodes in patients with implanted pacemakers. Methods: We examined episodes of AF in 207 patients (93 with SHD; 165 with SND) with known or suspected paroxysmal AF who underwent dual-chamber pacing. Results: Seventy-one percent of all patients experienced at least one episode of AF during follow-up, with a mean burden of 3.3 +/- 6.4 h/d (median, 0.2 hours) and a mean frequency of 11.7 +/- 26.0 episodes per day (median, 1.4). The proportion of episodes longer than 6 hours was greater in patients with SHD when compared to patients without SHD. In a logistic regression model adjusted for SND, gender, and the 2-way interactions of SND, sex, and SHD, SHD was a significant factor (P = .0188) with the odds ratio of having an episode longer than 6 hours 3.4 times higher for patients with SHD than for patients without SHD. Older patients with SHD had less frequent but longer episodes compared to younger patients. In patients without SHD, there was no comparable age difference. Burden, frequency, and average episode length were not influenced by the presence or absence of SND. Conclusions: Patients with SHD have longer episodes of AF supporting the concept that SHD influences the underlying substrate to favor perpetuation. (C) 2009 Elsevier Inc. All rights reserved. C1 [Reiter, Michael J.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Harsch, Manya; Lung, Te-Hsin; Munneke, Dave] Vitatron Clin Res, Minneapolis, MN USA. [Kim, Michael H.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Shalaby, Alaa] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA. RP Reiter, MJ (reprint author), 5083 Oak Hollow Dr, Morrison, CO 80465 USA. EM michael.reiter@uchse.edu NR 28 TC 3 Z9 3 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD MAR-APR PY 2009 VL 42 IS 2 BP 128 EP 135 DI 10.1016/j.jelectrocard.2008.09.002 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 419LC UT WOS:000264220000005 PM 18976775 ER PT J AU DiGregorio, BV Fung, HB Muller, AA AF DiGregorio, Bobert V. Fung, Horatio B. Muller, Allison A. TI RAPID DOSING OF CRITICAL CARE INFUSIONS: THE DOPAMINE AND NOREPINEPHRINE "CLOCKS" SO JOURNAL OF EMERGENCY NURSING LA English DT Editorial Material ID IN-HOSPITAL SETTINGS; ASHP NATIONAL-SURVEY; SAFETY C1 [DiGregorio, Bobert V.] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA. [DiGregorio, Bobert V.] Long Isl Univ, Pharmacotherapy Serv, Brooklyn, NY USA. [Fung, Horatio B.] James J Peters Vet Affairs Med Ctr, Med Surg Patient Care Ctr, Bronx, NY USA. RP DiGregorio, BV (reprint author), 73 Cty Courthouse Rd, Garden City Pk, NY 11040 USA. EM Robert.DiGregorio@liu.edu; mullera@email.chop.edu NR 13 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0099-1767 J9 J EMERG NURS JI J. Emerg. Nurs. PD MAR PY 2009 VL 35 IS 2 BP 165 EP 168 DI 10.1016/j.jen.2008.07.019 PG 4 WC Emergency Medicine; Nursing SC Emergency Medicine; Nursing GA 426TU UT WOS:000264731600030 ER PT J AU Ohno, T Sugimoto, M Nagashima, A Ogiwara, H Vilaichone, RK Mahachai, V Graham, DY Yamaoka, Y AF Ohno, Tomoyuki Sugimoto, Mitsushige Nagashima, Aiko Ogiwara, Hiroaki Vilaichone, Ratha-Korn Mahachai, Varocha Graham, David Y. Yamaoka, Yoshio TI Relationship between Helicobacter pylori hopQ genotype and clinical outcome in Asian and Western populations SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE gastric cancer; Helicobacter pylori; hopQ; virulence factor ID VACA; CAGA; GASTRITIS; INFECTION; ALLELES; JAPAN; GENE; VARIANTS; STRAINS; ADHESIN AB Outer membrane proteins of Helicobacter pylori mediate important pathogen-host interactions such as colonization, adhesion and the inflammatory response. hopQ genotypes have been suggested to be associated with increased risk of peptic ulcer. The aim of this study was to test the relation of hopQ genotype to H. pylori-related disease and histological changes in Asian and Western countries. hopQ genotype, cagA status and vacA genotype of H. pylori isolated from patients from Asian and Western countries were determined and the results were compared with the clinical presentation and gastric histology. Most Asian strains possessed virulent genotypes (hopQ type I, vacA s1-m1 and cagA-positive). In Western countries, hopQ type I genotype was significantly linked with vacA s1 and m1 genotypes and cagA-positive status. Inflammatory cell infiltration and atrophy scores were significantly higher in patients with hopQ type I strains than those with type II in Western patients. However, the hopQ type I genotype was not associated with an increased risk for peptic ulcer or gastric cancer, and had no additive effects to vacA genotypes or cagA-positive status. The expression of multiple putative virulence factors in Asian strains likely explains the relatively high incidence of clinical outcomes including gastric cancer compared with other parts of the world. Although hopQ genotype did not improve the predictive value above other genotyping for development of H. pylori-related gastroduodenal diseases, the hopQ genotype might be able to add a useful virulence marker for gastroduodenal diseases. C1 [Ohno, Tomoyuki; Sugimoto, Mitsushige; Nagashima, Aiko; Ogiwara, Hiroaki; Graham, David Y.; Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Ohno, Tomoyuki; Sugimoto, Mitsushige; Nagashima, Aiko; Ogiwara, Hiroaki; Graham, David Y.; Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Vilaichone, Ratha-Korn] Thammasat Univ Hosp, Dept Med, Gastroenterol Unit, Pathum Thani, Thailand. [Mahachai, Varocha] Chulalongkorn Univ Hosp, Dept Med, Gastroenterol Unit, Bangkok, Thailand. RP Yamaoka, Y (reprint author), Michael E Debakey Vet Affairs Med Ctr 111D, Dept Med Gastroenterol, Mol Pathogenesis Lab, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU Office of Research and Development Medical Research Service Department of Veterans Affairs; Public Health Service [DK56338]; Texas Gulf Coast Digestive Diseases Center; National Institutes of Health (NIH) [DK 62813] FX This material is based upon work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, by Public Health Service grant DK56338 which funds the Texas Gulf Coast Digestive Diseases Center. The project described was also supported by grant no. DK 62813 from the National Institutes of Health (NIH). These contents are solely the responsibility of the authors and do not necessarily represent the official views of the Veterans Affairs (VA) and NIH. The authors thank Professor Tatsuo Yamamoto (Niigata University School of Medicine) for suitable advice. NR 24 TC 12 Z9 14 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD MAR PY 2009 VL 24 IS 3 BP 462 EP 468 DI 10.1111/j.1440-1746.2008.05762.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 424FX UT WOS:000264552000020 PM 19226380 ER PT J AU Weisbord, SD Mor, MK Kim, S Hartwig, KC Sonel, AF Palevsky, PM Fine, MJ AF Weisbord, Steven D. Mor, Maria K. Kim, Sunghee Hartwig, Kathryn C. Sonel, Ali F. Palevsky, Paul M. Fine, Michael J. TI Factors Associated with the Use of Preventive Care for Contrast-Induced Acute Kidney Injury SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE predictors; contrast-induced acute kidney injury; patients; providers; preventive care ID HIGH-RISK PATIENTS; ACUTE-RENAL-FAILURE; INDUCED NEPHROPATHY; RADIOCONTRAST NEPHROPATHY; ACETYLCYSTEINE; MEDIA; METAANALYSIS; ANGIOGRAPHY; IODIXANOL; HYDRATION AB The factors that affect the implementation of preventive care for contrast-induced acute kidney injury (CIAKI) are unknown. To assess patient and provider factors associated with the use of preventive care for CIAKI. Prospective cohort study. Patients with kidney disease undergoing procedures with intravascular iodinated radiocontrast. We recorded the use of preventive care defined as the administration of: (1) pre- and post-procedure isotonic intravenous (IV) fluid, (2) N-acetylcysteine, and (3) iso-osmolal radiocontrast. We surveyed patients' providers to assess their knowledge, experience, and training on CIAKI and used multiple logistic regression to assess the independent associations of patient and provider factors with the use of these preventive interventions. We enrolled 660 patients and 87 providers. Patient factors associated with use of IV fluid and N-acetylcysteine were higher baseline serum creatinine (OR 1.5 and 5.0, p < 0.05) and inpatient status (OR 3.0 and 6.3, p < 0.05), while higher baseline serum creatinine was associated with the use of iso-osmolal contrast (OR = 13.4, p < 0.01). The primary provider characteristics associated with the use of IV fluid and N-acetylcysteine were a greater degree of prior training on CIAKI (OR 1.9 and 2.8, p < 0.05) and higher number of prior patients with CIAKI (OR 2.7 and 2.6, p < 0.05). Patient baseline kidney function and provider training and experience with CIAKI are independently associated with the use of preventive care. Efforts to increase and intensify the training providers receive on CIAKI may help decrease the incidence of this costly iatrogenic condition. C1 [Weisbord, Steven D.; Mor, Maria K.; Kim, Sunghee; Hartwig, Kathryn C.; Sonel, Ali F.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Hartwig, Kathryn C.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Mor, Maria K.; Kim, Sunghee] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15261 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU VA Health Services Research and Development Career Development [RCD 03-176]; VA Stars and Stripes Competitive Pilot Project; National Institute of Allergy and Infectious Diseases [K24 AI001769] FX This study and Dr. Weisbord were supported by a VA Health Services Research and Development Career Development Award (RCD 03-176) and a VA Stars and Stripes Competitive Pilot Project Fund award. Dr. Fine was supported in part by a mid-career development award (K24 AI001769) from the National Institute of Allergy and Infectious Diseases. All of the listed authors contributed to this work. NR 29 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2009 VL 24 IS 3 BP 289 EP 298 DI 10.1007/s11606-008-0894-4 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 407QL UT WOS:000263379300001 PM 19156472 ER PT J AU Liu, CF Bolkan, C Chan, D Yano, EM Rubenstein, LV Chaney, EF AF Liu, Chuan-Fen Bolkan, Cory Chan, Domin Yano, Elizabeth M. Rubenstein, Lisa V. Chaney, Edmund F. TI Dual Use of VA and Non-VA Services Among Primary Care Patients with Depression SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE dual use; depression; primary care; veterans ID OF-VETERANS-AFFAIRS; CLINICAL-PRACTICE GUIDELINES; ACUTE MYOCARDIAL-INFARCTION; MENTAL-HEALTH-SERVICES; FEMALE VETERANS; SCREENING QUESTIONNAIRES; MEDICARE SERVICES; AUDIT-C; DISORDERS; POPULATION AB Depression treatment requires close monitoring to achieve optimal, long-term control. Use of multiple sources of health care can affect coordination and continuity of treatment for depression. To assess levels of non-Veterans Health Administration (VA) use among depressed primary care patients by service type and examine patient factors associated with non-VA use. Cross-sectional comparison of dual and VA-only users among depressed primary care patients. Depression was defined as PHQ-9 a parts per thousand yen10. Five hundred fifty depressed patients from the baseline sample of a group-randomized trial of collaborative care for depression in ten VA primary care practices. VA and non-VA outpatient utilization for physical and emotional health problems in the prior 6 months, patient demographics, and co-morbid conditions. All measures were self-reported and obtained at the baseline interview. Overall, 46.8% of VA depressed primary care patients utilized non-VA care. Dual users were more likely to use acute care services (emergency room or inpatient), especially for physical health problems. Dual users of physical health services had more total visits, but fewer VA visits than VA-only users, while dual users of emotional health services had fewer total and VA visits. Factors associated with dual use were urban clinic location, having other insurance coverage, and dissatisfaction with physical health care in general. Almost half of depressed primary care patients used non-VA care, with most of their non-VA use for physical rather than emotional health problems. Care management strategies for depressed patients should include communication and coordination with non-VA providers. C1 [Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, Seattle, WA 98101 USA. [Liu, Chuan-Fen; Bolkan, Cory; Chaney, Edmund F.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. [Liu, Chuan-Fen; Bolkan, Cory] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Yano, Elizabeth M.; Rubenstein, Lisa V.] VA Greater Angeles Healthcare Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Sepulveda, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Dept Med, Los Angeles Sch Med, Los Angeles, CA 90024 USA. [Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA USA. [Chan, Domin; Chaney, Edmund F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Liu, CF (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM fliu@u.washington.edu NR 46 TC 20 Z9 20 U1 3 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2009 VL 24 IS 3 BP 305 EP 311 DI 10.1007/s11606-008-0867-7 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 407QL UT WOS:000263379300003 PM 19101777 ER PT J AU Borrero, S Nikolajski, C Rodriguez, KL Creinin, MD Arnold, RM Ibrahim, SA AF Borrero, Sonya Nikolajski, Cara Rodriguez, Keri L. Creinin, Mitchell D. Arnold, Robert M. Ibrahim, Said A. TI "Everything I Know I Learned from My Mother...or Not": Perspectives of African-American and White Women on Decisions About Tubal Sterilization SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE tubal sterilization; race; qualitative research; focus groups; decision making AB African-American women have had higher rates of female sterilization compared to white women since its emergence as a contraceptive method. The reasons underlying this observed racial difference are unknown. The goals of this study were to (1) explore what factors shape black and white women's decisions about tubal sterilization as a contraceptive method and (2) generate hypotheses about the relationship of race to the decision-making process. We conducted six focus groups stratified by tubal sterilization status and race. During each of the audio-recorded sessions, participants were asked to discuss reasons that women choose sterilization as a contraceptive method. The participants of the study were 24 African-American women and 14 white women. Transcripts of the sessions were qualitatively analyzed with particular attention to factors that might be unique to each of the two racial groups. Personal factors shaped black and white women's decisions regarding tubal sterilization. Preference for a convenient, highly effective contraceptive method was the main reason to get a tubal sterilization for women of both racial groups. We also identified socio-cultural differences that might explain why black women are more likely than white women to choose tubal sterilization over other contraceptive methods. An unanticipated, but clinically important, finding was that women often reported feeling that their doctors and the health-care system served as barriers to obtaining the desired procedure. Socio-cultural differences may help explain why black and white women choose different contraceptive methods. C1 [Borrero, Sonya; Nikolajski, Cara; Rodriguez, Keri L.; Arnold, Robert M.; Ibrahim, Said A.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya; Nikolajski, Cara; Rodriguez, Keri L.; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Rodriguez, Keri L.; Arnold, Robert M.] Univ Pittsburgh, Inst Doctor Patient Commun, Pittsburgh, PA USA. [Creinin, Mitchell D.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Creinin, Mitchell D.] Magee Womens Res Inst, Pittsburgh, PA USA. [Creinin, Mitchell D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Borrero, Sonya; Nikolajski, Cara; Rodriguez, Keri L.; Arnold, Robert M.; Ibrahim, Said A.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15260 USA. EM borrerosp@upmc.edu FU National Center for Research Resources (NCRR) [1 KL2 RR02415403]; National Institutes of Health (NIH); NIH Roadmap for Medical Research; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24AR055259]; VA HSR& D Merit Review Entry Program Award [MRP 04-410]; National Cancer Institute [3R01 CA-100387-03S1] FX This publication was made possible by Dr. Borrero's grant (no. 1 KL2 RR02415403) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official view of the NCRR or NIH. Dr. Ibrahim is supported by grant no. K24AR055259 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Rodriguez is supported by a VA HSR& D Merit Review Entry Program Award (MRP 04-410) and a Minority Supplement Award from the National Cancer Institute (3R01 CA-100387-03S1). NR 31 TC 24 Z9 24 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2009 VL 24 IS 3 BP 312 EP 319 DI 10.1007/s11606-008-0887-3 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 407QL UT WOS:000263379300004 PM 19107540 ER PT J AU Freiberg, MS Leaf, DA Goulet, JL Goetz, MB Oursler, KK Gibert, CL Rodriguez-Barradas, MC Butt, AA Justice, AC AF Freiberg, Matthew S. Leaf, David A. Goulet, Joseph L. Goetz, Matthew B. Oursler, Krisann K. Gibert, Cynthia L. Rodriguez-Barradas, Maria C. Butt, Adeel A. Justice, Amy C. TI The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV; cholesterol; hepatitis C; men; veterans; cardiovascular diseases ID CORONARY-HEART-DISEASE; HEPATITIS-C VIRUS; ANTIRETROVIRAL THERAPY; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; INFECTED INDIVIDUALS; RISK-FACTORS; PROTEASE INHIBITORS; ALCOHOL-USE; ADULTS AB To examine the association between HIV infection status and the receipt of lipid lowering therapy based on National Cholesterol Education Program/Adult Treatment Panel (NCEP/ATP III) guidelines and to assess whether HIV viral load and hepatitis C (HCV) status alters that association. A cross-sectional analysis of survey, laboratory, and pharmacy data from 1,577 male participants (59% HIV infected) of the Veterans Aging Cohort Five-Site Study, a prospective observational cohort of U.S. veterans with and without HIV infection. Receipt of lipid lowering therapy obtained from the VA pharmacy benefits management system was the main outcome. The prevalence of lipid lowering therapy among HIV-infected and HIV-uninfected veterans was 15.4% vs. 37.9%, respectively, p < 0.01. Among veterans who met NCEP/ATP III criteria for lipid lowering therapy, HIV-infected veterans had a significantly lower prevalence for the receipt of lipid lowering therapy (adjusted odds ratio (OR) = 0.43, 95% confidence interval (C.I.) 0.28-0.67) as compared with HIV-uninfected veterans. Among HIV-infected veterans, log HIV viral load (adjusted OR = 0.57, 95% CI, 0.41-0.81) and HIV-HCV co-infection (adjusted OR = 0.31, 95% CI = 0.13-0.75) were negatively associated with receipt of lipid lowering therapy. Exposure to HAART was not associated with receipt of lipid lowering therapy. Among those who met NCEP/ATP III criteria for lipid lowering therapy, HIV-infected veterans, particularly those with high HIV viral loads and HCV co-infection, were significantly less likely to receive lipid lowering therapy. This may be a modifiable mediator of cardiovascular disease among HIV-infected individuals. C1 [Freiberg, Matthew S.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. [Leaf, David A.; Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Goulet, Joseph L.; Justice, Amy C.] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA. [Oursler, Krisann K.] Univ Maryland, Sch Med, Baltimore VA Med Ctr, Baltimore, MD 21201 USA. [Gibert, Cynthia L.] George Washington Univ, Med Ctr, VA Med Ctr, Washington, DC 20037 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Freiberg, MS (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl, Pittsburgh, PA 15260 USA. EM freibergms@upmc.edu OI Goetz, Matthew/0000-0003-4542-992X; Goulet, Joseph/0000-0002-0842-804X FU NIH; NIAAA; NHLBI; [2U10 AA 13566]; [K23 AA015914]; [1R01HL095136-01] FX Funding: NIH, NIAAA, NHLBI: 2U10 AA 13566, K23 AA015914, and 1R01HL095136-01. NR 36 TC 13 Z9 13 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2009 VL 24 IS 3 BP 334 EP 340 DI 10.1007/s11606-008-0891-7 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 407QL UT WOS:000263379300007 PM 19127386 ER PT J AU Hildebrand, C Trowbridge, E Roach, MA Sullivan, AG Broman, AT Vogelman, B AF Hildebrand, Christopher Trowbridge, Elizabeth Roach, Mary A. Sullivan, Anne Gravel Broman, Aimee Teo Vogelman, Bennett TI Resident Self-Assessment and Self-Reflection: University of Wisconsin-Madison's Five-Year Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE practice-based learning and improvement; graduate medical education; chart review; ambulatory care settings ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-CARE; INTERNAL-MEDICINE; ACHIEVABLE BENCHMARKS; PRACTICE PERFORMANCE; PREVENTIVE HEALTH; IMPROVEMENT; EDUCATION; FEEDBACK; AUDIT AB Chart review represents a critical cornerstone for practice-based learning and improvement in our internal medicine residency program. To document residents' performance monitoring and improvement skills in their continuity clinics, their satisfaction with practice-based learning and improvement, and their ability to self-reflect on their performance. Retrospective longitudinal design with repeated measures. Eighty Internal Medicine residents abstracted data for 3 consecutive years from the medical records of their 4,390 patients in the University of Wisconsin-Madison (UW) Hospital and Clinics and William S. Middleton Veterans Administration (VA) outpatient clinics. Logistic modeling was used to determine the effect of postgraduate year, resident sex, graduation cohort, and clinic setting on residents' "compliance rate" on 17 nationally recognized health screening and chronic disease management parameters from 2003 to 2007. Residents' adherence to national preventive and chronic disease standards increased significantly from intern to subsequent years for administering immunizations, screening for diabetes, cholesterol, cancer, and behavioral risks, and for management of diabetes. Of the residents, 92% found the chart review exercise beneficial, with 63% reporting gains in understanding about their medical practices, 26% reflecting on specific gaps in their practices, and 8% taking critical action to improve their patient outcomes. This paper provides support for the feasibility and practicality of this limited-cost method of chart review. It also directs our residency program's attention in the continuity clinic to a key area important to internal medicine training programs by highlighting the potential benefit of enhancing residents' self-reflection skills. C1 [Hildebrand, Christopher] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Trowbridge, Elizabeth; Roach, Mary A.; Sullivan, Anne Gravel; Broman, Aimee Teo; Vogelman, Bennett] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Vogelman, B (reprint author), 600 Highland Ave J5-237 Clin Sci Ctr, Madison, WI 53792 USA. EM bsv@medicine.wisc.edu FU University of Wisconsin-Madison School of Medicine and Public Health; Residency Review Committee for Internal Medicine; University of Wisconsin Institute for Clinical and Translational Research; NIH Clinical and Translational Science Award [1 UL1 RR025011] FX Completion of this paper was made possible by a grant from the Medical Education and Research Committee (MERC) of the University of Wisconsin-Madison School of Medicine and Public Health as well as by the support of the Education Innovation Project of the Residency Review Committee for Internal Medicine, of which we are a participating residency. This research was also supported by the University of Wisconsin Institute for Clinical and Translational Research, funded through an NIH Clinical and Translational Science Award (CTSA), grant no. 1 UL1 RR025011. Earlier results of this paper were presented at the Association of Program Directors in Internal Medicine meeting (2004). We wish to acknowledge the programmatic efforts of Suzy Griffiths, Toni Prisk, Vonnie Schoenleber, Jessalyn Richter, and Erik Stava at various stages in the process of this work. NR 34 TC 11 Z9 11 U1 5 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2009 VL 24 IS 3 BP 361 EP 365 DI 10.1007/s11606-009-0904-1 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 407QL UT WOS:000263379300011 PM 19156469 ER PT J AU Willett, LL Paranjape, A Estrada, C AF Willett, Lisa L. Paranjape, Anuradha Estrada, Carlos TI Identifying Key Components for an Effective Case Report Poster: An Observational Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE case report; poster; evaluation tool; academic meetings ID PUBLICATION RATES; TRAINING-PROGRAMS; RESIDENT RESEARCH; ABSTRACTS; MEDICINE; MEETINGS AB Residents demonstrate scholarly activity by presenting posters at academic meetings. Although recommendations from national organizations are available, evidence identifying which components are most important is not. To develop and test an evaluation tool to measure the quality of case report posters and identify the specific components most in need of improvement. Faculty evaluators reviewed case report posters and provided on-site feedback to presenters at poster sessions of four annual academic general internal medicine meetings. A newly developed ten-item evaluation form measured poster quality for specific components of content, discussion, and format (5-point Likert scale, 1 = lowest, 5 = highest). Main outcome measure(s): Evaluation tool performance, including Cronbach alpha and inter-rater reliability, overall poster scores, differences across meetings and evaluators and specific components of the posters most in need of improvement. Forty-five evaluators from 20 medical institutions reviewed 347 posters. Cronbach's alpha of the evaluation form was 0.84 and inter-rater reliability, Spearman's rho 0.49 (p < 0.001). The median score was 4.1 (Q1 -Q3, 3.7-4.6)(Q1 = 25th, Q3 = 75th percentile). The national meeting median score was higher than the regional meetings (4.4 vs, 4.0, P < 0.001). We found no difference in faculty scores. The following areas were identified as most needing improvement: clearly state learning objectives, tie conclusions to learning objectives, and use appropriate amount of words. Our evaluation tool provides empirical data to guide trainees as they prepare posters for presentation which may improve poster quality and enhance their scholarly productivity. C1 [Willett, Lisa L.; Estrada, Carlos] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Paranjape, Anuradha] Temple Univ, Sch Med, Gen Internal Med Sect, Birmingham, AL USA. [Estrada, Carlos] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Willett, LL (reprint author), Univ Alabama, Dept Med, BDB 339,1530 3rd Ave S, Birmingham, AL 35294 USA. EM lwillett@uab.edu NR 26 TC 4 Z9 4 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2009 VL 24 IS 3 BP 393 EP 397 DI 10.1007/s11606-008-0860-1 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 407QL UT WOS:000263379300017 PM 19089510 ER PT J AU Sridhar, ARM Willett, LL Castiglioni, A Heudebert, G Landry, M Centor, RM Estrada, CA AF Sridhar, Arun R. Mahankali Willett, Lisa L. Castiglioni, Analia Heudebert, Gustavo Landry, Michael Centor, Robert M. Estrada, Carlos A. TI Scholarship Opportunities for Trainees and Clinician Educators: Learning Outcomes from a Case Report Writing Workshop SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE case reports; education; medical; educational measurement/methods; faculty; medical; internship and residency; internal medicine/education; mentors; program development; publishing; research/education; staff development; writing; writing/standards ID CASE SERIES; PROMOTION; DIAGNOSIS AB Publishing a case report demonstrates scholarly productivity for trainees and clinician-educators. To assess the learning outcomes from a case report writing workshop. Medical students, residents, fellows and clinician-educators attending a workshop. Case report writing workshop conducted nine times at different venues. Before and after each workshop, participants self-rated their perceived competence to write a case report, likelihood of submitting a case report to a meeting or for publication in the next 6-12 months, and perceived career benefit of writing a case report (on a five-point Likert scale). The 214 participants were from 3 countries and 27 states or provinces; most participants were trainees (64.5 %). Self-rated competence for writing a case report improved from a mean of 2.5 to 3.5 (a 0.99 increase; 95% CI, 0.88-1.12, p < 0.001). The perceived likelihood of submitting a case report, and the perceived career benefit of writing one, also showed statistically significant improvements (p = 0.002, p = 0.001; respectively). Nine of 98 participants published a case report 16-41 months after workshop completion. The workshop increased participants' perception that they could present or publish a case report. C1 [Castiglioni, Analia; Heudebert, Gustavo; Centor, Robert M.; Estrada, Carlos A.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Castiglioni, Analia; Heudebert, Gustavo; Centor, Robert M.; Estrada, Carlos A.] Univ Alabama, Div Gen Internal Med, Birmingham, AL USA. [Sridhar, Arun R. Mahankali] Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA. [Willett, Lisa L.; Castiglioni, Analia; Heudebert, Gustavo; Centor, Robert M.; Estrada, Carlos A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Landry, Michael] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. RP Estrada, CA (reprint author), Birmingham VA Med Ctr, 732 Fac Off Tower,510 20th St S, Birmingham, AL 35294 USA. EM cestrada@uab.edu NR 31 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2009 VL 24 IS 3 BP 398 EP 401 DI 10.1007/s11606-008-0873-9 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 407QL UT WOS:000263379300018 PM 19104902 ER PT J AU Razani, J Wong, JT Dafaeeboini, N Edwards-Lee, T Lu, P Alessi, C Josephson, K AF Razani, Jill Wong, Jennifer T. Dafaeeboini, Natalia Edwards-Lee, Terri Lu, Po Alessi, Cathy Josephson, Karen TI Predicting Everyday Functional Abilities of Dementia Patients With the Mini-Mental State Examination SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE activities of daily living; functional ability; dementia; Mini-Mental State Examination; Direct Assessment of Functional Status ID ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL PERFORMANCE; RATING-SCALE; IMPAIRMENT; DIAGNOSIS; UTILITY; HEALTH AB The Mini-Mental State Examination is a widely used cognitive screening measure. The purpose of the present study was to assess how 5 specific clusters of Mini-Mental State Examination items (ie, subscores) correlate with and predict specific areas of daily functioning in dementia patients, 61 patients with varied forms of dementia were administered the Mini-Mental State Examination and an observation-based daily functional test (the Direct Assessment of Functional Status). The results revealed that the orientation and attention subscores of the Mini-Mental State Examination correlated most significantly with most functional domains. The Mini-Mental State Examination language items correlated with all but the shopping and time orientation tasks, while the Mini-Mental State Examination recall items correlated with the Direct Assessment of Functional Status time orientation and shopping tasks. Stepwise regression analyses found that among the Mini-Mental State Examination subscores, orientation was the single, best independent predictor of daily functioning. C1 [Razani, Jill] Calif State Univ Northridge, Dept Psychol, Northridge, CA 91330 USA. [Wong, Jennifer T.] Univ Detroit Mercy, Detroit, MI 48221 USA. [Edwards-Lee, Terri] Univ Calif Los Angeles, Dept Neurol, Harbor UCLA Med Ctr, David Geffen Sch Med,Los Angeles Med Res Inst, Los Angeles, CA 90024 USA. [Alessi, Cathy; Josephson, Karen] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Alessi, Cathy; Josephson, Karen] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Razani, J (reprint author), Calif State Univ Northridge, Dept Psychol, 18111 Nordhoff St, Northridge, CA 91330 USA. EM jill.razani@csun.edu FU National Institute of General Medical Sciences (NIGMS) [GM048680, GM063787, GM008395] FX This study was conducted at California State University, Northridge, and was supported by National Institute of General Medical Sciences (NIGMS) grant GM048680 to JR. Additional support for the project was provided by NIGMS grants GM063787 (Minority Biomedical Research Support Program-Research Initiative for Scientific Enhancement) and GM008395 (Minority Access to Research Career). NR 20 TC 5 Z9 8 U1 0 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD MAR PY 2009 VL 22 IS 1 BP 62 EP 70 DI 10.1177/0891988708328217 PG 9 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 408ZL UT WOS:000263475400007 PM 19196632 ER PT J AU Mailloux, AW Young, MRI AF Mailloux, Adam W. Young, M. Rita I. TI NK-Dependent Increases in CCL22 Secretion Selectively Recruits Regulatory T Cells to the Tumor Microenvironment SO JOURNAL OF IMMUNOLOGY LA English DT Article ID FOSTERS IMMUNE PRIVILEGE; DEFICIENT BEIGE MICE; GROWTH-FACTOR-BETA; BONE-MARROW; DOWN-REGULATION; MHC EXPRESSION; DENDRITIC-CELL; CD4(+) CD25(+); LYMPHOCYTES; AUTOIMMUNITY AB Tumor-induced immune suppression involves the accumulation of immune-suppressive infiltrates in the microenvironment. This study demonstrates increased numbers of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) in the lungs of C57BL/6 mice hearing it metastatic Lewis lung carcinoma (LLC) variant. These Tregs suppressed the proliferation of endogenous CD4(+)CD25(-) cells and expressed higher levels of the chemokine receptor CCR4 than other types of T cells. LLC-bearing lungs secreted elevated levels of the CCR4-associated chemokine CCL22 compared with normal lungs. However, CCL22 was not secreted by LLC or normal epithelial controls, suggesting that CCL22 is secreted fly a nonepithelial component of the microenvironment. Migration assays revealed that medium conditioned by LLC-bearing lungs selectively recruited Tregs at higher frequencies than did medium conditioned by normal lungs. Neutralization or CCL22 significantly reduced this selective recruitment toward both conditioned media. A series of immunomagnetic isolations, FACS, and flow cytometric analyses were used to isolate different cellular fractions from both normal and LLC-bearing lungs. When isolated, only the NK-containing fractions secreted CCL22, and the same fraction isolated from LLC-bearing lungs secreted higher levels. Depletion of INK cells from both normal and LLC-bearing lung tissue significantly reduced CCL22 secretion, suggesting that a large portion of secreted CCL22 is NK cell dependent. Flow cytometric analysis of the lung NK compartments revealed no significant increase in NK cell numbers across LLC-bearing lung tissue as a whole as compared with normal tissue. However, immunofluorescent staining revealed an increased frequency of NK cells at the tumor periphery that were closely associated with the elevated FoxP3(+) infiltrate. The Journal of Immunology, 2009, 182: 2753-2765. C1 [Mailloux, Adam W.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29403 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA. [Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, Charleston, SC USA. RP Young, MRI (reprint author), Ralph H Johnson Vet Affairs Hosp, Res Serv 151, 109 Bee st, Charleston, SC 29401 USA. EM rita.young@med.va.gov FU NCI NIH HHS [CA8566, R01 CA085266-06, R01 CA097813, R01 CA128837-05, R01 CA128837, CA97813, R01 CA085266] NR 56 TC 40 Z9 45 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAR 1 PY 2009 VL 182 IS 5 BP 2753 EP 2765 DI 10.4049/jimmunol.0801124 PG 13 WC Immunology SC Immunology GA 411MG UT WOS:000263653100025 PM 19234170 ER PT J AU Kindy, MS Yu, J Zhu, H Hook, V Hook, G AF Kindy, M. S. Yu, J. Zhu, H. Hook, V. Hook, G. TI NOVEL PROTEOLYTIC MECHANISMS FOR BETA-AMYLOID PRODUCTION. SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-for-Neurochemistry CY MAR 07-11, 2009 CL Charleston, SC SP Amer Soc Neurochem C1 [Kindy, M. S.; Yu, J.; Zhu, H.] Med Univ S Carolina, Charleston, SC 29425 USA. [Hook, V.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Hook, G.] Amer Life Sci Pharmaceut Inc, San Diego, CA USA. [Kindy, M. S.] Ralph H Johnson Vet Affairs, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2009 VL 108 BP 70 EP 71 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 407AU UT WOS:000263336800149 ER PT J AU El-Amouri, SS Yu, J Zhu, H Kindy, MS AF El-Amouri, S. S. Yu, J. Zhu, H. Kindy, M. S. TI NEPRILYSIN: AN ENZYME CANDIDATE TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-for-Neurochemistry CY MAR 07-11, 2009 CL Charleston, SC SP Amer Soc Neurochem C1 [El-Amouri, S. S.; Yu, J.; Zhu, H.; Kindy, M. S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Kindy, M. S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2009 VL 108 BP 149 EP 149 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 407AU UT WOS:000263336800346 ER PT J AU Tang, XN Liu, LP Yenari, MA AF Tang, Xian N. Liu, Liping Yenari, Midori A. TI Combination Therapy with Hypothermia for Treatment of Cerebral Ischemia SO JOURNAL OF NEUROTRAUMA LA English DT Article; Proceedings Paper CT 2nd International Brain Hypothermia Symposium CY OCT, 2007 CL Miami Beach, FL DE hypothermia; neuroprotection; stroke; tissue plasminogen activator ID TISSUE-PLASMINOGEN ACTIVATOR; TRANSIENT GLOBAL-ISCHEMIA; COMBINED POSTISCHEMIC HYPOTHERMIA; PERMANENT FOCAL ISCHEMIA; MILD HYPOTHERMIA; ARTERY OCCLUSION; ACUTE STROKE; INFARCT SIZE; MODERATE HYPOTHERMIA; FOREBRAIN ISCHEMIA AB Mild hypothermia is an established neuroprotectant in the laboratory, showing remarkable and consistent effects across multiple laboratories and models of brain injury. At the clinical level, mild hypothermia has shown benefits in patients who have suffered cardiac arrest and in some pediatric populations suffering hypoxic brain insults. However, a review of the literature has demonstrated that in order to appreciate the maximum benefits of hypothermia, brain cooling needs to begin soon after the insult, maintained for relatively long period periods of time, and, in the case of ischemic stroke, should be applied in conjunction with the re-establishment of cerebral perfusion. Translating this to the clinical arena can be challenging, especially rapid cooling and the re-establishment of perfusion. The addition of a second neuroprotectant could potentially (1) enhance overall protection, (2) prolong the temporal therapeutic window for hypothermia, or (3) provide protection where hypothermic treatment is only transient. Combination therapies resulting in recanalization following ischemic stroke would improve the likelihood of a good outcome, as the experimental literature suggests more consistent neuroprotection against ischemia with reperfusion, than ischemia without. Since recombinant tissue plasiminogen activator (rt-PA) is the only FDA approved treatment for acute ischemic stroke, and acts to recanalize occluded vessels, it is an obvious initial strategy to combine with hypothermia. However, the effects of thrombolytics are also temperature dependent, and the risk of hemorrhage is significant. The experimental data nevertheless seem to favor a combinatorial approach. Thus, in order to apply hypothermia to a broader range of patients, combination strategies should be further investigated. C1 [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, Neurol VAMC 127, San Francisco, CA 94121 USA. [Tang, Xian N.; Yenari, Midori A.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Tang, Xian N.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA. [Liu, Liping] Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, Neurol VAMC 127, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU NINDS NIH HHS [P50 NS014543, R01 NS040516, P01 NS037520, P01 NS37520, P01 NS014543-300002, R01 NS40516, P01 NS037520-060004, P01 NS014543, R01 NS040516-02, R01 NS040516-01A1] NR 61 TC 23 Z9 26 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR PY 2009 VL 26 IS 3 BP 325 EP 331 DI 10.1089/neu.2008.0594 PG 7 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 420ZO UT WOS:000264327900005 PM 19216635 ER PT J AU Klein, HA AF Klein, Herbert A. TI Nuclear Medicine Radiation Risks SO JOURNAL OF NUCLEAR MEDICINE LA English DT Letter ID EXPOSURE C1 Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Klein, HA (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD MAR PY 2009 VL 50 IS 3 BP 489 EP 489 DI 10.2967/jnumed.108.058099 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 417OB UT WOS:000264084500030 PM 19223413 ER PT J AU Jones, DW Robertson, LD Figoni, SF AF Jones, D. W. Robertson, L. D. Figoni, S. F. TI A Strength-Endurance Index for Power Grip SO JOURNAL OF OCCUPATIONAL REHABILITATION LA English DT Article DE Exercise; Isometric; Hand strength; Muscle strength; Muscle fatigue ID PINCH STRENGTH AB Introduction The purpose of this study was to quantify muscle strength and endurance in power grip. Method Workers (74 M and 74 F, 18-72 years) squeezed a dynamometer for a 60 s, 18-cycle test. Initial strength (IS) and final strength (FS) were calculated as the mean peak force for cycles 1-3 and 16-18, respectively. Endurance was defined by the strength decrement index (SDI) where SDI = (IS - FS)/IS x 100. A grip strength-endurance analyzer was constructed from IS and SDI data which were depicted on two parallel, linearly scaled axes. Discrete IS and SDI scores were connected on each axis with a vector. The vector (Vmag) was measured directly from the analyzer and its direction identified from its slope. Integer scales transformed discrete IS and SDI scores into individual strength-endurance performance scores (SEPS). Results Better than 95% of the sample (n a parts per thousand yen 141) scored within acceptable test ranges defined as the combined sample mean +/- A 2SD, for SDI, Vmag and SEPS. Vmag was the best predictor for SEPS. Linear regression for SEPS was SEPS (combined) = 0.09 (Vmag) - 0.29: (SEE = 0.829). The analyzer revealed individual scores outside acceptable ranges for injured and uninjured efforts. Conclusion The development of a power grip strength-endurance analyzer provided a simple method to graph individual power grip performances. Converting strength and endurance scores to integers and summing them (SEPS) provided a simple means to represent individual estimates of power grip strength-endurance performance. C1 [Jones, D. W.] Calif State Univ Long Beach, Dept Kinesiol, Long Beach, CA 90840 USA. [Robertson, L. D.] Human Kinet Publisher, Champaign, IL 61825 USA. [Figoni, S. F.] VA Greater Angles Healthcare Syst, Dept Phys Med Kinesiotherapy, Los Angeles, CA 90073 USA. RP Jones, DW (reprint author), Calif State Univ Long Beach, Dept Kinesiol, 1250 Bellflower Blvd, Long Beach, CA 90840 USA. EM djones9@csulb.edu; loarnr@HKUSA.com; sfigoni@gmail.com NR 14 TC 2 Z9 3 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1053-0487 J9 J OCCUP REHABIL JI J. Occup. Rehabil. PD MAR PY 2009 VL 19 IS 1 BP 56 EP 63 DI 10.1007/s10926-009-9163-6 PG 8 WC Rehabilitation; Social Issues SC Rehabilitation; Social Issues GA 409RY UT WOS:000263524700006 PM 19214717 ER PT J AU Pousman, RM Pepper, C Pandharipande, P Ayers, GD Mills, B Diaz, J Collier, B Miller, R Jensen, G AF Pousman, Robert M. Pepper, Colleen Pandharipande, Pratik Ayers, Gregory D. Mills, Beth Diaz, Jose Collier, Brian Miller, Rick Jensen, Gordon TI Feasibility of Implementing a Reduced Fasting Protocol for Critically Ill Trauma Patients Undergoing Operative and Nonoperative Procedures SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE enteral nutrition; critically ill trauma patients; mechanical ventilation; complications; reduced fasting; procedures ID PARENTERAL-NUTRITION; PRACTICE GUIDELINES; ABDOMINAL-TRAUMA; SEPTIC MORBIDITY; CARE-UNIT; DELIVERY AB Background: This prospective, observational cohort study was designed to determine the feasibility of implementing a reduced enteral fasting protocol in mechanically ventilated trauma patients undergoing selected operative and nonoperative procedures. Methods: Critically ill, mechanically ventilated trauma patients undergoing selected operative and nonoperative procedures received enteral nutrition up until the time of the procedure, if receiving small bowel feeds, or received enteral nutrition that was discontinued 45 minutes before the procedure, if receiving gastric feeds. Results: Measures of delivery of nutrition Such as total enteral nutrition delivered and days required to reach nutrition goal were collected. Complications measured were death, incidence of ventilator-associated pneumonia, urinary tract infection, catheter-related bloodstream infection, wound infection, hypoglycemia, and emesis during procedures. No significant demographic differences were observed between the 2 groups. Patients in the intervention group showed trends toward greater total enteral nutrition delivered and faster attainment of target nutrition goals, although these measures were not statistically significant. Patients in the intervention group had rates of infective complications similar to those in the standard group. The median (interquartile range) for intensive care unit length of stay in the intervention group vs standard group was 7 (5, 15) vs 7 (5, 12) (P = 0.94), and the ventilator days were 8 (4.2, 14) vs 7 (3, 11) (P = 0.37). Conclusions: A reduced fasting protocol was feasible for selected operative procedures, with trends toward improving nutrition delivery and no increase in adverse outcomes. A larger randomized study of this approach is warranted before adoption of this practice can be advocated. (JPEN J Parenter Enteral Nutr. 2009;33:176-180) C1 [Pousman, Robert M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, W Los Angeles VA, Los Angeles, CA 90095 USA. [Pepper, Colleen; Pandharipande, Pratik] Vanderbilt Univ, Med Ctr, Dept Anesthesia Crit Care, Nashville, TN USA. [Diaz, Jose; Collier, Brian; Miller, Rick] Vanderbilt Univ, Med Ctr, Dept Surg, Div Trauma, Nashville, TN USA. [Ayers, Gregory D.; Miller, Rick] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA. [Mills, Beth] Vanderbilt Univ, Med Ctr, Ctr Human Nutr, Nashville, TN USA. [Jensen, Gordon] Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA. RP Pousman, RM (reprint author), 757 Iestwood Plaza,Suite 3325, Los Angeles, CA 90095 USA. EM frostitude@yahoo.com NR 18 TC 17 Z9 17 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD MAR-APR PY 2009 VL 33 IS 2 BP 176 EP 180 DI 10.1177/0148607108327527 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 410RL UT WOS:000263595700002 PM 19251911 ER PT J AU Paukert, AL Phillips, L Cully, JA LoboPrabhu, SM Lomax, JW Stanley, MA AF Paukert, Amber L. Phillips, Laura Cully, Jeffrey A. LoboPrabhu, Sheila M. Lomax, James W. Stanley, Melinda A. TI Integration of Religion into Cognitive-Behavioral Therapy for Geriatric Anxiety and Depression SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE depression; anxiety; older patients; elderly; religion; spirituality; evidence-based treatment ID ILL OLDER PATIENTS; MENTAL-HEALTH; ELDERLY PERSONS; LATE-LIFE; PSYCHOTHERAPY; ADULTS; SPIRITUALITY; DISORDERS; INTERVENTIONS; OUTCOMES AB Religion is important to most older adults, and research generally finds a positive relationship between religion and mental health. Among psychotherapies used in the treatment of anxiety and depression in older adults, cognitive-behavioral therapy (CBT) has the strongest evidence base. Incorporation of religion into CBT may increase its acceptability and effectiveness in this population. This article reviews studies that have examined the effects of integrating religion into CBT for depression and anxiety. These studies indicate that improvement in depressive and anxiety symptoms occurs earlier in treatment when CBT incorporates religion, although effects are equivalent at follow-up. The authors present recommendations for integrating religious beliefs and behaviors into CBT based on empirical literature concerning which aspects of religion affect mental health. A case example is also included that describes the integration of religion into CBT for an older man with cognitive impairment experiencing comorbid generalized anxiety disorder and major depressive disorder. It is recommended that clinicians consider the integration of religion into psychotherapy for older adults with depression or anxiety and that studies be conducted to examine the added benefit of incorporating religion into CBT for the treatment of depression and anxiety in older adults. (Journal of Psychiatric Practice 2009;15:103-112) C1 [Paukert, Amber L.] Vet Affairs Med Ctr, Seattle, WA 98108 USA. [Cully, Jeffrey A.; LoboPrabhu, Sheila M.; Stanley, Melinda A.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Phillips, Laura; Cully, Jeffrey A.; LoboPrabhu, Sheila M.; Lomax, James W.; Stanley, Melinda A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Paukert, AL (reprint author), Puget Sound Vet Affairs Med Ctr, 1660 S Columbian Way,Mail Stop,S-111-HBPC, Seattle, WA 98108 USA. EM Amber.Paukert@va.gov FU Houston VA HSR&D Center of Excellence [HFP90-020]; South Central Mental Illness Research Education and Clinical Center (MIRECC) FX This work was supported in part by the Houston VA HSR&D Center of Excellence (Houston Center for Quality of Care & Utilization Studies), HFP90-020, and a pilot grant to the last author from the South Central Mental Illness Research Education and Clinical Center (MIRECC). NR 80 TC 20 Z9 21 U1 4 U2 36 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-4160 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD MAR PY 2009 VL 15 IS 2 BP 103 EP 112 PG 10 WC Psychiatry SC Psychiatry GA 426PZ UT WOS:000264721500004 PM 19339844 ER PT J AU Yang, CC Jiang, XG AF Yang, Claire C. Jiang, Xiaogang TI Clinical Autonomic Neurophysiology and the Male Sexual Response: An Overview SO JOURNAL OF SEXUAL MEDICINE LA English DT Article CT 16th Annual Meeting of the American-Urological-Association-Foundation/Summer Research Conference on Sexual Medicine CY AUG 07-09, 2008 CL Baltimore, MD SP Amer Urol Assoc Fdn, Natl Inst Diabetes & Digestive & Kidney Dis DE Autonomic Nervous System; Clinical Neurophysiology; Male Sexual Response; Electrodiagnostic Testing; Evoked Cavernous Activity; Corpus Cavernosum Electromyography ID CORPUS CAVERNOSUM ELECTROMYOGRAPHY; SYMPATHETIC SKIN-RESPONSE; SINGLE POTENTIAL ANALYSIS; ERECTILE DYSFUNCTION; ELECTRICAL-ACTIVITY; HEALTHY-VOLUNTEERS; INNERVATION; PENIS; METHODOLOGY; DISORDERS AB Introduction. Clinical neurophysiology is the study of the human nervous system through the recording of bioelectrical activity. In the realm of male sexual functioning, this includes using electrophysiologic techniques to study the nerves subserving erection, emission, ejaculation, and orgasm. Aim. To introduce the reader to the principles of clinical neurophysiology as they relate to the male sexual response, particularly erection. Methods. We review the pertinent autonomic neuroanatomy and neurophysiology of reflexes relevant to the male sexual response, as well as summarize the genital electrodiagnostic tests that are being used to interrogate the autonomic innervation pertinent to male sexual functioning. Conclusions. The male sexual response is a coordinated series of interactions between the somatic and the autonomic nervous systems. Measurement of the autonomically mediated portions of the sexual reflexes is of great clinical interest, particularly in relation to erection. Advances in clinical electrodiagnostics now allow for consistent recording of evoked and spontaneous intrapenile electrical activity. However, before broad and widespread use of these techniques is possible, more investigations are needed. Yang CC, and Jiang X. Clinical autonomic neurophysiology and the male sexual response: An overview. J Sex Med 2009;6(suppl 3):221-228. C1 [Yang, Claire C.] VA Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA 98109 USA. [Jiang, Xiaogang] Univ Washington, Dept Urol, Seattle, WA 98195 USA. RP Yang, CC (reprint author), VA Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA 98109 USA. EM cyang@u.washington.edu FU NIDDK NIH HHS [R21 DK069315, R21 DK069315-02] NR 31 TC 10 Z9 10 U1 2 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1743-6095 J9 J SEX MED JI J. Sex. Med. PD MAR PY 2009 VL 6 BP 221 EP 228 DI 10.1111/j.1743-6109.2008.01180.x PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 452OZ UT WOS:000266552200004 PM 19267845 ER PT J AU Kinder, LS Bryson, CL Sun, H Williams, EC Bradley, KA AF Kinder, Leslie S. Bryson, Chris L. Sun, Haili Williams, Emily C. Bradley, Katharine A. TI Alcohol Screening Scores and All-Cause Mortality in Male Veterans Affairs Patients SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID PRIMARY-CARE PATIENTS; MENTAL-HEALTH; CONSUMPTION QUESTIONS; FOLLOW-UP; AUDIT-C; POPULATION; INTERVENTION; ASSOCIATION; VALIDATION; DISORDERS AB Objective: Extensive research demonstrates a J- or U-shaped association between in-depth interview measures of alcohol consumption and mortality. Little is known about the relationship between alcohol screening questionnaires and mortality. This study examined the association between scores (ranging from 0 to 12) on the three-item Alcohol Use Disorder Identification Test-Consumption Questionnaire (AUDIT-C) and mortality. Method: This cohort study included male outpatients from seven Veterans Affairs (VA) medical centers who completed the AUDIT-C on mailed surveys (1997-2000; n = 34,292) and who were followed for a mean of 2.5 years. Death was ascertained from VA databases. Results: In analyses adjusted for demographics, a U-shaped relationship was observed between AUDIT-C scores and all-cause mortality. Nondrinkers (AUDIT-C 0) and heavy drinkers (AUDIT-C 8-9 and 10-12) had increased risk of death compared with drinkers who screened negative for alcohol misuse (AUDIT-C 1-3): hazard ratios (HR) = 1.41 (95% confidence interval [Cl]: 1.29-1.54), 1.32 (1.03-1.69), and 1.47 (1.14-1.91), respectively. This association differed across age groups (p = .003). For men younger than 50 years, AUDIT-C scores 10-12 were associated with increased mortality (HR = 2.21, 95% Cl: 1.29-3.77), whereas for men age 50 or older, self-reported abstinence (AUDIT-C 0) was associated with increased mortality; compared with drinkers with AUDIT-C scores 1-3: HR for men 50-64 = 1.45 (1.19-1.77); HR for men 65 or older = 1.42 (1.28-1.58). Conclusions: A U-shaped association between the AUDIT-C and mortality was observed, with important differences by age group. This is the first study to demonstrate that a clinical scaled screening measure of alcohol use has a similar association with mortality to that observed in epidemiological research with lengthier measures. (J. Stud. Alcohol Drugs 70: 253-260, 2009) C1 [Kinder, Leslie S.; Bryson, Chris L.; Sun, Haili; Williams, Emily C.; Bradley, Katharine A.] NW Ctr Excellence Hlth Serv Res & Dev, Dept Vet Affairs, Seattle, WA 98101 USA. [Bryson, Chris L.] Primary & Specialty Med Care Serv, Dept Vet Affairs, VA Puget Sound, Seattle, WA USA. [Bryson, Chris L.; Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Williams, Emily C.] Ctr Excellence Substance Abuse Treatment & Educ, Dept Vet Affairs, VA Puget Sound, Seattle, WA USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Bryson, CL (reprint author), NW Ctr Excellence Hlth Serv Res & Dev, Dept Vet Affairs, 1100 Ol Way,Suite 1400, Seattle, WA 98101 USA. EM christopher.bryson@va.gov FU VA Health Services Research and Development (HSRD) [SDR96-002, HR99-376]; VA Investigator Initiated Research grant [IAC 05-206-1]; VA HSRD Fellowship; VA Career Development Award [RCD03-177] FX This research was supported by the Department of Veterans Affairs (VA) Ambulatory (Care Quality Improvement Project (ACQUIP), funded by VA Health Services Research and Development (HSR&D) grants SDR96-002 and HR99-376; VA Investigator Initiated Research grant IAC 05-206-1 awarded to Katharine A. Bradley, principal investigator; VA HSR&D Fellowship awarded to Leslie S. Kinder; and VA Career Development Award RCD03-177 awarded to Chris L. Bryson. The views expressed here are those of the authors and do not necessarily reflect the position or policy of the VA or the University of Washington. NR 39 TC 28 Z9 29 U1 1 U2 1 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAR PY 2009 VL 70 IS 2 BP 253 EP 260 PG 8 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 416SS UT WOS:000264026400011 PM 19261237 ER PT J AU Albrecht, J Werth, VP Bigby, M AF Albrecht, Joerg Werth, Victoria P. Bigby, Michael TI The role of case reports in evidence-based practice, with suggestions for improving their reporting SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID CUTANEOUS LUPUS-ERYTHEMATOSUS; MYCOPHENOLATE-MOFETIL; POTASSIUM-IODIDE; PEMPHIGUS-VULGARIS; CASE SERIES; VASCULITIS; PSORIASIS; NEPHROPATHY; TERBINAFINE; DISEASE AB Background: Case reports are part of the evidence hierarchy in evidence-based practice and guide an important part of dermatologic practice. Objective: This article discusses the role of case reports and series in evidence-based practice and suggests how to improve reporting. Methods: This article was inspired by a forum on the role of case reporting in dermatologic practice presented at a meeting of the American Academy of Dermatology. It is based on an informal literature review and the authors' experience in systematically reviewing case reports in medicine and dermatology. Results: Case reports significantly influence medicine. Often they are the first line of evidence for new therapies but rarely are sufficient to establish treatment efficacy. Frequently they are the first and sometimes major source for detecting rare adverse events. Guidelines for improving the reporting of case reports and series are discussed. Limitations: This paper represents the views of the authors and is neither a systematic review of the literature nor a formal consensus document. Conclusion: Case reports are an important part of medical literature and need to be taken seriously. (J Am Acad Dermatol 2009;60:412-8.) C1 [Albrecht, Joerg] John H Stroger Jr Hosp Cook Cty, Dept Med, Chicago, IL 60612 USA. [Albrecht, Joerg] John H Stroger Jr Hosp Cook Cty, Div Dermatol, Chicago, IL 60612 USA. [Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Bigby, Michael] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Bigby, Michael] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Albrecht, J (reprint author), John H Stroger Jr Hosp Cook Cty, Dept Med, Adm Bldg,5th Floor,1900 W Polk St, Chicago, IL 60612 USA. EM joerg.albrecht@gmail.com FU NIAMS NIH HHS [K24 AR002207] NR 50 TC 21 Z9 22 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAR PY 2009 VL 60 IS 3 BP 412 EP 418 DI 10.1016/j.jaad.2008.10.023 PG 7 WC Dermatology SC Dermatology GA 415KZ UT WOS:000263934000006 PM 19231639 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI SJOGREN SYNDROME SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter ID COMPLICATIONS C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Qual Assurance Dent Serv, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Univ Calif Los Angeles, Med Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD MAR PY 2009 VL 140 IS 3 BP 279 EP 279 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 418BI UT WOS:000264121800007 PM 19255168 ER PT J AU Wenger, NS Roth, CP Shekelle, PG Young, RT Solomon, DH Kamberg, CJ Chang, JT Louie, R Higashi, T MacLean, CH Adams, J Min, LC Ransohoff, K Hoffing, M Reuben, DB AF Wenger, Neil S. Roth, Carol P. Shekelle, Paul G. Young, Roy T. Solomon, David H. Kamberg, Caren J. Chang, John T. Louie, Rachel Higashi, Takahiro MacLean, Catherine H. Adams, John Min, Lillian C. Ransohoff, Kurt Hoffing, Marc Reuben, David B. TI A Practice-Based Intervention to Improve Primary Care for Falls, Urinary Incontinence, and Dementia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE practice-based intervention; geriatric quality of care; clinical care improvement ID RANDOMIZED CONTROLLED-TRIAL; QUALITY INDICATORS; OLDER-PEOPLE; CLINICAL-TRIAL; PRACTICE GUIDELINES; PREVENTING FALLS; GENERAL-PRACTICE; ELDERLY-PEOPLE; COMMUNITY; MANAGEMENT AB To determine whether a practice-based intervention can improve care for falls, urinary incontinence, and cognitive impairment. Controlled trial. Two community medical groups. Community-dwelling patients (357 at intervention sites and 287 at control sites) aged 75 and older identified as having difficulty with falls, incontinence, or cognitive impairment. Intervention and control practices received condition case-finding, but only intervention practices received a multicomponent practice-change intervention. Percentage of quality indicators satisfied measured using a 13-month medical record abstraction. Before the intervention, the quality of care was the same in intervention and control groups. Screening tripled the number of patients identified as needing care for falls, incontinence, or cognitive impairment. During the intervention, overall care for the three conditions was better in the intervention than the control group (41%, 95% confidence interval (CI)=35-46% vs 25%, 95% CI=20-30%, P <.001). Intervention group patients received better care for falls (44% vs 23%, P <.001) and incontinence (37% vs 22%, P <.001) but not for cognitive impairment (44% vs 41%, P=.67) than control group patients. The intervention was more effective for conditions identified by screening than for conditions identified through usual care. A practice-based intervention integrated into usual clinical care can improve primary care for falls and urinary incontinence, although even with the intervention, less than half of the recommended care for these conditions was provided. More-intensive interventions, such as embedding intervention components into an electronic medical record, will be needed to adequately improve care for falls and incontinence. C1 [Wenger, Neil S.; Young, Roy T.; Louie, Rachel; Min, Lillian C.; Reuben, David B.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Wenger, Neil S.; Roth, Carol P.; Shekelle, Paul G.; Solomon, David H.; Adams, John] RAND Corp, Santa Monica, CA USA. [Shekelle, Paul G.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kamberg, Caren J.] RAND, Washington, DC USA. [Chang, John T.] Zynx Hlth, Los Angeles, CA USA. [Higashi, Takahiro] Natl Canc Ctr, Tokyo 104, Japan. [MacLean, Catherine H.] WellPoint Inc, Programs Clin Excellence, Woodland Hills, CA USA. [Ransohoff, Kurt] Sansum Santa Barbara Med Fdn Clin, Santa Barbara, CA USA. [Hoffing, Marc] Desert Med Grp, Palm Springs, CA USA. RP Wenger, NS (reprint author), Univ Calif Los Angeles, Dept Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA. EM nwenger@mednet.ucla.edu NR 36 TC 52 Z9 53 U1 4 U2 15 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 IS 3 BP 547 EP 555 DI 10.1111/j.1532-5415.2008.02128.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 414JL UT WOS:000263859600023 PM 19175441 ER PT J AU Braddy, K Imam, SN Palla, KR Lee, TA AF Braddy, K. Imam, S. N. Palla, K. R. Lee, T. A. TI Practice Patterns for Vitamin D Deficiency/Insufficiency in Longterm Care: Are We Doing Enough? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Braddy, K.; Imam, S. N.; Palla, K. R.; Lee, T. A.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S174 EP S175 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900501 ER PT J AU Chi, R Haight, S Neuzil, K AF Chi, R. Haight, S. Neuzil, K. TI Suboptimal Immune Response to Influenza Vaccine in Community-Dwelling Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Chi, R.; Neuzil, K.] Univ Washington, Seattle, WA 98195 USA. [Chi, R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Haight, S.] St Louis Univ, Sch Med, St Louis, MO USA. [Neuzil, K.] PATH, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S60 EP S60 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900171 ER PT J AU Cohen, JA Hwang, U Morrison, RS AF Cohen, J. A. Hwang, U. Morrison, R. S. TI A descriptive study of palliative care patients admitted via the emergency department SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Cohen, J. A.; Hwang, U.; Morrison, R. S.] Mt Sinai Sch Med, New York, NY USA. [Morrison, R. S.] James J Peters VAMC, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S27 EP S27 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900074 ER PT J AU Diller, A Sanchez-Reilly, S Wittenberg-Lyles, E AF Diller, A. Sanchez-Reilly, S. Wittenberg-Lyles, E. TI Caregivers of Elderly with Cancer: Can Intervention before Hospice affect Quality of Life? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Diller, A.; Sanchez-Reilly, S.; Wittenberg-Lyles, E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, S.] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Wittenberg-Lyles, E.] Univ N Texas, Denton, TX 76203 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S130 EP S130 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900370 ER PT J AU Gordon, W Polansky, J Boscardin, J Fung, K Patil, S Steinman, M AF Gordon, W. Polansky, J. Boscardin, J. Fung, K. Patil, S. Steinman, M. TI Point-based vs. equation-based Framingham risk models: Minor simplification with major consequences SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Gordon, W.] Weill Cornell Med Coll, New York, NY USA. [Gordon, W.] Med Student Training Aging Res Program, San Francisco, CA USA. [Polansky, J.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Fung, K.; Patil, S.; Steinman, M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Boscardin, J.; Fung, K.; Patil, S.; Steinman, M.] UCSF, Div Geriatr, San Francisco, CA USA. [Boscardin, J.] UCSF, Div Biostat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S5 EP S6 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900014 ER PT J AU Gray, S Boudreau, R Newman, A Studenski, S Shorr, R Bauer, D Simonsick, E Hanlon, J AF Gray, S. Boudreau, R. Newman, A. Studenski, S. Shorr, R. Bauer, D. Simonsick, E. Hanlon, J. TI Angiotensin-converting Enzyme Inhibitor (ACEI) Medication Use and Persistent Lower Extremity Limitation (PLL) in Community Elderly: The Health, Aging and Body Composition Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Gray, S.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Boudreau, R.; Newman, A.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Newman, A.; Studenski, S.; Hanlon, J.] Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA USA. [Studenski, S.; Hanlon, J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA. [Studenski, S.; Hanlon, J.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Shorr, R.] N Florida S Georgia Vet Hlth Syst, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA. [Bauer, D.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Simonsick, E.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S176 EP S176 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900505 ER PT J AU Hung, WW Liu, S Du, Q Boockvar, K AF Hung, W. W. Liu, S. Du, Q. Boockvar, K. TI Changes in functional status during acute illness episodes in nursing home residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Hung, W. W.; Du, Q.; Boockvar, K.] Mt Sinai Sch Med, New York, NY USA. [Hung, W. W.; Boockvar, K.] James J Peters VA Med Ctr, Bronx, NY USA. [Liu, S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S148 EP S148 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900424 ER PT J AU Kenfield, MC Arciniegas, DB Anderson, C Howard, KL Filley, CM AF Kenfield, M. C. Arciniegas, D. B. Anderson, C. Howard, K. L. Filley, C. M. TI When Cognitive Evaluation Does Not Disclose a Neurologic Disorder: Experience of a University Behavioral Neurology Clinic SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Kenfield, M. C.; Arciniegas, D. B.; Anderson, C.; Howard, K. L.; Filley, C. M.] Univ Colorado Denver, Sch Med, Aurora, CO USA. [Arciniegas, D. B.; Anderson, C.; Filley, C. M.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S196 EP S197 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900563 ER PT J AU Linnebur, SA Fish, DD Ruscin, J Radcliff, T Oman, K Liebrecht, D Fish, R McNulty, MC Hutt, E AF Linnebur, S. A. Fish, D. D. Ruscin, J. Radcliff, T. Oman, K. Liebrecht, D. Fish, R. McNulty, M. C. Hutt, E. TI Impact of Educational Interventions Targeting Antibiotic Use for Nursing Home-Acquired Pneumonia (NHAP) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Linnebur, S. A.; Fish, D. D.; Radcliff, T.; Oman, K.; Liebrecht, D.; Fish, R.; McNulty, M. C.; Hutt, E.] Univ Colorado Denver, Aurora, CO USA. [Ruscin, J.] So Illinois Univ, Edwardsville, IL 62026 USA. [Radcliff, T.; Hutt, E.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S6 EP S6 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900016 ER PT J AU Markland, AD Walsh-Covarrubias, JB DuBeau, C Urist, MM Bland, KI Kilgore, LC Amling, CL Richter, HE AF Markland, A. D. Walsh-Covarrubias, J. B. DuBeau, C. Urist, M. M. Bland, K. I. Kilgore, L. C. Amling, C. L. Richter, H. E. TI Utilization of a Learners Needs Assessment for Geriatric Training among Three Surgical Training Programs SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Markland, A. D.] Birmingham VAMC, Birmingham, AL USA. [Markland, A. D.; Walsh-Covarrubias, J. B.; Urist, M. M.; Bland, K. I.; Kilgore, L. C.; Amling, C. L.; Richter, H. E.] Univ Alabama, Birmingham, AL USA. [Richter, H. E.] Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S35 EP S35 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900099 ER PT J AU Meo, N Hwang, U Morrison, R AF Meo, N. Hwang, U. Morrison, R. TI Resident Perceptions of Palliative Care Training in the Emergency Department. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Hwang, U.; Morrison, R.] Brookdale Dept Geriatr & Adult Dev, New York, NY USA. [Hwang, U.] James J Peters VAMC, GRECC, Bronx, NY USA. [Morrison, R.] Lillian & Benjamin Hertzberg Palliat Care Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S39 EP S39 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900110 ER EF